<SEC-DOCUMENT>0000939767-20-000150.txt : 20201105
<SEC-HEADER>0000939767-20-000150.hdr.sgml : 20201105
<ACCEPTANCE-DATETIME>20201105162148
ACCESSION NUMBER:		0000939767-20-000150
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		71
CONFORMED PERIOD OF REPORT:	20201002
FILED AS OF DATE:		20201105
DATE AS OF CHANGE:		20201105

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EXELIXIS, INC.
		CENTRAL INDEX KEY:			0000939767
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				043257395
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0101

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30235
		FILM NUMBER:		201290786

	BUSINESS ADDRESS:	
		STREET 1:		1851 HARBOR BAY PARKWAY
		CITY:			ALAMEDA
		STATE:			CA
		ZIP:			94502
		BUSINESS PHONE:		6508377000

	MAIL ADDRESS:	
		STREET 1:		1851 HARBOR BAY PARKWAY
		CITY:			ALAMEDA
		STATE:			CA
		ZIP:			94502

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXELIXIS INC
		DATE OF NAME CHANGE:	20000207

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXELIXIS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20000106
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>exel-20201002.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2020 Workiva--><!--r:a5daf19b-278e-4193-a378-e43e29a2ddec,g:725f21e5-a4e0-44a1-91a2-e65dc567c7d2,d:0283c6f517b447ec92f154ee691f4028--><html xmlns:exel="http://www.exelixis.com/20201002" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:srt="http://fasb.org/srt/2020-01-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>exel-20201002</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80L2ZyYWc6MzhmYWFlNjhmMzU5NDQ3NGJmMWJmZDZmNzNiMzA5ZTkvdGFibGU6MmYwYWE3NTg5ZGE2NDM0YWIxOWQzMDE0ODE0MDRmNzcvdGFibGVyYW5nZToyZjBhYTc1ODlkYTY0MzRhYjE5ZDMwMTQ4MTQwNGY3N18yLTEtMS0xLTA_1500a88a-62f6-4d42-88e2-e654a21e24cc">false</ix:nonNumeric><ix:nonNumeric contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80L2ZyYWc6MzhmYWFlNjhmMzU5NDQ3NGJmMWJmZDZmNzNiMzA5ZTkvdGFibGU6MmYwYWE3NTg5ZGE2NDM0YWIxOWQzMDE0ODE0MDRmNzcvdGFibGVyYW5nZToyZjBhYTc1ODlkYTY0MzRhYjE5ZDMwMTQ4MTQwNGY3N180LTEtMS0xLTA_9e5d612d-7c74-44e3-838a-4271a91fa74e">2020</ix:nonNumeric><ix:nonNumeric contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80L2ZyYWc6MzhmYWFlNjhmMzU5NDQ3NGJmMWJmZDZmNzNiMzA5ZTkvdGFibGU6MmYwYWE3NTg5ZGE2NDM0YWIxOWQzMDE0ODE0MDRmNzcvdGFibGVyYW5nZToyZjBhYTc1ODlkYTY0MzRhYjE5ZDMwMTQ4MTQwNGY3N181LTEtMS0xLTA_2291d85b-ecb9-47c9-9d8d-df4628e80f37">Q3</ix:nonNumeric><ix:nonNumeric contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80L2ZyYWc6MzhmYWFlNjhmMzU5NDQ3NGJmMWJmZDZmNzNiMzA5ZTkvdGFibGU6MmYwYWE3NTg5ZGE2NDM0YWIxOWQzMDE0ODE0MDRmNzcvdGFibGVyYW5nZToyZjBhYTc1ODlkYTY0MzRhYjE5ZDMwMTQ4MTQwNGY3N182LTEtMS0xLTA_c2684032-71f4-48d1-a4be-cf0dc4b0a31b">0000939767</ix:nonNumeric><ix:nonNumeric contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80L2ZyYWc6MzhmYWFlNjhmMzU5NDQ3NGJmMWJmZDZmNzNiMzA5ZTkvdGFibGU6MmYwYWE3NTg5ZGE2NDM0YWIxOWQzMDE0ODE0MDRmNzcvdGFibGVyYW5nZToyZjBhYTc1ODlkYTY0MzRhYjE5ZDMwMTQ4MTQwNGY3N183LTEtMS0xLTA_1a1509a8-facf-4724-88ed-5be04108837d">January 1</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="exel-20201002.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i889d2f8991ef4018930cd672e669b490_I20201026"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-10-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="iccc3837038f342898d73d67395904bae_I20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie736426c8e19488ea872e8da8ebb6578_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ia527955beb274c50967751e32dc17dff_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i663049bc589a41de99b922b6fb02f1bc_D20190629-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefbb93ab12054c04a4d0d55ad1aaf502_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75b81eceef094c2d86c24a00c59294e1_D20181229-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie72938b556dd42ada9b416a6b60b47fa_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic55505ff13f844188fb0751728d84cce_D20190629-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47085b4d4dbd42ac8d6b0c47740109da_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98f01433b4094674bd5e812d8d00d234_D20181229-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25bf6a1fad8f41f8b3dd9743b6494697_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88aea9011a624e6ab196817bcb69590c_D20190629-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iced2a1e2c6a1480d8302a1285f8e233c_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43a6c75a975a475a8220f03f17c813e5_D20181229-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i316676d09b8a43edb69e0d908574a669_I20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02f1924710584639831de419a08af15c_I20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46f2d57ee3234492ae78920271a99b39_I20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49c13447908e420384b91c447fbe71a9_I20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e76b251fbeb42f3a7cc3df6ca3a4230_I20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic40a4137775f410490cca3ab2ec24c82_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie823ac87cfcf453da0d0ee469a5208a4_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f63bc8277444a159ea4d49770eaf477_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97e9d031387d43198b6f05ff2861f3ab_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida20c4eb650547409d09265abf22aef1_I20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a1eac7bffc9475a9bbdda86813fd7ee_I20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7bf961275044b01a0c4a9ccebad588f_I20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a5031970ae845a8b4d0e06e3e6e4934_I20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c1980f2c4f24d4baa81b1ccba73febb_I20190628"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i013e4989ee6443b9afcc82a956f959f9_I20190628"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0dbb32931e346bfae3a3ca347f978ab_I20190628"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ad7ce0b72c9496489178748e0770609_I20190628"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if77bb429cb9c49c7a19d55f3f313ee70_I20190628"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd7f360120b34b36ae5e37843a1f7fd3_D20190629-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib60dcfd8f46a44b6b0c8dfc25001dd5e_D20190629-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ab198a265ed4c0494a01c26fc2f82c7_D20190629-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1082fd4f150346c182b846e3072e0c3f_D20190629-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05f14b5dcf314304b309c5e87df9f50a_I20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c6f2cb1dfbd41acbc289114955cd416_I20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3dac2e6ea3d14a2e8cc5b92c6af71211_I20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic827287aa3294c6a883bc9d0b8a0623f_I20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34bbe41183cc4f96afa896c1d7f86bb3_I20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-09-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f39a5eecfd64bbdb16dc650b0f43744_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8909ade88d7423e92687245874b7f72_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6b255ea4abe49edafb55d811bcad05b_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2614e82c41c1401c802f3cfcc0fa0efe_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5ea39c6afc94359bbe264fb14b43e10_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdb2053635ce46b7b040cfe89917a2b4_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id485c543ae654a6fa7b0799bc9c76368_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i168c5944094040729529b381e8529300_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifad3e2a4eb5e4ee8a6ee49d932419d11_I20181228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13b4a5caa8a046bb9f6cc3529e516e24_I20181228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1277e0158f8545d28d0907eafd290af9_I20181228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18bb90a064a742e5b5735480b882cb98_I20181228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i010170af21d84cd898d00c6336993dba_I20181228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d7219d185874a2188412be82a05f1ee_D20181229-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1aaa1630501a4eb1839161674cac9e08_D20181229-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b32b70c60b14ff19391f59a6db9dd0e_D20181229-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6dab0b7d12c64bcfa11c169e3789d3bf_D20181229-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="product"><xbrli:measure>exel:product</xbrli:measure></xbrli:unit><xbrli:context id="if5e8e1669be6453aa3ae0fc322692c38_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ResultingFromDiscoveryEffortsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe41da152065437483e7469fa266c06d_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductsDerivedFromCabozantinibMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9df0cd737b54a18828c9607339f712f_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductsDerivedFromOtherCompoundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>exel:segment</xbrli:measure></xbrli:unit><xbrli:context id="i6b8fc82f50494df690850a723f567147_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">exel:NewInformationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i53d5d16c99e24b1685ffd6417b746dc5_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i988d96d56fc8488e825029b9ae6e78da_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4f8f5605ff6401098c5e709f8d70e2f_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:MckessonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d8dbceba046414c9646347dd14f559d_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:MckessonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b8d3dbc1c5648e68dcec00585f82d14_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i458bde72c5d5486cb34c5d501fb3ca84_D20190629-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5535b1b3b1a487ea1ac2f456daeae47_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7500a3b3560547179833f5e227db7a5c_D20181229-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2148af2d149c45dbb0c184eb9a166068_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ed764ccd2a94897aeb76c66da22a057_D20190629-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbbf27901590404f947e7e8da56664d3_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6d312e664d54a13a0bb0c707a911341_D20181229-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id85db556f50145f28ee780d1a8a89976_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1234ea649134872b48e4dbb76f2d830_D20190629-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53da4333857a41c596e180b7605fb101_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d89b0fff8f440c5a47f0e0cbadc2d30_D20181229-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide4bbab6cf384b57a9b8addbd0e12d37_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad9dc86bff5e482395fb34a230d3bce2_D20190629-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97faf5b0431f41eeafdc9b84f69366b6_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdccf6af360349f19712f9f78dc3b258_D20181229-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide08272d8494485aa3f67140ad87e288_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c63f161b29d440b983b8d7886c07431_D20190629-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if80a8f9a26734cc1a3ab10698b7d38d1_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2a58f6e8634467fbb6096248e57b129_D20181229-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia60d29d213b7423f8b44089dbc426396_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84172e8ba8944bff9097e2420fc4a71d_D20190629-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i386a27a71d1b4955bcbcf10ffefe4dc9_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc5620147c964216bca8a91f88f53db3_D20181229-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib86d0fb1dcd542688f1f82783390f7d7_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73d4427b07944bb4a39082c52e7e3993_D20190629-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5702087f6d044b2f8cb91e6d9e024981_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i185156eb44914a05b07e512b521ee175_D20181229-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a1a12d3a1e34e64be6756a38f99157b_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fe0056abef84c0fb63cfb73f2dbaf5e_D20190629-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70fe222147914251b9dc10ce75948cf9_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacd7fc12f88842b1924368fbbf75cc1f_D20181229-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14e1a35d582a44a0a5026811d269e717_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iced8dcb1cd6a410d8111f8781e04944b_D20190629-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id929db05799d4a7ea908997e18680ab8_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaabc597e0f5940e89c79670faf29f78e_D20181229-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d6b1d115ff4494fb1233255cd7c2c19_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofOptumSpecialtyPharmacyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54ae6ae3ffc442a5b7b73749a9ee7058_D20190629-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofOptumSpecialtyPharmacyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff89a893303e4fa882dc5129bcbfb868_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofOptumSpecialtyPharmacyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief5d2999265b4a7ba5bbc8848a958c41_D20181229-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofOptumSpecialtyPharmacyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i586e46eec28e45cc9e06428a8195d748_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:TakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d79b47a315146babea975fec8dce552_D20190629-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:TakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3cb1cfcba4a24a5a95475dcd23a6d6a7_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:TakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a9ff92761624c878e628676f2c878f8_D20181229-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:TakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec0582c68f2e45809336de61a7ef2ffe_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71b0e797d9454761a9c3b48ce0cd6dc7_D20190629-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e8cff04ca5040a68e2a49c6e3601c97_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62c0d9fe6a22430782ddc2b6e95e7fea_D20181229-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3a34af32f82425db5a92b122c952662_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec35a82156214e73aba68b440656efba_D20190629-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6b900d2f20e47d098b552ec62a9e8d6_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie38bb019719d40208f85caefe75b164d_D20181229-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b85521d483a41f38d661425a8820625_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2db6d59506ab40b9822586497086d157_D20190629-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i477ac2490d6a414281cc99f9812014e7_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65978d0dcb28411cb73d35911d6e8d6c_D20181229-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67b11a0135a641a4bd4d22e09f7bfbcf_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i504cbdf3907f4152872efaf0c542118f_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b422997cdc1458bb19aa47286284ef0_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bb996de5a5f41699a6974a3f048c443_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9fee7c5808d4690b34490b6ca50b8db_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b664d4199b94af5a11e4871fd387735_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie771b9f5649b4d37b25de019253cf120_I20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07e441c2da394ce2b81f3584524ba9a1_I20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2f14853d41346db96816c2397b0613f_I20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icef64ef981c4433ab4d95dd86f4c12ae_I20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0813edb6dc1f42149871864785a370b0_I20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:TakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic563e3038d034910b191aa2e402f2d54_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i306ec623b7da464887c212d6bbb0c3b9_D20190629-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie769fec28ac9424ab1612b636240244f_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b97daa6c5714e879d52e0f5818a13e5_D20181229-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i625c660e5c2c47ffba3e54c798ef1200_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb1de3b33b4e4d3ea045adf1503e5b39_D20190629-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8fed9d02b6e436ebb1928ac49eccab8_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39ac5c13a0c242ad9f5edee49b33dee7_D20181229-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i911b510538cf4e2e9af50c7bbb5b99af_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7142efd22e1049f7852952c299c3d936_D20190629-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2cd405124b14735b901658a7069f2a6_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccf5e837fe3f43d6856e3b446cd61ef1_D20181229-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia423630adad04538bc955c381c570336_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5df4d5352b0b4f0ba481cb03390bc3df_D20190629-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcb0ee440b7e4dc0b3ff4215f20b3b2d_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6551575ad754a52ade8c9bd7ebfa664_D20181229-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17097e4a7b2744f3bb555de0fd06a162_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6130e6433ae14ecf9e3154f44ad89dcd_D20190629-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4048c98f09848dc973a93054bfd645e_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieffdd922a5584f5fb2c96d614a69b68c_D20181229-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb095da3afbd4daa9861c6249817cea0_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16a003aa5aa5428887c9c411dbc420fc_D20190629-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32bf9affdda745209b77e77dfc211f15_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i350a22df21c64d1c93c2524af875b962_D20181229-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b512ec06edc41c18dbe1037421ea9bb_I20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8670170a5094b3b904e1504aafbac8c_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:GlaxoSmithKlineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6d4cedf8c084744ba29969039e3b2e9_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8dbb49564117496fb5290d851754b098_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i681117f1aebd445288c3a111845dc5c8_D20190629-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71974296a61b4d89993136d3ef36daed_D20181229-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id774200cb5964ec7a9f457d6f01d6879_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CotellicMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3042085c439a4f33a184caed0a43f26b_D20190629-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CotellicMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i435fea9408f448279983514e753b98c2_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CotellicMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54179f4a09954324b9f756384579283e_D20181229-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CotellicMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02e9b643d49a417e9373b15e166ba536_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementWithCatalentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f29e6a4d7e4442a814e495bb866df20_I20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementWithCatalentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b107f2541f144959f65cffe2682f793_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementWithNBETherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9dc3e9657668420dbfcde5f6032f0548_I20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementWithNBETherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d1bc4ca714746459025e3f4409d9cd3_I20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51a81230a1d74e55a2566c55413e2b2a_I20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ba278ad76ca4fcd841ffefc73154898_I20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id17bab0418ae471988fdfa84040140f1_I20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifac6d9b9d2944e76a0f5c167b3983bc0_I20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ideca50ba198246c68d0bffddd169057c_I20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58a13023c0dd450eb2ee0d861f56e766_I20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f9a560b1450471a9fb3a5226dea5132_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic27aa82f118547bcaca2790c33dd963b_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f0bf831f83f4af59172086b8a97f3c4_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i785b48358c27484689107bc80f7a2cbb_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28526894a4b14f39b408ab8db78be75d_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1800b81e21784d189946618c1ae33956_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="investment"><xbrli:measure>exel:investment</xbrli:measure></xbrli:unit><xbrli:context id="ieadeb951ef494630818c3cc30b3da393_I20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0aad2b7015eb477c88c1ea01262ba619_I20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia338dcf4e5144bef8ca2ebd43f622d04_I20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i214b7f1c98384cd7ae5d32548266b97b_I20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e427409ff9d4828a3b7640315fdf49b_I20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ea639c496fd491897fbb9c377110819_I20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14689612fde84c3c940d88d417602b2a_I20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i105a4d34d1764fab907327463ccad490_I20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b6ffe686868432ab9437a164687d998_I20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c82661404c1488b9aa5b0c3a43ca9f4_I20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic69aa2cb176f4a9aa647d6c00a697fb9_I20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbb5a720eff3482091e3be625d787981_I20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d11a44c584e4c27b4cd486045540585_I20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6891e843a55d40c9a8f7f81e029810ef_I20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia145ea6fe2c34f45a3f0710801bc6531_I20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i295ed1efaf864ae9b0abe578705aae7c_I20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b2d74b62bf14b7399c48b032c3050fa_I20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecc5d76d94114b538c7cc261d3d7dbb9_I20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7eec7f6e4801439489ec8ab44f13dca5_I20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife2cb38c2462497fb4f2be87aacfcbe9_I20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e13458d32e445e6a3bdc3140700b3ef_I20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i727f7c37fa244a2d96022ada5bf8347f_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie98bf240c97e447183ba8f88a167242d_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d639ed777ff435ea5b6c19441e7ecff_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d9829f5158045228bedb41708d21afd_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7facc890253843839cb983e5f0c5d14c_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77e3015ed1f944988e83d686ba77f015_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5fb7e2d38294fdaa468d8855b980731_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2b721b19a1d4ee8a556e85a2c797759_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b010574af4c409fa174a0bc4c2b34e1_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icefaee59f19a40b0bbd4de9922c8c59c_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4060e618697434cad36b5db4d7c6111_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd8e36118a87443ca78892462d27bfab_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09f2281bdf9349038431afc18379805b_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9c4cc15650340169d2372d82bde6360_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i362da4b860134a89851c683e142464ef_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic072d7bdc3a747c3aa29c10bd5bd37e7_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76745aad80e54832855f5e01889a5b33_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c5d87cfd74f40ccabd0feeeecbb37cd_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6de1a52cb79c40518135c31ed1ad1ba2_I20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24f6503be5494081a0dbe6c993e81397_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbece5f4cfff4192b62909c119134d4d_I20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:OtherLongtermAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91d78c6281004d5e860e9762ede7f244_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:OtherLongtermAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8807e50c23c4d31ab20dcdcebd143c7_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d73a25521cd47598eec943fc3e67f0b_D20190629-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id10dbcb3d9244b64b3c0a11867e5072c_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2730b1b9796c4aaaa8efe5695e985946_D20181229-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94716cdf2585476f8d2241789b25429d_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia84c18733f11427b85d537694ee6b742_D20190629-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife7f80399bf046279aeacfddc3d5cb35_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb17c6080fe0476e875c10f986a8b090_D20181229-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6084a0d4002647d69b2148895c55cbd9_D20200520-20200520"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-20</xbrli:startDate><xbrli:endDate>2020-05-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c137f0c3b874241af6cdf35240fc6c4_I20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7840df292b24b97a39df16ab6f9e94c_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib477ff76a01e469abd582edacf5f60b7_I20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2fa39753eebb4b2da55065a78f952a39_D20180101-20181228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:PerformanceShareOptionsPSOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91d293b87e5445f5b5b67e1a9c37b9d2_I20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4972ebe551a741e48565ab4e7bcd8df1_I20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exel:StatusAxis">exel:AchievedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e5cec7e0ab144f59216d279d7df965d_I20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="exel:StatusAxis">exel:ProbableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21aab8a484c04ec2a5cff2d96ab82dbd_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7550f0f67bcf428b9b1a23a22d59a795_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41f51136e2dd4492aea05277671e9389_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if970e9016fc3406ea7bb57cbb0786e20_D20190629-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0cf80d622b4495e8ba855ad5bbe6234_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01d75cb9987e4a6e9148d6e76b57e666_D20181229-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i0283c6f517b447ec92f154ee691f4028_1"></div><div style="min-height:45pt;width:100%"><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:199.50pt"><tr><td style="width:1.0pt"></td><td style="width:97.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:97.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:21pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM </span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xL2ZyYWc6NzYyMWE0NTkyM2ExNDQ2Mzg0N2JiYjk0N2RjMmZiMDMvdGFibGU6YjBkNmYxMzliZDIzNDE1MmI5M2ZhNzUzODA4OTYzY2MvdGFibGVyYW5nZTpiMGQ2ZjEzOWJkMjM0MTUyYjkzZmE3NTM4MDg5NjNjY18wLTEtMS0xLTA_f399f45b-7de3-492e-8d3a-bf5ddfb505b1">10-Q</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.520%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xL2ZyYWc6NzYyMWE0NTkyM2ExNDQ2Mzg0N2JiYjk0N2RjMmZiMDMvdGFibGU6OGUxZjgzZWE4ZTkxNDY5ZmE1NDMxYTQxNDIxODk3ZDgvdGFibGVyYW5nZTo4ZTFmODNlYThlOTE0NjlmYTU0MzFhNDE0MjE4OTdkOF8wLTAtMS0xLTA_c48fbd04-6583-4df2-832f-4de5c4e1134e">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For the quarterly period ended <ix:nonNumeric contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xL2ZyYWc6NzYyMWE0NTkyM2ExNDQ2Mzg0N2JiYjk0N2RjMmZiMDMvdGV4dHJlZ2lvbjo3NjIxYTQ1OTIzYTE0NDYzODQ3YmJiOTQ3ZGMyZmIwM18xMTQ_f5106220-a284-4728-8b7e-900129e272fb">October&#160;2, 2020</ix:nonNumeric></span></div><div style="padding-left:36pt;text-align:center;text-indent:-36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">or</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.520%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xL2ZyYWc6NzYyMWE0NTkyM2ExNDQ2Mzg0N2JiYjk0N2RjMmZiMDMvdGFibGU6Yjg4YmQ4MWM3OWMxNDUzZGI3YWQ0MGQzYmUxMzNhNWMvdGFibGVyYW5nZTpiODhiZDgxYzc5YzE0NTNkYjdhZDQwZDNiZTEzM2E1Y18wLTAtMS0xLTA_53bb0400-c872-438b-8a16-017dfeb9301e">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </span></td></tr></table></div><div style="padding-left:36pt;text-align:center;text-indent:-36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xL2ZyYWc6NzYyMWE0NTkyM2ExNDQ2Mzg0N2JiYjk0N2RjMmZiMDMvdGV4dHJlZ2lvbjo3NjIxYTQ1OTIzYTE0NDYzODQ3YmJiOTQ3ZGMyZmIwM18xODc0_c991cace-a6ee-42d4-9094-e3eeb7f3a0c1">000-30235</ix:nonNumeric></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:200.25pt"><tr><td style="width:1.0pt"></td><td style="width:198.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:54pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"><div style="margin-top:9pt;text-align:center"><img src="exel-20201002_g1.jpg" alt="exel-20201002_g1.jpg" style="height:64px;width:188px;"/></div></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xL2ZyYWc6NzYyMWE0NTkyM2ExNDQ2Mzg0N2JiYjk0N2RjMmZiMDMvdGFibGU6MWI5YWExMDRjYTE3NGRiYThmOGU3NDA4ZDM1ZjY1MzcvdGFibGVyYW5nZToxYjlhYTEwNGNhMTc0ZGJhOGY4ZTc0MDhkMzVmNjUzN18xLTAtMS0xLTA_8df3c23f-7598-4947-8c9f-d363f8b8bfa1">EXELIXIS, INC.</ix:nonNumeric></span></td></tr><tr style="height:14pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.974%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xL2ZyYWc6NzYyMWE0NTkyM2ExNDQ2Mzg0N2JiYjk0N2RjMmZiMDMvdGFibGU6MWY3NmU2ZDYzNTBiNDhiNzk2MTMzZDBiOWZmYjRiYTIvdGFibGVyYW5nZToxZjc2ZTZkNjM1MGI0OGI3OTYxMzNkMGI5ZmZiNGJhMl8wLTAtMS0xLTA_006dbb54-f120-496a-89aa-87aeaf7be800">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xL2ZyYWc6NzYyMWE0NTkyM2ExNDQ2Mzg0N2JiYjk0N2RjMmZiMDMvdGFibGU6MWY3NmU2ZDYzNTBiNDhiNzk2MTMzZDBiOWZmYjRiYTIvdGFibGVyYW5nZToxZjc2ZTZkNjM1MGI0OGI3OTYxMzNkMGI5ZmZiNGJhMl8wLTEtMS0xLTA_5174f5d8-7902-4bf7-b6b2-e05c9fb75032">04-3257395</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification Number)</span></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xL2ZyYWc6NzYyMWE0NTkyM2ExNDQ2Mzg0N2JiYjk0N2RjMmZiMDMvdGV4dHJlZ2lvbjo3NjIxYTQ1OTIzYTE0NDYzODQ3YmJiOTQ3ZGMyZmIwM18xODc1_fc054253-3249-4434-bd7f-de762dc6f98a">1851 Harbor Bay Parkway</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xL2ZyYWc6NzYyMWE0NTkyM2ExNDQ2Mzg0N2JiYjk0N2RjMmZiMDMvdGV4dHJlZ2lvbjo3NjIxYTQ1OTIzYTE0NDYzODQ3YmJiOTQ3ZGMyZmIwM18xODgx_94f19f27-5134-4ee1-b237-83d30183ca00">Alameda,</ix:nonNumeric> <ix:nonNumeric contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xL2ZyYWc6NzYyMWE0NTkyM2ExNDQ2Mzg0N2JiYjk0N2RjMmZiMDMvdGV4dHJlZ2lvbjo3NjIxYTQ1OTIzYTE0NDYzODQ3YmJiOTQ3ZGMyZmIwM18xODc2_00fe4bac-f355-4aeb-b89e-2623be49c91e">CA</ix:nonNumeric> <ix:nonNumeric contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xL2ZyYWc6NzYyMWE0NTkyM2ExNDQ2Mzg0N2JiYjk0N2RjMmZiMDMvdGV4dHJlZ2lvbjo3NjIxYTQ1OTIzYTE0NDYzODQ3YmJiOTQ3ZGMyZmIwM18xODc3_6f453961-101e-4dc2-a97c-8e1bd1bd6034">94502</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xL2ZyYWc6NzYyMWE0NTkyM2ExNDQ2Mzg0N2JiYjk0N2RjMmZiMDMvdGV4dHJlZ2lvbjo3NjIxYTQ1OTIzYTE0NDYzODQ3YmJiOTQ3ZGMyZmIwM18xODgy_a7a7aaa7-d512-415a-aad5-153bf58b543c">650</ix:nonNumeric>) <ix:nonNumeric contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xL2ZyYWc6NzYyMWE0NTkyM2ExNDQ2Mzg0N2JiYjk0N2RjMmZiMDMvdGV4dHJlZ2lvbjo3NjIxYTQ1OTIzYTE0NDYzODQ3YmJiOTQ3ZGMyZmIwM18xODgz_8bddab05-3792-429c-b2f6-251a5cb91ddf">837-7000</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:38.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.990%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xL2ZyYWc6NzYyMWE0NTkyM2ExNDQ2Mzg0N2JiYjk0N2RjMmZiMDMvdGFibGU6OTkxNjgxMjE4MmZhNGJjNjhiN2JmMWZkOTY3MDY1OTMvdGFibGVyYW5nZTo5OTE2ODEyMTgyZmE0YmM2OGI3YmYxZmQ5NjcwNjU5M18xLTAtMS0xLTA_11fedd6d-336c-4e80-926f-7f1954a006c5">Common Stock $.001 Par Value per Share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xL2ZyYWc6NzYyMWE0NTkyM2ExNDQ2Mzg0N2JiYjk0N2RjMmZiMDMvdGFibGU6OTkxNjgxMjE4MmZhNGJjNjhiN2JmMWZkOTY3MDY1OTMvdGFibGVyYW5nZTo5OTE2ODEyMTgyZmE0YmM2OGI3YmYxZmQ5NjcwNjU5M18xLTEtMS0xLTA_814dbcc7-9a1b-48b8-9315-c7a960021705">EXEL</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xL2ZyYWc6NzYyMWE0NTkyM2ExNDQ2Mzg0N2JiYjk0N2RjMmZiMDMvdGFibGU6OTkxNjgxMjE4MmZhNGJjNjhiN2JmMWZkOTY3MDY1OTMvdGFibGVyYW5nZTo5OTE2ODEyMTgyZmE0YmM2OGI3YmYxZmQ5NjcwNjU5M18xLTItMS0xLTA_445ec0bb-7bfb-4d50-a4e3-72c1f721d76b">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xL2ZyYWc6NzYyMWE0NTkyM2ExNDQ2Mzg0N2JiYjk0N2RjMmZiMDMvdGV4dHJlZ2lvbjo3NjIxYTQ1OTIzYTE0NDYzODQ3YmJiOTQ3ZGMyZmIwM18xODc4_a12baf35-c5ac-490b-a759-a5f9faf342a3">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#253; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xL2ZyYWc6NzYyMWE0NTkyM2ExNDQ2Mzg0N2JiYjk0N2RjMmZiMDMvdGV4dHJlZ2lvbjo3NjIxYTQ1OTIzYTE0NDYzODQ3YmJiOTQ3ZGMyZmIwM18xODc5_2b86d76e-917b-4f9a-bcb4-a14ff1c664ba">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#253; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2&#160;of the Exchange Act.</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.695%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xL2ZyYWc6NzYyMWE0NTkyM2ExNDQ2Mzg0N2JiYjk0N2RjMmZiMDMvdGFibGU6ZGIzMzQzNzk5MDliNGYxYjkzZWM3NzAzOTcwMjE3YjkvdGFibGVyYW5nZTpkYjMzNDM3OTkwOWI0ZjFiOTNlYzc3MDM5NzAyMTdiOV8wLTAtMS0xLTA_3445ea10-09be-4d23-9346-2b413d204152">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xL2ZyYWc6NzYyMWE0NTkyM2ExNDQ2Mzg0N2JiYjk0N2RjMmZiMDMvdGFibGU6ZGIzMzQzNzk5MDliNGYxYjkzZWM3NzAzOTcwMjE3YjkvdGFibGVyYW5nZTpkYjMzNDM3OTkwOWI0ZjFiOTNlYzc3MDM5NzAyMTdiOV8xLTQtMS0xLTA_ce339056-25cf-42e7-916e-b6ab21ac4a10">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xL2ZyYWc6NzYyMWE0NTkyM2ExNDQ2Mzg0N2JiYjk0N2RjMmZiMDMvdGFibGU6ZGIzMzQzNzk5MDliNGYxYjkzZWM3NzAzOTcwMjE3YjkvdGFibGVyYW5nZTpkYjMzNDM3OTkwOWI0ZjFiOTNlYzc3MDM5NzAyMTdiOV8yLTEtMS0xLTA_a0ae8ddc-138e-4eed-ab35-7282b5642dae">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Securities Act.    </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xL2ZyYWc6NzYyMWE0NTkyM2ExNDQ2Mzg0N2JiYjk0N2RjMmZiMDMvdGV4dHJlZ2lvbjo3NjIxYTQ1OTIzYTE0NDYzODQ3YmJiOTQ3ZGMyZmIwM18xODgw_e733ed17-0c3b-4ec4-b439-8dc69b91fb21">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#253;</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of October&#160;26, 2020, there were <ix:nonFraction unitRef="shares" contextRef="i889d2f8991ef4018930cd672e669b490_I20201026" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xL2ZyYWc6NzYyMWE0NTkyM2ExNDQ2Mzg0N2JiYjk0N2RjMmZiMDMvdGV4dHJlZ2lvbjo3NjIxYTQ1OTIzYTE0NDYzODQ3YmJiOTQ3ZGMyZmIwM18xODE5_80dddb64-6428-493e-9aa8-67971b82fc59">310,243,961</ix:nonFraction> shares of the registrant&#8217;s common stock outstanding. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div></div></div><div id="i0283c6f517b447ec92f154ee691f4028_7"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUARTERLY REPORT ON FORM 10-Q</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.856%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_10">PART I - FINANCIAL INFORMATION</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_13">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_13">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_16">Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_22">Condensed Consolidated Statements of Income (Loss)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_22">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_25">Condensed Consolidated Statements of Comprehensive Income (Loss)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_25">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_31">Condensed Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_31">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_34">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_34">7</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_37">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_37">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_79">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_79">22</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_94">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_94">36</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_97">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_97">36</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_100">PART II - OTHER INFORMATION</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_103">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_103">37</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_106">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_106">37</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_109">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_109">59</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_112">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_112">59</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_115">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_115">59</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_118">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_118">59</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_121">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_121">59</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_124">SIGNATURES</a></span></div></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i0283c6f517b447ec92f154ee691f4028_10"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I - FINANCIAL INFORMATION</span></div><div id="i0283c6f517b447ec92f154ee691f4028_13"></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Item 1. Financial Statements</span></div><div id="i0283c6f517b447ec92f154ee691f4028_16"></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.717%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2019</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfNy0xLTEtMS0w_edaafdff-accb-4a66-b9e3-aac9c8e44aec">334,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfNy0zLTEtMS0w_e7e1a5fe-b5b6-4b14-9829-b36d5e6358c1">266,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfOC0xLTEtMS0w_6aa44340-f734-4d18-8e34-e4d0ecac75b5">853,835</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfOC0zLTEtMS0w_3d67b824-eba2-4e52-add4-6452b67a5d0e">585,742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfOS0xLTEtMS0w_254ff3c5-4760-4238-aaef-9ce3f616d5e0">166,138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfOS0zLTEtMS0w_227f2625-72a8-43b5-9382-4296ff98e577">119,073</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMTAtMS0xLTEtMA_c7ce7cf2-e265-4bac-87fc-fff50d81e140">19,319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMTAtMy0xLTEtMA_384c74b0-eff7-433a-a3d1-8bc270be3054">12,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMTItMS0xLTEtMA_9c5f9341-200e-4ca4-907e-048189321a83">34,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMTItMy0xLTEtMA_62300794-6ea8-4f64-8e44-9f31308d5191">26,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMTMtMS0xLTEtMA_b7ae591e-7bd9-4eff-b0d6-a5063351c16f">1,407,808</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMTMtMy0xLTEtMA_ac891fa4-39a3-484b-850e-4c0845c23f11">1,011,190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMTQtMS0xLTEtMA_85c51585-4e73-45c0-a2e0-62e7a4aeb3b2">358,079</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMTQtMy0xLTEtMA_3abf92e8-e92b-4fb3-b206-4c8065569eea">536,385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMTUtMS0xLTEtMA_2b9046d3-1b4b-4f80-bc6e-8b3705c78223">56,385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMTUtMy0xLTEtMA_76b670d3-8a00-41f2-b0f8-44c4f863e573">48,892</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMTYtMS0xLTEtMA_8735999c-da2f-4323-a10a-93bb40a754a3">155,678</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMTYtMy0xLTEtMA_634414dc-a874-4349-bc86-d53a09a31910">172,374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMTctMS0xLTEtMA_0fd1d683-a696-42b0-8bb3-603d88194c8c">63,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMTctMy0xLTEtMA_ec483cfc-b607-4c6d-9448-4cf39df7812c">63,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMTgtMS0xLTEtMA_0e76a723-d58e-4384-a5fa-f0650ff59b5c">69,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMTgtMy0xLTEtMA_1bd791ff-37ba-4ec1-92c0-c0544fb531a8">53,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMTktMS0xLTEtMA_611471a4-780f-41fb-b039-7728b72d16a1">2,111,043</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMTktMy0xLTEtMA_294c412d-a287-4ed4-b031-c6120b1b37ff">1,885,670</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMjItMS0xLTEtMA_43867823-f91f-4c1c-b5f3-868a75bc59a2">47,927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMjItMy0xLTEtMA_c412d07a-0cd7-4f9d-b3ab-707c0a814562">11,581</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMjMtMS0xLTEtMA_bf1fa1a3-0bb1-49c6-bc84-ec32dccf1ca6">40,782</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMjMtMy0xLTEtMA_cba198c9-afa5-4511-8f34-b0a6187a6339">37,364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical trial liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="-3" format="ixt:numdotdecimal" name="exel:AccruedClinicalLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMjQtMS0xLTEtMA_4ef9b0be-1aa9-41f3-81b2-adc6ccd8f5a0">47,074</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" decimals="-3" format="ixt:numdotdecimal" name="exel:AccruedClinicalLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMjQtMy0xLTEtMA_bc2de38e-ea4f-4200-b01b-4f691f2a702c">38,777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebates and fees due to customers</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CustomerRefundLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMjUtMS0xLTEtMA_2d718176-9d6a-4040-b71b-4b16be8eee80">19,129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CustomerRefundLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMjUtMy0xLTEtMA_511bb0de-d224-4cb6-b55e-0704ec825af1">18,719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued collaboration liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="-3" format="ixt:numdotdecimal" name="exel:AccruedCollaborationLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMjYtMS0xLTEtMA_67c284c9-f86e-4f36-bb65-5939b20f51a5">11,102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" decimals="-3" format="ixt:numdotdecimal" name="exel:AccruedCollaborationLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMjYtMy0xLTEtMA_26d376d1-4f69-4f5a-9e45-fbfa58a0ad93">11,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMjgtMS0xLTEtMA_535bd695-9999-4cf9-97c2-e1f15480c358">35,329</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMjgtMy0xLTEtMA_7ea7eb5f-e386-482c-8c2c-a8d8e435400a">24,449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMjktMS0xLTEtMA_b4e0768d-edd3-46f0-9c18-e92063f0ceec">201,343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMjktMy0xLTEtMA_e52b0b2a-f57a-4f7f-a41f-f16fea458c56">142,746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of deferred revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMzAtMS0xLTEtMA_0705bc8c-c1b8-4ae4-b64c-2eea9d990b24">9,322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMzAtMy0xLTEtMA_d5535281-53dd-437e-a96a-a035bb7652fe">6,596</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMzEtMS0xLTEtMA_9fa7f815-84ed-45d5-b999-e4b2d7d1fdd5">47,626</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMzEtMy0xLTEtMA_91d2912f-d279-44b6-b7d8-849f1030a237">48,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMzItMS0xLTEtMA_aa885db0-b803-4b18-977a-9b2d65d11b86">721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMzItMy0xLTEtMA_adefb194-a1d3-4db7-91d2-64910ed5b9d8">2,347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMzMtMS0xLTEtMA_20f8f94d-1e4d-4ee9-a894-dfaaa461c025">259,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMzMtMy0xLTEtMA_1f225ad5-140a-4831-957d-66fa57ec32e2">199,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="iccc3837038f342898d73d67395904bae_I20201002" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMzQtMS0xLTEtMA_74655d0c-3585-49f4-ac81-af58f627eeba"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMzQtMy0xLTEtMA_105a787c-0330-40f6-a7e5-e6da596bc0b8"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjdiNjJiZDZiNWE1ZTQwMmJhMGUyMzQwOGM3M2I2Y2JiXzEwOTk1MTE2Mjc4Njc_d76b876a-1318-4e9b-8efb-8fdbc0393108"><ix:nonFraction unitRef="usdPerShare" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjdiNjJiZDZiNWE1ZTQwMmJhMGUyMzQwOGM3M2I2Y2JiXzEwOTk1MTE2Mjc4Njc_eef76bad-25da-4e5e-a08b-0220a27e1f7a">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjdiNjJiZDZiNWE1ZTQwMmJhMGUyMzQwOGM3M2I2Y2JiXzEwOTk1MTE2Mjc4Nzc_1862a00e-7c62-44e4-84af-bb0548d793ce"><ix:nonFraction unitRef="shares" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjdiNjJiZDZiNWE1ZTQwMmJhMGUyMzQwOGM3M2I2Y2JiXzEwOTk1MTE2Mjc4Nzc_1f599f06-63c7-49d8-b75d-d250032817d5">10,000</ix:nonFraction></ix:nonFraction> shares authorized and <ix:nonFraction unitRef="shares" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjdiNjJiZDZiNWE1ZTQwMmJhMGUyMzQwOGM3M2I2Y2JiXzEwOTk1MTE2Mjc4ODI_3aea053a-caf6-446f-b42a-0d8a9432223b"><ix:nonFraction unitRef="shares" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjdiNjJiZDZiNWE1ZTQwMmJhMGUyMzQwOGM3M2I2Y2JiXzEwOTk1MTE2Mjc4ODI_472a1818-f0bc-47f9-83e0-6ff9da400efc">no</ix:nonFraction></ix:nonFraction> shares issued</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMzYtMS0xLTEtMA_ad18083a-a3aa-4180-a0f8-6a93ad6cdc36">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMzYtMy0xLTEtMA_51c9e082-78d7-40b7-9123-bb53daf926a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjY4ZDY4NTQ5YjQ2NTRkYzBhODQ4YmU2NDhlNDM2MDRhXzEwOTk1MTE2Mjc5NzY_8712d35c-e19b-472c-9809-0c9bb956640e"><ix:nonFraction unitRef="usdPerShare" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjY4ZDY4NTQ5YjQ2NTRkYzBhODQ4YmU2NDhlNDM2MDRhXzEwOTk1MTE2Mjc5NzY_f37b90b6-608b-4249-a87f-a7a20a416707">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjY4ZDY4NTQ5YjQ2NTRkYzBhODQ4YmU2NDhlNDM2MDRhXzEwOTk1MTE2Mjc5ODY_0730b9a4-ad42-4c54-877b-651ea944834d"><ix:nonFraction unitRef="shares" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjY4ZDY4NTQ5YjQ2NTRkYzBhODQ4YmU2NDhlNDM2MDRhXzEwOTk1MTE2Mjc5ODY_4ef0b4bc-b1da-446f-80eb-4f9a476938a6">400,000</ix:nonFraction></ix:nonFraction> shares authorized; issued and outstanding: <ix:nonFraction unitRef="shares" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjY4ZDY4NTQ5YjQ2NTRkYzBhODQ4YmU2NDhlNDM2MDRhXzEwOTk1MTE2Mjc5NTE_69523b6a-c663-4e03-ab06-6bfd99d5f069"><ix:nonFraction unitRef="shares" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjY4ZDY4NTQ5YjQ2NTRkYzBhODQ4YmU2NDhlNDM2MDRhXzEwOTk1MTE2Mjc5NTE_ba3779ff-f600-48ad-b09a-7a900d2f6171">309,402</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjY4ZDY4NTQ5YjQ2NTRkYzBhODQ4YmU2NDhlNDM2MDRhXzEwOTk1MTE2Mjc5NjI_8f2221b6-c4e0-421a-a077-facd7ecccf1b"><ix:nonFraction unitRef="shares" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjY4ZDY4NTQ5YjQ2NTRkYzBhODQ4YmU2NDhlNDM2MDRhXzEwOTk1MTE2Mjc5NjI_9f5ab816-98a0-4645-96eb-64c27caf80b4">304,831</ix:nonFraction></ix:nonFraction> at September&#160;30, 2020 and December&#160;31, 2019, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMzctMS0xLTEtMA_984945a9-eb25-4d64-a5f9-ea45cb52fca0">309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMzctMy0xLTEtMA_e429110f-f9db-426c-aab8-16293ff2993d">305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMzgtMS0xLTEtMA_3532ea22-2edf-47df-ad20-a05c1e0dca14">2,321,441</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMzgtMy0xLTEtMA_b68ab873-0853-4e9c-9d86-23db985d0cc6">2,241,947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMzktMS0xLTEtMA_b834c722-9e42-46db-92ad-1fd3e04b29b3">6,239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMzktMy0xLTEtMA_fc2277f4-5e40-445a-9382-18eff30a0d45">3,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfNDAtMS0xLTEtMA_522a6152-6e63-4dae-b02d-de69446842f5">475,958</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfNDAtMy0xLTEtMA_5936b155-f7ee-464f-a86b-0cc006da851e">559,351</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 29.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfNDEtMS0xLTEtMA_f477b16c-8040-45f9-8ccd-e825ecc95703">1,852,031</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfNDEtMy0xLTEtMA_32504f6b-e594-4ff5-a5bd-a89b57bf7e19">1,685,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 29.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfNDItMS0xLTEtMA_612a5478-4057-4952-afad-1cec6a99e47f">2,111,043</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfNDItMy0xLTEtMA_4b147253-29ef-4015-926f-17585d594c0c">1,885,670</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i0283c6f517b447ec92f154ee691f4028_22"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.715%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.742%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia527955beb274c50967751e32dc17dff_D20200704-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMy0xLTEtMS0w_3d02242e-90d7-43a7-a7b3-c4c1edfb3bb3">168,587</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i663049bc589a41de99b922b6fb02f1bc_D20190629-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMy0zLTEtMS0w_fd819f17-a8c5-4a8b-a9bc-685488fb8b99">191,768</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefbb93ab12054c04a4d0d55ad1aaf502_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMy01LTEtMS0w_1d3efd23-055c-4446-a217-f43399b9d307">541,197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75b81eceef094c2d86c24a00c59294e1_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMy03LTEtMS0w_615778d9-fa15-4ef0-8eaa-441ec490a96c">565,024</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie72938b556dd42ada9b416a6b60b47fa_D20200704-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfNC0xLTEtMS0w_6703c1b4-4147-4871-a2d7-8a09d86fd89d">33,205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic55505ff13f844188fb0751728d84cce_D20190629-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfNC0zLTEtMS0w_6f130490-08cf-4313-a2a0-aa497f6b24b6">69,137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47085b4d4dbd42ac8d6b0c47740109da_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfNC01LTEtMS0w_79ff62aa-c761-40eb-8130-ecb165967708">113,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f01433b4094674bd5e812d8d00d234_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfNC03LTEtMS0w_7ae6e83b-58d8-46a3-81de-e5d792000ad9">132,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25bf6a1fad8f41f8b3dd9743b6494697_D20200704-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfNS0xLTEtMS0w_db9876f8-23df-4efd-a3cf-8c3930714713">29,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88aea9011a624e6ab196817bcb69590c_D20190629-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfNS0zLTEtMS0w_0f050580-54fc-4b47-b2c6-68d7784d122c">10,798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iced2a1e2c6a1480d8302a1285f8e233c_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfNS01LTEtMS0w_d9893e92-456b-4aa0-aa42-4b799ab0a0ce">62,971</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43a6c75a975a475a8220f03f17c813e5_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfNS03LTEtMS0w_49e693e5-97b7-47ca-874a-e97e9f598797">29,998</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfNi0xLTEtMS0w_ff19af56-07e7-4ec7-b06f-d81185f6e3d2">231,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfNi0zLTEtMS0w_e0886dd0-db54-4615-8aaf-2c5811affafc">271,703</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfNi01LTEtMS0w_f494c235-1440-49bb-83b5-2829fc0f5eb6">717,486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfNi03LTEtMS0w_0e30034c-5aab-4718-934e-923558b32ec6">727,465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfOC0xLTEtMS0w_3ff76d75-62a3-4677-b6dd-1e5e3ffda2f2">8,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfOC0zLTEtMS0w_bb2df2f9-1b6c-4ed0-b0c4-2e47de7bbec3">7,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfOC01LTEtMS0w_dcf4d975-b23b-4a53-bfbb-82a1294c9c67">27,235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfOC03LTEtMS0w_538040e9-e7bc-4c84-802f-370e4e9384c6">22,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfOS0xLTEtMS0w_6a6f355f-65cf-4c97-9b39-5ae17cd07bde">176,762</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfOS0zLTEtMS0w_13665dd9-3a9f-4e58-ab46-878ba0a48c8d">97,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfOS01LTEtMS0w_7a57a545-fc53-4624-ab75-1f0dc6f11d74">393,572</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfOS03LTEtMS0w_b63022a7-20db-4a94-b6fe-22b65549f1b0">242,516</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTAtMS0xLTEtMA_3ebc7dc8-af6a-4d1b-9385-6b3cb3ab2980">88,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTAtMy0xLTEtMA_c5d75a84-056e-4b4c-800c-f353d2b6bddd">51,265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTAtNS0xLTEtMA_7417b59f-48d0-49af-953e-6b154e8c6ba1">210,916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTAtNy0xLTEtMA_48792d91-b1c2-47ca-9b27-96bb04808da8">170,218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTEtMS0xLTEtMA_67fbff87-5435-4713-a578-8eb191a007d3">273,672</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTEtMy0xLTEtMA_059b2542-ed4f-4fce-a94f-08a5c8d5e8cc">156,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTEtNS0xLTEtMA_498ee8b8-b6a5-495c-b9ed-02fce8d2d5d4">631,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTEtNy0xLTEtMA_47983846-40c4-47d6-bc25-1bd9cb711ddd">435,311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTItMS0xLTEtMA_8afa3ce3-ce85-4117-b4be-434e8e2c4ff9">42,580</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTItMy0xLTEtMA_09dc68ab-f302-46bf-a234-da72ae971a82">115,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTItNS0xLTEtMA_00c77dfc-beac-4311-86d2-923e9fbaead3">85,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTItNy0xLTEtMA_42aa19ba-2c99-47d3-81a0-49a078cf66b7">292,154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTMtMS0xLTEtMA_964fc70a-8bc5-4918-aa27-3c2c608dd7d6">3,994</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTMtMy0xLTEtMA_364219f4-e474-4baa-899b-111409844ea9">7,191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTMtNS0xLTEtMA_1792c516-b575-429b-9f6e-9f5f562f4feb">16,376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTMtNy0xLTEtMA_0c148e8d-e02b-4c3e-addf-76c9d11345cf">20,253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTQtMS0xLTEtMA_6c0b7bfd-bbe3-4976-b0a3-89a56a08b9e6">565</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTQtMy0xLTEtMA_fbd0aa1b-0820-48e4-a161-c774976cee39">140</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTQtNS0xLTEtMA_04396dbc-7bc8-49cf-9ed1-d9e23f94488c">571</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTQtNy0xLTEtMA_c8992384-8e39-40f0-a5bd-5644ef31181f">688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTUtMS0xLTEtMA_40adb407-3a86-477c-9957-bf6122bfedbf">38,021</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTUtMy0xLTEtMA_f7d0a351-bd2f-4eba-a377-e13ce3c0ecf2">122,657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTUtNS0xLTEtMA_25d16113-3172-4bd1-82f1-01d7a00b3cf1">102,710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTUtNy0xLTEtMA_238884d7-1371-4b1f-8c5c-095b783f9898">313,095</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for (benefit from) income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTYtMS0xLTEtMA_1739398f-2e30-41eb-99d5-eda949cc55f9">5,981</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTYtMy0xLTEtMA_a3ff79e0-71d5-4c8a-a804-a7994c6f6156">25,205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTYtNS0xLTEtMA_e1c359b4-3057-4de6-9da6-e841565d597e">19,317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTYtNy0xLTEtMA_54180849-8d76-4f81-8ba1-6e025e9a8d6f">60,826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTctMS0xLTEtMA_e14fdd44-f91f-4aa8-8680-c1ce4c535495">32,040</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTctMy0xLTEtMA_c230d74c-b0e6-47c5-b0c6-2fc1d389f218">97,452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTctNS0xLTEtMA_abfa2d1e-5ccf-42b5-84d6-40e96d4bcd40">83,393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTctNy0xLTEtMA_9bcc5c2b-55a6-4d0e-b747-be683cc26c85">252,269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTktMS0xLTEtMA_7a3147de-aef6-4bfa-95f9-00cc4ada70f9">0.10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTktMy0xLTEtMA_d6849b2a-127a-4ef8-bca4-87bb5574df34">0.32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTktNS0xLTEtMA_0ce389e6-f463-4470-9f6f-0c0f57c77414">0.27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTktNy0xLTEtMA_2a713e4f-985b-45b8-92d1-f77166c3ab6c">0.84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMjAtMS0xLTEtMA_7f9a4c55-e401-442f-8fa4-105892c23951">0.10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMjAtMy0xLTEtMA_19789304-e307-47ab-b0c5-170978039f50">0.31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMjAtNS0xLTEtMA_7572123f-74b1-484b-8639-040d6b395680">0.26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMjAtNy0xLTEtMA_f7ec4ab4-79db-4afc-8e6d-1c9da65693e3">0.80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMjItMS0xLTEtMA_ad71f298-fb89-4ea2-b645-546a307bf799">309,116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMjItMy0xLTEtMA_383b0a50-bc8b-4cab-8407-0ed04091d0ff">303,268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMjItNS0xLTEtMA_5deb2c6c-2f08-4e8c-af99-133a8fd8a946">307,437</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMjItNy0xLTEtMA_0b59a1e4-7c19-4daf-b7a4-3eda28981bce">301,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMjMtMS0xLTEtMA_fcb6fbba-e5c5-420c-8a09-7c56dcf33bbc">309,116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMjMtMy0xLTEtMA_c3338bce-f879-430e-8cb2-db360f2f7110">315,453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMjMtNS0xLTEtMA_9f5610da-8468-45b6-9380-b8894e2003c2">317,495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMjMtNy0xLTEtMA_800cc155-a1ef-4247-98e3-c11eac534e2b">315,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.</span></div><div id="i0283c6f517b447ec92f154ee691f4028_25"></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.715%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.742%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yNS9mcmFnOjRiMDI4MTFlZDYxYzRmZTNhYjc0YmZiYTMxMjMxZTAzL3RhYmxlOjIxNmE4NzZkZjY1YTQwNTA4MGU1ZTczYmU4YjA4MWNkL3RhYmxlcmFuZ2U6MjE2YTg3NmRmNjVhNDA1MDgwZTVlNzNiZThiMDgxY2RfMi0xLTEtMS0w_e14fdd44-f91f-4aa8-8680-c1ce4c535495">32,040</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yNS9mcmFnOjRiMDI4MTFlZDYxYzRmZTNhYjc0YmZiYTMxMjMxZTAzL3RhYmxlOjIxNmE4NzZkZjY1YTQwNTA4MGU1ZTczYmU4YjA4MWNkL3RhYmxlcmFuZ2U6MjE2YTg3NmRmNjVhNDA1MDgwZTVlNzNiZThiMDgxY2RfMi0zLTEtMS0w_c230d74c-b0e6-47c5-b0c6-2fc1d389f218">97,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yNS9mcmFnOjRiMDI4MTFlZDYxYzRmZTNhYjc0YmZiYTMxMjMxZTAzL3RhYmxlOjIxNmE4NzZkZjY1YTQwNTA4MGU1ZTczYmU4YjA4MWNkL3RhYmxlcmFuZ2U6MjE2YTg3NmRmNjVhNDA1MDgwZTVlNzNiZThiMDgxY2RfMi01LTEtMS0w_abfa2d1e-5ccf-42b5-84d6-40e96d4bcd40">83,393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yNS9mcmFnOjRiMDI4MTFlZDYxYzRmZTNhYjc0YmZiYTMxMjMxZTAzL3RhYmxlOjIxNmE4NzZkZjY1YTQwNTA4MGU1ZTczYmU4YjA4MWNkL3RhYmxlcmFuZ2U6MjE2YTg3NmRmNjVhNDA1MDgwZTVlNzNiZThiMDgxY2RfMi03LTEtMS0w_9bcc5c2b-55a6-4d0e-b747-be683cc26c85">252,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gains (losses) on available-for-sale debt securities, net of tax impact of $<ix:nonFraction unitRef="usd" contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yNS9mcmFnOjRiMDI4MTFlZDYxYzRmZTNhYjc0YmZiYTMxMjMxZTAzL3RhYmxlOjIxNmE4NzZkZjY1YTQwNTA4MGU1ZTczYmU4YjA4MWNkL3RhYmxlcmFuZ2U6MjE2YTg3NmRmNjVhNDA1MDgwZTVlNzNiZThiMDgxY2RfNC0wLTEtMS0wL3RleHRyZWdpb246MWVjYmUzOGQ1NDljNDgyYWEwODlkMzJkMTJhZTRjOTRfNTQ5NzU1ODEzOTAyMw_63dcde30-4207-4506-8859-6f040741e95d">453</ix:nonFraction>, $(<ix:nonFraction unitRef="usd" contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yNS9mcmFnOjRiMDI4MTFlZDYxYzRmZTNhYjc0YmZiYTMxMjMxZTAzL3RhYmxlOjIxNmE4NzZkZjY1YTQwNTA4MGU1ZTczYmU4YjA4MWNkL3RhYmxlcmFuZ2U6MjE2YTg3NmRmNjVhNDA1MDgwZTVlNzNiZThiMDgxY2RfNC0wLTEtMS0wL3RleHRyZWdpb246MWVjYmUzOGQ1NDljNDgyYWEwODlkMzJkMTJhZTRjOTRfNTQ5NzU1ODEzOTAzMw_34055de9-1da2-4cd4-9a19-b84c16b1f8a6">129</ix:nonFraction>), $(<ix:nonFraction unitRef="usd" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yNS9mcmFnOjRiMDI4MTFlZDYxYzRmZTNhYjc0YmZiYTMxMjMxZTAzL3RhYmxlOjIxNmE4NzZkZjY1YTQwNTA4MGU1ZTczYmU4YjA4MWNkL3RhYmxlcmFuZ2U6MjE2YTg3NmRmNjVhNDA1MDgwZTVlNzNiZThiMDgxY2RfNC0wLTEtMS0wL3RleHRyZWdpb246MWVjYmUzOGQ1NDljNDgyYWEwODlkMzJkMTJhZTRjOTRfNTQ5NzU1ODEzOTA0Mw_ff3cea69-a05e-4a7a-953e-3a2b5f9620d0">893</ix:nonFraction>) and $(<ix:nonFraction unitRef="usd" contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yNS9mcmFnOjRiMDI4MTFlZDYxYzRmZTNhYjc0YmZiYTMxMjMxZTAzL3RhYmxlOjIxNmE4NzZkZjY1YTQwNTA4MGU1ZTczYmU4YjA4MWNkL3RhYmxlcmFuZ2U6MjE2YTg3NmRmNjVhNDA1MDgwZTVlNzNiZThiMDgxY2RfNC0wLTEtMS0wL3RleHRyZWdpb246MWVjYmUzOGQ1NDljNDgyYWEwODlkMzJkMTJhZTRjOTRfNTQ5NzU1ODEzOTA1Mw_045a1430-e92a-4af1-9623-939cd9c9b731">936</ix:nonFraction>), respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yNS9mcmFnOjRiMDI4MTFlZDYxYzRmZTNhYjc0YmZiYTMxMjMxZTAzL3RhYmxlOjIxNmE4NzZkZjY1YTQwNTA4MGU1ZTczYmU4YjA4MWNkL3RhYmxlcmFuZ2U6MjE2YTg3NmRmNjVhNDA1MDgwZTVlNzNiZThiMDgxY2RfNC0xLTEtMS0w_ca4be55d-65f3-4301-be7a-6feead480ae3">1,601</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yNS9mcmFnOjRiMDI4MTFlZDYxYzRmZTNhYjc0YmZiYTMxMjMxZTAzL3RhYmxlOjIxNmE4NzZkZjY1YTQwNTA4MGU1ZTczYmU4YjA4MWNkL3RhYmxlcmFuZ2U6MjE2YTg3NmRmNjVhNDA1MDgwZTVlNzNiZThiMDgxY2RfNC0zLTEtMS0w_df59e7d2-0dd5-442d-8891-e383b7f2411f">461</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yNS9mcmFnOjRiMDI4MTFlZDYxYzRmZTNhYjc0YmZiYTMxMjMxZTAzL3RhYmxlOjIxNmE4NzZkZjY1YTQwNTA4MGU1ZTczYmU4YjA4MWNkL3RhYmxlcmFuZ2U6MjE2YTg3NmRmNjVhNDA1MDgwZTVlNzNiZThiMDgxY2RfNC01LTEtMS0w_b869689c-6c48-4b9f-a279-8b7cc4e2b058">3,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yNS9mcmFnOjRiMDI4MTFlZDYxYzRmZTNhYjc0YmZiYTMxMjMxZTAzL3RhYmxlOjIxNmE4NzZkZjY1YTQwNTA4MGU1ZTczYmU4YjA4MWNkL3RhYmxlcmFuZ2U6MjE2YTg3NmRmNjVhNDA1MDgwZTVlNzNiZThiMDgxY2RfNC03LTEtMS0w_add737e4-48fe-42a9-8767-4051927f5b51">3,369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income (loss)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yNS9mcmFnOjRiMDI4MTFlZDYxYzRmZTNhYjc0YmZiYTMxMjMxZTAzL3RhYmxlOjIxNmE4NzZkZjY1YTQwNTA4MGU1ZTczYmU4YjA4MWNkL3RhYmxlcmFuZ2U6MjE2YTg3NmRmNjVhNDA1MDgwZTVlNzNiZThiMDgxY2RfNi0xLTEtMS0w_1fefd1ae-e074-49f2-97d3-8b2794303963">33,641</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yNS9mcmFnOjRiMDI4MTFlZDYxYzRmZTNhYjc0YmZiYTMxMjMxZTAzL3RhYmxlOjIxNmE4NzZkZjY1YTQwNTA4MGU1ZTczYmU4YjA4MWNkL3RhYmxlcmFuZ2U6MjE2YTg3NmRmNjVhNDA1MDgwZTVlNzNiZThiMDgxY2RfNi0zLTEtMS0w_88c9d98e-91d6-4a8d-9192-cb60294b59ca">97,913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yNS9mcmFnOjRiMDI4MTFlZDYxYzRmZTNhYjc0YmZiYTMxMjMxZTAzL3RhYmxlOjIxNmE4NzZkZjY1YTQwNTA4MGU1ZTczYmU4YjA4MWNkL3RhYmxlcmFuZ2U6MjE2YTg3NmRmNjVhNDA1MDgwZTVlNzNiZThiMDgxY2RfNi01LTEtMS0w_39aa7fa5-3fda-4b07-ab7b-39a8c76ea291">86,563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yNS9mcmFnOjRiMDI4MTFlZDYxYzRmZTNhYjc0YmZiYTMxMjMxZTAzL3RhYmxlOjIxNmE4NzZkZjY1YTQwNTA4MGU1ZTczYmU4YjA4MWNkL3RhYmxlcmFuZ2U6MjE2YTg3NmRmNjVhNDA1MDgwZTVlNzNiZThiMDgxY2RfNi03LTEtMS0w_ebe005ee-bb78-46dd-8d8a-31d069d22e3e">255,638</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i0283c6f517b447ec92f154ee691f4028_31"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.307%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.439%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.680%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2020</span></td></tr><tr style="height:26pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June&#160;30, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i316676d09b8a43edb69e0d908574a669_I20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOmJjNDJlOGY4OTBhYTQ5NjJiYTdhZjk5OTgwZjczZTEyL3RhYmxlcmFuZ2U6YmM0MmU4Zjg5MGFhNDk2MmJhN2FmOTk5ODBmNzNlMTJfMjMtMS0xLTEtMA_b6c56174-e168-454b-a4bb-47c3b8cd0dfe">308,886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i316676d09b8a43edb69e0d908574a669_I20200703" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOmJjNDJlOGY4OTBhYTQ5NjJiYTdhZjk5OTgwZjczZTEyL3RhYmxlcmFuZ2U6YmM0MmU4Zjg5MGFhNDk2MmJhN2FmOTk5ODBmNzNlMTJfMjMtMy0xLTEtMA_1da14fb5-2fb0-49f2-9f32-76829fc6860c">309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02f1924710584639831de419a08af15c_I20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOmJjNDJlOGY4OTBhYTQ5NjJiYTdhZjk5OTgwZjczZTEyL3RhYmxlcmFuZ2U6YmM0MmU4Zjg5MGFhNDk2MmJhN2FmOTk5ODBmNzNlMTJfMjMtNS0xLTEtMA_7833a383-7d9d-4ebe-bdbd-84642912877b">2,269,093</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46f2d57ee3234492ae78920271a99b39_I20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOmJjNDJlOGY4OTBhYTQ5NjJiYTdhZjk5OTgwZjczZTEyL3RhYmxlcmFuZ2U6YmM0MmU4Zjg5MGFhNDk2MmJhN2FmOTk5ODBmNzNlMTJfMjMtNy0xLTEtMA_19b56244-a6d5-42c9-aca2-d5e706f3ea5f">7,840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49c13447908e420384b91c447fbe71a9_I20200703" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOmJjNDJlOGY4OTBhYTQ5NjJiYTdhZjk5OTgwZjczZTEyL3RhYmxlcmFuZ2U6YmM0MmU4Zjg5MGFhNDk2MmJhN2FmOTk5ODBmNzNlMTJfMjMtOS0xLTEtMA_1082d5d4-1561-47ca-874b-d99ff78881a3">443,918</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e76b251fbeb42f3a7cc3df6ca3a4230_I20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOmJjNDJlOGY4OTBhYTQ5NjJiYTdhZjk5OTgwZjczZTEyL3RhYmxlcmFuZ2U6YmM0MmU4Zjg5MGFhNDk2MmJhN2FmOTk5ODBmNzNlMTJfMjMtMTEtMS0xLTA_98980725-66f3-4ce2-8940-7c124e391ea2">1,833,324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic40a4137775f410490cca3ab2ec24c82_D20200704-20201002" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOmJjNDJlOGY4OTBhYTQ5NjJiYTdhZjk5OTgwZjczZTEyL3RhYmxlcmFuZ2U6YmM0MmU4Zjg5MGFhNDk2MmJhN2FmOTk5ODBmNzNlMTJfMjQtOS0xLTEtMA_a334065c-4ac4-4d96-aa87-ce8e04be0742">32,040</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOmJjNDJlOGY4OTBhYTQ5NjJiYTdhZjk5OTgwZjczZTEyL3RhYmxlcmFuZ2U6YmM0MmU4Zjg5MGFhNDk2MmJhN2FmOTk5ODBmNzNlMTJfMjQtMTEtMS0xLTA_234ae639-050e-4885-b1df-ea698571936e">32,040</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie823ac87cfcf453da0d0ee469a5208a4_D20200704-20201002" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOmJjNDJlOGY4OTBhYTQ5NjJiYTdhZjk5OTgwZjczZTEyL3RhYmxlcmFuZ2U6YmM0MmU4Zjg5MGFhNDk2MmJhN2FmOTk5ODBmNzNlMTJfMjUtNy0xLTEtMA_1b5d1a32-5a22-439c-abca-f130a24e49c0">1,601</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOmJjNDJlOGY4OTBhYTQ5NjJiYTdhZjk5OTgwZjczZTEyL3RhYmxlcmFuZ2U6YmM0MmU4Zjg5MGFhNDk2MmJhN2FmOTk5ODBmNzNlMTJfMjUtMTEtMS0xLTA_43161a5f-2254-4c2d-be7d-f240545cf07b">1,601</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under equity incentive and stock purchase plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0f63bc8277444a159ea4d49770eaf477_D20200704-20201002" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOmJjNDJlOGY4OTBhYTQ5NjJiYTdhZjk5OTgwZjczZTEyL3RhYmxlcmFuZ2U6YmM0MmU4Zjg5MGFhNDk2MmJhN2FmOTk5ODBmNzNlMTJfMjYtMS0xLTEtMA_49354f7d-3621-424a-953d-0913f17fc749">516</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97e9d031387d43198b6f05ff2861f3ab_D20200704-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOmJjNDJlOGY4OTBhYTQ5NjJiYTdhZjk5OTgwZjczZTEyL3RhYmxlcmFuZ2U6YmM0MmU4Zjg5MGFhNDk2MmJhN2FmOTk5ODBmNzNlMTJfMjYtNS0xLTEtMA_f89cbef3-de11-436e-9996-5d1fd6b535f9">1,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOmJjNDJlOGY4OTBhYTQ5NjJiYTdhZjk5OTgwZjczZTEyL3RhYmxlcmFuZ2U6YmM0MmU4Zjg5MGFhNDk2MmJhN2FmOTk5ODBmNzNlMTJfMjYtMTEtMS0xLTA_b30b761f-323e-4fe4-a475-1937340503f6">1,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock transactions associated with taxes withheld on equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97e9d031387d43198b6f05ff2861f3ab_D20200704-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOmJjNDJlOGY4OTBhYTQ5NjJiYTdhZjk5OTgwZjczZTEyL3RhYmxlcmFuZ2U6YmM0MmU4Zjg5MGFhNDk2MmJhN2FmOTk5ODBmNzNlMTJfMjctNS0xLTEtMA_215ab77e-c542-41bb-98e3-903ecdffdd80">5,179</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOmJjNDJlOGY4OTBhYTQ5NjJiYTdhZjk5OTgwZjczZTEyL3RhYmxlcmFuZ2U6YmM0MmU4Zjg5MGFhNDk2MmJhN2FmOTk5ODBmNzNlMTJfMjctMTEtMS0xLTA_bfb29a85-50f8-44d0-82b4-39ffdced8fe3">5,179</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97e9d031387d43198b6f05ff2861f3ab_D20200704-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOmJjNDJlOGY4OTBhYTQ5NjJiYTdhZjk5OTgwZjczZTEyL3RhYmxlcmFuZ2U6YmM0MmU4Zjg5MGFhNDk2MmJhN2FmOTk5ODBmNzNlMTJfMjgtNS0xLTEtMA_a3f64efe-c993-4ba8-b928-7640ac1d023e">55,655</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOmJjNDJlOGY4OTBhYTQ5NjJiYTdhZjk5OTgwZjczZTEyL3RhYmxlcmFuZ2U6YmM0MmU4Zjg5MGFhNDk2MmJhN2FmOTk5ODBmNzNlMTJfMjgtMTEtMS0xLTA_fa1912ca-353e-4ef7-b857-203cd66e7a95">55,655</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September&#160;30, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ida20c4eb650547409d09265abf22aef1_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOmJjNDJlOGY4OTBhYTQ5NjJiYTdhZjk5OTgwZjczZTEyL3RhYmxlcmFuZ2U6YmM0MmU4Zjg5MGFhNDk2MmJhN2FmOTk5ODBmNzNlMTJfMjktMS0xLTEtMA_3954f4e8-42e9-4d68-9517-f217255ac1e3">309,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida20c4eb650547409d09265abf22aef1_I20201002" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOmJjNDJlOGY4OTBhYTQ5NjJiYTdhZjk5OTgwZjczZTEyL3RhYmxlcmFuZ2U6YmM0MmU4Zjg5MGFhNDk2MmJhN2FmOTk5ODBmNzNlMTJfMjktMy0xLTEtMA_2a4e81be-05ec-45aa-a949-63ddc249d719">309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a1eac7bffc9475a9bbdda86813fd7ee_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOmJjNDJlOGY4OTBhYTQ5NjJiYTdhZjk5OTgwZjczZTEyL3RhYmxlcmFuZ2U6YmM0MmU4Zjg5MGFhNDk2MmJhN2FmOTk5ODBmNzNlMTJfMjktNS0xLTEtMA_e4239190-006e-4ab5-87b2-49829c6cdb8a">2,321,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7bf961275044b01a0c4a9ccebad588f_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOmJjNDJlOGY4OTBhYTQ5NjJiYTdhZjk5OTgwZjczZTEyL3RhYmxlcmFuZ2U6YmM0MmU4Zjg5MGFhNDk2MmJhN2FmOTk5ODBmNzNlMTJfMjktNy0xLTEtMA_b006b6df-aff2-4b56-a73b-50442693667f">6,239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a5031970ae845a8b4d0e06e3e6e4934_I20201002" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOmJjNDJlOGY4OTBhYTQ5NjJiYTdhZjk5OTgwZjczZTEyL3RhYmxlcmFuZ2U6YmM0MmU4Zjg5MGFhNDk2MmJhN2FmOTk5ODBmNzNlMTJfMjktOS0xLTEtMA_4875605d-bc3f-4382-b573-c0b8b338c1d9">475,958</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOmJjNDJlOGY4OTBhYTQ5NjJiYTdhZjk5OTgwZjczZTEyL3RhYmxlcmFuZ2U6YmM0MmU4Zjg5MGFhNDk2MmJhN2FmOTk5ODBmNzNlMTJfMjktMTEtMS0xLTA_dcdce783-81a8-4cca-9fbb-ff0dcd2df208">1,852,031</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.307%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.439%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.680%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30, 2019</span></td></tr><tr style="height:26pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June&#160;30, 2019</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6c1980f2c4f24d4baa81b1ccba73febb_I20190628" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjFhYzJmMjE2ZTUxNjQyMDg4OGUzZTI1ODdmY2Y2NzljL3RhYmxlcmFuZ2U6MWFjMmYyMTZlNTE2NDIwODg4ZTNlMjU4N2ZjZjY3OWNfMjMtMS0xLTEtMA_daec6fc7-d8bf-4680-8194-d60ed13a8c5f">302,785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c1980f2c4f24d4baa81b1ccba73febb_I20190628" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjFhYzJmMjE2ZTUxNjQyMDg4OGUzZTI1ODdmY2Y2NzljL3RhYmxlcmFuZ2U6MWFjMmYyMTZlNTE2NDIwODg4ZTNlMjU4N2ZjZjY3OWNfMjMtMy0xLTEtMA_e2f996d6-0583-490a-826e-c2f129896436">303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i013e4989ee6443b9afcc82a956f959f9_I20190628" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjFhYzJmMjE2ZTUxNjQyMDg4OGUzZTI1ODdmY2Y2NzljL3RhYmxlcmFuZ2U6MWFjMmYyMTZlNTE2NDIwODg4ZTNlMjU4N2ZjZjY3OWNfMjMtNS0xLTEtMA_059d6d41-587d-4911-a790-c8b66ddf88a8">2,211,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0dbb32931e346bfae3a3ca347f978ab_I20190628" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjFhYzJmMjE2ZTUxNjQyMDg4OGUzZTI1ODdmY2Y2NzljL3RhYmxlcmFuZ2U6MWFjMmYyMTZlNTE2NDIwODg4ZTNlMjU4N2ZjZjY3OWNfMjMtNy0xLTEtMA_774e747f-0605-4e20-9a04-765af53b80db">2,207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ad7ce0b72c9496489178748e0770609_I20190628" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjFhYzJmMjE2ZTUxNjQyMDg4OGUzZTI1ODdmY2Y2NzljL3RhYmxlcmFuZ2U6MWFjMmYyMTZlNTE2NDIwODg4ZTNlMjU4N2ZjZjY3OWNfMjMtOS0xLTEtMA_ffe26ae2-963d-4b4b-9fa1-78ba23a5ee17">725,546</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if77bb429cb9c49c7a19d55f3f313ee70_I20190628" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjFhYzJmMjE2ZTUxNjQyMDg4OGUzZTI1ODdmY2Y2NzljL3RhYmxlcmFuZ2U6MWFjMmYyMTZlNTE2NDIwODg4ZTNlMjU4N2ZjZjY3OWNfMjMtMTEtMS0xLTA_2856e9ec-0552-4df8-a465-cab1523b5650">1,488,632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd7f360120b34b36ae5e37843a1f7fd3_D20190629-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjFhYzJmMjE2ZTUxNjQyMDg4OGUzZTI1ODdmY2Y2NzljL3RhYmxlcmFuZ2U6MWFjMmYyMTZlNTE2NDIwODg4ZTNlMjU4N2ZjZjY3OWNfMjQtOS0xLTEtMA_12998603-4406-4d97-af95-620b0b7d442c">97,452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjFhYzJmMjE2ZTUxNjQyMDg4OGUzZTI1ODdmY2Y2NzljL3RhYmxlcmFuZ2U6MWFjMmYyMTZlNTE2NDIwODg4ZTNlMjU4N2ZjZjY3OWNfMjQtMTEtMS0xLTA_a6cafd49-45d7-4e62-a7c2-787f2174432d">97,452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib60dcfd8f46a44b6b0c8dfc25001dd5e_D20190629-20190927" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjFhYzJmMjE2ZTUxNjQyMDg4OGUzZTI1ODdmY2Y2NzljL3RhYmxlcmFuZ2U6MWFjMmYyMTZlNTE2NDIwODg4ZTNlMjU4N2ZjZjY3OWNfMjUtNy0xLTEtMA_08ba4f02-5843-47de-8506-006d67a47734">461</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjFhYzJmMjE2ZTUxNjQyMDg4OGUzZTI1ODdmY2Y2NzljL3RhYmxlcmFuZ2U6MWFjMmYyMTZlNTE2NDIwODg4ZTNlMjU4N2ZjZjY3OWNfMjUtMTEtMS0xLTA_247f524e-d9f9-4496-b5d4-d30f0144b57d">461</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under equity incentive and stock purchase plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8ab198a265ed4c0494a01c26fc2f82c7_D20190629-20190927" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjFhYzJmMjE2ZTUxNjQyMDg4OGUzZTI1ODdmY2Y2NzljL3RhYmxlcmFuZ2U6MWFjMmYyMTZlNTE2NDIwODg4ZTNlMjU4N2ZjZjY3OWNfMjYtMS0xLTEtMA_9f54dd95-8942-4a67-a6e0-13d58f51939b">991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ab198a265ed4c0494a01c26fc2f82c7_D20190629-20190927" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjFhYzJmMjE2ZTUxNjQyMDg4OGUzZTI1ODdmY2Y2NzljL3RhYmxlcmFuZ2U6MWFjMmYyMTZlNTE2NDIwODg4ZTNlMjU4N2ZjZjY3OWNfMjYtMy0xLTEtMA_20603cc5-91c9-460a-b0b5-5a08cc08a2ae">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1082fd4f150346c182b846e3072e0c3f_D20190629-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjFhYzJmMjE2ZTUxNjQyMDg4OGUzZTI1ODdmY2Y2NzljL3RhYmxlcmFuZ2U6MWFjMmYyMTZlNTE2NDIwODg4ZTNlMjU4N2ZjZjY3OWNfMjYtNS0xLTEtMA_66e8a85b-229e-4d72-8450-c4609087c7af">4,967</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjFhYzJmMjE2ZTUxNjQyMDg4OGUzZTI1ODdmY2Y2NzljL3RhYmxlcmFuZ2U6MWFjMmYyMTZlNTE2NDIwODg4ZTNlMjU4N2ZjZjY3OWNfMjYtMTEtMS0xLTA_b09ad653-b64c-4b60-9418-097ee3a4a0e2">4,968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock transactions associated with taxes withheld on equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1082fd4f150346c182b846e3072e0c3f_D20190629-20190927" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjFhYzJmMjE2ZTUxNjQyMDg4OGUzZTI1ODdmY2Y2NzljL3RhYmxlcmFuZ2U6MWFjMmYyMTZlNTE2NDIwODg4ZTNlMjU4N2ZjZjY3OWNfMjctNS0xLTEtMA_94d0a2ac-8062-4600-bf6a-588d4e2b8c16">935</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjFhYzJmMjE2ZTUxNjQyMDg4OGUzZTI1ODdmY2Y2NzljL3RhYmxlcmFuZ2U6MWFjMmYyMTZlNTE2NDIwODg4ZTNlMjU4N2ZjZjY3OWNfMjctMTEtMS0xLTA_9d7741c8-160f-45e8-bc83-88a890a0eb9f">935</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1082fd4f150346c182b846e3072e0c3f_D20190629-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjFhYzJmMjE2ZTUxNjQyMDg4OGUzZTI1ODdmY2Y2NzljL3RhYmxlcmFuZ2U6MWFjMmYyMTZlNTE2NDIwODg4ZTNlMjU4N2ZjZjY3OWNfMjgtNS0xLTEtMA_bedfe1cc-6197-4006-970b-e94907944d7e">13,139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjFhYzJmMjE2ZTUxNjQyMDg4OGUzZTI1ODdmY2Y2NzljL3RhYmxlcmFuZ2U6MWFjMmYyMTZlNTE2NDIwODg4ZTNlMjU4N2ZjZjY3OWNfMjgtMTEtMS0xLTA_e5eb2484-c8ed-4e51-a97c-1a830694bdbc">13,139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September&#160;30, 2019</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i05f14b5dcf314304b309c5e87df9f50a_I20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjFhYzJmMjE2ZTUxNjQyMDg4OGUzZTI1ODdmY2Y2NzljL3RhYmxlcmFuZ2U6MWFjMmYyMTZlNTE2NDIwODg4ZTNlMjU4N2ZjZjY3OWNfMjktMS0xLTEtMA_df5add31-4497-478d-bc14-07cbbef61a6d">303,776</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f14b5dcf314304b309c5e87df9f50a_I20190927" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjFhYzJmMjE2ZTUxNjQyMDg4OGUzZTI1ODdmY2Y2NzljL3RhYmxlcmFuZ2U6MWFjMmYyMTZlNTE2NDIwODg4ZTNlMjU4N2ZjZjY3OWNfMjktMy0xLTEtMA_95ef1792-5b75-4ec2-aff1-08e9dbb36626">304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6f2cb1dfbd41acbc289114955cd416_I20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjFhYzJmMjE2ZTUxNjQyMDg4OGUzZTI1ODdmY2Y2NzljL3RhYmxlcmFuZ2U6MWFjMmYyMTZlNTE2NDIwODg4ZTNlMjU4N2ZjZjY3OWNfMjktNS0xLTEtMA_7dd3c7fd-a8ce-441a-aa27-e786c9a3e51d">2,228,839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dac2e6ea3d14a2e8cc5b92c6af71211_I20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjFhYzJmMjE2ZTUxNjQyMDg4OGUzZTI1ODdmY2Y2NzljL3RhYmxlcmFuZ2U6MWFjMmYyMTZlNTE2NDIwODg4ZTNlMjU4N2ZjZjY3OWNfMjktNy0xLTEtMA_68ac871f-f5ac-4e5c-9fcd-4ae244fe9b94">2,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic827287aa3294c6a883bc9d0b8a0623f_I20190927" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjFhYzJmMjE2ZTUxNjQyMDg4OGUzZTI1ODdmY2Y2NzljL3RhYmxlcmFuZ2U6MWFjMmYyMTZlNTE2NDIwODg4ZTNlMjU4N2ZjZjY3OWNfMjktOS0xLTEtMA_6718163b-6d06-45bb-bc3d-35651d81e2f6">628,094</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34bbe41183cc4f96afa896c1d7f86bb3_I20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjFhYzJmMjE2ZTUxNjQyMDg4OGUzZTI1ODdmY2Y2NzljL3RhYmxlcmFuZ2U6MWFjMmYyMTZlNTE2NDIwODg4ZTNlMjU4N2ZjZjY3OWNfMjktMTEtMS0xLTA_62661179-25c1-4da4-a110-04941df5c1c7">1,603,717</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Continued on next page</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY - continued</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.307%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.439%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.680%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30, 2020</span></td></tr><tr style="height:26pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2019</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1f39a5eecfd64bbdb16dc650b0f43744_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjdjYzQyNDI1NjMzOTRhOGY4OWM5NjkyOTg2Mjc0MGI4L3RhYmxlcmFuZ2U6N2NjNDI0MjU2MzM5NGE4Zjg5Yzk2OTI5ODYyNzQwYjhfMTEtMS0xLTEtMA_8d9bc777-8f5b-40df-8dfb-ea850744577c">304,831</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f39a5eecfd64bbdb16dc650b0f43744_I20200103" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjdjYzQyNDI1NjMzOTRhOGY4OWM5NjkyOTg2Mjc0MGI4L3RhYmxlcmFuZ2U6N2NjNDI0MjU2MzM5NGE4Zjg5Yzk2OTI5ODYyNzQwYjhfMTEtMy0xLTEtMA_0d55f348-6a68-4090-9841-9223f1bb333a">305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8909ade88d7423e92687245874b7f72_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjdjYzQyNDI1NjMzOTRhOGY4OWM5NjkyOTg2Mjc0MGI4L3RhYmxlcmFuZ2U6N2NjNDI0MjU2MzM5NGE4Zjg5Yzk2OTI5ODYyNzQwYjhfMTEtNS0xLTEtMA_9a35e950-988c-4922-bf3b-884e8934435d">2,241,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6b255ea4abe49edafb55d811bcad05b_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjdjYzQyNDI1NjMzOTRhOGY4OWM5NjkyOTg2Mjc0MGI4L3RhYmxlcmFuZ2U6N2NjNDI0MjU2MzM5NGE4Zjg5Yzk2OTI5ODYyNzQwYjhfMTEtNy0xLTEtMA_874a494c-1c2e-4f20-8bbd-5e8fb929239e">3,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2614e82c41c1401c802f3cfcc0fa0efe_I20200103" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjdjYzQyNDI1NjMzOTRhOGY4OWM5NjkyOTg2Mjc0MGI4L3RhYmxlcmFuZ2U6N2NjNDI0MjU2MzM5NGE4Zjg5Yzk2OTI5ODYyNzQwYjhfMTEtOS0xLTEtMA_cf9ca389-2cba-42ff-9fdc-17299a419b9c">559,351</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjdjYzQyNDI1NjMzOTRhOGY4OWM5NjkyOTg2Mjc0MGI4L3RhYmxlcmFuZ2U6N2NjNDI0MjU2MzM5NGE4Zjg5Yzk2OTI5ODYyNzQwYjhfMTEtMTEtMS0xLTA_24f43b4a-7fa0-4ca9-b45b-541c8906a70d">1,685,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5ea39c6afc94359bbe264fb14b43e10_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjdjYzQyNDI1NjMzOTRhOGY4OWM5NjkyOTg2Mjc0MGI4L3RhYmxlcmFuZ2U6N2NjNDI0MjU2MzM5NGE4Zjg5Yzk2OTI5ODYyNzQwYjhfMTItOS0xLTEtMA_2c2f6b99-d271-4ff9-a722-be8b85be4247">83,393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjdjYzQyNDI1NjMzOTRhOGY4OWM5NjkyOTg2Mjc0MGI4L3RhYmxlcmFuZ2U6N2NjNDI0MjU2MzM5NGE4Zjg5Yzk2OTI5ODYyNzQwYjhfMTItMTEtMS0xLTA_dd1e5e9c-9eab-4c28-b62a-65996cf9347a">83,393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb2053635ce46b7b040cfe89917a2b4_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjdjYzQyNDI1NjMzOTRhOGY4OWM5NjkyOTg2Mjc0MGI4L3RhYmxlcmFuZ2U6N2NjNDI0MjU2MzM5NGE4Zjg5Yzk2OTI5ODYyNzQwYjhfMTMtNy0xLTEtMA_7f0930ee-968a-4d01-b168-4c433d920cf9">3,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjdjYzQyNDI1NjMzOTRhOGY4OWM5NjkyOTg2Mjc0MGI4L3RhYmxlcmFuZ2U6N2NjNDI0MjU2MzM5NGE4Zjg5Yzk2OTI5ODYyNzQwYjhfMTMtMTEtMS0xLTA_4f3110dc-8d21-4317-a59a-db37b65880b7">3,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under equity incentive and stock purchase plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id485c543ae654a6fa7b0799bc9c76368_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjdjYzQyNDI1NjMzOTRhOGY4OWM5NjkyOTg2Mjc0MGI4L3RhYmxlcmFuZ2U6N2NjNDI0MjU2MzM5NGE4Zjg5Yzk2OTI5ODYyNzQwYjhfMTQtMS0xLTEtMA_b846d63c-a140-4261-88da-20aaf799d37c">4,571</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id485c543ae654a6fa7b0799bc9c76368_D20200104-20201002" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjdjYzQyNDI1NjMzOTRhOGY4OWM5NjkyOTg2Mjc0MGI4L3RhYmxlcmFuZ2U6N2NjNDI0MjU2MzM5NGE4Zjg5Yzk2OTI5ODYyNzQwYjhfMTQtMy0xLTEtMA_c98c83df-2a37-4bd4-aa9b-682c11807d68">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i168c5944094040729529b381e8529300_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjdjYzQyNDI1NjMzOTRhOGY4OWM5NjkyOTg2Mjc0MGI4L3RhYmxlcmFuZ2U6N2NjNDI0MjU2MzM5NGE4Zjg5Yzk2OTI5ODYyNzQwYjhfMTQtNS0xLTEtMA_07a85213-4243-4fb0-8205-9b18ea43501f">19,823</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjdjYzQyNDI1NjMzOTRhOGY4OWM5NjkyOTg2Mjc0MGI4L3RhYmxlcmFuZ2U6N2NjNDI0MjU2MzM5NGE4Zjg5Yzk2OTI5ODYyNzQwYjhfMTQtMTEtMS0xLTA_b7132eba-a666-4cb0-a734-9572fb878ef4">19,827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock transactions associated with taxes withheld on equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i168c5944094040729529b381e8529300_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjdjYzQyNDI1NjMzOTRhOGY4OWM5NjkyOTg2Mjc0MGI4L3RhYmxlcmFuZ2U6N2NjNDI0MjU2MzM5NGE4Zjg5Yzk2OTI5ODYyNzQwYjhfMTUtNS0xLTEtMA_48a0eff1-6417-4fae-a475-d02181994aa1">26,120</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjdjYzQyNDI1NjMzOTRhOGY4OWM5NjkyOTg2Mjc0MGI4L3RhYmxlcmFuZ2U6N2NjNDI0MjU2MzM5NGE4Zjg5Yzk2OTI5ODYyNzQwYjhfMTUtMTEtMS0xLTA_5d8a0860-c4a4-406a-b4e3-ced19ffa14b1">26,120</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i168c5944094040729529b381e8529300_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjdjYzQyNDI1NjMzOTRhOGY4OWM5NjkyOTg2Mjc0MGI4L3RhYmxlcmFuZ2U6N2NjNDI0MjU2MzM5NGE4Zjg5Yzk2OTI5ODYyNzQwYjhfMTYtNS0xLTEtMA_9e9186b2-36c2-44b6-9be4-6775a6e08684">85,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjdjYzQyNDI1NjMzOTRhOGY4OWM5NjkyOTg2Mjc0MGI4L3RhYmxlcmFuZ2U6N2NjNDI0MjU2MzM5NGE4Zjg5Yzk2OTI5ODYyNzQwYjhfMTYtMTEtMS0xLTA_f89ab3a2-7fbc-47ca-aee6-ea0c410181e3">85,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September&#160;30, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ida20c4eb650547409d09265abf22aef1_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjdjYzQyNDI1NjMzOTRhOGY4OWM5NjkyOTg2Mjc0MGI4L3RhYmxlcmFuZ2U6N2NjNDI0MjU2MzM5NGE4Zjg5Yzk2OTI5ODYyNzQwYjhfMTctMS0xLTEtMA_d725fcb5-968b-43cc-9c73-04baccf2a442">309,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida20c4eb650547409d09265abf22aef1_I20201002" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjdjYzQyNDI1NjMzOTRhOGY4OWM5NjkyOTg2Mjc0MGI4L3RhYmxlcmFuZ2U6N2NjNDI0MjU2MzM5NGE4Zjg5Yzk2OTI5ODYyNzQwYjhfMTctMy0xLTEtMA_2fe1f7f1-c0e6-4827-99e8-d21e055b4cfe">309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a1eac7bffc9475a9bbdda86813fd7ee_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjdjYzQyNDI1NjMzOTRhOGY4OWM5NjkyOTg2Mjc0MGI4L3RhYmxlcmFuZ2U6N2NjNDI0MjU2MzM5NGE4Zjg5Yzk2OTI5ODYyNzQwYjhfMTctNS0xLTEtMA_b2b4b382-35cc-4948-a568-5d175f2fddc6">2,321,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7bf961275044b01a0c4a9ccebad588f_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjdjYzQyNDI1NjMzOTRhOGY4OWM5NjkyOTg2Mjc0MGI4L3RhYmxlcmFuZ2U6N2NjNDI0MjU2MzM5NGE4Zjg5Yzk2OTI5ODYyNzQwYjhfMTctNy0xLTEtMA_7fdb961c-d8bd-4c09-a6a4-dad3865f3720">6,239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a5031970ae845a8b4d0e06e3e6e4934_I20201002" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjdjYzQyNDI1NjMzOTRhOGY4OWM5NjkyOTg2Mjc0MGI4L3RhYmxlcmFuZ2U6N2NjNDI0MjU2MzM5NGE4Zjg5Yzk2OTI5ODYyNzQwYjhfMTctOS0xLTEtMA_fd2c555e-50e9-4485-8503-9b94d5d65595">475,958</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjdjYzQyNDI1NjMzOTRhOGY4OWM5NjkyOTg2Mjc0MGI4L3RhYmxlcmFuZ2U6N2NjNDI0MjU2MzM5NGE4Zjg5Yzk2OTI5ODYyNzQwYjhfMTctMTEtMS0xLTA_6b8e45d0-0eef-450c-82e3-de78dc68b2b3">1,852,031</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.307%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.439%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.680%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30, 2019</span></td></tr><tr style="height:26pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income (Loss)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2018</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifad3e2a4eb5e4ee8a6ee49d932419d11_I20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjYzMjRjZjJlNWYwNjRjOWNiNTJjM2U1NTc2YTUxMDhiL3RhYmxlcmFuZ2U6NjMyNGNmMmU1ZjA2NGM5Y2I1MmMzZTU1NzZhNTEwOGJfMTEtMS0xLTEtMA_d50416fc-cb3b-4f81-a85c-ad634253c547">299,876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifad3e2a4eb5e4ee8a6ee49d932419d11_I20181228" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjYzMjRjZjJlNWYwNjRjOWNiNTJjM2U1NTc2YTUxMDhiL3RhYmxlcmFuZ2U6NjMyNGNmMmU1ZjA2NGM5Y2I1MmMzZTU1NzZhNTEwOGJfMTEtMy0xLTEtMA_b9a91200-a6e5-42db-9d7e-a0c573a85291">300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13b4a5caa8a046bb9f6cc3529e516e24_I20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjYzMjRjZjJlNWYwNjRjOWNiNTJjM2U1NTc2YTUxMDhiL3RhYmxlcmFuZ2U6NjMyNGNmMmU1ZjA2NGM5Y2I1MmMzZTU1NzZhNTEwOGJfMTEtNS0xLTEtMA_67f200b6-7f03-4a44-9ef3-9b2a7b1e74ad">2,168,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1277e0158f8545d28d0907eafd290af9_I20181228" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjYzMjRjZjJlNWYwNjRjOWNiNTJjM2U1NTc2YTUxMDhiL3RhYmxlcmFuZ2U6NjMyNGNmMmU1ZjA2NGM5Y2I1MmMzZTU1NzZhNTEwOGJfMTEtNy0xLTEtMA_d941e194-d90e-480e-a89f-e4d2d6549e3b">701</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18bb90a064a742e5b5735480b882cb98_I20181228" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjYzMjRjZjJlNWYwNjRjOWNiNTJjM2U1NTc2YTUxMDhiL3RhYmxlcmFuZ2U6NjMyNGNmMmU1ZjA2NGM5Y2I1MmMzZTU1NzZhNTEwOGJfMTEtOS0xLTEtMA_3645918e-c910-4e6d-8b5b-5de10c2a737a">880,363</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i010170af21d84cd898d00c6336993dba_I20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjYzMjRjZjJlNWYwNjRjOWNiNTJjM2U1NTc2YTUxMDhiL3RhYmxlcmFuZ2U6NjMyNGNmMmU1ZjA2NGM5Y2I1MmMzZTU1NzZhNTEwOGJfMTEtMTEtMS0xLTA_a78d14ed-5bd3-4060-aa82-cdd689186153">1,287,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d7219d185874a2188412be82a05f1ee_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjYzMjRjZjJlNWYwNjRjOWNiNTJjM2U1NTc2YTUxMDhiL3RhYmxlcmFuZ2U6NjMyNGNmMmU1ZjA2NGM5Y2I1MmMzZTU1NzZhNTEwOGJfMTItOS0xLTEtMA_b0f1f760-1c88-431e-a17f-fde89dc8d511">252,269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjYzMjRjZjJlNWYwNjRjOWNiNTJjM2U1NTc2YTUxMDhiL3RhYmxlcmFuZ2U6NjMyNGNmMmU1ZjA2NGM5Y2I1MmMzZTU1NzZhNTEwOGJfMTItMTEtMS0xLTA_e8d111de-e06d-4c44-a1f8-2402b5e4c128">252,269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1aaa1630501a4eb1839161674cac9e08_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjYzMjRjZjJlNWYwNjRjOWNiNTJjM2U1NTc2YTUxMDhiL3RhYmxlcmFuZ2U6NjMyNGNmMmU1ZjA2NGM5Y2I1MmMzZTU1NzZhNTEwOGJfMTMtNy0xLTEtMA_325b8cff-6109-4831-ac75-c81c845e20c3">3,369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjYzMjRjZjJlNWYwNjRjOWNiNTJjM2U1NTc2YTUxMDhiL3RhYmxlcmFuZ2U6NjMyNGNmMmU1ZjA2NGM5Y2I1MmMzZTU1NzZhNTEwOGJfMTMtMTEtMS0xLTA_4fae4f42-b4dc-4d86-ba2f-67bbf6d1a0b2">3,369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under equity incentive and stock purchase plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7b32b70c60b14ff19391f59a6db9dd0e_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjYzMjRjZjJlNWYwNjRjOWNiNTJjM2U1NTc2YTUxMDhiL3RhYmxlcmFuZ2U6NjMyNGNmMmU1ZjA2NGM5Y2I1MmMzZTU1NzZhNTEwOGJfMTQtMS0xLTEtMA_69c2963f-8310-479d-9d64-e00f0e47bc77">3,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b32b70c60b14ff19391f59a6db9dd0e_D20181229-20190927" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjYzMjRjZjJlNWYwNjRjOWNiNTJjM2U1NTc2YTUxMDhiL3RhYmxlcmFuZ2U6NjMyNGNmMmU1ZjA2NGM5Y2I1MmMzZTU1NzZhNTEwOGJfMTQtMy0xLTEtMA_a550ae68-9576-4619-9606-fdb4034ac7bc">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dab0b7d12c64bcfa11c169e3789d3bf_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjYzMjRjZjJlNWYwNjRjOWNiNTJjM2U1NTc2YTUxMDhiL3RhYmxlcmFuZ2U6NjMyNGNmMmU1ZjA2NGM5Y2I1MmMzZTU1NzZhNTEwOGJfMTQtNS0xLTEtMA_002cf30f-e360-4a9a-bd1f-2e3346be09ab">23,244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjYzMjRjZjJlNWYwNjRjOWNiNTJjM2U1NTc2YTUxMDhiL3RhYmxlcmFuZ2U6NjMyNGNmMmU1ZjA2NGM5Y2I1MmMzZTU1NzZhNTEwOGJfMTQtMTEtMS0xLTA_882ea346-9757-400b-9f6f-c44928f45b71">23,248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock transactions associated with taxes withheld on equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6dab0b7d12c64bcfa11c169e3789d3bf_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjYzMjRjZjJlNWYwNjRjOWNiNTJjM2U1NTc2YTUxMDhiL3RhYmxlcmFuZ2U6NjMyNGNmMmU1ZjA2NGM5Y2I1MmMzZTU1NzZhNTEwOGJfMTUtNS0xLTEtMA_4704483e-5362-4f1f-8f20-72a4cf9435a0">3,369</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjYzMjRjZjJlNWYwNjRjOWNiNTJjM2U1NTc2YTUxMDhiL3RhYmxlcmFuZ2U6NjMyNGNmMmU1ZjA2NGM5Y2I1MmMzZTU1NzZhNTEwOGJfMTUtMTEtMS0xLTA_1fe7408f-114e-40cf-9fae-4bd23393c320">3,369</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dab0b7d12c64bcfa11c169e3789d3bf_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjYzMjRjZjJlNWYwNjRjOWNiNTJjM2U1NTc2YTUxMDhiL3RhYmxlcmFuZ2U6NjMyNGNmMmU1ZjA2NGM5Y2I1MmMzZTU1NzZhNTEwOGJfMTYtNS0xLTEtMA_eb48381b-db25-43f1-bc07-d0576751911d">40,747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjYzMjRjZjJlNWYwNjRjOWNiNTJjM2U1NTc2YTUxMDhiL3RhYmxlcmFuZ2U6NjMyNGNmMmU1ZjA2NGM5Y2I1MmMzZTU1NzZhNTEwOGJfMTYtMTEtMS0xLTA_65705e0f-7c8f-4eb1-a06c-908a8b7c88a8">40,747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September&#160;30, 2019</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i05f14b5dcf314304b309c5e87df9f50a_I20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjYzMjRjZjJlNWYwNjRjOWNiNTJjM2U1NTc2YTUxMDhiL3RhYmxlcmFuZ2U6NjMyNGNmMmU1ZjA2NGM5Y2I1MmMzZTU1NzZhNTEwOGJfMTctMS0xLTEtMA_f0c2c5f0-4ad2-4114-a666-12477da9aa94">303,776</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f14b5dcf314304b309c5e87df9f50a_I20190927" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjYzMjRjZjJlNWYwNjRjOWNiNTJjM2U1NTc2YTUxMDhiL3RhYmxlcmFuZ2U6NjMyNGNmMmU1ZjA2NGM5Y2I1MmMzZTU1NzZhNTEwOGJfMTctMy0xLTEtMA_98e4cbe3-8ffe-4a95-baf9-5cf5409482b5">304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c6f2cb1dfbd41acbc289114955cd416_I20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjYzMjRjZjJlNWYwNjRjOWNiNTJjM2U1NTc2YTUxMDhiL3RhYmxlcmFuZ2U6NjMyNGNmMmU1ZjA2NGM5Y2I1MmMzZTU1NzZhNTEwOGJfMTctNS0xLTEtMA_741cb046-ddb8-4354-a765-7c26f22142f1">2,228,839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dac2e6ea3d14a2e8cc5b92c6af71211_I20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjYzMjRjZjJlNWYwNjRjOWNiNTJjM2U1NTc2YTUxMDhiL3RhYmxlcmFuZ2U6NjMyNGNmMmU1ZjA2NGM5Y2I1MmMzZTU1NzZhNTEwOGJfMTctNy0xLTEtMA_6d0d66f7-f197-427c-bdff-16fe0c113ee7">2,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic827287aa3294c6a883bc9d0b8a0623f_I20190927" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjYzMjRjZjJlNWYwNjRjOWNiNTJjM2U1NTc2YTUxMDhiL3RhYmxlcmFuZ2U6NjMyNGNmMmU1ZjA2NGM5Y2I1MmMzZTU1NzZhNTEwOGJfMTctOS0xLTEtMA_03ff8834-a84a-437c-8d6b-73133ae13c4e">628,094</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34bbe41183cc4f96afa896c1d7f86bb3_I20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjYzMjRjZjJlNWYwNjRjOWNiNTJjM2U1NTc2YTUxMDhiL3RhYmxlcmFuZ2U6NjMyNGNmMmU1ZjA2NGM5Y2I1MmMzZTU1NzZhNTEwOGJfMTctMTEtMS0xLTA_77d24c7a-ad35-405e-a6b5-e9102d9bc215">1,603,717</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i0283c6f517b447ec92f154ee691f4028_34"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.459%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.824%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMi0xLTEtMS0w_abfa2d1e-5ccf-42b5-84d6-40e96d4bcd40">83,393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMi0zLTEtMS0w_9bcc5c2b-55a6-4d0e-b747-be683cc26c85">252,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfNC0xLTEtMS0w_eb644498-84ec-41b0-986c-e55f61a54746">6,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfNC0zLTEtMS0w_10969b3b-61da-4100-9fc4-a439c0738cc8">6,088</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfNS0xLTEtMS0w_6ebddb28-5062-40e0-8e20-ba1605868b44">85,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfNS0zLTEtMS0w_81374cf9-17f3-4505-baa5-4fc05c7b06f2">40,747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="exel:NoncashLeaseExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfNi0xLTEtMS0w_250f89d1-fdb6-454a-a173-1df167b07757">3,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="exel:NoncashLeaseExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfNi0zLTEtMS0w_2e02eba3-6283-43ce-b319-66fe9a744ce1">1,803</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfNy0xLTEtMS0w_ef9d2b90-fd64-49b6-8be5-447e2a4b2298">15,803</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfNy0zLTEtMS0w_365a8300-ff87-4347-84c4-7b561f6bb4b2">56,339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfOC0xLTEtMS0w_9229cbc9-6b41-457b-a003-03e90ab94f4f">1,609</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfOC0zLTEtMS0w_82f83531-612a-44e0-b1ab-c5acd42e81ba">621</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMTAtMS0xLTEtMA_e00457fc-11b9-4d20-ad52-cdcbece5afe7">47,074</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMTAtMy0xLTEtMA_01b8bab6-e16c-428b-96ff-9780370e3129">7,017</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMTEtMS0xLTEtMA_2e17b392-0275-44ae-b7e9-8118f0891b42">13,466</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMTEtMy0xLTEtMA_41e74bfa-0270-463e-bd93-fd2a55c714a6">3,528</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMTMtMS0xLTEtMA_f4a2952f-b181-47c4-a6c1-49d0fc299f27">15,868</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMTMtMy0xLTEtMA_7dd91519-93b2-4bed-ae7b-a8b171abee5d">14,108</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMTUtMS0xLTEtMA_c36dcde0-799f-4961-988f-b70c2a11db9b">4,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMTUtMy0xLTEtMA_d10b4069-f8bc-4a38-b881-52620ecb93ae">3,592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMTYtMS0xLTEtMA_8584fece-2084-4995-9007-3d12f77cbb88">51,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMTYtMy0xLTEtMA_c7210eb7-4a11-47ee-b6a4-13ae44f0dfec">33,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMTctMS0xLTEtMA_edd23108-967d-429f-866f-590f61dcc25b">175,689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMTctMy0xLTEtMA_e2a91981-b360-4c77-9b1e-93d0b0200bae">368,935</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property, equipment and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMTktMS0xLTEtMA_648a9347-2030-4067-b56a-fe78121b2ae7">16,055</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMTktMy0xLTEtMA_bd9c65a5-09dd-46cb-ba93-da7dd95a8c77">5,575</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMjEtMS0xLTEtMA_edf2d4c2-8420-42cc-b490-7fe870f98c4e">866,975</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMjEtMy0xLTEtMA_85e62d78-963a-40b8-88c2-80d0053b8ce8">887,698</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from maturities and sales of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMjItMS0xLTEtMA_16892b03-7ba3-4b99-bdf7-ea0e317f0784">781,324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMjItMy0xLTEtMA_bd2eec96-7a92-42bb-a525-965124e03dab">436,227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMjMtMS0xLTEtMA_6460daa9-0df2-4659-a5b0-acb8f34e3df5">101,706</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMjMtMy0xLTEtMA_13db9700-44d7-4ab5-aea2-ce4ba6360aef">457,046</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock under equity incentive and stock purchase plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMjUtMS0xLTEtMA_49398a1e-7a9d-44bf-a829-afea4355a1f3">19,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMjUtMy0xLTEtMA_49d9bebe-3cf7-4827-bac9-72a0d49f5f89">18,956</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes paid related to net share settlement of equity awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMjYtMS0xLTEtMA_772fdf84-6b61-45c3-b00f-5ae15172723d">26,120</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMjYtMy0xLTEtMA_078b0a7a-a6a0-4bd0-a549-62ed90c5e4b7">3,369</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMjgtMS0xLTEtMA_4da6190b-5a60-4865-814c-9522efaec118">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927" decimals="-3" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMjgtMy0xLTEtMA_eb9221cf-5bbc-41e7-ae1d-d5f262f0b119">34</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMjktMS0xLTEtMA_99a5269a-fb2a-43d9-a18f-b29824b2f8a0">6,438</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMjktMy0xLTEtMA_8d3df574-fda8-4091-938e-c3eef484fd83">15,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMzAtMS0xLTEtMA_05eefc28-ea79-410e-81c6-3a11595fbef1">67,545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMzAtMy0xLTEtMA_b1484be9-26a8-4455-a1e3-60258b5e6761">72,558</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMzEtMS0xLTEtMA_d403bd0e-5ca4-47be-8070-50a862b75e7e">268,137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i010170af21d84cd898d00c6336993dba_I20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMzEtMy0xLTEtMA_b1a2d24b-80cb-4638-9059-4d21bca3a4c8">315,875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMzItMS0xLTEtMA_e7188730-b966-4b39-90f0-7b2959141580">335,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34bbe41183cc4f96afa896c1d7f86bb3_I20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMzItMy0xLTEtMA_6c212593-0644-413d-8098-c34f492d76c0">243,317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplemental cash flow disclosures:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="exel:RightOfUseAssetObtainedInExchangeForLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMzctMS0xLTEtMA_5c5df418-8c77-4189-a3d6-a1189d44b9ca">1,824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="exel:RightOfUseAssetObtainedInExchangeForLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMzctMy0xLTEtMA_82ae9e14-3c30-4123-bb1f-9b8784fd59c0">12,944</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unpaid liabilities incurred for purchases of property and equipment</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMzgtMS0xLTEtMA_03912f5a-f9d4-418c-8c64-d7e6bda74134">843</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMzgtMy0xLTEtMA_4d248689-efa3-4e89-86ee-106b45ff51ba">159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unpaid liabilities incurred to acquire investments</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="-3" format="ixt:zerodash" name="exel:LiabilitiesExpendituresIncurredButNotYetPaidToRelatedPartyTransactions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMzktMS0xLTEtMA_79794ea1-f0f0-49ef-9186-56b037b3a72a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="exel:LiabilitiesExpendituresIncurredButNotYetPaidToRelatedPartyTransactions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMzktMy0xLTEtMA_586191b5-5f2a-4aa0-b2e7-83d4d19f0e4c">8,961</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i0283c6f517b447ec92f154ee691f4028_37"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div id="i0283c6f517b447ec92f154ee691f4028_40"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 1. <ix:nonNumeric contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80MC9mcmFnOjIwZjk1ZGUyZGQ0YzQ1MWZiZWU3MjM2ODkyNmFlNmE3L3RleHRyZWdpb246MjBmOTVkZTJkZDRjNDUxZmJlZTcyMzY4OTI2YWU2YTdfMjA3MzI_656ebf6e-d53b-4d36-a5fa-ecd702c0b96d" continuedAt="idda84c48c47b4bce9aadf6cb257c10d8" escape="true">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="idda84c48c47b4bce9aadf6cb257c10d8" continuedAt="i0249dbd6d81249aea4ac198181d71cfd"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Organization</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exelixis, Inc. (Exelixis, we, our or us) is an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our drug discovery and development capabilities and commercialization platform are the foundations upon which we intend to bring to market novel, effective and tolerable therapies to provide cancer patients with additional treatment options.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since we were founded in 1994, <ix:nonFraction unitRef="product" contextRef="if5e8e1669be6453aa3ae0fc322692c38_D20200104-20201002" decimals="INF" format="ixt-sec:numwordsen" name="exel:NumberofProductsinCommercialMarket" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80MC9mcmFnOjIwZjk1ZGUyZGQ0YzQ1MWZiZWU3MjM2ODkyNmFlNmE3L3RleHRyZWdpb246MjBmOTVkZTJkZDRjNDUxZmJlZTcyMzY4OTI2YWU2YTdfNTcw_d71d1502-0ed3-4694-a886-61eac96bdeb1">four</ix:nonFraction> products resulting from our discovery efforts&#160;have progressed through clinical development, received regulatory approval and established a commercial presence in various geographies around the world. <ix:nonFraction unitRef="product" contextRef="ibe41da152065437483e7469fa266c06d_D20200104-20201002" decimals="INF" format="ixt-sec:numwordsen" name="exel:NumberofProductsinCommercialMarket" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80MC9mcmFnOjIwZjk1ZGUyZGQ0YzQ1MWZiZWU3MjM2ODkyNmFlNmE3L3RleHRyZWdpb246MjBmOTVkZTJkZDRjNDUxZmJlZTcyMzY4OTI2YWU2YTdfNzcz_5f73edec-0a1b-4d46-9e46-91fe294af023">Two</ix:nonFraction> are derived from cabozantinib, our flagship molecule, an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. Our cabozantinib products are: CABOMETYX&#174; (cabozantinib) tablets approved for advanced renal cell carcinoma (RCC) and previously treated hepatocellular carcinoma; and COMETRIQ&#174;&#160;(cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer. For these types of cancer, cabozantinib has become or is becoming a standard of care. Beyond these approved indications, cabozantinib is currently the focus of a broad clinical development program and is being investigated both alone and in combination with other therapies in a wide variety of cancers.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other <ix:nonFraction unitRef="product" contextRef="ie9df0cd737b54a18828c9607339f712f_D20200104-20201002" decimals="INF" format="ixt-sec:numwordsen" name="exel:NumberofProductsinCommercialMarket" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80MC9mcmFnOjIwZjk1ZGUyZGQ0YzQ1MWZiZWU3MjM2ODkyNmFlNmE3L3RleHRyZWdpb246MjBmOTVkZTJkZDRjNDUxZmJlZTcyMzY4OTI2YWU2YTdfMTQ4OA_89ad324d-f7d4-4109-b7aa-48a3b79781b9">two</ix:nonFraction> products resulting from our discovery efforts are: COTELLIC&#174; (cobimetinib), an inhibitor of MEK, approved as part of multiple combination regimens to treat specific forms of advanced melanoma and marketed under a collaboration with Genentech, Inc. (a member of the Roche Group) (Genentech); and MINNEBRO&#174; (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor, approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo Company, Limited (Daiichi Sankyo).</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also remain committed to building our product pipeline by discovering and developing new therapies for cancer patients. Using our in-house drug discovery expertise, specifically in medicinal chemistry, tumor biology and pharmacology, we are advancing small molecule drug candidates toward and through preclinical development. In addition, we have augmented our internal drug discovery activities with multiple partnerships, including several that enable us to discover and advance various biologics, such as bispecific antibodies and antibody-drug conjugates (ADCs), and we continue to engage in business development initiatives aimed at identifying and in-licensing promising, early-stage oncology assets, which we can further develop utilizing our established clinical development infrastructure.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80MC9mcmFnOjIwZjk1ZGUyZGQ0YzQ1MWZiZWU3MjM2ODkyNmFlNmE3L3RleHRyZWdpb246MjBmOTVkZTJkZDRjNDUxZmJlZTcyMzY4OTI2YWU2YTdfMjA3NTk_2f151e08-3984-4f96-879f-896a78dbef04" escape="true">The accompanying Condensed Consolidated Financial Statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&#8217; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.</ix:nonNumeric></span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80MC9mcmFnOjIwZjk1ZGUyZGQ0YzQ1MWZiZWU3MjM2ODkyNmFlNmE3L3RleHRyZWdpb246MjBmOTVkZTJkZDRjNDUxZmJlZTcyMzY4OTI2YWU2YTdfMjA3NjI_be16dd2a-925e-41e7-8d2a-eb5bdc493bf1" escape="true">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of our financial statements for the periods presented have been included. Operating results for the three and nine months ended September&#160;30, 2020 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2020 or for any future period. The accompanying Condensed Consolidated Financial Statements and Notes thereto should be read in conjunction with our Consolidated Financial Statements and Notes thereto for the year ended December&#160;31, 2019, included in our Annual Report on Form 10-K filed with the SEC on February&#160;25, 2020.</ix:nonNumeric></span></div><div style="margin-top:9pt;text-indent:36pt"><ix:nonNumeric contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" name="us-gaap:FiscalPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80MC9mcmFnOjIwZjk1ZGUyZGQ0YzQ1MWZiZWU3MjM2ODkyNmFlNmE3L3RleHRyZWdpb246MjBmOTVkZTJkZDRjNDUxZmJlZTcyMzY4OTI2YWU2YTdfMjA3Mzc_32188ed7-b967-4c42-8c26-921fbe987890" continuedAt="i7921b65f5135431b8c080833e9041746" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Fiscal year 2020, which is a 52-week fiscal year, will end on January 1, 2021 and fiscal year 2019, which was a 53-week fiscal year, ended on January 3, 2020. For convenience, references in this report as of and for the fiscal periods ended October 2, 2020 and September 27, 2019, and as of and for the fiscal years ending January 1, 2021, and ended January 3, 2020, are indicated as being as of and for the fiscal periods ended September 30, 2020 and September 30, 2019 and the years ending </span></ix:nonNumeric></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_7">Table of Contents</a></span></div></div><ix:continuation id="i0249dbd6d81249aea4ac198181d71cfd" continuedAt="i48ccadbf503c49c8831b30ea5e3fc5f9"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7921b65f5135431b8c080833e9041746">December&#160;31, 2020 and ended December&#160;31, 2019, respectively. Similarly, references in this report to the first day of the fiscal year ending January 1, 2021 are indicated as being as of January 1, 2020.</ix:continuation></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80MC9mcmFnOjIwZjk1ZGUyZGQ0YzQ1MWZiZWU3MjM2ODkyNmFlNmE3L3RleHRyZWdpb246MjBmOTVkZTJkZDRjNDUxZmJlZTcyMzY4OTI2YWU2YTdfMjA3NTY_53b1ef88-1d39-41a1-9a20-8d92b78c9b30" escape="true">Certain prior period amounts in the accompanying Condensed Consolidated Financial Statements have been reclassified to conform to the current period presentation. Such reclassifications did not impact previously reported total revenues, income from operations, net income, total assets, total liabilities or total stockholders&#8217; equity.</ix:nonNumeric></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80MC9mcmFnOjIwZjk1ZGUyZGQ0YzQ1MWZiZWU3MjM2ODkyNmFlNmE3L3RleHRyZWdpb246MjBmOTVkZTJkZDRjNDUxZmJlZTcyMzY4OTI2YWU2YTdfMjA3NzU_ea659790-5807-4f51-ba0b-5bb8dba0cfef" escape="true">We operate in <ix:nonFraction unitRef="segment" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80MC9mcmFnOjIwZjk1ZGUyZGQ0YzQ1MWZiZWU3MjM2ODkyNmFlNmE3L3RleHRyZWdpb246MjBmOTVkZTJkZDRjNDUxZmJlZTcyMzY4OTI2YWU2YTdfNDU2MA_6e88aa5a-64b7-4f8a-a7ed-daa9bcee4d3b">one</ix:nonFraction> business segment that focuses on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.</ix:nonNumeric> </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our long-lived assets are located in the U.S. See &#8220;Note 2. Revenues&#8221; for enterprise-wide disclosures about product sales, revenues from major customers and revenues by geographic region.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80MC9mcmFnOjIwZjk1ZGUyZGQ0YzQ1MWZiZWU3MjM2ODkyNmFlNmE3L3RleHRyZWdpb246MjBmOTVkZTJkZDRjNDUxZmJlZTcyMzY4OTI2YWU2YTdfMjA3NTc_7770d901-6909-4ae4-b752-4de766bb35e9" continuedAt="icc1639949b7944988557f7a2e97cf36b" escape="true">The preparation of the accompanying Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</ix:nonNumeric></span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="icc1639949b7944988557f7a2e97cf36b">In March 2020, we received the Preliminary Calculation of our Branded Prescription Drug Fee for 2020, and in August 2020, the Final Calculation of our Branded Prescription Drug Fee for 2020 from the Internal Revenue Service for the 2018 sales year, which resulted in an increase in our estimate of such fees for the 2018 and 2019 sales years.</ix:continuation> Accordingly, we recorded an adjustment to increase selling, general and administrative expenses and our accrual for these fees by</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usd" contextRef="i6b8fc82f50494df690850a723f567147_D20200104-20201002" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80MC9mcmFnOjIwZjk1ZGUyZGQ0YzQ1MWZiZWU3MjM2ODkyNmFlNmE3L3RleHRyZWdpb246MjBmOTVkZTJkZDRjNDUxZmJlZTcyMzY4OTI2YWU2YTdfMTA0NDUzNjA0ODYxODA_e698a617-738a-4411-b4b5-eb700a07f77b">5.1</ix:nonFraction>&#160;million du</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ring t</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he nine months ended September 30, 2020. This adjustment resulted in a $<ix:nonFraction unitRef="usdPerShare" contextRef="i6b8fc82f50494df690850a723f567147_D20200104-20201002" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80MC9mcmFnOjIwZjk1ZGUyZGQ0YzQ1MWZiZWU3MjM2ODkyNmFlNmE3L3RleHRyZWdpb246MjBmOTVkZTJkZDRjNDUxZmJlZTcyMzY4OTI2YWU2YTdfNjUwNA_60ac4cfd-1be1-4bc5-b091-98fa9b4c4945">0.02</ix:nonFraction> decrease in basic and diluted earnings per share for the nine months ended September&#160;30, 2020.</span></div><ix:nonNumeric contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80MC9mcmFnOjIwZjk1ZGUyZGQ0YzQ1MWZiZWU3MjM2ODkyNmFlNmE3L3RleHRyZWdpb246MjBmOTVkZTJkZDRjNDUxZmJlZTcyMzY4OTI2YWU2YTdfMjA3Njc_b1659d10-cb08-4074-bbe7-893492d11301" continuedAt="ifc9f8c19d81e4b338ffc5376487f5eae" escape="true"><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2020, we adopted Accounting Standards Update (ASU) No.&#160;201</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8-18,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2018-18). ASU 2018-18 clarifies that certain transactions between collaborative arrangement participants should be accounted for as part of revenues under Accounting Standards Codification (ASC) Topic 606,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 606) when the counterparty is a customer for a distinct good or service (i.e. a unit of account). For units of account that are in the scope of Topic 606, all of the guidance in Topic 606 should be applied, including the guidance on recognition, measurement, presentation and disclosure. ASU 2018-18 precludes entities from presenting amounts related to transactions with a counterparty in a collaborative arrangement that is not a customer together with revenue from contracts with customers. If a portion of a distinct bundle of goods or services within an arrangement is not with a customer, then the unit of account is not within the scope of Topic 606, and the recognition and measurement of that unit of account shall be based on analogy to authoritative accounting literature or, if there is no appropriate analogy, a reasonable, rational, and consistently applied accounting policy election. Upon adoption of ASU 2018-18, we have presented revenues from performance obligations associated with our collaboration arrangements that are within the scope of Topic 606 (license revenues) separately from revenues from performance obligations that are not subject to Topic 606 (collaboration services revenues). The adoption of ASU 2018-18 was applied retrospectively, and prior periods have been restated to conform to the presentation prescribed by ASU 2018-18. The adoption of ASU 2018-18 did not impact total revenues for the prior period presented in the accompanying Condensed Consolidated Statements of Income. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2020, we adopted ASU No.&#160;2017-04,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Intangibles&#8212;Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2017-04)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ASU 2017-04 simplifies goodwill impairment testing by eliminating the second </span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_7">Table of Contents</a></span></div></div><ix:continuation id="i48ccadbf503c49c8831b30ea5e3fc5f9" continuedAt="i9e492caa0f0c49b9a94d2a21741cad42"><ix:continuation id="ifc9f8c19d81e4b338ffc5376487f5eae" continuedAt="i91bb638a769a4b39abae420a4ab15339"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">step of the impairment test. The amended guidance requires an impairment charge to be recognized for the amount by which the carrying amount of a reporting unit exceeds its fair value under a one-step impairment test. The adoption of ASU 2017-04 did not impact the accompanying Condensed Consolidated Financial Statements.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2020, we adopted ASU No.&#160;2016-13,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Financial Instruments&#8212;Credit Losses (Topic 326) </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASU 2016-13)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2016-13 implements an impairment model, known as the current expected credit loss model, that is based on expected losses rather than incurred losses. Under the new guidance, we will recognize our estimate of current expected credit losses as an allowance on financial assets measured at amortized cost, including accounts receivable, unbilled collaboration revenues, and investments classified as available for sale. Current expected credit losses were immaterial as of the date of adoption, and the adoption of ASU 2016-13 did not have a significant impact on the accompanying Condensed Consolidated Financial Statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investment Impairment</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quarterly, we assess each of our investments in debt securities available-for-sale whose fair value is below its cost basis to determine if the investment&#8217;s impairment is due to credit-related factors or noncredit-related factors. Factors considered in determining whether an impairment is credit-related include the extent to which the investment&#8217;s fair value is less than its cost basis, declines in published credit ratings, issuer default on interest or principal payments, and declines in the financial condition and near-term prospects of the issuer. If we determine a credit-related impairment exists, we will measure the credit loss based on a discounted cash flows model. Credit-related impairments on debt securities available-for-sale are recognized as an allowance for credit losses with a corresponding adjustment to other income, net in the accompanying Condensed Consolidated Statements of Income. The portion of the impairment that is not credit-related is recorded, net of applicable taxes, as a reduction of other comprehensive income.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected to exclude accrued interest from both the fair value and the amortized cost basis of debt securities available-for-sale for the purposes of identifying and measuring an impairment. We write-off accrued interest as a reduction of interest income when an issuer has defaulted on interest payments due on a security.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade receivables, net contain amounts billed to our customers for product sales, and amounts billed to our collaboration partners for development, regulatory and sales-based milestone payments, royalties on the sale of licensed products, profit-sharing arrangements, development cost reimbursements, and payments for product supply services. Our customers are primarily pharmaceutical and biotechnology companies that are located in the U.S., and collaboration partners that are located in Europe and Japan. As of September 30, 2020 and December 31, 2019, <ix:nonFraction unitRef="number" contextRef="i53d5d16c99e24b1685ffd6417b746dc5_D20200104-20201002" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80MC9mcmFnOjIwZjk1ZGUyZGQ0YzQ1MWZiZWU3MjM2ODkyNmFlNmE3L3RleHRyZWdpb246MjBmOTVkZTJkZDRjNDUxZmJlZTcyMzY4OTI2YWU2YTdfMTA0NDUzNjA0ODgwMTA_98a3bb96-b4c6-459f-8f23-c58cd2f0b117">47</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i988d96d56fc8488e825029b9ae6e78da_D20181229-20200103" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80MC9mcmFnOjIwZjk1ZGUyZGQ0YzQ1MWZiZWU3MjM2ODkyNmFlNmE3L3RleHRyZWdpb246MjBmOTVkZTJkZDRjNDUxZmJlZTcyMzY4OTI2YWU2YTdfMTA0NDUzNjA0ODgwMTU_6066c1a8-49c4-48c9-b0a1-38bac8a98899">38</ix:nonFraction>%, respectively, of our trade receivables were from our collaboration partner Ipsen Pharma SAS (Ipsen), and <ix:nonFraction unitRef="number" contextRef="ib4f8f5605ff6401098c5e709f8d70e2f_D20200104-20201002" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80MC9mcmFnOjIwZjk1ZGUyZGQ0YzQ1MWZiZWU3MjM2ODkyNmFlNmE3L3RleHRyZWdpb246MjBmOTVkZTJkZDRjNDUxZmJlZTcyMzY4OTI2YWU2YTdfMTA0NDUzNjA0ODgwMjA_1d9da526-374b-4424-85d8-08aed2f02c24">12</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i1d8dbceba046414c9646347dd14f559d_D20181229-20200103" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80MC9mcmFnOjIwZjk1ZGUyZGQ0YzQ1MWZiZWU3MjM2ODkyNmFlNmE3L3RleHRyZWdpb246MjBmOTVkZTJkZDRjNDUxZmJlZTcyMzY4OTI2YWU2YTdfMTA0NDUzNjA0ODgwMjU_63331217-b5cb-4fbd-a396-340fc58fb330">14</ix:nonFraction>% were from affiliates of McKesson Corporation. We record trade receivables net of allowances for credit losses and chargebacks, and cash discounts for prompt payment. We apply an aging method to estimate credit losses and consider our historical loss information, adjusted to account for current conditions, and reasonable and supportable forecasts of future economic conditions affecting our customers.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded goodwill amounts as the excess purchase price over tangible assets, liabilities and intangible assets acquired based on their estimated fair value. We review the carrying amount of goodwill for impairment annually and whenever events or changes in circumstance indicate that the carrying value may not be recoverable. We perform our annual assessment of the recoverability of our goodwill as of the first day of our fourth quarter. The assessment of recoverability may first consider qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. We perform a quantitative assessment if the qualitative assessment results in a more likely than not determination or if a qualitative assessment is not performed. The quantitative assessment determines whether the carrying amount of a reporting unit exceeds its fair value, in which case an impairment charge is recognized for the amount by which the carrying amount of a reporting unit exceeds its fair value, limited to the goodwill balance. We operate in <ix:nonFraction unitRef="segment" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80MC9mcmFnOjIwZjk1ZGUyZGQ0YzQ1MWZiZWU3MjM2ODkyNmFlNmE3L3RleHRyZWdpb246MjBmOTVkZTJkZDRjNDUxZmJlZTcyMzY4OTI2YWU2YTdfMTM1NDU_6e88aa5a-64b7-4f8a-a7ed-daa9bcee4d3b">one</ix:nonFraction> business segment, which is also considered to be our sole reporting unit and therefore, goodwill is tested for impairment at the enterprise level. We did <ix:nonFraction unitRef="usd" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:GoodwillImpairmentLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80MC9mcmFnOjIwZjk1ZGUyZGQ0YzQ1MWZiZWU3MjM2ODkyNmFlNmE3L3RleHRyZWdpb246MjBmOTVkZTJkZDRjNDUxZmJlZTcyMzY4OTI2YWU2YTdfMTM3MDI_613fe927-1eb6-41f0-8b9f-1f458f8f7c13">no</ix:nonFraction>t recognize any impairment charges in any of the periods presented.</span></div></ix:continuation></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_7">Table of Contents</a></span></div></div><ix:continuation id="i9e492caa0f0c49b9a94d2a21741cad42" continuedAt="ica1c29081f1641d786d8f9619f5cd8cb"><ix:continuation id="i91bb638a769a4b39abae420a4ab15339" continuedAt="i239bd4d94f0f4609934cd1fc658f8caa"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration Agreements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess whether our collaboration agreements are subject to ASC Topic 808,&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(Topic 808) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic&#160;808, we apply by analogy the unit of account guidance under Topic 606 to identify distinct performance obligations, and then determine whether a customer relationship exists for each distinct performance obligation. If we determine a performance obligation within the arrangement is with a customer, we apply the guidance in Topic 606. If a portion of a distinct bundle of goods or services within an arrangement is not with a customer, then the unit of account is not within the scope of Topic&#160;606, and the recognition and measurement of that unit of account shall be based on analogy to authoritative accounting literature or, if there is no appropriate analogy, a reasonable, rational, and consistently applied accounting policy election. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into collaboration arrangements, under which we license certain rights to our intellectual property to third parties. The terms of these arrangements typically include payments to us for one or more of the following: nonrefundable up-front license fees; development, regulatory and sales-based milestone payments; product supply services; development cost reimbursements; profit-sharing arrangements; and royalties on net sales of licensed products. As part of the accounting for these arrangements, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include forecasted revenues, clinical development timelines and costs, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Up-front License Fees: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from nonrefundable up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license, which generally occurs at or near the inception of the contract. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenues from nonrefundable up-front fees. We evaluate the measure of progress at the end of each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulatory and Development Milestone Payments: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of being achieved until uncertainty associated with the approvals has been resolved. The transaction price is then allocated to each performance obligation, on a relative standalone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achieving such development and regulatory milestones and any related variable consideration constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Supply Services:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Arrangements that include a promise for the future supply of drug product for either clinical development or commercial supply at the licensee&#8217;s discretion are generally considered as options. We assess if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Development Cost Reimbursements:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our collaboration arrangements may include promises of future clinical development and drug safety services, as well as participation on certain joint committees. When such services are provided to a customer, and they are distinct from the licenses provided to our collaboration partners, these promises are accounted for as a separate performance obligation which we estimate using internal development costs incurred and projections through the term of the arrangements. We record revenues for these services as the performance obligations are satisfied over time based on measure of progress. However, if we conclude that our collaboration partner is not a customer for those collaborative research and development activities, we present such payments as a reduction of research and development expenses.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Profit-sharing Arrangements: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of our collaboration agreement with Genentech for cobimetinib, we are entitled to a share of U.S. profits and losses received in connection with the commercialization of cobimetinib. We </span></div></ix:continuation></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_7">Table of Contents</a></span></div></div><ix:continuation id="ica1c29081f1641d786d8f9619f5cd8cb"><ix:continuation id="i239bd4d94f0f4609934cd1fc658f8caa"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">account for this arrangement in accordance with Topic 606. We have determined that we are an agent under the agreement and therefore revenues are recorded net of costs incurred. We record revenues for the variable consideration associated with the profits and losses under the collaboration agreement when it is probable that a significant reversal in the amount of cumulative revenues recognized will not occur.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty and Sales-based Milestone Payments:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For arrangements that include royalties and sales-based milestone payments, including milestone payments earned for the first commercial sale of a product, the license is deemed to be the predominant item to which such payments relate and we recognize revenues at the later of when the related sales occur or when the performance obligation to which the royalty has been allocated has been satisfied.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Financial Accounting Standards Board issued&#160;ASU 2019-12,&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740)-Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2019-12). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in ASC Topic 740, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and clarifying and amending existing guidance. ASU 2019-12 will be effective for us in the first quarter of 2021 with early adoption permitted. We are currently assessing the impact of ASU 2019-12 on our financial statements.</span></div></ix:continuation></ix:continuation><div id="i0283c6f517b447ec92f154ee691f4028_46"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 2. <ix:nonNumeric contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RleHRyZWdpb246MGE4MmQ4MjNlMWM0NDg1OWFkNTUzYmNhNmNhMTE1ZTdfNDg1MQ_963a1031-8c63-4ae5-9723-f78fd30f75bc" continuedAt="i168b1e562aa747c1a10e47f029fea22b" escape="true">REVENUES</ix:nonNumeric></span></div><ix:continuation id="i168b1e562aa747c1a10e47f029fea22b" continuedAt="i2a7d49eb1bf24ff29e95be1b563d6a0f"><ix:nonNumeric contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RleHRyZWdpb246MGE4MmQ4MjNlMWM0NDg1OWFkNTUzYmNhNmNhMTE1ZTdfNDg0Ng_77c0074a-3ffc-4852-bf67-4b5fe074dde1" continuedAt="ib5733f2d59d145b5910fa03ce3d29f1b" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.715%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.742%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product revenues</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b8d3dbc1c5648e68dcec00585f82d14_D20200704-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmIxMDRjYzQ2ODk0ODQzNDQ4YzdiMTFjYmNmMmU3MDUzL3RhYmxlcmFuZ2U6YjEwNGNjNDY4OTQ4NDM0NDhjN2IxMWNiY2YyZTcwNTNfMy0xLTEtMS0w_2874c770-08cb-40e2-8a9d-0a6441a07673">220,401</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i458bde72c5d5486cb34c5d501fb3ca84_D20190629-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmIxMDRjYzQ2ODk0ODQzNDQ4YzdiMTFjYmNmMmU3MDUzL3RhYmxlcmFuZ2U6YjEwNGNjNDY4OTQ4NDM0NDhjN2IxMWNiY2YyZTcwNTNfMy0zLTEtMS0w_38b7be91-6557-4d91-a664-f2e21d158e8a">239,916</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5535b1b3b1a487ea1ac2f456daeae47_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmIxMDRjYzQ2ODk0ODQzNDQ4YzdiMTFjYmNmMmU3MDUzL3RhYmxlcmFuZ2U6YjEwNGNjNDY4OTQ4NDM0NDhjN2IxMWNiY2YyZTcwNTNfMy01LTEtMS0w_3befb086-a11e-4b1f-ae1c-7cdb1490c7cd">702,865</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7500a3b3560547179833f5e227db7a5c_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmIxMDRjYzQ2ODk0ODQzNDQ4YzdiMTFjYmNmMmU3MDUzL3RhYmxlcmFuZ2U6YjEwNGNjNDY4OTQ4NDM0NDhjN2IxMWNiY2YyZTcwNTNfMy03LTEtMS0w_31686d66-e81e-4493-a6df-a723663c8a21">704,084</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounts and allowances</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2148af2d149c45dbb0c184eb9a166068_D20200704-20201002" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmIxMDRjYzQ2ODk0ODQzNDQ4YzdiMTFjYmNmMmU3MDUzL3RhYmxlcmFuZ2U6YjEwNGNjNDY4OTQ4NDM0NDhjN2IxMWNiY2YyZTcwNTNfNC0xLTEtMS0w_3f9dba84-ca75-40e1-a134-59d00919be82">51,814</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ed764ccd2a94897aeb76c66da22a057_D20190629-20190927" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmIxMDRjYzQ2ODk0ODQzNDQ4YzdiMTFjYmNmMmU3MDUzL3RhYmxlcmFuZ2U6YjEwNGNjNDY4OTQ4NDM0NDhjN2IxMWNiY2YyZTcwNTNfNC0zLTEtMS0w_bc1b5fec-e2f2-4a9d-b1b4-182dc9bc57ce">48,148</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifbbf27901590404f947e7e8da56664d3_D20200104-20201002" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmIxMDRjYzQ2ODk0ODQzNDQ4YzdiMTFjYmNmMmU3MDUzL3RhYmxlcmFuZ2U6YjEwNGNjNDY4OTQ4NDM0NDhjN2IxMWNiY2YyZTcwNTNfNC01LTEtMS0w_16b99c33-2e67-4226-b53c-6b79d5853068">161,668</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6d312e664d54a13a0bb0c707a911341_D20181229-20190927" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmIxMDRjYzQ2ODk0ODQzNDQ4YzdiMTFjYmNmMmU3MDUzL3RhYmxlcmFuZ2U6YjEwNGNjNDY4OTQ4NDM0NDhjN2IxMWNiY2YyZTcwNTNfNC03LTEtMS0w_6727c8b9-0f41-4639-b9e2-df80baceddaf">139,060</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia527955beb274c50967751e32dc17dff_D20200704-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmIxMDRjYzQ2ODk0ODQzNDQ4YzdiMTFjYmNmMmU3MDUzL3RhYmxlcmFuZ2U6YjEwNGNjNDY4OTQ4NDM0NDhjN2IxMWNiY2YyZTcwNTNfNS0xLTEtMS0w_3d02242e-90d7-43a7-a7b3-c4c1edfb3bb3">168,587</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i663049bc589a41de99b922b6fb02f1bc_D20190629-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmIxMDRjYzQ2ODk0ODQzNDQ4YzdiMTFjYmNmMmU3MDUzL3RhYmxlcmFuZ2U6YjEwNGNjNDY4OTQ4NDM0NDhjN2IxMWNiY2YyZTcwNTNfNS0zLTEtMS0w_fd819f17-a8c5-4a8b-a9bc-685488fb8b99">191,768</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefbb93ab12054c04a4d0d55ad1aaf502_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmIxMDRjYzQ2ODk0ODQzNDQ4YzdiMTFjYmNmMmU3MDUzL3RhYmxlcmFuZ2U6YjEwNGNjNDY4OTQ4NDM0NDhjN2IxMWNiY2YyZTcwNTNfNS01LTEtMS0w_1d3efd23-055c-4446-a217-f43399b9d307">541,197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75b81eceef094c2d86c24a00c59294e1_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmIxMDRjYzQ2ODk0ODQzNDQ4YzdiMTFjYmNmMmU3MDUzL3RhYmxlcmFuZ2U6YjEwNGNjNDY4OTQ4NDM0NDhjN2IxMWNiY2YyZTcwNTNfNS03LTEtMS0w_615778d9-fa15-4ef0-8eaa-441ec490a96c">565,024</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie72938b556dd42ada9b416a6b60b47fa_D20200704-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmIxMDRjYzQ2ODk0ODQzNDQ4YzdiMTFjYmNmMmU3MDUzL3RhYmxlcmFuZ2U6YjEwNGNjNDY4OTQ4NDM0NDhjN2IxMWNiY2YyZTcwNTNfNy0xLTEtMS0w_6703c1b4-4147-4871-a2d7-8a09d86fd89d">33,205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic55505ff13f844188fb0751728d84cce_D20190629-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmIxMDRjYzQ2ODk0ODQzNDQ4YzdiMTFjYmNmMmU3MDUzL3RhYmxlcmFuZ2U6YjEwNGNjNDY4OTQ4NDM0NDhjN2IxMWNiY2YyZTcwNTNfNy0zLTEtMS0w_6f130490-08cf-4313-a2a0-aa497f6b24b6">69,137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47085b4d4dbd42ac8d6b0c47740109da_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmIxMDRjYzQ2ODk0ODQzNDQ4YzdiMTFjYmNmMmU3MDUzL3RhYmxlcmFuZ2U6YjEwNGNjNDY4OTQ4NDM0NDhjN2IxMWNiY2YyZTcwNTNfNy01LTEtMS0w_79ff62aa-c761-40eb-8130-ecb165967708">113,318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f01433b4094674bd5e812d8d00d234_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmIxMDRjYzQ2ODk0ODQzNDQ4YzdiMTFjYmNmMmU3MDUzL3RhYmxlcmFuZ2U6YjEwNGNjNDY4OTQ4NDM0NDhjN2IxMWNiY2YyZTcwNTNfNy03LTEtMS0w_7ae6e83b-58d8-46a3-81de-e5d792000ad9">132,443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25bf6a1fad8f41f8b3dd9743b6494697_D20200704-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmIxMDRjYzQ2ODk0ODQzNDQ4YzdiMTFjYmNmMmU3MDUzL3RhYmxlcmFuZ2U6YjEwNGNjNDY4OTQ4NDM0NDhjN2IxMWNiY2YyZTcwNTNfOC0xLTEtMS0w_db9876f8-23df-4efd-a3cf-8c3930714713">29,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88aea9011a624e6ab196817bcb69590c_D20190629-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmIxMDRjYzQ2ODk0ODQzNDQ4YzdiMTFjYmNmMmU3MDUzL3RhYmxlcmFuZ2U6YjEwNGNjNDY4OTQ4NDM0NDhjN2IxMWNiY2YyZTcwNTNfOC0zLTEtMS0w_0f050580-54fc-4b47-b2c6-68d7784d122c">10,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iced2a1e2c6a1480d8302a1285f8e233c_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmIxMDRjYzQ2ODk0ODQzNDQ4YzdiMTFjYmNmMmU3MDUzL3RhYmxlcmFuZ2U6YjEwNGNjNDY4OTQ4NDM0NDhjN2IxMWNiY2YyZTcwNTNfOC01LTEtMS0w_d9893e92-456b-4aa0-aa42-4b799ab0a0ce">62,971</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43a6c75a975a475a8220f03f17c813e5_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmIxMDRjYzQ2ODk0ODQzNDQ4YzdiMTFjYmNmMmU3MDUzL3RhYmxlcmFuZ2U6YjEwNGNjNDY4OTQ4NDM0NDhjN2IxMWNiY2YyZTcwNTNfOC03LTEtMS0w_49e693e5-97b7-47ca-874a-e97e9f598797">29,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id85db556f50145f28ee780d1a8a89976_D20200704-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmIxMDRjYzQ2ODk0ODQzNDQ4YzdiMTFjYmNmMmU3MDUzL3RhYmxlcmFuZ2U6YjEwNGNjNDY4OTQ4NDM0NDhjN2IxMWNiY2YyZTcwNTNfOS0xLTEtMS0w_d3a07a9b-cb7f-4cda-a7cf-522420a1cb2b">62,505</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1234ea649134872b48e4dbb76f2d830_D20190629-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmIxMDRjYzQ2ODk0ODQzNDQ4YzdiMTFjYmNmMmU3MDUzL3RhYmxlcmFuZ2U6YjEwNGNjNDY4OTQ4NDM0NDhjN2IxMWNiY2YyZTcwNTNfOS0zLTEtMS0w_ff7c2597-0455-4919-94d3-18b27a538ca3">79,935</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53da4333857a41c596e180b7605fb101_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmIxMDRjYzQ2ODk0ODQzNDQ4YzdiMTFjYmNmMmU3MDUzL3RhYmxlcmFuZ2U6YjEwNGNjNDY4OTQ4NDM0NDhjN2IxMWNiY2YyZTcwNTNfOS01LTEtMS0w_3c654001-f7b6-4cdf-9211-aec464843800">176,289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d89b0fff8f440c5a47f0e0cbadc2d30_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmIxMDRjYzQ2ODk0ODQzNDQ4YzdiMTFjYmNmMmU3MDUzL3RhYmxlcmFuZ2U6YjEwNGNjNDY4OTQ4NDM0NDhjN2IxMWNiY2YyZTcwNTNfOS03LTEtMS0w_2d8ae740-cc88-4501-8215-4182ffc10fca">162,441</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmIxMDRjYzQ2ODk0ODQzNDQ4YzdiMTFjYmNmMmU3MDUzL3RhYmxlcmFuZ2U6YjEwNGNjNDY4OTQ4NDM0NDhjN2IxMWNiY2YyZTcwNTNfMTAtMS0xLTEtMA_ff19af56-07e7-4ec7-b06f-d81185f6e3d2">231,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmIxMDRjYzQ2ODk0ODQzNDQ4YzdiMTFjYmNmMmU3MDUzL3RhYmxlcmFuZ2U6YjEwNGNjNDY4OTQ4NDM0NDhjN2IxMWNiY2YyZTcwNTNfMTAtMy0xLTEtMA_e0886dd0-db54-4615-8aaf-2c5811affafc">271,703</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmIxMDRjYzQ2ODk0ODQzNDQ4YzdiMTFjYmNmMmU3MDUzL3RhYmxlcmFuZ2U6YjEwNGNjNDY4OTQ4NDM0NDhjN2IxMWNiY2YyZTcwNTNfMTAtNS0xLTEtMA_f494c235-1440-49bb-83b5-2829fc0f5eb6">717,486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmIxMDRjYzQ2ODk0ODQzNDQ4YzdiMTFjYmNmMmU3MDUzL3RhYmxlcmFuZ2U6YjEwNGNjNDY4OTQ4NDM0NDhjN2IxMWNiY2YyZTcwNTNfMTAtNy0xLTEtMA_0e30034c-5aab-4718-934e-923558b32ec6">727,465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RleHRyZWdpb246MGE4MmQ4MjNlMWM0NDg1OWFkNTUzYmNhNmNhMTE1ZTdfNDgyMA_48501c8f-036f-40fe-acc5-1f364755276a" continuedAt="i1b3123670a904740981729ea354bf7d1" escape="true">Net product revenues and license revenues are recorded in accordance with Topic 606. License revenues include the recognition of the portion of milestones payments allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the milestone would be achieved and a significant reversal of revenues would not occur, as well as royalty revenues and our share of profits under our collaboration agreement with Genentech. Collaboration services revenues were recorded in accordance with Topic 808 and by analogy to Topic 606. Collaboration services revenues include the recognition of deferred revenues for the portion of upfront and milestone payments allocated to our research and development services performance obligations, development cost reimbursements earned under our collaboration agreements, product supply revenues, net of product supply costs, and the royalties we paid to GlaxoSmithKline (GSK) on sales of products containing cabozantinib by our collaboration partners.</ix:nonNumeric></span></div><ix:continuation id="ib5733f2d59d145b5910fa03ce3d29f1b" continuedAt="i9628378d8dec452a916a5cd37749f8d4"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues by product were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.715%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.742%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CABOMETYX</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4bbab6cf384b57a9b8addbd0e12d37_D20200704-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmZjMjQwNWQ1NzBmYTQwOTM4NTkzNmM2NGQzMTc5NmZlL3RhYmxlcmFuZ2U6ZmMyNDA1ZDU3MGZhNDA5Mzg1OTM2YzY0ZDMxNzk2ZmVfMi0xLTEtMS0w_f306d664-8e82-44b9-842d-8044e87d01b0">159,555</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad9dc86bff5e482395fb34a230d3bce2_D20190629-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmZjMjQwNWQ1NzBmYTQwOTM4NTkzNmM2NGQzMTc5NmZlL3RhYmxlcmFuZ2U6ZmMyNDA1ZDU3MGZhNDA5Mzg1OTM2YzY0ZDMxNzk2ZmVfMi0zLTEtMS0w_8ce226b8-d36e-49e5-bb59-3b97af45290d">187,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97faf5b0431f41eeafdc9b84f69366b6_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmZjMjQwNWQ1NzBmYTQwOTM4NTkzNmM2NGQzMTc5NmZlL3RhYmxlcmFuZ2U6ZmMyNDA1ZDU3MGZhNDA5Mzg1OTM2YzY0ZDMxNzk2ZmVfMi01LTEtMS0w_65d9b115-4f5c-45fe-a1ab-71ead92ee2d8">522,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdccf6af360349f19712f9f78dc3b258_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmZjMjQwNWQ1NzBmYTQwOTM4NTkzNmM2NGQzMTc5NmZlL3RhYmxlcmFuZ2U6ZmMyNDA1ZDU3MGZhNDA5Mzg1OTM2YzY0ZDMxNzk2ZmVfMi03LTEtMS0w_c522b6d7-c7bd-4131-9146-185dd1a61d8b">552,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COMETRIQ</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide08272d8494485aa3f67140ad87e288_D20200704-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmZjMjQwNWQ1NzBmYTQwOTM4NTkzNmM2NGQzMTc5NmZlL3RhYmxlcmFuZ2U6ZmMyNDA1ZDU3MGZhNDA5Mzg1OTM2YzY0ZDMxNzk2ZmVfMy0xLTEtMS0w_12389131-32ef-4f8f-97d4-9e1115e68112">9,032</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c63f161b29d440b983b8d7886c07431_D20190629-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmZjMjQwNWQ1NzBmYTQwOTM4NTkzNmM2NGQzMTc5NmZlL3RhYmxlcmFuZ2U6ZmMyNDA1ZDU3MGZhNDA5Mzg1OTM2YzY0ZDMxNzk2ZmVfMy0zLTEtMS0w_bd2c2f7d-315e-4225-bb90-cf09874bbc12">4,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if80a8f9a26734cc1a3ab10698b7d38d1_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmZjMjQwNWQ1NzBmYTQwOTM4NTkzNmM2NGQzMTc5NmZlL3RhYmxlcmFuZ2U6ZmMyNDA1ZDU3MGZhNDA5Mzg1OTM2YzY0ZDMxNzk2ZmVfMy01LTEtMS0w_1d6079d7-8642-4696-914c-4176dd690990">18,816</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2a58f6e8634467fbb6096248e57b129_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmZjMjQwNWQ1NzBmYTQwOTM4NTkzNmM2NGQzMTc5NmZlL3RhYmxlcmFuZ2U6ZmMyNDA1ZDU3MGZhNDA5Mzg1OTM2YzY0ZDMxNzk2ZmVfMy03LTEtMS0w_8ff1b662-1d01-4cb8-8a79-3959d25decbb">12,709</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia527955beb274c50967751e32dc17dff_D20200704-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmZjMjQwNWQ1NzBmYTQwOTM4NTkzNmM2NGQzMTc5NmZlL3RhYmxlcmFuZ2U6ZmMyNDA1ZDU3MGZhNDA5Mzg1OTM2YzY0ZDMxNzk2ZmVfNC0xLTEtMS0w_4da31165-14d6-4ccd-add7-ec824a5df747">168,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i663049bc589a41de99b922b6fb02f1bc_D20190629-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmZjMjQwNWQ1NzBmYTQwOTM4NTkzNmM2NGQzMTc5NmZlL3RhYmxlcmFuZ2U6ZmMyNDA1ZDU3MGZhNDA5Mzg1OTM2YzY0ZDMxNzk2ZmVfNC0zLTEtMS0w_f70c46ac-bb5a-413f-b6a3-9524c7f44777">191,768</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefbb93ab12054c04a4d0d55ad1aaf502_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmZjMjQwNWQ1NzBmYTQwOTM4NTkzNmM2NGQzMTc5NmZlL3RhYmxlcmFuZ2U6ZmMyNDA1ZDU3MGZhNDA5Mzg1OTM2YzY0ZDMxNzk2ZmVfNC01LTEtMS0w_2b671381-43a2-4a56-a2ca-4bf476fc80c0">541,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75b81eceef094c2d86c24a00c59294e1_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmZjMjQwNWQ1NzBmYTQwOTM4NTkzNmM2NGQzMTc5NmZlL3RhYmxlcmFuZ2U6ZmMyNDA1ZDU3MGZhNDA5Mzg1OTM2YzY0ZDMxNzk2ZmVfNC03LTEtMS0w_b40a7679-cf64-4dbd-9df0-ba28bbc816f0">565,024</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_7">Table of Contents</a></span></div></div><ix:continuation id="i2a7d49eb1bf24ff29e95be1b563d6a0f" continuedAt="iafebeed9e03f424eb3b46845a3ab5d8b"><ix:continuation id="i9628378d8dec452a916a5cd37749f8d4"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The percentage of total revenues by customer who individually accounted for&#160;10%&#160;or more of our total revenues were as follows:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.742%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ipsen</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia60d29d213b7423f8b44089dbc426396_D20200704-20201002" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjk3NDcwZDRlZTY2MDRiMTlhYjdjMGRlMGU5YzU1M2MwL3RhYmxlcmFuZ2U6OTc0NzBkNGVlNjYwNGIxOWFiN2MwZGUwZTljNTUzYzBfMi0xLTEtMS0w_027860d7-a419-44e1-920a-5ea784e2c350">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i84172e8ba8944bff9097e2420fc4a71d_D20190629-20190927" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjk3NDcwZDRlZTY2MDRiMTlhYjdjMGRlMGU5YzU1M2MwL3RhYmxlcmFuZ2U6OTc0NzBkNGVlNjYwNGIxOWFiN2MwZGUwZTljNTUzYzBfMi0zLTEtMS0w_50c8ad72-d85a-4fbd-bd65-6873de8a8a1e">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i386a27a71d1b4955bcbcf10ffefe4dc9_D20200104-20201002" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjk3NDcwZDRlZTY2MDRiMTlhYjdjMGRlMGU5YzU1M2MwL3RhYmxlcmFuZ2U6OTc0NzBkNGVlNjYwNGIxOWFiN2MwZGUwZTljNTUzYzBfMi01LTEtMS0w_2a107627-b137-4528-9c03-8ff7e1120968">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icc5620147c964216bca8a91f88f53db3_D20181229-20190927" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjk3NDcwZDRlZTY2MDRiMTlhYjdjMGRlMGU5YzU1M2MwL3RhYmxlcmFuZ2U6OTc0NzBkNGVlNjYwNGIxOWFiN2MwZGUwZTljNTUzYzBfMi03LTEtMS0w_02e2d44e-e869-4468-88aa-029082e65df7">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of CVS Health Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib86d0fb1dcd542688f1f82783390f7d7_D20200704-20201002" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjk3NDcwZDRlZTY2MDRiMTlhYjdjMGRlMGU5YzU1M2MwL3RhYmxlcmFuZ2U6OTc0NzBkNGVlNjYwNGIxOWFiN2MwZGUwZTljNTUzYzBfMy0xLTEtMS0w_f7e5d41d-15eb-44c5-8711-73e4a761462b">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i73d4427b07944bb4a39082c52e7e3993_D20190629-20190927" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjk3NDcwZDRlZTY2MDRiMTlhYjdjMGRlMGU5YzU1M2MwL3RhYmxlcmFuZ2U6OTc0NzBkNGVlNjYwNGIxOWFiN2MwZGUwZTljNTUzYzBfMy0zLTEtMS0w_f862174c-af75-447d-93d7-90afa5a74bf7">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5702087f6d044b2f8cb91e6d9e024981_D20200104-20201002" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjk3NDcwZDRlZTY2MDRiMTlhYjdjMGRlMGU5YzU1M2MwL3RhYmxlcmFuZ2U6OTc0NzBkNGVlNjYwNGIxOWFiN2MwZGUwZTljNTUzYzBfMy01LTEtMS0w_8f62bfb7-0e15-4fc7-a9d9-7d2ca098c35a">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i185156eb44914a05b07e512b521ee175_D20181229-20190927" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjk3NDcwZDRlZTY2MDRiMTlhYjdjMGRlMGU5YzU1M2MwL3RhYmxlcmFuZ2U6OTc0NzBkNGVlNjYwNGIxOWFiN2MwZGUwZTljNTUzYzBfMy03LTEtMS0w_58f049f1-6245-44c4-b8da-7c9cedfab388">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of McKesson Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1a1a12d3a1e34e64be6756a38f99157b_D20200704-20201002" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjk3NDcwZDRlZTY2MDRiMTlhYjdjMGRlMGU5YzU1M2MwL3RhYmxlcmFuZ2U6OTc0NzBkNGVlNjYwNGIxOWFiN2MwZGUwZTljNTUzYzBfNC0xLTEtMS0w_af81039b-efed-4762-a168-8483e6bab405">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7fe0056abef84c0fb63cfb73f2dbaf5e_D20190629-20190927" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjk3NDcwZDRlZTY2MDRiMTlhYjdjMGRlMGU5YzU1M2MwL3RhYmxlcmFuZ2U6OTc0NzBkNGVlNjYwNGIxOWFiN2MwZGUwZTljNTUzYzBfNC0zLTEtMS0w_7fe22524-8ad0-4e36-821b-305b8dbb99bf">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i70fe222147914251b9dc10ce75948cf9_D20200104-20201002" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjk3NDcwZDRlZTY2MDRiMTlhYjdjMGRlMGU5YzU1M2MwL3RhYmxlcmFuZ2U6OTc0NzBkNGVlNjYwNGIxOWFiN2MwZGUwZTljNTUzYzBfNC01LTEtMS0w_588ef121-77b8-4e7e-9421-c4e031cb593d">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iacd7fc12f88842b1924368fbbf75cc1f_D20181229-20190927" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjk3NDcwZDRlZTY2MDRiMTlhYjdjMGRlMGU5YzU1M2MwL3RhYmxlcmFuZ2U6OTc0NzBkNGVlNjYwNGIxOWFiN2MwZGUwZTljNTUzYzBfNC03LTEtMS0w_188fa74f-4e35-4b62-8b6d-9c5ed6d20108">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of AmerisourceBergen Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i14e1a35d582a44a0a5026811d269e717_D20200704-20201002" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjk3NDcwZDRlZTY2MDRiMTlhYjdjMGRlMGU5YzU1M2MwL3RhYmxlcmFuZ2U6OTc0NzBkNGVlNjYwNGIxOWFiN2MwZGUwZTljNTUzYzBfNS0xLTEtMS0w_22b7168c-3933-4d6e-a943-210f44508afb">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iced8dcb1cd6a410d8111f8781e04944b_D20190629-20190927" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjk3NDcwZDRlZTY2MDRiMTlhYjdjMGRlMGU5YzU1M2MwL3RhYmxlcmFuZ2U6OTc0NzBkNGVlNjYwNGIxOWFiN2MwZGUwZTljNTUzYzBfNS0zLTEtMS0w_9783d827-1944-433b-92ef-1e4a82e5445a">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id929db05799d4a7ea908997e18680ab8_D20200104-20201002" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjk3NDcwZDRlZTY2MDRiMTlhYjdjMGRlMGU5YzU1M2MwL3RhYmxlcmFuZ2U6OTc0NzBkNGVlNjYwNGIxOWFiN2MwZGUwZTljNTUzYzBfNS01LTEtMS0w_330d8a10-5b54-4d5d-ba43-847d9519886a">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaabc597e0f5940e89c79670faf29f78e_D20181229-20190927" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjk3NDcwZDRlZTY2MDRiMTlhYjdjMGRlMGU5YzU1M2MwL3RhYmxlcmFuZ2U6OTc0NzBkNGVlNjYwNGIxOWFiN2MwZGUwZTljNTUzYzBfNS03LTEtMS0w_53fbcac5-4491-4bea-aa05-375c4a36deaf">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of Optum Specialty Pharmacy</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3d6b1d115ff4494fb1233255cd7c2c19_D20200704-20201002" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjk3NDcwZDRlZTY2MDRiMTlhYjdjMGRlMGU5YzU1M2MwL3RhYmxlcmFuZ2U6OTc0NzBkNGVlNjYwNGIxOWFiN2MwZGUwZTljNTUzYzBfNi0xLTEtMS0w_45229d3d-1bf3-41e5-925a-a83eaf64bccd">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i54ae6ae3ffc442a5b7b73749a9ee7058_D20190629-20190927" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjk3NDcwZDRlZTY2MDRiMTlhYjdjMGRlMGU5YzU1M2MwL3RhYmxlcmFuZ2U6OTc0NzBkNGVlNjYwNGIxOWFiN2MwZGUwZTljNTUzYzBfNi0zLTEtMS0w_67f501c0-4c04-474b-aa4b-37d4db9d3779">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iff89a893303e4fa882dc5129bcbfb868_D20200104-20201002" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjk3NDcwZDRlZTY2MDRiMTlhYjdjMGRlMGU5YzU1M2MwL3RhYmxlcmFuZ2U6OTc0NzBkNGVlNjYwNGIxOWFiN2MwZGUwZTljNTUzYzBfNi01LTEtMS0w_5a9ecaa1-31e1-42ab-bbbb-b8aca3deda6c">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ief5d2999265b4a7ba5bbc8848a958c41_D20181229-20190927" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjk3NDcwZDRlZTY2MDRiMTlhYjdjMGRlMGU5YzU1M2MwL3RhYmxlcmFuZ2U6OTc0NzBkNGVlNjYwNGIxOWFiN2MwZGUwZTljNTUzYzBfNi03LTEtMS0w_1b36af8c-deca-4ff8-a385-a6b8f9bf4c4e">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Takeda Pharmaceutical Company Limited (Takeda)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i586e46eec28e45cc9e06428a8195d748_D20200704-20201002" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjk3NDcwZDRlZTY2MDRiMTlhYjdjMGRlMGU5YzU1M2MwL3RhYmxlcmFuZ2U6OTc0NzBkNGVlNjYwNGIxOWFiN2MwZGUwZTljNTUzYzBfNy0xLTEtMS0w_53804a20-6c4f-42f6-a009-aeda89a4546d">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7d79b47a315146babea975fec8dce552_D20190629-20190927" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjk3NDcwZDRlZTY2MDRiMTlhYjdjMGRlMGU5YzU1M2MwL3RhYmxlcmFuZ2U6OTc0NzBkNGVlNjYwNGIxOWFiN2MwZGUwZTljNTUzYzBfNy0zLTEtMS0w_f382dd79-81d4-4b10-99eb-efb6563dbfa6">0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3cb1cfcba4a24a5a95475dcd23a6d6a7_D20200104-20201002" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjk3NDcwZDRlZTY2MDRiMTlhYjdjMGRlMGU5YzU1M2MwL3RhYmxlcmFuZ2U6OTc0NzBkNGVlNjYwNGIxOWFiN2MwZGUwZTljNTUzYzBfNy01LTEtMS0w_5c35cd91-f61e-4fc4-83d7-9d7da0e15502">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3a9ff92761624c878e628676f2c878f8_D20181229-20190927" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjk3NDcwZDRlZTY2MDRiMTlhYjdjMGRlMGU5YzU1M2MwL3RhYmxlcmFuZ2U6OTc0NzBkNGVlNjYwNGIxOWFiN2MwZGUwZTljNTUzYzBfNy03LTEtMS0w_c676824e-28b8-4e58-9372-4fae229e32da">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by geographic region were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.742%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec0582c68f2e45809336de61a7ef2ffe_D20200704-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmE4MzdkZjM4ZWIxMDRlYTViMzI5N2M5OGI1YTlkZjI2L3RhYmxlcmFuZ2U6YTgzN2RmMzhlYjEwNGVhNWIzMjk3Yzk4YjVhOWRmMjZfMi0xLTEtMS0w_440af340-c842-4ff5-9913-c1f65cec2c61">171,552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71b0e797d9454761a9c3b48ce0cd6dc7_D20190629-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmE4MzdkZjM4ZWIxMDRlYTViMzI5N2M5OGI1YTlkZjI2L3RhYmxlcmFuZ2U6YTgzN2RmMzhlYjEwNGVhNWIzMjk3Yzk4YjVhOWRmMjZfMi0zLTEtMS0w_4c33272d-36a8-4a30-a4e6-329ad9d4a3cf">194,484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e8cff04ca5040a68e2a49c6e3601c97_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmE4MzdkZjM4ZWIxMDRlYTViMzI5N2M5OGI1YTlkZjI2L3RhYmxlcmFuZ2U6YTgzN2RmMzhlYjEwNGVhNWIzMjk3Yzk4YjVhOWRmMjZfMi01LTEtMS0w_e4d1e087-5dd9-4c96-9073-5d26f112c6d5">549,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62c0d9fe6a22430782ddc2b6e95e7fea_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmE4MzdkZjM4ZWIxMDRlYTViMzI5N2M5OGI1YTlkZjI2L3RhYmxlcmFuZ2U6YTgzN2RmMzhlYjEwNGVhNWIzMjk3Yzk4YjVhOWRmMjZfMi03LTEtMS0w_95e904c7-bda3-49bd-9599-a33cabdb6752">572,957</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3a34af32f82425db5a92b122c952662_D20200704-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmE4MzdkZjM4ZWIxMDRlYTViMzI5N2M5OGI1YTlkZjI2L3RhYmxlcmFuZ2U6YTgzN2RmMzhlYjEwNGVhNWIzMjk3Yzk4YjVhOWRmMjZfMy0xLTEtMS0w_364d4b81-c12b-4414-a7e1-85b3ef776864">36,006</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec35a82156214e73aba68b440656efba_D20190629-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmE4MzdkZjM4ZWIxMDRlYTViMzI5N2M5OGI1YTlkZjI2L3RhYmxlcmFuZ2U6YTgzN2RmMzhlYjEwNGVhNWIzMjk3Yzk4YjVhOWRmMjZfMy0zLTEtMS0w_fb8568b7-3600-48ab-bae9-9b4011dcb2f0">76,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6b900d2f20e47d098b552ec62a9e8d6_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmE4MzdkZjM4ZWIxMDRlYTViMzI5N2M5OGI1YTlkZjI2L3RhYmxlcmFuZ2U6YTgzN2RmMzhlYjEwNGVhNWIzMjk3Yzk4YjVhOWRmMjZfMy01LTEtMS0w_b4896630-e904-4008-938b-6909dc0d092e">117,959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie38bb019719d40208f85caefe75b164d_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmE4MzdkZjM4ZWIxMDRlYTViMzI5N2M5OGI1YTlkZjI2L3RhYmxlcmFuZ2U6YTgzN2RmMzhlYjEwNGVhNWIzMjk3Yzk4YjVhOWRmMjZfMy03LTEtMS0w_6a747156-08b9-4236-ab37-86a017c2b4b8">120,134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b85521d483a41f38d661425a8820625_D20200704-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmE4MzdkZjM4ZWIxMDRlYTViMzI5N2M5OGI1YTlkZjI2L3RhYmxlcmFuZ2U6YTgzN2RmMzhlYjEwNGVhNWIzMjk3Yzk4YjVhOWRmMjZfNC0xLTEtMS0w_351b21df-bd51-4b5c-8c04-8920ff1a9099">23,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db6d59506ab40b9822586497086d157_D20190629-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmE4MzdkZjM4ZWIxMDRlYTViMzI5N2M5OGI1YTlkZjI2L3RhYmxlcmFuZ2U6YTgzN2RmMzhlYjEwNGVhNWIzMjk3Yzk4YjVhOWRmMjZfNC0zLTEtMS0w_9b841086-f62b-4964-9302-fd04dc8d4e59">1,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i477ac2490d6a414281cc99f9812014e7_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmE4MzdkZjM4ZWIxMDRlYTViMzI5N2M5OGI1YTlkZjI2L3RhYmxlcmFuZ2U6YTgzN2RmMzhlYjEwNGVhNWIzMjk3Yzk4YjVhOWRmMjZfNC01LTEtMS0w_d5c46123-cf71-439f-866b-ab75f06fcf76">50,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65978d0dcb28411cb73d35911d6e8d6c_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmE4MzdkZjM4ZWIxMDRlYTViMzI5N2M5OGI1YTlkZjI2L3RhYmxlcmFuZ2U6YTgzN2RmMzhlYjEwNGVhNWIzMjk3Yzk4YjVhOWRmMjZfNC03LTEtMS0w_64c07323-ccd1-4288-bb1f-0edfbc7304c1">34,374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmE4MzdkZjM4ZWIxMDRlYTViMzI5N2M5OGI1YTlkZjI2L3RhYmxlcmFuZ2U6YTgzN2RmMzhlYjEwNGVhNWIzMjk3Yzk4YjVhOWRmMjZfNS0xLTEtMS0w_240c95aa-376c-4f38-b30a-86cacfaaaadc">231,092</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmE4MzdkZjM4ZWIxMDRlYTViMzI5N2M5OGI1YTlkZjI2L3RhYmxlcmFuZ2U6YTgzN2RmMzhlYjEwNGVhNWIzMjk3Yzk4YjVhOWRmMjZfNS0zLTEtMS0w_e5d2f128-e0a4-4874-b440-9a0ca49abe2e">271,703</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmE4MzdkZjM4ZWIxMDRlYTViMzI5N2M5OGI1YTlkZjI2L3RhYmxlcmFuZ2U6YTgzN2RmMzhlYjEwNGVhNWIzMjk3Yzk4YjVhOWRmMjZfNS01LTEtMS0w_4bcf8ec1-b466-474e-b079-696f41257773">717,486</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmE4MzdkZjM4ZWIxMDRlYTViMzI5N2M5OGI1YTlkZjI2L3RhYmxlcmFuZ2U6YTgzN2RmMzhlYjEwNGVhNWIzMjk3Yzk4YjVhOWRmMjZfNS03LTEtMS0w_54a924c0-3cfb-4403-969f-f858a93c37f2">727,465</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1b3123670a904740981729ea354bf7d1" continuedAt="i56926ef1f64f4bbcb3bae1fbce29acd4">Net product revenues are attributed to geographic region based on the ship-to location. License and collaboration services revenues are attributed to geographic region based on the location of our collaboration partners&#8217; headquarters.</ix:continuation></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Sales Discounts and Allowances</span></div><ix:nonNumeric contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" name="exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RleHRyZWdpb246MGE4MmQ4MjNlMWM0NDg1OWFkNTUzYmNhNmNhMTE1ZTdfNDgyNw_eec01f03-b633-4f29-a0de-bf7f5e99c05d" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.905%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.742%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Chargebacks and Discounts for Prompt Payment</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Customer Credits/Fees and Co-pay Assistance</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Rebates</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2019</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67b11a0135a641a4bd4d22e09f7bfbcf_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjEwOGFmODMyOTY3ZDQxMTRiYmFmNzI0ZThjOGUxNzkzL3RhYmxlcmFuZ2U6MTA4YWY4MzI5NjdkNDExNGJiYWY3MjRlOGM4ZTE3OTNfMS0xLTEtMS0w_dfe11480-ddfa-42d6-8393-c6ce2e3d2d33">7,514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i504cbdf3907f4152872efaf0c542118f_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjEwOGFmODMyOTY3ZDQxMTRiYmFmNzI0ZThjOGUxNzkzL3RhYmxlcmFuZ2U6MTA4YWY4MzI5NjdkNDExNGJiYWY3MjRlOGM4ZTE3OTNfMS0zLTEtMS0w_ad15f1c7-d722-4bf5-95d0-0ea7db752cc6">3,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b422997cdc1458bb19aa47286284ef0_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjEwOGFmODMyOTY3ZDQxMTRiYmFmNzI0ZThjOGUxNzkzL3RhYmxlcmFuZ2U6MTA4YWY4MzI5NjdkNDExNGJiYWY3MjRlOGM4ZTE3OTNfMS01LTEtMS0w_58a63fab-1868-4a17-ac12-7fa50205d535">15,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjEwOGFmODMyOTY3ZDQxMTRiYmFmNzI0ZThjOGUxNzkzL3RhYmxlcmFuZ2U6MTA4YWY4MzI5NjdkNDExNGJiYWY3MjRlOGM4ZTE3OTNfMS05LTEtMS0w_3c575f1a-21ee-474d-b111-7e17ba28571e">26,233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to sales made in:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bb996de5a5f41699a6974a3f048c443_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjEwOGFmODMyOTY3ZDQxMTRiYmFmNzI0ZThjOGUxNzkzL3RhYmxlcmFuZ2U6MTA4YWY4MzI5NjdkNDExNGJiYWY3MjRlOGM4ZTE3OTNfMy0xLTEtMS0w_1344a60e-8725-48fa-8e8b-ebbe035b7166">108,166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9fee7c5808d4690b34490b6ca50b8db_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjEwOGFmODMyOTY3ZDQxMTRiYmFmNzI0ZThjOGUxNzkzL3RhYmxlcmFuZ2U6MTA4YWY4MzI5NjdkNDExNGJiYWY3MjRlOGM4ZTE3OTNfMy0zLTEtMS0w_30d22b56-53a8-470e-8be7-7cb19d9ad723">11,718</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b664d4199b94af5a11e4871fd387735_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjEwOGFmODMyOTY3ZDQxMTRiYmFmNzI0ZThjOGUxNzkzL3RhYmxlcmFuZ2U6MTA4YWY4MzI5NjdkNDExNGJiYWY3MjRlOGM4ZTE3OTNfMy01LTEtMS0w_0f907195-2cb1-47a0-b4cd-25978b26f03d">41,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjEwOGFmODMyOTY3ZDQxMTRiYmFmNzI0ZThjOGUxNzkzL3RhYmxlcmFuZ2U6MTA4YWY4MzI5NjdkNDExNGJiYWY3MjRlOGM4ZTE3OTNfMy05LTEtMS0w_5c147fa0-bd32-41aa-afb1-d3d555b74385">161,235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bb996de5a5f41699a6974a3f048c443_D20200104-20201002" decimals="-3" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjEwOGFmODMyOTY3ZDQxMTRiYmFmNzI0ZThjOGUxNzkzL3RhYmxlcmFuZ2U6MTA4YWY4MzI5NjdkNDExNGJiYWY3MjRlOGM4ZTE3OTNfNC0xLTEtMS0w_56e869b2-3b7e-472e-b63e-b60c98da5e58">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9fee7c5808d4690b34490b6ca50b8db_D20200104-20201002" decimals="-3" sign="-" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjEwOGFmODMyOTY3ZDQxMTRiYmFmNzI0ZThjOGUxNzkzL3RhYmxlcmFuZ2U6MTA4YWY4MzI5NjdkNDExNGJiYWY3MjRlOGM4ZTE3OTNfNC0zLTEtMS0w_c33c9887-61ff-4acb-bfef-367b8e2d8955">352</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b664d4199b94af5a11e4871fd387735_D20200104-20201002" decimals="-3" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjEwOGFmODMyOTY3ZDQxMTRiYmFmNzI0ZThjOGUxNzkzL3RhYmxlcmFuZ2U6MTA4YWY4MzI5NjdkNDExNGJiYWY3MjRlOGM4ZTE3OTNfNC01LTEtMS0w_6fdd08dc-045b-45a0-8613-fa1c6ee97f2e">752</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="-3" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjEwOGFmODMyOTY3ZDQxMTRiYmFmNzI0ZThjOGUxNzkzL3RhYmxlcmFuZ2U6MTA4YWY4MzI5NjdkNDExNGJiYWY3MjRlOGM4ZTE3OTNfNC05LTEtMS0w_358e8807-f51e-4335-9c5a-772ca4749a57">433</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and customer credits issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5bb996de5a5f41699a6974a3f048c443_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjEwOGFmODMyOTY3ZDQxMTRiYmFmNzI0ZThjOGUxNzkzL3RhYmxlcmFuZ2U6MTA4YWY4MzI5NjdkNDExNGJiYWY3MjRlOGM4ZTE3OTNfNS0xLTEtMS0w_8f5110ab-2834-4c91-a151-cebc68cc6619">107,118</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9fee7c5808d4690b34490b6ca50b8db_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjEwOGFmODMyOTY3ZDQxMTRiYmFmNzI0ZThjOGUxNzkzL3RhYmxlcmFuZ2U6MTA4YWY4MzI5NjdkNDExNGJiYWY3MjRlOGM4ZTE3OTNfNS0zLTEtMS0w_30cb7a29-1f85-43f2-957a-2cf6f80e6587">11,513</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8b664d4199b94af5a11e4871fd387735_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjEwOGFmODMyOTY3ZDQxMTRiYmFmNzI0ZThjOGUxNzkzL3RhYmxlcmFuZ2U6MTA4YWY4MzI5NjdkNDExNGJiYWY3MjRlOGM4ZTE3OTNfNS01LTEtMS0w_866785b0-6d8f-4de4-8262-9fa1bac65618">41,546</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjEwOGFmODMyOTY3ZDQxMTRiYmFmNzI0ZThjOGUxNzkzL3RhYmxlcmFuZ2U6MTA4YWY4MzI5NjdkNDExNGJiYWY3MjRlOGM4ZTE3OTNfNS05LTEtMS0w_ab686636-646f-490a-bc06-8a39e7011041">160,177</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September&#160;30, 2020</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie771b9f5649b4d37b25de019253cf120_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjEwOGFmODMyOTY3ZDQxMTRiYmFmNzI0ZThjOGUxNzkzL3RhYmxlcmFuZ2U6MTA4YWY4MzI5NjdkNDExNGJiYWY3MjRlOGM4ZTE3OTNfNi0xLTEtMS0w_9a9d7ed9-de66-486f-85dd-3b2f935b3e82">8,595</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e441c2da394ce2b81f3584524ba9a1_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjEwOGFmODMyOTY3ZDQxMTRiYmFmNzI0ZThjOGUxNzkzL3RhYmxlcmFuZ2U6MTA4YWY4MzI5NjdkNDExNGJiYWY3MjRlOGM4ZTE3OTNfNi0zLTEtMS0w_84d5a033-9b62-4f4f-b446-a8dd60158217">3,350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2f14853d41346db96816c2397b0613f_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjEwOGFmODMyOTY3ZDQxMTRiYmFmNzI0ZThjOGUxNzkzL3RhYmxlcmFuZ2U6MTA4YWY4MzI5NjdkNDExNGJiYWY3MjRlOGM4ZTE3OTNfNi01LTEtMS0w_18ab6b39-8f23-4c62-b483-63bd62e738f9">15,779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjEwOGFmODMyOTY3ZDQxMTRiYmFmNzI0ZThjOGUxNzkzL3RhYmxlcmFuZ2U6MTA4YWY4MzI5NjdkNDExNGJiYWY3MjRlOGM4ZTE3OTNfNi05LTEtMS0w_1a66f85c-1918-400f-808d-22bbcf92ac78">27,724</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:continuation id="i56926ef1f64f4bbcb3bae1fbce29acd4" continuedAt="icfd998a9cffa4f19a88e9d781ebaac7d"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowance for chargebacks and discounts for prompt payment is recorded as a reduction of trade receivables, net and the remaining reserves are recorded as rebates and fees due to customers in the accompanying Condensed Consolidated Balance Sheets. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Assets and Liabilities </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive payments from our collaboration partners based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. We may also recognize revenues in advance of the contractual billing schedule and such amounts are recorded, net of any allowance for credit losses, as a contract asset when recognized. Contract assets, which are presented in prepaid expenses and other current assets in the accompanying Condensed Consolidated Balance Sheets, we</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">re $<ix:nonFraction unitRef="usd" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="-5" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RleHRyZWdpb246MGE4MmQ4MjNlMWM0NDg1OWFkNTUzYmNhNmNhMTE1ZTdfMjY0Ng_27f0bcd9-f954-4514-b169-25b059c19330">0</ix:nonFraction> and&#160;$<ix:nonFraction unitRef="usd" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RleHRyZWdpb246MGE4MmQ4MjNlMWM0NDg1OWFkNTUzYmNhNmNhMTE1ZTdfMjY1NA_fccb6730-386a-424a-90c0-4c60554c8966">1.1</ix:nonFraction> million</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;as of&#160;September&#160;30, 2020 and December&#160;31, 2019, respectively. We may be required to defer recognition of revenues for upfront and milestone payments until we perform our obligations under these arrangements, and such amounts are recorded as deferred revenues upon receipt or when due. Contract liabilities we</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">re $<ix:nonFraction unitRef="usd" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RleHRyZWdpb246MGE4MmQ4MjNlMWM0NDg1OWFkNTUzYmNhNmNhMTE1ZTdfMjkzOA_86546085-39dc-4c0c-8992-ae84f5e36615">10.6</ix:nonFraction> million and&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RleHRyZWdpb246MGE4MmQ4MjNlMWM0NDg1OWFkNTUzYmNhNmNhMTE1ZTdfMjk0Ng_772ffe66-7bfe-4db4-873a-7014fda99929">6.6</ix:nonFraction> million&#160;as of&#160;September&#160;30, 2020 and </span></div></ix:continuation></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_7">Table of Contents</a></span></div></div><ix:continuation id="iafebeed9e03f424eb3b46845a3ab5d8b"><div style="margin-top:9pt"><ix:continuation id="icfd998a9cffa4f19a88e9d781ebaac7d" continuedAt="i5cd2f636186f423aa6cbd75e3e435d05"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2019, respectively. The current portion of th</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e contract liabilities totaling $<ix:nonFraction unitRef="usd" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RleHRyZWdpb246MGE4MmQ4MjNlMWM0NDg1OWFkNTUzYmNhNmNhMTE1ZTdfMzAzOA_9a0e26af-7748-4504-b518-15b04e115564">1.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RleHRyZWdpb246MGE4MmQ4MjNlMWM0NDg1OWFkNTUzYmNhNmNhMTE1ZTdfMzA0Ng_e0774037-7bf9-41ce-912e-a2444cda550c">0</ix:nonFraction> as of&#160;September&#160;30, 2020 and December&#160;31, 2019, respectively, are presented in other current liabilities and the remainder of the contract liabilities are presented in long-term portion of deferred revenues as of those dates in the accompanyi</span></ix:continuation><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5cd2f636186f423aa6cbd75e3e435d05">ng Condensed Consolidated Balance Sheets. For those contracts that have multiple performance obligations, contract&#160;assets and liabilities are reported on a&#160;net&#160;basis&#160;at the&#160;contract&#160;level.</ix:continuation> </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant changes in contract assets during the nine months ended September&#160;30, 2020 include the impact of a $<ix:nonFraction unitRef="usd" contextRef="icef64ef981c4433ab4d95dd86f4c12ae_I20201002" decimals="-5" format="ixt:numdotdecimal" name="exel:EligiblePaymentFromCollaborationForDevelopmentMilestoneAchievementUnderCollaborationsAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RleHRyZWdpb246MGE4MmQ4MjNlMWM0NDg1OWFkNTUzYmNhNmNhMTE1ZTdfMzUzMA_2cab4d54-ae79-40e2-b2de-6810144b6488">20.0</ix:nonFraction> million development milestone from Ipsen we determined was probable of achievement, which was offset by the impact of a $<ix:nonFraction unitRef="usd" contextRef="i0813edb6dc1f42149871864785a370b0_I20201002" decimals="-5" format="ixt:numdotdecimal" name="exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RleHRyZWdpb246MGE4MmQ4MjNlMWM0NDg1OWFkNTUzYmNhNmNhMTE1ZTdfMzY0NQ_db913dfc-d4c2-4b29-8f96-bcd05747a95e">10.0</ix:nonFraction> million milestone from Takeda which was recognized as revenues during the year ended December 31, 2019 and was achieved, invoiced and collected in the first quarter of 2020.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2020 and 2019, we recognized $<ix:nonFraction unitRef="usd" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RleHRyZWdpb246MGE4MmQ4MjNlMWM0NDg1OWFkNTUzYmNhNmNhMTE1ZTdfMzg1Mw_da981f4e-bd56-4092-8574-4dcaabeb32aa">6.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RleHRyZWdpb246MGE4MmQ4MjNlMWM0NDg1OWFkNTUzYmNhNmNhMTE1ZTdfMzg1OQ_02522412-630a-463d-91ee-6c4d040dc91f">2.7</ix:nonFraction> million, respectively, in revenues that were included in the beginning deferred revenues balance for those periods.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2020, we recognized $<ix:nonFraction unitRef="usd" contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RleHRyZWdpb246MGE4MmQ4MjNlMWM0NDg1OWFkNTUzYmNhNmNhMTE1ZTdfNDAwMw_ffc7ab45-fd05-4561-95db-1b355b9fe311">33.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RleHRyZWdpb246MGE4MmQ4MjNlMWM0NDg1OWFkNTUzYmNhNmNhMTE1ZTdfNDAxMg_6e02dc17-f0f9-4057-a002-1c881f1cb77a">115.3</ix:nonFraction> million, respectively, in revenues for performance obligations satisfied in previous periods as compared to $<ix:nonFraction unitRef="usd" contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RleHRyZWdpb246MGE4MmQ4MjNlMWM0NDg1OWFkNTUzYmNhNmNhMTE1ZTdfNDExNg_da7ecaf2-6a64-477b-bbc8-e12754f8e5ff">67.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RleHRyZWdpb246MGE4MmQ4MjNlMWM0NDg1OWFkNTUzYmNhNmNhMTE1ZTdfNDEyMw_da8c858f-039e-4b8b-894b-8b5bd55e6f79">129.0</ix:nonFraction> million during the comparable periods in 2019. Such revenues primarily related to milestone and royalty payments allocated to the license performance obligations for our collaborations with Ipsen, Takeda, Daiichi Sankyo and Genentech.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, $<ix:nonFraction unitRef="usd" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RleHRyZWdpb246MGE4MmQ4MjNlMWM0NDg1OWFkNTUzYmNhNmNhMTE1ZTdfNDM2MQ_86414fa2-c7ad-44b3-a6e1-c640da01e06f">88.9</ix:nonFraction> million of t</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he combined transaction prices for our Ipsen and Takeda collaborations were allocated to performance obligations that had not yet been satisfied. See &#8220;Note 3. Collaboration Agreements - Cabozantinib Commercial Collaborations - Performance Obligations and Transaction Prices for our Ipsen and Takeda Collaborations&#8221; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2019 for information about the expected timing to satisfy these performance obligations.</span></div></ix:continuation><div id="i0283c6f517b447ec92f154ee691f4028_49"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 3. <ix:nonNumeric contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RleHRyZWdpb246YWFhZjI4ZTg2ZTI3NDdhNjk4ODc4MTA3NmE5YzhjZTNfMTA0NDUzNjA0NzYwNzg_66fa4588-d6ae-4ff1-abf5-d34eacf97341" continuedAt="i582be04d76794d719d9ab7aa44705343" escape="true">COLLABORATION AGREEMENTS</ix:nonNumeric></span></div><ix:continuation id="i582be04d76794d719d9ab7aa44705343" continuedAt="ic146007841e8433d8fb3c187ce627659"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established multiple collaborations with leading pharmaceutical companies for the commercialization and further development of cabozantinib. Additionally, consistent with our business strategy prior to the commercialization of cabozantinib, we entered into other collaborations with leading pharmaceutical companies for other compounds and programs in our portfolio. Under these collaborations, we are generally entitled to receive milestone and royalty payments, and for certain collaborations receive payments for product supply services, development cost reimbursements, and/or profit-sharing payments. See &#8220;Note 2. Revenues&#8221; for additional information on revenues recognized under our collaboration agreements.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also established multiple collaborations with smaller, discovery-focused biotechnology companies to expand our product pipeline. Under these collaborations, we may be required to make milestone and royalty payments, and for certain collaborations make payments for development cost reimbursements and/or option exercise fees. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Note 3. Collaboration Agreements&#8221; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2019, or as further described below, for a description of each of our collaboration agreements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cabozantinib Collaborations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ipsen Collaboration </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In February 2016, we entered into a collaboration agreement with Ipsen for the commercialization and further development of cabozantinib. Under the terms of the collaboration agreement, as amended, Ipsen received exclusive commercialization rights for current and potential future cabozantinib indications outside of the U.S. and Japan. We have also agreed to collaborate with Ipsen on the development of cabozantinib for current and potential future indications. The parties&#8217; efforts are governed through a joint steering committee and appropriate subcommittees established to guide and oversee the collaboration&#8217;s operation and strategic direction; provided, however, that we retain final decision-making authority with respect to cabozantinib&#8217;s ongoing development. During the second quarter of 2020, Ipsen opted into and is now co-funding the development costs for CONTACT-01 and CONTACT-02, two phase 3 pivotal trials of cabozantinib in combination with atezolizumab in patients with previously treated, metastatic non-small cell lung cancer and metastatic castration-resistant prostate cancer, respectively, and the four remaining cohorts of COSMIC-021 it had not previously opted into. COSMIC-021 is a broad phase 1b study evaluating the safety and tolerability of cabozantinib in combination with atezolizumab in patients with locally advanced or metastatic solid tumors.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_7">Table of Contents</a></span></div></div><ix:continuation id="ic146007841e8433d8fb3c187ce627659" continuedAt="i95e584c590954734ba1729982eae5231"><ix:nonNumeric contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RleHRyZWdpb246YWFhZjI4ZTg2ZTI3NDdhNjk4ODc4MTA3NmE5YzhjZTNfNTU0NQ_51c51eb6-c3ea-4154-a1d3-0850a35a2ea0" continuedAt="ib5edc36eccc646e587c1c975def3ca67" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under the collaboration agreement with Ipsen were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.742%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic563e3038d034910b191aa2e402f2d54_D20200704-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RhYmxlOjFhNTdhNmNiZGNmYTRhNmJhZmI0YjhhYjU4YmYxZjUzL3RhYmxlcmFuZ2U6MWE1N2E2Y2JkY2ZhNGE2YmFmYjRiOGFiNThiZjFmNTNfMi0xLTEtMS0w_afec674b-cb2a-4975-b831-2a1ee4567cea">19,910</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306ec623b7da464887c212d6bbb0c3b9_D20190629-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RhYmxlOjFhNTdhNmNiZGNmYTRhNmJhZmI0YjhhYjU4YmYxZjUzL3RhYmxlcmFuZ2U6MWE1N2E2Y2JkY2ZhNGE2YmFmYjRiOGFiNThiZjFmNTNfMi0zLTEtMS0w_0fc33a16-c1d4-44e7-b717-a7e092ca24b5">66,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie769fec28ac9424ab1612b636240244f_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RhYmxlOjFhNTdhNmNiZGNmYTRhNmJhZmI0YjhhYjU4YmYxZjUzL3RhYmxlcmFuZ2U6MWE1N2E2Y2JkY2ZhNGE2YmFmYjRiOGFiNThiZjFmNTNfMi01LTEtMS0w_9f849b53-d2b2-44f2-944a-baefefe9b94c">71,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b97daa6c5714e879d52e0f5818a13e5_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RhYmxlOjFhNTdhNmNiZGNmYTRhNmJhZmI0YjhhYjU4YmYxZjUzL3RhYmxlcmFuZ2U6MWE1N2E2Y2JkY2ZhNGE2YmFmYjRiOGFiNThiZjFmNTNfMi03LTEtMS0w_36a87fa3-186e-4a93-958d-d16a9bf00bc1">95,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i625c660e5c2c47ffba3e54c798ef1200_D20200704-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RhYmxlOjFhNTdhNmNiZGNmYTRhNmJhZmI0YjhhYjU4YmYxZjUzL3RhYmxlcmFuZ2U6MWE1N2E2Y2JkY2ZhNGE2YmFmYjRiOGFiNThiZjFmNTNfMy0xLTEtMS0w_72c7bfc6-ae66-41b2-a94d-06aeee27db52">16,096</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb1de3b33b4e4d3ea045adf1503e5b39_D20190629-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RhYmxlOjFhNTdhNmNiZGNmYTRhNmJhZmI0YjhhYjU4YmYxZjUzL3RhYmxlcmFuZ2U6MWE1N2E2Y2JkY2ZhNGE2YmFmYjRiOGFiNThiZjFmNTNfMy0zLTEtMS0w_5de003e4-a8cc-4d15-8e1c-cffdd0a15455">9,607</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8fed9d02b6e436ebb1928ac49eccab8_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RhYmxlOjFhNTdhNmNiZGNmYTRhNmJhZmI0YjhhYjU4YmYxZjUzL3RhYmxlcmFuZ2U6MWE1N2E2Y2JkY2ZhNGE2YmFmYjRiOGFiNThiZjFmNTNfMy01LTEtMS0w_82217340-3ffd-4023-a89e-5196d6a4718f">46,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39ac5c13a0c242ad9f5edee49b33dee7_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RhYmxlOjFhNTdhNmNiZGNmYTRhNmJhZmI0YjhhYjU4YmYxZjUzL3RhYmxlcmFuZ2U6MWE1N2E2Y2JkY2ZhNGE2YmFmYjRiOGFiNThiZjFmNTNfMy03LTEtMS0w_57dbbbc3-0627-4c3b-945f-7c370451f258">24,815</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i911b510538cf4e2e9af50c7bbb5b99af_D20200704-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RhYmxlOjFhNTdhNmNiZGNmYTRhNmJhZmI0YjhhYjU4YmYxZjUzL3RhYmxlcmFuZ2U6MWE1N2E2Y2JkY2ZhNGE2YmFmYjRiOGFiNThiZjFmNTNfNC0xLTEtMS0w_cd425d71-2425-4cef-9b67-54fc5a56e4b6">36,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7142efd22e1049f7852952c299c3d936_D20190629-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RhYmxlOjFhNTdhNmNiZGNmYTRhNmJhZmI0YjhhYjU4YmYxZjUzL3RhYmxlcmFuZ2U6MWE1N2E2Y2JkY2ZhNGE2YmFmYjRiOGFiNThiZjFmNTNfNC0zLTEtMS0w_32274bcb-3c3f-4e84-84ed-48e09fd1671b">76,016</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2cd405124b14735b901658a7069f2a6_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RhYmxlOjFhNTdhNmNiZGNmYTRhNmJhZmI0YjhhYjU4YmYxZjUzL3RhYmxlcmFuZ2U6MWE1N2E2Y2JkY2ZhNGE2YmFmYjRiOGFiNThiZjFmNTNfNC01LTEtMS0w_fb9edcd0-9e4f-4b9c-ac71-b925fab87fe4">117,959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccf5e837fe3f43d6856e3b446cd61ef1_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RhYmxlOjFhNTdhNmNiZGNmYTRhNmJhZmI0YjhhYjU4YmYxZjUzL3RhYmxlcmFuZ2U6MWE1N2E2Y2JkY2ZhNGE2YmFmYjRiOGFiNThiZjFmNTNfNC03LTEtMS0w_fd82c477-8c2f-40b2-b32f-b7f394565f99">120,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2020, we are eligible to receive additional regulatory and development milestone payments from Ipsen totaling an aggregate of $<ix:nonFraction unitRef="usd" contextRef="icef64ef981c4433ab4d95dd86f4c12ae_I20201002" decimals="-5" format="ixt:numdotdecimal" name="exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RleHRyZWdpb246YWFhZjI4ZTg2ZTI3NDdhNjk4ODc4MTA3NmE5YzhjZTNfMTA5OTUxMTY0MDI3Mw_94f8da91-d264-4671-8b46-cc82cf3ab34f">59.0</ix:nonFraction> million, as well as sales-based milestones, including milestone payments earned for the first commercial sale of a product, of up to $<ix:nonFraction unitRef="usd" contextRef="icef64ef981c4433ab4d95dd86f4c12ae_I20201002" decimals="INF" format="ixt:numdotdecimal" name="exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RleHRyZWdpb246YWFhZjI4ZTg2ZTI3NDdhNjk4ODc4MTA3NmE5YzhjZTNfMTA5OTUxMTY0MDI5NQ_ef24dcf4-b555-446b-95cf-97426b90ae35">469.9</ix:nonFraction> million. We excluded these milestones from the transaction price as of September 30, 2020 because we determined such payments to be fully constrained under Topic 606 due to the fact that it was not probable that a significant reversal of cumulative revenue would not occur, given the inherent uncertainty of success with these milestones. We will re-evaluate the transaction price at each reporting period and as uncertain events are resolved or other changes in circumstances occur. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, $<ix:nonFraction unitRef="usd" contextRef="icef64ef981c4433ab4d95dd86f4c12ae_I20201002" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RleHRyZWdpb246YWFhZjI4ZTg2ZTI3NDdhNjk4ODc4MTA3NmE5YzhjZTNfMjgwNw_e49339cc-26b6-4e9a-9477-f779845e8e9c">42.6</ix:nonFraction> million of the tr</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ansaction price was allocated to our research and development services performance obligation that has not yet been satisfied.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, we entered into a collaboration agreement with Takeda. Under this collaboration agreement, as amended, Takeda has exclusive commercialization rights for current and potential future cabozantinib indications in Japan, and the parties have agreed to collaborate on the clinical development of cabozantinib in Japan. The operation and strategic direction of the parties&#8217; collaboration is governed through a joint executive committee and appropriate subcommittees.</span></div><ix:continuation id="ib5edc36eccc646e587c1c975def3ca67" continuedAt="i92697a95b7cf416ab9528173910fe94d"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under the collaboration agreement with Takeda were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.742%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia423630adad04538bc955c381c570336_D20200704-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RhYmxlOmI2MGYxODk0MTk5MDQzMDA5N2RjNDRjN2JhMjAyMDYxL3RhYmxlcmFuZ2U6YjYwZjE4OTQxOTkwNDMwMDk3ZGM0NGM3YmEyMDIwNjFfMi0xLTEtMS0w_30516fa6-bbf6-4a44-ae42-bebf7c6f7638">9,780</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5df4d5352b0b4f0ba481cb03390bc3df_D20190629-20190927" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RhYmxlOmI2MGYxODk0MTk5MDQzMDA5N2RjNDRjN2JhMjAyMDYxL3RhYmxlcmFuZ2U6YjYwZjE4OTQxOTkwNDMwMDk3ZGM0NGM3YmEyMDIwNjFfMi0zLTEtMS0w_9081fa59-7dcb-4569-bb0f-0ffc78178933">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcb0ee440b7e4dc0b3ff4215f20b3b2d_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RhYmxlOmI2MGYxODk0MTk5MDQzMDA5N2RjNDRjN2JhMjAyMDYxL3RhYmxlcmFuZ2U6YjYwZjE4OTQxOTkwNDMwMDk3ZGM0NGM3YmEyMDIwNjFfMi01LTEtMS0w_aa9cc672-8315-486a-bb90-a2a07d538cbe">32,726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6551575ad754a52ade8c9bd7ebfa664_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RhYmxlOmI2MGYxODk0MTk5MDQzMDA5N2RjNDRjN2JhMjAyMDYxL3RhYmxlcmFuZ2U6YjYwZjE4OTQxOTkwNDMwMDk3ZGM0NGM3YmEyMDIwNjFfMi03LTEtMS0w_9e293d57-7961-4de1-aad0-f966eb13028b">9,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17097e4a7b2744f3bb555de0fd06a162_D20200704-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RhYmxlOmI2MGYxODk0MTk5MDQzMDA5N2RjNDRjN2JhMjAyMDYxL3RhYmxlcmFuZ2U6YjYwZjE4OTQxOTkwNDMwMDk3ZGM0NGM3YmEyMDIwNjFfMy0xLTEtMS0w_792cc6b1-b528-4d73-8eb9-ae5fdc634094">13,204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6130e6433ae14ecf9e3154f44ad89dcd_D20190629-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RhYmxlOmI2MGYxODk0MTk5MDQzMDA5N2RjNDRjN2JhMjAyMDYxL3RhYmxlcmFuZ2U6YjYwZjE4OTQxOTkwNDMwMDk3ZGM0NGM3YmEyMDIwNjFfMy0zLTEtMS0w_99f42c92-a9d8-409f-9d21-83f4d2224160">1,187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4048c98f09848dc973a93054bfd645e_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RhYmxlOmI2MGYxODk0MTk5MDQzMDA5N2RjNDRjN2JhMjAyMDYxL3RhYmxlcmFuZ2U6YjYwZjE4OTQxOTkwNDMwMDk3ZGM0NGM3YmEyMDIwNjFfMy01LTEtMS0w_1c8ae7b6-bd11-4d07-b87d-d62ffe00bc2d">16,468</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieffdd922a5584f5fb2c96d614a69b68c_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RhYmxlOmI2MGYxODk0MTk5MDQzMDA5N2RjNDRjN2JhMjAyMDYxL3RhYmxlcmFuZ2U6YjYwZjE4OTQxOTkwNDMwMDk3ZGM0NGM3YmEyMDIwNjFfMy03LTEtMS0w_f1433497-db46-41d4-9ff0-fdf5a63aa596">5,189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb095da3afbd4daa9861c6249817cea0_D20200704-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RhYmxlOmI2MGYxODk0MTk5MDQzMDA5N2RjNDRjN2JhMjAyMDYxL3RhYmxlcmFuZ2U6YjYwZjE4OTQxOTkwNDMwMDk3ZGM0NGM3YmEyMDIwNjFfNC0xLTEtMS0w_65fd313a-0590-4943-ba57-42c3bab51bff">22,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16a003aa5aa5428887c9c411dbc420fc_D20190629-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RhYmxlOmI2MGYxODk0MTk5MDQzMDA5N2RjNDRjN2JhMjAyMDYxL3RhYmxlcmFuZ2U6YjYwZjE4OTQxOTkwNDMwMDk3ZGM0NGM3YmEyMDIwNjFfNC0zLTEtMS0w_2cb5bc0e-9314-4db2-80ad-3d7371ac1ce7">1,187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32bf9affdda745209b77e77dfc211f15_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RhYmxlOmI2MGYxODk0MTk5MDQzMDA5N2RjNDRjN2JhMjAyMDYxL3RhYmxlcmFuZ2U6YjYwZjE4OTQxOTkwNDMwMDk3ZGM0NGM3YmEyMDIwNjFfNC01LTEtMS0w_aecf1dfb-27e0-4bed-84ad-5e6c70127788">49,194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i350a22df21c64d1c93c2524af875b962_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RhYmxlOmI2MGYxODk0MTk5MDQzMDA5N2RjNDRjN2JhMjAyMDYxL3RhYmxlcmFuZ2U6YjYwZjE4OTQxOTkwNDMwMDk3ZGM0NGM3YmEyMDIwNjFfNC03LTEtMS0w_ff8d9137-50dd-4b8d-b8f9-a7aaf26f3951">14,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestone revenues for the three and nine months ended September&#160;30, 2020 included $<ix:nonFraction unitRef="usd" contextRef="ieb095da3afbd4daa9861c6249817cea0_D20200704-20201002" decimals="-5" format="ixt:numdotdecimal" name="exel:MilestonePaymentsEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RleHRyZWdpb246YWFhZjI4ZTg2ZTI3NDdhNjk4ODc4MTA3NmE5YzhjZTNfMTA0NDUzNjA0ODE4MDQ_04f83aac-5ec3-49bc-b912-bb5e87a57d7d"><ix:nonFraction unitRef="usd" contextRef="i32bf9affdda745209b77e77dfc211f15_D20200104-20201002" decimals="-5" format="ixt:numdotdecimal" name="exel:MilestonePaymentsEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RleHRyZWdpb246YWFhZjI4ZTg2ZTI3NDdhNjk4ODc4MTA3NmE5YzhjZTNfMTA0NDUzNjA0ODE4MDQ_544a3994-1e7a-4c56-8ff0-9fd0ec538947">9.2</ix:nonFraction></ix:nonFraction>&#160;million in revenues recognized in connection with a $<ix:nonFraction unitRef="usd" contextRef="i0b512ec06edc41c18dbe1037421ea9bb_I20201002" decimals="-5" format="ixt:numdotdecimal" name="exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RleHRyZWdpb246YWFhZjI4ZTg2ZTI3NDdhNjk4ODc4MTA3NmE5YzhjZTNfMTA0NDUzNjA0ODE4MTg_b21cbc85-aeeb-45cc-a78f-0e89b1043344">10.0</ix:nonFraction>&#160;million milestone we expect to achieve upon Takeda&#8217;s and Ono Pharmaceutical Co., Ltd.&#8217;s supplemental application to the Japanese Ministry of Health, Labour and Welfare for Manufacturing and Marketing Approval of CABOMETYX in combination with Opdivo for the treatment of patients with unresectable, advanced or metastatic RCC. At September 30, 2020, we have not yet received this milestone payment.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2020, Takeda opted into and is now co-funding the development costs for CONTACT-01, CONTACT-02 and certain cohorts of COSMIC-021. Concurrently, we entered into the third amendment to the collaboration agreement with Takeda (the Amendment), which modified certain cost sharing obligations related to the Japan-specific development costs associated with CONTACT-01 and CONTACT-02. We determined the Amendment represented a contract modification that was treated as a termination of an existing contract and the creation of a new contract under Topic 606. As a result, we allocated the remaining transaction price to the performance obligations identified in the contract. The two remaining performance obligations are the research and development services associated with committed studies described in &#8220;Note 3. Collaboration Agreements&#8221; of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, and the research and development services associated with CONTACT-01, CONTACT-02, and certain cohorts of COSMIC-021 studies. In allocating the transaction price for the modified contract we estimated the standalone selling price for the performance obligations. We utilized development costs incurred for these obligations in process and the projections of costs through the term of the arrangement. Revenue is recognized when, or as, we satisfy our performance obligations by transferring the promised services to Takeda. Revenue is being recognized using the cost proportional performance method, based on costs incurred to perform the research and development services, since the level of costs incurred over time is thought to best reflect the transfer of services to Takeda.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_7">Table of Contents</a></span></div></div><ix:continuation id="i95e584c590954734ba1729982eae5231" continuedAt="ibf090e1328fd40d8be8ad1230f612188"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are eligible to receive additional regulatory and development milestone payments, without contractual limit, for additional potential future indications. We are further eligible to receive sales-based milestones, including milestone payments earned for the first commercial sale of a product, of up to $<ix:nonFraction unitRef="usd" contextRef="i0b512ec06edc41c18dbe1037421ea9bb_I20201002" decimals="INF" format="ixt:numdotdecimal" name="exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RleHRyZWdpb246YWFhZjI4ZTg2ZTI3NDdhNjk4ODc4MTA3NmE5YzhjZTNfMTA0NDUzNjA0NzU5MTk_7e38c49a-68a5-4318-acad-da0eaab89109">124.0</ix:nonFraction>&#160;million. We excluded these milestones from the transaction price as of September 30, 2020 because we determined such payments to be fully constrained under Topic 606 due to the fact that it was not probable that a significant reversal of cumulative revenue would not occur, given the inherent uncertainty of success with these milestones. We will re-evaluate the transaction price at each reporting period and as uncertain events are resolved or other changes in circumstances occur. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, $<ix:nonFraction unitRef="usd" contextRef="i0b512ec06edc41c18dbe1037421ea9bb_I20201002" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RleHRyZWdpb246YWFhZjI4ZTg2ZTI3NDdhNjk4ODc4MTA3NmE5YzhjZTNfMTA5OTUxMTYzMzM0Mg_9127515e-f9ea-45f6-bc9f-494b93960e51">46.3</ix:nonFraction> million of the trans</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">action price was allocated to our research and development services performance obligations that has not yet been satisfied. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">GSK</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2002, we established a product development and commercialization collaboration agreement with GSK. We are required to pay a <ix:nonFraction unitRef="number" contextRef="ia8670170a5094b3b904e1504aafbac8c_D20200104-20201002" decimals="2" name="exel:CollaborationAgreementPercentOfRoyaltyOnNetSale" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RleHRyZWdpb246YWFhZjI4ZTg2ZTI3NDdhNjk4ODc4MTA3NmE5YzhjZTNfNDE5Mg_e030c443-c16b-4f52-83ea-1396b026ced8">3</ix:nonFraction>% royalty to GSK on the net sales of any product incorporating cabozantinib by us and our collaboration partners. Royalties earned by GSK in connection with the sales of cabozantinib are included in cost of goods sold for sales by us and as a reduction of collaboration services revenues for sales by our collaboration partners. Such royalties were $<ix:nonFraction unitRef="usd" contextRef="if6d4cedf8c084744ba29969039e3b2e9_D20200704-20201002" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RoyaltyExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RleHRyZWdpb246YWFhZjI4ZTg2ZTI3NDdhNjk4ODc4MTA3NmE5YzhjZTNfNDU0Mw_2fd8bb9d-f868-439e-87d7-d4ee5ab0fa7a">7.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8dbb49564117496fb5290d851754b098_D20200104-20201002" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RoyaltyExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RleHRyZWdpb246YWFhZjI4ZTg2ZTI3NDdhNjk4ODc4MTA3NmE5YzhjZTNfNDU1Mg_77d4c530-af04-411b-ab37-6f20237e77f7">23.7</ix:nonFraction> million during the three and nine months ended September&#160;30, 2020, respectively, as compared to $<ix:nonFraction unitRef="usd" contextRef="i681117f1aebd445288c3a111845dc5c8_D20190629-20190927" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RoyaltyExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RleHRyZWdpb246YWFhZjI4ZTg2ZTI3NDdhNjk4ODc4MTA3NmE5YzhjZTNfNDYwMw_1b2bf86e-5025-482e-8f32-e68b449fc0f3">8.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i71974296a61b4d89993136d3ef36daed_D20181229-20190927" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RoyaltyExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RleHRyZWdpb246YWFhZjI4ZTg2ZTI3NDdhNjk4ODc4MTA3NmE5YzhjZTNfNDYxMA_14d33bb8-b893-452a-9077-7fab15684492">23.1</ix:nonFraction> million during the comparable periods in 2019. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Genentech Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2006, we out-licensed the development and commercialization of cobimetinib to Genentech under a worldwide collaboration agreement. In&#160;November&#160;2015, the U.S. Food and Drug Administration (FDA) approved cobimetinib, under the brand name COTELLIC, in combination with Genentech&#8217;s ZELBORAF&#174;  (vemurafenib) for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma. COTELLIC in combination with ZELBORAF has also been approved in the European Union and multiple additional countries for use in the same indication. In July 2020, the FDA also approved COTELLIC for use in combination with ZELBORAF and TECENTRIQ&#174; (atezolizumab) for the treatment of patients with BRAF V600 mutation-positive advanced melanoma in previously untreated patients. <ix:continuation id="i92697a95b7cf416ab9528173910fe94d" continuedAt="ia3c626d14f1b4262822883baecac7704">License revenues under the collaboration agreement with Genentech were as follows (in thousands):</ix:continuation></span></div><div style="margin-top:9pt"><ix:continuation id="ia3c626d14f1b4262822883baecac7704"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.849%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.981%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.015%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.460%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Profits on U.S. commercialization</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id774200cb5964ec7a9f457d6f01d6879_D20200704-20201002" decimals="-3" format="ixt:numdotdecimal" name="exel:CollaborativeArrangementIncomeLossFromAgreement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RhYmxlOmU3NWRhMjE2NTg5NjQ3ZDJiYWQzNmZhMDk2ZDMxZjlkL3RhYmxlcmFuZ2U6ZTc1ZGEyMTY1ODk2NDdkMmJhZDM2ZmEwOTZkMzFmOWRfMi0xLTEtMS0w_998010f6-f985-4ce8-958b-f09748a6620b">1,595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3042085c439a4f33a184caed0a43f26b_D20190629-20190927" decimals="-3" format="ixt:numdotdecimal" name="exel:CollaborativeArrangementIncomeLossFromAgreement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RhYmxlOmU3NWRhMjE2NTg5NjQ3ZDJiYWQzNmZhMDk2ZDMxZjlkL3RhYmxlcmFuZ2U6ZTc1ZGEyMTY1ODk2NDdkMmJhZDM2ZmEwOTZkMzFmOWRfMi0zLTEtMS0w_e847e362-b91e-4467-9a06-8399aa6f0c01">1,102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i435fea9408f448279983514e753b98c2_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="exel:CollaborativeArrangementIncomeLossFromAgreement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RhYmxlOmU3NWRhMjE2NTg5NjQ3ZDJiYWQzNmZhMDk2ZDMxZjlkL3RhYmxlcmFuZ2U6ZTc1ZGEyMTY1ODk2NDdkMmJhZDM2ZmEwOTZkMzFmOWRfMi01LTEtMS0w_fd3bf188-9684-4cdd-bba6-188f376a0e52">4,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54179f4a09954324b9f756384579283e_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="exel:CollaborativeArrangementIncomeLossFromAgreement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RhYmxlOmU3NWRhMjE2NTg5NjQ3ZDJiYWQzNmZhMDk2ZDMxZjlkL3RhYmxlcmFuZ2U6ZTc1ZGEyMTY1ODk2NDdkMmJhZDM2ZmEwOTZkMzFmOWRfMi03LTEtMS0w_a0c6c5d1-c37e-4863-8f12-50f4b2387b19">3,507</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenues on ex-U.S. sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id774200cb5964ec7a9f457d6f01d6879_D20200704-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RhYmxlOmU3NWRhMjE2NTg5NjQ3ZDJiYWQzNmZhMDk2ZDMxZjlkL3RhYmxlcmFuZ2U6ZTc1ZGEyMTY1ODk2NDdkMmJhZDM2ZmEwOTZkMzFmOWRfMy0xLTEtMS0w_cbb238b4-e1ce-4c14-8d8d-29f1e2a2ae95">1,370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3042085c439a4f33a184caed0a43f26b_D20190629-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RhYmxlOmU3NWRhMjE2NTg5NjQ3ZDJiYWQzNmZhMDk2ZDMxZjlkL3RhYmxlcmFuZ2U6ZTc1ZGEyMTY1ODk2NDdkMmJhZDM2ZmEwOTZkMzFmOWRfMy0zLTEtMS0w_5f88e7c0-f7a9-4c64-a2ef-d444ef9f2a78">1,614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i435fea9408f448279983514e753b98c2_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RhYmxlOmU3NWRhMjE2NTg5NjQ3ZDJiYWQzNmZhMDk2ZDMxZjlkL3RhYmxlcmFuZ2U6ZTc1ZGEyMTY1ODk2NDdkMmJhZDM2ZmEwOTZkMzFmOWRfMy01LTEtMS0w_7d086d7d-df8f-40e2-b5dd-d174f506e214">3,804</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54179f4a09954324b9f756384579283e_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RhYmxlOmU3NWRhMjE2NTg5NjQ3ZDJiYWQzNmZhMDk2ZDMxZjlkL3RhYmxlcmFuZ2U6ZTc1ZGEyMTY1ODk2NDdkMmJhZDM2ZmEwOTZkMzFmOWRfMy03LTEtMS0w_44a4ad32-2eae-4d23-a226-3d4ab9f66cc8">4,426</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">In-Licensing Collaborations </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC, Catalent Pharma Solution LLC Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we entered into a collaboration and license agreement with Catalent, Inc.&#8217;s wholly owned subsidiaries Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC and Catalent Pharma Solutions, Inc., (individually and collectively referred to as Catalent). Under the terms of the agreement, we made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i02e9b643d49a417e9373b15e166ba536_D20200104-20201002" decimals="-5" format="ixt:numdotdecimal" name="exel:CollaborativeAgreementsUpfrontPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RleHRyZWdpb246YWFhZjI4ZTg2ZTI3NDdhNjk4ODc4MTA3NmE5YzhjZTNfMTA0NDUzNjA0NzU5MzU_7de06246-2bdc-463b-9ffe-d0c5bf5a67fe">10.0</ix:nonFraction>&#160;million in exchange to nominate and have the exclusive option to license four targets using Catalent&#8217;s ADC platform over a <ix:nonNumeric contextRef="i02e9b643d49a417e9373b15e166ba536_D20200104-20201002" format="ixt-sec:durwordsen" name="exel:CollaborationAndLicenseAgreementTargetSelectionTerm" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RleHRyZWdpb246YWFhZjI4ZTg2ZTI3NDdhNjk4ODc4MTA3NmE5YzhjZTNfNTQ5NzU1ODE1NzM2Mg_ca076b21-c61e-4874-8671-b5852eff58b1">three-year</ix:nonNumeric> period. In addition, we have a right to extend the target selection term to <ix:nonNumeric contextRef="i02e9b643d49a417e9373b15e166ba536_D20200104-20201002" format="ixt-sec:durwordsen" name="exel:CollaborationAndLicenseAgreementExtendedTargetSelectionTerm" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RleHRyZWdpb246YWFhZjI4ZTg2ZTI3NDdhNjk4ODc4MTA3NmE5YzhjZTNfMTA0NDUzNjA0NzYxMDc_a37c307f-d05b-40f4-a107-2212dd597c3a">five years</ix:nonNumeric> and nominate up to two additional targets for an additional payment of $<ix:nonFraction unitRef="usd" contextRef="i02e9b643d49a417e9373b15e166ba536_D20200104-20201002" decimals="-5" format="ixt:numdotdecimal" name="exel:CollaborationAgreementsAdditionalUpfrontPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RleHRyZWdpb246YWFhZjI4ZTg2ZTI3NDdhNjk4ODc4MTA3NmE5YzhjZTNfMTA0NDUzNjA0NzU5NTA_14732698-364a-40cc-9e00-945d18704b48">4.0</ix:nonFraction>&#160;million. We will also contribute research funding to Catalent for discovery and preclinical development work. For each option we decide to exercise, we will pay an exercise fee of $<ix:nonFraction unitRef="usd" contextRef="i4f29e6a4d7e4442a814e495bb866df20_I20201002" decimals="-5" format="ixt:numdotdecimal" name="exel:CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RleHRyZWdpb246YWFhZjI4ZTg2ZTI3NDdhNjk4ODc4MTA3NmE5YzhjZTNfMTA0NDUzNjA0NzU5NjI_7228a497-be7f-4603-89df-8932920cf559">2.0</ix:nonFraction>&#160;million, and would assume responsibilities for all subsequent clinical development, commercialization and global manufacturing of that program. Catalent would then become eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i4f29e6a4d7e4442a814e495bb866df20_I20201002" decimals="-5" format="ixt:numdotdecimal" name="exel:CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RleHRyZWdpb246YWFhZjI4ZTg2ZTI3NDdhNjk4ODc4MTA3NmE5YzhjZTNfMTA0NDUzNjA0NzU5NzY_9e04fb3c-0f05-4600-a641-3156f572cc5a">44.0</ix:nonFraction>&#160;million per compound in potential development milestone payments, $<ix:nonFraction unitRef="usd" contextRef="i4f29e6a4d7e4442a814e495bb866df20_I20201002" decimals="-5" format="ixt:numdotdecimal" name="exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RleHRyZWdpb246YWFhZjI4ZTg2ZTI3NDdhNjk4ODc4MTA3NmE5YzhjZTNfMTA0NDUzNjA0NzU5OTE_f5705eb0-d1e3-485b-8572-6ab54b65f289">60.0</ix:nonFraction>&#160;million per product in potential commercial milestone payments, as well as royalties on potential sales.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NBE Therapeutics AG (NBE) Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we entered into a collaboration and license agreement with NBE. Under the terms of the agreement, we made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i6b107f2541f144959f65cffe2682f793_D20200104-20201002" decimals="-5" format="ixt:numdotdecimal" name="exel:CollaborativeAgreementsUpfrontPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RleHRyZWdpb246YWFhZjI4ZTg2ZTI3NDdhNjk4ODc4MTA3NmE5YzhjZTNfMTA0NDUzNjA0NzYwMzM_5b1b3fd8-36e4-4088-98e9-83625611760d">25.0</ix:nonFraction>&#160;million in exchange for exclusive options to nominate four targets using NBE&#8217;s ADC platform over a <ix:nonNumeric contextRef="i6b107f2541f144959f65cffe2682f793_D20200104-20201002" format="ixt-sec:durwordsen" name="exel:CollaborationAndLicenseAgreementTargetSelectionTerm" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RleHRyZWdpb246YWFhZjI4ZTg2ZTI3NDdhNjk4ODc4MTA3NmE5YzhjZTNfNjA0NzMxMzk3MzQ0NA_8f21665e-9301-4741-9e8c-e63b99842f63">two-year</ix:nonNumeric> period. In addition, within the first <ix:nonNumeric contextRef="i6b107f2541f144959f65cffe2682f793_D20200104-20201002" format="ixt-sec:durwordsen" name="exel:CollaborationAndLicenseAgreementTargetSelectionExtensionOptionTerm" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RleHRyZWdpb246YWFhZjI4ZTg2ZTI3NDdhNjk4ODc4MTA3NmE5YzhjZTNfOTg5NTYwNDY2ODU2Mw_52aff017-93a7-4442-9dab-e72b25e373bc">eighteen months</ix:nonNumeric> of the agreement, we also have a right to extend the target selection term to <ix:nonNumeric contextRef="i6b107f2541f144959f65cffe2682f793_D20200104-20201002" format="ixt-sec:durwordsen" name="exel:CollaborationAndLicenseAgreementExtendedTargetSelectionTerm" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RleHRyZWdpb246YWFhZjI4ZTg2ZTI3NDdhNjk4ODc4MTA3NmE5YzhjZTNfMTA0NDUzNjA0NzYxODQ_ec5e7aab-7b1a-4a06-82b8-da4488e276ba">three years</ix:nonNumeric> for an additional payment of $<ix:nonFraction unitRef="usd" contextRef="i6b107f2541f144959f65cffe2682f793_D20200104-20201002" decimals="-5" format="ixt:numdotdecimal" name="exel:CollaborationAgreementsAdditionalUpfrontPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RleHRyZWdpb246YWFhZjI4ZTg2ZTI3NDdhNjk4ODc4MTA3NmE5YzhjZTNfMTA0NDUzNjA0NzYwMDY_f52e7d40-881a-465c-90ca-f489126b62da">2.0</ix:nonFraction>&#160;million. We will also contribute research funding to NBE for discovery and preclinical development work. For each option we decide to exercise, we will be </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibf090e1328fd40d8be8ad1230f612188">required to pay an exercise fee of $<ix:nonFraction unitRef="usd" contextRef="i9dc3e9657668420dbfcde5f6032f0548_I20201002" decimals="-5" format="ixt:numdotdecimal" name="exel:CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RleHRyZWdpb246YWFhZjI4ZTg2ZTI3NDdhNjk4ODc4MTA3NmE5YzhjZTNfMTA0NDUzNjA0NzYwMTg_0ebcc930-fe37-407a-989e-28a67e1f4d59">10.0</ix:nonFraction>&#160;million, and would assume responsibilities for all subsequent clinical development, commercialization and global manufacturing of that program. NBE would then become eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i9dc3e9657668420dbfcde5f6032f0548_I20201002" decimals="-5" format="ixt:numdotdecimal" name="exel:CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RleHRyZWdpb246YWFhZjI4ZTg2ZTI3NDdhNjk4ODc4MTA3NmE5YzhjZTNfMTA0NDUzNjA0NzYwNjQ_dbb1a67e-7073-40b1-a73b-f3aa0b222cc7">90.0</ix:nonFraction>&#160;million per program in potential development milestone payments, $<ix:nonFraction unitRef="usd" contextRef="i9dc3e9657668420dbfcde5f6032f0548_I20201002" decimals="-5" format="ixt:numdotdecimal" name="exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RleHRyZWdpb246YWFhZjI4ZTg2ZTI3NDdhNjk4ODc4MTA3NmE5YzhjZTNfMTA0NDUzNjA0NzYwNDg_e31b9348-57b3-4253-95bf-6d2ac5a8acd6">135.0</ix:nonFraction>&#160;million per program in potential commercial milestone payments, as well as royalties on potential sales.</ix:continuation></span></div><div id="i0283c6f517b447ec92f154ee691f4028_55"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 4. <ix:nonNumeric contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" name="exel:CashCashEquivalentsAndInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RleHRyZWdpb246OGZhODczZDFjZDY5NGI4YmE5NzUwZTE4NjFmNGMwMGFfMjI0NQ_387b2675-7acb-4ba6-bbca-6f9b56de9770" continuedAt="iedb458bb455f4b9eb822967c4fcf2410" escape="true">CASH AND INVESTMENTS</ix:nonNumeric></span></div><ix:continuation id="iedb458bb455f4b9eb822967c4fcf2410" continuedAt="iad68f2df443a44b3b54e7d837790c702"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash Equivalents </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RleHRyZWdpb246OGZhODczZDFjZDY5NGI4YmE5NzUwZTE4NjFmNGMwMGFfMjIzOQ_9add4554-6db9-463b-8673-4ec8649e1fb6" continuedAt="icce36013e7174646bd1db8c6f6fd3d5d" escape="true"><ix:nonNumeric contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RleHRyZWdpb246OGZhODczZDFjZDY5NGI4YmE5NzUwZTE4NjFmNGMwMGFfMjI0MA_d320285c-5c98-4b49-bcf8-25835e9ef95d" continuedAt="i5c3d63a0dfea4931a2a92d31d57118ac" escape="true">A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):</ix:nonNumeric></ix:nonNumeric></span></div><div style="margin-top:9pt;text-align:center"><ix:continuation id="icce36013e7174646bd1db8c6f6fd3d5d"><ix:continuation id="i5c3d63a0dfea4931a2a92d31d57118ac"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.717%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOjgzNGU2OWJhYzY0OTQ2YmE5NmY1YWI5NGYxY2Q0YjM2L3RhYmxlcmFuZ2U6ODM0ZTY5YmFjNjQ5NDZiYTk2ZjVhYjk0ZjFjZDRiMzZfMS0xLTEtMS0w_edaafdff-accb-4a66-b9e3-aac9c8e44aec">334,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOjgzNGU2OWJhYzY0OTQ2YmE5NmY1YWI5NGYxY2Q0YjM2L3RhYmxlcmFuZ2U6ODM0ZTY5YmFjNjQ5NDZiYTk2ZjVhYjk0ZjFjZDRiMzZfMS0zLTEtMS0w_e7e1a5fe-b5b6-4b14-9829-b36d5e6358c1">266,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash equivalents included in long-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOjgzNGU2OWJhYzY0OTQ2YmE5NmY1YWI5NGYxY2Q0YjM2L3RhYmxlcmFuZ2U6ODM0ZTY5YmFjNjQ5NDZiYTk2ZjVhYjk0ZjFjZDRiMzZfMy0xLTEtMS0w_83dcb8e0-4cbc-4fa0-88b2-94d1e66fdd6c">1,636</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOjgzNGU2OWJhYzY0OTQ2YmE5NmY1YWI5NGYxY2Q0YjM2L3RhYmxlcmFuZ2U6ODM0ZTY5YmFjNjQ5NDZiYTk2ZjVhYjk0ZjFjZDRiMzZfMy0zLTEtMS0w_414eafba-76c1-4e8d-8236-9f7830e8e8f7">1,636</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOjgzNGU2OWJhYzY0OTQ2YmE5NmY1YWI5NGYxY2Q0YjM2L3RhYmxlcmFuZ2U6ODM0ZTY5YmFjNjQ5NDZiYTk2ZjVhYjk0ZjFjZDRiMzZfNC0xLTEtMS0w_e086c422-f102-4dd1-ae70-a445f7da7a08">335,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOjgzNGU2OWJhYzY0OTQ2YmE5NmY1YWI5NGYxY2Q0YjM2L3RhYmxlcmFuZ2U6ODM0ZTY5YmFjNjQ5NDZiYTk2ZjVhYjk0ZjFjZDRiMzZfNC0zLTEtMS0w_6afd40fb-c135-47b1-9fd3-88a02c31e869">268,137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash equivalents consisted of certificates of deposit with original maturities of 90 days or less used to collateralize letters of credit. The long-term classification of restricted cash equivalents is based upon the remaining term of the underlying restriction.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Investments</span></div><ix:nonNumeric contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" name="us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RleHRyZWdpb246OGZhODczZDFjZDY5NGI4YmE5NzUwZTE4NjFmNGMwMGFfMjI1NA_73dd51a7-f71d-43ac-bcd1-ba5e5b813eaf" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and investments consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d1bc4ca714746459025e3f4409d9cd3_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfMy0xLTEtMS0w_fdf4ef6e-87b8-4a31-b1cd-fd7c60e0ccca">466,141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d1bc4ca714746459025e3f4409d9cd3_I20201002" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfMy0zLTEtMS0w_9d598546-69fa-44b4-8cec-e1a725c54716">225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d1bc4ca714746459025e3f4409d9cd3_I20201002" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfMy01LTEtMS0w_206d427c-a0e6-4ee4-b6e2-bd1292c25802">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d1bc4ca714746459025e3f4409d9cd3_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfMy03LTEtMS0w_f66fe802-2faf-4b0b-95ce-d7d7482e86cc">466,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51a81230a1d74e55a2566c55413e2b2a_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfNC0xLTEtMS0w_191190b6-19a8-4d23-a95b-906c43f75961">629,309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51a81230a1d74e55a2566c55413e2b2a_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfNC0zLTEtMS0w_5b81bfcd-1c16-4c15-8bdb-9f65b0779db5">7,526</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51a81230a1d74e55a2566c55413e2b2a_I20201002" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfNC01LTEtMS0w_d885fb9c-de1c-419a-8b82-412af33ff572">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51a81230a1d74e55a2566c55413e2b2a_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfNC03LTEtMS0w_21099f7f-15d6-4f73-853f-2567bf86ec40">636,815</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba278ad76ca4fcd841ffefc73154898_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfNS0xLTEtMS0w_4426b0a4-62bd-471c-850e-45de08fdaa23">213,449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba278ad76ca4fcd841ffefc73154898_I20201002" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfNS0zLTEtMS0w_e220d3b3-4c52-4d33-ac00-0a33e9ce29c6">354</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ba278ad76ca4fcd841ffefc73154898_I20201002" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfNS01LTEtMS0w_b5582b4e-2318-45b9-9582-bc9d104fe01b">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba278ad76ca4fcd841ffefc73154898_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfNS03LTEtMS0w_7645e90f-2aaf-4e74-8fcc-5c9fd60ad91c">213,793</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id17bab0418ae471988fdfa84040140f1_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfNi0xLTEtMS0w_2a1c7ee8-ded6-4c8f-ba26-4c835ae43e27">20,326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id17bab0418ae471988fdfa84040140f1_I20201002" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfNi0zLTEtMS0w_2c0ce464-8cbb-4239-a6b6-bcd85974a306">105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id17bab0418ae471988fdfa84040140f1_I20201002" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfNi01LTEtMS0w_55f69f7b-385d-4ec0-8c47-21a64971a850">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id17bab0418ae471988fdfa84040140f1_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfNi03LTEtMS0w_c0628c00-ade9-4e10-a523-c8e8e650d78d">20,431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfNy0xLTEtMS0w_1edd6462-6c54-496d-9dbc-b64ad9fc248d">1,329,225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfNy0zLTEtMS0w_6a83c44d-249b-4cc2-be30-d95d9a5c5d6d">8,210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfNy01LTEtMS0w_b7335511-b5ec-46e4-8a62-78e3572b8f49">30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfNy03LTEtMS0w_f7df6f0f-d03d-499c-8325-c973f12ac410">1,337,405</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac6d9b9d2944e76a0f5c167b3983bc0_I20201002" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfOC0xLTEtMS0w_304800d5-e3cc-42a1-8049-3c93ba05aa34">55,979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac6d9b9d2944e76a0f5c167b3983bc0_I20201002" decimals="-3" format="ixt:zerodash" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfOC0zLTEtMS0w_e7c738ec-e8af-47ab-b6c7-dca8de77c2b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac6d9b9d2944e76a0f5c167b3983bc0_I20201002" decimals="-3" format="ixt:zerodash" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfOC01LTEtMS0w_32e59a52-7112-4fee-b6f3-d8462ed75e03">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac6d9b9d2944e76a0f5c167b3983bc0_I20201002" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfOC03LTEtMS0w_37418c80-7190-46fa-8f85-03f190544695">55,979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ideca50ba198246c68d0bffddd169057c_I20201002" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfOS0xLTEtMS0w_b8e6ecb7-704c-45b0-b993-d7763aa54df4">96,992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ideca50ba198246c68d0bffddd169057c_I20201002" decimals="-3" format="ixt:zerodash" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfOS0zLTEtMS0w_d0850d3b-1169-414a-8277-2f5cc188cdb1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ideca50ba198246c68d0bffddd169057c_I20201002" decimals="-3" format="ixt:zerodash" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfOS01LTEtMS0w_50b40f3d-9caa-44ea-9508-271be5436625">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ideca50ba198246c68d0bffddd169057c_I20201002" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfOS03LTEtMS0w_d37d9672-1b5f-4db8-a484-01d68818fb8f">96,992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58a13023c0dd450eb2ee0d861f56e766_I20201002" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfMTAtMS0xLTEtMA_1b1e8be2-d118-495e-977a-eace41a2d55a">55,583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58a13023c0dd450eb2ee0d861f56e766_I20201002" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfMTAtMy0xLTEtMA_08107a74-39c1-4de6-a9d6-61578304036a">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58a13023c0dd450eb2ee0d861f56e766_I20201002" decimals="-3" format="ixt:zerodash" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfMTAtNS0xLTEtMA_c37fe11e-a30d-4c57-9550-8edb708617d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58a13023c0dd450eb2ee0d861f56e766_I20201002" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfMTAtNy0xLTEtMA_f85fd61f-61ea-472b-8bcd-879fae01a8d5">55,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfMTEtMS0xLTEtMA_614f5f06-c394-4764-8823-7d68ad685adb">1,537,779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfMTEtMy0xLTEtMA_cbae2520-fbfa-4897-969c-8b4c9c9accf2">8,211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfMTEtNS0xLTEtMA_808493ee-2403-4347-8e5c-c41ced0b9d76">30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfMTEtNy0xLTEtMA_04be8def-930b-41ab-9536-69d68835b4b3">1,545,960</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f9a560b1450471a9fb3a5226dea5132_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmYxZWQ5YzU5MGI3YzRjNTZhODBhMTUxNGNiOWJhMGMyL3RhYmxlcmFuZ2U6ZjFlZDljNTkwYjdjNGM1NmE4MGExNTE0Y2I5YmEwYzJfMy0xLTEtMS0w_6559794c-9353-4330-9a4d-850a8ea9a6b3">389,573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f9a560b1450471a9fb3a5226dea5132_I20200103" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmYxZWQ5YzU5MGI3YzRjNTZhODBhMTUxNGNiOWJhMGMyL3RhYmxlcmFuZ2U6ZjFlZDljNTkwYjdjNGM1NmE4MGExNTE0Y2I5YmEwYzJfMy0zLTEtMS0w_87b743b2-74de-4023-9c66-d46222d73b63">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f9a560b1450471a9fb3a5226dea5132_I20200103" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmYxZWQ5YzU5MGI3YzRjNTZhODBhMTUxNGNiOWJhMGMyL3RhYmxlcmFuZ2U6ZjFlZDljNTkwYjdjNGM1NmE4MGExNTE0Y2I5YmEwYzJfMy01LTEtMS0w_27ac9ac1-c6c5-43f4-8c9f-89dd23a17e18">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f9a560b1450471a9fb3a5226dea5132_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmYxZWQ5YzU5MGI3YzRjNTZhODBhMTUxNGNiOWJhMGMyL3RhYmxlcmFuZ2U6ZjFlZDljNTkwYjdjNGM1NmE4MGExNTE0Y2I5YmEwYzJfMy03LTEtMS0w_bdea8798-b2af-4002-a345-cf1a87c6775e">389,573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic27aa82f118547bcaca2790c33dd963b_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmYxZWQ5YzU5MGI3YzRjNTZhODBhMTUxNGNiOWJhMGMyL3RhYmxlcmFuZ2U6ZjFlZDljNTkwYjdjNGM1NmE4MGExNTE0Y2I5YmEwYzJfNC0xLTEtMS0w_b3e46530-ea7a-41aa-93c5-e6bcf32c4f21">752,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic27aa82f118547bcaca2790c33dd963b_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmYxZWQ5YzU5MGI3YzRjNTZhODBhMTUxNGNiOWJhMGMyL3RhYmxlcmFuZ2U6ZjFlZDljNTkwYjdjNGM1NmE4MGExNTE0Y2I5YmEwYzJfNC0zLTEtMS0w_28205767-c75e-4441-a618-bdcfd718723a">3,934</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic27aa82f118547bcaca2790c33dd963b_I20200103" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmYxZWQ5YzU5MGI3YzRjNTZhODBhMTUxNGNiOWJhMGMyL3RhYmxlcmFuZ2U6ZjFlZDljNTkwYjdjNGM1NmE4MGExNTE0Y2I5YmEwYzJfNC01LTEtMS0w_948c15c9-de67-4ce8-9662-c441e7941add">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic27aa82f118547bcaca2790c33dd963b_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmYxZWQ5YzU5MGI3YzRjNTZhODBhMTUxNGNiOWJhMGMyL3RhYmxlcmFuZ2U6ZjFlZDljNTkwYjdjNGM1NmE4MGExNTE0Y2I5YmEwYzJfNC03LTEtMS0w_fbf99b58-4841-41ab-b01c-6a7807a205ba">756,226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f0bf831f83f4af59172086b8a97f3c4_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmYxZWQ5YzU5MGI3YzRjNTZhODBhMTUxNGNiOWJhMGMyL3RhYmxlcmFuZ2U6ZjFlZDljNTkwYjdjNGM1NmE4MGExNTE0Y2I5YmEwYzJfNS0xLTEtMS0w_fd5114fc-acf3-4c13-9096-65bd5c896a55">166,483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f0bf831f83f4af59172086b8a97f3c4_I20200103" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmYxZWQ5YzU5MGI3YzRjNTZhODBhMTUxNGNiOWJhMGMyL3RhYmxlcmFuZ2U6ZjFlZDljNTkwYjdjNGM1NmE4MGExNTE0Y2I5YmEwYzJfNS0zLTEtMS0w_f05700c3-35af-4357-89c4-cc378173519f">187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f0bf831f83f4af59172086b8a97f3c4_I20200103" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmYxZWQ5YzU5MGI3YzRjNTZhODBhMTUxNGNiOWJhMGMyL3RhYmxlcmFuZ2U6ZjFlZDljNTkwYjdjNGM1NmE4MGExNTE0Y2I5YmEwYzJfNS01LTEtMS0w_3463a017-dbb4-4e64-bbb9-13bfd74574f2">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f0bf831f83f4af59172086b8a97f3c4_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmYxZWQ5YzU5MGI3YzRjNTZhODBhMTUxNGNiOWJhMGMyL3RhYmxlcmFuZ2U6ZjFlZDljNTkwYjdjNGM1NmE4MGExNTE0Y2I5YmEwYzJfNS03LTEtMS0w_eaf12556-dc76-485d-b95a-a8d454a282cc">166,665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmYxZWQ5YzU5MGI3YzRjNTZhODBhMTUxNGNiOWJhMGMyL3RhYmxlcmFuZ2U6ZjFlZDljNTkwYjdjNGM1NmE4MGExNTE0Y2I5YmEwYzJfNi0xLTEtMS0w_022f54a3-6fd7-4f77-b2b8-2ceadba4e73e">1,308,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmYxZWQ5YzU5MGI3YzRjNTZhODBhMTUxNGNiOWJhMGMyL3RhYmxlcmFuZ2U6ZjFlZDljNTkwYjdjNGM1NmE4MGExNTE0Y2I5YmEwYzJfNi0zLTEtMS0w_d33244e9-5a8f-4105-b168-33de6263cd8d">4,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmYxZWQ5YzU5MGI3YzRjNTZhODBhMTUxNGNiOWJhMGMyL3RhYmxlcmFuZ2U6ZjFlZDljNTkwYjdjNGM1NmE4MGExNTE0Y2I5YmEwYzJfNi01LTEtMS0w_b798c70a-9064-474f-9a03-dc62c03b8f1d">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmYxZWQ5YzU5MGI3YzRjNTZhODBhMTUxNGNiOWJhMGMyL3RhYmxlcmFuZ2U6ZjFlZDljNTkwYjdjNGM1NmE4MGExNTE0Y2I5YmEwYzJfNi03LTEtMS0w_7e93af25-c6fd-4511-ac92-89c9d192a1e4">1,312,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i785b48358c27484689107bc80f7a2cbb_I20200103" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmYxZWQ5YzU5MGI3YzRjNTZhODBhMTUxNGNiOWJhMGMyL3RhYmxlcmFuZ2U6ZjFlZDljNTkwYjdjNGM1NmE4MGExNTE0Y2I5YmEwYzJfNy0xLTEtMS0w_56c4b3d6-6d12-4b0e-ab7d-030fb0bfa823">40,964</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i785b48358c27484689107bc80f7a2cbb_I20200103" decimals="-3" format="ixt:zerodash" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmYxZWQ5YzU5MGI3YzRjNTZhODBhMTUxNGNiOWJhMGMyL3RhYmxlcmFuZ2U6ZjFlZDljNTkwYjdjNGM1NmE4MGExNTE0Y2I5YmEwYzJfNy0zLTEtMS0w_1dc8c8bc-35b1-4ff4-987a-4e4565173630">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i785b48358c27484689107bc80f7a2cbb_I20200103" decimals="-3" format="ixt:zerodash" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmYxZWQ5YzU5MGI3YzRjNTZhODBhMTUxNGNiOWJhMGMyL3RhYmxlcmFuZ2U6ZjFlZDljNTkwYjdjNGM1NmE4MGExNTE0Y2I5YmEwYzJfNy01LTEtMS0w_f7bab996-8d3e-4b64-a975-a2103e073e3c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i785b48358c27484689107bc80f7a2cbb_I20200103" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmYxZWQ5YzU5MGI3YzRjNTZhODBhMTUxNGNiOWJhMGMyL3RhYmxlcmFuZ2U6ZjFlZDljNTkwYjdjNGM1NmE4MGExNTE0Y2I5YmEwYzJfNy03LTEtMS0w_db86d582-7713-4256-89f7-0885f0bfcb33">40,964</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28526894a4b14f39b408ab8db78be75d_I20200103" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmYxZWQ5YzU5MGI3YzRjNTZhODBhMTUxNGNiOWJhMGMyL3RhYmxlcmFuZ2U6ZjFlZDljNTkwYjdjNGM1NmE4MGExNTE0Y2I5YmEwYzJfOC0xLTEtMS0w_78080aa4-6122-48f5-88f1-85203bb685b0">2,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28526894a4b14f39b408ab8db78be75d_I20200103" decimals="-3" format="ixt:zerodash" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmYxZWQ5YzU5MGI3YzRjNTZhODBhMTUxNGNiOWJhMGMyL3RhYmxlcmFuZ2U6ZjFlZDljNTkwYjdjNGM1NmE4MGExNTE0Y2I5YmEwYzJfOC0zLTEtMS0w_12988e84-69d1-441b-863f-20686d1efcc1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28526894a4b14f39b408ab8db78be75d_I20200103" decimals="-3" format="ixt:zerodash" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmYxZWQ5YzU5MGI3YzRjNTZhODBhMTUxNGNiOWJhMGMyL3RhYmxlcmFuZ2U6ZjFlZDljNTkwYjdjNGM1NmE4MGExNTE0Y2I5YmEwYzJfOC01LTEtMS0w_d57b2163-3554-4d3a-aceb-d523b319c2e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28526894a4b14f39b408ab8db78be75d_I20200103" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmYxZWQ5YzU5MGI3YzRjNTZhODBhMTUxNGNiOWJhMGMyL3RhYmxlcmFuZ2U6ZjFlZDljNTkwYjdjNGM1NmE4MGExNTE0Y2I5YmEwYzJfOC03LTEtMS0w_e72ffe85-a542-4f54-b30d-d8c70384fcca">2,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1800b81e21784d189946618c1ae33956_I20200103" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmYxZWQ5YzU5MGI3YzRjNTZhODBhMTUxNGNiOWJhMGMyL3RhYmxlcmFuZ2U6ZjFlZDljNTkwYjdjNGM1NmE4MGExNTE0Y2I5YmEwYzJfOS0xLTEtMS0w_c7e0b148-d83a-4bf5-b8d5-932b26108bbc">32,728</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1800b81e21784d189946618c1ae33956_I20200103" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmYxZWQ5YzU5MGI3YzRjNTZhODBhMTUxNGNiOWJhMGMyL3RhYmxlcmFuZ2U6ZjFlZDljNTkwYjdjNGM1NmE4MGExNTE0Y2I5YmEwYzJfOS0zLTEtMS0w_2ef0e9e4-aac8-40aa-a29d-ffc64f2f1187">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1800b81e21784d189946618c1ae33956_I20200103" decimals="-3" format="ixt:zerodash" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmYxZWQ5YzU5MGI3YzRjNTZhODBhMTUxNGNiOWJhMGMyL3RhYmxlcmFuZ2U6ZjFlZDljNTkwYjdjNGM1NmE4MGExNTE0Y2I5YmEwYzJfOS01LTEtMS0w_3e283fdf-4e00-4606-9858-cf7b238d0ea0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1800b81e21784d189946618c1ae33956_I20200103" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmYxZWQ5YzU5MGI3YzRjNTZhODBhMTUxNGNiOWJhMGMyL3RhYmxlcmFuZ2U6ZjFlZDljNTkwYjdjNGM1NmE4MGExNTE0Y2I5YmEwYzJfOS03LTEtMS0w_3d4603d8-7b51-44e3-9d86-77adfacebfe4">32,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmYxZWQ5YzU5MGI3YzRjNTZhODBhMTUxNGNiOWJhMGMyL3RhYmxlcmFuZ2U6ZjFlZDljNTkwYjdjNGM1NmE4MGExNTE0Y2I5YmEwYzJfMTAtMS0xLTEtMA_5e721370-8bd1-4fd8-8992-cb5cf3667279">1,384,510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmYxZWQ5YzU5MGI3YzRjNTZhODBhMTUxNGNiOWJhMGMyL3RhYmxlcmFuZ2U6ZjFlZDljNTkwYjdjNGM1NmE4MGExNTE0Y2I5YmEwYzJfMTAtMy0xLTEtMA_57d53d7e-269d-4952-982d-56c879b5f2fd">4,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmYxZWQ5YzU5MGI3YzRjNTZhODBhMTUxNGNiOWJhMGMyL3RhYmxlcmFuZ2U6ZjFlZDljNTkwYjdjNGM1NmE4MGExNTE0Y2I5YmEwYzJfMTAtNS0xLTEtMA_505eb758-483f-456e-ab97-6671b098ffc8">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmYxZWQ5YzU5MGI3YzRjNTZhODBhMTUxNGNiOWJhMGMyL3RhYmxlcmFuZ2U6ZjFlZDljNTkwYjdjNGM1NmE4MGExNTE0Y2I5YmEwYzJfMTAtNy0xLTEtMA_04d497f2-929e-41fc-8c52-5cbb24321543">1,388,628</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_7">Table of Contents</a></span></div></div><ix:continuation id="iad68f2df443a44b3b54e7d837790c702"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest receivable was $<ix:nonFraction unitRef="usd" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RleHRyZWdpb246OGZhODczZDFjZDY5NGI4YmE5NzUwZTE4NjFmNGMwMGFfNzUz_f9d08229-590c-45aa-8be9-a796171b0c3d">4.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RleHRyZWdpb246OGZhODczZDFjZDY5NGI4YmE5NzUwZTE4NjFmNGMwMGFfNzYw_aea0efad-9cd8-4624-897c-a5d6947f9fa8">6.2</ix:nonFraction> million as of September&#160;30, 2020 and December&#160;31, 2019, respectively, and is included in prepaid expenses and other current assets in the accompanying Condensed Consolidated Balance Sheets.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains and losses on the sales of investments were insignificant during the three and nine months ended September&#160;30, 2020 and 2019.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage credit risk associated with our investment portfolio through our investment policy, which limits purchases to high-quality issuers and limits the amount of our portfolio that can be invested in a single issuer. <ix:nonNumeric contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RleHRyZWdpb246OGZhODczZDFjZDY5NGI4YmE5NzUwZTE4NjFmNGMwMGFfMjIxNw_5ccaf71d-0e13-4b12-b8e7-9316a21ed2ce" continuedAt="i8157add36d0d41329d572212189b95d7" escape="true">The fair value and gross unrealized losses on debt securities available-for-sale in an unrealized loss position were as follows (in thousands):</ix:nonNumeric></span></div><ix:continuation id="i8157add36d0d41329d572212189b95d7"><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.459%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.824%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51a81230a1d74e55a2566c55413e2b2a_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOjBjNDRiYmMxNDA0ZDQ0Y2E5NjkxMzhjZDlhYTI4OWMzL3RhYmxlcmFuZ2U6MGM0NGJiYzE0MDRkNDRjYTk2OTEzOGNkOWFhMjg5YzNfMi05LTEtMS0w_1fdf8f10-bcb5-4426-aec6-b3886755c9cd">29,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51a81230a1d74e55a2566c55413e2b2a_I20201002" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOjBjNDRiYmMxNDA0ZDQ0Y2E5NjkxMzhjZDlhYTI4OWMzL3RhYmxlcmFuZ2U6MGM0NGJiYzE0MDRkNDRjYTk2OTEzOGNkOWFhMjg5YzNfMi0xMS0xLTEtMA_ae6a03ab-57e3-4c29-9878-f480d52f535f">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba278ad76ca4fcd841ffefc73154898_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOjBjNDRiYmMxNDA0ZDQ0Y2E5NjkxMzhjZDlhYTI4OWMzL3RhYmxlcmFuZ2U6MGM0NGJiYzE0MDRkNDRjYTk2OTEzOGNkOWFhMjg5YzNfMy05LTEtMS0w_6bc27a80-681e-4745-b049-9c6697490dbf">70,465</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ba278ad76ca4fcd841ffefc73154898_I20201002" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOjBjNDRiYmMxNDA0ZDQ0Y2E5NjkxMzhjZDlhYTI4OWMzL3RhYmxlcmFuZ2U6MGM0NGJiYzE0MDRkNDRjYTk2OTEzOGNkOWFhMjg5YzNfMy0xMS0xLTEtMA_fba1f4b5-e301-42ef-a6a6-d92418412fc8">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOjBjNDRiYmMxNDA0ZDQ0Y2E5NjkxMzhjZDlhYTI4OWMzL3RhYmxlcmFuZ2U6MGM0NGJiYzE0MDRkNDRjYTk2OTEzOGNkOWFhMjg5YzNfNi05LTEtMS0w_5ef5a47a-f553-4928-9e38-2bfe2b697eca">100,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOjBjNDRiYmMxNDA0ZDQ0Y2E5NjkxMzhjZDlhYTI4OWMzL3RhYmxlcmFuZ2U6MGM0NGJiYzE0MDRkNDRjYTk2OTEzOGNkOWFhMjg5YzNfNi0xMS0xLTEtMA_d9512807-59ed-45d9-b9ae-8d205d66c826">30</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.459%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.824%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic27aa82f118547bcaca2790c33dd963b_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmVhODRhN2I4MjY4NTQ1MGZhMWI2MTAzMTZlMzczNDg3L3RhYmxlcmFuZ2U6ZWE4NGE3YjgyNjg1NDUwZmExYjYxMDMxNmUzNzM0ODdfMi05LTEtMS0w_a1215e37-0b37-407a-9b96-ea4e0856f07b">14,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic27aa82f118547bcaca2790c33dd963b_I20200103" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmVhODRhN2I4MjY4NTQ1MGZhMWI2MTAzMTZlMzczNDg3L3RhYmxlcmFuZ2U6ZWE4NGE3YjgyNjg1NDUwZmExYjYxMDMxNmUzNzM0ODdfMi0xMS0xLTEtMA_731f4575-af92-4cb0-a613-5f2745dc56f1">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f0bf831f83f4af59172086b8a97f3c4_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmVhODRhN2I4MjY4NTQ1MGZhMWI2MTAzMTZlMzczNDg3L3RhYmxlcmFuZ2U6ZWE4NGE3YjgyNjg1NDUwZmExYjYxMDMxNmUzNzM0ODdfMy05LTEtMS0w_3332fabb-a451-4d43-84cb-9be109c5d2b3">2,848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f0bf831f83f4af59172086b8a97f3c4_I20200103" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmVhODRhN2I4MjY4NTQ1MGZhMWI2MTAzMTZlMzczNDg3L3RhYmxlcmFuZ2U6ZWE4NGE3YjgyNjg1NDUwZmExYjYxMDMxNmUzNzM0ODdfMy0xMS0xLTEtMA_1d8512eb-cf5e-4959-8e4d-3ed34b6c4ed1">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmVhODRhN2I4MjY4NTQ1MGZhMWI2MTAzMTZlMzczNDg3L3RhYmxlcmFuZ2U6ZWE4NGE3YjgyNjg1NDUwZmExYjYxMDMxNmUzNzM0ODdfNS05LTEtMS0w_a7cda02c-dd8f-4456-aee4-c821c67800bc">17,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmVhODRhN2I4MjY4NTQ1MGZhMWI2MTAzMTZlMzczNDg3L3RhYmxlcmFuZ2U6ZWE4NGE3YjgyNjg1NDUwZmExYjYxMDMxNmUzNzM0ODdfNS0xMS0xLTEtMA_781179c2-ccbb-44c4-8c40-da63300e76d9">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All securities presented have been in an unrealized loss position less than 12 months. There were <ix:nonFraction unitRef="investment" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RleHRyZWdpb246OGZhODczZDFjZDY5NGI4YmE5NzUwZTE4NjFmNGMwMGFfMTQ4MQ_aca373f9-749d-49ec-946c-dd5a7e2edf1b">16</ix:nonFraction> and <ix:nonFraction unitRef="investment" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RleHRyZWdpb246OGZhODczZDFjZDY5NGI4YmE5NzUwZTE4NjFmNGMwMGFfMTQ4OQ_17b6e2a7-cd79-4012-8fa3-4dda97f8e33c">9</ix:nonFraction> investments in an unrealized loss position as of September&#160;30, 2020 and December&#160;31, 2019, respectively. During the nine months ended September&#160;30, 2020 and 2019, we did <ix:nonFraction unitRef="usd" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RleHRyZWdpb246OGZhODczZDFjZDY5NGI4YmE5NzUwZTE4NjFmNGMwMGFfMTY0OTI2NzQ0Mzk3MQ_baf5c35f-07b3-426b-9902-dd67b0fe3278"><ix:nonFraction unitRef="usd" contextRef="i34bbe41183cc4f96afa896c1d7f86bb3_I20190927" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RleHRyZWdpb246OGZhODczZDFjZDY5NGI4YmE5NzUwZTE4NjFmNGMwMGFfMTY0OTI2NzQ0Mzk3MQ_d69aae4d-ea94-49a5-955e-f272fb16d1e4">no</ix:nonFraction></ix:nonFraction>t record an allowance for credit losses or other impairment charges on our investment securities. Based upon our quarterly impairment review, we determined that the unrealized losses were not attributed to credit risk but were primarily associated with changes in interest rates and market liquidity. Based on the scheduled maturities of our investments, we determined that it was more likely than not that we will hold these investments for a period of time sufficient for a recovery of our cost basis.</span></div><ix:nonNumeric contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RleHRyZWdpb246OGZhODczZDFjZDY5NGI4YmE5NzUwZTE4NjFmNGMwMGFfMjI0Nw_71c51f97-46e6-48d9-a93f-48813e3247f4" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of debt securities available-for-sale by contractual maturity was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.717%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOjg5NDNjN2IzMWU1YTQ3YmY4YjlkMjJjMjcyMjQxYzI1L3RhYmxlcmFuZ2U6ODk0M2M3YjMxZTVhNDdiZjhiOWQyMmMyNzIyNDFjMjVfMS0xLTEtMS0w_0a1fbb6b-5db4-4e03-be3e-32304f2e79b3">993,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOjg5NDNjN2IzMWU1YTQ3YmY4YjlkMjJjMjcyMjQxYzI1L3RhYmxlcmFuZ2U6ODk0M2M3YjMxZTVhNDdiZjhiOWQyMmMyNzIyNDFjMjVfMS0zLTEtMS0w_145f389f-809c-4de2-a454-6d93cfec814b">789,913</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOjg5NDNjN2IzMWU1YTQ3YmY4YjlkMjJjMjcyMjQxYzI1L3RhYmxlcmFuZ2U6ODk0M2M3YjMxZTVhNDdiZjhiOWQyMmMyNzIyNDFjMjVfMi0xLTEtMS0w_e96dd969-cf15-4083-9f1a-f8852059276c">344,194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOjg5NDNjN2IzMWU1YTQ3YmY4YjlkMjJjMjcyMjQxYzI1L3RhYmxlcmFuZ2U6ODk0M2M3YjMxZTVhNDdiZjhiOWQyMmMyNzIyNDFjMjVfMi0zLTEtMS0w_cbf4bd58-cd1f-4f6d-b652-a0aa31c0bdc8">522,551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOjg5NDNjN2IzMWU1YTQ3YmY4YjlkMjJjMjcyMjQxYzI1L3RhYmxlcmFuZ2U6ODk0M2M3YjMxZTVhNDdiZjhiOWQyMmMyNzIyNDFjMjVfMy0xLTEtMS0w_a068b0ea-9a50-441b-bc3e-0ad7839e870b">1,337,405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOjg5NDNjN2IzMWU1YTQ3YmY4YjlkMjJjMjcyMjQxYzI1L3RhYmxlcmFuZ2U6ODk0M2M3YjMxZTVhNDdiZjhiOWQyMmMyNzIyNDFjMjVfMy0zLTEtMS0w_7390248e-674a-4827-abfe-905d0a3aec06">1,312,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i0283c6f517b447ec92f154ee691f4028_61"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 5. <ix:nonNumeric contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RleHRyZWdpb246OGY1NzI5NjEwZmQ1NDVjMDhjYzhiMmRhNWNjMmVhYzlfMTU0Mg_035895a5-f7a6-46e7-8e84-3c97f3c9ec86" continuedAt="ic948e021823d41e3abcf38301b9421fd" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:continuation id="ic948e021823d41e3abcf38301b9421fd" continuedAt="i79f9624cb5e6434085ce414e8be3b63d"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value reflects the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy has the following three levels:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Level 1 -&#160;quoted prices (unadjusted) in active markets for identical assets and liabilities;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Level 2 -&#160;inputs other than level 1 that are observable either directly or indirectly, such as quoted prices in active markets for similar instruments or on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Level 3 -&#160;unobservable inputs that are supported by little or no market activity that are significant to the fair value measurement</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_7">Table of Contents</a></span></div></div><ix:continuation id="i79f9624cb5e6434085ce414e8be3b63d"><ix:nonNumeric contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RleHRyZWdpb246OGY1NzI5NjEwZmQ1NDVjMDhjYzhiMmRhNWNjMmVhYzlfMTU0Mw_07b9f471-e652-4e45-ab1c-3434a904bdbe" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.995%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieadeb951ef494630818c3cc30b3da393_I20201002" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjEyYWUyN2FkOTk4MjQwNzM5YzBhMjFkZjNkODYzYTNhL3RhYmxlcmFuZ2U6MTJhZTI3YWQ5OTgyNDA3MzljMGEyMWRmM2Q4NjNhM2FfMi0xLTEtMS0w_b23d1e7b-98f5-485b-9bfb-36882d74fdae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0aad2b7015eb477c88c1ea01262ba619_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjEyYWUyN2FkOTk4MjQwNzM5YzBhMjFkZjNkODYzYTNhL3RhYmxlcmFuZ2U6MTJhZTI3YWQ5OTgyNDA3MzljMGEyMWRmM2Q4NjNhM2FfMi0zLTEtMS0w_790c74c6-3327-46e4-a5f5-ed6ad420abf0">466,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia338dcf4e5144bef8ca2ebd43f622d04_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjEyYWUyN2FkOTk4MjQwNzM5YzBhMjFkZjNkODYzYTNhL3RhYmxlcmFuZ2U6MTJhZTI3YWQ5OTgyNDA3MzljMGEyMWRmM2Q4NjNhM2FfMi01LTEtMS0w_16bc5bb1-7ce5-469f-9257-87baf856e7e5">466,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i214b7f1c98384cd7ae5d32548266b97b_I20201002" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjEyYWUyN2FkOTk4MjQwNzM5YzBhMjFkZjNkODYzYTNhL3RhYmxlcmFuZ2U6MTJhZTI3YWQ5OTgyNDA3MzljMGEyMWRmM2Q4NjNhM2FfMy0xLTEtMS0w_4fdaf91f-7296-4016-ade0-93282687e308">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e427409ff9d4828a3b7640315fdf49b_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjEyYWUyN2FkOTk4MjQwNzM5YzBhMjFkZjNkODYzYTNhL3RhYmxlcmFuZ2U6MTJhZTI3YWQ5OTgyNDA3MzljMGEyMWRmM2Q4NjNhM2FfMy0zLTEtMS0w_0604b246-0416-4cb6-85c1-e47a850984b7">636,815</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ea639c496fd491897fbb9c377110819_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjEyYWUyN2FkOTk4MjQwNzM5YzBhMjFkZjNkODYzYTNhL3RhYmxlcmFuZ2U6MTJhZTI3YWQ5OTgyNDA3MzljMGEyMWRmM2Q4NjNhM2FfMy01LTEtMS0w_c3cca474-c295-4ba6-afc3-b0c4c613c141">636,815</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14689612fde84c3c940d88d417602b2a_I20201002" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjEyYWUyN2FkOTk4MjQwNzM5YzBhMjFkZjNkODYzYTNhL3RhYmxlcmFuZ2U6MTJhZTI3YWQ5OTgyNDA3MzljMGEyMWRmM2Q4NjNhM2FfNC0xLTEtMS0w_dd2f761e-dfc4-4643-afe2-79240d449903">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i105a4d34d1764fab907327463ccad490_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjEyYWUyN2FkOTk4MjQwNzM5YzBhMjFkZjNkODYzYTNhL3RhYmxlcmFuZ2U6MTJhZTI3YWQ5OTgyNDA3MzljMGEyMWRmM2Q4NjNhM2FfNC0zLTEtMS0w_62f133f5-bb48-4e5d-b8d7-aebf2c111add">213,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b6ffe686868432ab9437a164687d998_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjEyYWUyN2FkOTk4MjQwNzM5YzBhMjFkZjNkODYzYTNhL3RhYmxlcmFuZ2U6MTJhZTI3YWQ5OTgyNDA3MzljMGEyMWRmM2Q4NjNhM2FfNC01LTEtMS0w_4cf48fe3-cabb-46d1-853c-364bb0c01190">213,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c82661404c1488b9aa5b0c3a43ca9f4_I20201002" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjEyYWUyN2FkOTk4MjQwNzM5YzBhMjFkZjNkODYzYTNhL3RhYmxlcmFuZ2U6MTJhZTI3YWQ5OTgyNDA3MzljMGEyMWRmM2Q4NjNhM2FfNS0xLTEtMS0w_186a1777-a6ca-419e-addc-d4f213272585">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic69aa2cb176f4a9aa647d6c00a697fb9_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjEyYWUyN2FkOTk4MjQwNzM5YzBhMjFkZjNkODYzYTNhL3RhYmxlcmFuZ2U6MTJhZTI3YWQ5OTgyNDA3MzljMGEyMWRmM2Q4NjNhM2FfNS0zLTEtMS0w_5702290f-9eba-4fd4-897a-9921a7dcc636">20,431</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb5a720eff3482091e3be625d787981_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjEyYWUyN2FkOTk4MjQwNzM5YzBhMjFkZjNkODYzYTNhL3RhYmxlcmFuZ2U6MTJhZTI3YWQ5OTgyNDA3MzljMGEyMWRmM2Q4NjNhM2FfNS01LTEtMS0w_c7dd70df-d45a-4e06-869b-80ca0a3f67fb">20,431</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d11a44c584e4c27b4cd486045540585_I20201002" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjEyYWUyN2FkOTk4MjQwNzM5YzBhMjFkZjNkODYzYTNhL3RhYmxlcmFuZ2U6MTJhZTI3YWQ5OTgyNDA3MzljMGEyMWRmM2Q4NjNhM2FfNi0xLTEtMS0w_1670d7d0-c7ef-4306-8dab-303c59d0bcd3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6891e843a55d40c9a8f7f81e029810ef_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjEyYWUyN2FkOTk4MjQwNzM5YzBhMjFkZjNkODYzYTNhL3RhYmxlcmFuZ2U6MTJhZTI3YWQ5OTgyNDA3MzljMGEyMWRmM2Q4NjNhM2FfNi0zLTEtMS0w_29a14425-d16e-4f0c-bf57-991f5f421995">1,337,405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia145ea6fe2c34f45a3f0710801bc6531_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjEyYWUyN2FkOTk4MjQwNzM5YzBhMjFkZjNkODYzYTNhL3RhYmxlcmFuZ2U6MTJhZTI3YWQ5OTgyNDA3MzljMGEyMWRmM2Q4NjNhM2FfNi01LTEtMS0w_f5c4bb5b-ffb2-4a2b-b754-616ba1a4137b">1,337,405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i295ed1efaf864ae9b0abe578705aae7c_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjEyYWUyN2FkOTk4MjQwNzM5YzBhMjFkZjNkODYzYTNhL3RhYmxlcmFuZ2U6MTJhZTI3YWQ5OTgyNDA3MzljMGEyMWRmM2Q4NjNhM2FfNy0xLTEtMS0w_07f85f9b-ae83-4053-a638-b0538303e383">96,992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b2d74b62bf14b7399c48b032c3050fa_I20201002" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjEyYWUyN2FkOTk4MjQwNzM5YzBhMjFkZjNkODYzYTNhL3RhYmxlcmFuZ2U6MTJhZTI3YWQ5OTgyNDA3MzljMGEyMWRmM2Q4NjNhM2FfNy0zLTEtMS0w_dd471a85-30e5-4c1c-8670-824747674204">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecc5d76d94114b538c7cc261d3d7dbb9_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjEyYWUyN2FkOTk4MjQwNzM5YzBhMjFkZjNkODYzYTNhL3RhYmxlcmFuZ2U6MTJhZTI3YWQ5OTgyNDA3MzljMGEyMWRmM2Q4NjNhM2FfNy01LTEtMS0w_1b4cb321-fbac-48e6-954e-4ffb73dd0ec8">96,992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eec7f6e4801439489ec8ab44f13dca5_I20201002" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjEyYWUyN2FkOTk4MjQwNzM5YzBhMjFkZjNkODYzYTNhL3RhYmxlcmFuZ2U6MTJhZTI3YWQ5OTgyNDA3MzljMGEyMWRmM2Q4NjNhM2FfOC0xLTEtMS0w_139d1926-5c3d-4632-a153-a861f7180472">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife2cb38c2462497fb4f2be87aacfcbe9_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjEyYWUyN2FkOTk4MjQwNzM5YzBhMjFkZjNkODYzYTNhL3RhYmxlcmFuZ2U6MTJhZTI3YWQ5OTgyNDA3MzljMGEyMWRmM2Q4NjNhM2FfOC0zLTEtMS0w_aa568325-f6dc-425e-bb53-987c5cb2b5a2">55,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e13458d32e445e6a3bdc3140700b3ef_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjEyYWUyN2FkOTk4MjQwNzM5YzBhMjFkZjNkODYzYTNhL3RhYmxlcmFuZ2U6MTJhZTI3YWQ5OTgyNDA3MzljMGEyMWRmM2Q4NjNhM2FfOC01LTEtMS0w_e7482307-8264-4fac-82a1-c5c102a67ed7">55,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d11a44c584e4c27b4cd486045540585_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjEyYWUyN2FkOTk4MjQwNzM5YzBhMjFkZjNkODYzYTNhL3RhYmxlcmFuZ2U6MTJhZTI3YWQ5OTgyNDA3MzljMGEyMWRmM2Q4NjNhM2FfOS0xLTEtMS0w_05aaef1c-5510-4065-8797-c045e3f5bfa2">96,992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6891e843a55d40c9a8f7f81e029810ef_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjEyYWUyN2FkOTk4MjQwNzM5YzBhMjFkZjNkODYzYTNhL3RhYmxlcmFuZ2U6MTJhZTI3YWQ5OTgyNDA3MzljMGEyMWRmM2Q4NjNhM2FfOS0zLTEtMS0w_eef03668-1588-472e-9225-c03fcdbc6877">1,392,989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia145ea6fe2c34f45a3f0710801bc6531_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjEyYWUyN2FkOTk4MjQwNzM5YzBhMjFkZjNkODYzYTNhL3RhYmxlcmFuZ2U6MTJhZTI3YWQ5OTgyNDA3MzljMGEyMWRmM2Q4NjNhM2FfOS01LTEtMS0w_71d73a5c-54ca-4894-8474-45246f87aeb6">1,489,981</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.995%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i727f7c37fa244a2d96022ada5bf8347f_I20200103" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjFkNmVkOGY4ZDFjYTRjYWY4ODUxODI5OWVmODQwMDkyL3RhYmxlcmFuZ2U6MWQ2ZWQ4ZjhkMWNhNGNhZjg4NTE4Mjk5ZWY4NDAwOTJfMi0xLTEtMS0w_e452bf87-b7bc-4df6-a05b-0e0b2e21d973">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98bf240c97e447183ba8f88a167242d_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjFkNmVkOGY4ZDFjYTRjYWY4ODUxODI5OWVmODQwMDkyL3RhYmxlcmFuZ2U6MWQ2ZWQ4ZjhkMWNhNGNhZjg4NTE4Mjk5ZWY4NDAwOTJfMi0zLTEtMS0w_c6868dc4-51d8-4d4a-a7a3-de559a51c5ea">389,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d639ed777ff435ea5b6c19441e7ecff_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjFkNmVkOGY4ZDFjYTRjYWY4ODUxODI5OWVmODQwMDkyL3RhYmxlcmFuZ2U6MWQ2ZWQ4ZjhkMWNhNGNhZjg4NTE4Mjk5ZWY4NDAwOTJfMi01LTEtMS0w_b1fdee45-38a4-4a54-b01d-243000ea0f1d">389,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d9829f5158045228bedb41708d21afd_I20200103" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjFkNmVkOGY4ZDFjYTRjYWY4ODUxODI5OWVmODQwMDkyL3RhYmxlcmFuZ2U6MWQ2ZWQ4ZjhkMWNhNGNhZjg4NTE4Mjk5ZWY4NDAwOTJfMy0xLTEtMS0w_703c79d4-503b-43fb-90ff-24b7767d66d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7facc890253843839cb983e5f0c5d14c_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjFkNmVkOGY4ZDFjYTRjYWY4ODUxODI5OWVmODQwMDkyL3RhYmxlcmFuZ2U6MWQ2ZWQ4ZjhkMWNhNGNhZjg4NTE4Mjk5ZWY4NDAwOTJfMy0zLTEtMS0w_c9f66f13-ea50-4cbe-b6b6-a1d484c35fcc">756,226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77e3015ed1f944988e83d686ba77f015_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjFkNmVkOGY4ZDFjYTRjYWY4ODUxODI5OWVmODQwMDkyL3RhYmxlcmFuZ2U6MWQ2ZWQ4ZjhkMWNhNGNhZjg4NTE4Mjk5ZWY4NDAwOTJfMy01LTEtMS0w_80386749-4391-4d73-bb1a-47fe36b36725">756,226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5fb7e2d38294fdaa468d8855b980731_I20200103" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjFkNmVkOGY4ZDFjYTRjYWY4ODUxODI5OWVmODQwMDkyL3RhYmxlcmFuZ2U6MWQ2ZWQ4ZjhkMWNhNGNhZjg4NTE4Mjk5ZWY4NDAwOTJfNC0xLTEtMS0w_40ed2ef1-59fc-483e-a3be-27be5f5a9faf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2b721b19a1d4ee8a556e85a2c797759_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjFkNmVkOGY4ZDFjYTRjYWY4ODUxODI5OWVmODQwMDkyL3RhYmxlcmFuZ2U6MWQ2ZWQ4ZjhkMWNhNGNhZjg4NTE4Mjk5ZWY4NDAwOTJfNC0zLTEtMS0w_22654339-aa27-4ecc-9281-af6ae79b508f">166,665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b010574af4c409fa174a0bc4c2b34e1_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjFkNmVkOGY4ZDFjYTRjYWY4ODUxODI5OWVmODQwMDkyL3RhYmxlcmFuZ2U6MWQ2ZWQ4ZjhkMWNhNGNhZjg4NTE4Mjk5ZWY4NDAwOTJfNC01LTEtMS0w_6d213a14-6687-46a2-a7f2-46bc28479eef">166,665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icefaee59f19a40b0bbd4de9922c8c59c_I20200103" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjFkNmVkOGY4ZDFjYTRjYWY4ODUxODI5OWVmODQwMDkyL3RhYmxlcmFuZ2U6MWQ2ZWQ4ZjhkMWNhNGNhZjg4NTE4Mjk5ZWY4NDAwOTJfNS0xLTEtMS0w_88f14cf8-9b71-42cb-8ed9-88cc4d0e0080">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4060e618697434cad36b5db4d7c6111_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjFkNmVkOGY4ZDFjYTRjYWY4ODUxODI5OWVmODQwMDkyL3RhYmxlcmFuZ2U6MWQ2ZWQ4ZjhkMWNhNGNhZjg4NTE4Mjk5ZWY4NDAwOTJfNS0zLTEtMS0w_718cc587-a646-4955-988c-29b87ac3d1c7">1,312,464</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd8e36118a87443ca78892462d27bfab_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjFkNmVkOGY4ZDFjYTRjYWY4ODUxODI5OWVmODQwMDkyL3RhYmxlcmFuZ2U6MWQ2ZWQ4ZjhkMWNhNGNhZjg4NTE4Mjk5ZWY4NDAwOTJfNS01LTEtMS0w_b0cc0d9e-c625-48cf-9adc-ff94536652c9">1,312,464</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09f2281bdf9349038431afc18379805b_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjFkNmVkOGY4ZDFjYTRjYWY4ODUxODI5OWVmODQwMDkyL3RhYmxlcmFuZ2U6MWQ2ZWQ4ZjhkMWNhNGNhZjg4NTE4Mjk5ZWY4NDAwOTJfNi0xLTEtMS0w_5dae037a-0648-4b48-b1ab-95673748c568">2,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9c4cc15650340169d2372d82bde6360_I20200103" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjFkNmVkOGY4ZDFjYTRjYWY4ODUxODI5OWVmODQwMDkyL3RhYmxlcmFuZ2U6MWQ2ZWQ4ZjhkMWNhNGNhZjg4NTE4Mjk5ZWY4NDAwOTJfNi0zLTEtMS0w_25c613b8-e0f5-4a53-a16f-9cbfd01b718e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i362da4b860134a89851c683e142464ef_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjFkNmVkOGY4ZDFjYTRjYWY4ODUxODI5OWVmODQwMDkyL3RhYmxlcmFuZ2U6MWQ2ZWQ4ZjhkMWNhNGNhZjg4NTE4Mjk5ZWY4NDAwOTJfNi01LTEtMS0w_f8fa745d-d10c-4c77-9f5c-fa9532b8abf9">2,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic072d7bdc3a747c3aa29c10bd5bd37e7_I20200103" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjFkNmVkOGY4ZDFjYTRjYWY4ODUxODI5OWVmODQwMDkyL3RhYmxlcmFuZ2U6MWQ2ZWQ4ZjhkMWNhNGNhZjg4NTE4Mjk5ZWY4NDAwOTJfNy0xLTEtMS0w_a94cabc6-ba13-4f22-abc6-e263b50bab93">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76745aad80e54832855f5e01889a5b33_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjFkNmVkOGY4ZDFjYTRjYWY4ODUxODI5OWVmODQwMDkyL3RhYmxlcmFuZ2U6MWQ2ZWQ4ZjhkMWNhNGNhZjg4NTE4Mjk5ZWY4NDAwOTJfNy0zLTEtMS0w_6723dc85-b670-410f-a45d-5744fab578e2">32,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c5d87cfd74f40ccabd0feeeecbb37cd_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjFkNmVkOGY4ZDFjYTRjYWY4ODUxODI5OWVmODQwMDkyL3RhYmxlcmFuZ2U6MWQ2ZWQ4ZjhkMWNhNGNhZjg4NTE4Mjk5ZWY4NDAwOTJfNy01LTEtMS0w_31cc7f5e-1195-4c93-a007-17e9f934ea79">32,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icefaee59f19a40b0bbd4de9922c8c59c_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjFkNmVkOGY4ZDFjYTRjYWY4ODUxODI5OWVmODQwMDkyL3RhYmxlcmFuZ2U6MWQ2ZWQ4ZjhkMWNhNGNhZjg4NTE4Mjk5ZWY4NDAwOTJfOC0xLTEtMS0w_f4e89418-5305-4977-a0db-5edcde2af0c4">2,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4060e618697434cad36b5db4d7c6111_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjFkNmVkOGY4ZDFjYTRjYWY4ODUxODI5OWVmODQwMDkyL3RhYmxlcmFuZ2U6MWQ2ZWQ4ZjhkMWNhNGNhZjg4NTE4Mjk5ZWY4NDAwOTJfOC0zLTEtMS0w_464715d0-8b9a-488d-baa1-f209b2a474a1">1,345,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd8e36118a87443ca78892462d27bfab_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjFkNmVkOGY4ZDFjYTRjYWY4ODUxODI5OWVmODQwMDkyL3RhYmxlcmFuZ2U6MWQ2ZWQ4ZjhkMWNhNGNhZjg4NTE4Mjk5ZWY4NDAwOTJfOC01LTEtMS0w_bd3d087a-7ba1-4633-8861-7bc5dfd2f60e">1,347,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When available, we value investments based on quoted prices for those financial instruments, which is a Level 1 input. Our remaining investments are valued using third-party pricing sources, which use observable market prices, interest rates and yield curves observable at commonly quoted intervals for similar assets as observable inputs for pricing, which is a Level 2 input.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of our remaining financial assets and liabilities, which include cash, receivables and payables, approximate their fair values due to their short-term nature.</span></div></ix:continuation><div id="i0283c6f517b447ec92f154ee691f4028_64"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 6. <ix:nonNumeric contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82NC9mcmFnOmJkNjVhZGFjMzM3NDRiYWViNmNiMWRmZWJiMWUwMTgyL3RleHRyZWdpb246YmQ2NWFkYWMzMzc0NGJhZWI2Y2IxZGZlYmIxZTAxODJfMTkw_7ddb5c4d-ca87-4aa6-b622-52c16995a9c5" continuedAt="i16edba7889214826aac5fa03c47e469b" escape="true">INVENTORY</ix:nonNumeric></span></div><ix:continuation id="i16edba7889214826aac5fa03c47e469b"><ix:nonNumeric contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82NC9mcmFnOmJkNjVhZGFjMzM3NDRiYWViNmNiMWRmZWJiMWUwMTgyL3RleHRyZWdpb246YmQ2NWFkYWMzMzc0NGJhZWI2Y2IxZGZlYmIxZTAxODJfMTg2_57aa0087-0b4c-48a8-8163-e978e89d7489" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.717%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterials" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82NC9mcmFnOmJkNjVhZGFjMzM3NDRiYWViNmNiMWRmZWJiMWUwMTgyL3RhYmxlOmEzYjdjNzI5NWIwNTQ0NTQ4MmNlMTFjNWI4ODc3OGJjL3RhYmxlcmFuZ2U6YTNiN2M3Mjk1YjA1NDQ1NDgyY2UxMWM1Yjg4Nzc4YmNfMS0xLTEtMS0w_063d91bc-1c6c-4867-9d06-091c2b74ef25">5,298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterials" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82NC9mcmFnOmJkNjVhZGFjMzM3NDRiYWViNmNiMWRmZWJiMWUwMTgyL3RhYmxlOmEzYjdjNzI5NWIwNTQ0NTQ4MmNlMTFjNWI4ODc3OGJjL3RhYmxlcmFuZ2U6YTNiN2M3Mjk1YjA1NDQ1NDgyY2UxMWM1Yjg4Nzc4YmNfMS0zLTEtMS0w_c7f4a2f3-476f-4bcf-9502-f6a2b88f889d">2,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcess" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82NC9mcmFnOmJkNjVhZGFjMzM3NDRiYWViNmNiMWRmZWJiMWUwMTgyL3RhYmxlOmEzYjdjNzI5NWIwNTQ0NTQ4MmNlMTFjNWI4ODc3OGJjL3RhYmxlcmFuZ2U6YTNiN2M3Mjk1YjA1NDQ1NDgyY2UxMWM1Yjg4Nzc4YmNfMi0xLTEtMS0w_6244f32b-05d2-455d-8e15-772f42e24a63">17,911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcess" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82NC9mcmFnOmJkNjVhZGFjMzM3NDRiYWViNmNiMWRmZWJiMWUwMTgyL3RhYmxlOmEzYjdjNzI5NWIwNTQ0NTQ4MmNlMTFjNWI4ODc3OGJjL3RhYmxlcmFuZ2U6YTNiN2M3Mjk1YjA1NDQ1NDgyY2UxMWM1Yjg4Nzc4YmNfMi0zLTEtMS0w_27b05cb0-a714-43a9-8c05-adf8b728806e">9,447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoods" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82NC9mcmFnOmJkNjVhZGFjMzM3NDRiYWViNmNiMWRmZWJiMWUwMTgyL3RhYmxlOmEzYjdjNzI5NWIwNTQ0NTQ4MmNlMTFjNWI4ODc3OGJjL3RhYmxlcmFuZ2U6YTNiN2M3Mjk1YjA1NDQ1NDgyY2UxMWM1Yjg4Nzc4YmNfMy0xLTEtMS0w_5f4e30de-ab42-441a-bd28-4bfb6306fee2">4,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoods" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82NC9mcmFnOmJkNjVhZGFjMzM3NDRiYWViNmNiMWRmZWJiMWUwMTgyL3RhYmxlOmEzYjdjNzI5NWIwNTQ0NTQ4MmNlMTFjNWI4ODc3OGJjL3RhYmxlcmFuZ2U6YTNiN2M3Mjk1YjA1NDQ1NDgyY2UxMWM1Yjg4Nzc4YmNfMy0zLTEtMS0w_bd185a3b-451b-47a4-a3d2-2ecd0a4b11d7">4,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82NC9mcmFnOmJkNjVhZGFjMzM3NDRiYWViNmNiMWRmZWJiMWUwMTgyL3RhYmxlOmEzYjdjNzI5NWIwNTQ0NTQ4MmNlMTFjNWI4ODc3OGJjL3RhYmxlcmFuZ2U6YTNiN2M3Mjk1YjA1NDQ1NDgyY2UxMWM1Yjg4Nzc4YmNfNC0xLTEtMS0w_ca93adb2-ccd1-41a0-bf41-78c16fb9e085">27,744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82NC9mcmFnOmJkNjVhZGFjMzM3NDRiYWViNmNiMWRmZWJiMWUwMTgyL3RhYmxlOmEzYjdjNzI5NWIwNTQ0NTQ4MmNlMTFjNWI4ODc3OGJjL3RhYmxlcmFuZ2U6YTNiN2M3Mjk1YjA1NDQ1NDgyY2UxMWM1Yjg4Nzc4YmNfNC0zLTEtMS0w_2f7ff407-ed20-4105-b9b6-ee1a9a85fabe">16,523</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet classification:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion included in inventory</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de1a52cb79c40518135c31ed1ad1ba2_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82NC9mcmFnOmJkNjVhZGFjMzM3NDRiYWViNmNiMWRmZWJiMWUwMTgyL3RhYmxlOmEzYjdjNzI5NWIwNTQ0NTQ4MmNlMTFjNWI4ODc3OGJjL3RhYmxlcmFuZ2U6YTNiN2M3Mjk1YjA1NDQ1NDgyY2UxMWM1Yjg4Nzc4YmNfNi0xLTEtMS0w_97a5ce56-8b3d-453b-97ca-e0bbaadeaa11">19,319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f6503be5494081a0dbe6c993e81397_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82NC9mcmFnOmJkNjVhZGFjMzM3NDRiYWViNmNiMWRmZWJiMWUwMTgyL3RhYmxlOmEzYjdjNzI5NWIwNTQ0NTQ4MmNlMTFjNWI4ODc3OGJjL3RhYmxlcmFuZ2U6YTNiN2M3Mjk1YjA1NDQ1NDgyY2UxMWM1Yjg4Nzc4YmNfNi0zLTEtMS0w_bb02ce03-1360-4986-86c0-336575edce2d">12,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion included in other long-term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbece5f4cfff4192b62909c119134d4d_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82NC9mcmFnOmJkNjVhZGFjMzM3NDRiYWViNmNiMWRmZWJiMWUwMTgyL3RhYmxlOmEzYjdjNzI5NWIwNTQ0NTQ4MmNlMTFjNWI4ODc3OGJjL3RhYmxlcmFuZ2U6YTNiN2M3Mjk1YjA1NDQ1NDgyY2UxMWM1Yjg4Nzc4YmNfNy0xLTEtMS0w_7ea9852c-8fa6-46e2-ad20-d67a8888d4c8">8,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91d78c6281004d5e860e9762ede7f244_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82NC9mcmFnOmJkNjVhZGFjMzM3NDRiYWViNmNiMWRmZWJiMWUwMTgyL3RhYmxlOmEzYjdjNzI5NWIwNTQ0NTQ4MmNlMTFjNWI4ODc3OGJjL3RhYmxlcmFuZ2U6YTNiN2M3Mjk1YjA1NDQ1NDgyY2UxMWM1Yjg4Nzc4YmNfNy0zLTEtMS0w_82d91373-367a-4a3f-9707-c1e827885cb9">3,637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82NC9mcmFnOmJkNjVhZGFjMzM3NDRiYWViNmNiMWRmZWJiMWUwMTgyL3RhYmxlOmEzYjdjNzI5NWIwNTQ0NTQ4MmNlMTFjNWI4ODc3OGJjL3RhYmxlcmFuZ2U6YTNiN2M3Mjk1YjA1NDQ1NDgyY2UxMWM1Yjg4Nzc4YmNfOC0xLTEtMS0w_fab94578-9d10-448c-9c9e-1535ed59ff9e">27,744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82NC9mcmFnOmJkNjVhZGFjMzM3NDRiYWViNmNiMWRmZWJiMWUwMTgyL3RhYmxlOmEzYjdjNzI5NWIwNTQ0NTQ4MmNlMTFjNWI4ODc3OGJjL3RhYmxlcmFuZ2U6YTNiN2M3Mjk1YjA1NDQ1NDgyY2UxMWM1Yjg4Nzc4YmNfOC0zLTEtMS0w_d57b59dd-e054-4e0a-b0f3-8f33261e8aba">16,523</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Write-downs related to excess and expiring inventory were $<ix:nonFraction unitRef="usd" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryWriteDown" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82NC9mcmFnOmJkNjVhZGFjMzM3NDRiYWViNmNiMWRmZWJiMWUwMTgyL3RleHRyZWdpb246YmQ2NWFkYWMzMzc0NGJhZWI2Y2IxZGZlYmIxZTAxODJfMTM5_164dc53b-c697-4bfd-b9b1-6074ad328e9c">2.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryWriteDown" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82NC9mcmFnOmJkNjVhZGFjMzM3NDRiYWViNmNiMWRmZWJiMWUwMTgyL3RleHRyZWdpb246YmQ2NWFkYWMzMzc0NGJhZWI2Y2IxZGZlYmIxZTAxODJfMTQ2_badc0db0-5216-4489-96dd-5499db05cc06">0.4</ix:nonFraction> million for the nine months ended September&#160;30, 2020 and 2019, respectively.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="i0283c6f517b447ec92f154ee691f4028_67"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 7. <ix:nonNumeric contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RleHRyZWdpb246MGVjNTZiZTkxYWVmNGEyYmFhZTkyNGYwYmE2NTdhNDFfMTA0NDUzNjA0NzAzNTY_ac7b9ebf-811f-4102-bd8b-2f9d6fe68167" continuedAt="i2dbcc7d558264532895627d67287ed47" escape="true">STOCK-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="i2dbcc7d558264532895627d67287ed47" continuedAt="i2ba2e9257d2d461ba582e2ade404251d"><ix:nonNumeric contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RleHRyZWdpb246MGVjNTZiZTkxYWVmNGEyYmFhZTkyNGYwYmE2NTdhNDFfMzY5MQ_b36e070d-178b-4d71-85e8-1f563ea3e73a" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated the stock-based compensation expense for our equity incentive plans and our 2000 Employee Stock Purchase Plan (ESPP) as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.742%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8807e50c23c4d31ab20dcdcebd143c7_D20200704-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RhYmxlOjliYjIzZTg3MzhjZTQxM2JiNDAwYzc1YWZhOTJmNGNmL3RhYmxlcmFuZ2U6OWJiMjNlODczOGNlNDEzYmI0MDBjNzVhZmE5MmY0Y2ZfMi0xLTEtMS0w_6cf7d895-c7bf-47d6-bcca-1099b296b01c">18,936</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d73a25521cd47598eec943fc3e67f0b_D20190629-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RhYmxlOjliYjIzZTg3MzhjZTQxM2JiNDAwYzc1YWZhOTJmNGNmL3RhYmxlcmFuZ2U6OWJiMjNlODczOGNlNDEzYmI0MDBjNzVhZmE5MmY0Y2ZfMi0zLTEtMS0w_1fbecb53-c987-4014-801e-e862193461e3">4,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id10dbcb3d9244b64b3c0a11867e5072c_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RhYmxlOjliYjIzZTg3MzhjZTQxM2JiNDAwYzc1YWZhOTJmNGNmL3RhYmxlcmFuZ2U6OWJiMjNlODczOGNlNDEzYmI0MDBjNzVhZmE5MmY0Y2ZfMi01LTEtMS0w_c9874ad9-db38-40ff-ac97-b50baa35515e">30,134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2730b1b9796c4aaaa8efe5695e985946_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RhYmxlOjliYjIzZTg3MzhjZTQxM2JiNDAwYzc1YWZhOTJmNGNmL3RhYmxlcmFuZ2U6OWJiMjNlODczOGNlNDEzYmI0MDBjNzVhZmE5MmY0Y2ZfMi03LTEtMS0w_bbfaccde-3afa-4e35-b5eb-1ccfc800b2ec">13,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94716cdf2585476f8d2241789b25429d_D20200704-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RhYmxlOjliYjIzZTg3MzhjZTQxM2JiNDAwYzc1YWZhOTJmNGNmL3RhYmxlcmFuZ2U6OWJiMjNlODczOGNlNDEzYmI0MDBjNzVhZmE5MmY0Y2ZfMy0xLTEtMS0w_2eda64cb-304f-4908-9cc3-3c9e2fb6d8e8">36,719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia84c18733f11427b85d537694ee6b742_D20190629-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RhYmxlOjliYjIzZTg3MzhjZTQxM2JiNDAwYzc1YWZhOTJmNGNmL3RhYmxlcmFuZ2U6OWJiMjNlODczOGNlNDEzYmI0MDBjNzVhZmE5MmY0Y2ZfMy0zLTEtMS0w_09bf5d47-c5f6-4098-b257-43db1fa61089">8,838</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife7f80399bf046279aeacfddc3d5cb35_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RhYmxlOjliYjIzZTg3MzhjZTQxM2JiNDAwYzc1YWZhOTJmNGNmL3RhYmxlcmFuZ2U6OWJiMjNlODczOGNlNDEzYmI0MDBjNzVhZmE5MmY0Y2ZfMy01LTEtMS0w_c23a0599-5261-41ff-a75b-ca8caa699a43">55,657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb17c6080fe0476e875c10f986a8b090_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RhYmxlOjliYjIzZTg3MzhjZTQxM2JiNDAwYzc1YWZhOTJmNGNmL3RhYmxlcmFuZ2U6OWJiMjNlODczOGNlNDEzYmI0MDBjNzVhZmE5MmY0Y2ZfMy03LTEtMS0w_0a5d648a-0924-496e-bf7c-c3a3cbada506">27,002</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RhYmxlOjliYjIzZTg3MzhjZTQxM2JiNDAwYzc1YWZhOTJmNGNmL3RhYmxlcmFuZ2U6OWJiMjNlODczOGNlNDEzYmI0MDBjNzVhZmE5MmY0Y2ZfNC0xLTEtMS0w_fe4b38ed-474a-4eb6-b53c-08ea66399aa4">55,655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RhYmxlOjliYjIzZTg3MzhjZTQxM2JiNDAwYzc1YWZhOTJmNGNmL3RhYmxlcmFuZ2U6OWJiMjNlODczOGNlNDEzYmI0MDBjNzVhZmE5MmY0Y2ZfNC0zLTEtMS0w_858ccb36-44f2-428e-82db-13d26f9fe3bf">13,139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RhYmxlOjliYjIzZTg3MzhjZTQxM2JiNDAwYzc1YWZhOTJmNGNmL3RhYmxlcmFuZ2U6OWJiMjNlODczOGNlNDEzYmI0MDBjNzVhZmE5MmY0Y2ZfNC01LTEtMS0w_605a3b06-1280-43c6-a0e8-b26ea5200e31">85,791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RhYmxlOjliYjIzZTg3MzhjZTQxM2JiNDAwYzc1YWZhOTJmNGNmL3RhYmxlcmFuZ2U6OWJiMjNlODczOGNlNDEzYmI0MDBjNzVhZmE5MmY0Y2ZfNC03LTEtMS0w_79109854-4967-4129-9588-2c862782097a">40,747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, <ix:nonFraction unitRef="shares" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RleHRyZWdpb246MGVjNTZiZTkxYWVmNGEyYmFhZTkyNGYwYmE2NTdhNDFfMjEw_eb7688b3-e4d1-4d8e-b9c1-7fb642d5f4c2">16,900,406</ix:nonFraction> sh</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ares were available for grant under the Exelixis, Inc. 2017 Equity Incentive Plan (as amended and restated, the 2017 Plan). The share reserve is reduced by <ix:nonFraction unitRef="shares" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="INF" name="exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RleHRyZWdpb246MGVjNTZiZTkxYWVmNGEyYmFhZTkyNGYwYmE2NTdhNDFfMzcx_ca5bb823-ce59-4064-8fc3-ac2e830a0480">1</ix:nonFraction> share for each share issued pursuant to a stock option or stock appreciation award and <ix:nonFraction unitRef="shares" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="INF" name="exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RleHRyZWdpb246MGVjNTZiZTkxYWVmNGEyYmFhZTkyNGYwYmE2NTdhNDFfNDYx_aeddf999-263a-4213-b7c2-d63bebcc1998">1.5</ix:nonFraction> shares for full value awards granted in the form of restricted stock units (RSUs). On May&#160;20, 2020, at our 2020 Annual Meeting of Stockholders, our stockholders approved the amendment and restatement of the 2017 Plan. The amendment and restatement increased the share reserve under the 2017 Plan by <ix:nonFraction unitRef="shares" contextRef="i6084a0d4002647d69b2148895c55cbd9_D20200520-20200520" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RleHRyZWdpb246MGVjNTZiZTkxYWVmNGEyYmFhZTkyNGYwYmE2NTdhNDFfNzYz_07a12001-8db9-44be-9881-26c5fc49a0f9">21,000,000</ix:nonFraction> shares, subject to adjustment for certain changes in our capitalization, which became effective immediately upon stockholder approval.&#160;</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2020, we granted <ix:nonFraction unitRef="shares" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RleHRyZWdpb246MGVjNTZiZTkxYWVmNGEyYmFhZTkyNGYwYmE2NTdhNDFfMTAyOA_5b2b3bc5-6662-4fa9-8fbb-a14dcad50109">1,189,888</ix:nonFraction> stock options with a weighted average exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RleHRyZWdpb246MGVjNTZiZTkxYWVmNGEyYmFhZTkyNGYwYmE2NTdhNDFfMTA4Nw_cdbe7ad4-cfa4-4f57-84a3-919d89e16e80">21.84</ix:nonFraction> per share and a weighted average grant&#160;date fair&#160;value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RleHRyZWdpb246MGVjNTZiZTkxYWVmNGEyYmFhZTkyNGYwYmE2NTdhNDFfMTE0OA_cb86e085-9f65-41e0-97be-9c1327826ffa">9.61</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> per s</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hare. As of September&#160;30, 2020, there were <ix:nonFraction unitRef="shares" contextRef="iccc3837038f342898d73d67395904bae_I20201002" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RleHRyZWdpb246MGVjNTZiZTkxYWVmNGEyYmFhZTkyNGYwYmE2NTdhNDFfMTE4Mw_332cfd40-2d61-4140-b112-498e9c3ff63c">16,219,326</ix:nonFraction> stock options outstanding and $<ix:nonFraction unitRef="usd" contextRef="i6c137f0c3b874241af6cdf35240fc6c4_I20201002" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RleHRyZWdpb246MGVjNTZiZTkxYWVmNGEyYmFhZTkyNGYwYmE2NTdhNDFfMTIxOQ_c767a5ab-d4e7-47e7-9918-9afc52c67513">28.4</ix:nonFraction> million unrecognized compensation expense. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2020, we granted <ix:nonFraction unitRef="shares" contextRef="ie7840df292b24b97a39df16ab6f9e94c_D20200104-20201002" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RleHRyZWdpb246MGVjNTZiZTkxYWVmNGEyYmFhZTkyNGYwYmE2NTdhNDFfMTI4Nw_ef54e3cf-3dd0-4f17-9b30-e85f43a8f8af">2,813,888</ix:nonFraction> service-based RSUs with a weighted average grant&#160;date fair&#160;value of $<ix:nonFraction unitRef="usdPerShare" contextRef="ie7840df292b24b97a39df16ab6f9e94c_D20200104-20201002" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RleHRyZWdpb246MGVjNTZiZTkxYWVmNGEyYmFhZTkyNGYwYmE2NTdhNDFfMTM0NQ_f40d2f68-429a-4737-b97a-4aa4b757eec3">23.56</ix:nonFraction> per share. As of September&#160;30, 2020, there were <ix:nonFraction unitRef="shares" contextRef="ib477ff76a01e469abd582edacf5f60b7_I20201002" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RleHRyZWdpb246MGVjNTZiZTkxYWVmNGEyYmFhZTkyNGYwYmE2NTdhNDFfMTM4MQ_a2c15494-8d62-49c4-a10d-9a5ea83ee25d">6,554,909</ix:nonFraction> RSUs outstanding and $<ix:nonFraction unitRef="usd" contextRef="ib477ff76a01e469abd582edacf5f60b7_I20201002" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RleHRyZWdpb246MGVjNTZiZTkxYWVmNGEyYmFhZTkyNGYwYmE2NTdhNDFfMTQwNg_aad5c485-77b2-4be9-b802-13e8b966bd07">111.9</ix:nonFraction> million unrecognized compensation expense.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options and RSUs granted to employees during the nine months ended September&#160;30, 2020 have vesting conditions and contractual lives of a similar nature to those described in &#8220;Note 8. Employee Benefit Plans&#8221; of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year ended </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2018, in connection with our long-term incentive compensation program, we granted <ix:nonFraction unitRef="shares" contextRef="i2fa39753eebb4b2da55065a78f952a39_D20180101-20181228" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RleHRyZWdpb246MGVjNTZiZTkxYWVmNGEyYmFhZTkyNGYwYmE2NTdhNDFfMTg4Mg_69618f02-5cd5-4ac3-a39d-d00d26a026ab">308,365</ix:nonFraction> performance-based stock options (PSOs) to our President and Chief Executive Officer. In addition to the standard service-based vesting conditions included in our other stock options, these PSOs contain a market vesting condition such that they may not be exercised until, at any time after the grant date, the closing market price of our Common Stock is equal to or greater than <ix:nonFraction unitRef="number" contextRef="i2fa39753eebb4b2da55065a78f952a39_D20180101-20181228" decimals="INF" name="exel:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RleHRyZWdpb246MGVjNTZiZTkxYWVmNGEyYmFhZTkyNGYwYmE2NTdhNDFfMjI2NA_b928c64e-ac78-42ff-a25f-20c9e9bab499">125</ix:nonFraction>% of the per share exercise price of the PSOs over a period of at least 30 consecutive calendar days. This market vesting condition was achieved during the three months ended June&#160;30, 2020. The stock-based compensation expense for the PSOs is being recognized on an accelerated basis over the service period of the award, which commenced on the date of grant. The achievement of the market vesting condition did not impact the compensation expense recognized during the period.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of&#160;September&#160;30, 2020, there were&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i91d293b87e5445f5b5b67e1a9c37b9d2_I20201002" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RleHRyZWdpb246MGVjNTZiZTkxYWVmNGEyYmFhZTkyNGYwYmE2NTdhNDFfMjc2NA_a81d5fb9-19a3-44f8-98e6-e6272e2d32b4">8,186,977</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> performance-based restricted stock units (PSUs) outstanding with $<ix:nonFraction unitRef="usd" contextRef="i91d293b87e5445f5b5b67e1a9c37b9d2_I20201002" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RleHRyZWdpb246MGVjNTZiZTkxYWVmNGEyYmFhZTkyNGYwYmE2NTdhNDFfMjgzMg_273b8feb-67db-4380-a620-bb85be8e9531">129.7</ix:nonFraction> million in related unrecognized compensation expense. Expense recognition for PSUs commences when it is determined that achievement of the performance target is probable. Of the outstanding PSUs, <ix:nonFraction unitRef="shares" contextRef="i4972ebe551a741e48565ab4e7bcd8df1_I20201002" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RleHRyZWdpb246MGVjNTZiZTkxYWVmNGEyYmFhZTkyNGYwYmE2NTdhNDFfMzAyMw_02725c05-08ee-49e3-a150-13d94d0ab818">188,624</ix:nonFraction> relate to awards for which we achieved the performance target during 2019 or had determined during 2019 that it was probable that we would achieve the performance target during 2020. During 2020, we determined that it had become probable that we would achieve additional performance targets for <ix:nonFraction unitRef="shares" contextRef="i1e5cec7e0ab144f59216d279d7df965d_I20201002" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RleHRyZWdpb246MGVjNTZiZTkxYWVmNGEyYmFhZTkyNGYwYmE2NTdhNDFfMzM1NQ_a9b5af16-f68d-45e8-b98b-4f7db8eb8e57">2,947,563</ix:nonFraction> additional PSUs granted during 2018 and 2019. Total stock-based compensation expense for PSUs was $<ix:nonFraction unitRef="usd" contextRef="i21aab8a484c04ec2a5cff2d96ab82dbd_D20200704-20201002" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RleHRyZWdpb246MGVjNTZiZTkxYWVmNGEyYmFhZTkyNGYwYmE2NTdhNDFfMTA5OTUxMTYzNzM1Nw_f486f550-44c4-44f4-84d1-e479af97a28d">41.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7550f0f67bcf428b9b1a23a22d59a795_D20200104-20201002" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RleHRyZWdpb246MGVjNTZiZTkxYWVmNGEyYmFhZTkyNGYwYmE2NTdhNDFfMTA5OTUxMTYzNzM2NQ_bc09bff2-adb8-4bd0-b453-c2dfcb56ed2c">43.2</ix:nonFraction> million during the three and nine months ended September&#160;30, 2020, respectively. For more information about our PSUs, see &#8220;Note 8. Employee Benefit Plans&#8221; of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, in connection with our long-term incentive compensation program, we awarded <ix:nonFraction unitRef="shares" contextRef="i7550f0f67bcf428b9b1a23a22d59a795_D20200104-20201002" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RleHRyZWdpb246MGVjNTZiZTkxYWVmNGEyYmFhZTkyNGYwYmE2NTdhNDFfODI0NjMzNzIxNTk4MQ_0b553c03-fe02-4b5a-ab37-8daff717ed92">1,951,830</ix:nonFraction> PSUs (the target amount) that will vest upon the achievement of certain performance targets related to clinical trial positive top-line results and product approvals by the FDA (the 2020 PSUs). Employees may earn up to <ix:nonFraction unitRef="number" contextRef="ie7840df292b24b97a39df16ab6f9e94c_D20200104-20201002" decimals="INF" name="exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RleHRyZWdpb246MGVjNTZiZTkxYWVmNGEyYmFhZTkyNGYwYmE2NTdhNDFfMTA0NDUzNjA0NzAzNTg_c94bce6b-af88-4bf8-ac36-f60bd8898681">200</ix:nonFraction>% of the target amount or <ix:nonFraction unitRef="shares" contextRef="ie7840df292b24b97a39df16ab6f9e94c_D20200104-20201002" decimals="INF" format="ixt:numdotdecimal" name="exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumNumberOfSharesToVest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RleHRyZWdpb246MGVjNTZiZTkxYWVmNGEyYmFhZTkyNGYwYmE2NTdhNDFfMTA5OTUxMTYzNjg0NQ_41ac798c-9fec-4af0-ad27-748a5d0ea946">3,903,660</ix:nonFraction> shares, depending on the volume and the timing of achievement of the</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">performance targets. The 2020 PSUs </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2ba2e9257d2d461ba582e2ade404251d">were designed to drive the performance of our management team and employees toward the achievement of key corporate objectives and will be forfeited if the performance targets are not met by December 31, 2024.</ix:continuation></span></div><div id="i0283c6f517b447ec92f154ee691f4028_70"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 8. <ix:nonNumeric contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83MC9mcmFnOmNkMGQ3MmFhOTAwZTRmODFhZWJkZDQwYjAyOTZkOWJiL3RleHRyZWdpb246Y2QwZDcyYWE5MDBlNGY4MWFlYmRkNDBiMDI5NmQ5YmJfMzcy_effe1ce6-2ee8-4d47-8dd0-0bb11535e163" continuedAt="i2863f58554fc4dd2a894164655836b96" escape="true">INCOME TAXES</ix:nonNumeric></span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2863f58554fc4dd2a894164655836b96">Our effective income tax rate was <ix:nonFraction unitRef="number" contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83MC9mcmFnOmNkMGQ3MmFhOTAwZTRmODFhZWJkZDQwYjAyOTZkOWJiL3RleHRyZWdpb246Y2QwZDcyYWE5MDBlNGY4MWFlYmRkNDBiMDI5NmQ5YmJfNjE_d23cf9d4-4b52-4dea-81bd-d9366cdca430">15.7</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83MC9mcmFnOmNkMGQ3MmFhOTAwZTRmODFhZWJkZDQwYjAyOTZkOWJiL3RleHRyZWdpb246Y2QwZDcyYWE5MDBlNGY4MWFlYmRkNDBiMDI5NmQ5YmJfNzA_3364d063-1c6e-43e7-8655-c9cfd9a00f83">18.8</ix:nonFraction>% during the three and nine months ended September&#160;30, 2020, respectively, as compared to <ix:nonFraction unitRef="number" contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83MC9mcmFnOmNkMGQ3MmFhOTAwZTRmODFhZWJkZDQwYjAyOTZkOWJiL3RleHRyZWdpb246Y2QwZDcyYWE5MDBlNGY4MWFlYmRkNDBiMDI5NmQ5YmJfMTIy_4b645030-62aa-4e53-abf6-32c6c270feeb">20.5</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83MC9mcmFnOmNkMGQ3MmFhOTAwZTRmODFhZWJkZDQwYjAyOTZkOWJiL3RleHRyZWdpb246Y2QwZDcyYWE5MDBlNGY4MWFlYmRkNDBiMDI5NmQ5YmJfMTI5_99368446-6774-4e88-a333-26e1c9dbd245">19.4</ix:nonFraction>% for the comparable periods in 2019. The effective tax rate for the three and nine months ended September 30, 2020 differed from U.S. federal statutory tax rate of 21% primarily due to excess tax benefits related to the exercise of certain stock options and federal tax credits, offset by the non-deductible executive compensation during the periods. The effective tax rate for the three and nine months ended September&#160;30, 2019 differed from the U.S. federal statutory rate of&#160;21%&#160;primarily due to excess tax benefits related to the exercise of certain stock options and federal tax credits during the periods.</ix:continuation></span></div><div id="i0283c6f517b447ec92f154ee691f4028_73"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 9. <ix:nonNumeric contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83My9mcmFnOjY2MTU0MTc0NzE4ODQ1ZmVhNmE3Zjc2NDM1Yjk4YjQyL3RleHRyZWdpb246NjYxNTQxNzQ3MTg4NDVmZWE2YTdmNzY0MzViOThiNDJfNjIw_e4f39f40-1fbb-442b-bbf1-789c8f9bd465" continuedAt="i4c0540f54ecf4f20a942d025921113fb" escape="true">NET INCOME (LOSS) PER SHARE</ix:nonNumeric></span></div><ix:continuation id="i4c0540f54ecf4f20a942d025921113fb"><ix:nonNumeric contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83My9mcmFnOjY2MTU0MTc0NzE4ODQ1ZmVhNmE3Zjc2NDM1Yjk4YjQyL3RleHRyZWdpb246NjYxNTQxNzQ3MTg4NDVmZWE2YTdmNzY0MzViOThiNDJfNjM1_c8e54b7b-769b-474a-bae0-e57512fc282e" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss) per share - basic and diluted, were computed as follows (in thousands, except per share amounts):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.742%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83My9mcmFnOjY2MTU0MTc0NzE4ODQ1ZmVhNmE3Zjc2NDM1Yjk4YjQyL3RhYmxlOjc4OGRlODBiYTA5NzRmM2Q4ZmE0OGNiOTcyOThhMmYzL3RhYmxlcmFuZ2U6Nzg4ZGU4MGJhMDk3NGYzZDhmYTQ4Y2I5NzI5OGEyZjNfMy0xLTEtMS0w_e14fdd44-f91f-4aa8-8680-c1ce4c535495">32,040</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83My9mcmFnOjY2MTU0MTc0NzE4ODQ1ZmVhNmE3Zjc2NDM1Yjk4YjQyL3RhYmxlOjc4OGRlODBiYTA5NzRmM2Q4ZmE0OGNiOTcyOThhMmYzL3RhYmxlcmFuZ2U6Nzg4ZGU4MGJhMDk3NGYzZDhmYTQ4Y2I5NzI5OGEyZjNfMy0zLTEtMS0w_c230d74c-b0e6-47c5-b0c6-2fc1d389f218">97,452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83My9mcmFnOjY2MTU0MTc0NzE4ODQ1ZmVhNmE3Zjc2NDM1Yjk4YjQyL3RhYmxlOjc4OGRlODBiYTA5NzRmM2Q4ZmE0OGNiOTcyOThhMmYzL3RhYmxlcmFuZ2U6Nzg4ZGU4MGJhMDk3NGYzZDhmYTQ4Y2I5NzI5OGEyZjNfMy01LTEtMS0w_abfa2d1e-5ccf-42b5-84d6-40e96d4bcd40">83,393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83My9mcmFnOjY2MTU0MTc0NzE4ODQ1ZmVhNmE3Zjc2NDM1Yjk4YjQyL3RhYmxlOjc4OGRlODBiYTA5NzRmM2Q4ZmE0OGNiOTcyOThhMmYzL3RhYmxlcmFuZ2U6Nzg4ZGU4MGJhMDk3NGYzZDhmYTQ4Y2I5NzI5OGEyZjNfMy03LTEtMS0w_9bcc5c2b-55a6-4d0e-b747-be683cc26c85">252,269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding &#8212; basic</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83My9mcmFnOjY2MTU0MTc0NzE4ODQ1ZmVhNmE3Zjc2NDM1Yjk4YjQyL3RhYmxlOjc4OGRlODBiYTA5NzRmM2Q4ZmE0OGNiOTcyOThhMmYzL3RhYmxlcmFuZ2U6Nzg4ZGU4MGJhMDk3NGYzZDhmYTQ4Y2I5NzI5OGEyZjNfNS0xLTEtMS0w_ad71f298-fb89-4ea2-b645-546a307bf799">309,116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83My9mcmFnOjY2MTU0MTc0NzE4ODQ1ZmVhNmE3Zjc2NDM1Yjk4YjQyL3RhYmxlOjc4OGRlODBiYTA5NzRmM2Q4ZmE0OGNiOTcyOThhMmYzL3RhYmxlcmFuZ2U6Nzg4ZGU4MGJhMDk3NGYzZDhmYTQ4Y2I5NzI5OGEyZjNfNS0zLTEtMS0w_383b0a50-bc8b-4cab-8407-0ed04091d0ff">303,268</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83My9mcmFnOjY2MTU0MTc0NzE4ODQ1ZmVhNmE3Zjc2NDM1Yjk4YjQyL3RhYmxlOjc4OGRlODBiYTA5NzRmM2Q4ZmE0OGNiOTcyOThhMmYzL3RhYmxlcmFuZ2U6Nzg4ZGU4MGJhMDk3NGYzZDhmYTQ4Y2I5NzI5OGEyZjNfNS01LTEtMS0w_5deb2c6c-2f08-4e8c-af99-133a8fd8a946">307,437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83My9mcmFnOjY2MTU0MTc0NzE4ODQ1ZmVhNmE3Zjc2NDM1Yjk4YjQyL3RhYmxlOjc4OGRlODBiYTA5NzRmM2Q4ZmE0OGNiOTcyOThhMmYzL3RhYmxlcmFuZ2U6Nzg4ZGU4MGJhMDk3NGYzZDhmYTQ4Y2I5NzI5OGEyZjNfNS03LTEtMS0w_0b59a1e4-7c19-4daf-b7a4-3eda28981bce">301,999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002" decimals="-3" format="ixt:zerodash" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83My9mcmFnOjY2MTU0MTc0NzE4ODQ1ZmVhNmE3Zjc2NDM1Yjk4YjQyL3RhYmxlOjc4OGRlODBiYTA5NzRmM2Q4ZmE0OGNiOTcyOThhMmYzL3RhYmxlcmFuZ2U6Nzg4ZGU4MGJhMDk3NGYzZDhmYTQ4Y2I5NzI5OGEyZjNfNi0xLTEtMS0w_ad887d7f-671e-4374-a827-52a8817b1af3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83My9mcmFnOjY2MTU0MTc0NzE4ODQ1ZmVhNmE3Zjc2NDM1Yjk4YjQyL3RhYmxlOjc4OGRlODBiYTA5NzRmM2Q4ZmE0OGNiOTcyOThhMmYzL3RhYmxlcmFuZ2U6Nzg4ZGU4MGJhMDk3NGYzZDhmYTQ4Y2I5NzI5OGEyZjNfNi0zLTEtMS0w_d660de6f-4abf-49cb-84e9-14de39dadfe6">12,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83My9mcmFnOjY2MTU0MTc0NzE4ODQ1ZmVhNmE3Zjc2NDM1Yjk4YjQyL3RhYmxlOjc4OGRlODBiYTA5NzRmM2Q4ZmE0OGNiOTcyOThhMmYzL3RhYmxlcmFuZ2U6Nzg4ZGU4MGJhMDk3NGYzZDhmYTQ4Y2I5NzI5OGEyZjNfNi01LTEtMS0w_0d827cb5-513c-48be-86f6-522d1b51c3e2">10,058</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83My9mcmFnOjY2MTU0MTc0NzE4ODQ1ZmVhNmE3Zjc2NDM1Yjk4YjQyL3RhYmxlOjc4OGRlODBiYTA5NzRmM2Q4ZmE0OGNiOTcyOThhMmYzL3RhYmxlcmFuZ2U6Nzg4ZGU4MGJhMDk3NGYzZDhmYTQ4Y2I5NzI5OGEyZjNfNi03LTEtMS0w_ae1efd41-0137-46a7-a078-7c6ea4e50130">13,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding &#8212; diluted</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83My9mcmFnOjY2MTU0MTc0NzE4ODQ1ZmVhNmE3Zjc2NDM1Yjk4YjQyL3RhYmxlOjc4OGRlODBiYTA5NzRmM2Q4ZmE0OGNiOTcyOThhMmYzL3RhYmxlcmFuZ2U6Nzg4ZGU4MGJhMDk3NGYzZDhmYTQ4Y2I5NzI5OGEyZjNfNy0xLTEtMS0w_803f0d2a-bbdc-4ef4-bffb-d803c0103b39">309,116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83My9mcmFnOjY2MTU0MTc0NzE4ODQ1ZmVhNmE3Zjc2NDM1Yjk4YjQyL3RhYmxlOjc4OGRlODBiYTA5NzRmM2Q4ZmE0OGNiOTcyOThhMmYzL3RhYmxlcmFuZ2U6Nzg4ZGU4MGJhMDk3NGYzZDhmYTQ4Y2I5NzI5OGEyZjNfNy0zLTEtMS0w_67b9574c-6450-49ee-919c-f49b4b4803bc">315,453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83My9mcmFnOjY2MTU0MTc0NzE4ODQ1ZmVhNmE3Zjc2NDM1Yjk4YjQyL3RhYmxlOjc4OGRlODBiYTA5NzRmM2Q4ZmE0OGNiOTcyOThhMmYzL3RhYmxlcmFuZ2U6Nzg4ZGU4MGJhMDk3NGYzZDhmYTQ4Y2I5NzI5OGEyZjNfNy01LTEtMS0w_4e8b08e6-3bf8-4021-9776-f7d4824624af">317,495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83My9mcmFnOjY2MTU0MTc0NzE4ODQ1ZmVhNmE3Zjc2NDM1Yjk4YjQyL3RhYmxlOjc4OGRlODBiYTA5NzRmM2Q4ZmE0OGNiOTcyOThhMmYzL3RhYmxlcmFuZ2U6Nzg4ZGU4MGJhMDk3NGYzZDhmYTQ4Y2I5NzI5OGEyZjNfNy03LTEtMS0w_e597c94f-7aaa-4a7c-a731-1c6ad536fba0">315,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share &#8212; basic</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83My9mcmFnOjY2MTU0MTc0NzE4ODQ1ZmVhNmE3Zjc2NDM1Yjk4YjQyL3RhYmxlOjc4OGRlODBiYTA5NzRmM2Q4ZmE0OGNiOTcyOThhMmYzL3RhYmxlcmFuZ2U6Nzg4ZGU4MGJhMDk3NGYzZDhmYTQ4Y2I5NzI5OGEyZjNfOC0xLTEtMS0w_7a3147de-aef6-4bfa-95f9-00cc4ada70f9">0.10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83My9mcmFnOjY2MTU0MTc0NzE4ODQ1ZmVhNmE3Zjc2NDM1Yjk4YjQyL3RhYmxlOjc4OGRlODBiYTA5NzRmM2Q4ZmE0OGNiOTcyOThhMmYzL3RhYmxlcmFuZ2U6Nzg4ZGU4MGJhMDk3NGYzZDhmYTQ4Y2I5NzI5OGEyZjNfOC0zLTEtMS0w_d6849b2a-127a-4ef8-bca4-87bb5574df34">0.32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83My9mcmFnOjY2MTU0MTc0NzE4ODQ1ZmVhNmE3Zjc2NDM1Yjk4YjQyL3RhYmxlOjc4OGRlODBiYTA5NzRmM2Q4ZmE0OGNiOTcyOThhMmYzL3RhYmxlcmFuZ2U6Nzg4ZGU4MGJhMDk3NGYzZDhmYTQ4Y2I5NzI5OGEyZjNfOC01LTEtMS0w_0ce389e6-f463-4470-9f6f-0c0f57c77414">0.27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83My9mcmFnOjY2MTU0MTc0NzE4ODQ1ZmVhNmE3Zjc2NDM1Yjk4YjQyL3RhYmxlOjc4OGRlODBiYTA5NzRmM2Q4ZmE0OGNiOTcyOThhMmYzL3RhYmxlcmFuZ2U6Nzg4ZGU4MGJhMDk3NGYzZDhmYTQ4Y2I5NzI5OGEyZjNfOC03LTEtMS0w_2a713e4f-985b-45b8-92d1-f77166c3ab6c">0.84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share &#8212; diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83My9mcmFnOjY2MTU0MTc0NzE4ODQ1ZmVhNmE3Zjc2NDM1Yjk4YjQyL3RhYmxlOjc4OGRlODBiYTA5NzRmM2Q4ZmE0OGNiOTcyOThhMmYzL3RhYmxlcmFuZ2U6Nzg4ZGU4MGJhMDk3NGYzZDhmYTQ4Y2I5NzI5OGEyZjNfOS0xLTEtMS0w_7f9a4c55-e401-442f-8fa4-105892c23951">0.10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83My9mcmFnOjY2MTU0MTc0NzE4ODQ1ZmVhNmE3Zjc2NDM1Yjk4YjQyL3RhYmxlOjc4OGRlODBiYTA5NzRmM2Q4ZmE0OGNiOTcyOThhMmYzL3RhYmxlcmFuZ2U6Nzg4ZGU4MGJhMDk3NGYzZDhmYTQ4Y2I5NzI5OGEyZjNfOS0zLTEtMS0w_19789304-e307-47ab-b0c5-170978039f50">0.31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83My9mcmFnOjY2MTU0MTc0NzE4ODQ1ZmVhNmE3Zjc2NDM1Yjk4YjQyL3RhYmxlOjc4OGRlODBiYTA5NzRmM2Q4ZmE0OGNiOTcyOThhMmYzL3RhYmxlcmFuZ2U6Nzg4ZGU4MGJhMDk3NGYzZDhmYTQ4Y2I5NzI5OGEyZjNfOS01LTEtMS0w_7572123f-74b1-484b-8639-040d6b395680">0.26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83My9mcmFnOjY2MTU0MTc0NzE4ODQ1ZmVhNmE3Zjc2NDM1Yjk4YjQyL3RhYmxlOjc4OGRlODBiYTA5NzRmM2Q4ZmE0OGNiOTcyOThhMmYzL3RhYmxlcmFuZ2U6Nzg4ZGU4MGJhMDk3NGYzZDhmYTQ4Y2I5NzI5OGEyZjNfOS03LTEtMS0w_f7ec4ab4-79db-4afc-8e6d-1c9da65693e3">0.80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dilutive securities included stock options, RSUs, PSUs, PSOs and ESPP contributions.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain potential common shares were excluded from our calculation of weighted-average common shares outstanding - diluted because either they would have had an anti-dilutive effect on net income per share or they were related to shares from PSUs for which the contingent vesting condition had not been achieved. <ix:nonNumeric contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83My9mcmFnOjY2MTU0MTc0NzE4ODQ1ZmVhNmE3Zjc2NDM1Yjk4YjQyL3RleHRyZWdpb246NjYxNTQxNzQ3MTg4NDVmZWE2YTdmNzY0MzViOThiNDJfNjQ2_43d53379-2056-4d0d-9daa-fe58a9c8a5c5" continuedAt="i2d292ccd17f64f0298f25672ba7a8c8e" escape="true">The weighted-average potential common shares excluded from our calculation were as follows (in thousands):</ix:nonNumeric></span></div><div style="margin-top:9pt;text-align:center"><ix:continuation id="i2d292ccd17f64f0298f25672ba7a8c8e"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.742%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive securities and contingently issuable shares excluded</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i41f51136e2dd4492aea05277671e9389_D20200704-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83My9mcmFnOjY2MTU0MTc0NzE4ODQ1ZmVhNmE3Zjc2NDM1Yjk4YjQyL3RhYmxlOmNjYTZjZmNhYmNmMTQwZjViMGY1YTZkOGFkZDQ2ZTAxL3RhYmxlcmFuZ2U6Y2NhNmNmY2FiY2YxNDBmNWIwZjVhNmQ4YWRkNDZlMDFfMi0xLTEtMS0w_b0ff8aaa-fca1-45d3-97a9-6b671a4df1e7">27,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if970e9016fc3406ea7bb57cbb0786e20_D20190629-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83My9mcmFnOjY2MTU0MTc0NzE4ODQ1ZmVhNmE3Zjc2NDM1Yjk4YjQyL3RhYmxlOmNjYTZjZmNhYmNmMTQwZjViMGY1YTZkOGFkZDQ2ZTAxL3RhYmxlcmFuZ2U6Y2NhNmNmY2FiY2YxNDBmNWIwZjVhNmQ4YWRkNDZlMDFfMi0zLTEtMS0w_99352eac-f920-4118-b6ba-bc70daaca6a9">6,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib0cf80d622b4495e8ba855ad5bbe6234_D20200104-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83My9mcmFnOjY2MTU0MTc0NzE4ODQ1ZmVhNmE3Zjc2NDM1Yjk4YjQyL3RhYmxlOmNjYTZjZmNhYmNmMTQwZjViMGY1YTZkOGFkZDQ2ZTAxL3RhYmxlcmFuZ2U6Y2NhNmNmY2FiY2YxNDBmNWIwZjVhNmQ4YWRkNDZlMDFfMi01LTEtMS0w_0cc4bf38-5de0-4d43-93e1-4bd3f889c366">10,224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i01d75cb9987e4a6e9148d6e76b57e666_D20181229-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83My9mcmFnOjY2MTU0MTc0NzE4ODQ1ZmVhNmE3Zjc2NDM1Yjk4YjQyL3RhYmxlOmNjYTZjZmNhYmNmMTQwZjViMGY1YTZkOGFkZDQ2ZTAxL3RhYmxlcmFuZ2U6Y2NhNmNmY2FiY2YxNDBmNWIwZjVhNmQ4YWRkNDZlMDFfMi03LTEtMS0w_eaa53e2f-7958-4117-86c4-45399f364fd7">5,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div></ix:continuation><div id="i0283c6f517b447ec92f154ee691f4028_76"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 10. <ix:nonNumeric contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83Ni9mcmFnOmIzMDczNGMwOWNiZjQ5N2FiZGFkYzEwZjFjNTM1ZDQyL3RleHRyZWdpb246YjMwNzM0YzA5Y2JmNDk3YWJkYWRjMTBmMWM1MzVkNDJfMzEzMg_97b2e19e-f31d-47db-a874-8417dcd55a22" continuedAt="ifc618e97e747447588f32769aa5d3f5c" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><div style="margin-top:9pt;text-indent:36pt"><ix:continuation id="ifc618e97e747447588f32769aa5d3f5c" continuedAt="ibe199ab652524dcca15154e2179d3d52"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, we received a notice letter regarding an Abbreviated New Drug Application (ANDA) submitted to the FDA by MSN Pharmaceuticals, Inc. (MSN), requesting approval to market a generic version of CABOMETYX tablets.&#160;MSN&#8217;s initial notice letter included a Paragraph IV certification with respect to our&#160;U.S. Patent Nos.&#160;8,877,776, 9,724,342, 10,034,873 and 10,039,757, which are&#160;listed in the Approved Drug Products with Therapeutic Equivalence Evaluations, also referred to as the </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Orange Book.&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSN&#8217;s initial notice letter did not provide a Paragraph IV certification against U.S. Patent No. 7,579,473, the composition of matter patent, or U.S. Patent No. 8,497,284, a method of use patent. On October 29, 2019, we filed a complaint in the United States District Court for the District of Delaware for patent infringement against MSN asserting U.S. Patent No. 8,877,776 arising from MSN&#8217;s ANDA filing with the FDA. On November 20, 2019, MSN filed its response to the complaint, alleging that U.S. Patent No. 8,877,776 is invalid and not infringed. On May 5, 2020, we received notice from MSN that it had amended its ANDA to assert additional Paragraph IV certifications. The ANDA now requests approval to market a generic version of CABOMETYX tablets&#160;prior to&#160;expiration of the two previously-unasserted CABOMETYX patents: U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284.&#160;On May 11, 2020, we </span></ix:continuation></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_7">Table of Contents</a></span></div></div><ix:continuation id="ibe199ab652524dcca15154e2179d3d52"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">filed a complaint in the United States District Court for the District of Delaware for patent infringement against MSN asserting U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284 arising from MSN&#8217;s amended ANDA filing with the FDA. On May 22, 2020, MSN filed its response to the complaint, alleging that each of U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284 is invalid and not infringed. Neither of our complaints alleges infringement of U.S. Patent Nos. 9,724,342, 10,034,873 and 10,039,757. In our complaints, we are seeking, among other relief, an order that the effective date of any FDA approval of the ANDA would be a date no earlier than the expiration of all of U.S. Patent No. 7,579,473, U.S. Patent No. 8,497,284 and U.S. Patent No. 8,877,776, the latest of which expires on October 8, 2030, and equitable relief enjoining MSN from infringing these patents. These two lawsuits against MSN have been consolidated, and a bench trial has been scheduled for May 2022. The sale of a generic version of CABOMETYX earlier than its patent expiration could significantly decrease our revenues and thereby materially harm our business, financial condition and results of operations. It is not possible at this time to determine the likelihood of an unfavorable outcome or estimate of the amount or range of any potential loss. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also from time to time become a party or subject to various other legal proceedings and claims, either asserted or unasserted, which arise in the ordinary course of business. Some of these proceedings have involved, and may involve in the future, claims that are subject to substantial uncertainties and unascertainable damages.</span></div></ix:continuation><div id="i0283c6f517b447ec92f154ee691f4028_79"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains forward-looking statements. These statements are based on Exelixis, Inc.&#8217;s (Exelixis, we, our or us) current expectations, assumptions, estimates and projections about our business and our industry and involve known and unknown risks, uncertainties and other factors that may cause our company&#8217;s or our industry&#8217;s results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied in, or contemplated by, the forward-looking statements. Our actual results and the timing of events may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such a difference include those discussed in &#8220;Risk Factors&#8221; in Part II, Item&#160;1A of this Quarterly Report on Form 10-Q, as well as those discussed elsewhere in this report. These and many other factors could affect our future financial and operating results. We undertake no obligation to update any forward-looking statement to reflect events after the date of this report.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This discussion and analysis should be read in conjunction with our condensed consolidated financial statements and accompanying notes included in this report and the consolidated financial statements and accompanying notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2019 filed with the Securities and Exchange Commission (SEC) on February&#160;25, 2020.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Since we were founded in 1994, four products resulting from our discovery efforts&#160;have progressed through clinical development, received regulatory approval and established a commercial presence in various geographies around the world. Two are derived from cabozantinib, our flagship molecule, an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. Our cabozantinib products are: CABOMETYX&#174; (cabozantinib) tablets approved for advanced renal cell carcinoma (RCC) and previously treated hepatocellular carcinoma (HCC); and COMETRIQ&#174; (cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer (MTC). For these types of cancer, cabozantinib has become or is becoming a standard of care. The other two products resulting from our discovery efforts are: COTELLIC&#174; (cobimetinib), an inhibitor of MEK, approved as part of multiple combination regimens to treat specific forms of advanced melanoma and marketed under a collaboration with Genentech, Inc. (a member of the Roche Group) (Genentech); and MINNEBRO&#174; (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor, approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo Company, Limited (Daiichi Sankyo).</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Food and Drug Administration (FDA) first approved CABOMETYX for previously treated patients with advanced RCC in April 2016, and in December 2017 the FDA expanded CABOMETYX&#8217;s approval to include previously untreated patients with advanced RCC. Additionally, in January 2019, the FDA approved CABOMETYX for the treatment of patients with HCC who have been previously treated with sorafenib. Most recently on August 24, 2020, we announced a significant milestone for our program combining cabozantinib with immune checkpoint inhibitors (ICIs) with the submission a supplemental New Drug Application (sNDA) for CABOMETYX in combination with Bristol-Myers Squibb Company&#8217;s (BMS) Opdivo as a treatment of patients with advanced RCC to the FDA, and on October 19, 2020, we and BMS announced that </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the FDA had accepted our sNDA and BMS&#8217; supplemental Biologics License Application (sBLA), granted Priority Review to both applications and assigned a Prescription Drug User Fee Act (PDUFA) goal date, or target action date, of February 20, 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To develop and commercialize CABOMETYX and COMETRIQ outside the U.S., we have entered into license agreements with Ipsen Pharma SAS (Ipsen) and Takeda Pharmaceutical Company Limited (Takeda). We granted to Ipsen the rights to develop and commercialize cabozantinib outside of the U.S. and Japan, and to Takeda the rights to develop and commercialize cabozantinib in Japan. Both Ipsen and Takeda also contribute financially and operationally to the further global development and commercialization of cabozantinib in other potential indications, and we continue to work closely with them on these activities. Utilizing its regulatory expertise and established international oncology marketing network, Ipsen has continued to execute on its commercialization plans for CABOMETYX, having received regulatory approvals and launched in multiple territories outside of the U.S., including in the European Union (EU) and Canada, as a treatment for advanced RCC and for HCC in adults who have previously been treated with sorafenib. In addition, in September 2020, Ipsen and BMS submitted type II variation applications to the European Medicines Agency (EMA) to approve the combination of CABOMETYX and Opdivo as a treatment for advanced RCC, with the EMA validating the type II variations and beginning its centralized review process, and both Ipsen and BMS plan to submit applications to approve the combination in other territories beyond the EU. With respect to the Japanese market, Takeda has achieved important milestones in 2020, including receipt of Manufacturing and Marketing Approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) and first commercial sales of CABOMETYX as a treatment of patients with curatively unresectable or metastatic RCC. Takeda also submitted an application to the Japanese MHLW for Manufacturing and Marketing Approval of CABOMETYX as a treatment of patients with unresectable HCC who progressed after prior systemic therapy, and most recently in October 2020, Takeda and Ono Pharmaceutical Co., Ltd. (Ono), BMS&#8217; development and commercialization partner in Japan, submitted a supplemental application to the Japanese MHLW for Manufacturing and Marketing Approval of CABOMETYX in combination with Opdivo for the treatment of patients with unresectable, advanced or metastatic RCC.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our regulatory and commercialization efforts in the U.S. and the support provided to our collaboration partners for rest-of-world regulatory and commercialization activities, we are also pursuing other indications for cabozantinib that have the potential to increase the number of cancer patients who could benefit from this medicine.&#160;We are evaluating cabozantinib, both as a single agent and in combination with other therapies, in a broad development program comprising&#160;over 100 ongoing or planned clinical trials across multiple indications. We, along with our collaboration partners, sponsor some of the trials, and independent investigators conduct the remaining trials through our Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute&#8217;s Cancer Therapy Evaluation Program (NCI-CTEP) or our investigator-sponsored trial program. Informed by the available data from these clinical trials, we continue to advance cabozantinib&#8217;s development program with potentially label-enabling trials. One pivotal trial that has resulted from this effort is COSMIC-311, our ongoing phase 3 pivotal trial evaluating cabozantinib versus placebo in patients with radioiodine (RAI)-refractory differentiated thyroid cancer (DTC) who have progressed after up to two VEGF receptor-targeted therapies. We plan to conduct an analysis among the first 100 patients randomized in COSMIC-311 for the co-primary endpoint of objective response rate (ORR), and an interim analysis of progression-free survival (PFS) before the end of 2020.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are particularly interested in continuing to evaluate cabozantinib&#8217;s potential in combination with ICIs to determine if these combinations further improve outcomes for patients. Building on preclinical and clinical observations that cabozantinib may promote a more immune-permissive tumor environment potentially resulting in cooperative activity of cabozantinib in combination with these products, we are evaluating cabozantinib in combination with a variety of ICIs. CheckMate -9ER, a phase 3 pivotal trial evaluating the combination of cabozantinib and nivolumab compared to sunitinib in previously untreated advanced or metastatic RCC, for which we and our collaboration partner BMS announced positive top-line results in April 2020, is reflective of this strategy. The trial met its primary endpoint of PFS at final analysis, as well as the secondary endpoints of overall survival (OS) at a pre-specified interim analysis and ORR, and showed that the combination of cabozantinib with nivolumab significantly reduced the risk of disease progression or death compared with sunitinib (hazard ratio [HR]=0.51; 95% confidence interval [CI]: 0.41 to 0.64; p&lt;0.0001) and also significantly improved OS, reducing the risk of death by 40% compared with sunitinib (HR=0.60; 98.89% CI: 0.40 to 0.89; p&lt;0.0010), as well as demonstrated a superior ORR of 56% versus 27% for sunitinib. Data from CheckMate -9ER were presented at Presidential Symposium I at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 in September 2020 and served as the basis for the submission of our sNDA to the FDA for CABOMETYX in combination with Opdivo as a treatment of patients with advanced RCC. We have also collaborated with BMS on CheckMate -040, a multi-cohort phase 1/2 trial evaluating cabozantinib in combination with nivolumab and in combination with both nivolumab and ipilimumab in patients with previously treated or previously untreated advanced HCC, for which initial clinically meaningful results were presented at </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">American Society of Clinical Oncology&#8217;s (ASCO&#8217;s) Gastrointestinal Cancers Symposium in January 2020, and COSMIC-313, a phase 3 pivotal trial evaluating the triplet combination of cabozantinib, nivolumab and ipilimumab versus the combination of nivolumab and ipilimumab in patients with previously untreated advanced intermediate- or poor-risk RCC. We expect to complete enrollment for COSMIC-313 in early 2021 and to report top-line results of the event-driven analyses from the trial in the 2022 time frame. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In an effort to diversify our exploration of combinations with ICIs, we have also initiated multiple trials evaluating cabozantinib in combination with F. Hoffmann-La Roche Ltd.&#8217;s (Roche&#8217;s) ICI, atezolizumab, including COSMIC-312, a phase 3 pivotal trial evaluating cabozantinib in combination with atezolizumab versus sorafenib in previously untreated advanced HCC, for which we announced in August 2020 that enrollment was completed, and COSMIC-021, a broad phase 1b study evaluating the safety and tolerability of cabozantinib in combination with atezolizumab in patients with locally advanced or metastatic solid tumors. COSMIC-021 is divided into two parts: a dose-escalation phase, which was completed in 2018; and an expansion phase, which is ongoing. Findings from the dose-escalation stage of COSMIC-021 demonstrated that the combination was well-tolerated and showed encouraging anti-tumor activity in patients with advanced RCC. The expansion phase of COSMIC-021 comprises 24 total cohorts, with 20 cohorts evaluating the combination of cabozantinib and atezolizumab and four cohorts evaluating cabozantinib or atezolizumab as single-agent therapies. Based on continuing encouraging efficacy and safety data certain cohorts have been or may be further expanded, including the cohorts of patients with non-small cell lung cancer (NSCLC) who have been previously treated with an ICI and metastatic castration-resistant prostate cancer (mCRPC) who have been previously treated with enzalutamide and/or abiraterone acetate and experienced radiographic disease progression in soft tissue. We anticipate enrolling up to 1,732 patients in the trial in early 2021, although both the timing and final number of patients are subject to the initiation of additional cohorts or expansion of selected existing cohorts, as well as any further delays resulting from the COVID-19 pandemic. Since its initiation, data from COSMIC-021 have been instrumental in guiding our clinical development strategy for cabozantinib in combination with ICIs, including supporting the recent initiation of three phase 3 pivotal trials in collaboration with Roche evaluating the combination of cabozantinib with atezolizumab. The first, CONTACT-01, focuses on patients with metastatic NSCLC who have been previously treated with an ICI and platinum-containing chemotherapy; the second, CONTACT-02, focuses on patients with mCRPC who have been previously treated with one novel hormonal therapy; and the third, CONTACT-03, focuses on patients with inoperable, locally advanced or metastatic RCC who have progressed during or following treatment with an ICI as the immediate preceding therapy. Encouraging results from interim analyses of the mCRPC and NSCLC cohorts of COSMIC-021 were presented at ASCO&#8217;s Genitourinary Cancer Symposium in February 2020 and the 2020 ASCO Virtual Scientific Program in May 2020, respectively, and positive results from two RCC cohorts of COSMIC-021 were presented at the ESMO Virtual Congress 2020 in September 2020. Based on regulatory feedback from the FDA, and if supported by the clinical data, we intend to file with the FDA for accelerated approval in an mCRPC indication as early as 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also remain committed to building our product pipeline by discovering and developing new therapies for cancer patients. Using our in-house drug discovery expertise, specifically in medicinal chemistry, tumor biology and pharmacology, we are advancing small molecule drug candidates toward and through preclinical development. Notably, these efforts are led by some of the same experienced scientists that led the efforts to discover cabozantinib, cobimetinib and esaxerenone, which have been approved for commercialization. In addition, we have augmented our internal drug discovery activities with multiple partnerships, including several that enable us to discover and advance various biologics, such as bispecific antibodies and antibody-drug conjugates (ADCs), and we continue to engage in business development initiatives aimed at identifying and in-licensing promising, early-stage oncology assets, which we can further develop utilizing our established clinical development infrastructure. In total, we are advancing drug candidates across approximately 20 ongoing discovery programs toward and through preclinical development, with plans for up to four new compounds to reach Investigational New Drug (IND) filing status by the end of the second quarter of 2021. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first compounds to advance from our recent internal drug discovery efforts include XL092, a next-generation oral tyrosine kinase inhibitor that is currently in a phase 1 clinical trial in patients with advanced solid malignancies for which dose-escalation cohorts evaluating XL092, both as a single agent and in combination with atezolizumab, are currently enrolling. We presented data that support the ongoing clinical development of XL092 at the 32</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">nd</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> EORTC-NCI-AACR (ENA) Symposium in October 2020, and we expect that once recommended doses of both single-agent XL092 and XL092 in combination with atezolizumab are established, the trial will begin to enroll expansion cohorts for patients with clear cell and non-clear cell RCC, hormone-receptor positive breast cancer and mCRPC. In addition, we anticipate filing an IND for XL265, a TAM kinase-focused kinase inhibitor, in the first quarter of 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In furtherance of our business development strategy, in 2019, we entered into collaboration and license agreements with&#160;Aurigene Discovery Technologies Limited (Aurigene), which is focused on the discovery and development of novel small molecules as therapies for cancer, and Iconic Therapeutics, Inc. (Iconic), which is focused on the </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">advancement of a next-generation ADC program targeting tissue factor in solid tumors. In September 2020, we presented preclinical data that support the continued development of ICON-2, Iconic&#8217;s ADC comprised of an anti-tissue factor antibody and a proprietary linker-payload developed by Zymeworks Inc., at the World ADC Digital Conference, and in October 2020, we presented preclinical data that support the continued development of AUR102, the lead Aurigene program targeting cyclin-dependent kinase 7 (CDK7), at the 32</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">nd</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ENA Symposium. Both ICON-2 and AUR102 continue to progress through preclinical development and could result in IND filings in the fourth quarter of 2020. We have also made progress under our other collaborations with Invenra, Inc. (Invenra), which is focused on the discovery and development of multispecific antibodies for the treatment of cancer, and StemSynergy Therapeutics, Inc. (StemSynergy), which is focused on the discovery and development of novel oncology compounds aimed to inhibit tumor growth by targeting Casein Kinase 1 alpha. Most recently, in September 2020, we entered into additional collaboration agreements to develop multiple ADCs with Catalent, Inc.&#8217;s wholly owned subsidiaries Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC and Catalent Pharma Solutions, Inc. (individually and collectively referred to as Catalent), and with NBE-Therapeutics AG (NBE). To further enhance our early-stage pipeline, we expect to enter into additional, external collaborative relationships around assets and technologies that complement our internal drug discovery and development efforts.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Update</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of this Quarterly Report, the COVID-19 pandemic continues to have a modest impact on our business operations, in particular on our clinical trial, drug discovery and commercial activities. We have and continue to undertake considerable efforts to mitigate the various problems presented by this crisis, including as described below:</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Trials. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To varying degrees and at different rates across our clinical trials being conducted in regions impacted by COVID-19, we have experienced declines in screening and enrollment activity, delays in new site activations, and restrictions on the access to treatment sites that is necessary to monitor clinical study progress and administration. However, beginning with the second quarter of 2020, we experienced an increase in screening and enrollment activity, and overall, we and our collaboration partners, including principal investigators and personnel at clinical trial sites, have been successful in preventing material delays to our ongoing and planned clinical trials. We have done this through ongoing assessment of the pandemic&#8217;s impact and, wherever possible, taking proactive steps in compliance with guidance issued by the FDA, EMA and other regulatory agencies to support the safety of our patients and their access to treatment, as well as to maintain the high quality of our clinical trials. We recognize, however, that we may have to make further operational adjustments to our ongoing and planned clinical trials and that patient enrollment, and new clinical trial site initiations may be further slowed due to the COVID-19 pandemic, especially if it is further prolonged or grows in severity. </span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Drug Discovery and Preclinical Development. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have partially resumed internal drug discovery in our laboratories following a temporary suspension of these activities while we observed the shelter in place orders issued by the State of California and Alameda County. While this temporary suspension did not result in any significant changes to the timelines for our late-stage discovery work, we did experience modest delays in the advancement of certain of our early-stage programs. We also experienced some modest delays with respect to the portion of drug discovery work outsourced to third-party contractors in regions first impacted by COVID-19. However, those service providers have resumed discovery work and are meeting their contractual obligations in accordance with planned timelines. Prior to the COVID-19 pandemic, we largely outsourced preclinical development work to third-party contractors, and that work has continued without substantial delay or interference resulting from the COVID-19 pandemic. While we continue to utilize our resources effectively to move new product candidates toward the clinic, we may ultimately be unable to achieve our drug discovery and preclinical development objectives within the previously disclosed timelines due to the COVID-19 pandemic, especially if it is further prolonged or grows in severity.</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commercial Activities.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Although our field employees have limited their in-person promotional activities, they remain engaged with healthcare professionals and are available to them as an informational resource. Nevertheless, with healthcare professionals acutely focused on the COVID-19 pandemic and patient access to healthcare professionals limited due to shelter in place orders, we experienced a decrease in prescriptions for CABOMETYX during the second and third quarters of 2020, which we believe was, at least in part, attributable to the COVID-19 pandemic with respect to the second quarter of 2020. We also observed fluctuations in CABOMETYX ordering, and we believe that this effect could continue depending on developments related to the COVID-19 pandemic. Overall, despite the challenges posed by the pandemic, our commercial business has only experienced a modest impact. We believe this is the case largely because of the gravity of the cancer conditions that our products are indicated to treat and the fact that CABOMETYX has been available as an orally administrable cancer treatment in the U.S. since 2016, thereby establishing a safety and efficacy profile that is well known to healthcare </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">professionals. It remains possible, however, that over a longer period, changes to our standard sales and marketing practices resulting from the COVID-19 pandemic, including the shift from in-person to primarily telephonic and virtual interactions with healthcare professionals, along with obstacles to patient access to healthcare professionals, could diminish sales of our marketed products. </span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Supply Chain. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not experienced production delays or seen any significant impact to our clinical or commercial supply chain as a result of the COVID-19 pandemic. In addition, we continue to maintain substantial safety stock inventories for our commercial drug substance and drug products, which should be sufficient to maintain robust long-term supply. We continue to work closely with our third-party contract manufacturers, suppliers, comparator drug sourcing vendors and collaboration partners to&#160;safeguard both the timely production and delivery of our products. If the COVID-19 pandemic is further prolonged or becomes more severe, however, we are prepared to modify our manufacturing and supply chain operations as appropriate in response. </span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General Business </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operations. We have taken numerous temporary precautions to help mitigate the risk of transmission of the virus, including reducing the number of our employees working on-site at our Alameda headquarters under enhanced safety and social distancing protocols. Although having most of our employees continue to work remotely has required that we devise new ways of working and collaborating, to date we have not experienced any material reduction in productivity or interruptions in our general business operations. If the COVID-19 pandemic is further prolonged or becomes more severe, however, we may find it more challenging to maintain that level of productivity, to grow the company as we have anticipated, and to execute on our long-term business plans.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The circumstances surrounding the COVID-19 pandemic are volatile and subject to rapid change. Despite our mitigation efforts, we may experience delays or an inability to execute on our clinical and preclinical development plans, reduced revenues or other adverse impacts to our business, which are described in more detail in &#8220;Risk Factors&#8221; in Part II, Item 1A of this Quarterly Report on Form 10-Q. We recognize that this pandemic will continue to present unique challenges for us throughout 2020, and potentially in future years should the adverse effects of the COVID-19 pandemic continue indefinitely.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Third Quarter 2020 Business Updates and Financial Highlights</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2020, we continued to execute on our business objectives, generating significant revenues from operations and enabling us to continue to seek to maximize the clinical and commercial potential of our products and expand our product pipeline. Significant business updates and financial highlights for the quarter and subsequent to quarter-end include:</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Updates</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In July 2020, we announced the initiation of CONTACT-03, a global phase 3 pivotal trial evaluating cabozantinib in combination with atezolizumab in patients with inoperable, locally advanced or metastatic RCC who progressed during or following treatment with an ICI as the immediate preceding therapy. The co-primary endpoints of the trial are PFS per Response Evaluation Criteria in Solid Tumors (RECIST) v. 1.1 as assessed by independent review and OS, and the secondary endpoints include PFS, ORR and duration of response as assessed by the investigators.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In July 2020, the FDA approved the sBLA submitted by Genentech for atezolizumab plus cobimetinib and vemurafenib for the treatment of BRAF V600 mutation-positive advanced melanoma in previously untreated patients. The approval is based on positive results from IMspire150, a phase 3 pivotal trial that demonstrated that adding atezolizumab to cobimetinib and vemurafenib helped to reduce the risk of disease worsening or death, compared to placebo plus cobimetinib and vemurafenib. This is the second FDA approval for a regimen including cobimetinib, which we discovered and is now being developed by Genentech as part of a worldwide collaboration agreement between the two companies.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In August 2020, we announced the completion of patient enrollment in COSMIC-312, a global phase 3 pivotal trial evaluating cabozantinib in combination with atezolizumab versus sorafenib as a treatment of patients with previously untreated advanced HCC, providing the requisite patient population to conduct the event-driven analyses of the trial&#8217;s endpoints. Separately, patient enrollment remains open in China in order to enroll a sufficient number of patients to enable local registration, if supported by the clinical data. The co-primary endpoints of the trial are PFS and OS. Based on current event rates, we anticipate announcing top-line results in&#160;the first half of&#160;2021.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In August 2020, we announced the completion of patient enrollment in EXAMINER, the phase 4 trial evaluating the safety and efficacy of the 60 mg tablet formulation of cabozantinib compared with the 140 mg capsule </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">formulation, which is marketed as COMETRIQ, for the treatment of patients with progressive, metastatic MTC. EXAMINER is a post-marketing requirement from the FDA and the European Commission. The trial was designed to enroll up to 250 patients, and top-line results from the trial are anticipated later in 2020.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In September 2020, we announced a collaboration and license agreement with Catalent to develop multiple ADCs using Catalent&#8217;s proprietary SMARTag&#174; site-specific bioconjugation technology.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In September 2020, we announced a collaboration and license agreement with NBE to discover and develop multiple ADCs for oncology applications by leveraging NBE&#8217;s unique expertise and proprietary platforms in ADC discovery, including NBE&#8217;s SMAC-Technology&#8482; (a site-specific conjugation technology) and novel payloads.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In September 2020, we and Iconic announced preclinical data that support the continued development of ICON-2 for the treatment of diverse solid tumors. The data, which demonstrate the superior tolerability and exposure of ICON-2 compared with a monomethyl auristatin E anti-tissue factor ADC, were presented at the World ADC Digital Conference.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In September 2020, clinical data from CheckMate -9ER, a phase 3 pivotal trial evaluating the combination of cabozantinib and nivolumab compared to sunitinib in previously untreated advanced or metastatic RCC, were presented as part of Presidential Symposium I at the ESMO Virtual Congress 2020. In addition, clinical data from the clear cell RCC and non-clear cell RCC cohorts of COSMIC-021, a phase 1b trial of cabozantinib in combination with atezolizumab in patients with locally advanced or metastatic solid tumors, were presented as part of the GU Proffered Paper Session and as part of a poster presentation, respectively, at the ESMO Virtual Congress.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In September 2020, we announced that our collaboration partners Ipsen and BMS each submitted and received validation from the EMA for their type II variation applications for the combination of CABOMETYX and Opdivo as a treatment for advanced RCC.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In October 2020, we announced data that support the ongoing clinical development of XL092. The data, which suggest XL092 has a desirable therapeutic profile that pairs the potential for significant anti-tumor activity with a much shorter clinical pharmacokinetic half-life than cabozantinib, as well as a potential synergistic effect in combination with ICIs, were presented at the 32nd ENA Symposium. Later in October 2020, we announced enrollment of the first patient into the dose-escalation cohort of the combination arm of the phase 1 trial evaluating the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of XL092 alone and in combination with atezolizumab in patients with advanced solid tumors.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In October 2020, we and Aurigene announced preclinical data that support the continued development of AUR102. The data, which demonstrate that AUR102 effectively engages CDK7 and inhibits a key mediator of the cell cycle and transcription, were presented at the 32nd ENA Symposium.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In October 2020, we and BMS announced that the FDA had accepted our sNDA and BMS&#8217; sBLA, respectively, for CABOMETYX in combination with Opdivo for the treatment of patients with advanced RCC, granted Priority Review to both applications and assigned a PDUFA goal date of February 20, 2021.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In October 2020, our collaboration partner Takeda, along with Ono, submitted a supplemental application to the Japanese MHLW for Manufacturing and Marketing Approval of CABOMETYX in combination with Opdivo for the treatment of patients with unresectable, advanced or metastatic RCC.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Highlights</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Net product revenues for the third quarter of 2020 were $168.6 million, compared to $191.8 million for the third quarter of 2019.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Total revenues for the third quarter of 2020 were $231.1 million, compared to $271.7 million for the third quarter of 2019.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Research and development expenses for the third quarter of 2020 were $176.8 million, compared to $97.3 million for the third quarter of 2019.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Selling, general and administrative expenses for the third quarter of 2020 were $88.2 million, compared to $51.3 million for the third quarter of 2019.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Provision for (benefit from) income taxes for the third quarter of 2020 was $(6.0) million, compared to $25.2 million for the third quarter of 2019.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Net loss for the third quarter of 2020 was $(32.0) million, or $(0.10) per share, basic and diluted, compared to net income of $97.5 million, or $0.32 per share, basic and $0.31 per share diluted, for the third quarter of 2019.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Cash and investments were $1.5 billion as of September&#160;30, 2020, compared to $1.4 billion as of December&#160;31, 2019.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Results of Operations&#8221;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below for a discussion of the detailed components and analysis of the amounts above.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Challenges and Risks</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the challenges and risks imposed by the COVID-19 pandemic and described under &#8220;&#8212;COVID-19 Update&#8221; above, we will also continue to face challenges and risks that may impact our ability to execute on our remaining 2020 business objectives, and some of these risks to our business have been or may be exacerbated by the COVID-19 pandemic. In particular, for the foreseeable future, we expect our ability to generate sufficient cash flow to fund our business operations and growth will depend upon the continued commercial success of CABOMETYX, both alone or in combination with other therapies, as a treatment for the highly competitive indications for which it is approved, and possibly for other indications for which cabozantinib has been or is currently being evaluated in potentially label-enabling clinical trials, if warranted by the data generated from these trials. However, we cannot be certain that the clinical trials we and our collaboration partners are currently conducting, or may conduct in the future, will demonstrate adequate safety and efficacy in these additional indications to receive regulatory approval in the major commercial markets where CABOMETYX is approved. Even if we and our collaboration partners receive the required regulatory approvals to market cabozantinib for additional indications, we and our collaboration partners may not be able to commercialize CABOMETYX effectively and successfully in these additional indications. In addition, CABOMETYX will only continue to be commercially successful if private third-party and government payers continue to provide coverage and reimbursement. However, as is the case for all innovative pharmaceutical therapies, obtaining and maintaining coverage and reimbursement for CABOMETYX is becoming increasingly difficult, both within the U.S. and in foreign markets, because of growing concerns over healthcare cost containment and corresponding policy initiatives and activities aimed at limiting access to, and restricting the prices of, pharmaceuticals.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Achievement of our remaining 2020 business objectives and the continued success of CABOMETYX will also depend on the success of our development and commercialization strategies to navigate increased competition, including that from, but not limited to, the use of therapies that combine an ICI with another targeted agent to treat cancer. In the longer term, we may eventually face competition from potential manufacturers of generic versions of our marketed products, including the proposed generic version of CABOMETYX tablets that is the subject of an Abbreviated New Drug Application (ANDA) submitted to the FDA by MSN Pharmaceuticals, Inc. (MSN), which if approved, could result in significant decreases in the revenue derived from the U.S. sales of CABOMETYX and thereby materially harm our business and financial condition. Separately, our research and development objectives may be impeded by the challenges of scaling our organization to meet the demands of expanded drug development, unanticipated delays in clinical testing and the inherent risks and uncertainties associated with internal drug discovery operations, all of which may be increased as a result of the COVID-19 pandemic. In connection with efforts to expand our product pipeline, we may be unsuccessful in discovering new drug candidates or identifying appropriate candidates for in-licensing or acquisition.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of these challenges and risks are specific to our business, and others are common to companies in the biotechnology, biopharmaceutical and pharmaceutical industries with development and commercial operations. Moreover, as described under &#8220;&#8212;COVID-19 Update&#8221; above, these risks have been or may be exacerbated by the COVID-19 pandemic. For a more detailed discussion of challenges and risks we face, including those relating to the COVID-19 pandemic, see &#8220;Risk Factors&#8221; in Part II, Item 1A of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fiscal Year Convention</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Fiscal year 2020, which is a 52-week fiscal year, will end on January 1, 2021 and fiscal year 2019, which was a 53-week fiscal year, ended on January 3, 2020. For convenience, references in this report as of and for the three months ended October 2, 2020 and September 27, 2019, and as of and for the fiscal years ending January 1, 2021, and ended January 3, 2020, are indicated as being as of and for the three months ended September 30, 2020 and September 30, 2019 and the years ending December&#160;31, 2020 and ended December&#160;31, 2019, respectively. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><div id="i0283c6f517b447ec92f154ee691f4028_82"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by category were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.941%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.791%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,587&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,768&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541,197&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565,024&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,318&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,443&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,798&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,971&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,092&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,703&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717,486&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727,465&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Product Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross product revenues, discounts and allowances, and net product revenues were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.941%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.791%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent Change</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,401&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239,916&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">702,865&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">704,084&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounts and allowances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,814)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48,148)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(161,668)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(139,060)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,587&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,768&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541,197&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565,024&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues by product were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.941%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.791%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CABOMETYX</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,555&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,410&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522,381&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">552,315&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COMETRIQ</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,032&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,816&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,709&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,587&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,768&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541,197&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565,024&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decreases in product revenues for CABOMETYX for the three and nine months ended September&#160;30, 2020, as compared to the comparable periods in 2019, were</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> due to a decrease in sales volumes driven by decreases in prescriptions and lower customer inventory.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The increases in product revenues for COMETRIQ for the three and nine months ended September&#160;30, 2020, as compared to the comparable periods in 2019, were due to increases in the number of units of COMETRIQ sold, due to a comparator purchase of the product for use in a clinical trial.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our net product revenues to modestly decrease in 2020, as compared to fiscal 2019.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize product revenues net of discounts and allowances that are described in &#8220;Note&#160;1.&#160;Organization and Summary of Significant Accounting Policies&#8221; to our&#160;&#8220;Notes to Consolidated Financial Statements&#8221;&#160;included in our Annual Report on Form 10-K for the year ended December&#160;31, 2019. The 8% increase in discounts and allowances for the three months ended September 30, 2020, as compared to the comparable period in 2019, was primarily the result of an increase in the dollar amount of chargebacks related to Public Health Service hospitals, and to a lesser extent, an increase in Medicaid utilization and the dollar amount of the related Medicaid rebates. The 16% increase in discounts and allowances for the nine months ended September 30, 2020, as compared to the comparable period in 2019, was primarily the result of an increase in Public Health Service hospital utilization and the dollar amount of the related chargebacks. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our discounts and allowances as a percentage of gross revenues to increase during the remainder of 2020.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License revenues include the recognition of the portion of milestone payments allocated to the transfer of intellectual property licenses for which it had become probable in the related period that the milestone would be achieved </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and a significant reversal of revenues would not occur, as well as royalty revenues and the profit on the U.S. commercialization of COTELLIC from Genentech. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestone revenues, which are allocated between license revenues and collaboration services revenues, were $13.5 million and $57.1 million for the three and nine months ended September&#160;30, 2020, respectively, as compared to $50.6 million and $81.1 million for the comparable periods in 2019. Milestone revenues by period included the following:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Milestone revenues for the three and nine months ended September&#160;30, 2020 included $9.2 million in revenues recognized in connection with a $10.0 million milestone we expect to achieve upon Takeda&#8217;s and Ono&#8217;s submission of a supplemental application to the Japanese MHLW for Manufacturing and Marketing Approval of CABOMETYX in combination with Opdivo for the treatment of patients with unresectable, advanced or metastatic RCC.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Milestone revenues for the nine months ended September&#160;30, 2020 included $25.3 million in revenues recognized in connection with $31.0 million in milestones we achieved upon Takeda&#8217;s first commercial sale of CABOMETYX for the treatment of patients with curatively unresectable or metastatic RCC in Japan and $18.9 million in revenues recognized in connection with a $20.0 million development milestone from Ipsen we determined was probable of achievement. The milestone was achieved on October 1, 2020.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Milestone revenues for the three and nine months ended September&#160;30, 2019 included recognition of a $50.0 million commercial milestone from Ipsen that we earned in the third quarter of 2019 upon Ipsen&#8217;s achievement of $250.0 million in net sales of cabozantinib in its territories over four consecutive quarters. </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Milestone revenues for the nine months ended September&#160;30, 2019 also included recognition of a $20.0 million milestone from Daiichi Sankyo Company, Limited (Daiichi Sankyo) for the launch of MINNEBRO tablets for the treatment of patients with hypertension in Japan and $9.7 million in revenues recognized in connection with a $16.0 million milestone from Takeda for the submission in April 2019 of a regulatory application for cabozantinib for the treatment of patients with advanced RCC to the Japanese MHLW.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to uncertainties surrounding the timing and achievement of regulatory and development milestones, it is difficult to predict future milestone revenues and milestones can vary significantly from period to period.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalties increased primarily as a result of increases in royalties earned on Ipsen&#8217;s net sales of cabozantinib outside of the U.S. and Japan. Ipsen royalties were $19.9 million and $54.1 million for the three and nine months ended September&#160;30, 2020, respectively, compared to $16.4 million and $45.3 million for the comparable periods in 2019. Ipsen&#8217;s net sales of cabozantinib have continued to grow since their first commercial sale of the product in the fourth quarter of 2016, primarily due to increased demand of CABOMETYX, which, as of September&#160;30, 2020, is approved in 55 countries outside of the U.S. Royalties also increased due to the commercial launch of CABOMETYX for the treatment of patients with curatively unresectable or metastatic RCC in Japan by Takeda during the second quarter of 2020.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our share of profits on the U.S. commercialization of COTELLIC under our collaboration agreement with Genentech was $1.6 million and $4.4 million for the three and nine months ended September&#160;30, 2020, respectively, as compared to $1.1 million and $3.5 million for the comparable periods in 2019. We also earned royalties on ex-U.S. net sales of COTELLIC by Genentech of $1.4 million and $3.8 million for the three and nine months ended September&#160;30, 2020, compared to $1.6 million and $4.4 million for the comparable periods in 2019.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our license revenues to modestly decrease in 2020, as compared to fiscal 2019, as a result of a decrease in milestones expected to be achieved during the year.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Services Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration services revenues include the recognition of deferred revenue for the portion of upfront and milestone payments that have been allocated to research and development services performance obligations, development cost reimbursements earned under our collaboration agreements, product supply revenues, net of product supply costs, and the royalties we paid to GlaxoSmithKline (GSK) on sales by Ipsen of products containing cabozantinib.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Development cost reimbursements were $26.3 million and $60.3 million for the three and nine months ended September&#160;30, 2020, respectively, as compared to $12.0 million and $32.5 million for the comparable periods in 2019. The increases in development cost reimbursements were primarily a result of the reimbursements from Ipsen and Takeda associated with their decision to opt in and co-fund CONTACT-02 and additional cohorts of COSMIC-021 studies in 2020 and their respective share of the increase in spending on the COSMIC-312, COSMIC-021 and CONTACT-02 studies.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration services revenues were reduced by $2.9 million and $7.6 million for the 3% royalty we are required to pay GSK on the net sales by Ipsen and Takeda of any product incorporating cabozantinib for the three and nine months ended September&#160;30, 2020, respectively, compared to $2.2 million and $6.2 million for the comparable periods in 2019. As royalty generating sales of cabozantinib by Ipsen have increased as described above, our royalty payments to GSK have also increased.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect collaboration services revenues to increase in 2020, as compared to fiscal 2019, as a result of higher development cost reimbursements earned under our collaboration agreements.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Goods Sold</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of goods sold and our gross margin were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.941%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.791%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent Change</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,725&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,537&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,235&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,577&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold is related to our product revenues and consists primarily of a 3% royalty payable to GSK on U.S. net sales of any product incorporating cabozantinib, as well as the cost of inventory sold, indirect labor costs, write-downs related to expiring and excess inventory, and other third-party logistics costs. The increases in cost of goods sold for the three and nine months ended September&#160;30, 2020, as compared to the comparable periods in 2019, were primarily the result of increases in write-downs of excess and expiring inventory and certain period costs. We do not expect our gross margin to change significantly during the remainder of 2020.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.941%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.791%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent Change</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,762&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,295&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393,572&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242,516&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of clinical trial costs, personnel expenses, license and other collaboration costs, stock-based compensation, and consulting and outside services. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increases in research and development expenses for the three and nine months ended September&#160;30, 2020, as compared to the comparable periods in 2019, were primarily related to increases in clinical trial costs, licensing and other collaboration costs, stock-based compensation and personnel expenses, partially offset by the impact of increased development cost reimbursements. Clinical trial costs, which include services performed by third-party contract research organizations and other vendors who support our clinical trials, and comparator drug purchases, increased $34.2 million and $93.6 million for the three and nine months ended September&#160;30, 2020, respectively, as compared to the comparable periods in 2019. The increases in clinical trial costs were primarily due to costs associated with the expanding clinical trial program for cabozantinib, which includes CONTACT-02, COSMIC-313, COSMIC-312, and COSMIC-021. Licensing and other collaboration costs increased $24.9 million and $19.6 million for the three and nine months ended September 30, 2020, respectively, as compared to the comparable periods in 2019, primarily due to increases in upfront license fee payments from recent business development activities with two additional collaboration and license agreements focused on the discovery and development of ADCs. Stock-based compensation increased $14.6 million and $16.4 million for the three and nine months ended September&#160;30, 2020, respectively, as compared to the comparable periods in 2019, primarily due to the determination that a performance target for the PSUs granted in 2019 became probable of achievement. Personnel expenses increased $7.8 million and $22.6 million for the three and nine months ended September&#160;30, 2020, respectively, as compared to the comparable periods in 2019, primarily due to increases in headcount to support our expanding discovery and development efforts. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses for the three and nine months ended September&#160;30, 2020 were reduced by $6.3 million and $11.3 million, respectively, as a result of development cost reimbursements in connection with our collaboration arrangement with Roche; there were no such reimbursements during the comparable periods in 2019. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not track fully-burdened research and development expenses on a project-by-project basis.&#160;We group our research and development expenses into three categories: 1) development; 2) drug discovery; and 3) other. Our development group leads the development and implementation of our clinical and regulatory strategies and prioritizes disease indications in which our compounds are being or may be studied in clinical trials. Our drug discovery group utilizes a variety of technologies, including in-licensed technologies, to enable the rapid discovery, optimization and extensive characterization of lead compounds such that we are able to select development candidates with the best potential for further evaluation and advancement into clinical development.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses by category were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.715%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.742%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,055&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,612&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,388&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,964&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,077&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consulting and outside services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,852&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,084&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,907&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,884&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other development costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,754&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,771&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,824&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total development</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,308&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,857&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278,146&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,397&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Drug discovery:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License and other collaboration costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,761&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,910&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,013&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,390&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other drug discovery</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,703&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,896&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,844&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,870&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total drug discovery</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,464&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,806&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,857&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,260&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,990&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,632&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,569&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,859&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,762&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,295&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393,572&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242,516&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Primarily includes personnel expenses, consulting and outside services and laboratory supplies.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Includes stock-based compensation, the allocation of general corporate costs to research and development, and development cost reimbursements in connection with our December 2019 collaboration arrangement with Roche.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to reviewing the three categories of research and development expenses described above, we principally consider qualitative factors in making decisions regarding our research and development programs. These factors include enrollment in clinical trials for our drug candidates, preliminary data and final results from clinical trials, the potential indications for our drug candidates, the clinical and commercial potential for our drug candidates, and competitive dynamics. We also make our research and development decisions in the context of our overall business strategy. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are focusing our development efforts primarily on cabozantinib to maximize the therapeutic and commercial potential of this compound and, as a result, we expect that a significant portion of our research and development expenses will relate to the continuing clinical development program of cabozantinib, which includes over 100 ongoing or planned clinical trials across multiple indications. Notable company-sponsored studies resulting from this program include: COSMIC-021 and COSMIC-312, for which Roche is providing atezolizumab free of charge; COSMIC-313, for which BMS is providing nivolumab and ipilimumab free of charge; CONTACT-02 for which Roche is sharing in the development costs including the provision of atezolizumab free of charge; and COSMIC-311.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also remain committed to building our product pipeline by discovering and developing new therapies for cancer patients. In this regard, we conduct internal drug discovery activities with the goal of identifying new product candidates to advance into clinical trials. In addition, we have augmented our internal drug discovery activities with multiple partnerships, including several that enable us to discover and advance various biologics, such as bispecific antibodies and ADCs, and we continue to engage in business development initiatives aimed at identifying and in-licensing promising, early-stage oncology assets, which we can further develop utilizing our established clinical development infrastructure.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our research and development expenses to increase in 2020, as compared to fiscal 2019, driven by our ongoing clinical evaluation of cabozantinib and business development activities.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The length of time required for clinical development of a particular product candidate and our&#160;development costs for that product candidate may be impacted by the scope and timing of enrollment in clinical trials for the product </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidate, our decisions to develop a product candidate&#160;for additional indications and whether we pursue development of the product candidate or a particular indication with a collaborator or independently. For example, cabozantinib is being developed in multiple indications, and we do not yet know for how many of those indications we will ultimately pursue regulatory approval. In this regard, our decisions to pursue regulatory approval of cabozantinib for additional indications depend on several variables outside of our control, including the strength of the data generated in our prior, ongoing and potential future clinical trials. Furthermore, the scope and number of clinical trials required to obtain regulatory approval for each pursued indication is subject to the input of the applicable regulatory authorities, and we have not yet sought such input for all potential indications that we may elect to pursue. Even after having given such input, applicable regulatory authorities may subsequently require additional clinical studies prior to granting regulatory approval based on new data generated by us or other companies, or for other reasons outside of our control. As a condition to any regulatory approval, we may also be subject to post-marketing development commitments, including additional clinical trial requirements. As a result of the uncertainties discussed above, we are unable to determine the duration of, or total costs associated with the development of cabozantinib or any of our other research and development projects. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our potential therapeutic products are subject to a lengthy and uncertain regulatory process that may not result in our receipt of the necessary regulatory approvals. Failure to receive the necessary regulatory approvals would prevent us from commercializing the product candidates affected, including cabozantinib in any additional indications. In addition, clinical trials of our potential product candidates may fail to demonstrate safety and efficacy, which could prevent or significantly delay regulatory approval. A discussion of the risks and uncertainties with respect to our research and development activities, including completing the development of our product candidates, and the consequences to our business, financial position and growth prospects can be found in &#8220;Risk Factors&#8221; in Part&#160;II, Item&#160;1A of this Quarterly Report on Form&#160;10-Q.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.941%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.791%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent Change</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,265&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210,916&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,218&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses consist primarily of personnel expenses, stock-based compensation, marketing costs, and certain other administrative costs. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increases in selling, general and administrative expenses for the three and nine months ended September&#160;30, 2020, as compared to the comparable periods in 2019, were primarily related to the increases in stock-based compensation and personnel expenses; the increase for the three months ended September&#160;30, 2020 was also related to an increase in marketing costs. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation increased $27.9 million and $28.7 million for the three and nine months ended September 30, 2020, respectively, as compared to the comparable periods in 2019, primarily due to the determination that a performance target for the PSUs granted in 2019 became probable of achievement. Personnel expenses increased $3.2 million and $10.3 million for the three and nine months ended September&#160;30, 2020, respectively, as compared to the comparable periods in 2019, primarily due to increases in administrative headcount to support our commercial and research development organizations. Marketing costs increased $3.9 million for the three months ended September&#160;30, 2020, as compared to the comparable period in 2019, in preparation for the launch of CABOMETYX in combination with Opdivo for the treatment of patients with advanced RCC.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our selling, general and administrative expenses to increase in 2020, as compared to fiscal 2019, driven by our continued commercial investment in CABOMETYX, the growth of the broader organization and higher stock-based compensation expense.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-operating Income</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-operating income were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.941%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.791%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent Change</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,994&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,191&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,376&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,253&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(140)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(504&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">688&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-operating income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,559&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,051&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,947&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,941&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decreases in non-operating income for the three and nine months ended September&#160;30, 2020, as compared to the comparable periods in 2019, were primarily the result of the decreases in interest income due to lower interest rates. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provision for (Benefit from) Income Taxes</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for (benefit from) income taxes and effective income tax rates were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.941%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.791%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for (benefit from) income taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,981)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,205&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,317&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,826&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded an income tax benefit for the three months ended September&#160;30, 2020 as a result of a current period pre-tax loss, as compared to the comparable period in 2019 in which we reported pre-tax income. The decrease in provision for income taxes for the nine months ended September 30, 2020 as compared to the comparable period in 2019, was due the decrease in pre-tax income during the period. The effective tax rate for the three and nine months ended September&#160;30, 2020 differed from the U.S. federal statutory rate of 21% primarily due to excess tax benefits related to the exercise of certain stock options and federal tax credits, offset by non-deductible executive compensation during the periods. The effective tax rate for the three and nine months ended September&#160;30, 2019 differed from the U.S. federal statutory rate of&#160;21%&#160;primarily due to excess tax benefits related to the exercise of certain stock options and federal tax credits during the periods.</span></div><div id="i0283c6f517b447ec92f154ee691f4028_85"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, we had $1.5 billion in cash and investments, compared to $1.4 billion as of December&#160;31, 2019. We anticipate that the aggregate of our current cash and cash equivalents, short-term investments available for operations, product revenues and collaboration revenues will enable us to maintain our operations for a period of at least 12 months following the filing date of this report.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to spend significant amounts to fund the continued development and commercialization of cabozantinib. In addition, we intend to continue to expand our product pipeline through our internal drug discovery efforts and the execution of strategic transactions that align with our oncology drug expertise. Financing these activities could materially impact our liquidity and capital resources and may require us to incur debt or raise additional funds through the issuance of equity. Furthermore, even though we believe we have sufficient funds for our current and future operating plans, we may choose to incur debt or raise additional funds through the issuance of equity due to market conditions or strategic considerations. The COVID-19 pandemic has caused volatility in the U.S. and global financial markets and a downturn in the U.S. and global economy, which could adversely impact our rates of return for our invested cash resources, the availability and cost of credit, as well as our ability to&#160;raise additional funds in the capital markets. Among other things, our inability to access additional funds could in the future inhibit our ability to engage in larger-scale strategic transactions or investments.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources and Uses of Cash</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flow activities were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.459%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.824%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,689&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368,935&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101,706)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(457,046)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by financing activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,438)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,553&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-indent:72pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows provided by operating activities represent the cash receipts and disbursements related to all of our activities other than investing and financing activities. Cash provided by operating activities is derived by adjusting our net income for: non-cash operating items such as deferred taxes, stock-based compensation, depreciation, non-cash lease expense and changes in operating assets and liabilities which reflect timing differences between the receipt and payment of cash associated with transactions and when they are recognized in our Condensed Consolidated Statements of Income (Loss), the most significant of which may include the timing of milestones payments from our collaboration partners. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The most significant factors that contributed to the decrease in cash provided by operating activities for the nine months ended September&#160;30, 2020, as compared to the comparable period in 2019, were an increase in cash paid for operating expenses, a $53.0&#160;million decrease in milestone payments received, and other net changes in operating assets and liabilities described above.</span></div><div style="margin-top:9pt;text-indent:72pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in investing activities for the nine months ended September&#160;30, 2020 consisted of investment purchases of $867.0 million and purchases of property, equipment and other of $16.1 million, less cash provided by the maturities and sales of investments of $781.3 million.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in investing activities for the nine months ended September&#160;30, 2019 consisted of investment purchases of $887.7 million and property and equipment purchases of $5.6 million, less cash provided by the maturities and sales of investments of $436.2 million.</span></div><div style="margin-top:9pt;text-indent:72pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in financing activities for the nine months ended September&#160;30, 2020 consisted of $26.1 million of withholding taxes paid related to net share settlements of equity awards, partially offset by $19.7 million in proceeds from the issuance of common stock under our equity incentive and stock purchase plans.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by financing activities for the nine months ended September&#160;30, 2019 consisted of $19.0 million in proceeds from the issuance of common stock under our equity incentive and stock purchase plans, partially offset by $3.4 million of withholding taxes paid related to net share settlements of equity awards.</span></div><div id="i0283c6f517b447ec92f154ee691f4028_88"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no material changes outside of the ordinary course of business in our contractual obligations as of September&#160;30, 2020 from those disclosed in our Annual Report on Form 10-K for the year ended December&#160;31, 2019.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, we did not have any material off-balance-sheet arrangements, as defined by applicable SEC regulations.</span></div><div id="i0283c6f517b447ec92f154ee691f4028_91"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S. which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. An accounting policy is considered to be critical if it requires an accounting estimate to be made based on assumptions about matters that are highly uncertain at </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the time the estimate is made, and if different estimates that reasonably could have been used, or changes in the accounting estimates that are reasonably likely to occur periodically, could materially impact our Condensed Consolidated Financial Statements. On an ongoing basis, management evaluates its estimates including, but not limited to: those related to revenue recognition, including determining the nature and timing of satisfaction of performance obligations and determining the standalone selling price of performance obligations, and variable consideration such as rebates, chargebacks, sales returns and sales allowances as well as milestones included in collaboration arrangements; the amounts of revenues and expenses under our profit and loss sharing agreement; recoverability of inventory; the amounts of deferred tax assets and liabilities including the related valuation allowance; the accrual for certain liabilities including accrued clinical trial liabilities; and valuations of equity awards used to determine stock-based compensation, including certain awards with vesting subject to market or performance conditions. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Our senior management has discussed the development, selection and disclosure of these estimates with the Audit Committee of our Board of Directors. Actual results could differ materially from those estimates.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our critical accounting policies relating to revenue recognition, inventory, clinical trial accruals, stock-based compensation and income taxes reflect the more significant estimates and assumptions used in the preparation of our Condensed Consolidated Financial Statements.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes in our critical accounting policies and estimates during the nine months ended September&#160;30, 2020, as compared to the critical accounting policies and estimates disclosed in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included in our Annual Report on Form 10-K for the year ended December&#160;31, 2019 filed with the SEC on February&#160;25, 2020.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of the expected impact of recent accounting pronouncements, see &#8220;Note 1. Organization and Summary of Significant Accounting Policies&#8221; in the &#8220;Notes to Condensed Consolidated Financial Statements&#8221; contained in Part I, Item 1 of this Quarterly Report on Form 10-Q.</span></div><div id="i0283c6f517b447ec92f154ee691f4028_94"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our market risks as of September&#160;30, 2020 have not changed significantly from those described in Item&#160;7A of our Annual Report on Form 10-K for the year ended December&#160;31, 2019.</span></div><div id="i0283c6f517b447ec92f154ee691f4028_97"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of disclosure controls and procedures.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Based on the evaluation of our disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) of the Securities Exchange Act of 1934, as amended, or the Exchange Act) required by Rules 13a-15(b) or 15d-15(b) of the Exchange Act, our Chief Executive Officer and Chief Financial Officer have concluded that as of the end of the period covered by this report, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Limitations on the effectiveness of controls.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> A control system, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within an organization have been detected. Accordingly, our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure control system are met and, as set forth above, our principal executive officer and principal financial officer have concluded, based on their evaluation as of the end of the period covered by this report, that our disclosure controls and procedures were effective to provide reasonable assurance that the objectives of our disclosure control system were met.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in internal control over financial reporting. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting that occurred during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><div id="i0283c6f517b447ec92f154ee691f4028_100"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="i0283c6f517b447ec92f154ee691f4028_103"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, we received a notice letter regarding an ANDA submitted to the FDA by MSN, requesting approval to market a generic version of CABOMETYX tablets. MSN&#8217;s initial notice letter included a Paragraph IV certification with respect to our U.S. Patent Nos. 8,877,776, 9,724,342, 10,034,873 and 10,039,757, which are listed in the Approved Drug Products with Therapeutic Equivalence Evaluations, also referred to as the </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Orange Book. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSN&#8217;s initial notice letter did not provide a Paragraph IV certification against U.S. Patent No. 7,579,473, the composition of matter patent, or U.S. Patent No. 8,497,284, a method of use patent. On October 29, 2019, we filed a complaint in the United States District Court for the District of Delaware for patent infringement against MSN asserting U.S. Patent No. 8,877,776 arising from MSN&#8217;s ANDA filing with the FDA. On November 20, 2019, MSN filed its response to the complaint, alleging that U.S. Patent No. 8,877,776 is invalid and not infringed. On May 5, 2020, we received notice from MSN that it had amended its ANDA to assert additional Paragraph IV certifications. The ANDA now requests approval to market a generic version of CABOMETYX tablets prior to expiration of the two previously-unasserted CABOMETYX patents: U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284. On May 11, 2020, we filed a complaint in the United States District Court for the District of Delaware for patent infringement against MSN asserting U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284 arising from MSN&#8217;s amended ANDA filing with the FDA. On May 22, 2020, MSN filed its response to the complaint, alleging that each of U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284 is invalid and not infringed. Neither of our complaints alleges infringement of U.S. Patent Nos. 9,724,342, 10,034,873 and 10,039,757. In our complaints, we are seeking, among other relief, an order that the effective date of any FDA approval of the ANDA would be a date no earlier than the expiration of all of U.S. Patent No. 7,579,473, U.S. Patent No. 8,497,284 and U.S. Patent No. 8,877,776, the latest of which expires on October 8, 2030, and equitable relief enjoining MSN from infringing these patents. These two lawsuits against MSN have been consolidated, and a bench trial has been scheduled for May 2022.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also from time to time become a party or subject to various other legal proceedings and claims, either asserted or unasserted, which arise in the ordinary course of business. Some of these proceedings have involved, and may involve in the future, claims that are subject to substantial uncertainties and unascertainable damages.</span></div><div id="i0283c6f517b447ec92f154ee691f4028_106"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In addition to the risks discussed elsewhere in this report, the following are important factors that could cause actual results or events to differ materially from those contained in any forward-looking statements made by us or on our behalf. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not currently known to us or that we deem immaterial also may impair our business operations. If any of the following risks or such other risks actually occur, our business could be harmed.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business and Industry</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to grow our company is critically dependent upon the commercial success of CABOMETYX in its approved indications and the further clinical development, regulatory approval and commercial success of cabozantinib in additional indications.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that for the foreseeable future, our ability to maintain or meaningfully increase cash flow to fund our business operations and growth will depend upon the continued commercial success of CABOMETYX, both alone or in combination with other therapies, as a treatment for the highly competitive indications for which it is approved, and possibly for other indications for which cabozantinib has been or is currently being evaluated in potentially label-enabling clinical trials, if warranted by the data generated from these trials. In this regard, part of our strategy is to pursue additional indications for cabozantinib to increase the number of cancer patients who could benefit from this medicine. However, we cannot be certain that the clinical trials we and our collaboration partners are currently conducting, or may conduct in the future, will demonstrate adequate safety and efficacy in these additional indications to receive regulatory approval in the major commercial markets where CABOMETYX is approved. Even if we and our collaboration partners receive the required regulatory approvals to market cabozantinib for additional indications, we and our collaboration partners may not be able to commercialize CABOMETYX effectively and successfully in these additional indications. If revenue from CABOMETYX decreases or remains flat, or if we are unable to expand the labeled indications in major commercial markets where CABOMETYX is approved, or if we fail to achieve anticipated product royalties and collaboration milestones, whether as a result of the COVID-19 pandemic or otherwise, we may need to reduce our operating expenses, access other sources of </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cash or otherwise modify our business plans, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the COVID-19 pandemic is further prolonged or becomes more severe, our business operations and corresponding financial results could suffer, which could have a material adverse impact on our financial condition and prospects for growth.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business could be materially and adversely impacted by the ongoing COVID-19 pandemic, a disease caused by a novel coronavirus, SARS-CoV-2, which has spread globally. To date, the COVID-19 pandemic has had a modest impact on our business operations, in particular on our clinical trial, drug discovery and commercial activities. For example, to varying degrees and at different rates across our clinical trials being conducted in regions impacted by COVID-19, we experienced declines in screening and enrollment activity, delays in new site activations, and restrictions on access to treatment sites that is necessary to monitor clinical study progress and initiation. However, as the COVID-19 pandemic continues to surge in various parts of the world, the impact on our clinical development operations could grow more severe. We anticipate that a further prolonged, or more severe, global public health crisis could limit our ability to identify and work with clinical investigators at clinical trial sites globally to enroll, initiate and maintain treatment per protocol of patients for our ongoing COSMIC-311, COSMIC-312, COSMIC-313, COSMIC-021, CONTACT-01, CONTACT-02 and CONTACT-03 clinical trials. Disruptions to medical and administrative operations at clinical trial sites and the implementation of crisis management initiatives have and may continue to reduce personnel and other resources necessary to conduct our clinical trials, which could delay our clinical trial plans or require certain trials to be temporarily suspended. Moreover, quarantines and travel restrictions have impeded and may continue to impede patient movement or interrupt healthcare services, which we anticipate over time, could also interfere with and potentially negatively impact clinical trial results. In addition, new and increased costs connected with our efforts to mitigate the adverse impacts resulting from the COVID-19 pandemic on our clinical trials could cause the expenses we incur in administering those clinical trials to increase considerably. Specifically, with respect to our clinical trials evaluating cabozantinib in combination with therapies that must be administered via professional intravenous infusion, such as COSMIC-312, COSMIC-313, COSMIC-021, CONTACT-01, CONTACT-02 and CONTACT-03, limited patient movement or interrupted healthcare services at medical institutions have delayed in some instances and may continue to delay or prevent on-site infusion of the therapies being evaluated in combination with cabozantinib. If a sizable portion of patients in our combination studies are unable or unwilling to receive all components of the combination therapy being tested in accordance with the applicable clinical trial protocol, it could cause those studies to be delayed, suspended or prevented from producing statistically significant results.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending upon the duration and severity of the COVID-19 pandemic, we could also experience delays in the commencement of new clinical trials of cabozantinib, or our earlier-stage investigative product candidates. The COVID-19 pandemic could also impede internal clinical operations and delay our planning and preparation timelines for new clinical trials, as well as adversely affect our ability to obtain regulatory approval for clinical protocols and increase the operating expenses connected with these new clinical trials.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the COVID-19 pandemic caused us to suspend internal drug discovery work in our laboratories temporarily while we observed the shelter in place orders issued by the State of California and Alameda County. We also experienced some modest delays with respect to the portion of drug discovery work outsourced to third-party contractors in regions first impacted by COVID-19. While both internal drug discovery work in our laboratories and outsourced drug discovery activities have since partially resumed, we may be unable to maximize the potential of these programs due to reduced staffing and the imposition of increased safety protocols, and should the COVID-19 pandemic grow in severity, we may have to further scale back or suspend activities in the future. For example, as a result of spikes or surges in infection, positivity or hospitalization rates, we may choose or be required to suspend work in our laboratories, which will once again impede our internal drug discovery efforts. Prior to the COVID-19 pandemic, we largely outsourced preclinical development work, as well as certain drug discovery activities, to third-party contractors, and although to date that work has continued without substantial delay or interference, the COVID-19 pandemic could impede these third parties from providing timely deliverables to us in the future. As a result, should the COVID-19 pandemic be further prolonged or grow in severity, we may ultimately be unable to achieve our drug discovery and preclinical development objectives within the previously disclosed timelines, which could have a material adverse impact on our prospects for growth.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we believe that our commercial business has, to date, only experienced a modest impact related to the COVID-19 pandemic, it remains possible that over a longer period, changes to our standard sales and marketing practices, including the shift from in-person to primarily telephonic and virtual interactions with healthcare professionals, could negatively impact the flow of important information regarding our medicines, which along with obstacles to patient access to healthcare professionals, could diminish sales of our marketed products.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although as of the date of this Quarterly Report, we continue to maintain substantial safety stock inventories for our drug substance and drug products and have not experienced production delays or seen significant impairment to our supply chain as a result of the COVID-19 pandemic, our third-party contract manufacturers and suppliers could experience operational delays due to facility closures and other hardships as a result of the COVID-19 pandemic, which could impact our supply chain by potentially causing delays to or disruptions in the supply of our commercial or clinical products or product candidates. These delays or disruptions could be further exacerbated if the COVID-19 pandemic begins to impact essential distribution systems, which could substantially increase delivery times and costs, or otherwise adversely affect our ability to provide our products to customers and clinical trial sites and generate product revenues. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of this Quarterly Report, we have taken temporary precautions to help mitigate the risk of transmission of the virus, including: reducing the number of our employees working on-site at our Alameda headquarters under enhanced safety and social distancing protocols; suspending all non-essential business travel for our employees; and limiting the circumstances under which our field employees may engage in in-person promotional activities with healthcare professionals. Over a longer period, all of these measures could negatively affect our business operations and prospects in both foreseeable and unforeseeable ways. For instance, requiring employees to work remotely while we adhered to shelter in place orders limited our internal drug discovery activities, and although we have begun to allow our employees to return to our Alameda headquarters under enhanced safety and social distancing protocols, if we are forced to, or determine that we should, resume shelter in place restrictions for an extended period of time, this could eventually cause delays and otherwise negatively impact the effectiveness of these programs and impede our ability to execute on our long-term business plans. Further, extended periods of remote work could impede the focused attention of management or reduce the productivity of teams that would otherwise be working closely together.&#160;The COVID-19 pandemic has also caused volatility in the U.S. and global financial markets and a downturn in the U.S. and global economy, which could adversely impact our rates of return for our invested cash resources, the availability and cost of credit, as well as our ability to&#160;raise additional funds in the capital markets. Among other things, our inability to access additional funds could in the future inhibit our ability to engage in larger scale strategic transactions or investments.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we expect the COVID-19 pandemic to continue to have varying degrees of adverse impact on our business operations and, potentially in the future, our financial results, the extent of such adverse impact arising from the COVID-19 pandemic to our business and our financial results, as well as to the value of and market for our common stock, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the U.S. and in other countries, and the effectiveness of actions taken globally to contain and treat the disease.  These effects could materially and adversely affect our business, financial condition, results of operations and growth prospects, as further explained in the risks and uncertainties described elsewhere in this &#8216;&#8216;Risk Factors&#8217;&#8217; section.  In addition, to the extent the ongoing COVID-19 pandemic adversely impacts our business and financial results, it may also have the effect of exacerbating many of these other risks and uncertainties inherent to our business.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on Ipsen and Takeda for the commercial success of CABOMETYX in its approved indications outside of the U.S., and are unable to control the amount or timing of resources expended by these collaboration partners in the commercialization of CABOMETYX in its approved indications outside of the U.S.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely upon the regulatory, commercial, medical affairs, market access and other expertise and resources of our collaboration partners, Ipsen and Takeda, for commercialization of CABOMETYX in their respective territories outside of the U.S. We cannot control the amount and timing of resources that our collaboration partners dedicate to the commercialization of CABOMETYX, or to its marketing and distribution, and our ability to generate revenues from the commercialization of CABOMETYX by our collaboration partners depends on their ability to obtain and maintain regulatory approvals for, achieve market acceptance of, and to otherwise effectively market, CABOMETYX in its approved indications in their respective territories. Further, the operations of our collaboration partners, and ultimately their foreign sales of CABOMETYX, could be adversely affected by the degree and effectiveness of their respective corporate responses to the COVID-19 pandemic, as well as by the imposition of governmental price or other controls, political and economic instability, trade restrictions or barriers and changes in tariffs, escalating global trade and political tensions, or otherwise. If our collaboration partners are unable or unwilling to invest the resources necessary to commercialize CABOMETYX successfully in the EU, Japan and other international territories where it has been approved, this could reduce the amount of revenue we are due to receive under these collaboration agreements, thus resulting in harm to our business and operations.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to grow revenues from sales of CABOMETYX will depend upon the degree of market acceptance among physicians, patients, healthcare payers, and the medical community.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to increase or maintain revenues from sales of CABOMETYX for its approved indications is, and if approved for additional indications will be, highly dependent upon the extent of market acceptance of CABOMETYX among physicians, patients, government healthcare payers such as Medicare and Medicaid, commercial healthcare plans and the medical community. Market acceptance for CABOMETYX could depend on numerous factors, including the effectiveness and safety profile, or the perceived effectiveness and safety profile, of CABOMETYX compared to competing products, the strength of CABOMETYX sales and marketing efforts, the impact to healthcare systems and our ability to successfully communicate product information to healthcare professionals resulting from the COVID-19 pandemic, and changes in pricing and reimbursement for CABOMETYX. If CABOMETYX does not continue to be prescribed broadly for the treatment of its approved RCC and HCC indications, our product revenues could flatten or decrease, which could have a material adverse impact on our business, financial condition and results of operations. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our competitors may develop products and technologies that impair the relative value of our marketed products and any future product candidates.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology, biopharmaceutical and pharmaceutical industries are competitive and are characterized by constant technological change and diverse offerings of products, particularly in the area of novel oncology therapies. Many of our competitors have greater capital resources, larger research and development staff and facilities, deeper regulatory expertise and more extensive product manufacturing and commercial capabilities than we do, which may afford them a competitive advantage. Further, our competitors may be more effective at in-licensing and developing new commercial products that could render our products, and those of our collaboration partners, obsolete and noncompetitive. We face, and will continue to face, intense competition from biotechnology, biopharmaceutical and pharmaceutical companies, as well as academic research institutions, clinical reference laboratories and government agencies that are pursuing scientific and clinical research activities similar to ours.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, the specific indications for which CABOMETYX is currently or may be approved, based on the results from clinical trials currently evaluating cabozantinib, are highly competitive. Several novel therapies and combinations of therapies have been approved, are in advanced stages of clinical development or are under expedited regulatory review in these indications, and these other therapies are currently competing or are expected to compete with CABOMETYX. We believe our future success will depend upon our ability to maintain a competitive position with respect to the shifting landscape of therapeutic strategy following the advent of ICIs. While we have adapted our cabozantinib development strategy to address the use of therapies that combine ICIs with other targeted agents in indications for which CABOMETYX is approved, we cannot ensure that our ongoing or planned clinical trials will show efficacy in comparison to competing product combinations. Moreover, the complexities of such a development strategy have required and are likely to continue to require collaboration with some of our competitors.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to maintain or increase our internal sales, marketing, market access and product distribution capabilities for our products, we may be unable to maximize product revenues, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maintaining our sales, marketing, market access and product distribution capabilities requires significant resources, and there are numerous risks involved with maintaining and continuously improving such a commercial organization, including our potential inability to successfully recruit, train, retain and incentivize adequate numbers of qualified and effective sales and marketing personnel. We are competing for talent with numerous commercial- and precommercial-stage, oncology-focused biotechnology companies seeking to build out and maintain their commercial organizations, as well as other large pharmaceutical and biotechnology organizations that have extensive, well-funded and more experienced sales and marketing operations, and we may be unable to maintain or adequately scale our commercial organization as a result of such competition. Also, to the extent that the commercial opportunities for CABOMETYX grow over time, we may not properly scale the size and experience of our commercialization teams to market and sell CABOMETYX successfully in an expanded number of indications. If we are unable to maintain or scale our commercial function appropriately, or should we have to maintain primarily telephonic and virtual interactions in lieu of in-person meetings with healthcare professionals for an extended period of time as a result of the COVID-19 pandemic, we may not be able to maximize product revenues, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to enter into or maintain agreements with third parties to store, distribute and commercialize our products, we may be unable to maximize product revenues, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to commercialize our products successfully will depend, in part, on the adequacy of our distribution of those products to eligible patients. We currently rely on third-party providers for storage and distribution and on collaboration partners for ongoing commercialization and distribution of CABOMETYX and COMETRIQ in their respective territories outside of the U.S., as well as for access and distribution activities for the approved products under named patient use programs (or similar programs).</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current and anticipated future dependence upon the activities, support, and legal and regulatory compliance of third parties may adversely affect our ability to supply CABOMETYX and COMETRIQ on a timely and competitive basis. The services provided by these third parties may not be effective or timely, which risks may be increased as a result of the COVID-19 pandemic. In such cases, we may be unable to maintain, improve or renew our arrangements with these third parties or enter into new, alternative arrangements with other service providers, on acceptable terms or at all. If we are unable to contract successfully for effective third-party services on acceptable terms, our commercialization efforts and those of our collaboration partners may be delayed or otherwise adversely affected, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain or maintain coverage and reimbursement for our products from third-party payers, our business will suffer.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to commercialize our products successfully is highly dependent on the extent to which health insurance coverage and reimbursement is, and will be, available from third-party payers, including governmental payers, such as Medicare and Medicaid, and private health insurers. Third-party payers continue to scrutinize and manage access to pharmaceutical products and services and may limit reimbursement for newly approved products and indications. Patients are generally not capable of paying for CABOMETYX or COMETRIQ themselves and rely on third-party payers to pay for, or subsidize, the costs of their medications, among other medical costs. Accordingly, market acceptance of CABOMETYX and COMETRIQ is dependent on the extent to which coverage and reimbursement is available from third-party payers. If third-party payers do not provide coverage or reimbursement for CABOMETYX or COMETRIQ, our revenues and results of operations will suffer. In addition, even if third-party payers provide some coverage or reimbursement for CABOMETYX or COMETRIQ, the availability of such coverage or reimbursement for prescription drugs under private health insurance and managed care plans, which often varies based on the type of contract or plan purchased, may not be sufficient for patients to afford CABOMETYX or COMETRIQ.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to healthcare laws, regulations and enforcement; our failure to comply with those laws could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to federal and state healthcare laws and regulations, which laws and regulations are enforced by the federal government and the states in which we conduct our business. Should our compliance controls prove ineffective at preventing or mitigating the risk and impact of improper business conduct or inaccurate reporting, we could be subject to enforcement of the following, including, without limitation:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the federal Anti-Kickback Statute, which governs our business activities, including our marketing practices, medical educational programs, pricing policies, and relationships with healthcare providers or other entities;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the federal Food, Drug, and Cosmetic Act (FDCA) and its implementing regulations, which prohibit, among other things, the introduction or delivery for introduction into interstate commerce of any drug that is adulterated or misbranded;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">federal civil and criminal false claims laws, including the civil False Claims Act, and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payers that are false or fraudulent, or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the Health Insurance Portability and Accountability Act of 1996 (HIPAA) and its implementing regulations, which impose certain requirements relating to the privacy, security and transmission of individually identifiable health information on covered entities and business associates that access such information on behalf of a covered entity; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">state law equivalents of each of the above federal laws;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the Open Payments program of the Patient Protection and Affordable Care Act, as amended by the Healthcare and Education Reconciliation Act (PPACA), which was created under the Physician Payments Sunshine Act and its implementing regulations and requires certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually to the government information related to certain payments and other transfers of value to physicians (as defined by such law) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">state and local laws and regulations that require drug manufacturers to file reports relating to marketing activities, payments and other remuneration and items of value provided to healthcare professionals and entities, as well as state and local laws requiring the registration of pharmaceutical sales representatives; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">state and federal pharmaceutical price and price reporting laws and regulations that require us to provide notice of price increases or the introduction of new high-cost products, and/or file complex ancillary reports concerning prices and pricing and discount practices.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may be subject to the Foreign Corrupt Practices Act, a U.S. law which regulates certain financial relationships with foreign government officials (which could include, for example, medical professionals employed by national healthcare programs) and its foreign equivalents, as well as federal and state consumer protection and unfair competition laws.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These federal and state healthcare laws and regulations govern drug marketing practices, including off-label promotion. If our operations are found, or even alleged, to be in violation of the laws described above or other governmental regulations that apply to us, we, or our officers or employees, may be subject to significant penalties, including administrative civil and criminal penalties, damages, fines, regulatory penalties, the curtailment or restructuring of our operations, exclusion from participation in Medicare, Medicaid and other federal and state healthcare programs, imprisonment, reputational harm, additional reporting requirements and oversight, any of which would adversely affect our ability to sell our products and operate our business and also adversely affect our financial results. Of particular concern are suits filed under the civil False Claims Act, known as &#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; actions, which can be brought by any individual on behalf of the government. Under the False Claims Act, these individuals, commonly known as relators or &#8220;whistleblowers,&#8221; may potentially share in amounts paid by the entity to the government in fines or settlement. When an entity is determined to have violated the civil False Claims Act, or settles a lawsuit brought pursuant to the False Claims Act to avoid further prosecution, it may be required to pay up to three times the actual damages sustained by the government, plus civil penalties for each separate false claim. Defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources. Therefore, if any such action is brought against us, our business may be impaired, even if we are ultimately successful in our defense.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Current healthcare laws and regulations in the U.S. and future legislative or regulatory reforms to the U.S. healthcare system may affect our ability to commercialize our marketed products profitably.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal and state governments in the U.S. are considering legislative and regulatory proposals to change the U.S. healthcare system in ways that could affect our ability to continue to commercialize CABOMETYX and COMETRIQ profitably. Similarly, among policy makers and payers, there is significant interest in promoting such changes with the stated goals of containing healthcare costs, improving quality and expanding patient access. The life sciences industry and specifically the market for the sale, insurance coverage and distribution of pharmaceuticals has been a particular focus of these efforts and would likely be significantly affected by any major legislative or regulatory initiatives.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face related uncertainties as a result of efforts to repeal, substantially modify or invalidate some or all of the provisions of the PPACA. Notably, in December 2018, a Texas U.S. District Court Judge ruled that the PPACA is unconstitutional in its entirety because the penalty enforcing the &#8220;individual mandate&#8221; was repealed by Congress as part of the Tax Cuts and Jobs Act of 2017. Then, in December 2019, the U.S. Court of Appeals for the 5th Circuit upheld this District Court ruling that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the PPACA are invalid as well. While the U.S. Supreme Court has agreed to review an appeal of the 5th Circuit&#8217;s decision in November 2020, it is unclear how this decision, future decisions, subsequent appeals and other efforts will impact the PPACA. Additionally, the 2020 federal spending package permanently repealed, effective January 1, 2020, the PPACA-mandated &#8220;Cadillac&#8221; tax on high-cost employer-sponsored health coverage and medical device taxes, and, effective January 1, 2021, also eliminates the health insurer tax. Although such efforts have not significantly impacted our business to date, there is no assurance that the repeal, modification or invalidation of some or all of the provisions of the PPACA in the future, will not have a material adverse impact on our business, financial </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">condition and results of operations, and we cannot predict how future federal or state legislative or administrative changes relating to healthcare reform will affect our business.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there are pending federal and state-level legislative proposals that would significantly expand government-provided health insurance coverage, ranging from establishing a single-payer, national health insurance system to more limited &#8220;buy-in&#8221; options to existing public health insurance programs, each of which could have a significant impact on the healthcare industry. It is also possible that additional governmental actions will be taken to address the ongoing COVID-19 pandemic, and that such actions would have a significant impact on these public health insurance programs. While we cannot predict how future legislation (or enacted legislation that has yet to be implemented) will affect our business, such proposals could have the potential to impact access to and sales of our products.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of these developments and trends, third-party payers are increasingly attempting to contain healthcare costs by limiting coverage and the level of reimbursement of new drugs. These entities could refuse, limit or condition coverage for our products, such as by using tiered reimbursement or pressing for new forms of contracting, including, for example, the movement by insurers towards &#8220;value-based&#8221; contracting, any of which could adversely affect product sales. Furthermore, the expansion of the 340B Drug Discount Program has increased the number of purchasers who claim eligibility for significant discounts on branded drugs, including our marketed products. Due to the current volatility in regulatory and market dynamics, we are unable to predict the impact of any legislative, regulatory, third-party payer or policy actions, including potential cost containment and healthcare reform measures. If enacted, any such measures could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pricing for pharmaceutical products in the U.S. has come under increasing attention and scrutiny by federal and state governments, legislative bodies and enforcement agencies. These activities may result in actions that have the effect of reducing our revenue or harming our business or reputation.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been several recent U.S. Congressional inquiries, hearings and proposed and enacted federal legislation and rules, as well as Executive Orders, designed to, among other things: reduce or limit the prices of drugs and make them more affordable for patients (including, for example, by tying the prices that Medicare reimburses for physician-administered drugs to the prices of drugs in other countries); reform the structure and financing of Medicare Part D pharmaceutical benefits, including through increasing manufacturer contributions to offset Medicare beneficiary costs; bring more transparency to drug pricing rationale and methodologies; revise rebate payments for prescription drugs under Medicaid and the methodologies to calculate average manufacturer price and best price; and facilitate the importation of certain lower-cost drugs from other countries. While we cannot know the final form of any such legislative, regulatory and/or administrative measures, some of the pending legislative proposals or executive rulemaking, such as those incorporating International Pricing Index or Most-Favored-Nation models, if enacted, would likely have a significant and far-reaching impact on the biopharmaceutical industry and therefore also likely have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with its evaluation of proposals concerning the pricing of, and access to, pharmaceutical products, many companies in our industry have received governmental requests for documents and information relating to drug pricing and patient support programs. We could receive a similar request, which would require us to incur significant expense and divert the attention of management. Additionally, to the extent there are findings, or even allegations, of improper conduct on the part of the company, these findings could further harm our business, reputation and/or prospects.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including restrictions on pricing or reimbursement at the state government level, limitations on discounts to patients, marketing cost disclosure and transparency measures, and, in some cases, policies to encourage importation from other countries (subject to federal approval) and bulk purchasing, including the National Medicaid Pooling Initiative. For example, California adopted SB-17, which requires, among other provisions, pharmaceutical manufacturers to provide advance notice of price increases above a defined threshold to certain purchasers and related reports to the government. Such obligations to provide notices of price increases to purchasers may influence customer ordering patterns for CABOMETYX and COMETRIQ, which in turn may increase the volatility of our revenues as a reflection of changes in inventory volumes. Furthermore, adoption of these drug pricing transparency regulations, and our associated compliance obligations, may increase general and administrative costs and/or diminish our revenues as a result of the imposition of caps on pricing and price increases. Therefore, the implementation of these cost-containment measures or other healthcare reforms may result in fluctuations in our results of operations and limit our ability to generate product revenue or commercialize our products.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lengthy regulatory pricing and reimbursement procedures and cost control initiatives imposed by governments outside the U.S. could delay the marketing of and/or result in downward pressure on the price of our approved products resulting in a decrease in revenue.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the U.S., particularly in the EU, the pricing and reimbursement of prescription pharmaceuticals is generally subject to governmental control. In EU countries, pricing and reimbursement negotiations with governmental authorities or payers can take six to 12 months or longer after the initial marketing authorization is granted for a product, or after the marketing authorization for a new indication is granted. This can substantially delay broad availability of the product. To obtain reimbursement and/or pricing approval in some countries, our collaboration partner Ipsen may also be required to conduct a study that seeks to establish the cost effectiveness of CABOMETYX compared with other available established therapies. The conduct of such a study could also result in delays in the commercialization of CABOMETYX. Additionally, cost-control initiatives, increasingly based on affordability, could decrease the price we and Ipsen might establish for CABOMETYX, which would result in lower license revenues to us.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A significant and prolonged economic downturn, whether globally or just within the U.S., could have a substantial impact on our revenues and financial condition. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues are substantially dependent on the net pricing that we ultimately realize in payment for our marketed products, and commercial third-party payers do not receive the same degree of discounts and allowances that we provide to government payers. In the event of a significant and prolonged economic downturn, the number of patients enrolled in commercial health insurance programs is likely to decrease, particularly in the U.S. where workforce reductions could cause widespread loss of the private health insurance coverage typically provided by employers, and a commensurate shift of eligible individuals to government insurance programs or to the circumstance of lacking health insurance coverage altogether. The effects of the COVID-19 pandemic, among other catalysts, have already caused a downturn in the U.S. and global economy and significant levels of unemployment, and the duration and severity of this economic downturn are not yet known. Depending on the duration and severity of the COVID-19 pandemic, as well as other factors, we could experience a substantial decrease in revenues as a result of the increase in gross-to-net discounting applied to the price of our products due to a substantial shift from private health insurance coverage to government insurance coverage, and also a significant increase in demand for our patient assistance and/or free drug program, all or any of which would adversely affect our product revenues.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Enhanced governmental and private scrutiny over, or investigations or litigation involving, pharmaceutical manufacturer donations to patient assistance programs offered by charitable foundations could negatively impact our business practices, harm our reputation, divert the attention of management and increase our expenses</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To help patients afford our products, we have a patient assistance program and also occasionally make donations to independent charitable foundations that help financially needy patients. These types of programs designed to assist patients with affording pharmaceuticals have become the subject of Congressional interest and enhanced government scrutiny. The U.S. Department of Health and Human Services Office of Inspector General established specific guidelines permitting pharmaceutical manufacturers to make donations to charitable organizations that provide co-pay assistance to Medicare patients, provided that manufacturers meet certain specified compliance requirements. In the event we make such donations but are found not to have complied with these guidelines and other laws or regulations respecting the operation of these programs, we could be subject to significant damages, fines, penalties or other criminal, civil or administrative sanctions or enforcement actions. We also rely on a third-party hub provider and exercise oversight to monitor patient assistance program activities.  Hub providers are generally hired by manufacturers to assist patients with insurance coverage, financial assistance and treatment support after the patients receive a prescription from their healthcare professional. For manufacturers of specialty pharmaceuticals (including our marketed products), the ability to have a single point of contact for their therapies helps ensure efficient medication distribution to patients. Accordingly, our hub activities are also subject to scrutiny and may create risk for us if not conducted appropriately. A variety of entities, including independent charitable foundations and pharmaceutical manufacturers, but not including our company, have received subpoenas from the U.S. Department of Justice and other enforcement authorities seeking information related to their patient assistance programs and support. Should we receive a subpoena or other process, regardless of whether we are ultimately found to have complied with the regulations governing patient assistance programs, this type of government investigation could negatively impact our business practices, harm our reputation, divert the attention of management and increase our expenses.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to laws and regulations relating to privacy, data protection and the collection and processing of personal data. Failure to maintain compliance with these regulations could create additional liabilities for us.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The legislative and regulatory landscape for privacy and data protection continues to evolve globally and in the U.S. For example, the California Consumer Privacy Act of 2018 (CCPA) went into operation on January 1, 2020 and affords California residents expanded privacy rights and protections, including civil penalties for violations and statutory damages under a private right of action for data security breaches.  Similar legislative proposals are being advanced in other states and Congress is also considering federal privacy legislation. In addition, most healthcare providers are subject to privacy and security requirements under HIPAA. Although we are not directly subject to HIPAA, we could be subject to criminal penalties if we knowingly encourage, assist or otherwise facilitate a HIPAA-covered entity (or its business associate) to use or disclose individually identifiable health information in a manner not authorized or permitted by HIPAA. Other countries also have, or are developing, laws governing the collection, use and transmission of personal information. For example, the EU General Data Protection Regulation 2016/679 (GDPR) regulates the processing of personal data of individuals within the EU, even if, under certain circumstances, that processing occurs outside the EU, and also restricts transfers of such data to countries outside of the EU, including the U.S. Should we fail to provide adequate privacy or data security protections or maintain compliance with these laws and regulations, including the CCPA and GDPR, we could be subject to sanctions or other penalties, litigation or an increase in our cost of doing business.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legislation and regulatory action designed to facilitate the development, approval and adoption of generic drugs in the U.S., and the entrance of generic competitors, could limit the commercial potential of our products, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the FDCA, the FDA can approve an ANDA for a generic version of a branded drug without the applicant undertaking the human clinical testing necessary to obtain approval to market a new drug. The FDA can also approve a New Drug Application (NDA) under section 505(b)(2) of the FDCA that relies in whole or in part on the agency&#8217;s findings of safety and/or effectiveness for a previously approved drug. Both the ANDA and 505(b)(2) processes are discussed in more detail under &#8220;Item 1. Business&#8212;Government Regulation&#8212;FDA Review and Approval&#8221; in our Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC on February 25, 2020. In either case, if an ANDA or 505(b)(2) applicant submits an application referencing one of our marketed products prior to the expiry of one or more our </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Orange Book</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-listed patents for the applicable product, we may litigate with the potential generic competitor to protect our patent rights, which would result in substantial costs and divert the attention of management, and could have an adverse impact on our stock price. For example, we received Paragraph IV certification notice letters from MSN concerning the ANDA that it had filed with the FDA seeking approval to market a generic version of CABOMETYX tablets. It is possible that MSN or other companies, following FDA approval of an ANDA or 505(b)(2) NDA, could introduce generic versions of our marketed products before our patents expire if they do not infringe our patents or if it is determined that our patents are invalid or unenforceable, and we expect that generic cabozantinib products would be offered at a significantly lower price compared to our marketed cabozantinib products. Therefore, regardless of the regulatory approach, the introduction of a generic version of cabozantinib could significantly decrease our revenues and thereby materially harm our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. federal government has also taken numerous legislative and regulatory actions to expedite the development and approval of generic drugs and biosimilars. In August 2017, President Trump signed the FDA Reauthorization Act of 2017, which reauthorized the FDA user fee programs for prescription drugs, generic drugs, medical devices, and biosimilars, under which applicants for such products partially pay for the FDA&#8217;s pre-market review of their product candidates and pay other specified fees. The legislation also includes, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter alia,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> measures to expedite the development and approval of generic products, where generic competition is lacking even in the absence of exclusivities or listed patents. In addition, the FDA has also released a Drug Competition Action Plan, which proposes actions to broaden access to generic drugs and lower consumers&#8217; healthcare costs by, among other things, improving the efficiency of the generic drug approval process and supporting the development of complex generic drugs, and the FDA has taken steps to implement this plan. Moreover, both Congress and the FDA are considering various legislative and regulatory proposals focused on drug competition, including legislation focused on drug patenting and provision of drug to generic applicants for testing. For example, the Creating and Restoring Equal Access To Equivalent Samples (CREATES) Act of 2019, signed into law as part of the 2019 year-end federal spending package, purports to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products, including by allowing generic manufacturers access to branded drug samples. While the FDA has yet to issue guidance on the provisions of CREATES, its provisions do have the potential to facilitate the development and future approval of generic versions of our products, introducing generic competition that could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical testing of cabozantinib for new indications, or of new potential product candidates, is a lengthy, costly, complex and uncertain process and may fail to demonstrate safety and efficacy.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials are inherently risky and may reveal that cabozantinib, despite its approval for certain indications, or a new product candidate, is ineffective or has an unacceptable safety profile with respect to an intended use. Such results may significantly decrease the likelihood of regulatory approval of that product for a particular indication. Moreover, the results of preliminary studies do not necessarily predict clinical or commercial success, and late-stage or other potentially label-enabling clinical trials may fail to confirm the results observed in early-stage trials or preliminary studies. Although we have established timelines for manufacturing and clinical development of cabozantinib and our other product candidates based on existing knowledge of our compounds in development and industry metrics, we may not be able to meet those timelines.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may experience numerous unforeseen events, during or as a result of clinical investigations, that could delay or prevent commercialization of cabozantinib (or of other product candidates) in new indications, and in some cases, as described in the risk factor titled, &#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If the COVID-19 pandemic is further prolonged or becomes more severe, our business operations and corresponding financial results could suffer, which could have a material adverse impact on our financial condition and prospects for growth,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; the COVID-19 pandemic has already increased and may further increase the potential for such developments to occur. These may include:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">lack of acceptable efficacy or a tolerable safety profile;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">negative or inconclusive clinical trial results that require us to conduct further testing or to abandon projects;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">discovery or commercialization by our competitors of other compounds or therapies that show significantly improved safety or efficacy compared to cabozantinib or our other product candidates;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our inability to identify and maintain a sufficient number of trial sites; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">lower-than-anticipated patient registration or enrollment in our clinical testing; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">failure by our collaboration partners to provide us with an adequate and timely supply of product that complies with the applicable quality and regulatory requirements for a combination trial; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">failure of our third-party contract research organizations or investigators to satisfy their contractual obligations, including deviating from any trial protocols; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">withholding of authorization from regulators or institutional review boards to commence or conduct clinical trials or delays, suspensions or terminations of clinical research for various reasons, including noncompliance with regulatory requirements or a determination by these regulators and institutional review boards that participating patients are being exposed to unacceptable health risks.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If there are further delays in or termination of the clinical testing of cabozantinib or our other product candidates due to any of the events described above or otherwise, including as a result of the COVID-19 pandemic, our expenses could increase and our ability to generate revenues could be impaired, either of which could adversely impact our financial results. Furthermore, we rely on our collaboration partners to fund a significant portion of our clinical development programs. Should one or all of our collaboration partners decline to support future planned clinical trials, we will be entirely responsible for financing the further development of cabozantinib or our other product candidates and, as a result, we may be unable to execute our current business plans, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to pursue the further development of cabozantinib or our other product candidates or meet current or future requirements of the FDA or regulatory authorities in other jurisdictions in accordance with our stated timelines or at all. Our planned clinical trials may not begin on time, or at all, may not be completed on schedule, or at all, may not be sufficient for registration of our product candidates or may not result in an approvable product. The duration and the cost of clinical trials vary significantly as a result of factors relating to the clinical trial, including, among others: characteristics of the product candidate under investigation; the number of patients who ultimately participate in the clinical trial; the duration of patient follow-up; the number of clinical sites included in the trials; and the length of time required to enroll eligible patients.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any delay could limit our ability to generate revenues, cause us to incur additional expense and cause the market price of our common stock to decline significantly. Our partners under our collaboration agreements may experience similar risks with respect to the compounds we have out-licensed to them. If any of the events described above were to occur with such programs or compounds, the likelihood of receipt of milestones and royalties under such collaboration agreements could decrease.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy and uncertain and may not result in regulatory approvals for cabozantinib or our other product candidates, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activities associated with the research, development and commercialization of cabozantinib and our other product candidates are subject to extensive regulation by the FDA and other regulatory agencies in the U.S., as well as by comparable authorities in other countries. The processes of obtaining regulatory approvals in the U.S. and other foreign jurisdictions is expensive and often takes many years, if approval is obtained at all, and they can vary substantially based upon the type, complexity and novelty of the product candidates involved. For example, before an NDA or sNDA can be submitted to the FDA, or a marketing authorization application to the EMA or any application or submission to regulatory authorities in other jurisdictions, the product candidate must undergo extensive clinical trials, which can take many years and require substantial expenditures.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any clinical trial may fail to produce results satisfactory to the FDA or regulatory authorities in other jurisdictions. The FDA has substantial discretion in the approval process and may refuse to approve any NDA or sNDA or decide that our data is insufficient for approval and require additional preclinical, clinical or other studies. For example, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent regulatory approval of cabozantinib for any individual additional indications. In addition, we may encounter delays or rejections based upon changes in policy, which could cause delays in the approval or rejection of an application for cabozantinib or for our other product candidates.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if the FDA or a comparable authority in another jurisdiction approves cabozantinib for one or more new indications, such approval may be limited, imposing significant restrictions on the indicated uses, conditions for use, labeling, distribution, and/or production of the product and could impose requirements for post-approval studies, including additional research and clinical trials, all of which may result in significant expense and limit our and our collaboration partners&#8217; ability to commercialize cabozantinib in one or more new indications. For example, based on the regulatory feedback from the FDA, and if supported by the clinical data from COSMIC-021, we intend to file with the FDA for accelerated approval of cabozantinib in an mCRPC indication as early as 2021. We expect that as a condition of any potential approval under the FDA's accelerated approval pathway, the FDA will require us to perform confirmatory post-marketing clinical trials to confirm the clinical benefit, if any, of cabozantinib in combination with Roche&#8217;s atezolizumab in patients with locally advanced or metastatic solid tumors, such as mCRPC. Failure to complete any post-marketing requirements in accordance with the timelines and conditions set forth by the FDA could significantly increase costs or delay, limit or ultimately restrict the commercialization of cabozantinib in any additional indications. Further, these regulatory agencies could also impose various administrative, civil or criminal sanctions for failure to comply successfully with regulatory requirements, including withdrawal of product approval.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, on March 27, 2020, Congress enacted the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) in response to the COVID-19 pandemic. Amongst other provisions, the CARES Act made a number of changes to the FDCA aimed at preventing drug shortages. While we are still evaluating these and other CARES Act changes, these changes could impact our business. For example, in light of the COVID-19 pandemic, the FDA has issued a number of guidance documents describing the agency&#8217;s expectations for how drug manufacturers should comply with various FDA requirements during the pandemic, including with respect to conducting clinical trials, distributing drug samples, and reporting post-marketing adverse events. In addition, as a result of the COVID-19 pandemic, there has been increasing political and regulatory scrutiny of foreign-sourced drugs and foreign drug supply chains, resulting in proposed legislative and executive actions to incentivize or compel drug manufacturing operations to relocate to the United States. These political and regulatory developments and any further guidance documents issued by FDA that impact the requirements to which we are subject, as well as any equivalent federal or state legislative or regulatory initiatives, or similar measures outside of the United States, could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to expand our development pipeline, which could limit our growth and revenue potential.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is focused on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. In this regard, we have invested in substantial technical, financial and human resources toward internal drug discovery activities with the goal of identifying new product candidates to advance into clinical trials. Notwithstanding this investment, we temporarily suspended internal drug discovery in our laboratories due to the COVID-19 pandemic, among other limitations to our programs described in the risk factor titled, &#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If the COVID-19 pandemic is further prolonged or becomes more severe, our business operations and corresponding financial results could suffer, which could have a material adverse impact on our financial condition and prospects for growth.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;  While we have since partially resumed our drug </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">discovery operations, even assuming we successfully return these operations to full capacity in the future, many programs that initially show promise will ultimately fail to yield product candidates for multiple reasons. For example, product candidates may, on further study, be shown to have inadequate efficacy, harmful side effects, suboptimal pharmaceutical profiles or other characteristics suggesting that they are unlikely to be commercially viable products.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apart from our internal drug discovery efforts, our strategy to expand our development pipeline is also dependent on our ability to successfully identify and acquire or in-license relevant product candidates.&#160;However, the in-licensing and acquisition of product candidates is a highly competitive area, and many other companies are pursuing the same or similar product candidates to those that we may consider attractive. In particular, larger companies with more capital resources and more extensive clinical development and commercialization capabilities may have a competitive advantage over us.&#160;Furthermore, companies that perceive us to be a competitor may be unwilling to assign or license rights to us.&#160;We may also be unable to in-license or acquire additional product candidates on acceptable terms that would allow us to realize an appropriate return on our investment. Even if we succeed in our efforts to obtain rights to suitable product candidates, the competitive business environment may result in higher acquisition or licensing costs, and our investment in these potential products will remain subject to the inherent risks associated with the development and commercialization of new medicines. In certain circumstances, we may also be reliant on the licensor for the continued development of the in-licensed technology and their efforts to safeguard their underlying intellectual property.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to acquisitions, we may not be able to integrate the target company successfully into our existing business, maintain the key business relationships of the target, or retain key personnel of an acquired business. Furthermore, we could assume unknown or contingent liabilities or incur unanticipated expenses. Any acquisitions or investments made by us also could result in our spending significant amounts, issuing dilutive securities, assuming or incurring significant debt obligations and contingent liabilities, incurring large one-time expenses and acquiring intangible assets that could result in significant future amortization expense and significant write-offs, any of which could harm our financial condition and results of operations. If our internal drug discovery or business development efforts do not result in suitable product candidates, our business and prospects for growth could suffer.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Increasing use of social media could give rise to liability and result in harm to our business.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our employees are increasingly utilizing social media tools and our website as a means of communication. For example, we use Facebook and Twitter to communicate with the medical community and the investing public, although we do not intend to disclose material, nonpublic information through these means. Despite our efforts to monitor social media communications, there is risk that the unauthorized use of social media by us or our employees to communicate about our products or business, or any inadvertent disclosure of material, nonpublic information through these means, may result in violations of applicable laws and regulations, which may give rise to liability and result in harm to our business. In addition, there is also risk of inappropriate disclosure of sensitive information, which could result in significant legal and financial exposure and reputational damages that could potentially have a material adverse impact on our business, financial condition and results of operations. Furthermore, negative posts or comments about us or our products on social media could seriously damage our reputation, brand image and goodwill.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Capital Requirements, Accounting and Financial Results</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our profitability could be negatively impacted by our extensive clinical development, business development and commercialization activities for cabozantinib and pipeline expansion efforts relative to the revenues we generate.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we reported net income of $83.4 million for the nine months ended September&#160;30, 2020 and $321.0 million for the year ended December 31, 2019, respectively, we reported a net loss of $32.0 million for the three months ended September&#160;30, 2020. We may not be able to resume, maintain or increase profitability on a quarterly or annual basis, and we are unable to predict the extent of future profits or losses. The amount of our net profits or losses will depend, in part, on: the level of sales of CABOMETYX and COMETRIQ in the U.S.; achievement of clinical, regulatory and commercial milestones, if any, under our collaboration agreements; the amount of royalties from sales of CABOMETYX and COMETRIQ outside of the U.S. under our collaboration agreements; other collaboration revenues; and the level of our expenses, including for development and commercialization activities for cabozantinib and for any pipeline expansion efforts. We expect to continue to spend substantial amounts to fund the continued development of cabozantinib for additional indications and the commercialization of our approved products. In addition, we intend to continue to expand our product pipeline through our internal drug discovery efforts and the execution of additional partnerships through business development activities or strategic transactions that align with our oncology drug development, regulatory and commercial expertise, which efforts could involve substantial costs. To offset these costs in the future, we will need to generate </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">substantial revenues. If these costs exceed our current expectations, or we fail to achieve anticipated revenue targets, the market value of our common stock may decline.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our financial outlook may not be realized.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, in press releases and otherwise, we may publish estimates, forecasts or other forward-looking statements regarding our future financial or operating results, including estimated revenues, expenses and earnings. Any forecast of our future performance reflects various assumptions. These assumptions are subject to significant risks and uncertainties, and as a matter of course, any number of them may prove to be incorrect. Further, the achievement of any forecast depends on numerous assumptions and other factors (including those described in this discussion), many of which are beyond our control. Moreover, the impact of the COVID-19 pandemic on our profitability, especially if it is further prolonged or grows in severity, is difficult to predict. As a result, we cannot be certain that our performance will be consistent with any management estimates or forecasts or that the variation from such estimates or forecasts will not be material and adverse. Current and potential stockholders are cautioned not to base their entire analysis of our business and prospects upon isolated estimates or forecasts, but instead are encouraged to utilize our entire publicly available mix of historical and forward-looking information, as well as other available information regarding us, our products, the competitive landscape for our products, our commercialization, development and regulatory efforts, as well as those of our collaboration partners, and the biotechnology and pharmaceutical industry generally when evaluating our prospective financial or operating results.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If additional capital is not available to us when we need it, we may be unable to expand our product offerings and maintain business growth.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and investments were $1.5 billion as of September&#160;30, 2020, compared to $1.4 billion as of December&#160;31, 2019. Our business operations grew substantially during 2019 and the first nine months of 2020. In order to maintain business growth during the remainder of 2020, we plan to continue to execute on our U.S. commercialization plans for CABOMETYX, while reinvesting in our product pipeline through the continued development of cabozantinib and our other product candidates, internal discovery activities, and the execution of strategic transactions. Our ability to achieve these business objectives will depend on many factors including but not limited to: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the commercial success of both CABOMETYX and COMETRIQ and the revenues we generate from those approved products;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">costs associated with maintaining our expanded sales, marketing, market access, medical affairs and product distribution capabilities for CABOMETYX and COMETRIQ;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the achievement of stated regulatory and commercial milestones and royalties paid under our collaboration agreements with Ipsen and Takeda; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the commercial success of and revenues generated by products marketed under our collaboration and license agreements;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">future clinical trial results;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the impact of the COVID-19 pandemic on our ability to conduct critical business operations, including internal drug discovery activities, clinical trials and commercial operations;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the level of our investments in the expansion of our pipeline through internal drug discovery and business development activities;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the number and size of clinical trials we conduct and the cost of drug supply for such clinical trials evaluating our products with other therapeutic agents;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">trends and developments in the pricing of oncologic therapeutics in the U.S. and abroad, especially in the EU;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">scientific developments in the market for oncologic therapeutics and the timing of regulatory approvals for competing oncologic therapies; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the filing, maintenance, prosecution, defense and enforcement of patent claims and other intellectual property rights.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commitment of cash resources to CABOMETYX and the reinvestment in our product pipeline through the continued development of cabozantinib and increasing internal drug discovery activities, as well as through the execution of strategic transactions, could require us to obtain additional capital. We may seek such additional capital through some or all of the following methods: corporate collaborations; licensing arrangements; and public or private debt or equity financings. Our ability to obtain additional capital may depend on prevailing&#160;economic conditions&#160;and financial, business and other </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">factors beyond our control. Disruptions in the U.S. and&#160;global&#160;financial markets, including disruptions that have resulted and may continue to result from the COVID-19 pandemic and the related downturn in the U.S. and global economy, as well as future potential U.S. federal government shutdowns, rising interest rate environments, increased or changed tariffs and trade restrictions or otherwise, may adversely impact the availability and cost of credit, as well as our ability to raise additional funds in the capital markets. Economic and capital markets conditions have been, and continue to be, volatile. Continued instability in these market conditions may limit our ability to access the capital necessary to fund and grow our business.&#160;In particular, our inability to access additional funds, whether due to the COVID-19 pandemic or otherwise, could in the future inhibit our ability to engage in larger scale strategic transactions or investments. We do not know whether additional capital will be available when needed, or that, if available, we will obtain additional capital on terms favorable to us or our stockholders. If we are unable to raise additional funds when we need them, we may be unable to expand our product offerings and maintain business growth, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our financial results are impacted by management&#8217;s selection of accounting methods, certain assumptions and estimates and future changes in accounting standards.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accounting policies and methods are fundamental to how we record and report our financial condition and results of operations. Our management must exercise judgment in selecting and applying many of these accounting policies and methods so they comply with generally accepted accounting principles and reflect management&#8217;s judgment of the most appropriate manner to report our financial condition and results of operations. In some cases, management must select the accounting policy or method to apply from two or more alternatives, any of which may be reasonable under the circumstances, yet may result in our reporting materially different results than would have been reported under a different alternative.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain accounting policies are critical to the presentation of our financial condition and results of operations. We believe our critical accounting policies relating to revenue recognition, clinical trial accruals, inventory, stock-based compensation and income taxes reflect the more significant estimates and judgments used in the preparation of our Consolidated Financial Statements. Although we base our estimates and judgments on historical experience, our interpretation of existing accounting literature and on various other assumptions that we believe to be reasonable under the circumstances, if our assumptions prove to be materially incorrect, actual results may differ materially from these estimates.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, future changes in financial accounting standards may cause adverse, unexpected revenue fluctuations and affect our financial position or results of operations. New pronouncements from the Financial Accounting Standards Board and varying interpretations of pronouncements have occurred with frequency in the past and are expected to occur again in the future and, as a result, we may be required to make changes in our accounting policies. Those changes could adversely affect our reported revenues and expenses, our other results of operations or our current financial position.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our effective tax rate may fluctuate, and we may incur obligations in tax jurisdictions in excess of accrued amounts.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to income tax in the U.S. as well as numerous U.S. states and territories, municipalities, and other local jurisdictions. As a result, our effective tax rate is derived from various factors including the mix of forecast and actual earnings and applicable tax rates in the various places that we operate, the accounting for stock options and stock-based awards, and research and development spending. In preparing our financial statements, we estimate the amount of tax that will become payable in each jurisdiction. Our effective tax rate, however, may be different than experienced in the past due to numerous factors, including changes in tax laws, changes in the mix of our earnings from state to state, the results of examinations and audits of our tax filings, or our inability to secure or sustain acceptable agreements with tax authorities. Any of these factors could cause our effective tax rate to fluctuate.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use net operating losses and tax credits to offset future taxable income may be subject to limitations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2019, we had federal and, subject to the recent California franchise tax law change affecting California state net operating losses mentioned below, state net operating loss carryforwards of approximately $675 million. Portions of the federal and state net operating loss carryforwards will begin to expire, if not utilized, beginning in 2035 for federal income tax purposes and 2020 for state income tax purposes. Portions of these net operating loss carryforwards could expire unused and be unavailable to offset future income tax liabilities. Under the Internal Revenue Code (the Code) and similar state provisions, certain substantial changes in our ownership could result in an annual </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">limitation on the amount of net operating loss carryforwards that can be utilized in future years to offset future taxable income. The annual limitation may result in the expiration of a portion of our net operating losses and credit carryforwards before utilization. Based on our review and analysis, we concluded, as of December 31, 2019, that an ownership change, as defined under Section 382, had not occurred. However, if there is an ownership change under Section 382 of the Code in the future, we may not be able to utilize a material portion of our net operating losses. Furthermore, our ability to utilize our net operating losses is conditioned upon our maintaining profitability and generating U.S. federal taxable income. In addition, at the state level, there may be periods during which the use of net operating losses is suspended or otherwise limited. For example, California recently imposed limits on the usability of California state net operating losses to offset taxable income in tax years beginning after 2019 and before 2023.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The United Kingdom&#8217;s (UK&#8217;s) withdrawal from the EU&#160;may have a negative effect on global economic conditions, financial markets and our business.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the ratification of the Withdrawal Agreement by the European Parliament and UK Parliament, the UK left the EU on January 31, 2020 (commonly referred to as &#8220;Brexit&#8221;). The Withdrawal Agreement provides for a transition period until December 31, 2020, during which the UK remains in the single market and customs union and the free movement of goods, services, people and capital will continue, in order to ensure frictionless trade and business continuity until a long-term relationship is agreed. At the end of transition, the UK&#8217;s relationship with the EU will be determined by the new agreements it has entered into on trade and other areas of cooperation. The new agreements must be reached before the transition period ends. If not, the UK would have to rely on previous international conventions for security cooperation and would trade with the EU on World Trade Organization terms. The exception is Northern Ireland, whose trade in goods with the EU would be covered by the provisions in the Northern Ireland Protocol. As a result of the COVID-19 pandemic, planned negotiating rounds for the UK&#8217;s future relationship with the EU have not been progressing at a pace that would facilitate a final agreement on trade and cooperation between the UK and the EU prior to December 31, 2020. Under the formal withdrawal arrangements between the UK and the EU, the parties had until June 30, 2020 to agree to extend the transition period if required, and no such extension was agreed prior to such date. Under these circumstances, it is uncertain whether the UK and EU would agree to extend the transition period beyond December 31, 2020. Given the lack of comparable precedent, it is unclear what financial, trade, regulatory and legal implications Brexit will have and how it might affect us. For example, we rely on third-party contract manufacturing organization facilities located in the UK, responsible for packaging, labeling, storing and subsequently distributing supplies of our product to the EU. Any tariffs, differing regulatory requirements and other restrictions on the free movement of goods between the UK and the EU that ultimately result from Brexit may have an adverse impact on this part of our supply chain. Trade restrictions, changes to the regulatory approval or drug cost reimbursement systems, and additional administrative costs may impede the ability of our collaboration partner Ipsen to market our products in Europe. Furthermore, the initial announcement of Brexit caused significant volatility in global stock markets and currency exchange rate fluctuations; therefore, the Brexit transition may continue to adversely affect European and global economic and market conditions, which may cause third-party payers, including governmental organizations, to closely monitor their costs and reduce their spending budgets, and which could contribute to instability in the global financial and foreign exchange markets. Any of these effects of Brexit could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Relationships with Third Parties</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our clinical and commercial collaborations with major companies make us reliant on those companies for their continued performance, which subjects us to a number of risks.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established clinical and commercial collaborations with leading biotechnology, biopharmaceutical and pharmaceutical companies, including, Ipsen, Takeda, Roche and Genentech, BMS and Daiichi Sankyo, for the development and commercialization of our products, and our dependence on these collaboration partners subjects us to, a number of risks, including:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our collaboration partners&#8217; decision to terminate our collaboration, or their failure to comply with the terms of our collaboration agreements and related ancillary agreements, either intentionally or as a result of negligent performance;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our inability to control the amount and timing of resources that our collaboration partners devote to the development or commercialization of our products;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the possibility that our collaboration partners may stop or delay clinical trials, fail to supply us on a timely basis with product required for a combination trial (including as a result of the COVID-19 pandemic), or deliver product that fails to meet appropriate quality and regulatory standards;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">disputes that may arise between us and our collaboration partners that result in the delay or termination of the development or commercialization of our drug candidates, or that diminish or delay receipt of the economic benefits we are entitled to receive under the collaboration, or that result in costly litigation or arbitration;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the possibility that our collaboration partners may experience financial difficulties, including, without limitation, difficulties arising from the impact of the COVID-19 pandemic which prevent them from fulfilling their obligations under our agreements;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our collaboration partners&#8217; inability to obtain regulatory approvals in a timely manner, or at all; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our collaboration partners&#8217; failure to properly maintain or defend our intellectual property rights or their use of our intellectual property rights or proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property rights or expose us to potential litigation.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these risks materialize, we may not receive collaboration revenues or otherwise realize anticipated benefits from such collaborations, and our product development efforts and prospects for growth could be delayed or disrupted, all of which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our growth potential is dependent upon companies with which we have entered into in-licensing collaborations and similar business development relationships.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To expand our early-stage product pipeline, we have augmented our internal drug discovery activities with multiple in-licensing collaborations with smaller, discovery-focused biotechnology companies, including Aurigene, Iconic, StemSynergy, Invenra, Catalent and NBE. Our dependence on our relationships with these in-licensing partners subjects us to numerous risks, including:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our in-licensing partners&#8217; decision to terminate our relationship, or their failure to comply with the terms of our agreements, either intentionally or as a result of negligent performance;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">disputes that may arise between us and our collaboration partners that result in the delay or termination of research activities with respect to the licensed assets;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the possibility that our in-licensing partners may experience financial difficulties, including, without limitation, difficulties arising from the impact of the COVID-19 pandemic, which prevent them from fulfilling their obligations under our agreements;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our in-licensing partners&#8217; failure to properly maintain or defend their intellectual property rights or their use of third-party intellectual property rights or proprietary information in such a way as to invite litigation that could jeopardize or invalidate our license to develop these assets; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our in-licensing partners&#8217; failure to comply with applicable healthcare laws, as well as established guidelines, laws and regulations related to Good Manufacturing Practice and Good Laboratory Practice.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these risks materialize, we may not be able to expand our product pipeline or otherwise realize a return on the resources we will have invested to develop these early-stage assets, which could have a material adverse impact on our financial condition and prospects for growth.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If third parties upon which we rely to perform clinical trials for cabozantinib in new indications or for new potential product candidates do not perform as contractually required or expected, we may not be able to obtain regulatory approval for or commercialize cabozantinib or other product candidates beyond currently approved indications.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have the ability to conduct clinical trials for cabozantinib or for new potential product candidates independently, so we rely on independent third parties for the performance of these trials, such as the U.S. federal government (including NCI-CTEP, a department of the National Institutes of Health, with whom we have our CRADA), third-party contract research organizations, medical institutions, clinical investigators and contract laboratories to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or regulatory obligations or meet expected deadlines, whether as a result of the COVID-19 pandemic or otherwise, or if the third parties must be replaced or if the quality or accuracy of the data they generate or provide is compromised due to their failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our preclinical development activities or clinical trials may be extended, delayed, suspended or terminated, and we may not be able to obtain regulatory approval for or commercialize cabozantinib or other product candidates beyond currently approved indications. In addition, due to the complexity of our research initiatives, we may be unable to engage with third-party contract research organizations that have the necessary </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">experience and sophistication to further our internal drug discovery efforts, which would impede our ability to identify, develop and commercialize our potential product candidates.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We lack internal manufacturing capabilities necessary for us to produce materials required for certain preclinical activities and produce our products for clinical development or for commercial sale and rely on third parties to do so, which subjects us to various risks.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not own or operate manufacturing facilities, distribution facilities or resources for chemistry, manufacturing and control development activities, preclinical, clinical or commercial production and distribution for our current products and new product candidates. Instead, we rely on various third-party contract manufacturing organizations that, on our behalf, manufacture preclinical, clinical and commercial supplies of our products. As our operations continue to grow in these areas, we continue to appropriately expand our supply chain through secondary third-party contract manufacturers and suppliers.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To establish and manage our supply chain requires a significant financial commitment, the creation of numerous third-party contractual relationships and continued oversight of these third parties to fulfill compliance with applicable regulatory requirements. Although we maintain significant resources to directly and effectively oversee the activities and relationships with the companies in our supply chain, we do not have direct control over their operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our third-party contract manufacturers may not be able to produce material on a timely basis or manufacture material with the required quality standards, or in the quantity required to meet our preclinical, clinical development and commercial needs and applicable regulatory requirements, including as a result of the COVID-19 pandemic. Although as of the date of this Quarterly Report, we continue to maintain substantial safety stock inventories for our drug substance and drug products and have not experienced production delays or seen significant impairment to our supply chain as a result of the COVID-19 pandemic, our third-party contract manufacturers and suppliers could experience operational delays due to facility closures and other hardships as a result of the COVID-19 pandemic, which could impact our supply chain by potentially causing delays to or disruptions in the supply of our commercial or clinical products or product candidates. If our third-party contract manufacturers and suppliers do not continue to supply us with our products or product candidates in a timely fashion and in compliance with applicable quality and regulatory requirements, or if they otherwise fail or refuse to comply with their obligations to us under our manufacturing and supply arrangements, we may not have adequate remedies for any breach. Furthermore, their failure to supply us could impair or preclude meeting commercial or clinical product supply requirements for us or our partners, which could delay product development and future commercialization efforts and have a material adverse impact on our business, financial condition and results of operations. In addition, through our third-party contract manufacturers and data service providers, we continue to provide serialized commercial products as required to comply with the Drug Supply Chain Security Act (DSCSA). If our third-party contract manufacturers or data service providers fail to support our efforts to continue to comply with DSCSA and any future federal or state electronic pedigree requirements, we may face legal penalties or be restricted from selling our products</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our collaboration agreements with Ipsen and Takeda, we are responsible for the supply of CABOMETYX and COMETRIQ for global development and commercial purposes. Failure to meet our supply obligations under these collaboration agreements could impair our partners&#8217; ability to successfully develop and commercialize CABOMETYX and COMETRIQ and generate revenues to which we are entitled under the collaborations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If third-party scientific advisors and contractors we rely on to assist with our drug discovery efforts do not perform as expected, the expansion of our product pipeline may be delayed.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We work with scientific advisors at academic and other institutions, as well as third-party contractors in various locations throughout the world, that assist us in our research and development efforts, including in internal drug discovery and preclinical development strategy. These third parties are not our employees and may have other commitments or contractual obligations that limit their availability to us. Although these third-party scientific advisors and contractors generally agree not to do competing work, if a conflict of interest between their work for us and their work for another entity arises, we may lose their services. There has also been increased scrutiny surrounding the disclosures of payments made to medical researchers from companies in the pharmaceutical industry, and it is possible that the academic and other institutions that employ these medical researchers may prevent us from engaging them as scientific advisors and contractors or otherwise limit our access to these experts, or that the scientific advisors themselves may now be more reluctant to work with industry partners. Even if these scientific advisors and contractors with whom we have engaged intend to meet their contractual obligations, their ability to perform services may be impacted by external factors, as we experienced in the early stages of the COVID-19 pandemic. If we experience additional delays in the receipt of services, lose </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">work performed by these scientific advisors and contractors or are unable to engage them in the first place, our discovery and development efforts with respect to the matters on which they were working or would work in the future may be significantly delayed or otherwise adversely affected.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Information Technology and Intellectual Property</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Data breaches, cyber attacks and other failures in our information technology infrastructure could compromise our intellectual property or other sensitive information, damage our operations and cause significant harm to our business and reputation.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we collect, maintain and transmit sensitive data on our networks and systems, including our intellectual property and proprietary or confidential business information (such as research data and personal information) and confidential information with respect to our customers, clinical trial patients and our collaboration partners. We have also outsourced significant elements of our information technology infrastructure to third parties and, as a result, such third parties may or could have access to our confidential information. The secure maintenance of this information is critical to our business and reputation, and while we have enhanced and are continuing to enhance our cybersecurity efforts commensurate with the growth and complexity of our business, our systems and those of third-party service providers may be vulnerable to a cyber attack. Such vulnerabilities may be further exacerbated by the fact that our workforce is operating remotely as we comply with shelter in place orders and the recent rise in COVID-19 phishing attacks targeting remote workers. In addition, we are heavily dependent on the functioning of our information technology infrastructure to carry out our business processes, such as external and internal communications or access to clinical data and other key business information. Accordingly, both inadvertent disruptions to this infrastructure and cyber attacks could cause us to incur significant remediation or litigation costs, result in product development delays, disrupt critical business operations, expend key information technology resources and divert the attention of management. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous companies have been subject to a wide variety of security incidents, cyber attacks (including through use of ransomware) and other attempts to gain unauthorized access or otherwise compromise information technology systems. In fact, although the aggregate impact of cyber attacks on our operations and financial condition has not been material to date, we and our third-party vendors have frequently been the target of threats of this nature and expect them to continue. These threats can come from a variety of sources, ranging in sophistication from an individual hacker to a state-sponsored attack, and such threats can also vary in motive (including corporate espionage). Cyber attacks continue to become more prevalent and much harder to detect and defend against, and it is often difficult to anticipate or immediately detect such incidents and the damage caused by such incidents. These data breaches and any unauthorized access or disclosure of our information or intellectual property could compromise our intellectual property and expose our sensitive business information (or sensitive business information of our collaboration partners, which may lead to significant liability for us). A data security breach could also lead to public exposure of personal information of our clinical trial patients, employees or others. Any such event that leads to unauthorized access, use or disclosure of personal information, including personal information regarding our patients or employees, could harm our reputation and business, compel us to comply with federal and/or state breach notification laws and foreign law equivalents (including the GDPR), subject us to investigations and mandatory corrective action, or otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information, which could disrupt our business, result in increased costs or loss of revenue, and/or result in significant financial exposure. Furthermore, the costs of maintaining or upgrading our cybersecurity systems (including the recruitment and retention of experienced information technology professionals, who are in high demand) at the level necessary to keep up with our expanding operations and prevent against potential attacks are increasing, and despite our best efforts, our network security and data recovery measures and those of our vendors may still not be adequate to protect against such security breaches and disruptions, which could cause material harm to our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to adequately protect our intellectual property, third parties may be able to use our technology, which could adversely affect our ability to compete in the market.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success will depend in part upon our ability to obtain patents and maintain adequate protection of the intellectual property related to our technologies and products. The patent positions of biopharmaceutical companies, including our patent position, are generally uncertain and involve complex legal and factual questions. We will be able to protect our intellectual property rights from unauthorized use by third parties only to the extent that our technologies are covered by valid and enforceable patents or are effectively maintained as trade secrets. We will continue to apply for patents covering our technologies and products as, where and when we deem lawful and appropriate. However, these applications may be challenged or may fail to result in issued patents. Our issued patents have been and may in the future </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">be challenged by third parties as invalid or unenforceable under U.S. or foreign laws, or they may be infringed by third parties, and we are from time to time involved in the defense and enforcement of our patents or other intellectual property rights in a court of law, U.S. Patent and Trademark Office </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review or reexamination proceeding, foreign opposition proceeding or related legal and administrative proceeding in the U.S. and elsewhere. The costs of defending our patents or enforcing our proprietary rights in post-issuance administrative proceedings and litigation can be substantial and the outcome can be uncertain. An adverse outcome may allow third parties to use our intellectual property without a license and/or allow third parties to introduce generic and other competing products, any of which would negatively impact our business. Third parties may also attempt to invalidate or design around our patents, or assert that they are invalid or otherwise unenforceable, and seek to introduce generic versions of cabozantinib. For example, we received Paragraph IV certification notice letters from MSN concerning the ANDA that it had filed with the FDA seeking approval to market a generic version of CABOMETYX tablets. Should MSN or any other third parties receive FDA approval of an ANDA or a 505(b)(2) NDA with respect to cabozantinib, it is possible that such company or companies could introduce generic versions of our marketed products before our patents expire if they do not infringe our patents or if it is determined that our patents are invalid or unenforceable, and the resulting generic competition could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because patent applications can take many years to issue, third parties may have pending applications, unknown to us, which may later result in issued patents that cover the production, manufacture, commercialization or use of our product candidates. Our existing patents and any future patents we obtain may not be sufficiently broad to prevent others from practicing our technologies or from developing competing products. Furthermore, others may independently develop similar or alternative technologies or design around our patents. In addition, our patents may be challenged or invalidated or may fail to provide us with any competitive advantages, if, for example, others were the first to invent or to file patent applications for closely related inventions.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the U.S., and many companies have encountered significant problems in protecting and defending such rights in foreign jurisdictions. Many countries, including certain countries in Europe, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties (for example, the patent owner has failed to &#8220;work&#8221; the invention in that country or the third party has patented improvements). In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of the patent. Initiatives seeking compulsory licensing of life-saving drugs are also becoming increasingly prevalent in developing countries either through direct legislation or international initiatives. Governments in those developing countries could require that we grant compulsory licenses to allow competitors to manufacture and sell their own versions of our products or product candidates, thereby reducing our product sales. Moreover, the legal systems of certain countries, particularly certain developing countries, do not favor the aggressive enforcement of patent and other intellectual property protection, which makes it difficult to stop infringement. We rely on trade secret protection for some of our confidential and proprietary information. We have taken security measures to protect our proprietary information and trade secrets, but these measures may not provide adequate protection. While we seek to protect our proprietary information by entering into confidentiality agreements with employees, partners and consultants, we cannot provide assurance that our proprietary information will not be disclosed, or that we can meaningfully protect our trade secrets. In addition, our competitors may independently develop substantially equivalent proprietary information or may otherwise gain access to our trade secrets.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation or third-party claims of intellectual property infringement could require us to spend substantial time and money and adversely affect our ability to develop and commercialize products.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part upon our ability to avoid infringing patents and proprietary rights of third parties and not to breach any licenses that we have entered into with regard to our technologies and the technologies of third parties. Other parties have filed, and in the future are likely to file, patent applications covering products and technologies that we have developed or intend to develop. If patents covering technologies required by our operations are issued to others, we may have to obtain licenses from third parties, which may not be available on commercially reasonable terms, or at all, and may require us to pay substantial royalties, grant a cross-license to some of our patents to another patent holder or redesign the formulation of a product candidate so that we do not infringe third-party patents, which may be impossible to accomplish or could require substantial time and expense.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, third parties may obtain patents that relate to our technologies and claim that use of such technologies infringes on their patents or otherwise employs their proprietary technology without authorization. Regardless of their merit, such claims could require us to incur substantial costs and divert the attention of management and key technical </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">personnel in defending ourselves against any such claims or enforcing our own patents. In the event that a successful claim of patent infringement is brought against us, we may be required to pay damages and obtain one or more licenses from these third parties, subjecting us to substantial royalty payment obligations. We may not be able to obtain these licenses on commercially reasonable terms, or at all. Defense of any lawsuit or failure to obtain any of these licenses could adversely affect our ability to develop and commercialize products.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to damages resulting from claims that we, our employees or independent contractors have wrongfully used or disclosed alleged trade secrets of their former employers.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our employees and independent contractors were previously employed at universities or other biotechnology, biopharmaceutical or pharmaceutical companies, including our competitors or potential competitors. We may be subject to claims that we or these employees or independent contractors have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers, or used or sought to use patent inventions belonging to their former employers. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and divert the attention of management. If we fail in defending such claims, in addition to paying damages, we may lose valuable intellectual property rights or personnel. A loss of key research personnel and/or their work product could hamper or prevent our ability to develop or commercialize certain product candidates, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Employees and Location</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to manage our growth, there could be a material adverse impact on our business, financial condition and results of operations, and our prospects may be adversely affected.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced and expect to continue to experience growth in the number of our employees and in the scope of our operations. This growth places significant demands on our management and resources, and our current and planned personnel and operating practices may not be adequate to support our growth. To effectively manage our growth, we must continue to improve existing, and implement new, facilities, operational and financial systems, and procedures and controls, as well as expand, train and manage our growing employee base, and there can be no assurance that we will effectively manage our growth without experiencing operating inefficiencies or control deficiencies. We expect that we may need to increase our management personnel to oversee our expanding operations, and recruiting and retaining qualified individuals is difficult. If we are unable to manage our growth effectively, including as result of the COVID-19 pandemic or otherwise, or we are unsuccessful in recruiting qualified management personnel, there could be a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The loss of key personnel or the inability to retain and, where necessary, attract additional personnel could impair our ability to operate and expand our operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent upon the principal members of our management, as well as clinical, commercial and scientific staff, the loss of whose services might adversely impact the achievement of our objectives. Also, we may not have sufficient personnel to execute our business plans. Retaining and, where necessary, recruiting qualified clinical, commercial, scientific and pharmaceutical operations personnel will be critical to support activities related to advancing the development program for cabozantinib and our other product candidates, successfully executing upon our commercialization plan for cabozantinib and our internal proprietary research and development efforts. Competition is intense for experienced clinical, commercial, scientific and pharmaceutical operations personnel, and we may be unable to retain or recruit such personnel with the expertise or experience necessary to allow us to successfully develop and commercialize our products. Similarly, the COVID-19 pandemic could negatively impact the health of key personnel or make it difficult to recruit qualified personnel for critical positions. Further, all of our employees are employed &#8220;at will&#8221; and, therefore, may leave our employment at any time.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> Our operations might be interrupted by the occurrence of a natural disaster or other catastrophic event.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our headquarters in Alameda, California is located in the San Francisco Bay Area, and therefore our facilities are vulnerable to damage from earthquakes. Our earthquake insurance may not cover all of the damage we may suffer in the event of an earthquake. We are also vulnerable to damage from other types of disasters, including fires and floods, which have become a significant danger in California during recent years, as well as power loss, communications failures, aircraft disasters (due to the proximity of our headquarters to a major international airport), terrorism and similar events, and any insurance we may maintain may be inadequate to cover our losses. If any disaster were to occur, our ability to operate our </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">business at our facilities could be seriously, or potentially completely, impaired, causing significant delays in our programs and making it difficult for us to recover due to the unique nature of our research activities. Accordingly, an earthquake or other disaster could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Facility security breaches may disrupt our operations, subject us to liability and harm our operating results.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any break-in or trespass at our facilities that results in the misappropriation, theft, sabotage or any other type of security breach with respect to our proprietary and confidential information, including research or clinical data, or that results in damage to our research and development equipment and assets, or that results in physical or psychological harm to any of our employees, could subject us to liability or otherwise have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Environmental and Product Liability</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We use hazardous chemicals and biological materials in our business. Any claims relating to improper handling, storage or disposal of these materials could be time consuming and costly.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development processes involve the controlled use of hazardous materials, including chemicals and biological materials, and our operations can produce hazardous waste products. We cannot eliminate the risk of accidental contamination or discharge, or any resultant injury from these materials, and we may face liability under applicable laws for any injury or contamination that results from our use or the use by our collaboration partners or other third parties of these materials, and such liability may exceed our insurance coverage and our total assets. In addition, we may be required to indemnify our collaboration partners against all damages and other liabilities arising out of our development activities or products produced in connection with our collaborations with them. Moreover, our continued compliance with environmental laws and regulations may be expensive, and current or future environmental regulations may impair our research, development and production efforts.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face potential product liability exposure far in excess of our limited insurance coverage.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be held liable if any product we or our collaboration partners develop or commercialize causes injury or is found otherwise unsuitable during product testing, manufacturing, marketing or sale. Regardless of merit or eventual outcome, product liability claims could result in decreased demand for our products and product candidates, injury to our reputation, withdrawal of patients from our clinical trials, product recall, substantial monetary awards to third parties and the inability to commercialize any products that we may develop in the future. These claims might be made directly by consumers, healthcare providers, pharmaceutical companies or others selling or testing our products. We have obtained limited product liability insurance coverage for our clinical trials and commercial activities for cabozantinib in the amount of $20.0 million per occurrence and $20.0 million in the aggregate. However, our insurance may not reimburse us or may not be sufficient to reimburse us for expenses or losses we may suffer. Moreover, if insurance coverage becomes more expensive, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. On occasion, juries have awarded large judgments in class action lawsuits for claims based on drugs that had unanticipated side effects. In addition, the biotechnology, biopharmaceutical and pharmaceutical industries, in general, have been subject to significant medical malpractice litigation. A successful product liability claim or series of claims brought against us could harm our reputation and business and would decrease our cash reserves.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Common Stock</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our stock price has been and may in the future be highly volatile.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading price of our common stock has been highly volatile, and we believe the trading price of our common stock will remain highly volatile and may fluctuate substantially due to factors such as the following, many of which we cannot control:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the announcement of FDA approval or non-approval, or delays in the FDA review process with respect to cabozantinib, our collaboration partners&#8217; product candidates being developed in combination with cabozantinib, or our competitors&#8217; product candidates;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the commercial performance of both CABOMETYX and COMETRIQ and the revenues we generate from those approved products, including royalties paid under our collaboration and license agreements;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">adverse or inconclusive results or announcements related to our or our collaboration partners&#8217; clinical trials or delays in those clinical trials;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the timing of achievement of our clinical, regulatory, partnering, commercial and other milestones for cabozantinib or any of our other programs or product candidates;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our ability to make future investments in the expansion of our pipeline through internal drug discovery and business development activities;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our ability to obtain the materials and services, including an adequate product supply for any approved drug product, from our third-party vendors or do so at acceptable prices;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the timing and amount of expenses incurred for clinical development and manufacturing of cabozantinib;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">actions taken by regulatory agencies, both in the U.S. and abroad, with respect to cabozantinib or our clinical trials for cabozantinib; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">unanticipated regulatory actions taken by the FDA as a result of changing FDA standards and practices concerning the review of product candidates, including approvals at earlier stages of clinical development or with lesser developed data sets and expedited reviews;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the announcement of new products or clinical trial data by our competitors;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the announcement of regulatory applications, such as MSN&#8217;s ANDA, seeking approval of generic versions of our marketed products;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">quarterly variations in our or our competitors&#8217; results of operations;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">changes in our relationships with our collaboration partners, including the termination or modification of our agreements, or other events or conflicts that may affect our collaboration partners&#8217; timing and willingness to develop, or if approved, commercialize our products and product candidates out-licensed to them;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the announcement of an in-licensed product candidate or strategic acquisition;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">litigation, including intellectual property infringement and product liability lawsuits, involving us;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the impairment of acquired goodwill and other assets;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">changes in earnings estimates or recommendations by securities analysts, or financial guidance from our management team, and any failure to achieve the operating results projected by securities analysts or by our management team;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the entry into new financing arrangements;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">developments in the biotechnology, biopharmaceutical or pharmaceutical industry;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">sales of large blocks of our common stock or sales of our common stock by our executive officers, directors and significant stockholders;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">additions and departures of key personnel or board members;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the disposition of any of our technologies or compounds;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">significant fluctuations in interest rates or foreign currency exchange rates; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">general market, economic and political conditions and other factors, including factors unrelated to our operating performance or the operating performance of our competitors, such as the impact of the COVID-19 pandemic on financial markets.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These and other factors could have material adverse impact on the market price of our common stock. In addition, the stock markets in general, and the markets for biotechnology and pharmaceutical stocks in particular, have historically experienced significant volatility that has often been unrelated or disproportionate to the operating performance of particular companies. Likewise, as a result of significant changes in U.S. or global political and economic conditions, including the effects of the COVID-19 pandemic, policies governing foreign trade and healthcare spending and delivery, or future potential U.S. federal government shutdowns, the financial markets could continue to experience significant volatility that could also continue to negatively impact the markets for biotechnology and pharmaceutical stocks. These broad market fluctuations have adversely affected, and may in the future adversely affect the trading price of our common stock. Excessive volatility may continue for an extended period of time following the date of this report.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, following periods of volatility in the market price of a company&#8217;s securities, securities class action litigation has often been instituted. A securities class action suit against us could result in substantial costs and divert the attention of management, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent or deter attempts by our stockholders to replace or remove our current management, which could cause the market price of our common stock to decline.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our corporate charter and bylaws may discourage, delay or prevent an acquisition of us, a change in control, or attempts by our stockholders to replace or remove members of our current Board of Directors. Because our Board of Directors is responsible for appointing the members of our management team, these provisions could in turn affect any attempt by our stockholders to replace current members of our management team. These provisions include:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">a prohibition on actions by our stockholders by written consent;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the ability of our Board of Directors to issue preferred stock without stockholder approval, which could be used to institute a &#8220;poison pill&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our Board of Directors; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">advance notice requirements for director nominations and stockholder proposals.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</span></div><div id="i0283c6f517b447ec92f154ee691f4028_109"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds&#160;&#160;&#160;&#160;</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i0283c6f517b447ec92f154ee691f4028_112"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i0283c6f517b447ec92f154ee691f4028_115"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i0283c6f517b447ec92f154ee691f4028_118"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i0283c6f517b447ec92f154ee691f4028_121"></div><div style="-sec-extract:summary;margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.404%"><tr><td style="width:1.0%"></td><td style="width:8.480%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.187%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.833%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit Description</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Incorporation by Reference</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Herewith</span></div></td></tr><tr style="height:32pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Form</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">File Number</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit/</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Appendix</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reference</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Filing Date</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000119312510052759/dex31.htm">Amended and Restated Certificate of Incorporation of Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3/10/2010</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000119312510052759/dex32.htm">Certificate of Amendment of Amended and Restated Certificate of Incorporation of Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3/10/2010</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000119312512249218/d357973dex31.htm">Certificate of Amendment of Amended and Restated Certificate of Incorporation of Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5/25/2012</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976714000039/exel20141009exhibit31.htm">Certificate of Change of Registered Agent and/or Registered Office of Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/15/2014</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976714000039/exel20141009exhibit32.htm">Certificate of Ownership and Merger Merging X-Ceptor Therapeutics, Inc. with and into Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/15/2014</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="-sec-extract:summary;margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.404%"><tr><td style="width:1.0%"></td><td style="width:8.480%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.187%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.833%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit Description</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Incorporation by Reference</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Herewith</span></div></td></tr><tr style="height:32pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Form</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">File Number</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit/</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Appendix</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reference</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Filing Date</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976719000125/exhibit31certificateofamen.htm">Certificate of Amendment of Amended and Restated Certificate of Incorporation of Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/23/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976719000125/exhibit32amendedandrestate.htm">Amended and Restated Bylaws of Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2/20/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000101287000001947/0001012870-00-001947.txt">Specimen Common Stock Certificate</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-1,<br/>as amended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">333-96335</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4/7/2000</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20200930exhibit101.htm">Third Amendment dated September 3, 2020, to the Collaboration and License Agreement dated January 30, 2017, by and between Exelixis, Inc. and Takeda Pharmaceutical Company Limited.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20200930exhibit311.htm">Certification of Principal Executive Officer Pursuant to Exchange Act Rules 13a-14(a) and Rule 15d-14(a)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20200930exhibit312.htm">Certification of Principal Financial Officer Pursuant to Exchange Act Rules 13a-14(a) and Rule 15d-14(a)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.1&#8225;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20200930exhibit321.htm">Certifications of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The XBRL instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Labels Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Formatted as Inline XBRL and contained in Exhibit 101.</span></td></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.852%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.948%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portions of this exhibit have been omitted as being immaterial and would be competitively harmful if publicly disclosed.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8225;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This certification accompanies this Quarterly Report on Form 10-Q, is not deemed filed with the SEC and is not to be incorporated by reference into any filing of Exelixis, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of this Quarterly Report on Form 10-Q), irrespective of any general incorporation language contained in such filing. </span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><div id="i0283c6f517b447ec92f154ee691f4028_124"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0283c6f517b447ec92f154ee691f4028_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:71.428%"><tr><td style="width:1.0%"></td><td style="width:26.608%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.526%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">E</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">XELIXIS, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NC.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 5, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;C</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">HRISTOPHER</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> J. S</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ENNER</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Christopher J. Senner</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief&#160;Financial&#160;Officer </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Duly Authorized Officer and Principal Financial and Accounting Officer)</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exel20200930exhibit101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ie13a43f58e0640dbbc8209efaa1427c9_1"></div><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div><font><br></font></div></div><div style="margin-bottom:18pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THIRD AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Third Amendment to the Collaboration and License Agreement</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amendment</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) is entered into as of September 3, 2020 (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amendment Effective Date</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) by and between Exelixis, Inc., a Delaware company having an address at 1851 Harbor Bay Parkway, Alameda, CA, 94502, USA (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exelixis</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and Takeda Pharmaceutical Company Limited, a Japanese corporation with principal offices located at 1-1, Doshomachi 4-chome, Chuo-ku, Osaka 540-8645, JAPAN (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaborator</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).  Exelixis and Collaborator may be referred to herein individually as a &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Party</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; or collectively as the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Parties</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;.</font><font style="color:#2e2e2e;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:18pt;margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recitals</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Whereas,</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Exelixis and Collaborator are Parties to the Collaboration and License Agreement dated January 30, 2017, as amended on March 22, 2018, and May 7, 2019 (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">License Agreement</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), under which the Parties have been collaborating on the development and commercialization of cabozantinib in Japan&#59; and</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Whereas, </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Parties desire to enter into this Amendment to modify certain cost sharing obligations payable under the License Agreement on the terms and conditions set forth below.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Now, Therefore,</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in consideration of the foregoing premises and the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows&#58;</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;Tier 2 Indication</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 1.79 of the License Agreement is hereby deleted in its entirety and replaced with the following&#58;</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.79  &#8220;Tier 2 Indication&#8221; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">means &#91; * &#93;.  </font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;Development Costs</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 4.5(a) of the License Agreement is hereby deleted in its entirety and replaced with the following&#58; </font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.5 (a)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaborative Work Costs</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as set forth in Section 4.5(a)(ii) below, Exelixis shall be responsible for eighty percent (80%) and Collaborator shall be responsible for twenty percent (20%) of all Development Costs for any Development activities (including Clinical Trials) set forth in the GDP other than Independent Work, Collaborator Local Development Work and&#47;or Exelixis Local Development Work (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaborative Work</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).  For the avoidance of any doubt, such Development Costs with respect to the Collaborative Work shall include work performed by temporary workers and contractors on applicable activities and all Allowable Increases.  For the purpose of this Section 4.5(a), &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allowable Increases</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; are defined as increased Development Costs in connection with the Collaborative Work resulting from (A) changes in study design after the Effective Date that are approved by the JDC &#91; * &#93; (up to the amount of a mutually-agreed budget increase), (B) changes in regulatory requirements arising after the Effective Date (including changes required or recommended by Regulatory Authorities, but excluding changes required or recommended specifically by a Regulatory Authority of the Exelixis Territory solely for the benefit of the Exelixis Territory), or (C) extensions in the duration of Clinical Trials resulting from a lower than anticipated patient accrual rate, rate of clinical events, or higher rates of survival.  The Parties&#8217; foregoing Development Cost obligations with respect to the Collaborative Work (including Allowable Increases, if any) are subject to a maximum payment obligation of &#91; * &#93; of the amount specified in the Development </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Budget (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Budget Cap</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).  For clarification, notwithstanding Section 3.2(f), in the event that the Collaborative Work is conducted in accordance with the GDP and within the Budget Cap, no amendment of the Development Budget shall be required.  In the event that Development Costs are expected or anticipated to exceed the Budget Cap, the Party conducting the applicable Clinical Trial shall notify the other Party and the JDC shall meet to discuss amending the Development Budget.</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the foregoing subsection (i), for the Clinical Trials identified in subsections (A), (B) and (C) below in the Collaborator Territory (together, the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONTACT Trials</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), the Parties shall be responsible, except for Third Party Work (defined herein below), for all Development Costs associated with such CONTACT Trials as such costs are described below, and shall have such further rights and responsibilities associated with the CONTACT Trials as further described in the &#91; * &#93;.    </font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:40.5pt;text-align:justify;text-indent:139.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 3 Clinical Trial&#58; CONTACT-01, Protocol Title&#58; A Phase III, Multicenter, Randomized, Open-Label, Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Atezolizumab Given in Combination with Cabozantinib Versus Docetaxel Monotherapy in Patients with Metastatic Non-Small Cell Lung Cancer Previously Treated with an Anti-PD-L1&#47;PD-1 Antibody and Platinum-Containing Chemotherapy (Protocol Number GO41892)&#59; </font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:40.5pt;text-align:justify;text-indent:139.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 3 Clinical Trial&#58; CONTACT-02, Protocol Title&#58; A Phase III, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with High-Risk, Metastatic Castration-Resistant Prostate Cancer (Protocol Number XL184-315)&#59;</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:40.5pt;text-align:justify;text-indent:139.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">C.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 3 Clinical Trial&#58; CONTACT-03, Protocol Title&#58; A Phase III, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Atezolizumab Given in Combination with Cabozantinib Versus Cabozantinib Alone in Patients with Inoperable, Locally Advanced, or Metastatic Renal Cell Carcinoma Who Experienced Radiographic Tumor Progression During or After Immune Checkpoint Inhibitor Treatment (Protocol Number WO41994). </font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;Third Party Work</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following section shall be added as Section 4.15 of the License Agreement&#58;</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.15&#160;&#160;&#160;&#160;Third Party Work. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> If a Third Party is interested in pursuing additional Development work on a Product in Collaborator Territory that neither Party is interested in pursuing, then such Development work in Collaborator Territory may proceed with the approval of the JDC, and following each such approval such additional Development work shall be incorporated into the GDP by the JDC  (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Third Party Work</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, following the approval of the Third Party Work by the JDC, the Third Party may conduct the Third Party Work at its own costs unless agreed in writing with both Parties, provided that&#58; (A) it shall do so in accordance with the amended GDP&#59; (B) such Third Party Work shall be conducted under the oversight of the JDC&#59; (C) such Third Party Work shall be conducted in accordance with a separate agreement between the Third Party and the Parties&#59; and (D) no Third Party shall conduct Third Party Work in a manner that would have a material adverse effect on any Product(s) in either Party&#8217;s territory.  </font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;General Provisions</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.1&#160;&#160;&#160;&#160;Effect of Amendment</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Except as expressly modified herein, all terms and conditions set forth in the License Agreement, as in effect on the Amendment Effective Date, shall remain in full force and effect.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.2&#160;&#160;&#160;&#160;Entire Agreement</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The License Agreement as modified by this Amendment is both a final expression of the Parties&#8217; agreement and a complete and exclusive statement with respect to its subject matter.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="margin-bottom:6pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">They supersede all prior and contemporaneous agreements and communications, whether written or oral, of the Parties regarding this subject matter.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.3&#160;&#160;&#160;&#160;Severability</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  If, for any reason, any part of this Amendment is adjudicated invalid, unenforceable, or illegal by a court of competent jurisdiction, such adjudication shall not, to the extent feasible, affect or impair, in whole or in part, the validity, enforceability, or legality of any remaining portions of this Amendment.  All remaining portions shall remain in full force and effect as if the original Amendment had been executed without the invalidated, unenforceable, or illegal part.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.4&#160;&#160;&#160;&#160;Counterparts&#59; Electronic or Facsimile Signatures</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  This Amendment may be executed in any number of counterparts, each of which shall be an original, but all of which together shall constitute one instrument.  This Amendment may be executed and delivered electronically or by facsimile and upon such delivery such electronic or facsimile signature will be deemed to have the same effect as if the original signature had been delivered to the other Party.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#91;Signature Page Follows&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="margin-bottom:6pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;In Witness Whereof</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Parties hereto have caused this Third Amendment to be executed and entered into by their duly authorized representatives as of the Amendment Effective Date.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:48.736%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.064%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Exelixis, Inc.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;  &#47;s&#47; Michael M. Morrissey</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Name&#58;  Michael M. Morrissey, Ph.D.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Title&#58;  President and Chief Executive Officer</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Takeda Pharmaceutical Company Limited</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;  &#47;s&#47; Takafumi Horii</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Name&#58;  Takafumi (Taka) Horii</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Title&#58;  Vice President, </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Head of Japan Oncology Business Unit</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;Signature Page to the Third Amendment to the Collaboration and License Agreement&#93;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#91; * &#93; &#61; Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="margin-bottom:6pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>exel20200930exhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i89a489d5ecef415ead3b8e1d23f721fa_1"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXCHANGE ACT RULES 13a-14(a) and 15d-14(a),</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Michael M. Morrissey, Ph.D., certify that&#58;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Form 10-Q of Exelixis, Inc.&#59;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:43.601%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; M</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ICHAEL</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> M. M</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ORRISSEY</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Michael M. Morrissey, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer<br>(Principal Executive Officer)</font></td></tr></table></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;5, 2020 </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>exel20200930exhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i9a7a9968f0b346d28b1774f9606c4a49_1"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXCHANGE ACT RULES 13a-14(a) and 15d-14(a),</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Christopher J. Senner, certify that&#58;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Form 10-Q of Exelixis, Inc.&#59;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:43.601%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;C</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">HRISTOPHER</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> J. S</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ENNER&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Christopher J. Senner</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer<br>(Principal Financial Officer)</font></td></tr></table></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;5, 2020 </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>exel20200930exhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ifd8db9e316934b91a70904235d42edd4_1"></div><div style="min-height:49.5pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Michael M. Morrissey, Ph.D., the President and Chief Executive Officer of Exelixis, Inc. (the &#8220;Company&#8221;), and Christopher J. Senner, the Executive Vice President and Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge&#58;</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   1. &#160;&#160;&#160;&#160;The Company&#8217;s Quarterly Report on Form 10-Q for the period ended October&#160;2, 2020, to which this Certification is attached as Exhibit 32.1 (the &#8220;Report&#8221;), fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   2. &#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In Witness Whereof, the undersigned have set their hands hereto as of the 5th day of November 2020.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.410%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.241%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.413%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;M</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ICHAEL</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> M. M</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ORRISSEY&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;C</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">HRISTOPHER</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> J. S</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ENNER&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Michael M. Morrissey, Ph.D.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Christopher J. Senner</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer<br>(Principal Executive Officer)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer<br>(Principal Financial Officer)</font></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>exel-20201002.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:a5daf19b-278e-4193-a378-e43e29a2ddec,g:725f21e5-a4e0-44a1-91a2-e65dc567c7d2-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exel="http://www.exelixis.com/20201002" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:num="http://www.xbrl.org/dtr/type/numeric" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.exelixis.com/20201002">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20201002_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20201002_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20201002_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20201002_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.exelixis.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofIncomeLoss" roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncomeLoss" roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical" roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Comprehensive Income (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquity" roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity">
        <link:definition>1006007 - Statement - Condensed Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>1007008 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPolicies" roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies">
        <link:definition>2101101 - Disclosure - Organization and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails">
        <link:definition>2403401 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenues" roleURI="http://www.exelixis.com/role/Revenues">
        <link:definition>2104102 - Disclosure - Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesTables" roleURI="http://www.exelixis.com/role/RevenuesTables">
        <link:definition>2305301 - Disclosure - Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesbyDisaggregatedCategoryDetails" roleURI="http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails">
        <link:definition>2406402 - Disclosure - Revenues - Revenues by Disaggregated Category (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesNetProductRevenuesDisaggregatedbyProductDetails" roleURI="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails">
        <link:definition>2407403 - Disclosure - Revenues - Net Product Revenues Disaggregated by Product (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesDisaggregatedbySignificantCustomerDetails" roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails">
        <link:definition>2408404 - Disclosure - Revenues - Revenues Disaggregated by Significant Customer (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesDisaggregatedbyGeographicRegionDetails" roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails">
        <link:definition>2409405 - Disclosure - Revenues - Revenues Disaggregated by Geographic Region (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails" roleURI="http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails">
        <link:definition>2410406 - Disclosure - Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesContractAssetsandLiabilitiesDetails" roleURI="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails">
        <link:definition>2411407 - Disclosure - Revenues - Contract Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreements" roleURI="http://www.exelixis.com/role/CollaborationAgreements">
        <link:definition>2112103 - Disclosure - Collaboration Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsTables" roleURI="http://www.exelixis.com/role/CollaborationAgreementsTables">
        <link:definition>2313302 - Disclosure - Collaboration Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails">
        <link:definition>2414408 - Disclosure - Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsIpsenCollaborationDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails">
        <link:definition>2415409 - Disclosure - Collaboration Agreements - Ipsen Collaboration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails">
        <link:definition>2416410 - Disclosure - Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsTakedaCollaborationDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails">
        <link:definition>2417411 - Disclosure - Collaboration Agreements - Takeda Collaboration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsGSKDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsGSKDetails">
        <link:definition>2418412 - Disclosure - Collaboration Agreements - GSK (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails">
        <link:definition>2419413 - Disclosure - Collaboration Agreements - Royalty Revenues under the Collaboration Agreement with Genentech (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsInLicensingCollaborationsDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsInLicensingCollaborationsDetails">
        <link:definition>2420414 - Disclosure - Collaboration Agreements - In-Licensing Collaborations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsNBETherapeuticsAGNBECollaborationDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsNBETherapeuticsAGNBECollaborationDetails">
        <link:definition>2421415 - Disclosure - Collaboration Agreements - NBE Therapeutics AG (NBE) Collaboration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestments" roleURI="http://www.exelixis.com/role/CashandInvestments">
        <link:definition>2122104 - Disclosure - Cash and Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsTables" roleURI="http://www.exelixis.com/role/CashandInvestmentsTables">
        <link:definition>2323303 - Disclosure - Cash and Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails" roleURI="http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails">
        <link:definition>2424416 - Disclosure - Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsInvestmentsbySecurityTypeDetails" roleURI="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails">
        <link:definition>2425417 - Disclosure - Cash and Investments - Investments by Security Type (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsInvestmentsbySecurityTypeDetails_1" roleURI="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1">
        <link:definition>2425417 - Disclosure - Cash and Investments - Investments by Security Type (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsNarrativeDetails" roleURI="http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails">
        <link:definition>2426418 - Disclosure - Cash and Investments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails" roleURI="http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails">
        <link:definition>2427419 - Disclosure - Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails" roleURI="http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails">
        <link:definition>2428420 - Disclosure - Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.exelixis.com/role/FairValueMeasurements">
        <link:definition>2129105 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.exelixis.com/role/FairValueMeasurementsTables">
        <link:definition>2330304 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.exelixis.com/role/FairValueMeasurementsDetails">
        <link:definition>2431421 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.exelixis.com/role/Inventory">
        <link:definition>2132106 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.exelixis.com/role/InventoryTables">
        <link:definition>2333305 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetails" roleURI="http://www.exelixis.com/role/InventoryDetails">
        <link:definition>2434422 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.exelixis.com/role/StockBasedCompensation">
        <link:definition>2135107 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.exelixis.com/role/StockBasedCompensationTables">
        <link:definition>2336306 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails" roleURI="http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails">
        <link:definition>2437423 - Disclosure - Stock-Based Compensation - Allocated Employee Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>2438424 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.exelixis.com/role/IncomeTaxes">
        <link:definition>2139108 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.exelixis.com/role/IncomeTaxesDetails">
        <link:definition>2440425 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomeLossPerShare" roleURI="http://www.exelixis.com/role/NetIncomeLossPerShare">
        <link:definition>2141109 - Disclosure - Net Income (Loss) Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomeLossPerShareTables" roleURI="http://www.exelixis.com/role/NetIncomeLossPerShareTables">
        <link:definition>2342307 - Disclosure - Net Income (Loss) Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomeLossPerShareComputationofBasicandDilutedNetIncomePerShareDetails" roleURI="http://www.exelixis.com/role/NetIncomeLossPerShareComputationofBasicandDilutedNetIncomePerShareDetails">
        <link:definition>2443426 - Disclosure - Net Income (Loss) Per Share - Computation of Basic and Diluted Net Income Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomeLossPerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails" roleURI="http://www.exelixis.com/role/NetIncomeLossPerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails">
        <link:definition>2444427 - Disclosure - Net Income (Loss) Per Share - Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income (Loss) Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.exelixis.com/role/CommitmentsandContingencies">
        <link:definition>2145110 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" abstract="false" name="ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="exel_OtherLongtermAssetsMember" abstract="true" name="OtherLongtermAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_OrganizationAndSummaryOfSignificantPoliciesTable" abstract="true" name="OrganizationAndSummaryOfSignificantPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="exel_MckessonMember" abstract="true" name="MckessonMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_CollaborativeArrangementwithTakedaMember" abstract="true" name="CollaborativeArrangementwithTakedaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_CashCashEquivalentsAndInvestmentsTextBlock" abstract="false" name="CashCashEquivalentsAndInvestmentsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="exel_ResultingFromDiscoveryEffortsMember" abstract="true" name="ResultingFromDiscoveryEffortsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption" abstract="false" name="CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CollaborationAndLicenseAgreementTargetSelectionTerm" abstract="false" name="CollaborationAndLicenseAgreementTargetSelectionTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="exel_EarningsPerShareNumeratorAbstract" abstract="true" name="EarningsPerShareNumeratorAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" abstract="false" name="ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CollaborativeArrangementWithCatalentMember" abstract="true" name="CollaborativeArrangementWithCatalentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_CollaborativeArrangementWithNBETherapeuticsMember" abstract="true" name="CollaborativeArrangementWithNBETherapeuticsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_StatusDomain" abstract="true" name="StatusDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_ProbableMember" abstract="true" name="ProbableMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" abstract="true" name="AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CollaborativeArrangementwithIpsenMember" abstract="true" name="CollaborativeArrangementwithIpsenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_StatusAxis" abstract="true" name="StatusAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="exel_AchievedMember" abstract="true" name="AchievedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_EligiblePaymentFromCollaborationForDevelopmentMilestoneAchievementUnderCollaborationsAgreement" abstract="false" name="EligiblePaymentFromCollaborationForDevelopmentMilestoneAchievementUnderCollaborationsAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CollaborationAndLicenseAgreementExtendedTargetSelectionTerm" abstract="false" name="CollaborationAndLicenseAgreementExtendedTargetSelectionTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="exel_CabometyxMember" abstract="true" name="CabometyxMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_AffiliatesofMcKessonCorporationMember" abstract="true" name="AffiliatesofMcKessonCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_TakedaMember" abstract="true" name="TakedaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="exel_GlaxoSmithKlineMember" abstract="true" name="GlaxoSmithKlineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_ProductSalesDiscountsAndAllowancesMember" abstract="true" name="ProductSalesDiscountsAndAllowancesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_NoncashLeaseExpense" abstract="false" name="NoncashLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CollaborativeAgreementsUpfrontPayments" abstract="false" name="CollaborativeAgreementsUpfrontPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_AllowanceForProductRebatesMember" abstract="true" name="AllowanceForProductRebatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_CollaborativeArrangementIncomeLossFromAgreement" abstract="false" name="CollaborativeArrangementIncomeLossFromAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CollaborationMember" abstract="true" name="CollaborationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_CotellicMember" abstract="true" name="CotellicMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_ChargebacksAndDiscountsForPromptPaymentMember" abstract="true" name="ChargebacksAndDiscountsForPromptPaymentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_PerformanceShareOptionsPSOMember" abstract="true" name="PerformanceShareOptionsPSOMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" abstract="false" name="ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_AccruedCollaborationLiabilityCurrent" abstract="false" name="AccruedCollaborationLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" abstract="true" name="ValuationAllowancesAndReservesAdditionsToProvisionAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="exel_AffiliatesOfAmerisourceBergenCorporationMember" abstract="true" name="AffiliatesOfAmerisourceBergenCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="exel_CollaborativeArrangementwithGenentechMember" abstract="true" name="CollaborativeArrangementwithGenentechMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_AccruedClinicalLiabilitiesCurrent" abstract="false" name="AccruedClinicalLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ProductGrossMember" abstract="true" name="ProductGrossMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" abstract="false" name="CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" abstract="false" name="EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_MilestonePaymentsEarned" abstract="false" name="MilestonePaymentsEarned" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CollaborativeArrangementswithGlaxoSmithKlineMember" abstract="true" name="CollaborativeArrangementswithGlaxoSmithKlineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_IpsenMember" abstract="true" name="IpsenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_AffiliatesofOptumSpecialtyPharmacyMember" abstract="true" name="AffiliatesofOptumSpecialtyPharmacyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumNumberOfSharesToVest" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumNumberOfSharesToVest" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="exel_LiabilitiesExpendituresIncurredButNotYetPaidToRelatedPartyTransactions" abstract="false" name="LiabilitiesExpendituresIncurredButNotYetPaidToRelatedPartyTransactions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" abstract="false" name="CollaborationAgreementPercentOfRoyaltyOnNetSale" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" abstract="true" name="OrganizationAndSummaryOfSignificantPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="exel_RightOfUseAssetObtainedInExchangeForLeaseLiability" abstract="false" name="RightOfUseAssetObtainedInExchangeForLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ProductsDerivedFromCabozantinibMember" abstract="true" name="ProductsDerivedFromCabozantinibMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_NewInformationMember" abstract="true" name="NewInformationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_ProductsDerivedFromOtherCompoundsMember" abstract="true" name="ProductsDerivedFromOtherCompoundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" abstract="false" name="MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="exel_AffiliatesofCVSHealthCorporationMember" abstract="true" name="AffiliatesofCVSHealthCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CometriqMember" abstract="true" name="CometriqMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_EarningsPerShareDenominatorAbstract" abstract="true" name="EarningsPerShareDenominatorAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="exel_NumberofProductsinCommercialMarket" abstract="false" name="NumberofProductsinCommercialMarket" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="exel_CollaborationAndLicenseAgreementTargetSelectionExtensionOptionTerm" abstract="false" name="CollaborationAndLicenseAgreementTargetSelectionExtensionOptionTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CollaborationAgreementsAdditionalUpfrontPayments" abstract="false" name="CollaborationAgreementsAdditionalUpfrontPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>exel-20201002_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:a5daf19b-278e-4193-a378-e43e29a2ddec,g:725f21e5-a4e0-44a1-91a2-e65dc567c7d2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.exelixis.com/role/CoverPage" xlink:type="simple" xlink:href="exel-20201002.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="exel-20201002.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d8ef90da-ffb8-41bf-b42c-f25b39443631" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_9508c398-e3cc-44fe-9111-50fa653c651a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8ef90da-ffb8-41bf-b42c-f25b39443631" xlink:to="loc_us-gaap_LiabilitiesCurrent_9508c398-e3cc-44fe-9111-50fa653c651a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_1a71a0d7-8c00-489f-a883-332e15d1c6d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8ef90da-ffb8-41bf-b42c-f25b39443631" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_1a71a0d7-8c00-489f-a883-332e15d1c6d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f023dbfc-8662-4015-b6d1-fafc0c65d0c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8ef90da-ffb8-41bf-b42c-f25b39443631" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f023dbfc-8662-4015-b6d1-fafc0c65d0c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_64bd6669-d07d-4e5c-b789-2310715d3956" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8ef90da-ffb8-41bf-b42c-f25b39443631" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_64bd6669-d07d-4e5c-b789-2310715d3956" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_56be4ed7-1452-47b5-bbab-b704e13149f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_60abe38d-0a66-49b2-83e1-3a1ba7d75e9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_56be4ed7-1452-47b5-bbab-b704e13149f6" xlink:to="loc_us-gaap_PreferredStockValue_60abe38d-0a66-49b2-83e1-3a1ba7d75e9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_8c62deda-27db-4093-8d0a-2993af071622" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_56be4ed7-1452-47b5-bbab-b704e13149f6" xlink:to="loc_us-gaap_CommonStockValue_8c62deda-27db-4093-8d0a-2993af071622" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_7c748d29-a5bb-413f-ac0f-214ae1a323f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_56be4ed7-1452-47b5-bbab-b704e13149f6" xlink:to="loc_us-gaap_AdditionalPaidInCapital_7c748d29-a5bb-413f-ac0f-214ae1a323f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7b5a037b-32f3-4525-a802-c6c452b2317f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_56be4ed7-1452-47b5-bbab-b704e13149f6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7b5a037b-32f3-4525-a802-c6c452b2317f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ed7b650b-c486-4443-9f8f-7b16fc5565f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_56be4ed7-1452-47b5-bbab-b704e13149f6" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ed7b650b-c486-4443-9f8f-7b16fc5565f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_86a79b3d-acc1-4a51-ab44-050aaa144228" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_bd56886c-3059-4a8b-8f31-9c0dca39bf9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_86a79b3d-acc1-4a51-ab44-050aaa144228" xlink:to="loc_us-gaap_AssetsCurrent_bd56886c-3059-4a8b-8f31-9c0dca39bf9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_0d9199f3-9d97-42dd-a11b-ee3d53a674ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_86a79b3d-acc1-4a51-ab44-050aaa144228" xlink:to="loc_us-gaap_LongTermInvestments_0d9199f3-9d97-42dd-a11b-ee3d53a674ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_19857293-cd68-4dc5-8196-81cfe78c89b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_86a79b3d-acc1-4a51-ab44-050aaa144228" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_19857293-cd68-4dc5-8196-81cfe78c89b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_dbce8509-f149-4df2-b3be-40847fb05b6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_86a79b3d-acc1-4a51-ab44-050aaa144228" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_dbce8509-f149-4df2-b3be-40847fb05b6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_2fb50e51-014d-4a87-9170-d7cda40688a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_86a79b3d-acc1-4a51-ab44-050aaa144228" xlink:to="loc_us-gaap_Goodwill_2fb50e51-014d-4a87-9170-d7cda40688a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_0a18f7ca-8449-41e5-a6dd-2f272245d210" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_86a79b3d-acc1-4a51-ab44-050aaa144228" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_0a18f7ca-8449-41e5-a6dd-2f272245d210" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_50aae604-ce9d-4a7f-9cf2-271128bda584" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_40240e5c-6696-456b-ab47-9d00c394760c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_50aae604-ce9d-4a7f-9cf2-271128bda584" xlink:to="loc_us-gaap_AccountsPayableCurrent_40240e5c-6696-456b-ab47-9d00c394760c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_848c0712-bc84-4bf0-a72c-3418de0fa306" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_50aae604-ce9d-4a7f-9cf2-271128bda584" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_848c0712-bc84-4bf0-a72c-3418de0fa306" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccruedClinicalLiabilitiesCurrent_bd4b8ce5-056d-4d8e-a843-26482f84569b" xlink:href="exel-20201002.xsd#exel_AccruedClinicalLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_50aae604-ce9d-4a7f-9cf2-271128bda584" xlink:to="loc_exel_AccruedClinicalLiabilitiesCurrent_bd4b8ce5-056d-4d8e-a843-26482f84569b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent_f5c8ea49-328f-451c-9b92-7fb66f4b2b6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerRefundLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_50aae604-ce9d-4a7f-9cf2-271128bda584" xlink:to="loc_us-gaap_CustomerRefundLiabilityCurrent_f5c8ea49-328f-451c-9b92-7fb66f4b2b6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccruedCollaborationLiabilityCurrent_736af325-4352-4f08-a36f-fb47d773935b" xlink:href="exel-20201002.xsd#exel_AccruedCollaborationLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_50aae604-ce9d-4a7f-9cf2-271128bda584" xlink:to="loc_exel_AccruedCollaborationLiabilityCurrent_736af325-4352-4f08-a36f-fb47d773935b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_0691fbea-f37f-4b8e-ab20-13d65f36a7f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_50aae604-ce9d-4a7f-9cf2-271128bda584" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_0691fbea-f37f-4b8e-ab20-13d65f36a7f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d1a06120-f8ac-4564-ad6e-e123359cf506" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7e064198-e3fd-4f48-8de1-9defd94e6c7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d1a06120-f8ac-4564-ad6e-e123359cf506" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7e064198-e3fd-4f48-8de1-9defd94e6c7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_ea9e07f1-ba77-461a-8f53-ae213a37ad54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d1a06120-f8ac-4564-ad6e-e123359cf506" xlink:to="loc_us-gaap_ShortTermInvestments_ea9e07f1-ba77-461a-8f53-ae213a37ad54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_138cfeb2-cbdb-47f0-b458-0cb7866d69ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d1a06120-f8ac-4564-ad6e-e123359cf506" xlink:to="loc_us-gaap_ReceivablesNetCurrent_138cfeb2-cbdb-47f0-b458-0cb7866d69ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_2fad932a-c6f9-4946-8460-2b64efe1a373" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d1a06120-f8ac-4564-ad6e-e123359cf506" xlink:to="loc_us-gaap_InventoryNet_2fad932a-c6f9-4946-8460-2b64efe1a373" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ef66f99b-d901-4117-94a3-4a3caaa2660c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d1a06120-f8ac-4564-ad6e-e123359cf506" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ef66f99b-d901-4117-94a3-4a3caaa2660c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_7e81c469-7e61-48ab-b863-972a062cf330" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_c4e93284-5284-490f-83db-5f4a9995e66d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_7e81c469-7e61-48ab-b863-972a062cf330" xlink:to="loc_us-gaap_Liabilities_c4e93284-5284-490f-83db-5f4a9995e66d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_a4ce0f07-1e55-45dd-a72b-9dd0c1c4a7d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_7e81c469-7e61-48ab-b863-972a062cf330" xlink:to="loc_us-gaap_CommitmentsAndContingencies_a4ce0f07-1e55-45dd-a72b-9dd0c1c4a7d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2a88db00-4b4f-4b2d-a4f3-947b8c24fda4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_7e81c469-7e61-48ab-b863-972a062cf330" xlink:to="loc_us-gaap_StockholdersEquity_2a88db00-4b4f-4b2d-a4f3-947b8c24fda4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="exel-20201002.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss" xlink:type="simple" xlink:href="exel-20201002.xsd#CondensedConsolidatedStatementsofIncomeLoss"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_383ae369-2204-4244-8245-2caa81ff53e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5efe45da-7d90-45ff-9615-6fe2625a015e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_383ae369-2204-4244-8245-2caa81ff53e3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5efe45da-7d90-45ff-9615-6fe2625a015e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ad332ae1-26b5-450e-bad0-645ea85d819a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_383ae369-2204-4244-8245-2caa81ff53e3" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ad332ae1-26b5-450e-bad0-645ea85d819a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_e3608d7e-bf93-4399-9b3c-a5fdc4360e2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_65b44ff1-5017-4e8e-b441-79c601912a40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_e3608d7e-bf93-4399-9b3c-a5fdc4360e2b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_65b44ff1-5017-4e8e-b441-79c601912a40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer_579cbb26-8821-4654-a8e2-fc2fe32418e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_e3608d7e-bf93-4399-9b3c-a5fdc4360e2b" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomer_579cbb26-8821-4654-a8e2-fc2fe32418e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_aa4f0781-296a-413e-8148-ce25bffe6090" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_00114e82-a88d-4851-8069-9a82f222f85f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_aa4f0781-296a-413e-8148-ce25bffe6090" xlink:to="loc_us-gaap_OperatingIncomeLoss_00114e82-a88d-4851-8069-9a82f222f85f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther_a31d1133-4e6c-47d0-a9cf-01f6c66f31c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOther"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_aa4f0781-296a-413e-8148-ce25bffe6090" xlink:to="loc_us-gaap_InterestIncomeOther_a31d1133-4e6c-47d0-a9cf-01f6c66f31c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_fea7fde8-dc61-4b9f-9564-ad6cc634fe2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_aa4f0781-296a-413e-8148-ce25bffe6090" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_fea7fde8-dc61-4b9f-9564-ad6cc634fe2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_2694acc9-b7c5-451a-8066-cf3c073f2caf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_36f4ea21-e79a-425f-9056-1ac16a078e53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_2694acc9-b7c5-451a-8066-cf3c073f2caf" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_36f4ea21-e79a-425f-9056-1ac16a078e53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_0bcec864-09c3-4422-80ad-cfebe8f51540" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_2694acc9-b7c5-451a-8066-cf3c073f2caf" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_0bcec864-09c3-4422-80ad-cfebe8f51540" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_721f1a48-4fba-499c-aadb-24dc36cd031b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_2694acc9-b7c5-451a-8066-cf3c073f2caf" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_721f1a48-4fba-499c-aadb-24dc36cd031b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c86eacb8-5220-4338-9f34-f3af60d074c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_5dd44c4f-be1a-4a65-9c47-39cd6077a1a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_c86eacb8-5220-4338-9f34-f3af60d074c0" xlink:to="loc_us-gaap_Revenues_5dd44c4f-be1a-4a65-9c47-39cd6077a1a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_1ab10e19-9c99-4b03-a4dd-407e13f01d6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_c86eacb8-5220-4338-9f34-f3af60d074c0" xlink:to="loc_us-gaap_CostsAndExpenses_1ab10e19-9c99-4b03-a4dd-407e13f01d6f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="simple" xlink:href="exel-20201002.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeLoss"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_9e85aeed-1fff-4ef7-a40a-68d1b4d309e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2f9bcedc-9f3a-4597-b3cf-a25bbd936cbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_9e85aeed-1fff-4ef7-a40a-68d1b4d309e9" xlink:to="loc_us-gaap_NetIncomeLoss_2f9bcedc-9f3a-4597-b3cf-a25bbd936cbe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_349917db-4ae8-46fe-86e9-94d11bbcb652" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_9e85aeed-1fff-4ef7-a40a-68d1b4d309e9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_349917db-4ae8-46fe-86e9-94d11bbcb652" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical" xlink:type="simple" xlink:href="exel-20201002.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="exel-20201002.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="exel-20201002.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e66361dc-16dd-4488-959e-6b3f7634be6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_de361ca9-9224-4d1b-b182-311dd354e225" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e66361dc-16dd-4488-959e-6b3f7634be6d" xlink:to="loc_us-gaap_NetIncomeLoss_de361ca9-9224-4d1b-b182-311dd354e225" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_a0d35306-ab2a-4c53-8f74-ea944acf33f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e66361dc-16dd-4488-959e-6b3f7634be6d" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_a0d35306-ab2a-4c53-8f74-ea944acf33f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_6feca189-bcbd-4881-8d53-0e9fc7357ee5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e66361dc-16dd-4488-959e-6b3f7634be6d" xlink:to="loc_us-gaap_ShareBasedCompensation_6feca189-bcbd-4881-8d53-0e9fc7357ee5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NoncashLeaseExpense_85493788-40d2-4eec-91e2-8a738f091983" xlink:href="exel-20201002.xsd#exel_NoncashLeaseExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e66361dc-16dd-4488-959e-6b3f7634be6d" xlink:to="loc_exel_NoncashLeaseExpense_85493788-40d2-4eec-91e2-8a738f091983" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_af0a5432-1c54-4dde-a2a6-92c3602a946f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e66361dc-16dd-4488-959e-6b3f7634be6d" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_af0a5432-1c54-4dde-a2a6-92c3602a946f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_6105c31d-be2d-4b89-ba8b-8e4cf1aaefaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e66361dc-16dd-4488-959e-6b3f7634be6d" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_6105c31d-be2d-4b89-ba8b-8e4cf1aaefaa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_4634e09a-befb-4b9f-a512-a90fe92bf12d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e66361dc-16dd-4488-959e-6b3f7634be6d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_4634e09a-befb-4b9f-a512-a90fe92bf12d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_c81b6357-8804-4b11-8160-90e42107f762" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e66361dc-16dd-4488-959e-6b3f7634be6d" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_c81b6357-8804-4b11-8160-90e42107f762" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9a517ed3-3bcd-4eaf-a5b1-7746478c0f5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e66361dc-16dd-4488-959e-6b3f7634be6d" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9a517ed3-3bcd-4eaf-a5b1-7746478c0f5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_fe529c9e-4c7e-46fc-95b4-7fe0b02b00a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e66361dc-16dd-4488-959e-6b3f7634be6d" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_fe529c9e-4c7e-46fc-95b4-7fe0b02b00a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_6bbf800d-59d6-4048-b4ca-5437d527a47a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e66361dc-16dd-4488-959e-6b3f7634be6d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_6bbf800d-59d6-4048-b4ca-5437d527a47a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ee9b7c62-b0b1-435e-ac6a-10e706b86edc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a17ad5e2-2cc1-4ee8-9ab7-face3c277cbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ee9b7c62-b0b1-435e-ac6a-10e706b86edc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a17ad5e2-2cc1-4ee8-9ab7-face3c277cbe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c69bc9fb-8cc0-4f38-b2b9-0c3bf0054a8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ee9b7c62-b0b1-435e-ac6a-10e706b86edc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c69bc9fb-8cc0-4f38-b2b9-0c3bf0054a8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f48e87ef-d3f9-4d3a-9268-5ac67291ea33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ee9b7c62-b0b1-435e-ac6a-10e706b86edc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f48e87ef-d3f9-4d3a-9268-5ac67291ea33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_46d14814-12fd-4b7e-b251-054ec6afb9a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_373f19c7-8bbe-4bb5-b208-599df777058a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_46d14814-12fd-4b7e-b251-054ec6afb9a3" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_373f19c7-8bbe-4bb5-b208-599df777058a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_c98711b8-3e00-45f6-a0f4-4e34938baf03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_46d14814-12fd-4b7e-b251-054ec6afb9a3" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_c98711b8-3e00-45f6-a0f4-4e34938baf03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_9566fd6d-d024-44d0-8bf6-c73fee578b9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_46d14814-12fd-4b7e-b251-054ec6afb9a3" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_9566fd6d-d024-44d0-8bf6-c73fee578b9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b856c6e8-c64f-431e-8aa7-f05251115a8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_3a9e07b0-f786-4313-91ff-c349fd7de594" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b856c6e8-c64f-431e-8aa7-f05251115a8b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_3a9e07b0-f786-4313-91ff-c349fd7de594" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_d3d89186-d149-48a3-98ba-60de20e25f7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b856c6e8-c64f-431e-8aa7-f05251115a8b" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_d3d89186-d149-48a3-98ba-60de20e25f7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_20dd8129-e79c-4d69-b156-94885953be02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b856c6e8-c64f-431e-8aa7-f05251115a8b" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_20dd8129-e79c-4d69-b156-94885953be02" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="exel-20201002.xsd#OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="exel-20201002.xsd#OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#OrganizationandSummaryofSignificantAccountingPoliciesDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/Revenues" xlink:type="simple" xlink:href="exel-20201002.xsd#Revenues"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/Revenues" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesTables" xlink:type="simple" xlink:href="exel-20201002.xsd#RevenuesTables"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#RevenuesRevenuesbyDisaggregatedCategoryDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#RevenuesNetProductRevenuesDisaggregatedbyProductDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#RevenuesContractAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreements" xlink:type="simple" xlink:href="exel-20201002.xsd#CollaborationAgreements"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsTables" xlink:type="simple" xlink:href="exel-20201002.xsd#CollaborationAgreementsTables"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#CollaborationAgreementsIpsenCollaborationDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#CollaborationAgreementsTakedaCollaborationDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsGSKDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#CollaborationAgreementsGSKDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsGSKDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsInLicensingCollaborationsDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#CollaborationAgreementsInLicensingCollaborationsDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsInLicensingCollaborationsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsNBETherapeuticsAGNBECollaborationDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#CollaborationAgreementsNBETherapeuticsAGNBECollaborationDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsNBETherapeuticsAGNBECollaborationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestments" xlink:type="simple" xlink:href="exel-20201002.xsd#CashandInvestments"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashandInvestments" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsTables" xlink:type="simple" xlink:href="exel-20201002.xsd#CashandInvestmentsTables"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6d7340ca-9e06-4433-a3cf-0c6fbd48f5e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_67e4665f-b57a-48cc-b365-3c1cf6cc6847" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6d7340ca-9e06-4433-a3cf-0c6fbd48f5e4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_67e4665f-b57a-48cc-b365-3c1cf6cc6847" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsNoncurrent_d752d5fd-296f-4ab4-bed5-206bd5d55c72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashEquivalentsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6d7340ca-9e06-4433-a3cf-0c6fbd48f5e4" xlink:to="loc_us-gaap_RestrictedCashEquivalentsNoncurrent_d752d5fd-296f-4ab4-bed5-206bd5d55c72" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#CashandInvestmentsInvestmentsbySecurityTypeDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f10c9833-8505-428d-af26-f691710b2efe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_80451ba4-d671-452f-92f6-7c1713a2b1aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f10c9833-8505-428d-af26-f691710b2efe" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_80451ba4-d671-452f-92f6-7c1713a2b1aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f5e8585b-27c5-47e6-81e2-ba3b4fc2258d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f10c9833-8505-428d-af26-f691710b2efe" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f5e8585b-27c5-47e6-81e2-ba3b4fc2258d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7c793b0c-6bc8-4465-9ef1-0d8c95163f11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f10c9833-8505-428d-af26-f691710b2efe" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7c793b0c-6bc8-4465-9ef1-0d8c95163f11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_dd44a45f-4a4f-45fc-b65f-ee6e87e38836" xlink:href="exel-20201002.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_d94dacdb-4cf9-474e-aa23-7868fe24c47e" xlink:href="exel-20201002.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_dd44a45f-4a4f-45fc-b65f-ee6e87e38836" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_d94dacdb-4cf9-474e-aa23-7868fe24c47e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_54982c27-1ce0-437c-8e4b-e64360c5c7d7" xlink:href="exel-20201002.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_dd44a45f-4a4f-45fc-b65f-ee6e87e38836" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_54982c27-1ce0-437c-8e4b-e64360c5c7d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_750c623d-9897-4b1c-91a6-8c108c71d509" xlink:href="exel-20201002.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_dd44a45f-4a4f-45fc-b65f-ee6e87e38836" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_750c623d-9897-4b1c-91a6-8c108c71d509" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_e9dab484-5fc7-4a1f-8658-cd7368c81f16" xlink:href="exel-20201002.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_e0caf67c-f74f-4ff6-92dc-e601860e42fe" xlink:href="exel-20201002.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_e9dab484-5fc7-4a1f-8658-cd7368c81f16" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_e0caf67c-f74f-4ff6-92dc-e601860e42fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_83a873a6-b6ee-43b1-bd13-f06f2e31426f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_e9dab484-5fc7-4a1f-8658-cd7368c81f16" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_83a873a6-b6ee-43b1-bd13-f06f2e31426f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_cae7023a-f498-4769-9963-c0c73c32efa0" xlink:href="exel-20201002.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e50aab6d-4822-4f1f-8f28-79eec905649f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_cae7023a-f498-4769-9963-c0c73c32efa0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e50aab6d-4822-4f1f-8f28-79eec905649f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_465b6b9f-8937-4833-9891-9855db5768a9" xlink:href="exel-20201002.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_cae7023a-f498-4769-9963-c0c73c32efa0" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_465b6b9f-8937-4833-9891-9855db5768a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ea56efbb-65b0-4ae1-849e-ab50e15aa4e6" xlink:href="exel-20201002.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_e5e72d1b-6540-4692-a7c3-baf8456132c6" xlink:href="exel-20201002.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ea56efbb-65b0-4ae1-849e-ab50e15aa4e6" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_e5e72d1b-6540-4692-a7c3-baf8456132c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_07895e6b-148e-4d0d-8710-b23ff68a3240" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ea56efbb-65b0-4ae1-849e-ab50e15aa4e6" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_07895e6b-148e-4d0d-8710-b23ff68a3240" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_08d9652b-8094-4aea-b405-a317f51f92d7" xlink:href="exel-20201002.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_fe6c5207-ec9a-4a8b-a280-9eebf6c8c315" xlink:href="exel-20201002.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_08d9652b-8094-4aea-b405-a317f51f92d7" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_fe6c5207-ec9a-4a8b-a280-9eebf6c8c315" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ed4046fc-d1c0-49d7-98c5-acf54c2b3a4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_08d9652b-8094-4aea-b405-a317f51f92d7" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ed4046fc-d1c0-49d7-98c5-acf54c2b3a4e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1" xlink:type="simple" xlink:href="exel-20201002.xsd#CashandInvestmentsInvestmentsbySecurityTypeDetails_1"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_30a8ab30-dd92-4f36-a971-2ae7f0182bc7" xlink:href="exel-20201002.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_7cf64735-b0e2-4d03-adb1-70024f0b8483" xlink:href="exel-20201002.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_30a8ab30-dd92-4f36-a971-2ae7f0182bc7" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_7cf64735-b0e2-4d03-adb1-70024f0b8483" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_efe1ce77-38dd-4806-b05e-59e4d406c49d" xlink:href="exel-20201002.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_30a8ab30-dd92-4f36-a971-2ae7f0182bc7" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_efe1ce77-38dd-4806-b05e-59e4d406c49d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_dbf375bc-5e50-490f-b34b-49921f70df89" xlink:href="exel-20201002.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_30a8ab30-dd92-4f36-a971-2ae7f0182bc7" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_dbf375bc-5e50-490f-b34b-49921f70df89" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#CashandInvestmentsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bc666b95-af2e-4167-b4ee-60172db95f8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_d64579e3-b56e-4eb0-9f19-004e4d0c0451" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bc666b95-af2e-4167-b4ee-60172db95f8d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_d64579e3-b56e-4eb0-9f19-004e4d0c0451" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_7e2a70e6-c347-45b0-beed-4ea273bfcebe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bc666b95-af2e-4167-b4ee-60172db95f8d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_7e2a70e6-c347-45b0-beed-4ea273bfcebe" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="exel-20201002.xsd#FairValueMeasurements"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="exel-20201002.xsd#FairValueMeasurementsTables"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#FairValueMeasurementsDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_d8ba0f23-4d8f-4f23-980d-36791d8168d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fde53fca-9a7c-4171-adbc-6e37b431229c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_d8ba0f23-4d8f-4f23-980d-36791d8168d4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fde53fca-9a7c-4171-adbc-6e37b431229c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_61ecb0af-fd04-4a4c-9bc3-fdf8dc29c664" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_d8ba0f23-4d8f-4f23-980d-36791d8168d4" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_61ecb0af-fd04-4a4c-9bc3-fdf8dc29c664" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/Inventory" xlink:type="simple" xlink:href="exel-20201002.xsd#Inventory"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/Inventory" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryTables" xlink:type="simple" xlink:href="exel-20201002.xsd#InventoryTables"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/InventoryTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#InventoryDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_e8d6fecf-9716-4f99-b3f7-36bb165fc22b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_ec27ef87-4676-49b0-80d5-f7fd704278b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_e8d6fecf-9716-4f99-b3f7-36bb165fc22b" xlink:to="loc_us-gaap_InventoryRawMaterials_ec27ef87-4676-49b0-80d5-f7fd704278b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_222332d8-d7a1-44e3-a0a2-b5c32a44a1b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_e8d6fecf-9716-4f99-b3f7-36bb165fc22b" xlink:to="loc_us-gaap_InventoryWorkInProcess_222332d8-d7a1-44e3-a0a2-b5c32a44a1b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_687d15ce-4fd4-407a-856d-1a0411f76a42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_e8d6fecf-9716-4f99-b3f7-36bb165fc22b" xlink:to="loc_us-gaap_InventoryFinishedGoods_687d15ce-4fd4-407a-856d-1a0411f76a42" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="exel-20201002.xsd#StockBasedCompensation"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="exel-20201002.xsd#StockBasedCompensationTables"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxes" xlink:type="simple" xlink:href="exel-20201002.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#IncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/IncomeTaxesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerShare" xlink:type="simple" xlink:href="exel-20201002.xsd#NetIncomeLossPerShare"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerShareTables" xlink:type="simple" xlink:href="exel-20201002.xsd#NetIncomeLossPerShareTables"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerShareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerShareComputationofBasicandDilutedNetIncomePerShareDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#NetIncomeLossPerShareComputationofBasicandDilutedNetIncomePerShareDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerShareComputationofBasicandDilutedNetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7477b126-5cc6-4f2c-85cf-a3f61cbd8bd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a424ed6d-190f-495d-93f1-8c9e1e8044de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7477b126-5cc6-4f2c-85cf-a3f61cbd8bd0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a424ed6d-190f-495d-93f1-8c9e1e8044de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_9b4deb9c-b541-41e8-b55c-6c3513bf9bb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7477b126-5cc6-4f2c-85cf-a3f61cbd8bd0" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_9b4deb9c-b541-41e8-b55c-6c3513bf9bb0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#NetIncomeLossPerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="exel-20201002.xsd#CommitmentsandContingencies"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CommitmentsandContingencies" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>exel-20201002_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:a5daf19b-278e-4193-a378-e43e29a2ddec,g:725f21e5-a4e0-44a1-91a2-e65dc567c7d2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CoverPage" xlink:type="simple" xlink:href="exel-20201002.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CoverPage" xlink:type="extended" id="i561175bef9204fa68ff79b07c74e3b97_CoverPage"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="exel-20201002.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" id="i10db426b85b74ea1b7acf0aba6447144_CondensedConsolidatedBalanceSheets"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="exel-20201002.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" id="id296bc9572884ae4b7da166345f6ae1a_CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss" xlink:type="simple" xlink:href="exel-20201002.xsd#CondensedConsolidatedStatementsofIncomeLoss"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss" xlink:type="extended" id="ifa5eddf8139e4bf1b5d694279cdda161_CondensedConsolidatedStatementsofIncomeLoss">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_63fee708-5804-4023-a5fe-dec97b854612" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7557748e-1210-408a-b228-7920464f214b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_63fee708-5804-4023-a5fe-dec97b854612" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7557748e-1210-408a-b228-7920464f214b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer_ff2ccb05-955c-44c5-9911-f293692c1ee0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_63fee708-5804-4023-a5fe-dec97b854612" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomer_ff2ccb05-955c-44c5-9911-f293692c1ee0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_3933a02e-90da-4fa8-a185-5a8e6c2eec15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_63fee708-5804-4023-a5fe-dec97b854612" xlink:to="loc_us-gaap_Revenues_3933a02e-90da-4fa8-a185-5a8e6c2eec15" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_47b2e016-563f-47a1-910a-8ef420b88d2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_63fee708-5804-4023-a5fe-dec97b854612" xlink:to="loc_us-gaap_OperatingExpensesAbstract_47b2e016-563f-47a1-910a-8ef420b88d2a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_0ffbfa6c-d605-473f-86c9-85f3cb0f609a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_47b2e016-563f-47a1-910a-8ef420b88d2a" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_0ffbfa6c-d605-473f-86c9-85f3cb0f609a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_0121b1cb-f8c2-4ee5-86bd-9dfdd65700b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_47b2e016-563f-47a1-910a-8ef420b88d2a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_0121b1cb-f8c2-4ee5-86bd-9dfdd65700b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_13e30474-d251-46ce-852b-3c5c86c3bd9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_47b2e016-563f-47a1-910a-8ef420b88d2a" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_13e30474-d251-46ce-852b-3c5c86c3bd9b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_0e6cac06-9cb5-4a9a-81ef-0e5718880a6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_47b2e016-563f-47a1-910a-8ef420b88d2a" xlink:to="loc_us-gaap_CostsAndExpenses_0e6cac06-9cb5-4a9a-81ef-0e5718880a6b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_aa42eb12-4d79-44ce-a270-65b4b15ab513" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_63fee708-5804-4023-a5fe-dec97b854612" xlink:to="loc_us-gaap_OperatingIncomeLoss_aa42eb12-4d79-44ce-a270-65b4b15ab513" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther_86af4c80-5c49-46ef-b4ca-63ee66f21b7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_63fee708-5804-4023-a5fe-dec97b854612" xlink:to="loc_us-gaap_InterestIncomeOther_86af4c80-5c49-46ef-b4ca-63ee66f21b7b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_645b950a-b06f-4b54-8d50-ba6db9d22d7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_63fee708-5804-4023-a5fe-dec97b854612" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_645b950a-b06f-4b54-8d50-ba6db9d22d7b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_25365e46-9625-4eaf-9938-2d6ce4819b5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_63fee708-5804-4023-a5fe-dec97b854612" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_25365e46-9625-4eaf-9938-2d6ce4819b5a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_229e7668-1666-4d13-89eb-0deeaee55afa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_63fee708-5804-4023-a5fe-dec97b854612" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_229e7668-1666-4d13-89eb-0deeaee55afa" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0f5c7e91-ad61-41fd-b4c3-a2afd1953685" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_63fee708-5804-4023-a5fe-dec97b854612" xlink:to="loc_us-gaap_NetIncomeLoss_0f5c7e91-ad61-41fd-b4c3-a2afd1953685" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_7b8317ca-2127-4a9e-a0bc-48197b7d25c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_63fee708-5804-4023-a5fe-dec97b854612" xlink:to="loc_us-gaap_EarningsPerShareAbstract_7b8317ca-2127-4a9e-a0bc-48197b7d25c1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_eb73f721-9112-4199-a922-6c55839987aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7b8317ca-2127-4a9e-a0bc-48197b7d25c1" xlink:to="loc_us-gaap_EarningsPerShareBasic_eb73f721-9112-4199-a922-6c55839987aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_2899ae64-67bf-4f3f-9276-24dbcf284e79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7b8317ca-2127-4a9e-a0bc-48197b7d25c1" xlink:to="loc_us-gaap_EarningsPerShareDiluted_2899ae64-67bf-4f3f-9276-24dbcf284e79" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_79aa4263-2235-4928-8073-10e11c424fa4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_63fee708-5804-4023-a5fe-dec97b854612" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_79aa4263-2235-4928-8073-10e11c424fa4" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5c4c0292-e71a-4191-aa3b-2ff26a322419" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_79aa4263-2235-4928-8073-10e11c424fa4" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5c4c0292-e71a-4191-aa3b-2ff26a322419" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8a71bd5b-00f9-44c9-a75a-f430afc26c1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_79aa4263-2235-4928-8073-10e11c424fa4" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8a71bd5b-00f9-44c9-a75a-f430afc26c1d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_86aaae84-6ef2-4ea0-9f37-21b43fbac8a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_63fee708-5804-4023-a5fe-dec97b854612" xlink:to="loc_us-gaap_StatementTable_86aaae84-6ef2-4ea0-9f37-21b43fbac8a5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_321788ce-5760-4d57-af65-2f16621c39a1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_86aaae84-6ef2-4ea0-9f37-21b43fbac8a5" xlink:to="loc_srt_ProductOrServiceAxis_321788ce-5760-4d57-af65-2f16621c39a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_321788ce-5760-4d57-af65-2f16621c39a1_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_321788ce-5760-4d57-af65-2f16621c39a1" xlink:to="loc_srt_ProductsAndServicesDomain_321788ce-5760-4d57-af65-2f16621c39a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ff4168aa-9c15-4af5-b0b0-699f16bea560" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_321788ce-5760-4d57-af65-2f16621c39a1" xlink:to="loc_srt_ProductsAndServicesDomain_ff4168aa-9c15-4af5-b0b0-699f16bea560" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_5b81d016-6ef9-4969-b0ad-142ca5fd91ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ff4168aa-9c15-4af5-b0b0-699f16bea560" xlink:to="loc_us-gaap_ProductMember_5b81d016-6ef9-4969-b0ad-142ca5fd91ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_14b2820b-adab-4562-8658-ae058073edbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ff4168aa-9c15-4af5-b0b0-699f16bea560" xlink:to="loc_us-gaap_LicenseMember_14b2820b-adab-4562-8658-ae058073edbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_7585ceef-b1dd-42f6-bc1b-738ea558df41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ff4168aa-9c15-4af5-b0b0-699f16bea560" xlink:to="loc_us-gaap_ServiceMember_7585ceef-b1dd-42f6-bc1b-738ea558df41" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="simple" xlink:href="exel-20201002.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeLoss"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="extended" id="i3d628f0ad46c4f8f946ec0db6a3499fe_CondensedConsolidatedStatementsofComprehensiveIncomeLoss"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical" xlink:type="simple" xlink:href="exel-20201002.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical" xlink:type="extended" id="idfca87fce08f41fca83b2a18aed77c72_CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="exel-20201002.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="iab6418b062a94f4697e3609f857ec0e7_CondensedConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_9386fad3-a409-45ac-8aa5-31529dd477e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c58bd9d7-0990-42a3-b976-12c4189f3b68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9386fad3-a409-45ac-8aa5-31529dd477e1" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c58bd9d7-0990-42a3-b976-12c4189f3b68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9586eaac-cd9e-4d0b-a0a5-53b543dfbecf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c58bd9d7-0990-42a3-b976-12c4189f3b68" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_9586eaac-cd9e-4d0b-a0a5-53b543dfbecf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_43b05a44-f74e-4094-83ef-74133d177b58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c58bd9d7-0990-42a3-b976-12c4189f3b68" xlink:to="loc_us-gaap_StockholdersEquity_43b05a44-f74e-4094-83ef-74133d177b58" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fab3c5cf-c673-46d8-b66d-23b841724393" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c58bd9d7-0990-42a3-b976-12c4189f3b68" xlink:to="loc_us-gaap_NetIncomeLoss_fab3c5cf-c673-46d8-b66d-23b841724393" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_9152293e-345e-4ba0-8d84-bc6220c62af9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c58bd9d7-0990-42a3-b976-12c4189f3b68" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_9152293e-345e-4ba0-8d84-bc6220c62af9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2ce97830-4199-4fe8-aa94-aa4ae3d0d1ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c58bd9d7-0990-42a3-b976-12c4189f3b68" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2ce97830-4199-4fe8-aa94-aa4ae3d0d1ab" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_9cbc9dce-fd07-4973-abdb-821c581a4c52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c58bd9d7-0990-42a3-b976-12c4189f3b68" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_9cbc9dce-fd07-4973-abdb-821c581a4c52" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_9d65baf0-4484-4d84-a7ef-fa4087a36e2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c58bd9d7-0990-42a3-b976-12c4189f3b68" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_9d65baf0-4484-4d84-a7ef-fa4087a36e2c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8d789b6b-116f-4119-964a-70cb32bbd48d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c58bd9d7-0990-42a3-b976-12c4189f3b68" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8d789b6b-116f-4119-964a-70cb32bbd48d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b45e59de-7f97-44cf-8c53-ea4be0c6a378" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_cd6f1601-b1d4-4a0f-8cad-ca0be3f7e233" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_5e4b8829-0cfd-45b5-849c-8dcbb2c41692" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_9386fad3-a409-45ac-8aa5-31529dd477e1" xlink:to="loc_us-gaap_StatementTable_5e4b8829-0cfd-45b5-849c-8dcbb2c41692" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f6b37188-0ad7-426f-a361-dc6bbfc3e604" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_5e4b8829-0cfd-45b5-849c-8dcbb2c41692" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f6b37188-0ad7-426f-a361-dc6bbfc3e604" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f6b37188-0ad7-426f-a361-dc6bbfc3e604_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f6b37188-0ad7-426f-a361-dc6bbfc3e604" xlink:to="loc_us-gaap_EquityComponentDomain_f6b37188-0ad7-426f-a361-dc6bbfc3e604_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a2bb5481-d8a3-4ca0-8d27-2a93fe5d2b7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f6b37188-0ad7-426f-a361-dc6bbfc3e604" xlink:to="loc_us-gaap_EquityComponentDomain_a2bb5481-d8a3-4ca0-8d27-2a93fe5d2b7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_408b3778-33d5-45b7-825d-4d7fa0a7c1fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a2bb5481-d8a3-4ca0-8d27-2a93fe5d2b7d" xlink:to="loc_us-gaap_CommonStockMember_408b3778-33d5-45b7-825d-4d7fa0a7c1fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_11c6acbe-6816-4de2-97d7-e2f5621f3950" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a2bb5481-d8a3-4ca0-8d27-2a93fe5d2b7d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_11c6acbe-6816-4de2-97d7-e2f5621f3950" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_592ff816-b223-40c8-b30c-0c93a2f7995b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a2bb5481-d8a3-4ca0-8d27-2a93fe5d2b7d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_592ff816-b223-40c8-b30c-0c93a2f7995b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_77965132-b24e-45c1-a9e1-d83bb1285d70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a2bb5481-d8a3-4ca0-8d27-2a93fe5d2b7d" xlink:to="loc_us-gaap_RetainedEarningsMember_77965132-b24e-45c1-a9e1-d83bb1285d70" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="exel-20201002.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended" id="i3ad2f3dcb37d4f39a8ed2e65330d0557_CondensedConsolidatedStatementsofCashFlows"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="exel-20201002.xsd#OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="extended" id="id617fcff69484ea0ae050d3a760891e6_OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="exel-20201002.xsd#OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended" id="ia03cfe4b6d9a46218c02ee25cd5050df_OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#OrganizationandSummaryofSignificantAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="extended" id="ie6821682d3674e16b55a43509f8787bd_OrganizationandSummaryofSignificantAccountingPoliciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_d0fb258e-3a40-4f6e-b86d-712531ef54f0" xlink:href="exel-20201002.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NumberofProductsinCommercialMarket_39626d1c-6537-4d71-9ca2-ad099e3718b5" xlink:href="exel-20201002.xsd#exel_NumberofProductsinCommercialMarket"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_d0fb258e-3a40-4f6e-b86d-712531ef54f0" xlink:to="loc_exel_NumberofProductsinCommercialMarket_39626d1c-6537-4d71-9ca2-ad099e3718b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_7b5cc5e7-4518-42bb-963f-437343ca6b52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_d0fb258e-3a40-4f6e-b86d-712531ef54f0" xlink:to="loc_us-gaap_NumberOfOperatingSegments_7b5cc5e7-4518-42bb-963f-437343ca6b52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_13830c12-1c83-433a-9113-14f8bad9c265" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_d0fb258e-3a40-4f6e-b86d-712531ef54f0" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_13830c12-1c83-433a-9113-14f8bad9c265" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_34a8a3af-ea8b-4aab-b9e8-597477e4b0a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_d0fb258e-3a40-4f6e-b86d-712531ef54f0" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_34a8a3af-ea8b-4aab-b9e8-597477e4b0a4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_5e26c10c-69c9-448a-810b-a30ee88227f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_d0fb258e-3a40-4f6e-b86d-712531ef54f0" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_5e26c10c-69c9-448a-810b-a30ee88227f8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_1504acce-1fd3-4463-948d-a422c1352d34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_d0fb258e-3a40-4f6e-b86d-712531ef54f0" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_1504acce-1fd3-4463-948d-a422c1352d34" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_b3372a7a-ebea-440f-8761-dbdf78465df4" xlink:href="exel-20201002.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_d0fb258e-3a40-4f6e-b86d-712531ef54f0" xlink:to="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_b3372a7a-ebea-440f-8761-dbdf78465df4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_efcd99fb-f03b-4ec7-9739-16947d95cf20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_b3372a7a-ebea-440f-8761-dbdf78465df4" xlink:to="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_efcd99fb-f03b-4ec7-9739-16947d95cf20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_efcd99fb-f03b-4ec7-9739-16947d95cf20_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_efcd99fb-f03b-4ec7-9739-16947d95cf20" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_efcd99fb-f03b-4ec7-9739-16947d95cf20_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_dec083a3-4120-4f24-b196-6296c36da186" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_efcd99fb-f03b-4ec7-9739-16947d95cf20" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_dec083a3-4120-4f24-b196-6296c36da186" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NewInformationMember_2cf3aa2a-8bfb-4930-91b6-661ef87485b0" xlink:href="exel-20201002.xsd#exel_NewInformationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_dec083a3-4120-4f24-b196-6296c36da186" xlink:to="loc_exel_NewInformationMember_2cf3aa2a-8bfb-4930-91b6-661ef87485b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6ecc86ab-5076-4eb5-869c-f427fc3c9a2b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_b3372a7a-ebea-440f-8761-dbdf78465df4" xlink:to="loc_srt_ProductOrServiceAxis_6ecc86ab-5076-4eb5-869c-f427fc3c9a2b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6ecc86ab-5076-4eb5-869c-f427fc3c9a2b_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_6ecc86ab-5076-4eb5-869c-f427fc3c9a2b" xlink:to="loc_srt_ProductsAndServicesDomain_6ecc86ab-5076-4eb5-869c-f427fc3c9a2b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d38bd709-f010-4eed-897d-fd2811e5a8b5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_6ecc86ab-5076-4eb5-869c-f427fc3c9a2b" xlink:to="loc_srt_ProductsAndServicesDomain_d38bd709-f010-4eed-897d-fd2811e5a8b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ResultingFromDiscoveryEffortsMember_3bd766b9-d769-41df-bdeb-31d445204021" xlink:href="exel-20201002.xsd#exel_ResultingFromDiscoveryEffortsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d38bd709-f010-4eed-897d-fd2811e5a8b5" xlink:to="loc_exel_ResultingFromDiscoveryEffortsMember_3bd766b9-d769-41df-bdeb-31d445204021" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductsDerivedFromCabozantinibMember_10109475-4ad5-404b-9d0f-69d05c5d441b" xlink:href="exel-20201002.xsd#exel_ProductsDerivedFromCabozantinibMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d38bd709-f010-4eed-897d-fd2811e5a8b5" xlink:to="loc_exel_ProductsDerivedFromCabozantinibMember_10109475-4ad5-404b-9d0f-69d05c5d441b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductsDerivedFromOtherCompoundsMember_52018253-9d96-4e7d-b1dc-0ce27efd12f5" xlink:href="exel-20201002.xsd#exel_ProductsDerivedFromOtherCompoundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d38bd709-f010-4eed-897d-fd2811e5a8b5" xlink:to="loc_exel_ProductsDerivedFromOtherCompoundsMember_52018253-9d96-4e7d-b1dc-0ce27efd12f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_44d16326-82dc-44f2-9d88-226a58f86b52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_b3372a7a-ebea-440f-8761-dbdf78465df4" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_44d16326-82dc-44f2-9d88-226a58f86b52" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_44d16326-82dc-44f2-9d88-226a58f86b52_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_44d16326-82dc-44f2-9d88-226a58f86b52" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_44d16326-82dc-44f2-9d88-226a58f86b52_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5f7a4226-0237-473d-8bd7-460b8822aa8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_44d16326-82dc-44f2-9d88-226a58f86b52" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5f7a4226-0237-473d-8bd7-460b8822aa8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_56b21a3c-10d4-4c79-8f67-22688ebf4758" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5f7a4226-0237-473d-8bd7-460b8822aa8f" xlink:to="loc_us-gaap_AccountsReceivableMember_56b21a3c-10d4-4c79-8f67-22688ebf4758" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_e834ecdc-3aa9-40f7-b6e6-0071ee5f8db3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_b3372a7a-ebea-440f-8761-dbdf78465df4" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_e834ecdc-3aa9-40f7-b6e6-0071ee5f8db3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_e834ecdc-3aa9-40f7-b6e6-0071ee5f8db3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_e834ecdc-3aa9-40f7-b6e6-0071ee5f8db3" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_e834ecdc-3aa9-40f7-b6e6-0071ee5f8db3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_4586b671-5c1c-4b32-abf0-0a9857007c63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_e834ecdc-3aa9-40f7-b6e6-0071ee5f8db3" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_4586b671-5c1c-4b32-abf0-0a9857007c63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_38daa32c-5824-40f0-a8b3-174ef9c8e8e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_4586b671-5c1c-4b32-abf0-0a9857007c63" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_38daa32c-5824-40f0-a8b3-174ef9c8e8e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_963f0d2f-d014-44a6-8a73-be2e142a1543" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_b3372a7a-ebea-440f-8761-dbdf78465df4" xlink:to="loc_srt_MajorCustomersAxis_963f0d2f-d014-44a6-8a73-be2e142a1543" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_963f0d2f-d014-44a6-8a73-be2e142a1543_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_963f0d2f-d014-44a6-8a73-be2e142a1543" xlink:to="loc_srt_NameOfMajorCustomerDomain_963f0d2f-d014-44a6-8a73-be2e142a1543_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_ee08c0db-b7d5-490b-91c5-7b78e2aa0b6d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_963f0d2f-d014-44a6-8a73-be2e142a1543" xlink:to="loc_srt_NameOfMajorCustomerDomain_ee08c0db-b7d5-490b-91c5-7b78e2aa0b6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_IpsenMember_e09e7b0d-ceb9-422d-b840-a5768e5c48b2" xlink:href="exel-20201002.xsd#exel_IpsenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_ee08c0db-b7d5-490b-91c5-7b78e2aa0b6d" xlink:to="loc_exel_IpsenMember_e09e7b0d-ceb9-422d-b840-a5768e5c48b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MckessonMember_e654db35-ce1c-4139-97d6-c8a59cb2f28c" xlink:href="exel-20201002.xsd#exel_MckessonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_ee08c0db-b7d5-490b-91c5-7b78e2aa0b6d" xlink:to="loc_exel_MckessonMember_e654db35-ce1c-4139-97d6-c8a59cb2f28c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/Revenues" xlink:type="simple" xlink:href="exel-20201002.xsd#Revenues"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/Revenues" xlink:type="extended" id="i18f75a587dbb4ec093a07b7ddf39403c_Revenues"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesTables" xlink:type="simple" xlink:href="exel-20201002.xsd#RevenuesTables"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesTables" xlink:type="extended" id="i8ddd0b996e0649589de40b394aa37aae_RevenuesTables"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#RevenuesRevenuesbyDisaggregatedCategoryDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails" xlink:type="extended" id="i85b2b3d42e89480bb6b7edbadeef8a0f_RevenuesRevenuesbyDisaggregatedCategoryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_f49ae673-1082-454d-8fa0-fba2d39da430" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_98cb9bf6-44e2-402f-ba6d-6a8b94772781" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f49ae673-1082-454d-8fa0-fba2d39da430" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_98cb9bf6-44e2-402f-ba6d-6a8b94772781" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer_909ec054-5279-4671-8a14-095bebd57f39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f49ae673-1082-454d-8fa0-fba2d39da430" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomer_909ec054-5279-4671-8a14-095bebd57f39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_8864f626-e546-4b70-b007-de049396b125" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f49ae673-1082-454d-8fa0-fba2d39da430" xlink:to="loc_us-gaap_Revenues_8864f626-e546-4b70-b007-de049396b125" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_0dc59b1d-8211-4cd2-a410-468e0c5bb3b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f49ae673-1082-454d-8fa0-fba2d39da430" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_0dc59b1d-8211-4cd2-a410-468e0c5bb3b5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_78e35e6d-191a-4914-ad5c-e94da393b203" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_0dc59b1d-8211-4cd2-a410-468e0c5bb3b5" xlink:to="loc_srt_ProductOrServiceAxis_78e35e6d-191a-4914-ad5c-e94da393b203" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_78e35e6d-191a-4914-ad5c-e94da393b203_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_78e35e6d-191a-4914-ad5c-e94da393b203" xlink:to="loc_srt_ProductsAndServicesDomain_78e35e6d-191a-4914-ad5c-e94da393b203_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_05425924-44f1-449c-bc74-d8aa9b765c4c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_78e35e6d-191a-4914-ad5c-e94da393b203" xlink:to="loc_srt_ProductsAndServicesDomain_05425924-44f1-449c-bc74-d8aa9b765c4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_3f990d9e-4e73-4782-8f27-3e31c085d8e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_05425924-44f1-449c-bc74-d8aa9b765c4c" xlink:to="loc_us-gaap_ProductMember_3f990d9e-4e73-4782-8f27-3e31c085d8e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductGrossMember_cf0f7be8-fcee-4d2f-a022-b7f2d2a3e370" xlink:href="exel-20201002.xsd#exel_ProductGrossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_3f990d9e-4e73-4782-8f27-3e31c085d8e0" xlink:to="loc_exel_ProductGrossMember_cf0f7be8-fcee-4d2f-a022-b7f2d2a3e370" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductSalesDiscountsAndAllowancesMember_936299c9-8d19-4ac4-a580-d39f1c899ec6" xlink:href="exel-20201002.xsd#exel_ProductSalesDiscountsAndAllowancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_3f990d9e-4e73-4782-8f27-3e31c085d8e0" xlink:to="loc_exel_ProductSalesDiscountsAndAllowancesMember_936299c9-8d19-4ac4-a580-d39f1c899ec6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationMember_160b5702-53b4-49e8-be89-48291ae4a8c1" xlink:href="exel-20201002.xsd#exel_CollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_05425924-44f1-449c-bc74-d8aa9b765c4c" xlink:to="loc_exel_CollaborationMember_160b5702-53b4-49e8-be89-48291ae4a8c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_73acaa50-1938-4709-ae8f-67ca014c26a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_CollaborationMember_160b5702-53b4-49e8-be89-48291ae4a8c1" xlink:to="loc_us-gaap_LicenseMember_73acaa50-1938-4709-ae8f-67ca014c26a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_2782a7a3-03c2-4d1e-913f-aee9537dadbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_CollaborationMember_160b5702-53b4-49e8-be89-48291ae4a8c1" xlink:to="loc_us-gaap_ServiceMember_2782a7a3-03c2-4d1e-913f-aee9537dadbf" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#RevenuesNetProductRevenuesDisaggregatedbyProductDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails" xlink:type="extended" id="i7fe8ba314823488bb56b7ac08d774a73_RevenuesNetProductRevenuesDisaggregatedbyProductDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_cbc93ab9-1ac2-42cd-b43b-746dd1d6edee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_11fdc818-379d-4cab-b685-3481d4c63030" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_cbc93ab9-1ac2-42cd-b43b-746dd1d6edee" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_11fdc818-379d-4cab-b685-3481d4c63030" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_ab405d16-504f-4bd1-b52e-5263baf4fe10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_cbc93ab9-1ac2-42cd-b43b-746dd1d6edee" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_ab405d16-504f-4bd1-b52e-5263baf4fe10" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b8536a6f-b874-4c6a-95e1-69393fcc1794" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ab405d16-504f-4bd1-b52e-5263baf4fe10" xlink:to="loc_srt_ProductOrServiceAxis_b8536a6f-b874-4c6a-95e1-69393fcc1794" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b8536a6f-b874-4c6a-95e1-69393fcc1794_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_b8536a6f-b874-4c6a-95e1-69393fcc1794" xlink:to="loc_srt_ProductsAndServicesDomain_b8536a6f-b874-4c6a-95e1-69393fcc1794_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_aaf04895-d3d2-4490-a29b-61f8d80d8ea3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_b8536a6f-b874-4c6a-95e1-69393fcc1794" xlink:to="loc_srt_ProductsAndServicesDomain_aaf04895-d3d2-4490-a29b-61f8d80d8ea3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_e1481e4e-7be7-4e26-8e0b-9c50f3395de0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_aaf04895-d3d2-4490-a29b-61f8d80d8ea3" xlink:to="loc_us-gaap_ProductMember_e1481e4e-7be7-4e26-8e0b-9c50f3395de0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CabometyxMember_d4351e40-8981-400d-843f-ffffb9232b74" xlink:href="exel-20201002.xsd#exel_CabometyxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_e1481e4e-7be7-4e26-8e0b-9c50f3395de0" xlink:to="loc_exel_CabometyxMember_d4351e40-8981-400d-843f-ffffb9232b74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CometriqMember_d3f69728-f4e0-4f0d-b9b6-ad501691aaa4" xlink:href="exel-20201002.xsd#exel_CometriqMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_e1481e4e-7be7-4e26-8e0b-9c50f3395de0" xlink:to="loc_exel_CometriqMember_d3f69728-f4e0-4f0d-b9b6-ad501691aaa4" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails" xlink:type="extended" id="i4407950fabe04040b360df89e6b5f7de_RevenuesRevenuesDisaggregatedbySignificantCustomerDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_a43be800-edbd-4d66-bd83-49c9685f221c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_f834c8fd-e569-4916-91b2-094dc9c51294" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_a43be800-edbd-4d66-bd83-49c9685f221c" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_f834c8fd-e569-4916-91b2-094dc9c51294" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_a6d525be-e887-4213-85b7-e79ca6d5512d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_a43be800-edbd-4d66-bd83-49c9685f221c" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_a6d525be-e887-4213-85b7-e79ca6d5512d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_456b3e91-7968-4ce2-b7c9-43c56154c010" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_a6d525be-e887-4213-85b7-e79ca6d5512d" xlink:to="loc_srt_MajorCustomersAxis_456b3e91-7968-4ce2-b7c9-43c56154c010" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_456b3e91-7968-4ce2-b7c9-43c56154c010_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_456b3e91-7968-4ce2-b7c9-43c56154c010" xlink:to="loc_srt_NameOfMajorCustomerDomain_456b3e91-7968-4ce2-b7c9-43c56154c010_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_9799160b-8905-4d0f-9a47-531cf361b28b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_456b3e91-7968-4ce2-b7c9-43c56154c010" xlink:to="loc_srt_NameOfMajorCustomerDomain_9799160b-8905-4d0f-9a47-531cf361b28b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_IpsenMember_83060371-c4e9-4d08-88a1-1bf8a281d72b" xlink:href="exel-20201002.xsd#exel_IpsenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_9799160b-8905-4d0f-9a47-531cf361b28b" xlink:to="loc_exel_IpsenMember_83060371-c4e9-4d08-88a1-1bf8a281d72b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofCVSHealthCorporationMember_68316bb0-1cf1-4429-8f45-d7004fa013b5" xlink:href="exel-20201002.xsd#exel_AffiliatesofCVSHealthCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_9799160b-8905-4d0f-9a47-531cf361b28b" xlink:to="loc_exel_AffiliatesofCVSHealthCorporationMember_68316bb0-1cf1-4429-8f45-d7004fa013b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofMcKessonCorporationMember_8bb03087-dbd8-431c-a3e9-cce0478e9052" xlink:href="exel-20201002.xsd#exel_AffiliatesofMcKessonCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_9799160b-8905-4d0f-9a47-531cf361b28b" xlink:to="loc_exel_AffiliatesofMcKessonCorporationMember_8bb03087-dbd8-431c-a3e9-cce0478e9052" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember_0042e2fd-c100-410a-8e99-0eb3a72c5b12" xlink:href="exel-20201002.xsd#exel_AffiliatesOfAmerisourceBergenCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_9799160b-8905-4d0f-9a47-531cf361b28b" xlink:to="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember_0042e2fd-c100-410a-8e99-0eb3a72c5b12" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofOptumSpecialtyPharmacyMember_dbcfc006-e17a-479a-b4ed-913bd8525ff9" xlink:href="exel-20201002.xsd#exel_AffiliatesofOptumSpecialtyPharmacyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_9799160b-8905-4d0f-9a47-531cf361b28b" xlink:to="loc_exel_AffiliatesofOptumSpecialtyPharmacyMember_dbcfc006-e17a-479a-b4ed-913bd8525ff9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TakedaMember_d989756f-8340-438d-894b-d01b60b91026" xlink:href="exel-20201002.xsd#exel_TakedaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_9799160b-8905-4d0f-9a47-531cf361b28b" xlink:to="loc_exel_TakedaMember_d989756f-8340-438d-894b-d01b60b91026" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2084c9c5-014d-41c4-8061-62a6254f0416" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_a6d525be-e887-4213-85b7-e79ca6d5512d" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2084c9c5-014d-41c4-8061-62a6254f0416" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2084c9c5-014d-41c4-8061-62a6254f0416_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2084c9c5-014d-41c4-8061-62a6254f0416" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2084c9c5-014d-41c4-8061-62a6254f0416_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8a53489c-9bfc-404f-a7da-ef65346219dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2084c9c5-014d-41c4-8061-62a6254f0416" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8a53489c-9bfc-404f-a7da-ef65346219dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_db2c77f7-c5e1-486c-9d83-9e22dd15851f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8a53489c-9bfc-404f-a7da-ef65346219dd" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_db2c77f7-c5e1-486c-9d83-9e22dd15851f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_1c81ac32-18b6-4f2d-88cd-8d536ec8eb04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_a6d525be-e887-4213-85b7-e79ca6d5512d" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_1c81ac32-18b6-4f2d-88cd-8d536ec8eb04" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_1c81ac32-18b6-4f2d-88cd-8d536ec8eb04_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_1c81ac32-18b6-4f2d-88cd-8d536ec8eb04" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_1c81ac32-18b6-4f2d-88cd-8d536ec8eb04_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_cd2d3a15-e109-40a7-be54-c7e32b48bd62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_1c81ac32-18b6-4f2d-88cd-8d536ec8eb04" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_cd2d3a15-e109-40a7-be54-c7e32b48bd62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_52cc2a00-f851-4e4d-a472-ebc50bd29d45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_cd2d3a15-e109-40a7-be54-c7e32b48bd62" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_52cc2a00-f851-4e4d-a472-ebc50bd29d45" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails" xlink:type="extended" id="ief76b528c53744cbaaebd45c52efaa5b_RevenuesRevenuesDisaggregatedbyGeographicRegionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_f2969aff-26dc-48e8-bfa1-0ee1c8f4e834" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1a19f058-93bc-4d38-ab66-f21cdc3de8c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f2969aff-26dc-48e8-bfa1-0ee1c8f4e834" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1a19f058-93bc-4d38-ab66-f21cdc3de8c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_ba51faa0-4887-4182-8121-6895b5434892" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f2969aff-26dc-48e8-bfa1-0ee1c8f4e834" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_ba51faa0-4887-4182-8121-6895b5434892" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_c6c20ab7-9834-44d1-b242-dbd14481ba2b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ba51faa0-4887-4182-8121-6895b5434892" xlink:to="loc_srt_StatementGeographicalAxis_c6c20ab7-9834-44d1-b242-dbd14481ba2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c6c20ab7-9834-44d1-b242-dbd14481ba2b_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_c6c20ab7-9834-44d1-b242-dbd14481ba2b" xlink:to="loc_srt_SegmentGeographicalDomain_c6c20ab7-9834-44d1-b242-dbd14481ba2b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c52f3312-f244-4103-812b-87491195f8a6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_c6c20ab7-9834-44d1-b242-dbd14481ba2b" xlink:to="loc_srt_SegmentGeographicalDomain_c52f3312-f244-4103-812b-87491195f8a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_6462a3a5-c90c-438a-89e8-db96d67bdc5f" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_c52f3312-f244-4103-812b-87491195f8a6" xlink:to="loc_country_US_6462a3a5-c90c-438a-89e8-db96d67bdc5f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_4f011af6-7cce-4e12-9dc3-bda29a1deabc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_c52f3312-f244-4103-812b-87491195f8a6" xlink:to="loc_srt_EuropeMember_4f011af6-7cce-4e12-9dc3-bda29a1deabc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_00fc2e25-9f8e-460b-ac8c-52993b661c0f" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_c52f3312-f244-4103-812b-87491195f8a6" xlink:to="loc_country_JP_00fc2e25-9f8e-460b-ac8c-52993b661c0f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails" xlink:type="extended" id="i0699ab56329a4171bfec6da0694e46a4_RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_902c78d9-9e22-48d0-8a33-d3a7ec431e76" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_2d690f7c-8b48-45ce-8ce6-39bbf3b1985a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_902c78d9-9e22-48d0-8a33-d3a7ec431e76" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_2d690f7c-8b48-45ce-8ce6-39bbf3b1985a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_2ff28851-100c-4325-bdc7-f6a7e8fdccf7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_2d690f7c-8b48-45ce-8ce6-39bbf3b1985a" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_2ff28851-100c-4325-bdc7-f6a7e8fdccf7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_5f3716a5-5432-4b83-bb90-1231bb78b369" xlink:href="exel-20201002.xsd#exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_2d690f7c-8b48-45ce-8ce6-39bbf3b1985a" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_5f3716a5-5432-4b83-bb90-1231bb78b369" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_fd2f68df-9d1e-422e-9bd2-63ca01374289" xlink:href="exel-20201002.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_5f3716a5-5432-4b83-bb90-1231bb78b369" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_fd2f68df-9d1e-422e-9bd2-63ca01374289" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_ceb17cc0-708c-471a-ab53-7e6c17baabec" xlink:href="exel-20201002.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_5f3716a5-5432-4b83-bb90-1231bb78b369" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_ceb17cc0-708c-471a-ab53-7e6c17baabec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_9e5c9e2b-e65d-49fb-858f-bd00a655351c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_2d690f7c-8b48-45ce-8ce6-39bbf3b1985a" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_9e5c9e2b-e65d-49fb-858f-bd00a655351c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_b73583ef-d08b-4d9a-a018-dca75f3b80c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_f9debe47-fe52-4a81-9b43-ff9faf014602" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_902c78d9-9e22-48d0-8a33-d3a7ec431e76" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_f9debe47-fe52-4a81-9b43-ff9faf014602" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_b99be74e-82d0-4721-96f0-d526a3b6e018" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_f9debe47-fe52-4a81-9b43-ff9faf014602" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_b99be74e-82d0-4721-96f0-d526a3b6e018" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_b99be74e-82d0-4721-96f0-d526a3b6e018_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_b99be74e-82d0-4721-96f0-d526a3b6e018" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_b99be74e-82d0-4721-96f0-d526a3b6e018_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_0bec23ce-58a9-467f-9b3c-9a7545678d3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_b99be74e-82d0-4721-96f0-d526a3b6e018" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_0bec23ce-58a9-467f-9b3c-9a7545678d3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_aaca362e-623e-49ad-adef-ec3debc0e004" xlink:href="exel-20201002.xsd#exel_ChargebacksAndDiscountsForPromptPaymentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_0bec23ce-58a9-467f-9b3c-9a7545678d3a" xlink:to="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_aaca362e-623e-49ad-adef-ec3debc0e004" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_25176a43-ee6d-4522-8c57-db1b8e4dc138" xlink:href="exel-20201002.xsd#exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_0bec23ce-58a9-467f-9b3c-9a7545678d3a" xlink:to="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_25176a43-ee6d-4522-8c57-db1b8e4dc138" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AllowanceForProductRebatesMember_90eb5b2f-5f6a-409c-b668-d7cb2f6fa5f4" xlink:href="exel-20201002.xsd#exel_AllowanceForProductRebatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_0bec23ce-58a9-467f-9b3c-9a7545678d3a" xlink:to="loc_exel_AllowanceForProductRebatesMember_90eb5b2f-5f6a-409c-b668-d7cb2f6fa5f4" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#RevenuesContractAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails" xlink:type="extended" id="i596cf68e2e254aae98a3b01a85eed373_RevenuesContractAssetsandLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_98b9be4d-5695-456a-a396-88ae66ce99ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_fb6ab2bb-d8ac-4b50-938c-0d3cd17f08e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_98b9be4d-5695-456a-a396-88ae66ce99ad" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_fb6ab2bb-d8ac-4b50-938c-0d3cd17f08e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_86454e5c-20bd-4ccc-ab17-1a8174766e9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_98b9be4d-5695-456a-a396-88ae66ce99ad" xlink:to="loc_us-gaap_ContractWithCustomerLiability_86454e5c-20bd-4ccc-ab17-1a8174766e9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_ffc5a3f1-b3fc-4a9f-8ea2-f5ae3d5369a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_98b9be4d-5695-456a-a396-88ae66ce99ad" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_ffc5a3f1-b3fc-4a9f-8ea2-f5ae3d5369a3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_EligiblePaymentFromCollaborationForDevelopmentMilestoneAchievementUnderCollaborationsAgreement_39c17deb-bff8-4017-98c5-7cff9c6f0812" xlink:href="exel-20201002.xsd#exel_EligiblePaymentFromCollaborationForDevelopmentMilestoneAchievementUnderCollaborationsAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_98b9be4d-5695-456a-a396-88ae66ce99ad" xlink:to="loc_exel_EligiblePaymentFromCollaborationForDevelopmentMilestoneAchievementUnderCollaborationsAgreement_39c17deb-bff8-4017-98c5-7cff9c6f0812" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_d84852f5-c82e-4052-b8f2-cc6937a51c9e" xlink:href="exel-20201002.xsd#exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_98b9be4d-5695-456a-a396-88ae66ce99ad" xlink:to="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_d84852f5-c82e-4052-b8f2-cc6937a51c9e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_25db2c61-24ab-4806-a06a-727427ee1e63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_98b9be4d-5695-456a-a396-88ae66ce99ad" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_25db2c61-24ab-4806-a06a-727427ee1e63" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_75349601-38a5-4bdb-8747-3d5a0e01e4d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_98b9be4d-5695-456a-a396-88ae66ce99ad" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_75349601-38a5-4bdb-8747-3d5a0e01e4d2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_e9dea905-0ade-4600-9416-c7dbbd16396a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_98b9be4d-5695-456a-a396-88ae66ce99ad" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_e9dea905-0ade-4600-9416-c7dbbd16396a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_b8a71ef8-1817-496c-b045-cb6ec7b5226c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_98b9be4d-5695-456a-a396-88ae66ce99ad" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_b8a71ef8-1817-496c-b045-cb6ec7b5226c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_77c4eff3-664f-45cd-9b56-11d45d672a45" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b8a71ef8-1817-496c-b045-cb6ec7b5226c" xlink:to="loc_srt_MajorCustomersAxis_77c4eff3-664f-45cd-9b56-11d45d672a45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_77c4eff3-664f-45cd-9b56-11d45d672a45_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_77c4eff3-664f-45cd-9b56-11d45d672a45" xlink:to="loc_srt_NameOfMajorCustomerDomain_77c4eff3-664f-45cd-9b56-11d45d672a45_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_b6dd7ab1-df9a-4a4e-bebb-77674c404692" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_77c4eff3-664f-45cd-9b56-11d45d672a45" xlink:to="loc_srt_NameOfMajorCustomerDomain_b6dd7ab1-df9a-4a4e-bebb-77674c404692" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TakedaMember_72a00cab-a34f-4646-8037-3dcc28993ce9" xlink:href="exel-20201002.xsd#exel_TakedaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_b6dd7ab1-df9a-4a4e-bebb-77674c404692" xlink:to="loc_exel_TakedaMember_72a00cab-a34f-4646-8037-3dcc28993ce9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_50acb59d-83a1-45e7-85c6-a4712e5308df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b8a71ef8-1817-496c-b045-cb6ec7b5226c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_50acb59d-83a1-45e7-85c6-a4712e5308df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_50acb59d-83a1-45e7-85c6-a4712e5308df_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_50acb59d-83a1-45e7-85c6-a4712e5308df" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_50acb59d-83a1-45e7-85c6-a4712e5308df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f05e0ee5-a2f2-4e8d-a62f-eff6ca5e2c0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_50acb59d-83a1-45e7-85c6-a4712e5308df" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f05e0ee5-a2f2-4e8d-a62f-eff6ca5e2c0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_0da0cf62-2c11-41f3-8eb0-5c2d30f0cad2" xlink:href="exel-20201002.xsd#exel_CollaborativeArrangementwithIpsenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f05e0ee5-a2f2-4e8d-a62f-eff6ca5e2c0b" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_0da0cf62-2c11-41f3-8eb0-5c2d30f0cad2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreements" xlink:type="simple" xlink:href="exel-20201002.xsd#CollaborationAgreements"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreements" xlink:type="extended" id="iacab5825cde842a4a6e85564f6472025_CollaborationAgreements"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsTables" xlink:type="simple" xlink:href="exel-20201002.xsd#CollaborationAgreementsTables"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsTables" xlink:type="extended" id="ief3696360b5b40a192d52e4fd59e7782_CollaborationAgreementsTables"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails" xlink:type="extended" id="idfd65de921aa466689beb983af498685_CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5ec6bbb5-b33f-44b3-8646-f9635625592e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_072fc440-b00a-44a4-bcff-8a9148c67ee2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5ec6bbb5-b33f-44b3-8646-f9635625592e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_072fc440-b00a-44a4-bcff-8a9148c67ee2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer_5486cbb1-4ffe-4972-addb-2a493572bbb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5ec6bbb5-b33f-44b3-8646-f9635625592e" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomer_5486cbb1-4ffe-4972-addb-2a493572bbb9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_1e00675c-cf8b-4044-ab64-e67555b230f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5ec6bbb5-b33f-44b3-8646-f9635625592e" xlink:to="loc_us-gaap_Revenues_1e00675c-cf8b-4044-ab64-e67555b230f4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_60ef9047-3d65-4b6b-af3f-df917f400902" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5ec6bbb5-b33f-44b3-8646-f9635625592e" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_60ef9047-3d65-4b6b-af3f-df917f400902" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6b5f5c95-6221-4e09-b112-d8636c6f81de" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_60ef9047-3d65-4b6b-af3f-df917f400902" xlink:to="loc_srt_ProductOrServiceAxis_6b5f5c95-6221-4e09-b112-d8636c6f81de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6b5f5c95-6221-4e09-b112-d8636c6f81de_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_6b5f5c95-6221-4e09-b112-d8636c6f81de" xlink:to="loc_srt_ProductsAndServicesDomain_6b5f5c95-6221-4e09-b112-d8636c6f81de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5a5e8f47-7bcc-4371-9e00-27c71ffff49e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_6b5f5c95-6221-4e09-b112-d8636c6f81de" xlink:to="loc_srt_ProductsAndServicesDomain_5a5e8f47-7bcc-4371-9e00-27c71ffff49e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_f29daac2-553c-4ac4-a275-f29509b963bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5a5e8f47-7bcc-4371-9e00-27c71ffff49e" xlink:to="loc_us-gaap_LicenseMember_f29daac2-553c-4ac4-a275-f29509b963bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_dedddcb2-64ba-465f-8ea4-dffaf75a5d11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5a5e8f47-7bcc-4371-9e00-27c71ffff49e" xlink:to="loc_us-gaap_ServiceMember_dedddcb2-64ba-465f-8ea4-dffaf75a5d11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2527dfbf-a456-4749-a42a-dd2ec7be15df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_60ef9047-3d65-4b6b-af3f-df917f400902" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2527dfbf-a456-4749-a42a-dd2ec7be15df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2527dfbf-a456-4749-a42a-dd2ec7be15df_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2527dfbf-a456-4749-a42a-dd2ec7be15df" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2527dfbf-a456-4749-a42a-dd2ec7be15df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_15be06f6-0921-4b5a-bc16-add3bcec788c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2527dfbf-a456-4749-a42a-dd2ec7be15df" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_15be06f6-0921-4b5a-bc16-add3bcec788c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_26800b9f-0287-41bd-8c47-20ff2a282777" xlink:href="exel-20201002.xsd#exel_CollaborativeArrangementwithIpsenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_15be06f6-0921-4b5a-bc16-add3bcec788c" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_26800b9f-0287-41bd-8c47-20ff2a282777" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#CollaborationAgreementsIpsenCollaborationDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails" xlink:type="extended" id="i81ceabac6f4b40ddad7173ea3ae10c98_CollaborationAgreementsIpsenCollaborationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_33f90da8-7138-460a-abda-b6dfd5572028" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_6cc12635-0075-4aaa-8ab6-99a12e93476d" xlink:href="exel-20201002.xsd#exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_33f90da8-7138-460a-abda-b6dfd5572028" xlink:to="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_6cc12635-0075-4aaa-8ab6-99a12e93476d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_e776dad4-2d34-47df-8c48-c301ea7a04c4" xlink:href="exel-20201002.xsd#exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_33f90da8-7138-460a-abda-b6dfd5572028" xlink:to="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_e776dad4-2d34-47df-8c48-c301ea7a04c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_60fb25d6-e0d7-4df6-afcf-9e247f724233" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_33f90da8-7138-460a-abda-b6dfd5572028" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_60fb25d6-e0d7-4df6-afcf-9e247f724233" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_36fb0476-7b3a-48d8-a518-e4d4f7eec994" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_33f90da8-7138-460a-abda-b6dfd5572028" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_36fb0476-7b3a-48d8-a518-e4d4f7eec994" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3636908f-a7aa-47f7-8c6b-1e9fce6d4e34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_36fb0476-7b3a-48d8-a518-e4d4f7eec994" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3636908f-a7aa-47f7-8c6b-1e9fce6d4e34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3636908f-a7aa-47f7-8c6b-1e9fce6d4e34_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3636908f-a7aa-47f7-8c6b-1e9fce6d4e34" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3636908f-a7aa-47f7-8c6b-1e9fce6d4e34_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a7b95c03-e39d-444f-9abe-91d852bd073d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3636908f-a7aa-47f7-8c6b-1e9fce6d4e34" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a7b95c03-e39d-444f-9abe-91d852bd073d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_81a31a57-39f0-4d51-b095-1a1ad47eda8b" xlink:href="exel-20201002.xsd#exel_CollaborativeArrangementwithIpsenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a7b95c03-e39d-444f-9abe-91d852bd073d" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_81a31a57-39f0-4d51-b095-1a1ad47eda8b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails" xlink:type="extended" id="ie88c5438e48b4ce88a2fee663fbf21aa_CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_82018673-4e2d-446a-9dde-aa75ba31f498" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fb0dbc97-b997-427f-9346-2cf15f380494" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_82018673-4e2d-446a-9dde-aa75ba31f498" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fb0dbc97-b997-427f-9346-2cf15f380494" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer_31d90f75-4f17-41fc-b905-034f4803ccf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_82018673-4e2d-446a-9dde-aa75ba31f498" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomer_31d90f75-4f17-41fc-b905-034f4803ccf3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_b1477d76-a0c5-447a-8ed5-bc33ba4ce100" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_82018673-4e2d-446a-9dde-aa75ba31f498" xlink:to="loc_us-gaap_Revenues_b1477d76-a0c5-447a-8ed5-bc33ba4ce100" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_761ec797-2e79-465c-98d3-46d73d1f0e1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_82018673-4e2d-446a-9dde-aa75ba31f498" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_761ec797-2e79-465c-98d3-46d73d1f0e1d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1bcbfacf-bf63-489e-9f06-23bc11fef83b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_761ec797-2e79-465c-98d3-46d73d1f0e1d" xlink:to="loc_srt_ProductOrServiceAxis_1bcbfacf-bf63-489e-9f06-23bc11fef83b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1bcbfacf-bf63-489e-9f06-23bc11fef83b_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_1bcbfacf-bf63-489e-9f06-23bc11fef83b" xlink:to="loc_srt_ProductsAndServicesDomain_1bcbfacf-bf63-489e-9f06-23bc11fef83b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0d2a63d4-e45a-44c6-8f7c-6dcdc2113043" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_1bcbfacf-bf63-489e-9f06-23bc11fef83b" xlink:to="loc_srt_ProductsAndServicesDomain_0d2a63d4-e45a-44c6-8f7c-6dcdc2113043" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_b405f157-106b-4fd9-9eb0-e79197094cd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0d2a63d4-e45a-44c6-8f7c-6dcdc2113043" xlink:to="loc_us-gaap_LicenseMember_b405f157-106b-4fd9-9eb0-e79197094cd0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_82257e57-9b25-4957-8a76-260917ffb8ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0d2a63d4-e45a-44c6-8f7c-6dcdc2113043" xlink:to="loc_us-gaap_ServiceMember_82257e57-9b25-4957-8a76-260917ffb8ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_19442610-fdea-47f8-a2d6-1a394158c8a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_761ec797-2e79-465c-98d3-46d73d1f0e1d" xlink:to="loc_us-gaap_TypeOfArrangementAxis_19442610-fdea-47f8-a2d6-1a394158c8a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_19442610-fdea-47f8-a2d6-1a394158c8a9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_19442610-fdea-47f8-a2d6-1a394158c8a9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_19442610-fdea-47f8-a2d6-1a394158c8a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_20f004ff-ec02-4647-bcac-53dd036ab82b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_19442610-fdea-47f8-a2d6-1a394158c8a9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_20f004ff-ec02-4647-bcac-53dd036ab82b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_baa0111a-c4af-418a-ac6c-6d986bbd50c4" xlink:href="exel-20201002.xsd#exel_CollaborativeArrangementwithTakedaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_20f004ff-ec02-4647-bcac-53dd036ab82b" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_baa0111a-c4af-418a-ac6c-6d986bbd50c4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#CollaborationAgreementsTakedaCollaborationDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails" xlink:type="extended" id="ib7cabb7fc4a74993a68f89e6878f7170_CollaborationAgreementsTakedaCollaborationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_084d770d-0bdd-4b5b-98e6-7174b0565f99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MilestonePaymentsEarned_c8308f33-d573-4bda-bd3b-9d74affd9adc" xlink:href="exel-20201002.xsd#exel_MilestonePaymentsEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_084d770d-0bdd-4b5b-98e6-7174b0565f99" xlink:to="loc_exel_MilestonePaymentsEarned_c8308f33-d573-4bda-bd3b-9d74affd9adc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_140ae9cd-5b10-4de1-a05f-fff7daef638c" xlink:href="exel-20201002.xsd#exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_084d770d-0bdd-4b5b-98e6-7174b0565f99" xlink:to="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_140ae9cd-5b10-4de1-a05f-fff7daef638c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_9a780839-1a55-494a-8046-aaaacad758cd" xlink:href="exel-20201002.xsd#exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_084d770d-0bdd-4b5b-98e6-7174b0565f99" xlink:to="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_9a780839-1a55-494a-8046-aaaacad758cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_7f8fe266-195e-4f00-9905-3fc964d8163f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_084d770d-0bdd-4b5b-98e6-7174b0565f99" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_7f8fe266-195e-4f00-9905-3fc964d8163f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f290be1d-3651-428c-aa98-4ad661c41755" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_084d770d-0bdd-4b5b-98e6-7174b0565f99" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f290be1d-3651-428c-aa98-4ad661c41755" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_0946e8fa-5f2e-46e8-a31f-636b50cb9830" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f290be1d-3651-428c-aa98-4ad661c41755" xlink:to="loc_us-gaap_TypeOfArrangementAxis_0946e8fa-5f2e-46e8-a31f-636b50cb9830" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0946e8fa-5f2e-46e8-a31f-636b50cb9830_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0946e8fa-5f2e-46e8-a31f-636b50cb9830" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0946e8fa-5f2e-46e8-a31f-636b50cb9830_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_afe04204-e263-4d6a-a3fc-5f70443ca119" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0946e8fa-5f2e-46e8-a31f-636b50cb9830" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_afe04204-e263-4d6a-a3fc-5f70443ca119" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_0b92d1e4-27b7-4c56-a178-fa6f6283630b" xlink:href="exel-20201002.xsd#exel_CollaborativeArrangementwithTakedaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_afe04204-e263-4d6a-a3fc-5f70443ca119" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_0b92d1e4-27b7-4c56-a178-fa6f6283630b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsGSKDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#CollaborationAgreementsGSKDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsGSKDetails" xlink:type="extended" id="idf51680e27174d4182db81f6c1ca70e4_CollaborationAgreementsGSKDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aff73c75-c203-4ea3-810e-895683afe2c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_d1c9e492-32fb-4252-9860-5b3269e2382e" xlink:href="exel-20201002.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aff73c75-c203-4ea3-810e-895683afe2c0" xlink:to="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_d1c9e492-32fb-4252-9860-5b3269e2382e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_44e6d752-90aa-4c41-8a2c-5ff2bd41ae74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aff73c75-c203-4ea3-810e-895683afe2c0" xlink:to="loc_us-gaap_RoyaltyExpense_44e6d752-90aa-4c41-8a2c-5ff2bd41ae74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c835bdb1-bd7f-4d7a-8188-d2d09f9ef603" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aff73c75-c203-4ea3-810e-895683afe2c0" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c835bdb1-bd7f-4d7a-8188-d2d09f9ef603" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_40f20a83-a4ab-45d8-b163-596fe3f2ae4d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c835bdb1-bd7f-4d7a-8188-d2d09f9ef603" xlink:to="loc_srt_MajorCustomersAxis_40f20a83-a4ab-45d8-b163-596fe3f2ae4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_40f20a83-a4ab-45d8-b163-596fe3f2ae4d_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_40f20a83-a4ab-45d8-b163-596fe3f2ae4d" xlink:to="loc_srt_NameOfMajorCustomerDomain_40f20a83-a4ab-45d8-b163-596fe3f2ae4d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_5c765de6-6bc8-427e-80e9-591dee494f35" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_40f20a83-a4ab-45d8-b163-596fe3f2ae4d" xlink:to="loc_srt_NameOfMajorCustomerDomain_5c765de6-6bc8-427e-80e9-591dee494f35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_GlaxoSmithKlineMember_cdcfb642-8e1e-4e66-8f44-30d396760a6e" xlink:href="exel-20201002.xsd#exel_GlaxoSmithKlineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_5c765de6-6bc8-427e-80e9-591dee494f35" xlink:to="loc_exel_GlaxoSmithKlineMember_cdcfb642-8e1e-4e66-8f44-30d396760a6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_fa926bbe-0e1b-41cc-a15f-eca3a2a7ea3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c835bdb1-bd7f-4d7a-8188-d2d09f9ef603" xlink:to="loc_us-gaap_TypeOfArrangementAxis_fa926bbe-0e1b-41cc-a15f-eca3a2a7ea3f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fa926bbe-0e1b-41cc-a15f-eca3a2a7ea3f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_fa926bbe-0e1b-41cc-a15f-eca3a2a7ea3f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fa926bbe-0e1b-41cc-a15f-eca3a2a7ea3f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ea4acb5-5441-48fb-b8d9-a1f3a955715d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_fa926bbe-0e1b-41cc-a15f-eca3a2a7ea3f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ea4acb5-5441-48fb-b8d9-a1f3a955715d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_eddb3b92-8517-40df-b073-215270c5a768" xlink:href="exel-20201002.xsd#exel_CollaborativeArrangementswithGlaxoSmithKlineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ea4acb5-5441-48fb-b8d9-a1f3a955715d" xlink:to="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_eddb3b92-8517-40df-b073-215270c5a768" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails" xlink:type="extended" id="i042e80c8d1d341d9be6f79254ce3bb0e_CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_284289a0-a979-42d8-bfd0-339a72301d0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementIncomeLossFromAgreement_59cd1ed7-8a02-4b2e-a8f0-391ac8c70db6" xlink:href="exel-20201002.xsd#exel_CollaborativeArrangementIncomeLossFromAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_284289a0-a979-42d8-bfd0-339a72301d0c" xlink:to="loc_exel_CollaborativeArrangementIncomeLossFromAgreement_59cd1ed7-8a02-4b2e-a8f0-391ac8c70db6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_350387ac-762f-4b7f-9ff9-cc9750cb284a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_284289a0-a979-42d8-bfd0-339a72301d0c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_350387ac-762f-4b7f-9ff9-cc9750cb284a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_86aefe8c-9097-4d70-af74-7514b23df378" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_284289a0-a979-42d8-bfd0-339a72301d0c" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_86aefe8c-9097-4d70-af74-7514b23df378" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2715f837-b2ae-49fe-9488-38d53784b43f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_86aefe8c-9097-4d70-af74-7514b23df378" xlink:to="loc_srt_ProductOrServiceAxis_2715f837-b2ae-49fe-9488-38d53784b43f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2715f837-b2ae-49fe-9488-38d53784b43f_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_2715f837-b2ae-49fe-9488-38d53784b43f" xlink:to="loc_srt_ProductsAndServicesDomain_2715f837-b2ae-49fe-9488-38d53784b43f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fd3b82ee-8d63-4517-99fb-94d24688ad61" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_2715f837-b2ae-49fe-9488-38d53784b43f" xlink:to="loc_srt_ProductsAndServicesDomain_fd3b82ee-8d63-4517-99fb-94d24688ad61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CotellicMember_be0e77f7-9705-4c5e-8bbb-060633089b67" xlink:href="exel-20201002.xsd#exel_CotellicMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_fd3b82ee-8d63-4517-99fb-94d24688ad61" xlink:to="loc_exel_CotellicMember_be0e77f7-9705-4c5e-8bbb-060633089b67" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1d289fb6-29af-4dee-a8cb-da4a402d8bb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_86aefe8c-9097-4d70-af74-7514b23df378" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1d289fb6-29af-4dee-a8cb-da4a402d8bb1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1d289fb6-29af-4dee-a8cb-da4a402d8bb1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1d289fb6-29af-4dee-a8cb-da4a402d8bb1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1d289fb6-29af-4dee-a8cb-da4a402d8bb1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bd811e20-5f59-477b-b697-c64491617d8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1d289fb6-29af-4dee-a8cb-da4a402d8bb1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bd811e20-5f59-477b-b697-c64491617d8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember_d0a2b917-9243-4e3a-85ec-a954ff59b803" xlink:href="exel-20201002.xsd#exel_CollaborativeArrangementwithGenentechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bd811e20-5f59-477b-b697-c64491617d8e" xlink:to="loc_exel_CollaborativeArrangementwithGenentechMember_d0a2b917-9243-4e3a-85ec-a954ff59b803" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsInLicensingCollaborationsDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#CollaborationAgreementsInLicensingCollaborationsDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsInLicensingCollaborationsDetails" xlink:type="extended" id="i0ed525a4529642c4b52a2eb8216e8aec_CollaborationAgreementsInLicensingCollaborationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_393d79fc-825b-49d7-bfba-e81ef404e092" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeAgreementsUpfrontPayments_afc0314f-e86f-4e96-8b9c-f0aef12de77e" xlink:href="exel-20201002.xsd#exel_CollaborativeAgreementsUpfrontPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_393d79fc-825b-49d7-bfba-e81ef404e092" xlink:to="loc_exel_CollaborativeAgreementsUpfrontPayments_afc0314f-e86f-4e96-8b9c-f0aef12de77e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAndLicenseAgreementTargetSelectionTerm_c6170d38-68b2-41ce-98d4-94aab735fa39" xlink:href="exel-20201002.xsd#exel_CollaborationAndLicenseAgreementTargetSelectionTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_393d79fc-825b-49d7-bfba-e81ef404e092" xlink:to="loc_exel_CollaborationAndLicenseAgreementTargetSelectionTerm_c6170d38-68b2-41ce-98d4-94aab735fa39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAndLicenseAgreementExtendedTargetSelectionTerm_6743ef42-baf4-4474-a257-b310fd0d5288" xlink:href="exel-20201002.xsd#exel_CollaborationAndLicenseAgreementExtendedTargetSelectionTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_393d79fc-825b-49d7-bfba-e81ef404e092" xlink:to="loc_exel_CollaborationAndLicenseAgreementExtendedTargetSelectionTerm_6743ef42-baf4-4474-a257-b310fd0d5288" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementsAdditionalUpfrontPayments_b416c279-78df-411c-91f1-bc6b2b37a7fa" xlink:href="exel-20201002.xsd#exel_CollaborationAgreementsAdditionalUpfrontPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_393d79fc-825b-49d7-bfba-e81ef404e092" xlink:to="loc_exel_CollaborationAgreementsAdditionalUpfrontPayments_b416c279-78df-411c-91f1-bc6b2b37a7fa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption_976d5ea2-06a3-4f5f-8364-86098fdcb48e" xlink:href="exel-20201002.xsd#exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_393d79fc-825b-49d7-bfba-e81ef404e092" xlink:to="loc_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption_976d5ea2-06a3-4f5f-8364-86098fdcb48e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_fe4efcc1-b676-49b2-9377-5d466cbcba69" xlink:href="exel-20201002.xsd#exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_393d79fc-825b-49d7-bfba-e81ef404e092" xlink:to="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_fe4efcc1-b676-49b2-9377-5d466cbcba69" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_ad2a79fa-c86f-4abc-8b78-8ecd11a53e85" xlink:href="exel-20201002.xsd#exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_393d79fc-825b-49d7-bfba-e81ef404e092" xlink:to="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_ad2a79fa-c86f-4abc-8b78-8ecd11a53e85" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9e572244-1acd-4b1c-b95d-d686ce71c54f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_393d79fc-825b-49d7-bfba-e81ef404e092" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9e572244-1acd-4b1c-b95d-d686ce71c54f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d62b478b-d962-4d48-ac18-62ae85bff403" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9e572244-1acd-4b1c-b95d-d686ce71c54f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d62b478b-d962-4d48-ac18-62ae85bff403" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d62b478b-d962-4d48-ac18-62ae85bff403_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d62b478b-d962-4d48-ac18-62ae85bff403" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d62b478b-d962-4d48-ac18-62ae85bff403_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7919dc29-e4f9-4897-abfb-561742cea3d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d62b478b-d962-4d48-ac18-62ae85bff403" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7919dc29-e4f9-4897-abfb-561742cea3d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementWithCatalentMember_e22afd09-5c68-46fa-959b-63e9e4ba4f9a" xlink:href="exel-20201002.xsd#exel_CollaborativeArrangementWithCatalentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7919dc29-e4f9-4897-abfb-561742cea3d0" xlink:to="loc_exel_CollaborativeArrangementWithCatalentMember_e22afd09-5c68-46fa-959b-63e9e4ba4f9a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsNBETherapeuticsAGNBECollaborationDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#CollaborationAgreementsNBETherapeuticsAGNBECollaborationDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsNBETherapeuticsAGNBECollaborationDetails" xlink:type="extended" id="i86c247b99eda42b8808692c8ae19127a_CollaborationAgreementsNBETherapeuticsAGNBECollaborationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6e6bd937-6547-4851-b55a-461688e4c8f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeAgreementsUpfrontPayments_2697dbde-044d-4640-86d2-7038f396613a" xlink:href="exel-20201002.xsd#exel_CollaborativeAgreementsUpfrontPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6e6bd937-6547-4851-b55a-461688e4c8f9" xlink:to="loc_exel_CollaborativeAgreementsUpfrontPayments_2697dbde-044d-4640-86d2-7038f396613a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAndLicenseAgreementTargetSelectionTerm_2b739fc8-42a6-463c-bb97-8378acd01f87" xlink:href="exel-20201002.xsd#exel_CollaborationAndLicenseAgreementTargetSelectionTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6e6bd937-6547-4851-b55a-461688e4c8f9" xlink:to="loc_exel_CollaborationAndLicenseAgreementTargetSelectionTerm_2b739fc8-42a6-463c-bb97-8378acd01f87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAndLicenseAgreementTargetSelectionExtensionOptionTerm_cdf92863-6438-451a-a91e-c8792f872192" xlink:href="exel-20201002.xsd#exel_CollaborationAndLicenseAgreementTargetSelectionExtensionOptionTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6e6bd937-6547-4851-b55a-461688e4c8f9" xlink:to="loc_exel_CollaborationAndLicenseAgreementTargetSelectionExtensionOptionTerm_cdf92863-6438-451a-a91e-c8792f872192" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAndLicenseAgreementExtendedTargetSelectionTerm_8675d5e1-3772-4d58-a552-2af562d05454" xlink:href="exel-20201002.xsd#exel_CollaborationAndLicenseAgreementExtendedTargetSelectionTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6e6bd937-6547-4851-b55a-461688e4c8f9" xlink:to="loc_exel_CollaborationAndLicenseAgreementExtendedTargetSelectionTerm_8675d5e1-3772-4d58-a552-2af562d05454" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementsAdditionalUpfrontPayments_5141bbeb-fc79-40c9-8bbf-a8996835946d" xlink:href="exel-20201002.xsd#exel_CollaborationAgreementsAdditionalUpfrontPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6e6bd937-6547-4851-b55a-461688e4c8f9" xlink:to="loc_exel_CollaborationAgreementsAdditionalUpfrontPayments_5141bbeb-fc79-40c9-8bbf-a8996835946d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption_70e28d52-9d05-4f0a-8fe0-affaae44792c" xlink:href="exel-20201002.xsd#exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6e6bd937-6547-4851-b55a-461688e4c8f9" xlink:to="loc_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption_70e28d52-9d05-4f0a-8fe0-affaae44792c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_e3bfb9de-7837-40bf-8136-8ccc65f2a447" xlink:href="exel-20201002.xsd#exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6e6bd937-6547-4851-b55a-461688e4c8f9" xlink:to="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_e3bfb9de-7837-40bf-8136-8ccc65f2a447" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_abafc8e8-f8b1-42d1-8e7a-86113ce4ad1e" xlink:href="exel-20201002.xsd#exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6e6bd937-6547-4851-b55a-461688e4c8f9" xlink:to="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_abafc8e8-f8b1-42d1-8e7a-86113ce4ad1e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_679e0aa6-d2c1-4e84-8987-4493e0f88bd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6e6bd937-6547-4851-b55a-461688e4c8f9" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_679e0aa6-d2c1-4e84-8987-4493e0f88bd8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_b242c935-8e4a-4288-8a98-bd8df44ebf71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_679e0aa6-d2c1-4e84-8987-4493e0f88bd8" xlink:to="loc_us-gaap_TypeOfArrangementAxis_b242c935-8e4a-4288-8a98-bd8df44ebf71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b242c935-8e4a-4288-8a98-bd8df44ebf71_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b242c935-8e4a-4288-8a98-bd8df44ebf71" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b242c935-8e4a-4288-8a98-bd8df44ebf71_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a8f1ac9d-b311-46ba-b810-c5887044f07b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b242c935-8e4a-4288-8a98-bd8df44ebf71" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a8f1ac9d-b311-46ba-b810-c5887044f07b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementWithNBETherapeuticsMember_c484a4af-4c59-4ea8-af69-793b731d5945" xlink:href="exel-20201002.xsd#exel_CollaborativeArrangementWithNBETherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a8f1ac9d-b311-46ba-b810-c5887044f07b" xlink:to="loc_exel_CollaborativeArrangementWithNBETherapeuticsMember_c484a4af-4c59-4ea8-af69-793b731d5945" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestments" xlink:type="simple" xlink:href="exel-20201002.xsd#CashandInvestments"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashandInvestments" xlink:type="extended" id="ie21b5e6edee445b481a8766c650dd341_CashandInvestments"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsTables" xlink:type="simple" xlink:href="exel-20201002.xsd#CashandInvestmentsTables"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsTables" xlink:type="extended" id="ic3be37e874ed426c8ba11de8e250f463_CashandInvestmentsTables"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended" id="i5002c573058648a4b1606c6047a0a6c9_CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#CashandInvestmentsInvestmentsbySecurityTypeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails" xlink:type="extended" id="i68cc21aeb9b44e00b9d97ed12fe7aeee_CashandInvestmentsInvestmentsbySecurityTypeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_93c8bc86-bf8c-497a-a502-b922490420b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_29b5da4c-fdfe-4d9b-9be4-5d11ed459c59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_93c8bc86-bf8c-497a-a502-b922490420b3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_29b5da4c-fdfe-4d9b-9be4-5d11ed459c59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_56acd437-eed6-4707-8afa-9fc1d785a226" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_93c8bc86-bf8c-497a-a502-b922490420b3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_56acd437-eed6-4707-8afa-9fc1d785a226" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f4dfd03f-8ceb-4f83-92fc-f8fbffe6947a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_93c8bc86-bf8c-497a-a502-b922490420b3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f4dfd03f-8ceb-4f83-92fc-f8fbffe6947a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_89b74728-56b3-4c74-86d0-4d59d78d0b50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_93c8bc86-bf8c-497a-a502-b922490420b3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_89b74728-56b3-4c74-86d0-4d59d78d0b50" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_91b9f674-b3b3-4f20-b892-d534676e7591" xlink:href="exel-20201002.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_93c8bc86-bf8c-497a-a502-b922490420b3" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_91b9f674-b3b3-4f20-b892-d534676e7591" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_d39380e3-fba3-42bf-bdb7-288aa55627b3" xlink:href="exel-20201002.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_93c8bc86-bf8c-497a-a502-b922490420b3" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_d39380e3-fba3-42bf-bdb7-288aa55627b3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_adcd03bf-426b-403f-8db4-805f3a08e36a" xlink:href="exel-20201002.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_93c8bc86-bf8c-497a-a502-b922490420b3" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_adcd03bf-426b-403f-8db4-805f3a08e36a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_b062bc44-f0d6-4944-8cb5-3d53adc802d7" xlink:href="exel-20201002.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_93c8bc86-bf8c-497a-a502-b922490420b3" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_b062bc44-f0d6-4944-8cb5-3d53adc802d7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_2fb23b4d-4da4-4ea6-88c4-1b970cb49c89" xlink:href="exel-20201002.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_93c8bc86-bf8c-497a-a502-b922490420b3" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_2fb23b4d-4da4-4ea6-88c4-1b970cb49c89" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b3f5800a-3d93-4acf-ab1c-6c129b478d0d" xlink:href="exel-20201002.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_93c8bc86-bf8c-497a-a502-b922490420b3" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b3f5800a-3d93-4acf-ab1c-6c129b478d0d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8b6ee16c-d210-45e5-a66d-1e95803290f7" xlink:href="exel-20201002.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_93c8bc86-bf8c-497a-a502-b922490420b3" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8b6ee16c-d210-45e5-a66d-1e95803290f7" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_6a1cb2cd-5052-4926-924b-c4110317694f" xlink:href="exel-20201002.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_93c8bc86-bf8c-497a-a502-b922490420b3" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_6a1cb2cd-5052-4926-924b-c4110317694f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8b5f559f-025f-4660-9af8-8206cb050741" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_93c8bc86-bf8c-497a-a502-b922490420b3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8b5f559f-025f-4660-9af8-8206cb050741" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_12cdbc9f-3bc8-45eb-9ea8-c9f7d40898de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8b5f559f-025f-4660-9af8-8206cb050741" xlink:to="loc_us-gaap_FinancialInstrumentAxis_12cdbc9f-3bc8-45eb-9ea8-c9f7d40898de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_12cdbc9f-3bc8-45eb-9ea8-c9f7d40898de_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_12cdbc9f-3bc8-45eb-9ea8-c9f7d40898de" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_12cdbc9f-3bc8-45eb-9ea8-c9f7d40898de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3b099349-6abb-4c75-af92-bfe2455a1a40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_12cdbc9f-3bc8-45eb-9ea8-c9f7d40898de" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3b099349-6abb-4c75-af92-bfe2455a1a40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_62b79a40-e13f-4929-8f08-2d147ca3c46c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3b099349-6abb-4c75-af92-bfe2455a1a40" xlink:to="loc_us-gaap_CommercialPaperMember_62b79a40-e13f-4929-8f08-2d147ca3c46c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_8f3e9e31-77ef-4330-8b94-6231cf132acd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3b099349-6abb-4c75-af92-bfe2455a1a40" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_8f3e9e31-77ef-4330-8b94-6231cf132acd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_f73329a5-5556-4ed5-87c6-13223c40836b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3b099349-6abb-4c75-af92-bfe2455a1a40" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_f73329a5-5556-4ed5-87c6-13223c40836b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_6e062e9a-7e41-404e-b29f-8e6299c4cc29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3b099349-6abb-4c75-af92-bfe2455a1a40" xlink:to="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_6e062e9a-7e41-404e-b29f-8e6299c4cc29" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_db86c1e4-d4c2-44fb-b094-2437abd11523" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3b099349-6abb-4c75-af92-bfe2455a1a40" xlink:to="loc_us-gaap_CashMember_db86c1e4-d4c2-44fb-b094-2437abd11523" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_f254bfa2-f280-4e13-9fd9-3088d1daa292" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3b099349-6abb-4c75-af92-bfe2455a1a40" xlink:to="loc_us-gaap_MoneyMarketFundsMember_f254bfa2-f280-4e13-9fd9-3088d1daa292" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_60b83dd8-78b3-48f0-9cd7-fe7d3eea0c04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3b099349-6abb-4c75-af92-bfe2455a1a40" xlink:to="loc_us-gaap_CertificatesOfDepositMember_60b83dd8-78b3-48f0-9cd7-fe7d3eea0c04" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#CashandInvestmentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails" xlink:type="extended" id="i0cc8a721943e48ecb5c863dcd914be1d_CashandInvestmentsNarrativeDetails"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails" xlink:type="extended" id="i0c3768191fff4b49bd3930eb089fae43_CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a37f61f4-39e2-4373-937f-441fad28f6c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_c0b61496-7ee1-40bd-b5eb-59a4c02edcfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a37f61f4-39e2-4373-937f-441fad28f6c8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_c0b61496-7ee1-40bd-b5eb-59a4c02edcfe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_b203c768-0b57-4404-865e-7364ad3087dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_c0b61496-7ee1-40bd-b5eb-59a4c02edcfe" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_b203c768-0b57-4404-865e-7364ad3087dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_27181b3d-0c3c-4516-8d35-fb27731b80f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_c0b61496-7ee1-40bd-b5eb-59a4c02edcfe" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_27181b3d-0c3c-4516-8d35-fb27731b80f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_01601bd4-1138-44dd-94fe-d9c137c1448e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a37f61f4-39e2-4373-937f-441fad28f6c8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_01601bd4-1138-44dd-94fe-d9c137c1448e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_5d6633c4-4b0c-45a4-af0a-b4585351e9b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_01601bd4-1138-44dd-94fe-d9c137c1448e" xlink:to="loc_us-gaap_FinancialInstrumentAxis_5d6633c4-4b0c-45a4-af0a-b4585351e9b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5d6633c4-4b0c-45a4-af0a-b4585351e9b3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5d6633c4-4b0c-45a4-af0a-b4585351e9b3" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5d6633c4-4b0c-45a4-af0a-b4585351e9b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_603d0cc5-96ea-487b-b2ff-33358b359950" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5d6633c4-4b0c-45a4-af0a-b4585351e9b3" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_603d0cc5-96ea-487b-b2ff-33358b359950" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_48238737-44f9-40ac-8068-2354fde87c34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_603d0cc5-96ea-487b-b2ff-33358b359950" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_48238737-44f9-40ac-8068-2354fde87c34" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_e2442322-b0e2-4191-8d62-0f9e99a41de2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_603d0cc5-96ea-487b-b2ff-33358b359950" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_e2442322-b0e2-4191-8d62-0f9e99a41de2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails" xlink:type="extended" id="if704b60761f349c5aab46aa261dd7688_CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="exel-20201002.xsd#FairValueMeasurements"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/FairValueMeasurements" xlink:type="extended" id="i76404b73b8614a2793ecdec5f3d0cec9_FairValueMeasurements"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="exel-20201002.xsd#FairValueMeasurementsTables"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:type="extended" id="i287fce99777d4a11be513f818ad2d216_FairValueMeasurementsTables"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#FairValueMeasurementsDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="extended" id="i50caec597b8d4ef0b0dc07088e1e1c58_FairValueMeasurementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_24243fd2-89b7-435d-a1f2-c37e4035a03a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1226ada6-d974-4f3e-bdfa-e5547dc898da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_24243fd2-89b7-435d-a1f2-c37e4035a03a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1226ada6-d974-4f3e-bdfa-e5547dc898da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e29c9213-8b25-493d-aab6-37d6e140d802" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_24243fd2-89b7-435d-a1f2-c37e4035a03a" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e29c9213-8b25-493d-aab6-37d6e140d802" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_848c3006-6c37-4425-8baa-63b8c1b87e6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_24243fd2-89b7-435d-a1f2-c37e4035a03a" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_848c3006-6c37-4425-8baa-63b8c1b87e6b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_80e5ac73-3b5e-4aa7-bc0a-c272ce95c625" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_24243fd2-89b7-435d-a1f2-c37e4035a03a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_80e5ac73-3b5e-4aa7-bc0a-c272ce95c625" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_c7e749a6-6497-48fc-af01-3a9f92c116c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_80e5ac73-3b5e-4aa7-bc0a-c272ce95c625" xlink:to="loc_us-gaap_FinancialInstrumentAxis_c7e749a6-6497-48fc-af01-3a9f92c116c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c7e749a6-6497-48fc-af01-3a9f92c116c6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c7e749a6-6497-48fc-af01-3a9f92c116c6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c7e749a6-6497-48fc-af01-3a9f92c116c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_53d8d52d-9f2d-4c45-9428-bd4de2e71b90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c7e749a6-6497-48fc-af01-3a9f92c116c6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_53d8d52d-9f2d-4c45-9428-bd4de2e71b90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_b05b4145-8cd8-481b-949c-12bd7dc5a442" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_53d8d52d-9f2d-4c45-9428-bd4de2e71b90" xlink:to="loc_us-gaap_CommercialPaperMember_b05b4145-8cd8-481b-949c-12bd7dc5a442" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_48ae5142-7497-4957-a0fe-f14de68ae27c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_53d8d52d-9f2d-4c45-9428-bd4de2e71b90" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_48ae5142-7497-4957-a0fe-f14de68ae27c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_1d58abf1-dd80-4bda-a338-3eee60c6d794" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_53d8d52d-9f2d-4c45-9428-bd4de2e71b90" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_1d58abf1-dd80-4bda-a338-3eee60c6d794" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_6af1b2fa-c0bf-4150-b960-6fdc676b1170" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_53d8d52d-9f2d-4c45-9428-bd4de2e71b90" xlink:to="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_6af1b2fa-c0bf-4150-b960-6fdc676b1170" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_8d5aecec-099a-4b19-88d6-ab5eba7d96c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_53d8d52d-9f2d-4c45-9428-bd4de2e71b90" xlink:to="loc_us-gaap_MoneyMarketFundsMember_8d5aecec-099a-4b19-88d6-ab5eba7d96c3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_d9b9d253-b365-4f62-bef4-0676621cad03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_53d8d52d-9f2d-4c45-9428-bd4de2e71b90" xlink:to="loc_us-gaap_CertificatesOfDepositMember_d9b9d253-b365-4f62-bef4-0676621cad03" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e0993f47-1fed-4143-a410-e846dad99901" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_80e5ac73-3b5e-4aa7-bc0a-c272ce95c625" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e0993f47-1fed-4143-a410-e846dad99901" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e0993f47-1fed-4143-a410-e846dad99901_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e0993f47-1fed-4143-a410-e846dad99901" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e0993f47-1fed-4143-a410-e846dad99901_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_330634dc-6916-498c-afe4-66449b0ad048" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e0993f47-1fed-4143-a410-e846dad99901" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_330634dc-6916-498c-afe4-66449b0ad048" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_6878fbbb-c0ba-4351-a7ef-322e68685d05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_330634dc-6916-498c-afe4-66449b0ad048" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_6878fbbb-c0ba-4351-a7ef-322e68685d05" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_1ca3b98f-2512-43c0-92af-471a30c0137b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_330634dc-6916-498c-afe4-66449b0ad048" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_1ca3b98f-2512-43c0-92af-471a30c0137b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8233291d-6076-4b2b-b371-111a654b75ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_80e5ac73-3b5e-4aa7-bc0a-c272ce95c625" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8233291d-6076-4b2b-b371-111a654b75ac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_8233291d-6076-4b2b-b371-111a654b75ac_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8233291d-6076-4b2b-b371-111a654b75ac" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_8233291d-6076-4b2b-b371-111a654b75ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_48f84886-71dc-4d0a-ad29-cb993ed32ed1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8233291d-6076-4b2b-b371-111a654b75ac" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_48f84886-71dc-4d0a-ad29-cb993ed32ed1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_61478404-b408-4b5f-bd1e-a3cb092a0f62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_48f84886-71dc-4d0a-ad29-cb993ed32ed1" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_61478404-b408-4b5f-bd1e-a3cb092a0f62" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/Inventory" xlink:type="simple" xlink:href="exel-20201002.xsd#Inventory"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/Inventory" xlink:type="extended" id="i104a27f9b5724742af8545f431e047ca_Inventory"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryTables" xlink:type="simple" xlink:href="exel-20201002.xsd#InventoryTables"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/InventoryTables" xlink:type="extended" id="if489369b626443d492cb01c7bd38c921_InventoryTables"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#InventoryDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/InventoryDetails" xlink:type="extended" id="i90a65af7d867461fa4ee449ab62f25f1_InventoryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_1cb6b540-7eed-4588-87f0-1d2309d59957" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_1f69cb67-5691-483e-9edd-3e440b18c3ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_1cb6b540-7eed-4588-87f0-1d2309d59957" xlink:to="loc_us-gaap_InventoryRawMaterials_1f69cb67-5691-483e-9edd-3e440b18c3ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_e47891f0-b3cd-4bbb-8476-abaf5d81bca6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_1cb6b540-7eed-4588-87f0-1d2309d59957" xlink:to="loc_us-gaap_InventoryWorkInProcess_e47891f0-b3cd-4bbb-8476-abaf5d81bca6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_fb41004d-7987-4318-8a0f-530678f8a656" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_1cb6b540-7eed-4588-87f0-1d2309d59957" xlink:to="loc_us-gaap_InventoryFinishedGoods_fb41004d-7987-4318-8a0f-530678f8a656" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_e1869870-dc1d-4f5d-8f28-22fd365ffe01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_1cb6b540-7eed-4588-87f0-1d2309d59957" xlink:to="loc_us-gaap_InventoryGross_e1869870-dc1d-4f5d-8f28-22fd365ffe01" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_e4e9d8ed-088e-4306-bdf0-b61d3ec0747f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_1cb6b540-7eed-4588-87f0-1d2309d59957" xlink:to="loc_us-gaap_InventoryCurrentTable_e4e9d8ed-088e-4306-bdf0-b61d3ec0747f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_f5cf7886-9ce4-46ee-809b-291e6f04e63f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_e4e9d8ed-088e-4306-bdf0-b61d3ec0747f" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_f5cf7886-9ce4-46ee-809b-291e6f04e63f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_f5cf7886-9ce4-46ee-809b-291e6f04e63f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_f5cf7886-9ce4-46ee-809b-291e6f04e63f" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_f5cf7886-9ce4-46ee-809b-291e6f04e63f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_cb94b6f7-6c61-4c0a-891f-59638e110c54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_f5cf7886-9ce4-46ee-809b-291e6f04e63f" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_cb94b6f7-6c61-4c0a-891f-59638e110c54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember_1928e865-5879-445e-a33f-fc252ed8f091" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_cb94b6f7-6c61-4c0a-891f-59638e110c54" xlink:to="loc_us-gaap_InventoriesMember_1928e865-5879-445e-a33f-fc252ed8f091" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OtherLongtermAssetsMember_42559c42-b4ab-4707-a77a-39c6506b8783" xlink:href="exel-20201002.xsd#exel_OtherLongtermAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_cb94b6f7-6c61-4c0a-891f-59638e110c54" xlink:to="loc_exel_OtherLongtermAssetsMember_42559c42-b4ab-4707-a77a-39c6506b8783" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="exel-20201002.xsd#StockBasedCompensation"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensation" xlink:type="extended" id="i0478cab4cf3848bfa656d2b9de12f6c6_StockBasedCompensation"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="exel-20201002.xsd#StockBasedCompensationTables"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationTables" xlink:type="extended" id="icc0f3229e7e3467787ee8cda9858bfc8_StockBasedCompensationTables"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="extended" id="i2dec3ac63e5343c49d2b29c916b074e0_StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6d6538fc-d45a-4413-b43b-f38f0426c14d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_a9de469a-c7cc-451d-9888-ab12d3f606eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6d6538fc-d45a-4413-b43b-f38f0426c14d" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_a9de469a-c7cc-451d-9888-ab12d3f606eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_fd57737a-9885-4486-bf3e-836e4bb1d0bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6d6538fc-d45a-4413-b43b-f38f0426c14d" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_fd57737a-9885-4486-bf3e-836e4bb1d0bd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_f9fb4487-a709-4508-833a-0782315649eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_fd57737a-9885-4486-bf3e-836e4bb1d0bd" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_f9fb4487-a709-4508-833a-0782315649eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f9fb4487-a709-4508-833a-0782315649eb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f9fb4487-a709-4508-833a-0782315649eb" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f9fb4487-a709-4508-833a-0782315649eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_354fe3ef-9ddd-4215-b0e1-de4155f052d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f9fb4487-a709-4508-833a-0782315649eb" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_354fe3ef-9ddd-4215-b0e1-de4155f052d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4fc9f53d-94a4-4372-bba1-a51ac1f1139c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_354fe3ef-9ddd-4215-b0e1-de4155f052d7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4fc9f53d-94a4-4372-bba1-a51ac1f1139c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_83fda334-f4ea-4cf4-b9a1-d982f17c8d27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_354fe3ef-9ddd-4215-b0e1-de4155f052d7" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_83fda334-f4ea-4cf4-b9a1-d982f17c8d27" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended" id="i6998c4156cab4e3cb088abbcb468a9b4_StockBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1bd4985-2ead-4327-abea-318ab2b27183" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_fac0cf60-b917-4ea2-b92a-f2ea49a8bb21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1bd4985-2ead-4327-abea-318ab2b27183" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_fac0cf60-b917-4ea2-b92a-f2ea49a8bb21" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_b0a30a03-7b87-4662-bd73-f9ae4c68a97b" xlink:href="exel-20201002.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1bd4985-2ead-4327-abea-318ab2b27183" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_b0a30a03-7b87-4662-bd73-f9ae4c68a97b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_344ef76f-254e-4e95-b59c-14a089b93847" xlink:href="exel-20201002.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1bd4985-2ead-4327-abea-318ab2b27183" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_344ef76f-254e-4e95-b59c-14a089b93847" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c473eadb-3940-417a-a873-1f78c255de2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1bd4985-2ead-4327-abea-318ab2b27183" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c473eadb-3940-417a-a873-1f78c255de2b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8225a5fe-8d96-44ef-a841-28d0726a47b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1bd4985-2ead-4327-abea-318ab2b27183" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8225a5fe-8d96-44ef-a841-28d0726a47b8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6cc4836e-e08a-478d-8832-f57d7dfe5f0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1bd4985-2ead-4327-abea-318ab2b27183" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6cc4836e-e08a-478d-8832-f57d7dfe5f0f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_dca23cdd-9de8-4c46-887d-6618116d1c2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1bd4985-2ead-4327-abea-318ab2b27183" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_dca23cdd-9de8-4c46-887d-6618116d1c2a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40b9f62c-f9a5-4ac3-88ad-4fdfcd461025" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1bd4985-2ead-4327-abea-318ab2b27183" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40b9f62c-f9a5-4ac3-88ad-4fdfcd461025" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1d0edf13-d1f4-4c72-88c5-1269879d661e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1bd4985-2ead-4327-abea-318ab2b27183" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1d0edf13-d1f4-4c72-88c5-1269879d661e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8785e398-025d-4dbf-a93d-b91ad090d848" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1bd4985-2ead-4327-abea-318ab2b27183" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8785e398-025d-4dbf-a93d-b91ad090d848" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ac6cddf4-3207-4a37-8489-008ffee5a2e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1bd4985-2ead-4327-abea-318ab2b27183" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ac6cddf4-3207-4a37-8489-008ffee5a2e9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_03f0e87e-64f7-461c-a599-61563f5b1864" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1bd4985-2ead-4327-abea-318ab2b27183" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_03f0e87e-64f7-461c-a599-61563f5b1864" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises_29975b7d-baa8-4c96-af42-88ccb973bdf6" xlink:href="exel-20201002.xsd#exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1bd4985-2ead-4327-abea-318ab2b27183" xlink:to="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises_29975b7d-baa8-4c96-af42-88ccb973bdf6" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_4b4112d9-b8ad-47ea-a9cc-ea66d10d5500" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1bd4985-2ead-4327-abea-318ab2b27183" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_4b4112d9-b8ad-47ea-a9cc-ea66d10d5500" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_7ae94848-fc90-46fd-9aae-8c5771b0755a" xlink:href="exel-20201002.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1bd4985-2ead-4327-abea-318ab2b27183" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_7ae94848-fc90-46fd-9aae-8c5771b0755a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumNumberOfSharesToVest_83c25785-eba4-4d7f-826c-640572b4b4d2" xlink:href="exel-20201002.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumNumberOfSharesToVest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1bd4985-2ead-4327-abea-318ab2b27183" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumNumberOfSharesToVest_83c25785-eba4-4d7f-826c-640572b4b4d2" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_716297b6-6bdc-402f-a465-9392ec2107e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1bd4985-2ead-4327-abea-318ab2b27183" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_716297b6-6bdc-402f-a465-9392ec2107e9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_948898c4-f8c1-41cb-9917-91bd114f36d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_716297b6-6bdc-402f-a465-9392ec2107e9" xlink:to="loc_us-gaap_AwardTypeAxis_948898c4-f8c1-41cb-9917-91bd114f36d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_948898c4-f8c1-41cb-9917-91bd114f36d8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_948898c4-f8c1-41cb-9917-91bd114f36d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_948898c4-f8c1-41cb-9917-91bd114f36d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b5858c54-c7f1-4988-a377-a2750a15cb14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_948898c4-f8c1-41cb-9917-91bd114f36d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b5858c54-c7f1-4988-a377-a2750a15cb14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b840f526-c81e-4620-a41d-93344a333db5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b5858c54-c7f1-4988-a377-a2750a15cb14" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b840f526-c81e-4620-a41d-93344a333db5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_59a04b44-1b43-4f99-8c93-2ec9a108c8b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b5858c54-c7f1-4988-a377-a2750a15cb14" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_59a04b44-1b43-4f99-8c93-2ec9a108c8b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_PerformanceShareOptionsPSOMember_f48c4734-37ad-4721-9d21-2df2be9b908e" xlink:href="exel-20201002.xsd#exel_PerformanceShareOptionsPSOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b5858c54-c7f1-4988-a377-a2750a15cb14" xlink:to="loc_exel_PerformanceShareOptionsPSOMember_f48c4734-37ad-4721-9d21-2df2be9b908e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_96ce9c0c-2659-4d8d-80b4-fa8010ef1254" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b5858c54-c7f1-4988-a377-a2750a15cb14" xlink:to="loc_us-gaap_PerformanceSharesMember_96ce9c0c-2659-4d8d-80b4-fa8010ef1254" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_StatusAxis_0ccde698-44c0-4f1a-8eb1-58125dcc2b2c" xlink:href="exel-20201002.xsd#exel_StatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_716297b6-6bdc-402f-a465-9392ec2107e9" xlink:to="loc_exel_StatusAxis_0ccde698-44c0-4f1a-8eb1-58125dcc2b2c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_StatusDomain_0ccde698-44c0-4f1a-8eb1-58125dcc2b2c_default" xlink:href="exel-20201002.xsd#exel_StatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exel_StatusAxis_0ccde698-44c0-4f1a-8eb1-58125dcc2b2c" xlink:to="loc_exel_StatusDomain_0ccde698-44c0-4f1a-8eb1-58125dcc2b2c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_StatusDomain_199bbed4-8512-4b86-941c-2fc7c48474d8" xlink:href="exel-20201002.xsd#exel_StatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exel_StatusAxis_0ccde698-44c0-4f1a-8eb1-58125dcc2b2c" xlink:to="loc_exel_StatusDomain_199bbed4-8512-4b86-941c-2fc7c48474d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AchievedMember_93ba9f7c-f9ea-49c6-81f0-f60b715bbdd9" xlink:href="exel-20201002.xsd#exel_AchievedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_StatusDomain_199bbed4-8512-4b86-941c-2fc7c48474d8" xlink:to="loc_exel_AchievedMember_93ba9f7c-f9ea-49c6-81f0-f60b715bbdd9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProbableMember_218818f3-5dc7-4d05-92a4-29d2279ad6ec" xlink:href="exel-20201002.xsd#exel_ProbableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_StatusDomain_199bbed4-8512-4b86-941c-2fc7c48474d8" xlink:to="loc_exel_ProbableMember_218818f3-5dc7-4d05-92a4-29d2279ad6ec" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxes" xlink:type="simple" xlink:href="exel-20201002.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/IncomeTaxes" xlink:type="extended" id="i568cd7f87e844e3b8e333eb66298f742_IncomeTaxes"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#IncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/IncomeTaxesDetails" xlink:type="extended" id="i6aef074be5204e068eb33889e9425bdb_IncomeTaxesDetails"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerShare" xlink:type="simple" xlink:href="exel-20201002.xsd#NetIncomeLossPerShare"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerShare" xlink:type="extended" id="ie6af2c46812b45daa859e55bf7b3ffb2_NetIncomeLossPerShare"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerShareTables" xlink:type="simple" xlink:href="exel-20201002.xsd#NetIncomeLossPerShareTables"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerShareTables" xlink:type="extended" id="ie32b49634c5d46eb9b4d73ed3ed7a7ea_NetIncomeLossPerShareTables"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerShareComputationofBasicandDilutedNetIncomePerShareDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#NetIncomeLossPerShareComputationofBasicandDilutedNetIncomePerShareDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerShareComputationofBasicandDilutedNetIncomePerShareDetails" xlink:type="extended" id="ib5ebd1af408f4b1abdbf56aa397949c2_NetIncomeLossPerShareComputationofBasicandDilutedNetIncomePerShareDetails"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#NetIncomeLossPerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails" xlink:type="extended" id="i7e043c9936ab446995e41d0afb06dd1d_NetIncomeLossPerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f78698ba-4ef2-41e6-b243-7fd436ca3544" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_23132e80-cd56-4a09-9f1b-761556bd8431" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f78698ba-4ef2-41e6-b243-7fd436ca3544" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_23132e80-cd56-4a09-9f1b-761556bd8431" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5faff420-28b1-4c3d-95a5-b5d651355ad8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f78698ba-4ef2-41e6-b243-7fd436ca3544" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5faff420-28b1-4c3d-95a5-b5d651355ad8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d8784e68-9eb2-4606-8735-b5c28eb6de81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5faff420-28b1-4c3d-95a5-b5d651355ad8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d8784e68-9eb2-4606-8735-b5c28eb6de81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d8784e68-9eb2-4606-8735-b5c28eb6de81_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d8784e68-9eb2-4606-8735-b5c28eb6de81" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d8784e68-9eb2-4606-8735-b5c28eb6de81_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4b686fb1-3d9c-4d77-b9d0-84c39ab6dc6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d8784e68-9eb2-4606-8735-b5c28eb6de81" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4b686fb1-3d9c-4d77-b9d0-84c39ab6dc6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_b2683c17-4584-4031-b87c-42aac66a2218" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4b686fb1-3d9c-4d77-b9d0-84c39ab6dc6a" xlink:to="loc_us-gaap_StockCompensationPlanMember_b2683c17-4584-4031-b87c-42aac66a2218" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="exel-20201002.xsd#CommitmentsandContingencies"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CommitmentsandContingencies" xlink:type="extended" id="i168cc25c3c824f8f9028d08927c9c6ec_CommitmentsandContingencies"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>exel-20201002_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:a5daf19b-278e-4193-a378-e43e29a2ddec,g:725f21e5-a4e0-44a1-91a2-e65dc567c7d2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_cc248976-fdc2-4c41-a27e-3ddfd62d9ad0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs awarded (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_8d43644e-3765-4cd4-bbb2-3c8d495c2317_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_9a2cfe35-24e7-46b9-a493-7df34df98963_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_107b20be-a14b-4496-bb7a-5c804bb0542b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember_4f4f0f8b-446f-400d-85f4-f59bdaf3ea4a_terseLabel_en-US" xlink:label="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal bonds</link:label>
    <link:label id="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember_label_en-US" xlink:label="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US States and Political Subdivisions Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:to="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ProbableMember_c884b711-7c5c-4c54-9b6f-56fe6405ec98_terseLabel_en-US" xlink:label="lab_exel_ProbableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probable</link:label>
    <link:label id="lab_exel_ProbableMember_label_en-US" xlink:label="lab_exel_ProbableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probable [Member]</link:label>
    <link:label id="lab_exel_ProbableMember_documentation_en-US" xlink:label="lab_exel_ProbableMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProbableMember" xlink:href="exel-20201002.xsd#exel_ProbableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProbableMember" xlink:to="lab_exel_ProbableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3fffb9b3-62a0-4251-869d-eece05b70edb_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a709f3fe-337a-4052-a4d1-3fa47b42fcfd_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_729a3183-78d7-416b-924b-27144b65a463_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted in the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementIncomeLossFromAgreement_bc4359ae-f912-4422-bae7-e67a0fb59167_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementIncomeLossFromAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profits on U.S. commercialization</link:label>
    <link:label id="lab_exel_CollaborativeArrangementIncomeLossFromAgreement_label_en-US" xlink:label="lab_exel_CollaborativeArrangementIncomeLossFromAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Income (Loss) From Agreement</link:label>
    <link:label id="lab_exel_CollaborativeArrangementIncomeLossFromAgreement_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementIncomeLossFromAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Income (Loss) from Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementIncomeLossFromAgreement" xlink:href="exel-20201002.xsd#exel_CollaborativeArrangementIncomeLossFromAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementIncomeLossFromAgreement" xlink:to="lab_exel_CollaborativeArrangementIncomeLossFromAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CotellicMember_ff7c47e0-72ca-47da-8e36-079bc77d166e_terseLabel_en-US" xlink:label="lab_exel_CotellicMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cotellic</link:label>
    <link:label id="lab_exel_CotellicMember_label_en-US" xlink:label="lab_exel_CotellicMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cotellic [Member]</link:label>
    <link:label id="lab_exel_CotellicMember_documentation_en-US" xlink:label="lab_exel_CotellicMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cotellic [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CotellicMember" xlink:href="exel-20201002.xsd#exel_CotellicMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CotellicMember" xlink:to="lab_exel_CotellicMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_d1ce7f67-5484-4f23-8d2c-0afe3b7d0ec8_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsAndInvestmentsTextBlock_1e2e9fe5-85da-4f2b-996f-9bf4e354e646_terseLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsAndInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH AND INVESTMENTS</link:label>
    <link:label id="lab_exel_CashCashEquivalentsAndInvestmentsTextBlock_label_en-US" xlink:label="lab_exel_CashCashEquivalentsAndInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Investments [Text Block]</link:label>
    <link:label id="lab_exel_CashCashEquivalentsAndInvestmentsTextBlock_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsAndInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Investments [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsAndInvestmentsTextBlock" xlink:href="exel-20201002.xsd#exel_CashCashEquivalentsAndInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsAndInvestmentsTextBlock" xlink:to="lab_exel_CashCashEquivalentsAndInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_c5eebe82-282a-4430-b842-d299cfd4b68f_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_574d4f57-5347-4992-9406-f1fd36317b33_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e4a72c8f-68c1-4e13-85b9-d5471080ddb9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_03380508-31ea-4e97-a86f-b97d7221838f_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments available-for-sale, fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_77625066-062d-42e7-a890-f92b2da7ca2f_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt securities available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8ccaa219-e8a0-46fa-afe3-ab6c0aab6396_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt securities available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_a5f0db29-4da9-4876-800b-d765ef433e50_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceMember_60f8661f-fe65-4da0-bb88-168fd926c3ce_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration services revenues</link:label>
    <link:label id="lab_us-gaap_ServiceMember_label_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember" xlink:to="lab_us-gaap_ServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_4a3b582e-dd40-4765-8105-9db60366a857_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_efac7332-15a2-40a3-8fa6-df7522172375_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_997998be-07af-45d9-b0c5-eafe27f9f029_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_429276d2-d2d4-424a-a453-7c33deae47b7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in share reserve under 2017 plan (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ec8bfe28-4724-49f6-afc1-7bac31478bf6_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_750079d0-d2ad-4c1e-b421-deaecbe63522_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory write-down</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_fa7d2af3-e53f-4e0d-9602-6033730fc9ae_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_PerformanceShareOptionsPSOMember_57637c46-d603-43f4-9498-efadbfcdf88e_terseLabel_en-US" xlink:label="lab_exel_PerformanceShareOptionsPSOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share Options (PSO)</link:label>
    <link:label id="lab_exel_PerformanceShareOptionsPSOMember_label_en-US" xlink:label="lab_exel_PerformanceShareOptionsPSOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share Options (PSO) [Member]</link:label>
    <link:label id="lab_exel_PerformanceShareOptionsPSOMember_documentation_en-US" xlink:label="lab_exel_PerformanceShareOptionsPSOMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share Options (PSO) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_PerformanceShareOptionsPSOMember" xlink:href="exel-20201002.xsd#exel_PerformanceShareOptionsPSOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_PerformanceShareOptionsPSOMember" xlink:to="lab_exel_PerformanceShareOptionsPSOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_47198a3c-ddd8-42e2-b50d-1b098db66583_terseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of royalty on net sale</link:label>
    <link:label id="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_label_en-US" xlink:label="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Percent Of Royalty On Net Sale</link:label>
    <link:label id="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_documentation_en-US" xlink:label="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Percent Of Royalty On Net Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:href="exel-20201002.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:to="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ProductsDerivedFromOtherCompoundsMember_1671a842-6551-43df-a207-a1ecea62bc2d_terseLabel_en-US" xlink:label="lab_exel_ProductsDerivedFromOtherCompoundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products derived from other compounds</link:label>
    <link:label id="lab_exel_ProductsDerivedFromOtherCompoundsMember_label_en-US" xlink:label="lab_exel_ProductsDerivedFromOtherCompoundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products Derived From Other Compounds [Member]</link:label>
    <link:label id="lab_exel_ProductsDerivedFromOtherCompoundsMember_documentation_en-US" xlink:label="lab_exel_ProductsDerivedFromOtherCompoundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products Derived From Other Compounds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductsDerivedFromOtherCompoundsMember" xlink:href="exel-20201002.xsd#exel_ProductsDerivedFromOtherCompoundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProductsDerivedFromOtherCompoundsMember" xlink:to="lab_exel_ProductsDerivedFromOtherCompoundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_16199f04-ea17-4b78-9434-fda237c58da0_terseLabel_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum potential to vest, percentage</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_label_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Maximum Potential To Vest</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_documentation_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Maximum Potential To Vest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" xlink:href="exel-20201002.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" xlink:to="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_6e94d2df-9bba-415a-9672-e920c3a21a0a_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_57b6cf59-22a4-4857-b91c-870a7babaad0_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturing after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_IpsenMember_b4d51745-f45d-4384-8819-c2989b2b769d_terseLabel_en-US" xlink:label="lab_exel_IpsenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen</link:label>
    <link:label id="lab_exel_IpsenMember_label_en-US" xlink:label="lab_exel_IpsenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen [Member]</link:label>
    <link:label id="lab_exel_IpsenMember_documentation_en-US" xlink:label="lab_exel_IpsenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_IpsenMember" xlink:href="exel-20201002.xsd#exel_IpsenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_IpsenMember" xlink:to="lab_exel_IpsenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_99cb7df1-f805-4390-9479-8d8e664513d3_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0fcd77ca-9d49-4e9d-a824-e489905d2204_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_da1270bb-077d-4aa4-bcfa-749517ebe834_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement with GlaxoSmithKline</link:label>
    <link:label id="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_label_en-US" xlink:label="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements with Glaxo Smith Kline [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements with Glaxo Smith Kline</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:href="exel-20201002.xsd#exel_CollaborativeArrangementswithGlaxoSmithKlineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:to="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_ce565126-9c98-4498-812d-091dbc068ee6_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_d6d28b74-5e87-4bcf-bc6e-b60e43a6ec9c_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_c5490bd7-6e56-437c-ae65-580f45dd26f3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_430e7e68-50e2-4b2c-878e-b8e0c5f8b47c_terseLabel_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current period</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_label_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Current Period</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_documentation_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Current Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:href="exel-20201002.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:to="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_ea9a53c3-76e4-4f15-a5c7-af05d4a9136b_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AchievedMember_5092a908-35d3-4210-b1b6-97895594641b_terseLabel_en-US" xlink:label="lab_exel_AchievedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achieved</link:label>
    <link:label id="lab_exel_AchievedMember_label_en-US" xlink:label="lab_exel_AchievedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achieved [Member]</link:label>
    <link:label id="lab_exel_AchievedMember_documentation_en-US" xlink:label="lab_exel_AchievedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achieved [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AchievedMember" xlink:href="exel-20201002.xsd#exel_AchievedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AchievedMember" xlink:to="lab_exel_AchievedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_b107404d-1be1-40bc-8a1d-dd5052834922_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_2698ee1d-3046-4307-9b37-d7d52da70e95_terseLabel_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision related to sales made in:</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_label_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves, Additions To Provision [Abstract]</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_documentation_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves, Additions To Provision [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:href="exel-20201002.xsd#exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:to="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_c617e9d5-6c60-4a6a-97e9-3581e290546b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_174132d0-6390-4c55-adde-408880978e34_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_347a2928-fee5-4c59-b796-24a0f1b10f00_terseLabel_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior periods</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_label_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Prior Period</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_documentation_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Prior Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:href="exel-20201002.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:to="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_fcd8dcc8-d082-4dd3-9fd3-0ed6194b247e_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:to="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_cd559428-9e4b-40c3-91d4-1e5ba1cb7165_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_2be10838-4bf2-45c8-8f10-07a9b290ea2b_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_3ced9c6d-3f02-4cba-bab7-49d448850816_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_136dbaf1-6739-4dff-8704-a41c2bf8401c_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiscalPeriod_a79ccc45-74e0-4fb1-a4f9-0ab2f3bcaa74_terseLabel_en-US" xlink:label="lab_us-gaap_FiscalPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fiscal Period</link:label>
    <link:label id="lab_us-gaap_FiscalPeriod_label_en-US" xlink:label="lab_us-gaap_FiscalPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fiscal Period, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiscalPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiscalPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiscalPeriod" xlink:to="lab_us-gaap_FiscalPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_dbb66122-2745-4bcc-a6de-914ca8d25583_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_f515e536-deac-49a7-88eb-1845f61b4e6a_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_eb6f59dc-8bd7-482c-b927-285b92ae182e_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Employee Benefits, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b532acc6-e21b-4d03-babe-f577533ade69_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_b368e3cf-a24b-44f1-8ac3-b78becae3b79_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_a7c4fc16-378a-42d2-a3ef-39a197f4f591_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock transactions associated with taxes withheld on equity awards</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_734b0ee0-25cb-42af-ab9f-41f55facdc75_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_a2135581-0b17-47b1-bb16-beaabc61c799_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under equity incentive and stock purchase plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRefundLiabilityCurrent_758e92f1-3d17-452c-8f5f-f5873d33405d_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rebates and fees due to customers</link:label>
    <link:label id="lab_us-gaap_CustomerRefundLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_CustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Refund Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerRefundLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRefundLiabilityCurrent" xlink:to="lab_us-gaap_CustomerRefundLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_50c88b98-5248-48b3-868d-a489f16da8aa_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_f962162c-0935-4795-8052-30172b58e214_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_OtherLongtermAssetsMember_5b265362-0d5e-43dd-bf55-7f4586bc6951_terseLabel_en-US" xlink:label="lab_exel_OtherLongtermAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion included in other long-term assets</link:label>
    <link:label id="lab_exel_OtherLongtermAssetsMember_label_en-US" xlink:label="lab_exel_OtherLongtermAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-term Assets [Member]</link:label>
    <link:label id="lab_exel_OtherLongtermAssetsMember_documentation_en-US" xlink:label="lab_exel_OtherLongtermAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-term Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OtherLongtermAssetsMember" xlink:href="exel-20201002.xsd#exel_OtherLongtermAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OtherLongtermAssetsMember" xlink:to="lab_exel_OtherLongtermAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_d6442ed4-0eef-4521-9c96-8f995cab189e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_1faf05df-3040-4311-b172-f6e5106d31ce_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AccruedCollaborationLiabilityCurrent_16604059-ecc9-470b-ae75-65af31651926_terseLabel_en-US" xlink:label="lab_exel_AccruedCollaborationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued collaboration liabilities</link:label>
    <link:label id="lab_exel_AccruedCollaborationLiabilityCurrent_label_en-US" xlink:label="lab_exel_AccruedCollaborationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Collaboration Liability, Current</link:label>
    <link:label id="lab_exel_AccruedCollaborationLiabilityCurrent_documentation_en-US" xlink:label="lab_exel_AccruedCollaborationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Collaboration Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccruedCollaborationLiabilityCurrent" xlink:href="exel-20201002.xsd#exel_AccruedCollaborationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AccruedCollaborationLiabilityCurrent" xlink:to="lab_exel_AccruedCollaborationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_6dd17cc8-ee9f-4cc3-a064-369682d4ed9d_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_fcf38010-6702-40cd-86c0-67de2bfe3000_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AllowanceForProductRebatesMember_411bae2c-9974-4bc8-bde8-16c8e7ad5fb2_terseLabel_en-US" xlink:label="lab_exel_AllowanceForProductRebatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rebates</link:label>
    <link:label id="lab_exel_AllowanceForProductRebatesMember_label_en-US" xlink:label="lab_exel_AllowanceForProductRebatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Product Rebates [Member]</link:label>
    <link:label id="lab_exel_AllowanceForProductRebatesMember_documentation_en-US" xlink:label="lab_exel_AllowanceForProductRebatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Product Rebates [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AllowanceForProductRebatesMember" xlink:href="exel-20201002.xsd#exel_AllowanceForProductRebatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AllowanceForProductRebatesMember" xlink:to="lab_exel_AllowanceForProductRebatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_a232cbb9-526b-462d-9bb5-0e140256ae58_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_84851cb5-d831-4d2b-84e6-9251c234eed6_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborationAndLicenseAgreementExtendedTargetSelectionTerm_9054bc5d-5494-4356-aea1-b319689a0d4d_terseLabel_en-US" xlink:label="lab_exel_CollaborationAndLicenseAgreementExtendedTargetSelectionTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration target selection extended, term</link:label>
    <link:label id="lab_exel_CollaborationAndLicenseAgreementExtendedTargetSelectionTerm_label_en-US" xlink:label="lab_exel_CollaborationAndLicenseAgreementExtendedTargetSelectionTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And License Agreement, Extended Target Selection Term</link:label>
    <link:label id="lab_exel_CollaborationAndLicenseAgreementExtendedTargetSelectionTerm_documentation_en-US" xlink:label="lab_exel_CollaborationAndLicenseAgreementExtendedTargetSelectionTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And License Agreement, Extended Target Selection Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAndLicenseAgreementExtendedTargetSelectionTerm" xlink:href="exel-20201002.xsd#exel_CollaborationAndLicenseAgreementExtendedTargetSelectionTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAndLicenseAgreementExtendedTargetSelectionTerm" xlink:to="lab_exel_CollaborationAndLicenseAgreementExtendedTargetSelectionTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateTypeDomain_ae790969-dc9a-4b4b-bba5-167b22b8dc5e_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateTypeDomain_label_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:to="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_70cdc8d4-9e6a-4e41-82e2-3dabe6c8cb07_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7bb5811e-fd77-4dce-98a3-388d5da533cb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_bc690758-4168-43b2-921f-2f4dc734df84_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments available-for-sale, gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_012c2fff-98dc-4c24-afa1-ce0a0c8aae17_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_f450ffcb-9fc2-4590-927d-9e82e5385e1b_terseLabel_en-US" xlink:label="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum amount eligible for commercial milestones under collaborations agreement</link:label>
    <link:label id="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_label_en-US" xlink:label="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Amount Eligible For Commercial Milestones Under Collaborations Agreement</link:label>
    <link:label id="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_documentation_en-US" xlink:label="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Amount Eligible For Commercial Milestones Under Collaborations Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:href="exel-20201002.xsd#exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:to="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_a8dcfa12-bc96-496c-b2a3-944c42cb84d3_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_d766bc6a-d49f-4a24-9b84-1aedea710f66_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_f8a548f5-d70e-458b-bab9-66c4a416a62c_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b9c4a8a3-61a9-45ad-824b-191bdbea92a5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_06655e01-2198-45f2-958c-463f380aec9a_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturing in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_2573db4e-72a6-4994-941c-0eabcfaa19be_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury and government-sponsored enterprises</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_671a424b-bf2d-41e8-a021-4754b5144e07_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_d8ac06f6-0f67-4e5d-8362-105ce05f67dd_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_963c3c9b-96cb-45c6-97ee-3a7923649878_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_5711dc5c-c7d5-463a-ba57-505f1483931d_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ProductsDerivedFromCabozantinibMember_ae3a4053-a3b3-441b-bc7a-8e32d1c3e7d8_terseLabel_en-US" xlink:label="lab_exel_ProductsDerivedFromCabozantinibMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products derived from cabozantinib</link:label>
    <link:label id="lab_exel_ProductsDerivedFromCabozantinibMember_label_en-US" xlink:label="lab_exel_ProductsDerivedFromCabozantinibMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products Derived From Cabozantinib [Member]</link:label>
    <link:label id="lab_exel_ProductsDerivedFromCabozantinibMember_documentation_en-US" xlink:label="lab_exel_ProductsDerivedFromCabozantinibMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products Derived from Cabozantinib [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductsDerivedFromCabozantinibMember" xlink:href="exel-20201002.xsd#exel_ProductsDerivedFromCabozantinibMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProductsDerivedFromCabozantinibMember" xlink:to="lab_exel_ProductsDerivedFromCabozantinibMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_GlaxoSmithKlineMember_52a15cf0-7467-4929-abb8-238d1f7f3a0d_terseLabel_en-US" xlink:label="lab_exel_GlaxoSmithKlineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GSK</link:label>
    <link:label id="lab_exel_GlaxoSmithKlineMember_label_en-US" xlink:label="lab_exel_GlaxoSmithKlineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glaxo Smith Kline [Member]</link:label>
    <link:label id="lab_exel_GlaxoSmithKlineMember_documentation_en-US" xlink:label="lab_exel_GlaxoSmithKlineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glaxo Smith Kline [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_GlaxoSmithKlineMember" xlink:href="exel-20201002.xsd#exel_GlaxoSmithKlineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_GlaxoSmithKlineMember" xlink:to="lab_exel_GlaxoSmithKlineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b78c3806-6c32-45fd-8210-35a68e2f0890_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_0ba0b4c9-7304-4380-9664-4c14da5a7dfb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_f9d41f83-7ca6-4b55-9c4b-008b090eb95f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_ae1f6828-3988-452b-ba57-811c3d43a779_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_823ac793-3e1b-42df-90b9-fb85a180bf59_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b996841b-bec9-4f59-8f09-a9274d201caa_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_e5319ad5-955f-48c1-95d6-c4185dd24bba_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_a1db28ad-3c1e-4d7d-b1be-5e15a6c89510_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0a3e8ca4-882c-43bb-9d25-016138bbe188_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from contract with customer</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7d95366f-d480-414e-ae1d-e2de1ece91f4_netLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_eef6924e-1613-4435-a532-60a60841356e_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty revenues on ex-U.S. sales</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_2b609d42-2932-4013-bd73-7bbad046c98b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLineItems_3a8652b7-4033-47ae-83f3-717f76f07809_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems" xlink:to="lab_us-gaap_InventoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_6d74e876-ef1e-4ea0-a6fd-c1565e832339_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total financial assets carried at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborationMember_5bd5727c-8f59-4c96-a056-2ca631c3eac0_verboseLabel_en-US" xlink:label="lab_exel_CollaborationMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total collaboration revenues</link:label>
    <link:label id="lab_exel_CollaborationMember_label_en-US" xlink:label="lab_exel_CollaborationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration [Member]</link:label>
    <link:label id="lab_exel_CollaborationMember_documentation_en-US" xlink:label="lab_exel_CollaborationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationMember" xlink:href="exel-20201002.xsd#exel_CollaborationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationMember" xlink:to="lab_exel_CollaborationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborationAndLicenseAgreementTargetSelectionExtensionOptionTerm_88e6d86b-ee2a-452a-aa75-c1b5db632626_terseLabel_en-US" xlink:label="lab_exel_CollaborationAndLicenseAgreementTargetSelectionExtensionOptionTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration extension option</link:label>
    <link:label id="lab_exel_CollaborationAndLicenseAgreementTargetSelectionExtensionOptionTerm_label_en-US" xlink:label="lab_exel_CollaborationAndLicenseAgreementTargetSelectionExtensionOptionTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And License Agreement, Target Selection, Extension Option Term</link:label>
    <link:label id="lab_exel_CollaborationAndLicenseAgreementTargetSelectionExtensionOptionTerm_documentation_en-US" xlink:label="lab_exel_CollaborationAndLicenseAgreementTargetSelectionExtensionOptionTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And License Agreement, Target Selection, Extension Option Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAndLicenseAgreementTargetSelectionExtensionOptionTerm" xlink:href="exel-20201002.xsd#exel_CollaborationAndLicenseAgreementTargetSelectionExtensionOptionTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAndLicenseAgreementTargetSelectionExtensionOptionTerm" xlink:to="lab_exel_CollaborationAndLicenseAgreementTargetSelectionExtensionOptionTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e5e55549-74ad-4a78-bf58-c45013b6897b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_f663457e-1fb6-45c6-ba67-11eef1fd35d7_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of total revenues</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_256ac29a-fa5c-4fce-917a-1f9e6665815c_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_50897dad-0808-43af-95d5-5ae52b4aad21_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_3a6ea4b0-664a-4261-bdd7-53106e9581a1_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with customer, liability, current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_8d31276b-fdce-4da4-8ada-24cdae01bc99_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_NumberofProductsinCommercialMarket_adac08c0-0609-487c-9e91-36f7582e2093_terseLabel_en-US" xlink:label="lab_exel_NumberofProductsinCommercialMarket" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of products that entered in the commercial marketplace</link:label>
    <link:label id="lab_exel_NumberofProductsinCommercialMarket_label_en-US" xlink:label="lab_exel_NumberofProductsinCommercialMarket" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Products in Commercial Market</link:label>
    <link:label id="lab_exel_NumberofProductsinCommercialMarket_documentation_en-US" xlink:label="lab_exel_NumberofProductsinCommercialMarket" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Products in Commercial Market</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NumberofProductsinCommercialMarket" xlink:href="exel-20201002.xsd#exel_NumberofProductsinCommercialMarket"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_NumberofProductsinCommercialMarket" xlink:to="lab_exel_NumberofProductsinCommercialMarket" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_f9a37006-9c66-4d73-9fc1-4b631d490f34_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_354a2d3a-2aa2-4d5b-a7fb-a8353d49dbf4_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted in the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_b73f7e8a-480c-4b15-ba85-113d8fd1950c_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_EarningsPerShareNumeratorAbstract_84886f40-9950-4d28-b80e-f12d18ccfa06_terseLabel_en-US" xlink:label="lab_exel_EarningsPerShareNumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_exel_EarningsPerShareNumeratorAbstract_label_en-US" xlink:label="lab_exel_EarningsPerShareNumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Numerator [Abstract]</link:label>
    <link:label id="lab_exel_EarningsPerShareNumeratorAbstract_documentation_en-US" xlink:label="lab_exel_EarningsPerShareNumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Numerator [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_EarningsPerShareNumeratorAbstract" xlink:href="exel-20201002.xsd#exel_EarningsPerShareNumeratorAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_EarningsPerShareNumeratorAbstract" xlink:to="lab_exel_EarningsPerShareNumeratorAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementWithNBETherapeuticsMember_19fcd182-ac28-431f-994e-508f25cd59b5_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementWithNBETherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement With NBE Therapeutics</link:label>
    <link:label id="lab_exel_CollaborativeArrangementWithNBETherapeuticsMember_label_en-US" xlink:label="lab_exel_CollaborativeArrangementWithNBETherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement With NBE Therapeutics [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementWithNBETherapeuticsMember_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementWithNBETherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement With NBE Therapeutics</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementWithNBETherapeuticsMember" xlink:href="exel-20201002.xsd#exel_CollaborativeArrangementWithNBETherapeuticsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementWithNBETherapeuticsMember" xlink:to="lab_exel_CollaborativeArrangementWithNBETherapeuticsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_920fd288-75e8-4e3c-b071-af66dc416f16_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_736f2cfd-e915-430f-9a86-13e0f1a72c25_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ec9e9b8c-78ac-4bf0-822c-bd53ce90eed8_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5d494c0e-4345-454a-920c-41fb537a0fe2_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_6574a8b0-9dc5-4fa7-a0d8-f1c9216854bc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income (Loss) Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_bdd2296d-dd47-4fe0-91d7-2ad215b27337_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_4d9cc9ba-afe2-4490-905d-8aae19697e71_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) per share - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_5f0990c5-5c02-4424-8b7c-9fb6a363c9a3_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of business segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_49b2a9ca-5340-4a25-85a6-e743f23c1155_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_19a78803-4ecd-49af-8ce9-b57163ffd098_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryCurrentTable_6a0c349b-97f8-4815-8a61-c10b61b09e5a_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:label id="lab_us-gaap_InventoryCurrentTable_label_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCurrentTable" xlink:to="lab_us-gaap_InventoryCurrentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_2e1bee78-3bb4-4202-98e4-136ebcef01be_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumNumberOfSharesToVest_427f94fa-9028-4bd8-8c66-9c44cad81e6e_terseLabel_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumNumberOfSharesToVest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional shares to be earned (in shares)</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumNumberOfSharesToVest_label_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumNumberOfSharesToVest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Maximum Number of Shares to Vest</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumNumberOfSharesToVest_documentation_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumNumberOfSharesToVest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Maximum Number of Shares to Vest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumNumberOfSharesToVest" xlink:href="exel-20201002.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumNumberOfSharesToVest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumNumberOfSharesToVest" xlink:to="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumNumberOfSharesToVest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_48bcae01-af0c-45c0-bca0-243cfeab70ae_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes and Tax Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_8e280029-5c46-4666-acaf-2630f20bc012_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_c9ea1f78-2b25-4604-a0e4-415f024fe031_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CabometyxMember_64267acc-a376-4777-aabf-c607fb8b7075_terseLabel_en-US" xlink:label="lab_exel_CabometyxMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CABOMETYX</link:label>
    <link:label id="lab_exel_CabometyxMember_label_en-US" xlink:label="lab_exel_CabometyxMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cabometyx [Member]</link:label>
    <link:label id="lab_exel_CabometyxMember_documentation_en-US" xlink:label="lab_exel_CabometyxMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cabometyx [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CabometyxMember" xlink:href="exel-20201002.xsd#exel_CabometyxMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CabometyxMember" xlink:to="lab_exel_CabometyxMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_cc01ff3c-8fa2-4745-8967-eea44feca12e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining performance obligation</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_5900742f-9ab8-4885-a39b-94efda9d7083_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_795b5a91-074b-435c-9579-c6f45034d611_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeOther_8359daaf-773c-46be-bdbc-7688f07d6fe5_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOther_label_en-US" xlink:label="lab_us-gaap_InterestIncomeOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOther" xlink:to="lab_us-gaap_InterestIncomeOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_bc3bb00b-992b-4947-828e-5f7f0587a37e_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_0d6643a3-9576-4187-8490-5f1553dd6fd1_terseLabel_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in share reserve after all other awards (in shares)</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_label_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Other Awards</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_documentation_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award,Reduction of Number of Shares in Share Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:href="exel-20201002.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:to="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_2ba692e0-c9ba-458c-b2df-9c531f0785ee_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 309,402 and 304,831 at September&#160;30, 2020 and December&#160;31, 2019, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermInvestments_fc3b05b6-aa3a-4fe2-80d6-399b8955ce03_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments" xlink:to="lab_us-gaap_LongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_0693cd30-06c5-4acb-ba92-c6abddc01e1e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in earnings per share due to change in accounting estimate (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_MckessonMember_525dde61-83de-4b40-92ed-875a83bed7b5_terseLabel_en-US" xlink:label="lab_exel_MckessonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mckesson</link:label>
    <link:label id="lab_exel_MckessonMember_label_en-US" xlink:label="lab_exel_MckessonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mckesson [Member]</link:label>
    <link:label id="lab_exel_MckessonMember_documentation_en-US" xlink:label="lab_exel_MckessonMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mckesson</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MckessonMember" xlink:href="exel-20201002.xsd#exel_MckessonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_MckessonMember" xlink:to="lab_exel_MckessonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_e4f72c97-2efd-458b-b155-6497537efe0f_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_MilestonePaymentsEarned_922770c1-b481-434b-a91d-17d143837058_terseLabel_en-US" xlink:label="lab_exel_MilestonePaymentsEarned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments earned</link:label>
    <link:label id="lab_exel_MilestonePaymentsEarned_label_en-US" xlink:label="lab_exel_MilestonePaymentsEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments Earned</link:label>
    <link:label id="lab_exel_MilestonePaymentsEarned_documentation_en-US" xlink:label="lab_exel_MilestonePaymentsEarned" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments Earned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MilestonePaymentsEarned" xlink:href="exel-20201002.xsd#exel_MilestonePaymentsEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_MilestonePaymentsEarned" xlink:to="lab_exel_MilestonePaymentsEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_8504f43e-5b52-4cab-849d-7d0d81f276e8_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f49f460e-37a2-4d4a-a36e-14ef10d1cac4_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5f301c53-43f7-496d-adfe-8204b7e63bf1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_7c29eaea-08bc-4f2c-b2ed-9151212279d1_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_StatusDomain_8e2f1b1b-93b3-4980-ac4b-a96d23f2c342_terseLabel_en-US" xlink:label="lab_exel_StatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Status [Domain]</link:label>
    <link:label id="lab_exel_StatusDomain_label_en-US" xlink:label="lab_exel_StatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Status [Domain]</link:label>
    <link:label id="lab_exel_StatusDomain_documentation_en-US" xlink:label="lab_exel_StatusDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_StatusDomain" xlink:href="exel-20201002.xsd#exel_StatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_StatusDomain" xlink:to="lab_exel_StatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_17be98c7-d24b-4b16-9a0d-c9a3b06d92f9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Computation of Basic and Diluted Net Income (Loss) Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_3bec717b-8a70-4e26-bb26-d11be88545d8_terseLabel_en-US" xlink:label="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances</link:label>
    <link:label id="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_label_en-US" xlink:label="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]</link:label>
    <link:label id="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_documentation_en-US" xlink:label="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:href="exel-20201002.xsd#exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:to="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_5c7d518f-fb41-4ec0-b959-1df89b89d614_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under equity incentive and stock purchase plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AccruedClinicalLiabilitiesCurrent_312bea1f-572c-400e-a708-c3019b3fe056_terseLabel_en-US" xlink:label="lab_exel_AccruedClinicalLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical trial liabilities</link:label>
    <link:label id="lab_exel_AccruedClinicalLiabilitiesCurrent_label_en-US" xlink:label="lab_exel_AccruedClinicalLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Liabilities, Current</link:label>
    <link:label id="lab_exel_AccruedClinicalLiabilitiesCurrent_documentation_en-US" xlink:label="lab_exel_AccruedClinicalLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccruedClinicalLiabilitiesCurrent" xlink:href="exel-20201002.xsd#exel_AccruedClinicalLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AccruedClinicalLiabilitiesCurrent" xlink:to="lab_exel_AccruedClinicalLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cb00adbc-5869-4f97-be98-9a2169728401_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value, awarded (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_dc58ff9e-ec64-41c9-b2fd-a5aceb569924_terseLabel_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in share reserve after stock option or stock appreciation award (in shares)</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_label_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Stock Option Or Stock Appreciation Award</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_documentation_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award,Reduction of Number of Shares in Share Reserve After Stock Option or Stock Appreciation Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:href="exel-20201002.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:to="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_cc437821-7dfc-41ce-a55a-5a487bd2e373_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_dc404a0a-f403-4a5d-98b8-604a41a2f92e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Classification of Financial Assets Measured and Recorded at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_b914baae-2408-4ee3-b676-a9c2ed2612ac_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COLLABORATION AGREEMENTS</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2443e017-ea5f-4d04-b0ad-73e40d84c618_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_d8e4321d-8758-4e8a-b531-c14d7f11e26d_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_85ed9594-cffa-479e-9b96-b2419ffc00b4_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_38e9bc88-fa16-478a-aa3f-cc56b170a5eb_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_620fa2a8-27bb-4f69-86aa-52441ba3f734_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_eb31c161-624b-4443-96e2-73d5303201bd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, number of shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_8a15d898-f3a2-4773-8fd2-93ba1ea77498_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ProductSalesDiscountsAndAllowancesMember_56a96fef-e893-49a7-b487-fa17585a66ed_terseLabel_en-US" xlink:label="lab_exel_ProductSalesDiscountsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounts and allowances</link:label>
    <link:label id="lab_exel_ProductSalesDiscountsAndAllowancesMember_label_en-US" xlink:label="lab_exel_ProductSalesDiscountsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, Sales Discounts And Allowances [Member]</link:label>
    <link:label id="lab_exel_ProductSalesDiscountsAndAllowancesMember_documentation_en-US" xlink:label="lab_exel_ProductSalesDiscountsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, Sales Discounts And Allowances [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductSalesDiscountsAndAllowancesMember" xlink:href="exel-20201002.xsd#exel_ProductSalesDiscountsAndAllowancesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProductSalesDiscountsAndAllowancesMember" xlink:to="lab_exel_ProductSalesDiscountsAndAllowancesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_e5f4f86f-d135-4ab7-9791-38e3ffc2d4c3_terseLabel_en-US" xlink:label="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Customer Credits/Fees and Co-pay Assistance</link:label>
    <link:label id="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_label_en-US" xlink:label="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member]</link:label>
    <link:label id="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_documentation_en-US" xlink:label="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:href="exel-20201002.xsd#exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:to="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_9f7d2a57-5ea1-469d-a906-c81e85d47ee5_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis_2db806ac-e9da-4314-be99-4151fd59e134_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:to="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_TakedaMember_de9b53ae-a3e4-4460-97b4-2b2d9843e62b_terseLabel_en-US" xlink:label="lab_exel_TakedaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda Pharmaceutical Company Limited (Takeda)</link:label>
    <link:label id="lab_exel_TakedaMember_85e84f9c-f8ee-46da-adc1-f51b734e27e8_verboseLabel_en-US" xlink:label="lab_exel_TakedaMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda</link:label>
    <link:label id="lab_exel_TakedaMember_label_en-US" xlink:label="lab_exel_TakedaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda [Member]</link:label>
    <link:label id="lab_exel_TakedaMember_documentation_en-US" xlink:label="lab_exel_TakedaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TakedaMember" xlink:href="exel-20201002.xsd#exel_TakedaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_TakedaMember" xlink:to="lab_exel_TakedaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_af3fd7a2-c864-4e4d-a079-6ce6300df3c8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashEquivalentsNoncurrent_32dd1ec5-6142-46f8-99e9-0c3e1f85cb50_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash equivalents included in long-term investments</link:label>
    <link:label id="lab_us-gaap_RestrictedCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_6df26c46-8e89-4a37-996f-51bd3e0d5039_terseLabel_en-US" xlink:label="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chargebacks and Discounts for Prompt Payment</link:label>
    <link:label id="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_label_en-US" xlink:label="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chargebacks And Discounts For Prompt Payment [Member]</link:label>
    <link:label id="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_documentation_en-US" xlink:label="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chargebacks And Discounts For Prompt Payment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:href="exel-20201002.xsd#exel_ChargebacksAndDiscountsForPromptPaymentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:to="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_2a2a4871-4e0a-47d7-970c-3a9baca617c1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_62d31c77-d13e-4e49-9405-4902d5209b2c_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1a260c25-28e3-49f8-b326-ac71e723bfea_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_daa4cf1b-3ab3-4fe2-b6e0-daa9ed1156af_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_10670867-b370-4f88-a3b5-4b73513c71ae_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_86580343-a1a1-47ad-a9dd-5f6ec0b8c63b_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_aabc881b-74f0-4e7d-bc2b-c01b22030090_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember_dee77355-9db5-4f75-bc48-fb1440b64476_terseLabel_en-US" xlink:label="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of AmerisourceBergen Corporation</link:label>
    <link:label id="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember_label_en-US" xlink:label="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates Of Amerisource Bergen Corporation [Member]</link:label>
    <link:label id="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember_documentation_en-US" xlink:label="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates Of Amerisource Bergen Corporation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:href="exel-20201002.xsd#exel_AffiliatesOfAmerisourceBergenCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:to="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_6c391cb5-190f-4b62-9b72-825eea39fd1e_terseLabel_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Policies [Table]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_label_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Policies [Table]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_documentation_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Policies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:href="exel-20201002.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:to="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_fd0f7b01-bfc6-4c13-8e8e-d0933b8adbae_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a0f1f6e8-7c7e-4de3-87fa-5ae39a032c61_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_16131f9c-6d54-475e-b125-5e10254de0f1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterials_27d1284f-4a2d-407a-b465-737235ed90bc_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_4ae97a79-f2f7-4321-a14b-13e4a5db214b_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unpaid liabilities incurred for purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_184b9913-37e9-4ac7-8b61-0303deee7201_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_24c54182-685f-4d12-9d0d-14c6b193fb3e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_a0b6b299-b2fc-4646-847b-7b2c09432b74_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_df5b7d5a-6a9a-4866-b7cd-c40541d5c511_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_4146e233-5262-42fa-a2d4-8ffdec599d2d_totalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, restricted cash and restricted cash equivalents and available-for-sale debt securities, amortized cost</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="exel-20201002.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_a441e6d2-77cc-40be-85fc-6c89b55126d8_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ba5dd534-8d7a-4c34-ad24-6ca4930a1a0e_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, available-for-sale, amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d466b5fb-07fc-464d-9246-d3bef0261643_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive shares (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_a861fb39-4b9e-43c5-9368-aa2a929ffaf4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities and sales of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8e7843a6-b9ab-450d-8616-181be18a4ccc_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments available-for-sale, gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AffiliatesofMcKessonCorporationMember_cdc37535-1e75-4f9b-8b72-a72b3dc94126_terseLabel_en-US" xlink:label="lab_exel_AffiliatesofMcKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of McKesson Corporation</link:label>
    <link:label id="lab_exel_AffiliatesofMcKessonCorporationMember_label_en-US" xlink:label="lab_exel_AffiliatesofMcKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of McKesson Corporation [Member]</link:label>
    <link:label id="lab_exel_AffiliatesofMcKessonCorporationMember_documentation_en-US" xlink:label="lab_exel_AffiliatesofMcKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of McKesson Corporation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofMcKessonCorporationMember" xlink:href="exel-20201002.xsd#exel_AffiliatesofMcKessonCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AffiliatesofMcKessonCorporationMember" xlink:to="lab_exel_AffiliatesofMcKessonCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_d75301c8-bac6-4303-8848-76a16c4b683d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_ccd50577-14f5-49f0-b857-2e87f370d2a4_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_c5728eaa-353e-4b3b-8c5d-748c8e8d5dfb_verboseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenues</link:label>
    <link:label id="lab_us-gaap_ProductMember_b2f863ff-e7ed-4233-b6bf-1d1c02d23528_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenues</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_9ddbfcd0-6ab5-4c15-b080-9eb8ea5334cc_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_0b30e7f7-3dee-4a3f-9431-8ab62eaa3c67_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_7591c409-3fb5-48d2-a50f-8c4dcb579dd2_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at December&#160;31, 2019</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_cd1b487b-49f6-4a4a-9082-2c171e580a9b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at September&#160;30, 2020</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_cb38b7e1-fe54-49cd-9ecb-43c9c2ee3dcf_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_45476c5a-9b64-40fd-9b96-ab683ae8552b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashMember_ff7673d0-7aad-4786-88d8-a3f79bb8bc7d_terseLabel_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_CashMember_label_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashMember" xlink:to="lab_us-gaap_CashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_de67e845-4ea5-4718-b956-8ab3abd2948b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_75ca1d87-28a8-4e99-b000-2c3367bcaeeb_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_114f340d-4ef4-436b-b0d3-bcda049f124a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_7992e02b-aff0-451d-9a29-6a298e616f67_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementwithTakedaMember_d7859673-6444-4695-b6d2-04daec58c354_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithTakedaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Takeda</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithTakedaMember_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithTakedaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Takeda [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithTakedaMember_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithTakedaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Takeda [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember" xlink:href="exel-20201002.xsd#exel_CollaborativeArrangementwithTakedaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithTakedaMember" xlink:to="lab_exel_CollaborativeArrangementwithTakedaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_112966a1-6a95-4f28-8f12-911034a8384c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_509d0ed8-8da4-4417-a869-950f5f708eff_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_edff94aa-c1a3-48c3-9a99-ad745774d924_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_f4c4be67-468d-4231-b628-968a9a76aa2c_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_d8236b52-7e97-4f28-bc62-2611e18c381b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2e292a00-824a-4300-85cf-c1724b2ad346_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember_d3dcca61-ae12-41e7-9758-dfa818b1461e_terseLabel_en-US" xlink:label="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of Optum Specialty Pharmacy</link:label>
    <link:label id="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember_label_en-US" xlink:label="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of Optum Specialty Pharmacy [Member]</link:label>
    <link:label id="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember_documentation_en-US" xlink:label="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of Optum Specialty Pharmacy [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofOptumSpecialtyPharmacyMember" xlink:href="exel-20201002.xsd#exel_AffiliatesofOptumSpecialtyPharmacyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AffiliatesofOptumSpecialtyPharmacyMember" xlink:to="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_3e259618-35c5-4bb9-bbec-8e76bd0a20b4_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_9f067f79-9e1f-40f1-ac6c-5fccb12b9df6_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_a10bbdd7-a4ce-494b-85e8-210f5b15f9e0_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVENTORY</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_60710ebc-3613-4339-ba9b-43da1d4af614_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_6de834d7-0629-4b47-9edd-4a8e90e0ff30_totalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, restricted cash and restricted cash equivalents and available-for-sale debt securities</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:href="exel-20201002.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_326e5d36-9690-4ce3-9ec2-164b970ab1dc_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_5149b329-8dff-4172-baa7-382deb0d6598_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_48d3a6a4-86db-4a3a-97d2-792a95204a42_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables, net</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent" xlink:to="lab_us-gaap_ReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_LiabilitiesExpendituresIncurredButNotYetPaidToRelatedPartyTransactions_3852db1e-b87c-4f5d-b380-0f95dd6af84d_terseLabel_en-US" xlink:label="lab_exel_LiabilitiesExpendituresIncurredButNotYetPaidToRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unpaid liabilities incurred to acquire investments</link:label>
    <link:label id="lab_exel_LiabilitiesExpendituresIncurredButNotYetPaidToRelatedPartyTransactions_label_en-US" xlink:label="lab_exel_LiabilitiesExpendituresIncurredButNotYetPaidToRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities Expenditures Incurred But Not Yet Paid To Related Party Transactions</link:label>
    <link:label id="lab_exel_LiabilitiesExpendituresIncurredButNotYetPaidToRelatedPartyTransactions_documentation_en-US" xlink:label="lab_exel_LiabilitiesExpendituresIncurredButNotYetPaidToRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities Expenditures Incurred But Not Yet Paid To Related Party Transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LiabilitiesExpendituresIncurredButNotYetPaidToRelatedPartyTransactions" xlink:href="exel-20201002.xsd#exel_LiabilitiesExpendituresIncurredButNotYetPaidToRelatedPartyTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LiabilitiesExpendituresIncurredButNotYetPaidToRelatedPartyTransactions" xlink:to="lab_exel_LiabilitiesExpendituresIncurredButNotYetPaidToRelatedPartyTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_ad9f9919-ae90-45b1-99c3-b4ac1c36259c_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_c78c9f1a-ef1a-4f11-a7a8-e26be61b1946_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_08819b1e-b297-4067-8f0f-896abd5ac91d_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum amount eligible for development and regulatory milestones</link:label>
    <link:label id="lab_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_label_en-US" xlink:label="lab_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Maximum Amount Eligible For Development And Regulatory Milestones</link:label>
    <link:label id="lab_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum amount eligible for development and regulatory milestones under collaborations agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" xlink:href="exel-20201002.xsd#exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" xlink:to="lab_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_9fe07f03-6858-4fb1-9d3c-aa29e5442833_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_NoncashLeaseExpense_8cb8a346-aea9-4620-a590-32c88fe0794e_terseLabel_en-US" xlink:label="lab_exel_NoncashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_exel_NoncashLeaseExpense_label_en-US" xlink:label="lab_exel_NoncashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Lease Expense</link:label>
    <link:label id="lab_exel_NoncashLeaseExpense_documentation_en-US" xlink:label="lab_exel_NoncashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Lease Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NoncashLeaseExpense" xlink:href="exel-20201002.xsd#exel_NoncashLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_NoncashLeaseExpense" xlink:to="lab_exel_NoncashLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_8969644c-4b46-4e7d-a123-6a4356c3ead0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_b2fe075b-660c-48bb-bfb6-5b47d3fa71cf_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5aa51c97-a94c-49d5-9da9-0016a9b96e65_totalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, restricted cash and restricted cash equivalents and available-for-sale debt securities, gross unrealized gains</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="exel-20201002.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_550191f8-4032-4ed7-a030-6f7ca7ece514_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of awards outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0f3a026d-346b-496d-bdcf-669ca80b629f_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_45470a85-cfe5-4eab-b174-4e300297719b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant-date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_c90d2fbe-d74d-453e-9ca2-6d5ee7c0cd40_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gains (losses) on available-for-sale debt securities, net of tax impact of $453, $(129), $(893) and $(936), respectively</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0a1a946b-b8c9-4040-9d40-c2d0d9b843e2_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c4b5dece-e168-4bf0-b07f-7c8a6887cbf5_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_a2e8c694-f1ed-4e8e-999f-9572211dfd5d_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_464ef718-3945-4e6a-9f37-838c34118d1d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gains (losses) on available-for-sale debt securities, net of tax impact of $453, $(129), $(893) and $(936), respectively</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_081171b7-3efd-4679-af58-598c30087043_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_8c507ad0-0c73-46f0-87e8-a97301081a5c_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_700f1e78-62fd-4e46-bdd1-dbccc4361025_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_7f99b424-80e1-45a8-ace6-64627694a7af_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_8ecd5481-db2d-4a06-bb12-4a5f00b53e88_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_d9b92099-c8ed-4693-8419-521c7c989f07_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_8f3b7a91-635f-42d9-a304-a19b7723bc18_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_label_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:to="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_7800e649-a950-4302-8e5f-0b9232f5aa99_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_a7e2a792-4f56-4f06-a3ec-6a9c20c20bd3_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments by Security Type</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_4538ba26-c1a6-4ae6-9913-7db35b427c3b_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_4b7eb972-f979-4996-8fb0-d949cad2e086_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueNotFromContractWithCustomer_f71d8d87-c091-4f1a-9e5f-b528ffc8f8d3_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueNotFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue not from contract with customer</link:label>
    <link:label id="lab_us-gaap_RevenueNotFromContractWithCustomer_label_en-US" xlink:label="lab_us-gaap_RevenueNotFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Not from Contract with Customer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueNotFromContractWithCustomer" xlink:to="lab_us-gaap_RevenueNotFromContractWithCustomer" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_b180dba1-4504-4362-9a74-d33827ff043a_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_bf99281b-257f-47dc-aa9b-a10c1eaa2d25_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_e28a29d3-772f-4806-89eb-00ff07531436_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion of deferred revenues</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_cc992427-03ed-439e-b5d9-1ac3eabc6fa2_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_e06e955b-f9da-48ac-8cc3-16b8700ae891_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_e6a800e6-db13-44e6-9658-e94da6425126_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental cash flow disclosure:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_StatusAxis_c9f5cb68-aa6e-4760-8b37-7a810b264cd1_terseLabel_en-US" xlink:label="lab_exel_StatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Status [Axis]</link:label>
    <link:label id="lab_exel_StatusAxis_label_en-US" xlink:label="lab_exel_StatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Status [Axis]</link:label>
    <link:label id="lab_exel_StatusAxis_documentation_en-US" xlink:label="lab_exel_StatusAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_StatusAxis" xlink:href="exel-20201002.xsd#exel_StatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_StatusAxis" xlink:to="lab_exel_StatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_7a51adfc-b9e2-40ea-847b-a7ffb8d9bbf3_terseLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, restricted cash and restricted cash equivalents</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:href="exel-20201002.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyExpense_389ca3d3-e2a8-4f52-937f-8edcd85e1319_verboseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty expense</link:label>
    <link:label id="lab_us-gaap_RoyaltyExpense_label_en-US" xlink:label="lab_us-gaap_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyExpense" xlink:to="lab_us-gaap_RoyaltyExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_b55e96e9-4023-4bef-979d-cb3b042f5eaa_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allocated Employee Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_6db004a7-c487-4823-bfca-3474e6ce5da0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_8a1a3bc8-c10c-406f-a559-24b06f172190_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_d344e45f-5c4f-41a2-bdb3-664ca591d0cc_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_8a8d335c-bff9-494d-b757-3c4c13dc6410_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Collaborative Revenues Under Collaboration Agreement</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_35d77ac9-b0a5-4d46-9eca-80afbfaa96ff_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b93a2a55-f173-4d24-969f-22a46cdc7065_negatedTotalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, restricted cash and restricted cash equivalents and available-for-sale debt securities, gross unrealized losses</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="exel-20201002.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_7c3664c3-3ac6-42f1-875e-35502cb0fadb_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of revenues recognized included in the beginning contract liability balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_05413cae-a9a1-4586-a96e-1f098f92117a_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_137a3ed0-468a-45f1-87e9-95eb80bf35e9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_8b508139-4c65-4a0a-a5d3-14ec749f679f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3162d798-2f7d-4913-a231-3eddd52626a1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_NewInformationMember_08e52493-c26b-45c3-97c3-ccd6b477912b_terseLabel_en-US" xlink:label="lab_exel_NewInformationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New information</link:label>
    <link:label id="lab_exel_NewInformationMember_label_en-US" xlink:label="lab_exel_NewInformationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Information [Member]</link:label>
    <link:label id="lab_exel_NewInformationMember_documentation_en-US" xlink:label="lab_exel_NewInformationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Information [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NewInformationMember" xlink:href="exel-20201002.xsd#exel_NewInformationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_NewInformationMember" xlink:to="lab_exel_NewInformationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_f58afc86-1b87-49c5-bb07-0ad6d0bee72d_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_70e56a88-648a-4c76-8f1a-bc7a1b680f85_terseLabel_en-US" xlink:label="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction related to a milestone</link:label>
    <link:label id="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_e9cd90d0-45be-443e-939f-1db3b0ab76fe_verboseLabel_en-US" xlink:label="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eligible payment from collaboration for development and regulatory milestone achievement under collaborations agreement</link:label>
    <link:label id="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_label_en-US" xlink:label="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eligible Payment From Collaboration For Development And Regulatory Milestone Achievement Under Collaborations Agreement</link:label>
    <link:label id="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_documentation_en-US" xlink:label="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eligible Payment From Collaboration For Development And Regulatory Milestone Achievement Under Collaborations Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" xlink:href="exel-20201002.xsd#exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" xlink:to="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_9f1f6ca0-0ccd-44b7-aa83-5d82c02eadff_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_41012b08-6dc9-4e77-b9b2-8f552b2057e4_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGross_e4c10e36-f744-46cf-b029-eb21b7ddc045_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_InventoryGross_label_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_6e7ac6df-b9af-4529-a31f-1558f2d92441_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_6bb80874-2212-464e-b8c0-f07fc89419e8_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_ab829a0a-572e-4885-aeed-f369419cc44d_terseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive securities and contingently issuable shares excluded</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember" xlink:to="lab_us-gaap_StockCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_666ef0d7-3a3f-4ad3-a78a-35d04086cc16_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_7bbeeef8-7c01-4918-8b8b-928aff24f40f_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract assets</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_country_JP_9baac2e8-9aab-4024-8c91-0459fcd96957_terseLabel_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Japan</link:label>
    <link:label id="lab_country_JP_label_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JAPAN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP" xlink:to="lab_country_JP" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ce5d1440-dd85-4152-83f0-bff4375d17c0_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_e4e299b1-5a28-4f9d-aa1c-fc4c96178f09_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues recognized for performance obligations satisfied in previous periods</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Performance Obligation Satisfied in Previous Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:to="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1ccba8b6-683a-466f-aef5-393cdffcff44_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_8de5531a-2689-49f3-a1e3-acbe589a73a3_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_c023a8d2-014f-4ad3-8035-26e6598921d9_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_985dc9c5-e0dc-4c2b-8927-159dff03b01a_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_e353cb74-2f32-4a02-bcb2-4b91aacd72c2_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_1f8d0899-2c68-4cb6-a40c-3d5d7a3cab4b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_d9003f40-91de-4d44-ad41-8c9a5275be0a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_c48f8b03-b236-440e-9a82-c7902509a4dd_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_EligiblePaymentFromCollaborationForDevelopmentMilestoneAchievementUnderCollaborationsAgreement_141be8de-d41d-4fa1-8231-ccfd0fa7d3e0_terseLabel_en-US" xlink:label="lab_exel_EligiblePaymentFromCollaborationForDevelopmentMilestoneAchievementUnderCollaborationsAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eligible development milestone under collaborative agreement</link:label>
    <link:label id="lab_exel_EligiblePaymentFromCollaborationForDevelopmentMilestoneAchievementUnderCollaborationsAgreement_label_en-US" xlink:label="lab_exel_EligiblePaymentFromCollaborationForDevelopmentMilestoneAchievementUnderCollaborationsAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eligible Payment From Collaboration For Development Milestone Achievement Under Collaborations Agreement</link:label>
    <link:label id="lab_exel_EligiblePaymentFromCollaborationForDevelopmentMilestoneAchievementUnderCollaborationsAgreement_documentation_en-US" xlink:label="lab_exel_EligiblePaymentFromCollaborationForDevelopmentMilestoneAchievementUnderCollaborationsAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eligible Payment From Collaboration For Development Milestone Achievement Under Collaborations Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_EligiblePaymentFromCollaborationForDevelopmentMilestoneAchievementUnderCollaborationsAgreement" xlink:href="exel-20201002.xsd#exel_EligiblePaymentFromCollaborationForDevelopmentMilestoneAchievementUnderCollaborationsAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_EligiblePaymentFromCollaborationForDevelopmentMilestoneAchievementUnderCollaborationsAgreement" xlink:to="lab_exel_EligiblePaymentFromCollaborationForDevelopmentMilestoneAchievementUnderCollaborationsAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_30ace3f2-7bd0-484c-a8fd-17277014f355_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_04c7947d-59f6-4dd9-be26-770b26e35a00_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4ca9fbeb-1545-48f5-96c9-e07880432ebe_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_098fa3f9-39cd-44bd-b0ff-51bc5100e191_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_ff3f7490-1097-4a80-83dd-cbcfcab88436_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of investments in an unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption_c63ddd54-4728-4160-b278-10c867e24c9f_terseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option exercise fee payment, if exercised</link:label>
    <link:label id="lab_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption_label_en-US" xlink:label="lab_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Option Exercise Fee Payment, Upon Exercising Option</link:label>
    <link:label id="lab_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption_documentation_en-US" xlink:label="lab_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Option Exercise Fee Payment, Upon Exercising Option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption" xlink:href="exel-20201002.xsd#exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption" xlink:to="lab_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_a9d56628-63e2-40e9-aea2-f8a73ef41c49_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_c0569c20-a778-4b53-a27d-563e9f15f9b2_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_a99be526-7352-494b-b5ec-5278aa09ec93_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_1406e817-eb2e-48d2-870e-d276aba739da_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REVENUES</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises_5589e7a8-2ac5-475f-85f0-c9a17e5bc03f_terseLabel_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, options, percent of common stock share price triggering PSO exercises</link:label>
    <link:label id="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises_label_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Percent Of Common Stock Share Price Triggering PSO Exercises</link:label>
    <link:label id="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises_documentation_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Percent Of Common Stock Share Price Triggering PSO Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises" xlink:href="exel-20201002.xsd#exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises" xlink:to="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeAgreementsUpfrontPayments_ef9fef8b-e05d-4b34-bd9a-7e644de8c840_terseLabel_en-US" xlink:label="lab_exel_CollaborativeAgreementsUpfrontPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment</link:label>
    <link:label id="lab_exel_CollaborativeAgreementsUpfrontPayments_label_en-US" xlink:label="lab_exel_CollaborativeAgreementsUpfrontPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreements, Upfront Payments</link:label>
    <link:label id="lab_exel_CollaborativeAgreementsUpfrontPayments_documentation_en-US" xlink:label="lab_exel_CollaborativeAgreementsUpfrontPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreements, Upfront Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeAgreementsUpfrontPayments" xlink:href="exel-20201002.xsd#exel_CollaborativeAgreementsUpfrontPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeAgreementsUpfrontPayments" xlink:to="lab_exel_CollaborativeAgreementsUpfrontPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_1a1f8c87-cfbd-4fd9-8a01-03b3dc9e7962_terseLabel_en-US" xlink:label="lab_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligations</link:label>
    <link:label id="lab_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_label_en-US" xlink:label="lab_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-Of-Use Asset Obtained In Exchange For Lease Liability</link:label>
    <link:label id="lab_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_documentation_en-US" xlink:label="lab_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-Of-Use Asset Obtained In Exchange For Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability" xlink:href="exel-20201002.xsd#exel_RightOfUseAssetObtainedInExchangeForLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability" xlink:to="lab_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_2285fe20-cad8-456c-9b18-bfad750f0ebd_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_3f795ad1-c051-4ed8-86c5-6e2c359917cc_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_031cb70e-2487-46a8-a741-5faf16d28f89_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_fe885b71-3705-43e4-abc1-c6ea4d9c58f1_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_46de2feb-0a99-4d64-9970-736dc5246267_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_20345a52-5a13-459b-a0fb-f6c39497f8ae_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_cbc5d73a-a171-4bc7-9a15-68404c4a8273_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for (benefit from) income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementwithGenentechMember_816509d7-5107-4670-9b7e-37d7c942a6f7_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithGenentechMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Genentech</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithGenentechMember_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithGenentechMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Genentech [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithGenentechMember_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithGenentechMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Genentech [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember" xlink:href="exel-20201002.xsd#exel_CollaborativeArrangementwithGenentechMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithGenentechMember" xlink:to="lab_exel_CollaborativeArrangementwithGenentechMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_ad6023e7-953c-45ea-b2a2-44a3b426684d_terseLabel_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Policies [Line Items]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_label_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Policies [Line Items]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_documentation_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Policies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:href="exel-20201002.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:to="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_6a47fd61-0a4d-48dc-b16f-619c361e9e55_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_7181c126-a2e1-43b0-a96e-4837137b9e77_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a4a70a63-87d9-4c98-861a-d53fe48dc454_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_22bf988c-be23-493c-8079-15b7fab7f2a3_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e39e888f-fcad-4330-810c-8487fd7a116d_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9d0e0533-e431-48c9-964c-94ba7428cdff_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_b7bbc4aa-4e91-427c-93b9-23fa790c2637_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_7401f6af-d53b-4216-aafd-81096aa2b142_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Cash Equivalents and Investments by Contractual Maturity</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_ebb4fde3-16b0-4749-83ca-439c56e12034_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_67583d5f-8548-4e3a-ae8a-1b9f0fca7151_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_71869c37-1c49-4b21-b9aa-17bd16b01b22_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_c66b58af-da3b-48cc-9df0-05f9e3287f51_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) per share - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestReceivable_07cc2923-7657-4cbc-8516-9065677a86ba_terseLabel_en-US" xlink:label="lab_us-gaap_InterestReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest receivable</link:label>
    <link:label id="lab_us-gaap_InterestReceivable_label_en-US" xlink:label="lab_us-gaap_InterestReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivable" xlink:to="lab_us-gaap_InterestReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_cdcaec8c-61f0-49fb-bf9c-8a87996652b0_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborationAgreementsAdditionalUpfrontPayments_2d18680f-44f2-4070-85c7-217d45ee257a_terseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementsAdditionalUpfrontPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional payments</link:label>
    <link:label id="lab_exel_CollaborationAgreementsAdditionalUpfrontPayments_label_en-US" xlink:label="lab_exel_CollaborationAgreementsAdditionalUpfrontPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreements, Additional Upfront Payments</link:label>
    <link:label id="lab_exel_CollaborationAgreementsAdditionalUpfrontPayments_documentation_en-US" xlink:label="lab_exel_CollaborationAgreementsAdditionalUpfrontPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreements, Additional Upfront Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementsAdditionalUpfrontPayments" xlink:href="exel-20201002.xsd#exel_CollaborationAgreementsAdditionalUpfrontPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAgreementsAdditionalUpfrontPayments" xlink:to="lab_exel_CollaborationAgreementsAdditionalUpfrontPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_342da122-fa1d-439c-8c2e-e381a5be1b3d_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_93ce375d-0308-4de2-be1e-c5a8ef5e3386_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenMember_a8a5fb61-0f46-4820-99d0-da8b63753c2f_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Ipsen</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenMember_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Ipsen [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenMember_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Ipsen [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember" xlink:href="exel-20201002.xsd#exel_CollaborativeArrangementwithIpsenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithIpsenMember" xlink:to="lab_exel_CollaborativeArrangementwithIpsenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_453984dd-5fe0-4ed9-98d8-2bd465de92d6_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with customer, liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_a33c5fcb-722d-423d-93ea-d13353b42aac_totalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, restricted cash and restricted cash equivalents, amortized cost</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:href="exel-20201002.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CometriqMember_afc6c6a6-f04b-4f0c-94b2-54e6794bd796_terseLabel_en-US" xlink:label="lab_exel_CometriqMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMETRIQ</link:label>
    <link:label id="lab_exel_CometriqMember_label_en-US" xlink:label="lab_exel_CometriqMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cometriq [Member]</link:label>
    <link:label id="lab_exel_CometriqMember_documentation_en-US" xlink:label="lab_exel_CometriqMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cometriq [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CometriqMember" xlink:href="exel-20201002.xsd#exel_CometriqMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CometriqMember" xlink:to="lab_exel_CometriqMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AffiliatesofCVSHealthCorporationMember_b1ca7253-e6e8-47e3-88e8-a5c5f6600bdb_terseLabel_en-US" xlink:label="lab_exel_AffiliatesofCVSHealthCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of CVS Health Corporation</link:label>
    <link:label id="lab_exel_AffiliatesofCVSHealthCorporationMember_label_en-US" xlink:label="lab_exel_AffiliatesofCVSHealthCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of CVS Health Corporation [Member]</link:label>
    <link:label id="lab_exel_AffiliatesofCVSHealthCorporationMember_documentation_en-US" xlink:label="lab_exel_AffiliatesofCVSHealthCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of CVS Health Corporation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofCVSHealthCorporationMember" xlink:href="exel-20201002.xsd#exel_AffiliatesofCVSHealthCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AffiliatesofCVSHealthCorporationMember" xlink:to="lab_exel_AffiliatesofCVSHealthCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_5ddcafed-c56d-4654-bbc8-529f735ac684_negatedTerseLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, restricted cash and restricted cash equivalents, gross unrealized loss</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:href="exel-20201002.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_2ce09fe2-e300-4cf6-9c0f-3f4a00f27d4b_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_b02ba75a-c06f-4cee-8f5f-ccb2678ee88d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_ebdbc8b0-b10b-4002-9135-e5f8e4b57265_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_06481b6c-82e6-4533-8d51-9387ddb41833_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License revenues</link:label>
    <link:label id="lab_us-gaap_LicenseMember_173ca8e0-5576-492c-9924-f75af5ca0025_verboseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License revenues</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_21140126-9bdc-4a76-81f4-c98b6d15f491_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_1dc44152-99c3-48d1-b836-25388606219e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments and customer credits issued</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ResultingFromDiscoveryEffortsMember_5ed5e132-db21-4485-a370-0524d7d9105d_terseLabel_en-US" xlink:label="lab_exel_ResultingFromDiscoveryEffortsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Resulting from discovery efforts</link:label>
    <link:label id="lab_exel_ResultingFromDiscoveryEffortsMember_label_en-US" xlink:label="lab_exel_ResultingFromDiscoveryEffortsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Resulting From Discovery Efforts [Member]</link:label>
    <link:label id="lab_exel_ResultingFromDiscoveryEffortsMember_documentation_en-US" xlink:label="lab_exel_ResultingFromDiscoveryEffortsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Resulting From Discovery Efforts [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ResultingFromDiscoveryEffortsMember" xlink:href="exel-20201002.xsd#exel_ResultingFromDiscoveryEffortsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ResultingFromDiscoveryEffortsMember" xlink:to="lab_exel_ResultingFromDiscoveryEffortsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_36ae69d9-4547-496e-8f61-584c3a70daea_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, equipment and other</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_5aeadde0-5e38-46bf-bdf7-e8bcbc73accc_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_9b88c975-eeb2-4289-89a0-e16eee57924d_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_2bc8126a-3201-47aa-9d4f-02fe502b368b_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_7acf86b9-867d-48a6-bd80-23464b1e918a_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_3deb4515-1f55-436a-984a-b008dd687e93_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for credit losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_c58cdc4a-1e2e-4df3-8691-6cf2a19285aa_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_EarningsPerShareDenominatorAbstract_b0c6571b-4bda-48bd-8e29-d68134a170b5_terseLabel_en-US" xlink:label="lab_exel_EarningsPerShareDenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_exel_EarningsPerShareDenominatorAbstract_label_en-US" xlink:label="lab_exel_EarningsPerShareDenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Denominator [Abstract]</link:label>
    <link:label id="lab_exel_EarningsPerShareDenominatorAbstract_documentation_en-US" xlink:label="lab_exel_EarningsPerShareDenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Denominator [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_EarningsPerShareDenominatorAbstract" xlink:href="exel-20201002.xsd#exel_EarningsPerShareDenominatorAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_EarningsPerShareDenominatorAbstract" xlink:to="lab_exel_EarningsPerShareDenominatorAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e187b555-9240-404c-b336-35c945cc9c36_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0f05a346-d93d-4e55-a161-eb084e336ae8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_15124efa-be29-4488-9a82-c7fa7afa54a5_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_1a8ce915-3606-4224-9ff7-a7d1bdd719bd_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4a6e5e1b-b9d6-499b-ba02-3e630c0b4e3f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_93391870-7666-4816-91f7-1ad8dee4a3df_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_dbef500b-a95a-4fd7-b200-d4d1ad198b54_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5330d34b-1390-4b26-ba99-575f97ca601a_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_da441e38-87a4-43b2-9a64-34950a8ac507_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_26eee035-85c5-4c87-8ad0-c8802294532d_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ProductGrossMember_790f2df1-9bea-44f4-b134-2ff1167dc476_terseLabel_en-US" xlink:label="lab_exel_ProductGrossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross product revenues</link:label>
    <link:label id="lab_exel_ProductGrossMember_label_en-US" xlink:label="lab_exel_ProductGrossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, Gross [Member]</link:label>
    <link:label id="lab_exel_ProductGrossMember_documentation_en-US" xlink:label="lab_exel_ProductGrossMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, Gross [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductGrossMember" xlink:href="exel-20201002.xsd#exel_ProductGrossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProductGrossMember" xlink:to="lab_exel_ProductGrossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_e66fd798-58ff-4940-bfa6-ae8b06e1c4d1_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_c7a40716-4b99-4c55-a8ab-f1d035fea622_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementWithCatalentMember_c6d4afe6-5f39-4829-8441-3dca3dd89156_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementWithCatalentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement With Catalent</link:label>
    <link:label id="lab_exel_CollaborativeArrangementWithCatalentMember_label_en-US" xlink:label="lab_exel_CollaborativeArrangementWithCatalentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement With Catalent [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementWithCatalentMember_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementWithCatalentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement With Catalent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementWithCatalentMember" xlink:href="exel-20201002.xsd#exel_CollaborativeArrangementWithCatalentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementWithCatalentMember" xlink:to="lab_exel_CollaborativeArrangementWithCatalentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_23238c96-7b01-48c6-87a8-1c154ceaaa36_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_a9d5b5c7-a635-4c09-a94e-8acb1dfd78fa_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock under equity incentive and stock purchase plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_3905b87d-c236-40d4-8843-40d3958adf89_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_25817bd4-f6ff-4252-b804-90132735dd2b_terseLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, restricted cash and restricted cash equivalents, gross unrealized gain</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:href="exel-20201002.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_36e4a9e6-38f1-40b8-ad7b-826bca7e943b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_label_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:to="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborationAndLicenseAgreementTargetSelectionTerm_b8fae9b7-84b5-4b17-a227-7a4280ff1e32_terseLabel_en-US" xlink:label="lab_exel_CollaborationAndLicenseAgreementTargetSelectionTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration term</link:label>
    <link:label id="lab_exel_CollaborationAndLicenseAgreementTargetSelectionTerm_label_en-US" xlink:label="lab_exel_CollaborationAndLicenseAgreementTargetSelectionTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And License Agreement, Target Selection Term</link:label>
    <link:label id="lab_exel_CollaborationAndLicenseAgreementTargetSelectionTerm_documentation_en-US" xlink:label="lab_exel_CollaborationAndLicenseAgreementTargetSelectionTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And License Agreement, Target Selection Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAndLicenseAgreementTargetSelectionTerm" xlink:href="exel-20201002.xsd#exel_CollaborationAndLicenseAgreementTargetSelectionTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAndLicenseAgreementTargetSelectionTerm" xlink:to="lab_exel_CollaborationAndLicenseAgreementTargetSelectionTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_442edd07-526b-448e-8cf9-f63d936937da_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_0bc86338-068a-4038-853c-51a9166ea2c8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid related to net share settlement of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_968503d9-c3ac-4049-94f0-a69c2454e6f4_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET INCOME (LOSS) PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cffcc027-9c69-49e9-8572-d3650ca28a63_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_1c7bcc39-8e7e-495f-978b-e10ddff728d4_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_43e9434f-8f77-4bab-9133-a53c45fc2525_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_96b88227-a65b-4bf6-8fd8-11d1d1dd15f4_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoriesMember_b7ee2b73-b85b-4cd2-b35b-dd4d99aabeeb_terseLabel_en-US" xlink:label="lab_us-gaap_InventoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion included in inventory</link:label>
    <link:label id="lab_us-gaap_InventoriesMember_label_en-US" xlink:label="lab_us-gaap_InventoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoriesMember" xlink:to="lab_us-gaap_InventoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_da14341b-929e-4e11-93d5-a408ea366406_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_b9350ec0-8aae-4ae2-be1d-b5dc8830ee83_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_7f548df9-fa42-4ba0-8843-8284a91a0ad4_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>exel-20201002_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:a5daf19b-278e-4193-a378-e43e29a2ddec,g:725f21e5-a4e0-44a1-91a2-e65dc567c7d2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.exelixis.com/role/CoverPage" xlink:type="simple" xlink:href="exel-20201002.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_2e8a17aa-b14b-451b-9440-e062a378af5a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_b1dbce59-2805-46c5-84e5-d0060a401540" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e8a17aa-b14b-451b-9440-e062a378af5a" xlink:to="loc_dei_DocumentType_b1dbce59-2805-46c5-84e5-d0060a401540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_347e11e9-cbe0-4473-9170-bc4def8eace3" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e8a17aa-b14b-451b-9440-e062a378af5a" xlink:to="loc_dei_DocumentQuarterlyReport_347e11e9-cbe0-4473-9170-bc4def8eace3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_4d02b948-3b4e-43a2-9f77-814dbf1fd1b4" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e8a17aa-b14b-451b-9440-e062a378af5a" xlink:to="loc_dei_DocumentPeriodEndDate_4d02b948-3b4e-43a2-9f77-814dbf1fd1b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_38924b37-e31e-4cb3-bb23-07e634483210" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e8a17aa-b14b-451b-9440-e062a378af5a" xlink:to="loc_dei_DocumentTransitionReport_38924b37-e31e-4cb3-bb23-07e634483210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_4fd2ace7-a145-4516-a1c3-8ffc94e384a5" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e8a17aa-b14b-451b-9440-e062a378af5a" xlink:to="loc_dei_EntityFileNumber_4fd2ace7-a145-4516-a1c3-8ffc94e384a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_734b92de-55e7-4473-8676-6ec5e376039d" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e8a17aa-b14b-451b-9440-e062a378af5a" xlink:to="loc_dei_EntityRegistrantName_734b92de-55e7-4473-8676-6ec5e376039d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_3999b260-fa2c-46d8-be1b-e047f0e96363" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e8a17aa-b14b-451b-9440-e062a378af5a" xlink:to="loc_dei_EntityIncorporationStateCountryCode_3999b260-fa2c-46d8-be1b-e047f0e96363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_b15b317f-dbfa-4e63-af3a-6f2cfa2c7c9e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e8a17aa-b14b-451b-9440-e062a378af5a" xlink:to="loc_dei_EntityTaxIdentificationNumber_b15b317f-dbfa-4e63-af3a-6f2cfa2c7c9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_727a6add-3f4f-4954-ba6f-9eabf04ca6c4" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e8a17aa-b14b-451b-9440-e062a378af5a" xlink:to="loc_dei_EntityAddressAddressLine1_727a6add-3f4f-4954-ba6f-9eabf04ca6c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_c6ae2d45-5eae-462f-8be1-63cfd2bc959f" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e8a17aa-b14b-451b-9440-e062a378af5a" xlink:to="loc_dei_EntityAddressCityOrTown_c6ae2d45-5eae-462f-8be1-63cfd2bc959f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_37c9618f-14a2-4356-9957-81fcabb7f4d3" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e8a17aa-b14b-451b-9440-e062a378af5a" xlink:to="loc_dei_EntityAddressStateOrProvince_37c9618f-14a2-4356-9957-81fcabb7f4d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_db78b6d4-4dfe-44e4-bb96-d3d569b1af15" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e8a17aa-b14b-451b-9440-e062a378af5a" xlink:to="loc_dei_EntityAddressPostalZipCode_db78b6d4-4dfe-44e4-bb96-d3d569b1af15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_3971d33c-cec6-41dd-93cd-9a37a047a812" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e8a17aa-b14b-451b-9440-e062a378af5a" xlink:to="loc_dei_CityAreaCode_3971d33c-cec6-41dd-93cd-9a37a047a812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_4a87f5e1-16ff-4617-9d36-a9afe7896953" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e8a17aa-b14b-451b-9440-e062a378af5a" xlink:to="loc_dei_LocalPhoneNumber_4a87f5e1-16ff-4617-9d36-a9afe7896953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_fe45df33-24ae-4243-a167-688d4731d4ee" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e8a17aa-b14b-451b-9440-e062a378af5a" xlink:to="loc_dei_Security12bTitle_fe45df33-24ae-4243-a167-688d4731d4ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_4cf86a6b-e96e-4af6-b613-7bb1462bf70c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e8a17aa-b14b-451b-9440-e062a378af5a" xlink:to="loc_dei_TradingSymbol_4cf86a6b-e96e-4af6-b613-7bb1462bf70c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_e8058d80-c1db-4389-9449-ba0134cbb74d" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e8a17aa-b14b-451b-9440-e062a378af5a" xlink:to="loc_dei_SecurityExchangeName_e8058d80-c1db-4389-9449-ba0134cbb74d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_fc151da8-6b41-4be4-8d04-5de3b310361f" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e8a17aa-b14b-451b-9440-e062a378af5a" xlink:to="loc_dei_EntityCurrentReportingStatus_fc151da8-6b41-4be4-8d04-5de3b310361f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_a5b008c6-6216-40a9-b934-fa6f3dd2bfe1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e8a17aa-b14b-451b-9440-e062a378af5a" xlink:to="loc_dei_EntityInteractiveDataCurrent_a5b008c6-6216-40a9-b934-fa6f3dd2bfe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_0b5433d4-3cbf-4b10-96b5-9dcd0ae0a0df" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e8a17aa-b14b-451b-9440-e062a378af5a" xlink:to="loc_dei_EntityFilerCategory_0b5433d4-3cbf-4b10-96b5-9dcd0ae0a0df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_44cb5a3a-5c9b-45e9-a686-2feca92c32f3" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e8a17aa-b14b-451b-9440-e062a378af5a" xlink:to="loc_dei_EntitySmallBusiness_44cb5a3a-5c9b-45e9-a686-2feca92c32f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_7d06634e-156a-4608-9086-f6f64fdcb291" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e8a17aa-b14b-451b-9440-e062a378af5a" xlink:to="loc_dei_EntityEmergingGrowthCompany_7d06634e-156a-4608-9086-f6f64fdcb291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_e14b8429-6734-40e5-8f50-9d2f959ab618" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e8a17aa-b14b-451b-9440-e062a378af5a" xlink:to="loc_dei_EntityShellCompany_e14b8429-6734-40e5-8f50-9d2f959ab618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_62e9454a-08ef-4ba5-86f7-a6fea5a27408" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e8a17aa-b14b-451b-9440-e062a378af5a" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_62e9454a-08ef-4ba5-86f7-a6fea5a27408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_a6ef3484-6906-4215-9a1d-46b9fe3b863b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e8a17aa-b14b-451b-9440-e062a378af5a" xlink:to="loc_dei_AmendmentFlag_a6ef3484-6906-4215-9a1d-46b9fe3b863b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_d12c642f-fd57-477c-998d-8d66264c34f8" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e8a17aa-b14b-451b-9440-e062a378af5a" xlink:to="loc_dei_DocumentFiscalYearFocus_d12c642f-fd57-477c-998d-8d66264c34f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_23205ef0-f644-4f40-9143-b164ed006794" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e8a17aa-b14b-451b-9440-e062a378af5a" xlink:to="loc_dei_DocumentFiscalPeriodFocus_23205ef0-f644-4f40-9143-b164ed006794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_f73ccb23-4d44-413d-883e-70a88b61999a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e8a17aa-b14b-451b-9440-e062a378af5a" xlink:to="loc_dei_EntityCentralIndexKey_f73ccb23-4d44-413d-883e-70a88b61999a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_b957be79-d9c3-43d9-903c-77a06f4ca25b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2e8a17aa-b14b-451b-9440-e062a378af5a" xlink:to="loc_dei_CurrentFiscalYearEndDate_b957be79-d9c3-43d9-903c-77a06f4ca25b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="exel-20201002.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_1a24764c-14d5-44ad-a178-d50291605a0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_58dd1269-624c-448c-abbc-111f445b5f01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1a24764c-14d5-44ad-a178-d50291605a0e" xlink:to="loc_us-gaap_AssetsAbstract_58dd1269-624c-448c-abbc-111f445b5f01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_91443b6a-05f8-4155-8af2-1c9b4942fc44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_58dd1269-624c-448c-abbc-111f445b5f01" xlink:to="loc_us-gaap_AssetsCurrentAbstract_91443b6a-05f8-4155-8af2-1c9b4942fc44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_677b3978-2f67-4254-9430-03eb9b30c5aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_91443b6a-05f8-4155-8af2-1c9b4942fc44" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_677b3978-2f67-4254-9430-03eb9b30c5aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_584e1c53-7625-4ce1-9af8-b178a4b0ab9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_91443b6a-05f8-4155-8af2-1c9b4942fc44" xlink:to="loc_us-gaap_ShortTermInvestments_584e1c53-7625-4ce1-9af8-b178a4b0ab9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_c2c1a793-8924-407d-9527-77a14ae57bdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_91443b6a-05f8-4155-8af2-1c9b4942fc44" xlink:to="loc_us-gaap_ReceivablesNetCurrent_c2c1a793-8924-407d-9527-77a14ae57bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_a2cdbd34-9ea8-4048-bbdd-a1b6a9c3b199" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_91443b6a-05f8-4155-8af2-1c9b4942fc44" xlink:to="loc_us-gaap_InventoryNet_a2cdbd34-9ea8-4048-bbdd-a1b6a9c3b199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_151665aa-cb9f-4397-ad23-5b760f2a36d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_91443b6a-05f8-4155-8af2-1c9b4942fc44" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_151665aa-cb9f-4397-ad23-5b760f2a36d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_bde8588e-d56a-40d6-9c13-afe3cbc6e37c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_91443b6a-05f8-4155-8af2-1c9b4942fc44" xlink:to="loc_us-gaap_AssetsCurrent_bde8588e-d56a-40d6-9c13-afe3cbc6e37c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_3644f11f-e86b-4939-964f-a40b1c1b1d3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_58dd1269-624c-448c-abbc-111f445b5f01" xlink:to="loc_us-gaap_LongTermInvestments_3644f11f-e86b-4939-964f-a40b1c1b1d3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7cfc4d20-1254-4b08-9357-761d3e3f677d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_58dd1269-624c-448c-abbc-111f445b5f01" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_7cfc4d20-1254-4b08-9357-761d3e3f677d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_2f72b601-d54a-41db-b7df-2e074c219271" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_58dd1269-624c-448c-abbc-111f445b5f01" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_2f72b601-d54a-41db-b7df-2e074c219271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_00bd02e4-05cb-4f08-9ff8-764efb99ee90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_58dd1269-624c-448c-abbc-111f445b5f01" xlink:to="loc_us-gaap_Goodwill_00bd02e4-05cb-4f08-9ff8-764efb99ee90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_09bc5637-d309-4a18-9a29-ee1a090a845b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_58dd1269-624c-448c-abbc-111f445b5f01" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_09bc5637-d309-4a18-9a29-ee1a090a845b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b0993528-f8f7-437f-890c-3c28bfc01398" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_58dd1269-624c-448c-abbc-111f445b5f01" xlink:to="loc_us-gaap_Assets_b0993528-f8f7-437f-890c-3c28bfc01398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_aeabb88a-b751-43a3-b515-92d8b091015b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1a24764c-14d5-44ad-a178-d50291605a0e" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_aeabb88a-b751-43a3-b515-92d8b091015b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_0ecd6c05-6e85-468c-b42a-d9d5425c668e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_aeabb88a-b751-43a3-b515-92d8b091015b" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_0ecd6c05-6e85-468c-b42a-d9d5425c668e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_b06a714d-8df9-4d3e-aa06-b6744cacd6a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0ecd6c05-6e85-468c-b42a-d9d5425c668e" xlink:to="loc_us-gaap_AccountsPayableCurrent_b06a714d-8df9-4d3e-aa06-b6744cacd6a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_325f39cb-ef57-4da3-a082-980d0f2c0fbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0ecd6c05-6e85-468c-b42a-d9d5425c668e" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_325f39cb-ef57-4da3-a082-980d0f2c0fbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccruedClinicalLiabilitiesCurrent_197c201d-e703-43ce-9260-adcab976bcec" xlink:href="exel-20201002.xsd#exel_AccruedClinicalLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0ecd6c05-6e85-468c-b42a-d9d5425c668e" xlink:to="loc_exel_AccruedClinicalLiabilitiesCurrent_197c201d-e703-43ce-9260-adcab976bcec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent_5fd7ac1c-4d26-4d2c-9eb3-489264317eb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerRefundLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0ecd6c05-6e85-468c-b42a-d9d5425c668e" xlink:to="loc_us-gaap_CustomerRefundLiabilityCurrent_5fd7ac1c-4d26-4d2c-9eb3-489264317eb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccruedCollaborationLiabilityCurrent_9b1e6f55-6baa-4fd5-9a9b-d7a470f95e23" xlink:href="exel-20201002.xsd#exel_AccruedCollaborationLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0ecd6c05-6e85-468c-b42a-d9d5425c668e" xlink:to="loc_exel_AccruedCollaborationLiabilityCurrent_9b1e6f55-6baa-4fd5-9a9b-d7a470f95e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_2a15b5c1-5669-4ef6-8cb7-74e9eaca220b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0ecd6c05-6e85-468c-b42a-d9d5425c668e" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_2a15b5c1-5669-4ef6-8cb7-74e9eaca220b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_bd755c4f-67dd-440d-b2d3-2295e7cb531c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0ecd6c05-6e85-468c-b42a-d9d5425c668e" xlink:to="loc_us-gaap_LiabilitiesCurrent_bd755c4f-67dd-440d-b2d3-2295e7cb531c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_bedf1a65-15c2-4dfb-a2f5-c6facb484e86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_aeabb88a-b751-43a3-b515-92d8b091015b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_bedf1a65-15c2-4dfb-a2f5-c6facb484e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_bf44873d-a55c-46f4-a237-2272ca6ab883" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_aeabb88a-b751-43a3-b515-92d8b091015b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_bf44873d-a55c-46f4-a237-2272ca6ab883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_bc5ec596-9a39-4394-b363-e670aaec4137" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_aeabb88a-b751-43a3-b515-92d8b091015b" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_bc5ec596-9a39-4394-b363-e670aaec4137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_04fb41ff-3b29-428e-8511-437a67e19b42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_aeabb88a-b751-43a3-b515-92d8b091015b" xlink:to="loc_us-gaap_Liabilities_04fb41ff-3b29-428e-8511-437a67e19b42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_0608b0c3-dd95-44e4-b80c-73749cbbb700" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_aeabb88a-b751-43a3-b515-92d8b091015b" xlink:to="loc_us-gaap_CommitmentsAndContingencies_0608b0c3-dd95-44e4-b80c-73749cbbb700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_4277b57b-4022-4e9b-a90b-0b23badcde6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_aeabb88a-b751-43a3-b515-92d8b091015b" xlink:to="loc_us-gaap_StockholdersEquityAbstract_4277b57b-4022-4e9b-a90b-0b23badcde6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_3743e0be-4967-4a52-923d-492275fd1fd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4277b57b-4022-4e9b-a90b-0b23badcde6b" xlink:to="loc_us-gaap_PreferredStockValue_3743e0be-4967-4a52-923d-492275fd1fd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_4dc8509f-c9d7-4e26-be0e-c057c1b8e22d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4277b57b-4022-4e9b-a90b-0b23badcde6b" xlink:to="loc_us-gaap_CommonStockValue_4dc8509f-c9d7-4e26-be0e-c057c1b8e22d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_262d1b29-50db-4ba8-8d4b-24ece0910931" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4277b57b-4022-4e9b-a90b-0b23badcde6b" xlink:to="loc_us-gaap_AdditionalPaidInCapital_262d1b29-50db-4ba8-8d4b-24ece0910931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5931b5aa-5d7a-48f0-8f9d-c0991e0d48c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4277b57b-4022-4e9b-a90b-0b23badcde6b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5931b5aa-5d7a-48f0-8f9d-c0991e0d48c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0649fd31-f1a5-467e-8592-e8ee4479af3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4277b57b-4022-4e9b-a90b-0b23badcde6b" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0649fd31-f1a5-467e-8592-e8ee4479af3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_39507404-2b84-4731-bdd1-60cd69c0323c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4277b57b-4022-4e9b-a90b-0b23badcde6b" xlink:to="loc_us-gaap_StockholdersEquity_39507404-2b84-4731-bdd1-60cd69c0323c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_7c9d6d6b-8f21-4d95-be17-1f603549969c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_aeabb88a-b751-43a3-b515-92d8b091015b" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_7c9d6d6b-8f21-4d95-be17-1f603549969c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_e08ef299-57b4-4e4d-a07f-878856e0021a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1a24764c-14d5-44ad-a178-d50291605a0e" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_e08ef299-57b4-4e4d-a07f-878856e0021a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_3018f30e-e687-4293-8434-7885723879a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1a24764c-14d5-44ad-a178-d50291605a0e" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_3018f30e-e687-4293-8434-7885723879a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="exel-20201002.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_b5640894-1388-437f-a1e8-0c9bed5f0d26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6fe25c24-8071-48f2-94de-be4709473060" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b5640894-1388-437f-a1e8-0c9bed5f0d26" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6fe25c24-8071-48f2-94de-be4709473060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_7c57ce32-5b57-4af3-9aad-fcd17df95fdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6fe25c24-8071-48f2-94de-be4709473060" xlink:to="loc_us-gaap_StockholdersEquityAbstract_7c57ce32-5b57-4af3-9aad-fcd17df95fdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_35ee740e-b3c4-41ff-a8a9-84361ae10652" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_7c57ce32-5b57-4af3-9aad-fcd17df95fdb" xlink:to="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_35ee740e-b3c4-41ff-a8a9-84361ae10652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_c00fc677-a834-4ce6-b064-515615f50bbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_35ee740e-b3c4-41ff-a8a9-84361ae10652" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_c00fc677-a834-4ce6-b064-515615f50bbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_9b975aaa-390b-455f-95ce-062f22611cc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_35ee740e-b3c4-41ff-a8a9-84361ae10652" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_9b975aaa-390b-455f-95ce-062f22611cc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_186a8741-57a9-406f-b53c-4158754c093d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_35ee740e-b3c4-41ff-a8a9-84361ae10652" xlink:to="loc_us-gaap_PreferredStockSharesIssued_186a8741-57a9-406f-b53c-4158754c093d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f280a855-6388-4a64-a6c5-ed51f59fc482" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_7c57ce32-5b57-4af3-9aad-fcd17df95fdb" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f280a855-6388-4a64-a6c5-ed51f59fc482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_cc10f260-45f0-4a05-9c2d-2b2c97a22a27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f280a855-6388-4a64-a6c5-ed51f59fc482" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_cc10f260-45f0-4a05-9c2d-2b2c97a22a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_5021648d-0c8e-44e8-a9c3-6dcc7859a7be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f280a855-6388-4a64-a6c5-ed51f59fc482" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_5021648d-0c8e-44e8-a9c3-6dcc7859a7be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_191fd00b-ba8a-4ce2-be1c-fba1fa18ca88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f280a855-6388-4a64-a6c5-ed51f59fc482" xlink:to="loc_us-gaap_CommonStockSharesIssued_191fd00b-ba8a-4ce2-be1c-fba1fa18ca88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_7307b5bb-5bc7-46db-8a1f-4b40d82eb10d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f280a855-6388-4a64-a6c5-ed51f59fc482" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_7307b5bb-5bc7-46db-8a1f-4b40d82eb10d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss" xlink:type="simple" xlink:href="exel-20201002.xsd#CondensedConsolidatedStatementsofIncomeLoss"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_a5d8bca2-1ea6-44f9-996b-00f3cdf89e89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_86aaae84-6ef2-4ea0-9f37-21b43fbac8a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a5d8bca2-1ea6-44f9-996b-00f3cdf89e89" xlink:to="loc_us-gaap_StatementTable_86aaae84-6ef2-4ea0-9f37-21b43fbac8a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_321788ce-5760-4d57-af65-2f16621c39a1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_86aaae84-6ef2-4ea0-9f37-21b43fbac8a5" xlink:to="loc_srt_ProductOrServiceAxis_321788ce-5760-4d57-af65-2f16621c39a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ff4168aa-9c15-4af5-b0b0-699f16bea560" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_321788ce-5760-4d57-af65-2f16621c39a1" xlink:to="loc_srt_ProductsAndServicesDomain_ff4168aa-9c15-4af5-b0b0-699f16bea560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_5b81d016-6ef9-4969-b0ad-142ca5fd91ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ff4168aa-9c15-4af5-b0b0-699f16bea560" xlink:to="loc_us-gaap_ProductMember_5b81d016-6ef9-4969-b0ad-142ca5fd91ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_14b2820b-adab-4562-8658-ae058073edbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ff4168aa-9c15-4af5-b0b0-699f16bea560" xlink:to="loc_us-gaap_LicenseMember_14b2820b-adab-4562-8658-ae058073edbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_7585ceef-b1dd-42f6-bc1b-738ea558df41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ff4168aa-9c15-4af5-b0b0-699f16bea560" xlink:to="loc_us-gaap_ServiceMember_7585ceef-b1dd-42f6-bc1b-738ea558df41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_63fee708-5804-4023-a5fe-dec97b854612" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_86aaae84-6ef2-4ea0-9f37-21b43fbac8a5" xlink:to="loc_us-gaap_StatementLineItems_63fee708-5804-4023-a5fe-dec97b854612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7557748e-1210-408a-b228-7920464f214b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_63fee708-5804-4023-a5fe-dec97b854612" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7557748e-1210-408a-b228-7920464f214b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer_ff2ccb05-955c-44c5-9911-f293692c1ee0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_63fee708-5804-4023-a5fe-dec97b854612" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomer_ff2ccb05-955c-44c5-9911-f293692c1ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_3933a02e-90da-4fa8-a185-5a8e6c2eec15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_63fee708-5804-4023-a5fe-dec97b854612" xlink:to="loc_us-gaap_Revenues_3933a02e-90da-4fa8-a185-5a8e6c2eec15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_47b2e016-563f-47a1-910a-8ef420b88d2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_63fee708-5804-4023-a5fe-dec97b854612" xlink:to="loc_us-gaap_OperatingExpensesAbstract_47b2e016-563f-47a1-910a-8ef420b88d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_0ffbfa6c-d605-473f-86c9-85f3cb0f609a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_47b2e016-563f-47a1-910a-8ef420b88d2a" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_0ffbfa6c-d605-473f-86c9-85f3cb0f609a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_0121b1cb-f8c2-4ee5-86bd-9dfdd65700b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_47b2e016-563f-47a1-910a-8ef420b88d2a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_0121b1cb-f8c2-4ee5-86bd-9dfdd65700b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_13e30474-d251-46ce-852b-3c5c86c3bd9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_47b2e016-563f-47a1-910a-8ef420b88d2a" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_13e30474-d251-46ce-852b-3c5c86c3bd9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_0e6cac06-9cb5-4a9a-81ef-0e5718880a6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_47b2e016-563f-47a1-910a-8ef420b88d2a" xlink:to="loc_us-gaap_CostsAndExpenses_0e6cac06-9cb5-4a9a-81ef-0e5718880a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_aa42eb12-4d79-44ce-a270-65b4b15ab513" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_63fee708-5804-4023-a5fe-dec97b854612" xlink:to="loc_us-gaap_OperatingIncomeLoss_aa42eb12-4d79-44ce-a270-65b4b15ab513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther_86af4c80-5c49-46ef-b4ca-63ee66f21b7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_63fee708-5804-4023-a5fe-dec97b854612" xlink:to="loc_us-gaap_InterestIncomeOther_86af4c80-5c49-46ef-b4ca-63ee66f21b7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_645b950a-b06f-4b54-8d50-ba6db9d22d7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_63fee708-5804-4023-a5fe-dec97b854612" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_645b950a-b06f-4b54-8d50-ba6db9d22d7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_25365e46-9625-4eaf-9938-2d6ce4819b5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_63fee708-5804-4023-a5fe-dec97b854612" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_25365e46-9625-4eaf-9938-2d6ce4819b5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_229e7668-1666-4d13-89eb-0deeaee55afa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_63fee708-5804-4023-a5fe-dec97b854612" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_229e7668-1666-4d13-89eb-0deeaee55afa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0f5c7e91-ad61-41fd-b4c3-a2afd1953685" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_63fee708-5804-4023-a5fe-dec97b854612" xlink:to="loc_us-gaap_NetIncomeLoss_0f5c7e91-ad61-41fd-b4c3-a2afd1953685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_7b8317ca-2127-4a9e-a0bc-48197b7d25c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_63fee708-5804-4023-a5fe-dec97b854612" xlink:to="loc_us-gaap_EarningsPerShareAbstract_7b8317ca-2127-4a9e-a0bc-48197b7d25c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_eb73f721-9112-4199-a922-6c55839987aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7b8317ca-2127-4a9e-a0bc-48197b7d25c1" xlink:to="loc_us-gaap_EarningsPerShareBasic_eb73f721-9112-4199-a922-6c55839987aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_2899ae64-67bf-4f3f-9276-24dbcf284e79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7b8317ca-2127-4a9e-a0bc-48197b7d25c1" xlink:to="loc_us-gaap_EarningsPerShareDiluted_2899ae64-67bf-4f3f-9276-24dbcf284e79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_79aa4263-2235-4928-8073-10e11c424fa4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_63fee708-5804-4023-a5fe-dec97b854612" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_79aa4263-2235-4928-8073-10e11c424fa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5c4c0292-e71a-4191-aa3b-2ff26a322419" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_79aa4263-2235-4928-8073-10e11c424fa4" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5c4c0292-e71a-4191-aa3b-2ff26a322419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8a71bd5b-00f9-44c9-a75a-f430afc26c1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_79aa4263-2235-4928-8073-10e11c424fa4" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8a71bd5b-00f9-44c9-a75a-f430afc26c1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="simple" xlink:href="exel-20201002.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeLoss"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ea0f0d3a-e30d-4f0a-8618-7c0b3805332d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3eed63eb-c326-41f8-a1b6-4275ccdf0f45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ea0f0d3a-e30d-4f0a-8618-7c0b3805332d" xlink:to="loc_us-gaap_NetIncomeLoss_3eed63eb-c326-41f8-a1b6-4275ccdf0f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_13b4ca7c-f22b-44c4-803e-99913fb48c39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ea0f0d3a-e30d-4f0a-8618-7c0b3805332d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_13b4ca7c-f22b-44c4-803e-99913fb48c39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5f09f86c-60c7-44d9-80d5-5ac0a47566bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_13b4ca7c-f22b-44c4-803e-99913fb48c39" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5f09f86c-60c7-44d9-80d5-5ac0a47566bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_19894c6d-1c7a-4989-acd5-5e1239cb7bb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ea0f0d3a-e30d-4f0a-8618-7c0b3805332d" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_19894c6d-1c7a-4989-acd5-5e1239cb7bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical" xlink:type="simple" xlink:href="exel-20201002.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3a0f1cd6-056c-4824-aed3-f40e2669ba75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_70333771-f18e-4b5a-8baf-1f10b306b35b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3a0f1cd6-056c-4824-aed3-f40e2669ba75" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_70333771-f18e-4b5a-8baf-1f10b306b35b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_32f24b1d-c4cf-437a-a2e1-37d331053e79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_70333771-f18e-4b5a-8baf-1f10b306b35b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_32f24b1d-c4cf-437a-a2e1-37d331053e79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="exel-20201002.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_1723c820-1c77-4294-aeca-f1500485d07e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_5e4b8829-0cfd-45b5-849c-8dcbb2c41692" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_1723c820-1c77-4294-aeca-f1500485d07e" xlink:to="loc_us-gaap_StatementTable_5e4b8829-0cfd-45b5-849c-8dcbb2c41692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f6b37188-0ad7-426f-a361-dc6bbfc3e604" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5e4b8829-0cfd-45b5-849c-8dcbb2c41692" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f6b37188-0ad7-426f-a361-dc6bbfc3e604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a2bb5481-d8a3-4ca0-8d27-2a93fe5d2b7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f6b37188-0ad7-426f-a361-dc6bbfc3e604" xlink:to="loc_us-gaap_EquityComponentDomain_a2bb5481-d8a3-4ca0-8d27-2a93fe5d2b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_408b3778-33d5-45b7-825d-4d7fa0a7c1fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a2bb5481-d8a3-4ca0-8d27-2a93fe5d2b7d" xlink:to="loc_us-gaap_CommonStockMember_408b3778-33d5-45b7-825d-4d7fa0a7c1fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_11c6acbe-6816-4de2-97d7-e2f5621f3950" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a2bb5481-d8a3-4ca0-8d27-2a93fe5d2b7d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_11c6acbe-6816-4de2-97d7-e2f5621f3950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_592ff816-b223-40c8-b30c-0c93a2f7995b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a2bb5481-d8a3-4ca0-8d27-2a93fe5d2b7d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_592ff816-b223-40c8-b30c-0c93a2f7995b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_77965132-b24e-45c1-a9e1-d83bb1285d70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a2bb5481-d8a3-4ca0-8d27-2a93fe5d2b7d" xlink:to="loc_us-gaap_RetainedEarningsMember_77965132-b24e-45c1-a9e1-d83bb1285d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_9386fad3-a409-45ac-8aa5-31529dd477e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5e4b8829-0cfd-45b5-849c-8dcbb2c41692" xlink:to="loc_us-gaap_StatementLineItems_9386fad3-a409-45ac-8aa5-31529dd477e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c58bd9d7-0990-42a3-b976-12c4189f3b68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9386fad3-a409-45ac-8aa5-31529dd477e1" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c58bd9d7-0990-42a3-b976-12c4189f3b68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9586eaac-cd9e-4d0b-a0a5-53b543dfbecf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c58bd9d7-0990-42a3-b976-12c4189f3b68" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_9586eaac-cd9e-4d0b-a0a5-53b543dfbecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_43b05a44-f74e-4094-83ef-74133d177b58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c58bd9d7-0990-42a3-b976-12c4189f3b68" xlink:to="loc_us-gaap_StockholdersEquity_43b05a44-f74e-4094-83ef-74133d177b58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fab3c5cf-c673-46d8-b66d-23b841724393" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c58bd9d7-0990-42a3-b976-12c4189f3b68" xlink:to="loc_us-gaap_NetIncomeLoss_fab3c5cf-c673-46d8-b66d-23b841724393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_9152293e-345e-4ba0-8d84-bc6220c62af9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c58bd9d7-0990-42a3-b976-12c4189f3b68" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_9152293e-345e-4ba0-8d84-bc6220c62af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2ce97830-4199-4fe8-aa94-aa4ae3d0d1ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c58bd9d7-0990-42a3-b976-12c4189f3b68" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2ce97830-4199-4fe8-aa94-aa4ae3d0d1ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_9cbc9dce-fd07-4973-abdb-821c581a4c52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c58bd9d7-0990-42a3-b976-12c4189f3b68" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_9cbc9dce-fd07-4973-abdb-821c581a4c52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_9d65baf0-4484-4d84-a7ef-fa4087a36e2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c58bd9d7-0990-42a3-b976-12c4189f3b68" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_9d65baf0-4484-4d84-a7ef-fa4087a36e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8d789b6b-116f-4119-964a-70cb32bbd48d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c58bd9d7-0990-42a3-b976-12c4189f3b68" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8d789b6b-116f-4119-964a-70cb32bbd48d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b45e59de-7f97-44cf-8c53-ea4be0c6a378" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c58bd9d7-0990-42a3-b976-12c4189f3b68" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_b45e59de-7f97-44cf-8c53-ea4be0c6a378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_cd6f1601-b1d4-4a0f-8cad-ca0be3f7e233" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c58bd9d7-0990-42a3-b976-12c4189f3b68" xlink:to="loc_us-gaap_StockholdersEquity_cd6f1601-b1d4-4a0f-8cad-ca0be3f7e233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="exel-20201002.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0c5f527e-d7bd-4f66-ae05-4b93a627f0f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3bb3a998-d6fc-42e4-b667-17ac3f6b8400" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0c5f527e-d7bd-4f66-ae05-4b93a627f0f9" xlink:to="loc_us-gaap_NetIncomeLoss_3bb3a998-d6fc-42e4-b667-17ac3f6b8400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2b469f45-502d-4d9d-a0b0-82b580bcf697" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0c5f527e-d7bd-4f66-ae05-4b93a627f0f9" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2b469f45-502d-4d9d-a0b0-82b580bcf697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_506aacb7-046a-4c7c-a252-d05c61029733" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2b469f45-502d-4d9d-a0b0-82b580bcf697" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_506aacb7-046a-4c7c-a252-d05c61029733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_eee95098-a214-4250-9e10-48b81033cbca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2b469f45-502d-4d9d-a0b0-82b580bcf697" xlink:to="loc_us-gaap_ShareBasedCompensation_eee95098-a214-4250-9e10-48b81033cbca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NoncashLeaseExpense_8dc9c1f4-77c5-4e01-8a7a-af8fc95b40f5" xlink:href="exel-20201002.xsd#exel_NoncashLeaseExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2b469f45-502d-4d9d-a0b0-82b580bcf697" xlink:to="loc_exel_NoncashLeaseExpense_8dc9c1f4-77c5-4e01-8a7a-af8fc95b40f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_85e5acab-1f8b-4a1b-9211-2668cc1813d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2b469f45-502d-4d9d-a0b0-82b580bcf697" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_85e5acab-1f8b-4a1b-9211-2668cc1813d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_5bbed690-7172-4c0c-b203-42c06f8eb948" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2b469f45-502d-4d9d-a0b0-82b580bcf697" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_5bbed690-7172-4c0c-b203-42c06f8eb948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7a058f9e-db29-40f4-901c-305f64230eec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2b469f45-502d-4d9d-a0b0-82b580bcf697" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7a058f9e-db29-40f4-901c-305f64230eec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_997cb08a-d2ad-4c3c-836b-34e8856e2380" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7a058f9e-db29-40f4-901c-305f64230eec" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_997cb08a-d2ad-4c3c-836b-34e8856e2380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_7b73e0b1-3b51-4c9f-9436-6c30b1f25bef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7a058f9e-db29-40f4-901c-305f64230eec" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_7b73e0b1-3b51-4c9f-9436-6c30b1f25bef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_642b773d-fd12-413b-8bb7-2ce9abb90339" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7a058f9e-db29-40f4-901c-305f64230eec" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_642b773d-fd12-413b-8bb7-2ce9abb90339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_3e151620-1dea-4590-bda6-aab7343cc5bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7a058f9e-db29-40f4-901c-305f64230eec" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_3e151620-1dea-4590-bda6-aab7343cc5bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_743fa505-a439-4350-8d11-11c3cf21ad3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7a058f9e-db29-40f4-901c-305f64230eec" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_743fa505-a439-4350-8d11-11c3cf21ad3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_86f5373f-1f20-4a2d-8776-96cbfbec8e3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0c5f527e-d7bd-4f66-ae05-4b93a627f0f9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_86f5373f-1f20-4a2d-8776-96cbfbec8e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_11362621-218e-428c-96b2-2a68c6d55589" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0c5f527e-d7bd-4f66-ae05-4b93a627f0f9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_11362621-218e-428c-96b2-2a68c6d55589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_46403ee3-7a0e-4db7-b356-700216a457ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_11362621-218e-428c-96b2-2a68c6d55589" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_46403ee3-7a0e-4db7-b356-700216a457ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_c2bc5f68-8921-41ee-a1ba-ba4f9f681989" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_11362621-218e-428c-96b2-2a68c6d55589" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_c2bc5f68-8921-41ee-a1ba-ba4f9f681989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_95ddf966-97ec-4d29-af5e-56713833e2c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_11362621-218e-428c-96b2-2a68c6d55589" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_95ddf966-97ec-4d29-af5e-56713833e2c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5c40f0fb-3598-4856-a908-68666afd09ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_11362621-218e-428c-96b2-2a68c6d55589" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5c40f0fb-3598-4856-a908-68666afd09ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_efb6ae26-68a4-44bc-b46b-c2ab00df40fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0c5f527e-d7bd-4f66-ae05-4b93a627f0f9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_efb6ae26-68a4-44bc-b46b-c2ab00df40fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_06d46a82-fadb-41d1-bcad-35f0b4b9b355" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_efb6ae26-68a4-44bc-b46b-c2ab00df40fb" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_06d46a82-fadb-41d1-bcad-35f0b4b9b355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_7ddab7a1-092a-441f-9198-aa073a886ed2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_efb6ae26-68a4-44bc-b46b-c2ab00df40fb" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_7ddab7a1-092a-441f-9198-aa073a886ed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_84da22e5-b9b9-4e2a-956b-9c4c2eeed44a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_efb6ae26-68a4-44bc-b46b-c2ab00df40fb" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_84da22e5-b9b9-4e2a-956b-9c4c2eeed44a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3bd63dc8-e536-4f6b-8d72-a9f336b6c9a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_efb6ae26-68a4-44bc-b46b-c2ab00df40fb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3bd63dc8-e536-4f6b-8d72-a9f336b6c9a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e1dc9825-9965-4261-8adf-2b3c57b15d2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0c5f527e-d7bd-4f66-ae05-4b93a627f0f9" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e1dc9825-9965-4261-8adf-2b3c57b15d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_817eca47-2d7b-45e8-9e70-d5540669166e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0c5f527e-d7bd-4f66-ae05-4b93a627f0f9" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_817eca47-2d7b-45e8-9e70-d5540669166e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fcbebc3f-7f02-4039-aaea-adb0f81d1da9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0c5f527e-d7bd-4f66-ae05-4b93a627f0f9" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fcbebc3f-7f02-4039-aaea-adb0f81d1da9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_4d89a80e-df9e-4621-b20a-f4701e68d296" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0c5f527e-d7bd-4f66-ae05-4b93a627f0f9" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_4d89a80e-df9e-4621-b20a-f4701e68d296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_0473507a-e9ef-4bee-8000-9c33297faee5" xlink:href="exel-20201002.xsd#exel_RightOfUseAssetObtainedInExchangeForLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_4d89a80e-df9e-4621-b20a-f4701e68d296" xlink:to="loc_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_0473507a-e9ef-4bee-8000-9c33297faee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_466e3c65-1fac-4766-9e99-8e2be412ecf0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_4d89a80e-df9e-4621-b20a-f4701e68d296" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_466e3c65-1fac-4766-9e99-8e2be412ecf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LiabilitiesExpendituresIncurredButNotYetPaidToRelatedPartyTransactions_535887e0-696e-4ce0-ab7d-ec60c66e0a22" xlink:href="exel-20201002.xsd#exel_LiabilitiesExpendituresIncurredButNotYetPaidToRelatedPartyTransactions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_4d89a80e-df9e-4621-b20a-f4701e68d296" xlink:to="loc_exel_LiabilitiesExpendituresIncurredButNotYetPaidToRelatedPartyTransactions_535887e0-696e-4ce0-ab7d-ec60c66e0a22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="exel-20201002.xsd#OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_db45a7c3-6794-4d54-a274-c879ca6f00be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_d892b173-45cf-4cc2-8254-3668d10504de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_db45a7c3-6794-4d54-a274-c879ca6f00be" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_d892b173-45cf-4cc2-8254-3668d10504de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="exel-20201002.xsd#OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2ecdfc2c-ad51-4768-84ac-ed6c5337de17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_8f9e2a4e-218c-43c8-837c-c071d55ddfd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2ecdfc2c-ad51-4768-84ac-ed6c5337de17" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_8f9e2a4e-218c-43c8-837c-c071d55ddfd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_a9fe2aa6-5ef7-458b-b706-eb459960fae6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2ecdfc2c-ad51-4768-84ac-ed6c5337de17" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_a9fe2aa6-5ef7-458b-b706-eb459960fae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiscalPeriod_5ad62e49-915c-4db5-8a6e-89badc8102ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiscalPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2ecdfc2c-ad51-4768-84ac-ed6c5337de17" xlink:to="loc_us-gaap_FiscalPeriod_5ad62e49-915c-4db5-8a6e-89badc8102ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_323d2975-1d35-4455-bfa0-91f7f5252896" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2ecdfc2c-ad51-4768-84ac-ed6c5337de17" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_323d2975-1d35-4455-bfa0-91f7f5252896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_fcad7f4a-99c4-4889-a0a4-b78000cc0241" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2ecdfc2c-ad51-4768-84ac-ed6c5337de17" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_fcad7f4a-99c4-4889-a0a4-b78000cc0241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_42599eaa-d824-428b-a851-f733c29d6b2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2ecdfc2c-ad51-4768-84ac-ed6c5337de17" xlink:to="loc_us-gaap_UseOfEstimates_42599eaa-d824-428b-a851-f733c29d6b2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_449b2ec6-4a80-485a-a1b9-4f8331142ce8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2ecdfc2c-ad51-4768-84ac-ed6c5337de17" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_449b2ec6-4a80-485a-a1b9-4f8331142ce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_1b76c146-038e-4890-8caf-4d312379aa7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2ecdfc2c-ad51-4768-84ac-ed6c5337de17" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_1b76c146-038e-4890-8caf-4d312379aa7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#OrganizationandSummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_66b56d9c-b5df-4c8a-adbe-db0bf313dec8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_b3372a7a-ebea-440f-8761-dbdf78465df4" xlink:href="exel-20201002.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_66b56d9c-b5df-4c8a-adbe-db0bf313dec8" xlink:to="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_b3372a7a-ebea-440f-8761-dbdf78465df4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_efcd99fb-f03b-4ec7-9739-16947d95cf20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_b3372a7a-ebea-440f-8761-dbdf78465df4" xlink:to="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_efcd99fb-f03b-4ec7-9739-16947d95cf20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_dec083a3-4120-4f24-b196-6296c36da186" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_efcd99fb-f03b-4ec7-9739-16947d95cf20" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_dec083a3-4120-4f24-b196-6296c36da186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NewInformationMember_2cf3aa2a-8bfb-4930-91b6-661ef87485b0" xlink:href="exel-20201002.xsd#exel_NewInformationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_dec083a3-4120-4f24-b196-6296c36da186" xlink:to="loc_exel_NewInformationMember_2cf3aa2a-8bfb-4930-91b6-661ef87485b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6ecc86ab-5076-4eb5-869c-f427fc3c9a2b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_b3372a7a-ebea-440f-8761-dbdf78465df4" xlink:to="loc_srt_ProductOrServiceAxis_6ecc86ab-5076-4eb5-869c-f427fc3c9a2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d38bd709-f010-4eed-897d-fd2811e5a8b5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_6ecc86ab-5076-4eb5-869c-f427fc3c9a2b" xlink:to="loc_srt_ProductsAndServicesDomain_d38bd709-f010-4eed-897d-fd2811e5a8b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ResultingFromDiscoveryEffortsMember_3bd766b9-d769-41df-bdeb-31d445204021" xlink:href="exel-20201002.xsd#exel_ResultingFromDiscoveryEffortsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d38bd709-f010-4eed-897d-fd2811e5a8b5" xlink:to="loc_exel_ResultingFromDiscoveryEffortsMember_3bd766b9-d769-41df-bdeb-31d445204021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductsDerivedFromCabozantinibMember_10109475-4ad5-404b-9d0f-69d05c5d441b" xlink:href="exel-20201002.xsd#exel_ProductsDerivedFromCabozantinibMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d38bd709-f010-4eed-897d-fd2811e5a8b5" xlink:to="loc_exel_ProductsDerivedFromCabozantinibMember_10109475-4ad5-404b-9d0f-69d05c5d441b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductsDerivedFromOtherCompoundsMember_52018253-9d96-4e7d-b1dc-0ce27efd12f5" xlink:href="exel-20201002.xsd#exel_ProductsDerivedFromOtherCompoundsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d38bd709-f010-4eed-897d-fd2811e5a8b5" xlink:to="loc_exel_ProductsDerivedFromOtherCompoundsMember_52018253-9d96-4e7d-b1dc-0ce27efd12f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_44d16326-82dc-44f2-9d88-226a58f86b52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_b3372a7a-ebea-440f-8761-dbdf78465df4" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_44d16326-82dc-44f2-9d88-226a58f86b52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5f7a4226-0237-473d-8bd7-460b8822aa8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_44d16326-82dc-44f2-9d88-226a58f86b52" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5f7a4226-0237-473d-8bd7-460b8822aa8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_56b21a3c-10d4-4c79-8f67-22688ebf4758" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5f7a4226-0237-473d-8bd7-460b8822aa8f" xlink:to="loc_us-gaap_AccountsReceivableMember_56b21a3c-10d4-4c79-8f67-22688ebf4758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_e834ecdc-3aa9-40f7-b6e6-0071ee5f8db3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_b3372a7a-ebea-440f-8761-dbdf78465df4" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_e834ecdc-3aa9-40f7-b6e6-0071ee5f8db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_4586b671-5c1c-4b32-abf0-0a9857007c63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_e834ecdc-3aa9-40f7-b6e6-0071ee5f8db3" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_4586b671-5c1c-4b32-abf0-0a9857007c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_38daa32c-5824-40f0-a8b3-174ef9c8e8e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_4586b671-5c1c-4b32-abf0-0a9857007c63" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_38daa32c-5824-40f0-a8b3-174ef9c8e8e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_963f0d2f-d014-44a6-8a73-be2e142a1543" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_b3372a7a-ebea-440f-8761-dbdf78465df4" xlink:to="loc_srt_MajorCustomersAxis_963f0d2f-d014-44a6-8a73-be2e142a1543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_ee08c0db-b7d5-490b-91c5-7b78e2aa0b6d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_963f0d2f-d014-44a6-8a73-be2e142a1543" xlink:to="loc_srt_NameOfMajorCustomerDomain_ee08c0db-b7d5-490b-91c5-7b78e2aa0b6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_IpsenMember_e09e7b0d-ceb9-422d-b840-a5768e5c48b2" xlink:href="exel-20201002.xsd#exel_IpsenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_ee08c0db-b7d5-490b-91c5-7b78e2aa0b6d" xlink:to="loc_exel_IpsenMember_e09e7b0d-ceb9-422d-b840-a5768e5c48b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MckessonMember_e654db35-ce1c-4139-97d6-c8a59cb2f28c" xlink:href="exel-20201002.xsd#exel_MckessonMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_ee08c0db-b7d5-490b-91c5-7b78e2aa0b6d" xlink:to="loc_exel_MckessonMember_e654db35-ce1c-4139-97d6-c8a59cb2f28c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_d0fb258e-3a40-4f6e-b86d-712531ef54f0" xlink:href="exel-20201002.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_b3372a7a-ebea-440f-8761-dbdf78465df4" xlink:to="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_d0fb258e-3a40-4f6e-b86d-712531ef54f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NumberofProductsinCommercialMarket_39626d1c-6537-4d71-9ca2-ad099e3718b5" xlink:href="exel-20201002.xsd#exel_NumberofProductsinCommercialMarket"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_d0fb258e-3a40-4f6e-b86d-712531ef54f0" xlink:to="loc_exel_NumberofProductsinCommercialMarket_39626d1c-6537-4d71-9ca2-ad099e3718b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_7b5cc5e7-4518-42bb-963f-437343ca6b52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_d0fb258e-3a40-4f6e-b86d-712531ef54f0" xlink:to="loc_us-gaap_NumberOfOperatingSegments_7b5cc5e7-4518-42bb-963f-437343ca6b52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_13830c12-1c83-433a-9113-14f8bad9c265" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_d0fb258e-3a40-4f6e-b86d-712531ef54f0" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_13830c12-1c83-433a-9113-14f8bad9c265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_34a8a3af-ea8b-4aab-b9e8-597477e4b0a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_d0fb258e-3a40-4f6e-b86d-712531ef54f0" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_34a8a3af-ea8b-4aab-b9e8-597477e4b0a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_5e26c10c-69c9-448a-810b-a30ee88227f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_d0fb258e-3a40-4f6e-b86d-712531ef54f0" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_5e26c10c-69c9-448a-810b-a30ee88227f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_1504acce-1fd3-4463-948d-a422c1352d34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_d0fb258e-3a40-4f6e-b86d-712531ef54f0" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_1504acce-1fd3-4463-948d-a422c1352d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/Revenues" xlink:type="simple" xlink:href="exel-20201002.xsd#Revenues"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/Revenues" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f4a10882-020c-4d4f-8cdb-8829b9b6b2c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_d29c0082-f561-43b4-9536-ff9f4d31ec0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f4a10882-020c-4d4f-8cdb-8829b9b6b2c3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_d29c0082-f561-43b4-9536-ff9f4d31ec0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesTables" xlink:type="simple" xlink:href="exel-20201002.xsd#RevenuesTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6317deae-ae50-4d08-a86b-f8bc9d60eac1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_e965ab83-ff67-4e42-a599-1415e4116803" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6317deae-ae50-4d08-a86b-f8bc9d60eac1" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_e965ab83-ff67-4e42-a599-1415e4116803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_24896b86-0bc5-4d31-9361-415927d60960" xlink:href="exel-20201002.xsd#exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6317deae-ae50-4d08-a86b-f8bc9d60eac1" xlink:to="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_24896b86-0bc5-4d31-9361-415927d60960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#RevenuesRevenuesbyDisaggregatedCategoryDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_916e4ebe-0778-49e6-b579-3f0aae21875d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_0dc59b1d-8211-4cd2-a410-468e0c5bb3b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_916e4ebe-0778-49e6-b579-3f0aae21875d" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_0dc59b1d-8211-4cd2-a410-468e0c5bb3b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_78e35e6d-191a-4914-ad5c-e94da393b203" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_0dc59b1d-8211-4cd2-a410-468e0c5bb3b5" xlink:to="loc_srt_ProductOrServiceAxis_78e35e6d-191a-4914-ad5c-e94da393b203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_05425924-44f1-449c-bc74-d8aa9b765c4c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_78e35e6d-191a-4914-ad5c-e94da393b203" xlink:to="loc_srt_ProductsAndServicesDomain_05425924-44f1-449c-bc74-d8aa9b765c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_3f990d9e-4e73-4782-8f27-3e31c085d8e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_05425924-44f1-449c-bc74-d8aa9b765c4c" xlink:to="loc_us-gaap_ProductMember_3f990d9e-4e73-4782-8f27-3e31c085d8e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductGrossMember_cf0f7be8-fcee-4d2f-a022-b7f2d2a3e370" xlink:href="exel-20201002.xsd#exel_ProductGrossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_3f990d9e-4e73-4782-8f27-3e31c085d8e0" xlink:to="loc_exel_ProductGrossMember_cf0f7be8-fcee-4d2f-a022-b7f2d2a3e370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductSalesDiscountsAndAllowancesMember_936299c9-8d19-4ac4-a580-d39f1c899ec6" xlink:href="exel-20201002.xsd#exel_ProductSalesDiscountsAndAllowancesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_3f990d9e-4e73-4782-8f27-3e31c085d8e0" xlink:to="loc_exel_ProductSalesDiscountsAndAllowancesMember_936299c9-8d19-4ac4-a580-d39f1c899ec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationMember_160b5702-53b4-49e8-be89-48291ae4a8c1" xlink:href="exel-20201002.xsd#exel_CollaborationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_05425924-44f1-449c-bc74-d8aa9b765c4c" xlink:to="loc_exel_CollaborationMember_160b5702-53b4-49e8-be89-48291ae4a8c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_73acaa50-1938-4709-ae8f-67ca014c26a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_CollaborationMember_160b5702-53b4-49e8-be89-48291ae4a8c1" xlink:to="loc_us-gaap_LicenseMember_73acaa50-1938-4709-ae8f-67ca014c26a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_2782a7a3-03c2-4d1e-913f-aee9537dadbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_CollaborationMember_160b5702-53b4-49e8-be89-48291ae4a8c1" xlink:to="loc_us-gaap_ServiceMember_2782a7a3-03c2-4d1e-913f-aee9537dadbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_f49ae673-1082-454d-8fa0-fba2d39da430" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_0dc59b1d-8211-4cd2-a410-468e0c5bb3b5" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_f49ae673-1082-454d-8fa0-fba2d39da430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_98cb9bf6-44e2-402f-ba6d-6a8b94772781" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f49ae673-1082-454d-8fa0-fba2d39da430" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_98cb9bf6-44e2-402f-ba6d-6a8b94772781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer_909ec054-5279-4671-8a14-095bebd57f39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f49ae673-1082-454d-8fa0-fba2d39da430" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomer_909ec054-5279-4671-8a14-095bebd57f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_8864f626-e546-4b70-b007-de049396b125" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f49ae673-1082-454d-8fa0-fba2d39da430" xlink:to="loc_us-gaap_Revenues_8864f626-e546-4b70-b007-de049396b125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#RevenuesNetProductRevenuesDisaggregatedbyProductDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1a6c3b44-73af-405a-8673-0c7c29e11306" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_ab405d16-504f-4bd1-b52e-5263baf4fe10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1a6c3b44-73af-405a-8673-0c7c29e11306" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_ab405d16-504f-4bd1-b52e-5263baf4fe10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b8536a6f-b874-4c6a-95e1-69393fcc1794" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ab405d16-504f-4bd1-b52e-5263baf4fe10" xlink:to="loc_srt_ProductOrServiceAxis_b8536a6f-b874-4c6a-95e1-69393fcc1794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_aaf04895-d3d2-4490-a29b-61f8d80d8ea3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_b8536a6f-b874-4c6a-95e1-69393fcc1794" xlink:to="loc_srt_ProductsAndServicesDomain_aaf04895-d3d2-4490-a29b-61f8d80d8ea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_e1481e4e-7be7-4e26-8e0b-9c50f3395de0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_aaf04895-d3d2-4490-a29b-61f8d80d8ea3" xlink:to="loc_us-gaap_ProductMember_e1481e4e-7be7-4e26-8e0b-9c50f3395de0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CabometyxMember_d4351e40-8981-400d-843f-ffffb9232b74" xlink:href="exel-20201002.xsd#exel_CabometyxMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_e1481e4e-7be7-4e26-8e0b-9c50f3395de0" xlink:to="loc_exel_CabometyxMember_d4351e40-8981-400d-843f-ffffb9232b74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CometriqMember_d3f69728-f4e0-4f0d-b9b6-ad501691aaa4" xlink:href="exel-20201002.xsd#exel_CometriqMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_e1481e4e-7be7-4e26-8e0b-9c50f3395de0" xlink:to="loc_exel_CometriqMember_d3f69728-f4e0-4f0d-b9b6-ad501691aaa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_cbc93ab9-1ac2-42cd-b43b-746dd1d6edee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ab405d16-504f-4bd1-b52e-5263baf4fe10" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_cbc93ab9-1ac2-42cd-b43b-746dd1d6edee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_11fdc818-379d-4cab-b685-3481d4c63030" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_cbc93ab9-1ac2-42cd-b43b-746dd1d6edee" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_11fdc818-379d-4cab-b685-3481d4c63030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1bfef32c-4309-452f-9acf-6035e4ff9906" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_a6d525be-e887-4213-85b7-e79ca6d5512d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1bfef32c-4309-452f-9acf-6035e4ff9906" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_a6d525be-e887-4213-85b7-e79ca6d5512d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_456b3e91-7968-4ce2-b7c9-43c56154c010" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_a6d525be-e887-4213-85b7-e79ca6d5512d" xlink:to="loc_srt_MajorCustomersAxis_456b3e91-7968-4ce2-b7c9-43c56154c010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_9799160b-8905-4d0f-9a47-531cf361b28b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_456b3e91-7968-4ce2-b7c9-43c56154c010" xlink:to="loc_srt_NameOfMajorCustomerDomain_9799160b-8905-4d0f-9a47-531cf361b28b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_IpsenMember_83060371-c4e9-4d08-88a1-1bf8a281d72b" xlink:href="exel-20201002.xsd#exel_IpsenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_9799160b-8905-4d0f-9a47-531cf361b28b" xlink:to="loc_exel_IpsenMember_83060371-c4e9-4d08-88a1-1bf8a281d72b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofCVSHealthCorporationMember_68316bb0-1cf1-4429-8f45-d7004fa013b5" xlink:href="exel-20201002.xsd#exel_AffiliatesofCVSHealthCorporationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_9799160b-8905-4d0f-9a47-531cf361b28b" xlink:to="loc_exel_AffiliatesofCVSHealthCorporationMember_68316bb0-1cf1-4429-8f45-d7004fa013b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofMcKessonCorporationMember_8bb03087-dbd8-431c-a3e9-cce0478e9052" xlink:href="exel-20201002.xsd#exel_AffiliatesofMcKessonCorporationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_9799160b-8905-4d0f-9a47-531cf361b28b" xlink:to="loc_exel_AffiliatesofMcKessonCorporationMember_8bb03087-dbd8-431c-a3e9-cce0478e9052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember_0042e2fd-c100-410a-8e99-0eb3a72c5b12" xlink:href="exel-20201002.xsd#exel_AffiliatesOfAmerisourceBergenCorporationMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_9799160b-8905-4d0f-9a47-531cf361b28b" xlink:to="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember_0042e2fd-c100-410a-8e99-0eb3a72c5b12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofOptumSpecialtyPharmacyMember_dbcfc006-e17a-479a-b4ed-913bd8525ff9" xlink:href="exel-20201002.xsd#exel_AffiliatesofOptumSpecialtyPharmacyMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_9799160b-8905-4d0f-9a47-531cf361b28b" xlink:to="loc_exel_AffiliatesofOptumSpecialtyPharmacyMember_dbcfc006-e17a-479a-b4ed-913bd8525ff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TakedaMember_d989756f-8340-438d-894b-d01b60b91026" xlink:href="exel-20201002.xsd#exel_TakedaMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_9799160b-8905-4d0f-9a47-531cf361b28b" xlink:to="loc_exel_TakedaMember_d989756f-8340-438d-894b-d01b60b91026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2084c9c5-014d-41c4-8061-62a6254f0416" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_a6d525be-e887-4213-85b7-e79ca6d5512d" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2084c9c5-014d-41c4-8061-62a6254f0416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8a53489c-9bfc-404f-a7da-ef65346219dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2084c9c5-014d-41c4-8061-62a6254f0416" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8a53489c-9bfc-404f-a7da-ef65346219dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_db2c77f7-c5e1-486c-9d83-9e22dd15851f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8a53489c-9bfc-404f-a7da-ef65346219dd" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_db2c77f7-c5e1-486c-9d83-9e22dd15851f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_1c81ac32-18b6-4f2d-88cd-8d536ec8eb04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_a6d525be-e887-4213-85b7-e79ca6d5512d" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_1c81ac32-18b6-4f2d-88cd-8d536ec8eb04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_cd2d3a15-e109-40a7-be54-c7e32b48bd62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_1c81ac32-18b6-4f2d-88cd-8d536ec8eb04" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_cd2d3a15-e109-40a7-be54-c7e32b48bd62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_52cc2a00-f851-4e4d-a472-ebc50bd29d45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_cd2d3a15-e109-40a7-be54-c7e32b48bd62" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_52cc2a00-f851-4e4d-a472-ebc50bd29d45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_a43be800-edbd-4d66-bd83-49c9685f221c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_a6d525be-e887-4213-85b7-e79ca6d5512d" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_a43be800-edbd-4d66-bd83-49c9685f221c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_f834c8fd-e569-4916-91b2-094dc9c51294" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_a43be800-edbd-4d66-bd83-49c9685f221c" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_f834c8fd-e569-4916-91b2-094dc9c51294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2e19a8ea-aba6-45cc-9dba-1ffad2cd909f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_ba51faa0-4887-4182-8121-6895b5434892" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2e19a8ea-aba6-45cc-9dba-1ffad2cd909f" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_ba51faa0-4887-4182-8121-6895b5434892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_c6c20ab7-9834-44d1-b242-dbd14481ba2b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ba51faa0-4887-4182-8121-6895b5434892" xlink:to="loc_srt_StatementGeographicalAxis_c6c20ab7-9834-44d1-b242-dbd14481ba2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c52f3312-f244-4103-812b-87491195f8a6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_c6c20ab7-9834-44d1-b242-dbd14481ba2b" xlink:to="loc_srt_SegmentGeographicalDomain_c52f3312-f244-4103-812b-87491195f8a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_6462a3a5-c90c-438a-89e8-db96d67bdc5f" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_c52f3312-f244-4103-812b-87491195f8a6" xlink:to="loc_country_US_6462a3a5-c90c-438a-89e8-db96d67bdc5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_4f011af6-7cce-4e12-9dc3-bda29a1deabc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_c52f3312-f244-4103-812b-87491195f8a6" xlink:to="loc_srt_EuropeMember_4f011af6-7cce-4e12-9dc3-bda29a1deabc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_00fc2e25-9f8e-460b-ac8c-52993b661c0f" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_c52f3312-f244-4103-812b-87491195f8a6" xlink:to="loc_country_JP_00fc2e25-9f8e-460b-ac8c-52993b661c0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_f2969aff-26dc-48e8-bfa1-0ee1c8f4e834" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ba51faa0-4887-4182-8121-6895b5434892" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_f2969aff-26dc-48e8-bfa1-0ee1c8f4e834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1a19f058-93bc-4d38-ab66-f21cdc3de8c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f2969aff-26dc-48e8-bfa1-0ee1c8f4e834" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1a19f058-93bc-4d38-ab66-f21cdc3de8c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2bcc424e-f221-4b9a-ac65-a3640079e085" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_f9debe47-fe52-4a81-9b43-ff9faf014602" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2bcc424e-f221-4b9a-ac65-a3640079e085" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_f9debe47-fe52-4a81-9b43-ff9faf014602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_b99be74e-82d0-4721-96f0-d526a3b6e018" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_f9debe47-fe52-4a81-9b43-ff9faf014602" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_b99be74e-82d0-4721-96f0-d526a3b6e018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_0bec23ce-58a9-467f-9b3c-9a7545678d3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_b99be74e-82d0-4721-96f0-d526a3b6e018" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_0bec23ce-58a9-467f-9b3c-9a7545678d3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_aaca362e-623e-49ad-adef-ec3debc0e004" xlink:href="exel-20201002.xsd#exel_ChargebacksAndDiscountsForPromptPaymentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_0bec23ce-58a9-467f-9b3c-9a7545678d3a" xlink:to="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_aaca362e-623e-49ad-adef-ec3debc0e004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_25176a43-ee6d-4522-8c57-db1b8e4dc138" xlink:href="exel-20201002.xsd#exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_0bec23ce-58a9-467f-9b3c-9a7545678d3a" xlink:to="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_25176a43-ee6d-4522-8c57-db1b8e4dc138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AllowanceForProductRebatesMember_90eb5b2f-5f6a-409c-b668-d7cb2f6fa5f4" xlink:href="exel-20201002.xsd#exel_AllowanceForProductRebatesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_0bec23ce-58a9-467f-9b3c-9a7545678d3a" xlink:to="loc_exel_AllowanceForProductRebatesMember_90eb5b2f-5f6a-409c-b668-d7cb2f6fa5f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_902c78d9-9e22-48d0-8a33-d3a7ec431e76" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_f9debe47-fe52-4a81-9b43-ff9faf014602" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_902c78d9-9e22-48d0-8a33-d3a7ec431e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_2d690f7c-8b48-45ce-8ce6-39bbf3b1985a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_902c78d9-9e22-48d0-8a33-d3a7ec431e76" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_2d690f7c-8b48-45ce-8ce6-39bbf3b1985a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_2ff28851-100c-4325-bdc7-f6a7e8fdccf7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_2d690f7c-8b48-45ce-8ce6-39bbf3b1985a" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_2ff28851-100c-4325-bdc7-f6a7e8fdccf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_5f3716a5-5432-4b83-bb90-1231bb78b369" xlink:href="exel-20201002.xsd#exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_2d690f7c-8b48-45ce-8ce6-39bbf3b1985a" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_5f3716a5-5432-4b83-bb90-1231bb78b369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_fd2f68df-9d1e-422e-9bd2-63ca01374289" xlink:href="exel-20201002.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_5f3716a5-5432-4b83-bb90-1231bb78b369" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_fd2f68df-9d1e-422e-9bd2-63ca01374289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_ceb17cc0-708c-471a-ab53-7e6c17baabec" xlink:href="exel-20201002.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_5f3716a5-5432-4b83-bb90-1231bb78b369" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_ceb17cc0-708c-471a-ab53-7e6c17baabec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_9e5c9e2b-e65d-49fb-858f-bd00a655351c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_2d690f7c-8b48-45ce-8ce6-39bbf3b1985a" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_9e5c9e2b-e65d-49fb-858f-bd00a655351c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_b73583ef-d08b-4d9a-a018-dca75f3b80c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_2d690f7c-8b48-45ce-8ce6-39bbf3b1985a" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_b73583ef-d08b-4d9a-a018-dca75f3b80c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#RevenuesContractAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_32afe375-5d24-4a59-9729-3a14bd402471" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_b8a71ef8-1817-496c-b045-cb6ec7b5226c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_32afe375-5d24-4a59-9729-3a14bd402471" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_b8a71ef8-1817-496c-b045-cb6ec7b5226c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_77c4eff3-664f-45cd-9b56-11d45d672a45" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b8a71ef8-1817-496c-b045-cb6ec7b5226c" xlink:to="loc_srt_MajorCustomersAxis_77c4eff3-664f-45cd-9b56-11d45d672a45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_b6dd7ab1-df9a-4a4e-bebb-77674c404692" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_77c4eff3-664f-45cd-9b56-11d45d672a45" xlink:to="loc_srt_NameOfMajorCustomerDomain_b6dd7ab1-df9a-4a4e-bebb-77674c404692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TakedaMember_72a00cab-a34f-4646-8037-3dcc28993ce9" xlink:href="exel-20201002.xsd#exel_TakedaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_b6dd7ab1-df9a-4a4e-bebb-77674c404692" xlink:to="loc_exel_TakedaMember_72a00cab-a34f-4646-8037-3dcc28993ce9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_50acb59d-83a1-45e7-85c6-a4712e5308df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b8a71ef8-1817-496c-b045-cb6ec7b5226c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_50acb59d-83a1-45e7-85c6-a4712e5308df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f05e0ee5-a2f2-4e8d-a62f-eff6ca5e2c0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_50acb59d-83a1-45e7-85c6-a4712e5308df" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f05e0ee5-a2f2-4e8d-a62f-eff6ca5e2c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_0da0cf62-2c11-41f3-8eb0-5c2d30f0cad2" xlink:href="exel-20201002.xsd#exel_CollaborativeArrangementwithIpsenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f05e0ee5-a2f2-4e8d-a62f-eff6ca5e2c0b" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_0da0cf62-2c11-41f3-8eb0-5c2d30f0cad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_98b9be4d-5695-456a-a396-88ae66ce99ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b8a71ef8-1817-496c-b045-cb6ec7b5226c" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_98b9be4d-5695-456a-a396-88ae66ce99ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_fb6ab2bb-d8ac-4b50-938c-0d3cd17f08e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_98b9be4d-5695-456a-a396-88ae66ce99ad" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_fb6ab2bb-d8ac-4b50-938c-0d3cd17f08e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_86454e5c-20bd-4ccc-ab17-1a8174766e9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_98b9be4d-5695-456a-a396-88ae66ce99ad" xlink:to="loc_us-gaap_ContractWithCustomerLiability_86454e5c-20bd-4ccc-ab17-1a8174766e9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_ffc5a3f1-b3fc-4a9f-8ea2-f5ae3d5369a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_98b9be4d-5695-456a-a396-88ae66ce99ad" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_ffc5a3f1-b3fc-4a9f-8ea2-f5ae3d5369a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_EligiblePaymentFromCollaborationForDevelopmentMilestoneAchievementUnderCollaborationsAgreement_39c17deb-bff8-4017-98c5-7cff9c6f0812" xlink:href="exel-20201002.xsd#exel_EligiblePaymentFromCollaborationForDevelopmentMilestoneAchievementUnderCollaborationsAgreement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_98b9be4d-5695-456a-a396-88ae66ce99ad" xlink:to="loc_exel_EligiblePaymentFromCollaborationForDevelopmentMilestoneAchievementUnderCollaborationsAgreement_39c17deb-bff8-4017-98c5-7cff9c6f0812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_d84852f5-c82e-4052-b8f2-cc6937a51c9e" xlink:href="exel-20201002.xsd#exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_98b9be4d-5695-456a-a396-88ae66ce99ad" xlink:to="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_d84852f5-c82e-4052-b8f2-cc6937a51c9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_25db2c61-24ab-4806-a06a-727427ee1e63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_98b9be4d-5695-456a-a396-88ae66ce99ad" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_25db2c61-24ab-4806-a06a-727427ee1e63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_75349601-38a5-4bdb-8747-3d5a0e01e4d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_98b9be4d-5695-456a-a396-88ae66ce99ad" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_75349601-38a5-4bdb-8747-3d5a0e01e4d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_e9dea905-0ade-4600-9416-c7dbbd16396a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_98b9be4d-5695-456a-a396-88ae66ce99ad" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_e9dea905-0ade-4600-9416-c7dbbd16396a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreements" xlink:type="simple" xlink:href="exel-20201002.xsd#CollaborationAgreements"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_220a0aab-9cd3-41d3-a1a0-b19e7481aa1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_dd067998-28d5-4143-8a9e-c6d2dde97d6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_220a0aab-9cd3-41d3-a1a0-b19e7481aa1b" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_dd067998-28d5-4143-8a9e-c6d2dde97d6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsTables" xlink:type="simple" xlink:href="exel-20201002.xsd#CollaborationAgreementsTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d1afa1b2-0b7b-4838-b246-118d1f3170e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_c73f87cc-5146-4452-8b95-ffef655e0da9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d1afa1b2-0b7b-4838-b246-118d1f3170e9" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_c73f87cc-5146-4452-8b95-ffef655e0da9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2f7374d3-f51a-4448-8c8e-3a5c060af401" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_60ef9047-3d65-4b6b-af3f-df917f400902" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2f7374d3-f51a-4448-8c8e-3a5c060af401" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_60ef9047-3d65-4b6b-af3f-df917f400902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6b5f5c95-6221-4e09-b112-d8636c6f81de" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_60ef9047-3d65-4b6b-af3f-df917f400902" xlink:to="loc_srt_ProductOrServiceAxis_6b5f5c95-6221-4e09-b112-d8636c6f81de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5a5e8f47-7bcc-4371-9e00-27c71ffff49e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_6b5f5c95-6221-4e09-b112-d8636c6f81de" xlink:to="loc_srt_ProductsAndServicesDomain_5a5e8f47-7bcc-4371-9e00-27c71ffff49e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_f29daac2-553c-4ac4-a275-f29509b963bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5a5e8f47-7bcc-4371-9e00-27c71ffff49e" xlink:to="loc_us-gaap_LicenseMember_f29daac2-553c-4ac4-a275-f29509b963bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_dedddcb2-64ba-465f-8ea4-dffaf75a5d11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5a5e8f47-7bcc-4371-9e00-27c71ffff49e" xlink:to="loc_us-gaap_ServiceMember_dedddcb2-64ba-465f-8ea4-dffaf75a5d11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2527dfbf-a456-4749-a42a-dd2ec7be15df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_60ef9047-3d65-4b6b-af3f-df917f400902" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2527dfbf-a456-4749-a42a-dd2ec7be15df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_15be06f6-0921-4b5a-bc16-add3bcec788c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2527dfbf-a456-4749-a42a-dd2ec7be15df" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_15be06f6-0921-4b5a-bc16-add3bcec788c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_26800b9f-0287-41bd-8c47-20ff2a282777" xlink:href="exel-20201002.xsd#exel_CollaborativeArrangementwithIpsenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_15be06f6-0921-4b5a-bc16-add3bcec788c" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_26800b9f-0287-41bd-8c47-20ff2a282777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5ec6bbb5-b33f-44b3-8646-f9635625592e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_60ef9047-3d65-4b6b-af3f-df917f400902" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5ec6bbb5-b33f-44b3-8646-f9635625592e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_072fc440-b00a-44a4-bcff-8a9148c67ee2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5ec6bbb5-b33f-44b3-8646-f9635625592e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_072fc440-b00a-44a4-bcff-8a9148c67ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer_5486cbb1-4ffe-4972-addb-2a493572bbb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5ec6bbb5-b33f-44b3-8646-f9635625592e" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomer_5486cbb1-4ffe-4972-addb-2a493572bbb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_1e00675c-cf8b-4044-ab64-e67555b230f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5ec6bbb5-b33f-44b3-8646-f9635625592e" xlink:to="loc_us-gaap_Revenues_1e00675c-cf8b-4044-ab64-e67555b230f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#CollaborationAgreementsIpsenCollaborationDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a92b2fc1-0b6d-4e6b-b3e0-b233738d9a1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_36fb0476-7b3a-48d8-a518-e4d4f7eec994" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a92b2fc1-0b6d-4e6b-b3e0-b233738d9a1e" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_36fb0476-7b3a-48d8-a518-e4d4f7eec994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3636908f-a7aa-47f7-8c6b-1e9fce6d4e34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_36fb0476-7b3a-48d8-a518-e4d4f7eec994" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3636908f-a7aa-47f7-8c6b-1e9fce6d4e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a7b95c03-e39d-444f-9abe-91d852bd073d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3636908f-a7aa-47f7-8c6b-1e9fce6d4e34" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a7b95c03-e39d-444f-9abe-91d852bd073d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_81a31a57-39f0-4d51-b095-1a1ad47eda8b" xlink:href="exel-20201002.xsd#exel_CollaborativeArrangementwithIpsenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a7b95c03-e39d-444f-9abe-91d852bd073d" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_81a31a57-39f0-4d51-b095-1a1ad47eda8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_33f90da8-7138-460a-abda-b6dfd5572028" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_36fb0476-7b3a-48d8-a518-e4d4f7eec994" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_33f90da8-7138-460a-abda-b6dfd5572028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_6cc12635-0075-4aaa-8ab6-99a12e93476d" xlink:href="exel-20201002.xsd#exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_33f90da8-7138-460a-abda-b6dfd5572028" xlink:to="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_6cc12635-0075-4aaa-8ab6-99a12e93476d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_e776dad4-2d34-47df-8c48-c301ea7a04c4" xlink:href="exel-20201002.xsd#exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_33f90da8-7138-460a-abda-b6dfd5572028" xlink:to="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_e776dad4-2d34-47df-8c48-c301ea7a04c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_60fb25d6-e0d7-4df6-afcf-9e247f724233" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_33f90da8-7138-460a-abda-b6dfd5572028" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_60fb25d6-e0d7-4df6-afcf-9e247f724233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_387b2995-ed35-45e0-8cd9-8d64b6f5f266" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_761ec797-2e79-465c-98d3-46d73d1f0e1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_387b2995-ed35-45e0-8cd9-8d64b6f5f266" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_761ec797-2e79-465c-98d3-46d73d1f0e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1bcbfacf-bf63-489e-9f06-23bc11fef83b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_761ec797-2e79-465c-98d3-46d73d1f0e1d" xlink:to="loc_srt_ProductOrServiceAxis_1bcbfacf-bf63-489e-9f06-23bc11fef83b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0d2a63d4-e45a-44c6-8f7c-6dcdc2113043" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_1bcbfacf-bf63-489e-9f06-23bc11fef83b" xlink:to="loc_srt_ProductsAndServicesDomain_0d2a63d4-e45a-44c6-8f7c-6dcdc2113043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_b405f157-106b-4fd9-9eb0-e79197094cd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0d2a63d4-e45a-44c6-8f7c-6dcdc2113043" xlink:to="loc_us-gaap_LicenseMember_b405f157-106b-4fd9-9eb0-e79197094cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_82257e57-9b25-4957-8a76-260917ffb8ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0d2a63d4-e45a-44c6-8f7c-6dcdc2113043" xlink:to="loc_us-gaap_ServiceMember_82257e57-9b25-4957-8a76-260917ffb8ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_19442610-fdea-47f8-a2d6-1a394158c8a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_761ec797-2e79-465c-98d3-46d73d1f0e1d" xlink:to="loc_us-gaap_TypeOfArrangementAxis_19442610-fdea-47f8-a2d6-1a394158c8a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_20f004ff-ec02-4647-bcac-53dd036ab82b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_19442610-fdea-47f8-a2d6-1a394158c8a9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_20f004ff-ec02-4647-bcac-53dd036ab82b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_baa0111a-c4af-418a-ac6c-6d986bbd50c4" xlink:href="exel-20201002.xsd#exel_CollaborativeArrangementwithTakedaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_20f004ff-ec02-4647-bcac-53dd036ab82b" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_baa0111a-c4af-418a-ac6c-6d986bbd50c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_82018673-4e2d-446a-9dde-aa75ba31f498" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_761ec797-2e79-465c-98d3-46d73d1f0e1d" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_82018673-4e2d-446a-9dde-aa75ba31f498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fb0dbc97-b997-427f-9346-2cf15f380494" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_82018673-4e2d-446a-9dde-aa75ba31f498" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fb0dbc97-b997-427f-9346-2cf15f380494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer_31d90f75-4f17-41fc-b905-034f4803ccf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_82018673-4e2d-446a-9dde-aa75ba31f498" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomer_31d90f75-4f17-41fc-b905-034f4803ccf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_b1477d76-a0c5-447a-8ed5-bc33ba4ce100" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_82018673-4e2d-446a-9dde-aa75ba31f498" xlink:to="loc_us-gaap_Revenues_b1477d76-a0c5-447a-8ed5-bc33ba4ce100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#CollaborationAgreementsTakedaCollaborationDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_910d42dc-b68f-42da-b795-3cee3e20f376" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f290be1d-3651-428c-aa98-4ad661c41755" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_910d42dc-b68f-42da-b795-3cee3e20f376" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f290be1d-3651-428c-aa98-4ad661c41755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_0946e8fa-5f2e-46e8-a31f-636b50cb9830" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f290be1d-3651-428c-aa98-4ad661c41755" xlink:to="loc_us-gaap_TypeOfArrangementAxis_0946e8fa-5f2e-46e8-a31f-636b50cb9830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_afe04204-e263-4d6a-a3fc-5f70443ca119" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0946e8fa-5f2e-46e8-a31f-636b50cb9830" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_afe04204-e263-4d6a-a3fc-5f70443ca119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_0b92d1e4-27b7-4c56-a178-fa6f6283630b" xlink:href="exel-20201002.xsd#exel_CollaborativeArrangementwithTakedaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_afe04204-e263-4d6a-a3fc-5f70443ca119" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_0b92d1e4-27b7-4c56-a178-fa6f6283630b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_084d770d-0bdd-4b5b-98e6-7174b0565f99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f290be1d-3651-428c-aa98-4ad661c41755" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_084d770d-0bdd-4b5b-98e6-7174b0565f99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MilestonePaymentsEarned_c8308f33-d573-4bda-bd3b-9d74affd9adc" xlink:href="exel-20201002.xsd#exel_MilestonePaymentsEarned"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_084d770d-0bdd-4b5b-98e6-7174b0565f99" xlink:to="loc_exel_MilestonePaymentsEarned_c8308f33-d573-4bda-bd3b-9d74affd9adc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_140ae9cd-5b10-4de1-a05f-fff7daef638c" xlink:href="exel-20201002.xsd#exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_084d770d-0bdd-4b5b-98e6-7174b0565f99" xlink:to="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_140ae9cd-5b10-4de1-a05f-fff7daef638c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_9a780839-1a55-494a-8046-aaaacad758cd" xlink:href="exel-20201002.xsd#exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_084d770d-0bdd-4b5b-98e6-7174b0565f99" xlink:to="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_9a780839-1a55-494a-8046-aaaacad758cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_7f8fe266-195e-4f00-9905-3fc964d8163f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_084d770d-0bdd-4b5b-98e6-7174b0565f99" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_7f8fe266-195e-4f00-9905-3fc964d8163f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsGSKDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#CollaborationAgreementsGSKDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsGSKDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_efa78048-349b-411a-b38d-e3174d79b446" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c835bdb1-bd7f-4d7a-8188-d2d09f9ef603" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_efa78048-349b-411a-b38d-e3174d79b446" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c835bdb1-bd7f-4d7a-8188-d2d09f9ef603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_40f20a83-a4ab-45d8-b163-596fe3f2ae4d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c835bdb1-bd7f-4d7a-8188-d2d09f9ef603" xlink:to="loc_srt_MajorCustomersAxis_40f20a83-a4ab-45d8-b163-596fe3f2ae4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_5c765de6-6bc8-427e-80e9-591dee494f35" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_40f20a83-a4ab-45d8-b163-596fe3f2ae4d" xlink:to="loc_srt_NameOfMajorCustomerDomain_5c765de6-6bc8-427e-80e9-591dee494f35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_GlaxoSmithKlineMember_cdcfb642-8e1e-4e66-8f44-30d396760a6e" xlink:href="exel-20201002.xsd#exel_GlaxoSmithKlineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_5c765de6-6bc8-427e-80e9-591dee494f35" xlink:to="loc_exel_GlaxoSmithKlineMember_cdcfb642-8e1e-4e66-8f44-30d396760a6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_fa926bbe-0e1b-41cc-a15f-eca3a2a7ea3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c835bdb1-bd7f-4d7a-8188-d2d09f9ef603" xlink:to="loc_us-gaap_TypeOfArrangementAxis_fa926bbe-0e1b-41cc-a15f-eca3a2a7ea3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ea4acb5-5441-48fb-b8d9-a1f3a955715d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_fa926bbe-0e1b-41cc-a15f-eca3a2a7ea3f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ea4acb5-5441-48fb-b8d9-a1f3a955715d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_eddb3b92-8517-40df-b073-215270c5a768" xlink:href="exel-20201002.xsd#exel_CollaborativeArrangementswithGlaxoSmithKlineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ea4acb5-5441-48fb-b8d9-a1f3a955715d" xlink:to="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_eddb3b92-8517-40df-b073-215270c5a768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aff73c75-c203-4ea3-810e-895683afe2c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c835bdb1-bd7f-4d7a-8188-d2d09f9ef603" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aff73c75-c203-4ea3-810e-895683afe2c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_d1c9e492-32fb-4252-9860-5b3269e2382e" xlink:href="exel-20201002.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aff73c75-c203-4ea3-810e-895683afe2c0" xlink:to="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_d1c9e492-32fb-4252-9860-5b3269e2382e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_44e6d752-90aa-4c41-8a2c-5ff2bd41ae74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aff73c75-c203-4ea3-810e-895683afe2c0" xlink:to="loc_us-gaap_RoyaltyExpense_44e6d752-90aa-4c41-8a2c-5ff2bd41ae74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9a0dbdf9-e483-4298-9e51-10aec1399827" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_86aefe8c-9097-4d70-af74-7514b23df378" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9a0dbdf9-e483-4298-9e51-10aec1399827" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_86aefe8c-9097-4d70-af74-7514b23df378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2715f837-b2ae-49fe-9488-38d53784b43f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_86aefe8c-9097-4d70-af74-7514b23df378" xlink:to="loc_srt_ProductOrServiceAxis_2715f837-b2ae-49fe-9488-38d53784b43f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fd3b82ee-8d63-4517-99fb-94d24688ad61" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_2715f837-b2ae-49fe-9488-38d53784b43f" xlink:to="loc_srt_ProductsAndServicesDomain_fd3b82ee-8d63-4517-99fb-94d24688ad61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CotellicMember_be0e77f7-9705-4c5e-8bbb-060633089b67" xlink:href="exel-20201002.xsd#exel_CotellicMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_fd3b82ee-8d63-4517-99fb-94d24688ad61" xlink:to="loc_exel_CotellicMember_be0e77f7-9705-4c5e-8bbb-060633089b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1d289fb6-29af-4dee-a8cb-da4a402d8bb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_86aefe8c-9097-4d70-af74-7514b23df378" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1d289fb6-29af-4dee-a8cb-da4a402d8bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bd811e20-5f59-477b-b697-c64491617d8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1d289fb6-29af-4dee-a8cb-da4a402d8bb1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bd811e20-5f59-477b-b697-c64491617d8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember_d0a2b917-9243-4e3a-85ec-a954ff59b803" xlink:href="exel-20201002.xsd#exel_CollaborativeArrangementwithGenentechMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bd811e20-5f59-477b-b697-c64491617d8e" xlink:to="loc_exel_CollaborativeArrangementwithGenentechMember_d0a2b917-9243-4e3a-85ec-a954ff59b803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_284289a0-a979-42d8-bfd0-339a72301d0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_86aefe8c-9097-4d70-af74-7514b23df378" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_284289a0-a979-42d8-bfd0-339a72301d0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementIncomeLossFromAgreement_59cd1ed7-8a02-4b2e-a8f0-391ac8c70db6" xlink:href="exel-20201002.xsd#exel_CollaborativeArrangementIncomeLossFromAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_284289a0-a979-42d8-bfd0-339a72301d0c" xlink:to="loc_exel_CollaborativeArrangementIncomeLossFromAgreement_59cd1ed7-8a02-4b2e-a8f0-391ac8c70db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_350387ac-762f-4b7f-9ff9-cc9750cb284a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_284289a0-a979-42d8-bfd0-339a72301d0c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_350387ac-762f-4b7f-9ff9-cc9750cb284a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsInLicensingCollaborationsDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#CollaborationAgreementsInLicensingCollaborationsDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsInLicensingCollaborationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0cffc53f-e195-452b-8599-a397142869c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9e572244-1acd-4b1c-b95d-d686ce71c54f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0cffc53f-e195-452b-8599-a397142869c0" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9e572244-1acd-4b1c-b95d-d686ce71c54f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d62b478b-d962-4d48-ac18-62ae85bff403" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9e572244-1acd-4b1c-b95d-d686ce71c54f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d62b478b-d962-4d48-ac18-62ae85bff403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7919dc29-e4f9-4897-abfb-561742cea3d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d62b478b-d962-4d48-ac18-62ae85bff403" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7919dc29-e4f9-4897-abfb-561742cea3d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementWithCatalentMember_e22afd09-5c68-46fa-959b-63e9e4ba4f9a" xlink:href="exel-20201002.xsd#exel_CollaborativeArrangementWithCatalentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7919dc29-e4f9-4897-abfb-561742cea3d0" xlink:to="loc_exel_CollaborativeArrangementWithCatalentMember_e22afd09-5c68-46fa-959b-63e9e4ba4f9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_393d79fc-825b-49d7-bfba-e81ef404e092" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9e572244-1acd-4b1c-b95d-d686ce71c54f" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_393d79fc-825b-49d7-bfba-e81ef404e092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeAgreementsUpfrontPayments_afc0314f-e86f-4e96-8b9c-f0aef12de77e" xlink:href="exel-20201002.xsd#exel_CollaborativeAgreementsUpfrontPayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_393d79fc-825b-49d7-bfba-e81ef404e092" xlink:to="loc_exel_CollaborativeAgreementsUpfrontPayments_afc0314f-e86f-4e96-8b9c-f0aef12de77e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAndLicenseAgreementTargetSelectionTerm_c6170d38-68b2-41ce-98d4-94aab735fa39" xlink:href="exel-20201002.xsd#exel_CollaborationAndLicenseAgreementTargetSelectionTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_393d79fc-825b-49d7-bfba-e81ef404e092" xlink:to="loc_exel_CollaborationAndLicenseAgreementTargetSelectionTerm_c6170d38-68b2-41ce-98d4-94aab735fa39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAndLicenseAgreementExtendedTargetSelectionTerm_6743ef42-baf4-4474-a257-b310fd0d5288" xlink:href="exel-20201002.xsd#exel_CollaborationAndLicenseAgreementExtendedTargetSelectionTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_393d79fc-825b-49d7-bfba-e81ef404e092" xlink:to="loc_exel_CollaborationAndLicenseAgreementExtendedTargetSelectionTerm_6743ef42-baf4-4474-a257-b310fd0d5288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementsAdditionalUpfrontPayments_b416c279-78df-411c-91f1-bc6b2b37a7fa" xlink:href="exel-20201002.xsd#exel_CollaborationAgreementsAdditionalUpfrontPayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_393d79fc-825b-49d7-bfba-e81ef404e092" xlink:to="loc_exel_CollaborationAgreementsAdditionalUpfrontPayments_b416c279-78df-411c-91f1-bc6b2b37a7fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption_976d5ea2-06a3-4f5f-8364-86098fdcb48e" xlink:href="exel-20201002.xsd#exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_393d79fc-825b-49d7-bfba-e81ef404e092" xlink:to="loc_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption_976d5ea2-06a3-4f5f-8364-86098fdcb48e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_fe4efcc1-b676-49b2-9377-5d466cbcba69" xlink:href="exel-20201002.xsd#exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_393d79fc-825b-49d7-bfba-e81ef404e092" xlink:to="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_fe4efcc1-b676-49b2-9377-5d466cbcba69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_ad2a79fa-c86f-4abc-8b78-8ecd11a53e85" xlink:href="exel-20201002.xsd#exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_393d79fc-825b-49d7-bfba-e81ef404e092" xlink:to="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_ad2a79fa-c86f-4abc-8b78-8ecd11a53e85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsNBETherapeuticsAGNBECollaborationDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#CollaborationAgreementsNBETherapeuticsAGNBECollaborationDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsNBETherapeuticsAGNBECollaborationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_857cf740-096c-43c5-ba83-05b8911a9b39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_679e0aa6-d2c1-4e84-8987-4493e0f88bd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_857cf740-096c-43c5-ba83-05b8911a9b39" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_679e0aa6-d2c1-4e84-8987-4493e0f88bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_b242c935-8e4a-4288-8a98-bd8df44ebf71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_679e0aa6-d2c1-4e84-8987-4493e0f88bd8" xlink:to="loc_us-gaap_TypeOfArrangementAxis_b242c935-8e4a-4288-8a98-bd8df44ebf71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a8f1ac9d-b311-46ba-b810-c5887044f07b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b242c935-8e4a-4288-8a98-bd8df44ebf71" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a8f1ac9d-b311-46ba-b810-c5887044f07b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementWithNBETherapeuticsMember_c484a4af-4c59-4ea8-af69-793b731d5945" xlink:href="exel-20201002.xsd#exel_CollaborativeArrangementWithNBETherapeuticsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a8f1ac9d-b311-46ba-b810-c5887044f07b" xlink:to="loc_exel_CollaborativeArrangementWithNBETherapeuticsMember_c484a4af-4c59-4ea8-af69-793b731d5945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6e6bd937-6547-4851-b55a-461688e4c8f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_679e0aa6-d2c1-4e84-8987-4493e0f88bd8" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6e6bd937-6547-4851-b55a-461688e4c8f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeAgreementsUpfrontPayments_2697dbde-044d-4640-86d2-7038f396613a" xlink:href="exel-20201002.xsd#exel_CollaborativeAgreementsUpfrontPayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6e6bd937-6547-4851-b55a-461688e4c8f9" xlink:to="loc_exel_CollaborativeAgreementsUpfrontPayments_2697dbde-044d-4640-86d2-7038f396613a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAndLicenseAgreementTargetSelectionTerm_2b739fc8-42a6-463c-bb97-8378acd01f87" xlink:href="exel-20201002.xsd#exel_CollaborationAndLicenseAgreementTargetSelectionTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6e6bd937-6547-4851-b55a-461688e4c8f9" xlink:to="loc_exel_CollaborationAndLicenseAgreementTargetSelectionTerm_2b739fc8-42a6-463c-bb97-8378acd01f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAndLicenseAgreementTargetSelectionExtensionOptionTerm_cdf92863-6438-451a-a91e-c8792f872192" xlink:href="exel-20201002.xsd#exel_CollaborationAndLicenseAgreementTargetSelectionExtensionOptionTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6e6bd937-6547-4851-b55a-461688e4c8f9" xlink:to="loc_exel_CollaborationAndLicenseAgreementTargetSelectionExtensionOptionTerm_cdf92863-6438-451a-a91e-c8792f872192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAndLicenseAgreementExtendedTargetSelectionTerm_8675d5e1-3772-4d58-a552-2af562d05454" xlink:href="exel-20201002.xsd#exel_CollaborationAndLicenseAgreementExtendedTargetSelectionTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6e6bd937-6547-4851-b55a-461688e4c8f9" xlink:to="loc_exel_CollaborationAndLicenseAgreementExtendedTargetSelectionTerm_8675d5e1-3772-4d58-a552-2af562d05454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementsAdditionalUpfrontPayments_5141bbeb-fc79-40c9-8bbf-a8996835946d" xlink:href="exel-20201002.xsd#exel_CollaborationAgreementsAdditionalUpfrontPayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6e6bd937-6547-4851-b55a-461688e4c8f9" xlink:to="loc_exel_CollaborationAgreementsAdditionalUpfrontPayments_5141bbeb-fc79-40c9-8bbf-a8996835946d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption_70e28d52-9d05-4f0a-8fe0-affaae44792c" xlink:href="exel-20201002.xsd#exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6e6bd937-6547-4851-b55a-461688e4c8f9" xlink:to="loc_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption_70e28d52-9d05-4f0a-8fe0-affaae44792c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_e3bfb9de-7837-40bf-8136-8ccc65f2a447" xlink:href="exel-20201002.xsd#exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6e6bd937-6547-4851-b55a-461688e4c8f9" xlink:to="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_e3bfb9de-7837-40bf-8136-8ccc65f2a447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_abafc8e8-f8b1-42d1-8e7a-86113ce4ad1e" xlink:href="exel-20201002.xsd#exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6e6bd937-6547-4851-b55a-461688e4c8f9" xlink:to="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_abafc8e8-f8b1-42d1-8e7a-86113ce4ad1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestments" xlink:type="simple" xlink:href="exel-20201002.xsd#CashandInvestments"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d0122935-1f89-4f6c-adda-c572ff90e32c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsAndInvestmentsTextBlock_051448d0-eef2-4e72-8a18-e188189c3a82" xlink:href="exel-20201002.xsd#exel_CashCashEquivalentsAndInvestmentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d0122935-1f89-4f6c-adda-c572ff90e32c" xlink:to="loc_exel_CashCashEquivalentsAndInvestmentsTextBlock_051448d0-eef2-4e72-8a18-e188189c3a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsTables" xlink:type="simple" xlink:href="exel-20201002.xsd#CashandInvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_912a739a-8856-4295-981f-08b3cf9c9959" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_206ef7c2-4e07-4fe2-9106-950963771fbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_912a739a-8856-4295-981f-08b3cf9c9959" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_206ef7c2-4e07-4fe2-9106-950963771fbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_a1f30b06-0efd-4e42-9982-ce14f4047bfa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_912a739a-8856-4295-981f-08b3cf9c9959" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_a1f30b06-0efd-4e42-9982-ce14f4047bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_3b46872c-574a-4e68-a665-6d31f3387e5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_912a739a-8856-4295-981f-08b3cf9c9959" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_3b46872c-574a-4e68-a665-6d31f3387e5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_2fb5e2b7-419a-44b6-80d8-b5e965f6878a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_912a739a-8856-4295-981f-08b3cf9c9959" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_2fb5e2b7-419a-44b6-80d8-b5e965f6878a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_271eedbf-f96b-4721-bf83-59bcb26d4591" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_912a739a-8856-4295-981f-08b3cf9c9959" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_271eedbf-f96b-4721-bf83-59bcb26d4591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c21dc56b-4669-4674-8550-2d7070654e6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_6c74d2da-cbac-482e-ada0-5ce7d69b1626" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c21dc56b-4669-4674-8550-2d7070654e6c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAbstract_6c74d2da-cbac-482e-ada0-5ce7d69b1626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_03c543c6-ea78-47b1-be2f-62cdabf81517" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_6c74d2da-cbac-482e-ada0-5ce7d69b1626" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_03c543c6-ea78-47b1-be2f-62cdabf81517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsNoncurrent_93299c75-cbfa-453e-9e51-06a788997d42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashEquivalentsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_6c74d2da-cbac-482e-ada0-5ce7d69b1626" xlink:to="loc_us-gaap_RestrictedCashEquivalentsNoncurrent_93299c75-cbfa-453e-9e51-06a788997d42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3c9b17e1-692b-4b1b-9d87-3cfdb782a62f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_6c74d2da-cbac-482e-ada0-5ce7d69b1626" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3c9b17e1-692b-4b1b-9d87-3cfdb782a62f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#CashandInvestmentsInvestmentsbySecurityTypeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_40752151-d228-4860-bf77-dfde8992374f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8b5f559f-025f-4660-9af8-8206cb050741" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_40752151-d228-4860-bf77-dfde8992374f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8b5f559f-025f-4660-9af8-8206cb050741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_12cdbc9f-3bc8-45eb-9ea8-c9f7d40898de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8b5f559f-025f-4660-9af8-8206cb050741" xlink:to="loc_us-gaap_FinancialInstrumentAxis_12cdbc9f-3bc8-45eb-9ea8-c9f7d40898de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3b099349-6abb-4c75-af92-bfe2455a1a40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_12cdbc9f-3bc8-45eb-9ea8-c9f7d40898de" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3b099349-6abb-4c75-af92-bfe2455a1a40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_62b79a40-e13f-4929-8f08-2d147ca3c46c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3b099349-6abb-4c75-af92-bfe2455a1a40" xlink:to="loc_us-gaap_CommercialPaperMember_62b79a40-e13f-4929-8f08-2d147ca3c46c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_8f3e9e31-77ef-4330-8b94-6231cf132acd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3b099349-6abb-4c75-af92-bfe2455a1a40" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_8f3e9e31-77ef-4330-8b94-6231cf132acd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_f73329a5-5556-4ed5-87c6-13223c40836b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3b099349-6abb-4c75-af92-bfe2455a1a40" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_f73329a5-5556-4ed5-87c6-13223c40836b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_6e062e9a-7e41-404e-b29f-8e6299c4cc29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3b099349-6abb-4c75-af92-bfe2455a1a40" xlink:to="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_6e062e9a-7e41-404e-b29f-8e6299c4cc29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_db86c1e4-d4c2-44fb-b094-2437abd11523" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3b099349-6abb-4c75-af92-bfe2455a1a40" xlink:to="loc_us-gaap_CashMember_db86c1e4-d4c2-44fb-b094-2437abd11523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_f254bfa2-f280-4e13-9fd9-3088d1daa292" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3b099349-6abb-4c75-af92-bfe2455a1a40" xlink:to="loc_us-gaap_MoneyMarketFundsMember_f254bfa2-f280-4e13-9fd9-3088d1daa292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_60b83dd8-78b3-48f0-9cd7-fe7d3eea0c04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3b099349-6abb-4c75-af92-bfe2455a1a40" xlink:to="loc_us-gaap_CertificatesOfDepositMember_60b83dd8-78b3-48f0-9cd7-fe7d3eea0c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_93c8bc86-bf8c-497a-a502-b922490420b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8b5f559f-025f-4660-9af8-8206cb050741" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_93c8bc86-bf8c-497a-a502-b922490420b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_29b5da4c-fdfe-4d9b-9be4-5d11ed459c59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_93c8bc86-bf8c-497a-a502-b922490420b3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_29b5da4c-fdfe-4d9b-9be4-5d11ed459c59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_56acd437-eed6-4707-8afa-9fc1d785a226" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_93c8bc86-bf8c-497a-a502-b922490420b3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_56acd437-eed6-4707-8afa-9fc1d785a226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f4dfd03f-8ceb-4f83-92fc-f8fbffe6947a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_93c8bc86-bf8c-497a-a502-b922490420b3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f4dfd03f-8ceb-4f83-92fc-f8fbffe6947a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_89b74728-56b3-4c74-86d0-4d59d78d0b50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_93c8bc86-bf8c-497a-a502-b922490420b3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_89b74728-56b3-4c74-86d0-4d59d78d0b50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_91b9f674-b3b3-4f20-b892-d534676e7591" xlink:href="exel-20201002.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_93c8bc86-bf8c-497a-a502-b922490420b3" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_91b9f674-b3b3-4f20-b892-d534676e7591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_d39380e3-fba3-42bf-bdb7-288aa55627b3" xlink:href="exel-20201002.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_93c8bc86-bf8c-497a-a502-b922490420b3" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_d39380e3-fba3-42bf-bdb7-288aa55627b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_adcd03bf-426b-403f-8db4-805f3a08e36a" xlink:href="exel-20201002.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_93c8bc86-bf8c-497a-a502-b922490420b3" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_adcd03bf-426b-403f-8db4-805f3a08e36a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_b062bc44-f0d6-4944-8cb5-3d53adc802d7" xlink:href="exel-20201002.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_93c8bc86-bf8c-497a-a502-b922490420b3" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_b062bc44-f0d6-4944-8cb5-3d53adc802d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_2fb23b4d-4da4-4ea6-88c4-1b970cb49c89" xlink:href="exel-20201002.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_93c8bc86-bf8c-497a-a502-b922490420b3" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_2fb23b4d-4da4-4ea6-88c4-1b970cb49c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b3f5800a-3d93-4acf-ab1c-6c129b478d0d" xlink:href="exel-20201002.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_93c8bc86-bf8c-497a-a502-b922490420b3" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b3f5800a-3d93-4acf-ab1c-6c129b478d0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8b6ee16c-d210-45e5-a66d-1e95803290f7" xlink:href="exel-20201002.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_93c8bc86-bf8c-497a-a502-b922490420b3" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8b6ee16c-d210-45e5-a66d-1e95803290f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_6a1cb2cd-5052-4926-924b-c4110317694f" xlink:href="exel-20201002.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_93c8bc86-bf8c-497a-a502-b922490420b3" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_6a1cb2cd-5052-4926-924b-c4110317694f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1" xlink:type="simple" xlink:href="exel-20201002.xsd#CashandInvestmentsInvestmentsbySecurityTypeDetails_1"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#CashandInvestmentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d7c7c9d6-4d8e-483f-9439-9eaad21f504d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable_55c878c1-ede0-49dd-b8ca-3179526a312e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d7c7c9d6-4d8e-483f-9439-9eaad21f504d" xlink:to="loc_us-gaap_InterestReceivable_55c878c1-ede0-49dd-b8ca-3179526a312e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_5b502477-ccdf-4cc5-b762-90fd1efe67b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d7c7c9d6-4d8e-483f-9439-9eaad21f504d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_5b502477-ccdf-4cc5-b762-90fd1efe67b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_29d5d439-77c6-42fa-b63b-8939ae2ea53f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d7c7c9d6-4d8e-483f-9439-9eaad21f504d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_29d5d439-77c6-42fa-b63b-8939ae2ea53f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d20525da-c449-44c7-b111-b1bcd0462b94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_01601bd4-1138-44dd-94fe-d9c137c1448e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d20525da-c449-44c7-b111-b1bcd0462b94" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_01601bd4-1138-44dd-94fe-d9c137c1448e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_5d6633c4-4b0c-45a4-af0a-b4585351e9b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_01601bd4-1138-44dd-94fe-d9c137c1448e" xlink:to="loc_us-gaap_FinancialInstrumentAxis_5d6633c4-4b0c-45a4-af0a-b4585351e9b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_603d0cc5-96ea-487b-b2ff-33358b359950" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5d6633c4-4b0c-45a4-af0a-b4585351e9b3" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_603d0cc5-96ea-487b-b2ff-33358b359950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_48238737-44f9-40ac-8068-2354fde87c34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_603d0cc5-96ea-487b-b2ff-33358b359950" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_48238737-44f9-40ac-8068-2354fde87c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_e2442322-b0e2-4191-8d62-0f9e99a41de2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_603d0cc5-96ea-487b-b2ff-33358b359950" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_e2442322-b0e2-4191-8d62-0f9e99a41de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a37f61f4-39e2-4373-937f-441fad28f6c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_01601bd4-1138-44dd-94fe-d9c137c1448e" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a37f61f4-39e2-4373-937f-441fad28f6c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_c0b61496-7ee1-40bd-b5eb-59a4c02edcfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a37f61f4-39e2-4373-937f-441fad28f6c8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_c0b61496-7ee1-40bd-b5eb-59a4c02edcfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_b203c768-0b57-4404-865e-7364ad3087dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_c0b61496-7ee1-40bd-b5eb-59a4c02edcfe" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_b203c768-0b57-4404-865e-7364ad3087dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_27181b3d-0c3c-4516-8d35-fb27731b80f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_c0b61496-7ee1-40bd-b5eb-59a4c02edcfe" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_27181b3d-0c3c-4516-8d35-fb27731b80f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_068c20f2-18fd-4272-b35d-e108f9cfe426" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_1403ffee-f7ce-4953-928e-ba0c8ae6a4a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_068c20f2-18fd-4272-b35d-e108f9cfe426" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_1403ffee-f7ce-4953-928e-ba0c8ae6a4a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_93451a5e-eeca-4442-ba13-e83085fc326f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_068c20f2-18fd-4272-b35d-e108f9cfe426" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_93451a5e-eeca-4442-ba13-e83085fc326f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_04455add-e34c-41a2-b4e7-1b8cb4fbd4f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_068c20f2-18fd-4272-b35d-e108f9cfe426" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_04455add-e34c-41a2-b4e7-1b8cb4fbd4f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="exel-20201002.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_efaef5ff-c448-4b33-be19-4aba6fa07d5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_02a9bf72-2774-405b-a000-efe7f1af9664" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_efaef5ff-c448-4b33-be19-4aba6fa07d5d" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_02a9bf72-2774-405b-a000-efe7f1af9664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="exel-20201002.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_372f16dd-7700-494c-9371-08b1fdd48012" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_e439ba99-1c06-428a-9364-f262816010b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_372f16dd-7700-494c-9371-08b1fdd48012" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_e439ba99-1c06-428a-9364-f262816010b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#FairValueMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_aef951e1-f3c8-4da6-a841-21cba516fae5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_80e5ac73-3b5e-4aa7-bc0a-c272ce95c625" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_aef951e1-f3c8-4da6-a841-21cba516fae5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_80e5ac73-3b5e-4aa7-bc0a-c272ce95c625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_c7e749a6-6497-48fc-af01-3a9f92c116c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_80e5ac73-3b5e-4aa7-bc0a-c272ce95c625" xlink:to="loc_us-gaap_FinancialInstrumentAxis_c7e749a6-6497-48fc-af01-3a9f92c116c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_53d8d52d-9f2d-4c45-9428-bd4de2e71b90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c7e749a6-6497-48fc-af01-3a9f92c116c6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_53d8d52d-9f2d-4c45-9428-bd4de2e71b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_b05b4145-8cd8-481b-949c-12bd7dc5a442" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_53d8d52d-9f2d-4c45-9428-bd4de2e71b90" xlink:to="loc_us-gaap_CommercialPaperMember_b05b4145-8cd8-481b-949c-12bd7dc5a442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_48ae5142-7497-4957-a0fe-f14de68ae27c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_53d8d52d-9f2d-4c45-9428-bd4de2e71b90" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_48ae5142-7497-4957-a0fe-f14de68ae27c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_1d58abf1-dd80-4bda-a338-3eee60c6d794" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_53d8d52d-9f2d-4c45-9428-bd4de2e71b90" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_1d58abf1-dd80-4bda-a338-3eee60c6d794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_6af1b2fa-c0bf-4150-b960-6fdc676b1170" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_53d8d52d-9f2d-4c45-9428-bd4de2e71b90" xlink:to="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_6af1b2fa-c0bf-4150-b960-6fdc676b1170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_8d5aecec-099a-4b19-88d6-ab5eba7d96c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_53d8d52d-9f2d-4c45-9428-bd4de2e71b90" xlink:to="loc_us-gaap_MoneyMarketFundsMember_8d5aecec-099a-4b19-88d6-ab5eba7d96c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_d9b9d253-b365-4f62-bef4-0676621cad03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_53d8d52d-9f2d-4c45-9428-bd4de2e71b90" xlink:to="loc_us-gaap_CertificatesOfDepositMember_d9b9d253-b365-4f62-bef4-0676621cad03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e0993f47-1fed-4143-a410-e846dad99901" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_80e5ac73-3b5e-4aa7-bc0a-c272ce95c625" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e0993f47-1fed-4143-a410-e846dad99901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_330634dc-6916-498c-afe4-66449b0ad048" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e0993f47-1fed-4143-a410-e846dad99901" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_330634dc-6916-498c-afe4-66449b0ad048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_6878fbbb-c0ba-4351-a7ef-322e68685d05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_330634dc-6916-498c-afe4-66449b0ad048" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_6878fbbb-c0ba-4351-a7ef-322e68685d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_1ca3b98f-2512-43c0-92af-471a30c0137b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_330634dc-6916-498c-afe4-66449b0ad048" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_1ca3b98f-2512-43c0-92af-471a30c0137b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8233291d-6076-4b2b-b371-111a654b75ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_80e5ac73-3b5e-4aa7-bc0a-c272ce95c625" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8233291d-6076-4b2b-b371-111a654b75ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_48f84886-71dc-4d0a-ad29-cb993ed32ed1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8233291d-6076-4b2b-b371-111a654b75ac" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_48f84886-71dc-4d0a-ad29-cb993ed32ed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_61478404-b408-4b5f-bd1e-a3cb092a0f62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_48f84886-71dc-4d0a-ad29-cb993ed32ed1" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_61478404-b408-4b5f-bd1e-a3cb092a0f62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_24243fd2-89b7-435d-a1f2-c37e4035a03a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_80e5ac73-3b5e-4aa7-bc0a-c272ce95c625" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_24243fd2-89b7-435d-a1f2-c37e4035a03a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1226ada6-d974-4f3e-bdfa-e5547dc898da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_24243fd2-89b7-435d-a1f2-c37e4035a03a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1226ada6-d974-4f3e-bdfa-e5547dc898da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e29c9213-8b25-493d-aab6-37d6e140d802" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_24243fd2-89b7-435d-a1f2-c37e4035a03a" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e29c9213-8b25-493d-aab6-37d6e140d802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_848c3006-6c37-4425-8baa-63b8c1b87e6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_24243fd2-89b7-435d-a1f2-c37e4035a03a" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_848c3006-6c37-4425-8baa-63b8c1b87e6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/Inventory" xlink:type="simple" xlink:href="exel-20201002.xsd#Inventory"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_54113d64-f71e-4053-9756-a42932819fa5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_e4928ebd-d684-4a5b-918b-8f4f0243b03f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_54113d64-f71e-4053-9756-a42932819fa5" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_e4928ebd-d684-4a5b-918b-8f4f0243b03f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryTables" xlink:type="simple" xlink:href="exel-20201002.xsd#InventoryTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_afa52d24-b358-468a-939b-d8f47c886c42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_c321f93c-8ea4-4263-9722-23d95cf087fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_afa52d24-b358-468a-939b-d8f47c886c42" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_c321f93c-8ea4-4263-9722-23d95cf087fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#InventoryDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_91734990-1235-4ed9-be64-d377c7623f4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_e4e9d8ed-088e-4306-bdf0-b61d3ec0747f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_91734990-1235-4ed9-be64-d377c7623f4d" xlink:to="loc_us-gaap_InventoryCurrentTable_e4e9d8ed-088e-4306-bdf0-b61d3ec0747f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_f5cf7886-9ce4-46ee-809b-291e6f04e63f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_e4e9d8ed-088e-4306-bdf0-b61d3ec0747f" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_f5cf7886-9ce4-46ee-809b-291e6f04e63f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_cb94b6f7-6c61-4c0a-891f-59638e110c54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_f5cf7886-9ce4-46ee-809b-291e6f04e63f" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_cb94b6f7-6c61-4c0a-891f-59638e110c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember_1928e865-5879-445e-a33f-fc252ed8f091" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_cb94b6f7-6c61-4c0a-891f-59638e110c54" xlink:to="loc_us-gaap_InventoriesMember_1928e865-5879-445e-a33f-fc252ed8f091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OtherLongtermAssetsMember_42559c42-b4ab-4707-a77a-39c6506b8783" xlink:href="exel-20201002.xsd#exel_OtherLongtermAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_cb94b6f7-6c61-4c0a-891f-59638e110c54" xlink:to="loc_exel_OtherLongtermAssetsMember_42559c42-b4ab-4707-a77a-39c6506b8783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_1cb6b540-7eed-4588-87f0-1d2309d59957" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_e4e9d8ed-088e-4306-bdf0-b61d3ec0747f" xlink:to="loc_us-gaap_InventoryLineItems_1cb6b540-7eed-4588-87f0-1d2309d59957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_1f69cb67-5691-483e-9edd-3e440b18c3ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_1cb6b540-7eed-4588-87f0-1d2309d59957" xlink:to="loc_us-gaap_InventoryRawMaterials_1f69cb67-5691-483e-9edd-3e440b18c3ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_e47891f0-b3cd-4bbb-8476-abaf5d81bca6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_1cb6b540-7eed-4588-87f0-1d2309d59957" xlink:to="loc_us-gaap_InventoryWorkInProcess_e47891f0-b3cd-4bbb-8476-abaf5d81bca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_fb41004d-7987-4318-8a0f-530678f8a656" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_1cb6b540-7eed-4588-87f0-1d2309d59957" xlink:to="loc_us-gaap_InventoryFinishedGoods_fb41004d-7987-4318-8a0f-530678f8a656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_e1869870-dc1d-4f5d-8f28-22fd365ffe01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_1cb6b540-7eed-4588-87f0-1d2309d59957" xlink:to="loc_us-gaap_InventoryGross_e1869870-dc1d-4f5d-8f28-22fd365ffe01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_2d87c014-4b7f-4aac-9025-8f9a7a07d668" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_91734990-1235-4ed9-be64-d377c7623f4d" xlink:to="loc_us-gaap_InventoryWriteDown_2d87c014-4b7f-4aac-9025-8f9a7a07d668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="exel-20201002.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b7cbb77a-281a-4cb5-a9f7-bbfa3385fb92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_07b61ad4-403e-4f2c-b3bd-0ccc84c36f75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b7cbb77a-281a-4cb5-a9f7-bbfa3385fb92" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_07b61ad4-403e-4f2c-b3bd-0ccc84c36f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="exel-20201002.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6cbb4f71-0aa7-4a19-a488-5f357808149c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_383bd7bb-561d-4695-ab27-80b883661f64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6cbb4f71-0aa7-4a19-a488-5f357808149c" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_383bd7bb-561d-4695-ab27-80b883661f64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_207763c8-0ccd-480a-9f25-2f2c5fed20ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_fd57737a-9885-4486-bf3e-836e4bb1d0bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_207763c8-0ccd-480a-9f25-2f2c5fed20ce" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_fd57737a-9885-4486-bf3e-836e4bb1d0bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_f9fb4487-a709-4508-833a-0782315649eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_fd57737a-9885-4486-bf3e-836e4bb1d0bd" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_f9fb4487-a709-4508-833a-0782315649eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_354fe3ef-9ddd-4215-b0e1-de4155f052d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f9fb4487-a709-4508-833a-0782315649eb" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_354fe3ef-9ddd-4215-b0e1-de4155f052d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4fc9f53d-94a4-4372-bba1-a51ac1f1139c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_354fe3ef-9ddd-4215-b0e1-de4155f052d7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4fc9f53d-94a4-4372-bba1-a51ac1f1139c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_83fda334-f4ea-4cf4-b9a1-d982f17c8d27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_354fe3ef-9ddd-4215-b0e1-de4155f052d7" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_83fda334-f4ea-4cf4-b9a1-d982f17c8d27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6d6538fc-d45a-4413-b43b-f38f0426c14d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_fd57737a-9885-4486-bf3e-836e4bb1d0bd" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6d6538fc-d45a-4413-b43b-f38f0426c14d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_a9de469a-c7cc-451d-9888-ab12d3f606eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6d6538fc-d45a-4413-b43b-f38f0426c14d" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_a9de469a-c7cc-451d-9888-ab12d3f606eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e51c0648-b71a-4ba9-b6fb-a50cc8e21dea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_716297b6-6bdc-402f-a465-9392ec2107e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e51c0648-b71a-4ba9-b6fb-a50cc8e21dea" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_716297b6-6bdc-402f-a465-9392ec2107e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_948898c4-f8c1-41cb-9917-91bd114f36d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_716297b6-6bdc-402f-a465-9392ec2107e9" xlink:to="loc_us-gaap_AwardTypeAxis_948898c4-f8c1-41cb-9917-91bd114f36d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b5858c54-c7f1-4988-a377-a2750a15cb14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_948898c4-f8c1-41cb-9917-91bd114f36d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b5858c54-c7f1-4988-a377-a2750a15cb14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b840f526-c81e-4620-a41d-93344a333db5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b5858c54-c7f1-4988-a377-a2750a15cb14" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b840f526-c81e-4620-a41d-93344a333db5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_59a04b44-1b43-4f99-8c93-2ec9a108c8b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b5858c54-c7f1-4988-a377-a2750a15cb14" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_59a04b44-1b43-4f99-8c93-2ec9a108c8b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_PerformanceShareOptionsPSOMember_f48c4734-37ad-4721-9d21-2df2be9b908e" xlink:href="exel-20201002.xsd#exel_PerformanceShareOptionsPSOMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b5858c54-c7f1-4988-a377-a2750a15cb14" xlink:to="loc_exel_PerformanceShareOptionsPSOMember_f48c4734-37ad-4721-9d21-2df2be9b908e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_96ce9c0c-2659-4d8d-80b4-fa8010ef1254" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b5858c54-c7f1-4988-a377-a2750a15cb14" xlink:to="loc_us-gaap_PerformanceSharesMember_96ce9c0c-2659-4d8d-80b4-fa8010ef1254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_StatusAxis_0ccde698-44c0-4f1a-8eb1-58125dcc2b2c" xlink:href="exel-20201002.xsd#exel_StatusAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_716297b6-6bdc-402f-a465-9392ec2107e9" xlink:to="loc_exel_StatusAxis_0ccde698-44c0-4f1a-8eb1-58125dcc2b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_StatusDomain_199bbed4-8512-4b86-941c-2fc7c48474d8" xlink:href="exel-20201002.xsd#exel_StatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_StatusAxis_0ccde698-44c0-4f1a-8eb1-58125dcc2b2c" xlink:to="loc_exel_StatusDomain_199bbed4-8512-4b86-941c-2fc7c48474d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AchievedMember_93ba9f7c-f9ea-49c6-81f0-f60b715bbdd9" xlink:href="exel-20201002.xsd#exel_AchievedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_StatusDomain_199bbed4-8512-4b86-941c-2fc7c48474d8" xlink:to="loc_exel_AchievedMember_93ba9f7c-f9ea-49c6-81f0-f60b715bbdd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProbableMember_218818f3-5dc7-4d05-92a4-29d2279ad6ec" xlink:href="exel-20201002.xsd#exel_ProbableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_StatusDomain_199bbed4-8512-4b86-941c-2fc7c48474d8" xlink:to="loc_exel_ProbableMember_218818f3-5dc7-4d05-92a4-29d2279ad6ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1bd4985-2ead-4327-abea-318ab2b27183" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_716297b6-6bdc-402f-a465-9392ec2107e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1bd4985-2ead-4327-abea-318ab2b27183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_fac0cf60-b917-4ea2-b92a-f2ea49a8bb21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1bd4985-2ead-4327-abea-318ab2b27183" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_fac0cf60-b917-4ea2-b92a-f2ea49a8bb21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_b0a30a03-7b87-4662-bd73-f9ae4c68a97b" xlink:href="exel-20201002.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1bd4985-2ead-4327-abea-318ab2b27183" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_b0a30a03-7b87-4662-bd73-f9ae4c68a97b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_344ef76f-254e-4e95-b59c-14a089b93847" xlink:href="exel-20201002.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1bd4985-2ead-4327-abea-318ab2b27183" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_344ef76f-254e-4e95-b59c-14a089b93847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c473eadb-3940-417a-a873-1f78c255de2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1bd4985-2ead-4327-abea-318ab2b27183" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c473eadb-3940-417a-a873-1f78c255de2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8225a5fe-8d96-44ef-a841-28d0726a47b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1bd4985-2ead-4327-abea-318ab2b27183" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8225a5fe-8d96-44ef-a841-28d0726a47b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6cc4836e-e08a-478d-8832-f57d7dfe5f0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1bd4985-2ead-4327-abea-318ab2b27183" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6cc4836e-e08a-478d-8832-f57d7dfe5f0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_dca23cdd-9de8-4c46-887d-6618116d1c2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1bd4985-2ead-4327-abea-318ab2b27183" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_dca23cdd-9de8-4c46-887d-6618116d1c2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40b9f62c-f9a5-4ac3-88ad-4fdfcd461025" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1bd4985-2ead-4327-abea-318ab2b27183" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40b9f62c-f9a5-4ac3-88ad-4fdfcd461025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1d0edf13-d1f4-4c72-88c5-1269879d661e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1bd4985-2ead-4327-abea-318ab2b27183" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1d0edf13-d1f4-4c72-88c5-1269879d661e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8785e398-025d-4dbf-a93d-b91ad090d848" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1bd4985-2ead-4327-abea-318ab2b27183" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8785e398-025d-4dbf-a93d-b91ad090d848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ac6cddf4-3207-4a37-8489-008ffee5a2e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1bd4985-2ead-4327-abea-318ab2b27183" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ac6cddf4-3207-4a37-8489-008ffee5a2e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_03f0e87e-64f7-461c-a599-61563f5b1864" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1bd4985-2ead-4327-abea-318ab2b27183" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_03f0e87e-64f7-461c-a599-61563f5b1864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises_29975b7d-baa8-4c96-af42-88ccb973bdf6" xlink:href="exel-20201002.xsd#exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1bd4985-2ead-4327-abea-318ab2b27183" xlink:to="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises_29975b7d-baa8-4c96-af42-88ccb973bdf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_4b4112d9-b8ad-47ea-a9cc-ea66d10d5500" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1bd4985-2ead-4327-abea-318ab2b27183" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_4b4112d9-b8ad-47ea-a9cc-ea66d10d5500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_7ae94848-fc90-46fd-9aae-8c5771b0755a" xlink:href="exel-20201002.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1bd4985-2ead-4327-abea-318ab2b27183" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_7ae94848-fc90-46fd-9aae-8c5771b0755a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumNumberOfSharesToVest_83c25785-eba4-4d7f-826c-640572b4b4d2" xlink:href="exel-20201002.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumNumberOfSharesToVest"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1bd4985-2ead-4327-abea-318ab2b27183" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumNumberOfSharesToVest_83c25785-eba4-4d7f-826c-640572b4b4d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxes" xlink:type="simple" xlink:href="exel-20201002.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0ca2382b-4b4e-48f9-b244-43fbe3813e71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_99dfeb5a-8510-4c4f-9e04-b64745ade64c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0ca2382b-4b4e-48f9-b244-43fbe3813e71" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_99dfeb5a-8510-4c4f-9e04-b64745ade64c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1cfde5d2-c0a6-4afe-bbd8-955cc4028da4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_6006454e-2013-437a-ae4f-4b10a036d0f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1cfde5d2-c0a6-4afe-bbd8-955cc4028da4" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_6006454e-2013-437a-ae4f-4b10a036d0f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerShare" xlink:type="simple" xlink:href="exel-20201002.xsd#NetIncomeLossPerShare"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_6cc48628-f27f-4a06-b28f-701c99a5c2a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_8a23965b-82af-49fb-b5b9-15479f551fef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6cc48628-f27f-4a06-b28f-701c99a5c2a7" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_8a23965b-82af-49fb-b5b9-15479f551fef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerShareTables" xlink:type="simple" xlink:href="exel-20201002.xsd#NetIncomeLossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_601481f8-fa15-4ff0-9f7e-f089018adb90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_88739aa2-7f38-49da-9fa9-a0692853f605" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_601481f8-fa15-4ff0-9f7e-f089018adb90" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_88739aa2-7f38-49da-9fa9-a0692853f605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_f9fa5912-b32a-4c11-b73e-bab67fcb3781" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_601481f8-fa15-4ff0-9f7e-f089018adb90" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_f9fa5912-b32a-4c11-b73e-bab67fcb3781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerShareComputationofBasicandDilutedNetIncomePerShareDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#NetIncomeLossPerShareComputationofBasicandDilutedNetIncomePerShareDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerShareComputationofBasicandDilutedNetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a9e53f0b-8b08-4ea3-9b51-fe646bafc757" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_EarningsPerShareNumeratorAbstract_ca606241-8de7-4505-a1fe-0f6c6dba283f" xlink:href="exel-20201002.xsd#exel_EarningsPerShareNumeratorAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a9e53f0b-8b08-4ea3-9b51-fe646bafc757" xlink:to="loc_exel_EarningsPerShareNumeratorAbstract_ca606241-8de7-4505-a1fe-0f6c6dba283f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_18b53d79-14ff-4d1c-9dbd-131cc0653819" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_EarningsPerShareNumeratorAbstract_ca606241-8de7-4505-a1fe-0f6c6dba283f" xlink:to="loc_us-gaap_NetIncomeLoss_18b53d79-14ff-4d1c-9dbd-131cc0653819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_EarningsPerShareDenominatorAbstract_9c52dcae-084b-4562-aeac-6b63308b9cc7" xlink:href="exel-20201002.xsd#exel_EarningsPerShareDenominatorAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a9e53f0b-8b08-4ea3-9b51-fe646bafc757" xlink:to="loc_exel_EarningsPerShareDenominatorAbstract_9c52dcae-084b-4562-aeac-6b63308b9cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_814f4075-4988-4d0b-84cd-78910387052a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_EarningsPerShareDenominatorAbstract_9c52dcae-084b-4562-aeac-6b63308b9cc7" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_814f4075-4988-4d0b-84cd-78910387052a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_2ef459e2-50ff-4461-bc62-1710fd74c396" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_EarningsPerShareDenominatorAbstract_9c52dcae-084b-4562-aeac-6b63308b9cc7" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_2ef459e2-50ff-4461-bc62-1710fd74c396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ea4095e3-060c-41c8-bcb5-5b7790af0090" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_EarningsPerShareDenominatorAbstract_9c52dcae-084b-4562-aeac-6b63308b9cc7" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ea4095e3-060c-41c8-bcb5-5b7790af0090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_a63d5e18-b7cc-4ac4-a004-6d7da2678404" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a9e53f0b-8b08-4ea3-9b51-fe646bafc757" xlink:to="loc_us-gaap_EarningsPerShareBasic_a63d5e18-b7cc-4ac4-a004-6d7da2678404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_3a58c236-0670-4993-9d23-280801eed7e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a9e53f0b-8b08-4ea3-9b51-fe646bafc757" xlink:to="loc_us-gaap_EarningsPerShareDiluted_3a58c236-0670-4993-9d23-280801eed7e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails" xlink:type="simple" xlink:href="exel-20201002.xsd#NetIncomeLossPerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_160dacc7-4207-491d-ab75-6732e4f6a83d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5faff420-28b1-4c3d-95a5-b5d651355ad8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_160dacc7-4207-491d-ab75-6732e4f6a83d" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5faff420-28b1-4c3d-95a5-b5d651355ad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d8784e68-9eb2-4606-8735-b5c28eb6de81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5faff420-28b1-4c3d-95a5-b5d651355ad8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d8784e68-9eb2-4606-8735-b5c28eb6de81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4b686fb1-3d9c-4d77-b9d0-84c39ab6dc6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d8784e68-9eb2-4606-8735-b5c28eb6de81" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4b686fb1-3d9c-4d77-b9d0-84c39ab6dc6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_b2683c17-4584-4031-b87c-42aac66a2218" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4b686fb1-3d9c-4d77-b9d0-84c39ab6dc6a" xlink:to="loc_us-gaap_StockCompensationPlanMember_b2683c17-4584-4031-b87c-42aac66a2218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f78698ba-4ef2-41e6-b243-7fd436ca3544" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5faff420-28b1-4c3d-95a5-b5d651355ad8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f78698ba-4ef2-41e6-b243-7fd436ca3544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_23132e80-cd56-4a09-9f1b-761556bd8431" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f78698ba-4ef2-41e6-b243-7fd436ca3544" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_23132e80-cd56-4a09-9f1b-761556bd8431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="exel-20201002.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_75dbf397-a1d4-4c2f-a635-8d0de2c5970a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_fc853344-601f-444a-b6f4-14f63126641f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_75dbf397-a1d4-4c2f-a635-8d0de2c5970a" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_fc853344-601f-444a-b6f4-14f63126641f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>exel-20201002_g1.jpg
<TEXT>
begin 644 exel-20201002_g1.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M                ]M8  0    #3+4A0("
M                                     !%C<')T   !4    #-D97-C
M   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "&    !1G
M6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D   "Q
M (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M96%S   $
M#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#
M   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A
M8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$
M             !)S4D="($E%0S8Q.38V+3(N,0
M                                            6%E:(        /-1
M  $    !%LQ865H@                     %A96B        !OH@  ./4
M  .06%E:(        &*9  "WA0  &-I865H@        )*    ^$  "VSV1E
M<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:               %DE%
M0R!H='1P.B\O=W=W+FEE8RYC:
M                          !D97-C         "Y)14,@-C$Y-C8M,BXQ
M($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(              "Y)
M14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M                            9&5S8P         L4F5F97)E;F-E(%9I
M97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E
M9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M                             '9I97<      !.D_@ 47RX $,\4  /M
MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P         !
M                         H\    "<VEG(     !#4E0@8W5R=@
M  0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C
M &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$ Q@#+ -
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MUTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I- DU*39--W$XE3FY.MT\
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MNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$
M P$! 0$! 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0
M 0)W  $" Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E
M\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W
M>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'
MR,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]
M_**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBH;FZBLK>2::1(88U+.[L%5%'4DG@ 4-VU8*[=D345R/A/X[^"O'
MWBF70]!\6>'=:U:&$SRVEAJ$5S+%&"%+,$8XP2!SZCU%==6-'$4JT>:E)26U
MTT_R.C$86OAY\F(@XNU[--.SV=GT"BBBMCG"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKD_C5\9-!^ /PTU3Q
M5XCNOLNF:7'N8+@R3N>%BC!(W.QP /?D@ D8UZ].C3E6K-1C%-MO1)+=LZ,+
MA:V)K1P^'BY3FTHI*[;;LDEW;.1_:_\ VN?#W[(/PU;6M8_TS5+S=%I6F1OM
MEOY@,]?X8UR"SD< @#+%5/Y'_M'_ +8OCW]J/7);CQ-K5Q_9WF;H-)MF,5A:
MCMMCSAB/[S;F]^U4OVHOVE->_:I^+5]XIUQC&LA\FQLE<M%IUL"=D2?3)+-@
M;F+' S@=Y_P3=_97/[4/[0]G#?V[2>%_#>W4=78K\DJ@_NK<GUD<8Q_<60CI
M7\J\4<79AQ9FD<KRUN-&4N6,=5S=Y3\NMGI%+:]V?WCP-X>Y1P#D4\]SF*EB
M81YYR=GR=H4[];VC=:RD][61]V_\$F_V5!\!_@,GB75;4Q^)O&Z)=R!Q\]K9
M]8(O8L"9&'!RZ@\I7U=2!0JX' %+7]-9'D]#*\#2P&'^&"MZOJWYMW;]3^).
M*.(L5GN:5LUQC]^K)NW1+:,5Y15DO)!1117K'@A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY2I[]%'7\:^/:*_%,P\3N(\7*[Q#@NT$HI?-+F^]L_I;*/!'@W 045@U4?\
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M5D?Y@YACZ^-Q-3&8J7-4J2<I-]6W=O[PHHHKH.,**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHKE?C?X\_X57\&O%?B4;=V@Z1=7Z
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MTL DV[EMX_O22L/[J(&8^RFOW/\ A9\-=*^#GPYT;POHL/V?2]#M4M8%/WF
MZLQ[LS$L3W+$U\>?\$9?V5/^$)\ 7?Q,U>WVZIXF1K725=>8+)6&Z3D<&5UX
M_P!B-2.'-?<E?U1X1<*_V=EO]HUU^]KV:\H?97_;WQ/RY>Q_"?TA.._[7SG^
MQ\+*]#"MIVVE4VD_^W?A79\W1A1117Z\?SV%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0H YK^AO ?FOC>W[O[_?/Y%^E5R6RQ?:_??=^Z+%%%%?T,?R"%%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KG?BSX%C^)_PM\2>&
MYMHCU_2[G3R3T7S8F3/X;L_A7145G6I1JTW3FKJ2:?H]S;#UYT*L:U)VE%II
M]FG='\]-_8S:9?36UQ&T-Q;R-%(C=493@@^X(-0U])?\%4/V?I/@?^U9JU];
MPF/1?&1;6;)P/E$CG_2(_J)=S8[+(E?-M?P5G65U<NQU7 UOBIR:];;/T:U7
MDS_5CAO/*.<970S3#_#5BI>C:U7K%W3\T%%%%>8>T%%%% !1110 4444 %%%
M% 'JG[$GPXD^*_[67@'150R1R:O#=7  SF& ^?)_XY&P_&OW(K\Y/^"(/[/\
MESKGB3XE7T#"WM8_[%TLL.'D;:\[C_=41J".#YCCL:_1NOZP\&\GEA,D>*J*
MSK2<E_A6B_&[7DT?P/\ 2.XBAF'$RP-%WCAH*+_QR]Z7W)Q3[-,****_7#^?
MPHHHH **** "BBO+?VN/VI-$_9,^$=YXBU1H[B^DS!I>G[]LFH7&.%'<*.K-
MV'J2 >7'8VAA*$\5B9*,(*[;Z)?U\SNRS+<3F&+IX'!P<ZE1J,4MVW_6KV2U
M>AYO_P %(OVYX?V4?AX-(T6:&;QUX@A86,>0W]G0G*F[=?8@A >&8$\A&%?D
M'J&H3ZM?3W5U-+<75S(TTTLC%GE=CEF8GDDDDDGJ36Y\6/BIK?QL^(>J>*/$
M5XU[JVK3&:9^BKV5$'\**H"J.P KG:_C/CCC&OG^/]L[QI1NH1[+N_[SZ]M%
MT/\ 2#PO\.L-PEE2PZM*O4LZL^[Z17]V.J7?66C=@HHJ2VMI+RXCAACDEEE8
M)'&B[F<G@  =2:^*2OH?I6VK/H+_ ()J_LJ_\-.?M#V?]HVWG>%O#&W4=6W+
MF.?!_=6Y['S''([HLG0XK]E0H5<#@"O$OV!/V78_V5/V>M-T>XB0>(M4QJ&M
M2#D_:' _=9R?EC4!.#@D,PQN->W5_9?AOPK_ &)E,8U5:M4M*?==H_\ ;J_%
ML_SA\9.._P#6;/YSH2OAZ-X4^S2?O3_[?>J?\JC?8****_0#\E"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \&_
MX*'?LGK^U?\  .ZL;&-#XGT(M?Z,Y.-\@7#P$^DBC'8;@A/ K\8M0T^?2;Z>
MUNH9;>ZMI&BFBD4J\3J<,K \@@@@@]"*_H6KX1_X*@_\$X9OB'+??$GP'9^9
MKB)YNM:5"OS:B!UN(@.LP'WD'WP,CY\A_P 1\6.!*F/A_;& C>I%6G%;RBMF
MN[CVZK;:S_ISP"\4Z655/]7LVGRT:CO3D]H3>\6^D9/5/92O?23:_-&BG$;3
M@C:5ZBFU_,)_;@4444 %%%% !1110 5U'P8^$.M?'CXF:/X4T"W-QJ6L3B).
M#LA7J\KGLB*"Q/H#UXK)\)>$M4\>>)+/1]%L+K5-4U"016UK;1F269CV 'MD
M^P!/:OUX_P""=W["%I^R+X&;4M76WN_'6N0A=0N$(=;&+.X6T3>@(!<C[S =
M0JU]QP+P9B,_QJA9JC%ISEY?RK^\^G9:]#\Q\4?$C"<)Y8ZEU+$S35.'=_S2
M7\L>O=^ZM7=>R? KX.Z7\ ?A)H?A#1U_T'1+80B0C#7$A):25A_>=RS'W:NN
MHHK^SL/AZ="E&C15HQ222V22LE\D?YNXO%5L57GB<1)RG-N4F]VV[MOS;U"B
MBBMCG"BBB@ HHJ&\O(=,LYKBXFBM[>W1I)99'"I$@&2S$\  #))XQ2;MJQI-
MNR,7XG_$W1?@YX"U3Q-XBO8]/T?2(3//*_7T"J/XF8D*JCEF( ZU^+/[8/[5
MNM?M<?%NY\0:ENM=-M\P:3IP;*6%OG@>[MP7;N>F%"@>E?\ !2?]NV;]J?Q]
M_8>@W$B> ]!F/V0 %?[3G&0;EQUVX)"*>BDG@L0/E^OY2\4./GFU?^SL%+_9
MX/5K[<EU_P *^SWW[6_O/P.\*5D&%6<9G#_:ZJT3_P"74'T\IR^UV7N_S7**
M**_(3^A K[$_X(_?LJGXN_&23QUJMNSZ!X)D5[;>OR7.H$;HP/7RAB0]PQB[
M&OD[P;X0U#Q_XMTW0])MVN]3UBYCL[6%>LDCL%4>W)'/05^Y/[,/P#T_]FCX
M(Z'X/T_RY#IT.Z[N%7!O+EOFEE/?EB<9Y"A1V%?JWA/PK_:>:?7*ZO2H6;[.
M7V5\OB?HD]S\'\?.//[#R/\ L["RM7Q5XJV\8?;EY7ORKU;7PGH%%%%?UL?Y
M_A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG_16OB9_X5-]_P#':/\ AM;XR?\ 16OB9_X5-]_\=KS+YO:CYO:BR"[/3?\
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M5-]_\=KS+YO:CYO:BR"[/3?^&UOC)_T5KXF?^%3??_':/^&UOC)_T5KXF?\
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MXI?$:\L[SQ%I\$\$_B2\DBGC:YC5D93(0RD$@@C!!K]YJ_G4_9>_Y.5^'?\
MV,VF_P#I5%7]%=8U#2F%%%%9EA1110 4444 %%%>'_M\?MHZ3^Q+\$)O$%Q'
M#?:]J3&TT33G?;]KN,9+-CGRHP0S$?[*Y!84;@;'[5O[:?@']CCPHFH^,-4V
MWETK&QTJU EO[\C^Y'D87L78J@) )R0#^:/[0/\ P77^*7Q$O[BW\#VNF^ ]
M))*Q.L27VH.O^U)*IC&?18P5S]XX!KY#^+7Q=\1_'3Q]J'B?Q5JMUK&M:F^^
M:XF;H.R*.B(HX55 "@8 %<Y\WM6\::6YBY-GJVL?MV_&K7+UKB;XL?$*.1NH
MM]?N;=.I/W(W5>_I_(56_P"&UOC)_P!%:^)G_A4WW_QVO,OF]J/F]JOE0KL]
M-_X;6^,G_16OB9_X5-]_\=H_X;6^,G_16OB9_P"%3??_ !VO,OF]J/F]J+(+
ML^C_ -D7]KKXL>)?VK_AAINI?$_XAZAI^H>+=*MKJUN?$=Y+#<Q/>1*\;HTA
M5E9205((()!K]UJ_GG_8I_Y/(^$O_8Y:/_Z70U_0Q6-3<TAL%%%%9EA1110
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M66\G^2Z)+HE9):)!1117<>6%%%% !1110 5^<?\ P5H_;Y_MBYO/A3X-OO\
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M5.S/V:HHHK,L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV_:@^("^-?%5GN\ ^&;@8AE7Y=:NUPPAP>#$G!D['(3G+$?LJB+$BJJA548
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MKF/F]JZ?X*_\EC\)?]AFS_\ 1Z4@/Z/J***Y3H"BBB@ HHHH **** "BBB@
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MYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:OVC_X(E_
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MF]J/F]J #YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J
M#YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]JU? W@;6/B9XOT
M[P_X?TZZU;6=6F6WM+2W3=),Y[#VZDDX  ). ":0'UG_ ,$0O@'-\4_VPHO$
MTT!?2? -H]_(Y'R&YE5H8$_WN9)!_P!<?P/[.UX;_P $^?V.K3]BW]GNQ\.L
MT-UXAU!OM^N7<?W9KIE V(3SY<:@(O3."V 6(KW*N>4KLVBK(****DH****
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M1110 4444 %4M?U^Q\*:'>:GJ5U;V.GV$+3W%S.X2."-1EF8G@  5=K\O_\
M@JQ^WY_PM?6KCX;^#[[=X8TR;;J]Y"WRZI<(?]6I'WH8V'7H[C(R%4GY7B_B
MK#9#@'BZ^LGI"/64O\ENWT7G9/[KP]X$QO%6:QR_#>[!:U)VTA'J_5[175^2
M;7DW_!0;]MN^_:]^)NRRDFMO!>ANT>DVA!4SGHUS(/\ GHXZ _<7 X)8M\^4
M45_%N:YIB<QQ4\;BY<TYN[?Z+LDM$NB/]*,AR/!Y/@*66Y?#EI4U9+\VWU;>
MK?5ML****\\]8***^C/^"9G[*O\ PTS^T+;2ZC;^;X6\*;-1U3>N8[AMW[FW
M/_71E)([HC]\5Z64977S+&4\#AE>=1I+]6_)+5^2/'X@SS"Y-EM;-,8[4Z47
M)^?9+SD[)>;1]W?\$K/V5?\ AGO]G^+6=4M_+\4>-%CO[H.N'MK?!,$/J#M8
MNPZAG(/W17U%117]S9+E-#+,#3P&'^&"MZ]V_-N[?FS_ "[XDX@Q6=YG6S7&
M/WZLFWV2V45Y15DO)!1117J'AA1110 4444 %?,O_!8K_E''\1O^X;_Z<[2O
MIJOF7_@L5_RCC^(W_<-_].=I51W0'X:?-[4?-[4?-[4?-[5TG.'S>U'S>U'S
M>U'S>U !\WM1\WM1\WM1\WM0 ?-[5T_P5_Y+'X2_[#-G_P"CTKF/F]JZ?X*_
M\EC\)?\ 89L__1Z4@/Z/J***Y3H"BBB@ HHHH **** "J^K:K:Z#I5S?7UQ#
M9V=G$T]Q/,X2."-069V8\!0 22> !5BOSE_X+G?MM2>%M#@^#OAV[\N]U:);
MOQ'+&?FBMR08K;/8R8WL.#M"#D.13BKNPF[(^4O^"FW_  4!OOVS_BJUEI,]
MQ;_#_P /3,FDVIRGVU_NM>2K_>;D*",HAQP6?/S#\WM1\WM1\WM72E96,-P^
M;VH^;VH^;VH^;VI@'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?
M-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4
M'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U
M'S>U'S>U !\WM4NG:C<:3J$-W:3S6MU:R+-#-"Y22)U.596'(8$ @CD$9J+Y
MO:K.AZ)>>)M:M-.T^UFO+^_F2WM[>%"\D\CD*J*!R220 /4T ?K1_P $D/\
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M"OA'2X=)T?3Q\L:?,\SG[TDCGEY&QRQY.!V  ZRBBLS0**** "BBB@ HHHH
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MQ#:V=G$T\\\SA(X8U!+,S'@* "23P *_$/\ X*@_M]W7[9OQ:-CH\\T/P_\
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M[DRV/RZ^;VH^;VH^;VH^;VKI,0^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J
M#YO:CYO:CYO:OT"_X(5?L_>!_CJ?BE_PF7A70O$W]E_V3]C_ +1M$N/LWF?;
M=^S<#C=L3..NT>E*3LKC2N?G[\WM1\WM7] O_#O[X(_]$K\"_P#@HB_PH_X=
M_?!'_HE?@7_P41?X5G[5%^S9_/U\WM1\WM7] O\ P[^^"/\ T2OP+_X*(O\
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M_P#T>E<Q\WM73_!7_DL?A+_L,V?_ */2D!_1]1117*= 4444 %%%% !1110
MV2,2JRLH96&"".M?CA_P4I_9%;]EOXZS3:7:F/P?XG+WNDE1\EJ<_O;7/_3-
MB-H_N,G)(-?LC7E?[8O[--A^U9\"]5\+W7DPZAM^U:5=.,_9+M =C9[*V2C8
M_A=N^*^#\0N$XY[E;ITU^^IWE!^?6/I):>MGT/U3PAX^EPMGD:M9_P"SU;0J
MKLKZ3]8/7ORN26Y^&]%:'BKPOJ'@GQ+J&CZK:RV6I:7<26MU;R##0R(Q5E/T
M(-9]?QC.,H2<9*S6Y_I%3J1G%3@[IZIK9I]4%%%%24%%%% !1110!Z=^R)^T
MEJ'[*OQRTGQ59^;-9QM]GU.T1L?;;1R/,3ZC 9<]&1?>OV\\(^+-/\=>%M/U
MK2;J.^TO5K>.[M+B/[LL3J&5O7D'H>17\^M?H1_P1F_:^^SW$WPEUZZ_=R&2
M\\/22-]UN6FM1]?FD7W$@[J*_;/!_C#ZGB_['Q,OW=5^XWTGV]);>J7=G\T_
M2(\/?[1P"XBP4?WU!6FEO*GW]8/7_"W?9(_12BBBOZ@/X="BBB@ HHHH ***
M* "BBB@ HHHH ***^>_^"@W[;=C^R'\,=EC)#<^--<1H])M2 P@'1KF0?W$[
M _?; Y <KY^:YIALNPD\;BY<L(*[?Z+NV]$NK/6R'(\;G&/I9;E\.:K4=DOS
M;?1):M]$FSR?_@JQ^WW_ ,*IT*X^''@^^V^)]4AVZM=PM\VE6[C_ %:MVFD4
M]1RBG/!92/R_J[XA\07WBS7;S5-2NI[[4-0F:XN;B9]TDTC'+,Q[DG-4J_BW
MB_BK$Y]CWBZVD5I"/2,?\WNWU?DDE_I1X>\"8/A3*8Y?AO>F]:D[:SEW]%M%
M=%YMME%%%?*GW04444 365E-J5Y#;V\4DUQ<.(XXT7<TC$X"@=R20,5^UW[!
MO[,,/[*O[/>EZ)+%'_;^H8U#6I5Y+W+@93/]V-=J#'!VEL L:^%?^"/7[*O_
M  M;XOR^/=7M?,T'P9(#9AURMUJ!&4Z]?*4^9V(8Q=>17ZI5_2?@OPK[*A+.
M\0O>G>,/*/VI?-JR\D^C/XQ^DEQY]8Q,.&,)+W:=IU;=9->['_MU/F:[M=8A
M1117[R?RJ%%%% !1110 4444 %?,O_!8K_E''\1O^X;_ .G.TKZ:KYE_X+%?
M\HX_B-_W#?\ TYVE5'= ?AI\WM1\WM1\WM1\WM72<X?-[4?-[4?-[4?-[4 '
MS>U'S>U'S>U'S>U !\WM73_!7_DL?A+_ +#-G_Z/2N8^;VKI_@K_ ,EC\)?]
MAFS_ /1Z4@/Z/J***Y3H"BBB@ HHHH **** .7^-/Q6TWX&_";Q%XPU=O^)?
MX=L);Z50<-+L4E8U_P!IVPH]V%?SQ_%GXG:M\:?B;KOBS7)O/U;Q!>R7MRPS
MM5G;.U1V51A5'90!VK]0/^"_7Q[;PM\&?"_P]LYMMQXKO&U&_"M_RZVV-B,/
M1YG5A[P&OR>^;VK:G'2YE-ZV#YO:CYO:CYO:CYO:M2 ^;VH^;VH^;VH^;VH
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M* "BBB@#^?G_ (*!_P#)[GQ5_P"QFOO_ $:U>0?-[5Z__P % _\ D]SXJ_\
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MH#GCY4\Z3\I)I!_P&OE+YO:NW_:;\7GX@?M'>/M<,GF#5O$5_=J<Y&U[B1E
MZ\ $ >PKB/F]JZH[&#W#YO:CYO:CYO:CYO:F(/F]J/F]J/F]J/F]J #YO:CY
MO:CYO:CYO:@#[)_X(Y?L.V?[3WQANO%7B:U6Z\'^"7CD-M(,QZE>M\T43#^*
M- "[CO\ (I!5FK]G%4(N!P!T'I7S7_P2/^%T/PO_ &#/!02-4NO$,<NMW;C_
M ):O/(2A/TA6%?\ @-?2E<TI79M%604445)04444 %%%% !1110 4444 >7_
M +1_[&_PY_:NT7[+XU\-V>H7,:;+?48AY-_:?[DR_-@'G:<H3U4U^<?[2_\
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ML%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *\G_ &S/V2M!_;*^"5]X3UC;;W8_TC2M1";I--N@#MD'
MJIY5E_B5CT."/6** /YO_C!\(]>^!'Q*U?PGXFLFT_6M%G,%Q$>5/=70_P 2
M,I#*W0J0>]<U\WM7[3_\%8?^">Z?M:?#3_A)_#-JO_"PO"\#&W5!SK%L,LUJ
M?]L'+1G^\2O ?*_BU<6\EI<20S1O#-$Q1T<;61AP01V(KIC*Z,91L-^;VH^;
MVH^;VH^;VJB0^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:OU9_X(P_\
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MK_R6/PE_V&;/_P!'I7,?-[5T_P %?^2Q^$O^PS9_^CTI ?T?4445RG0%%%%
M!1110 4444 ?S.W5S)>W4DTK&269B[L>K,3DDTSYO:G7%O):7$D4BM')&Q1U
M88*D<$&F_-[5UG.'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-
M[4?-[4 ?O[_P3LU^U\2_L-?"VXLS&88_#UM:MY9./,A7R9.YYWQMGWSTZ#VB
MOR]_X(=?MSZ;X6@F^#OBB]CLUO+IKOPU<SOMC:60CS+/)X4LWSH/XF:09W%
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ML%%%%24%%%% !1110 4444 %%%% !1110 5^;_\ P<0_\B9\+?\ K\U'_P!
MMZ_2"OS?_P"#B'_D3/A;_P!?FH_^@6]5'<F6Q^77S>U'S>U'S>U'S>U=)B'S
M>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[5^F?_!NGT^,7_<%_]R%?F9\W
MM7Z9_P#!NGT^,7_<%_\ <A45/A*CN?IE1117.;!1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX9_\#9_\*/\ B(7\9?\ 1._#/_@;/_A1R,.9'ZM45^4O_$0OXR_Z)WX9_P#
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M% !1110 4444 %?,O_!8K_E''\1O^X;_ .G.TKZ:KYE_X+%?\HX_B-_W#?\
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M_K,_@,**** "BBB@ HHHH **** "BBB@ HHHH *^9?\ @L5_RCC^(W_<-_\
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M?L1?#W0[J-H;Y]-_M&Y1AATDNI'N2K?[2B4+[;<5E4V+I[GN-%%%8FH4444
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M]M3P=^VG\/?[9\,W#6^H6>U-4TBX8?:M-D.<!AT9&P=LB\, >C!E'K]?SD?
MOXZ>)OV<?B9IWBSPGJ,FFZQIK<'[T=Q&?O12KT>-@,%3[$8(!'[G_L.?MH^'
M_P!M?X/PZ_I?EV6M6.V#6M*+[I-/G(SQW:-\$H_<9!PRL!C.%C:,KGM%%%%9
ME!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(:?:W5JTGA'P[)'J.O2L/W;Q*V4M\_WIF7;CKM#L/NU^[JJ$7 X Z#TKS?\
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M% !1110 5^;_ /P<0_\ (F?"W_K\U'_T"WK](*_-_P#X.(?^1,^%O_7YJ/\
MZ!;U4=R9;'Y=?-[4?-[4?-[4?-[5TF(?-[4?-[4?-[4?-[4 'S>U'S>U'S>U
M'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\W
MM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\WM1\W
MM1\WM0 ?-[4?-[4?-[4?-[4 'S>U7?#'AG4/&GB.QTC2;.?4-3U*=+:UMH5W
M23RN0JJH]22*L^!? 6M?$[Q59Z'X=TN^UK5]0<1V]I9PF660^P'8=23P!R<
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MVH^;VH^;VH /F]JZ?X*_\EC\)?\ 89L__1Z5S'S>U=/\%?\ DL?A+_L,V?\
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M_NRC_B'3_P"JQ?\ EJ?_ '97Z944<\@Y4?F;_P 0Z?\ U6+_ ,M3_P"[*/\
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M9_\ !NGT^,7_ '!?_<A42=D5'</^(=/_ *K%_P"6I_\ =E'_ !#I_P#58O\
MRU/_ +LK],J*QYY&G*C\S?\ B'3_ .JQ?^6I_P#=E'_$.G_U6+_RU/\ [LK]
M,J*.>0<J/S-_XAT_^JQ?^6I_]V4?\0Z?_58O_+4_^[*_3*BCGD'*C\S?^(=/
M_JL7_EJ?_=E'_$.G_P!5B_\ +4_^[*_3*BCGD'*C\S?^(=/_ *K%_P"6I_\
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MK^ABL*FYK3V"BBBLRPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%1116)H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG_Z/2N8^;VKI_@K_ ,EC\)?]AFS_ /1Z4@/Z/J***Y3H"BBB@ HHHH ****
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M_L6+'_T2M>P5X_\ \$_?^3(?A5_V+%C_ .B5KV"N0WCL%%%% PHHHH ****
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MS>U?IG_P;I]/C%_W!?\ W(5%3X2H[GZ94445SFP4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!PO[4'_)M/Q$_[%G4O
M_266OYU/F]J_HK_:@_Y-I^(G_8LZE_Z2RU_.I\WM6U(SJ!\WM1\WM1\WM1\W
MM6IF'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0!Z;^Q3_P GD?"7_L<M'_\
M2Z&OZ&*_GG_8I_Y/(^$O_8Y:/_Z70U_0Q6%3<UI[!1116984444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !7S+_P6*_Y1Q_$;_N&_^G.TKZ:KYE_X
M+%?\HX_B-_W#?_3G:54=T!^&GS>U'S>U'S>U'S>U=)SA\WM1\WM1\WM1\WM0
M ?-[4?-[4?-[4?-[4 'S>U=/\%?^2Q^$O^PS9_\ H]*YCYO:NG^"O_)8_"7_
M &&;/_T>E(#^CZBBBN4Z HHHH **** "BBB@ HHHH ***K:IJ=MHFF7%[>3P
MVMG9Q-//-*P6.%%&YF8G@  $DGTI2DDKO8J,7)\L=SYI_P""J'[57_#/'[/\
MND:7<F+Q/XT$EA:%&Q):V^,3S@]00K!%/!#2 C[IK\@J]<_;9_:7N/VJOV@=
M7\2;I5TB(_8M'@?@PVB$[,CLSDEV'9G(Z 5Y'7\7>(?%+SO-I5:;_=0]V'HM
MY?\ ;SU]++H?Z2>$/ JX8X?IT*RM7J^_4[\S6D?^W%IVOS-;A1117PI^I!11
M10 445]#?\$]?V(;S]KKXF>=J"3V_@G0Y%?5;I<J;ENJVL;?WV_B(^ZN3G)4
M'T<IRO$YEBX8+"1YIS=DOU?9+=OHCR,^SW!9-@*F99A/EI4U=O\ ))=6WHEU
M;L>N?\$H?V!_^%E:Q;?$WQ?9AO#NG2DZ+93)E=2G0X,S C!BC8$ ?Q.#V4AO
MTZJGH>BV?AG1;33M/M8+*QL(4M[:WA0)'!&@"JBJ. H   ]!5RO[3X1X7PV0
MX".#H:RWG+K*7?T6R71>=V_\UO$#CK&\59K+,,5I!:4X7TA'HO-O>3ZOR22*
M***^H/APHHHH **** "OS<_X++?L@?V#K,7Q8T&UQ9Z@R6NOQQI@0S\+%<$#
ML_",>/F"=2YK](ZQ_'?@?2_B7X-U3P_K5JEYI6L6SVEU"W\<;C!P>Q'4$<@@
M$<BOF>+N&Z6>99/ U-);Q?\ +);/TZ/R;/MO#WC3$<+YW2S.E=Q^&<?YH/XE
MZ]8_WDNA_/W17HG[4G[/.J?LO?&O5_".I;Y5LW\VQNBNT7MJQ/E2CZ@8(&<,
MK#/%>=U_$.,PE7"UYX:O'EG%M-/HUHS_ $VR_'X?'8:GC,+)2IU$I1:V::NF
M%%%%<YV!1110 4444 :_@3QQJGPT\9Z7X@T6Z:SU71[E+NUF7^!T.1D=P>A!
MX()!R":_<']EK]H72_VH/@GH_B[3=D;7B>5?6H;<;*Z4#S8C]"<@GJK*>]?A
M/7U!_P $M_VOO^&;_C8NAZQ=>7X1\82):W9=ODLKC.V*X]AD[7/ VMDYV"OU
M+PLXP_LC,OJN(E:C6LGVC+[,OT?D[O8_#?'3P]_UAR;Z]A(WQ.'3E&V\H;RA
MYO[4?--+XF?KY1117]='^?(4444 %%%% !1110 4444 %?,O_!8K_E''\1O^
MX;_Z<[2OIJOF7_@L5_RCC^(W_<-_].=I51W0'X:?-[4?-[4?-[4?-[5TG.'S
M>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[5T_P5_Y+'X2_[#-G_P"CTKF/
MF]JZ?X*_\EC\)?\ 89L__1Z4@/Z/J***Y3H"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\B?^"_'PLMO"O[
M2_AOQ1;1I&WBS1O+NL=99[9]F\_]LGA7Z1U^NU?EE_P<.^*8;OXB?#'1%9?M
M&GZ=?7SK@9"SRPHI]>3;M^1]ZNGN3+8_.?YO:CYO:CYO:CYO:N@Q#YO:CYO:
MCYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J_0#_@WOT]I/V@O'5UN79#X>2(CN2]
MS&1_Z ?S%?G_ /-[5^D/_!N[X?\ /\5?%/5MO_'K::=: G//F/<.0!T/^J'N
M,CU-1/X2H[GZB4445SFP4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?S\_P#!0/\ Y/<^
M*O\ V,U]_P"C6KR#YO:O7_\ @H'_ ,GN?%7_ +&:^_\ 1K5Y!\WM75'8YP^;
MVH^;VH^;VH^;VI@'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0!_0+_P3]_Y,
MA^%7_8L6/_HE:]@KQ_\ X)^_\F0_"K_L6+'_ -$K7L%<AO'8****!A1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M7/\ Q4^*&A_!;X>ZMXI\27T>G:+HMNUQ=3OV4=%4=69B0JJ.22 .M 'G?[<7
M[8NB?L6?!*[\2:AY5WJ]SFVT732V&U"Y(X!QR(T^\[=AP/F90?P;^)_Q,UOX
MR?$#5O%'B.^EU+6]<N&N;NXDZNQX  Z*J@!54<*H &  *]$_;@_;$US]M+XW
M7GB;4O-M=)M\VVBZ:6RNGVH.0#V,C?>=N[<?=50/'OF]JZ(1LC&4KA\WM1\W
MM1\WM1\WM5DA\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U?<
MG_!'G_@GA_PT#XSC^(WC"Q\SP3X>N/\ 0+6=/W>M7B'N#]Z&,\MV9@%Y <4G
M*RN"U/HC_@C7_P $\/\ A3OAB#XJ>,;#9XJURW_XDMI.GSZ3:..96!^[-*I^
MJH<<%V4??-%%<S=W<Z$K!1112 *\P_:[_98T#]L#X*:EX/UU5A:;]_I]\$#2
M:;=*#LF3\R&&1N5F&1G->GT4 ?SB_&_X+^(/V>OBEK'@_P 469L]8T68Q2J.
M4E4\I(A_B1U(93W!'TKE/F]J_;?_ (*H?\$_8?VP_A;_ &UH%O"OQ"\,PLVG
MM@*=4@&6:T=O?)9"> Y(X#L1^)E[93:;>36]Q#+;W%N[1RQ2(5>-@<%2#R""
M""#R"*Z(RN8RC8C^;VH^;VH^;VH^;VJR0^;VH^;VH^;VH^;VH /F]J/F]J/F
M]J/F]J #YO:OU)_X(O?\%$3XGT^S^#OC2^SJ%E&5\,WT\G-S$HS]C8G^)!GR
M_51MXVJ#^6WS>U3Z1J]UX?U:UO[&YGL[VQF2XM[B"0QRP2(0RNK#E6! ((Y!
MI2C=6&G8_I>HKYC_ ."8W[?-K^VC\(_LVK2P0^/?#<:1:Q;J @O%Z+=QK_=?
M^(#A7R, %<_3E<NQN%%%% !1110 4444 %%%% !7YO\ _!Q#_P B9\+?^OS4
M?_0+>OT@K\W_ /@XA_Y$SX6_]?FH_P#H%O51W)EL?EU\WM1\WM1\WM1\WM72
M8A\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U?IG_ ,&Z?3XQ?]P7_P!R
M%?F9\WM7Z9_\&Z?3XQ?]P7_W(5%3X2H[GZ94445SFP4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!PO[4'_ ";3\1/^
MQ9U+_P!)9:_G4^;VK^BO]J#_ )-I^(G_ &+.I?\ I++7\ZGS>U;4C.H'S>U'
MS>U'S>U'S>U:F8?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U 'IO[%/\ R>1\
M)?\ L<M'_P#2Z&OZ&*_GG_8I_P"3R/A+_P!CEH__ *70U_0Q6%3<UI[!1116
M984444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7S+_P %BO\ E''\
M1O\ N&_^G.TKZ:KYE_X+%?\ *./XC?\ <-_].=I51W0'X:?-[4?-[4?-[4?-
M[5TG.'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[5T_P5_P"2Q^$O^PS9
M_P#H]*YCYO:NG^"O_)8_"7_89L__ $>E(#^CZBBBN4Z HHHH **** "BBB@
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MBFNZQ(S,P55&22> * &WEY#IUI+<7$L<-O"ADDDD8*D:@9))/  '.37X&?\
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MT>WT^ZEM+&S:!Y(T"L4+72L5R.,J#["N\_XB /@W_P!"S\3/_!=8_P#R77Y
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M>S0<[/U__P"(@#X-_P#0L_$S_P %UC_\ET?\1 'P;_Z%GXF?^"ZQ_P#DNOR
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M0>"#51E9W$U<_F@^;VH^;VKZQ_X*I?\ !/N;]C[XH#7/#]O*_P /?$\[&P8
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M!\&_^A9^)G_@NL?_ )+K\@/F]J/F]J/9H.=GZ_\ _$0!\&_^A9^)G_@NL?\
MY+H_XB /@W_T+/Q,_P#!=8__ "77Y ?-[4?-[4>S0<[/U_\ ^(@#X-_]"S\3
M/_!=8_\ R71_Q$ ?!O\ Z%GXF?\ @NL?_DNOR ^;VH^;VH]F@YV?K_\ \1 '
MP;_Z%GXF?^"ZQ_\ DNC_ (B /@W_ -"S\3/_  76/_R77Y ?-[4?-[4>S0<[
M/U__ .(@#X-_]"S\3/\ P76/_P ET?\ $0!\&_\ H6?B9_X+K'_Y+K\@/F]J
M/F]J/9H.=GZ__P#$0!\&_P#H6?B9_P""ZQ_^2Z/^(@#X-_\ 0L_$S_P76/\
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M<G1K9N?*'I*W!<]1]WLQ;QS_ ()+_L#?VM<6?Q6\8V2M:PGS/#EC.F?.<?\
M+XZG^%?^68/4_/QM0G]&J_I#PFX!]E&.>9A'WG_#B^B?VWYO[/9:]5;^-?'[
MQ6^L3GPOE$_<B[5I+[37_+M/LG\?=^[LG<HHHK]\/Y1"BBB@ HHHH **** "
MBBB@ HHHH *X/]I/X#:3^TK\&M:\(:LJK'J46;:XVY:SN%YBF7W5L9 ZJ67H
M37>45SXK"TL31EAZ\>:,DTT^J>C1U8''5\'B(8O#2<:D&I1:W33NG\F?S_\
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MIMW&.6:'?[_>Z^O.9]FQ^T1^Z-%?BG9?\%O?CY:VRI)K'AZY89_>2:-$&/\
MWS@?I27_ /P6[^/EY!MCUGP_:MG.^+1H2WT^;</TH]FQ\Z/VMJ#4M2M]'L);
MJ\N(;6U@4O+-,XCCC4=RQX ^M?A1XL_X*O?M!>,XVCN/B/J5K&V<+86=K9%
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MSI&AEUY%NC9N)1[/(J(#U'DOV:OT:KGJ/6QM%:!1114%!1110 4444 %%%%
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MWM1\WM1\WM0!)9V<VH7<5O;Q23S3N(XXXU+/(Q. H Y))(&!UK]J_P#@E/\
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MFS_]'I7,?-[5U?P(LY-1^.'@VWA7S)KC7;&.-<@;F-P@ R?>D!_1U1117*=
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MWA?P$\VK_P!HXZ/^SP>B?VY+I_A77N_=[V_GOQQ\5ED&$>3Y9/\ VNJM6O\
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M ,EC\)?]AFS_ /1Z5S'S>U=/\%?^2Q^$O^PS9_\ H]*0']'U%%%<IT!1110
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M=I'96D"_\LXT4*O/<\<D\DDD\FMBBBN<V"BBB@ HHHH **** "BBB@ HHHH
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M--+^#7PTT+PIHL9ATOP_916-L&.6*HH7<Q[LV"Q/<DFNAKF;N[G0M$%%%%(
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M1W0'X:?-[4?-[4?-[4?-[5TG.'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#^?G_@H'_R>Y\5?^QFOO_1K5Y!\WM7Z(_M4_P#!
M&CXO?&;]I'QQXLTBY\'KI?B+6;F_M1<:C*DHCDD++N41$!L'IDUP/_#ASXW?
M\_?@7_P:2_\ QFNA21CRL^+/F]J/F]J^T_\ APY\;O\ G[\"_P#@TE_^,T?\
M.'/C=_S]^!?_  :2_P#QFGS(.5GQ9\WM1\WM7VG_ ,.'/C=_S]^!?_!I+_\
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M/C=_S]^!?_!I+_\ &:/^'#GQN_Y^_ O_ (-)?_C-',@Y6?%GS>U'S>U?:?\
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M<K/BSYO:CYO:OM/_ (<.?&[_ )^_ O\ X-)?_C-'_#ASXW?\_?@7_P &DO\
M\9HYD'*SXL^;VH^;VK[3_P"'#GQN_P"?OP+_ .#27_XS1_PX<^-W_/WX%_\
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M(.5GQ9\WM1\WM7VG_P .'/C=_P _?@7_ ,&DO_QFC_APY\;O^?OP+_X-)?\
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M,4 \J]@G;<P5B/DC;'!YQ]:<=P/Y_P#YO:CYO:OM/_APY\;O^?OP+_X-)?\
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M:ZH_LWZ-O GL,-/B?%Q]ZI>%*_2*?O2_[>:Y5ULGTD%%%%?@I_58445]>?\
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M-\-O#%IHOA_2['1=)L4V6]G9P+##$/95 ')R2>I)).:UJ**S*"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% &3XI\!Z'XXM_)UK1=)UB'&-E[:1W"XY[.".Y_,U
MYKXE_8 ^"?BQV:\^%O@A6<Y9K;2HK5F//),04YY/U_ 5[!11=@?-&L?\$?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX/\ >23TJ27V5WA%_*4M=DFRBBBOVT_F8**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR;U;;U;;[MA1116QSA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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##__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>exel-20201002_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2020-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:exel="http://www.exelixis.com/20201002"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="exel-20201002.xsd" xlink:type="simple"/>
    <context id="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i889d2f8991ef4018930cd672e669b490_I20201026">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2020-10-26</instant>
        </period>
    </context>
    <context id="iccc3837038f342898d73d67395904bae_I20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2020-10-02</instant>
        </period>
    </context>
    <context id="ie736426c8e19488ea872e8da8ebb6578_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="ia527955beb274c50967751e32dc17dff_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i663049bc589a41de99b922b6fb02f1bc_D20190629-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="iefbb93ab12054c04a4d0d55ad1aaf502_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i75b81eceef094c2d86c24a00c59294e1_D20181229-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="ie72938b556dd42ada9b416a6b60b47fa_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="ic55505ff13f844188fb0751728d84cce_D20190629-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="i47085b4d4dbd42ac8d6b0c47740109da_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i98f01433b4094674bd5e812d8d00d234_D20181229-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="i25bf6a1fad8f41f8b3dd9743b6494697_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i88aea9011a624e6ab196817bcb69590c_D20190629-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="iced2a1e2c6a1480d8302a1285f8e233c_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i43a6c75a975a475a8220f03f17c813e5_D20181229-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="i316676d09b8a43edb69e0d908574a669_I20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-03</instant>
        </period>
    </context>
    <context id="i02f1924710584639831de419a08af15c_I20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-03</instant>
        </period>
    </context>
    <context id="i46f2d57ee3234492ae78920271a99b39_I20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-03</instant>
        </period>
    </context>
    <context id="i49c13447908e420384b91c447fbe71a9_I20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-03</instant>
        </period>
    </context>
    <context id="i4e76b251fbeb42f3a7cc3df6ca3a4230_I20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2020-07-03</instant>
        </period>
    </context>
    <context id="ic40a4137775f410490cca3ab2ec24c82_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="ie823ac87cfcf453da0d0ee469a5208a4_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i0f63bc8277444a159ea4d49770eaf477_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i97e9d031387d43198b6f05ff2861f3ab_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="ida20c4eb650547409d09265abf22aef1_I20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-02</instant>
        </period>
    </context>
    <context id="i9a1eac7bffc9475a9bbdda86813fd7ee_I20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-02</instant>
        </period>
    </context>
    <context id="ic7bf961275044b01a0c4a9ccebad588f_I20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-02</instant>
        </period>
    </context>
    <context id="i8a5031970ae845a8b4d0e06e3e6e4934_I20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-02</instant>
        </period>
    </context>
    <context id="i6c1980f2c4f24d4baa81b1ccba73febb_I20190628">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="i013e4989ee6443b9afcc82a956f959f9_I20190628">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="ib0dbb32931e346bfae3a3ca347f978ab_I20190628">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="i7ad7ce0b72c9496489178748e0770609_I20190628">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="if77bb429cb9c49c7a19d55f3f313ee70_I20190628">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="ifd7f360120b34b36ae5e37843a1f7fd3_D20190629-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="ib60dcfd8f46a44b6b0c8dfc25001dd5e_D20190629-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="i8ab198a265ed4c0494a01c26fc2f82c7_D20190629-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="i1082fd4f150346c182b846e3072e0c3f_D20190629-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="i05f14b5dcf314304b309c5e87df9f50a_I20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="i1c6f2cb1dfbd41acbc289114955cd416_I20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="i3dac2e6ea3d14a2e8cc5b92c6af71211_I20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="ic827287aa3294c6a883bc9d0b8a0623f_I20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="i34bbe41183cc4f96afa896c1d7f86bb3_I20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="i1f39a5eecfd64bbdb16dc650b0f43744_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="ia8909ade88d7423e92687245874b7f72_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="ic6b255ea4abe49edafb55d811bcad05b_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="i2614e82c41c1401c802f3cfcc0fa0efe_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="ia5ea39c6afc94359bbe264fb14b43e10_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="icdb2053635ce46b7b040cfe89917a2b4_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="id485c543ae654a6fa7b0799bc9c76368_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i168c5944094040729529b381e8529300_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="ifad3e2a4eb5e4ee8a6ee49d932419d11_I20181228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="i13b4a5caa8a046bb9f6cc3529e516e24_I20181228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="i1277e0158f8545d28d0907eafd290af9_I20181228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="i18bb90a064a742e5b5735480b882cb98_I20181228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="i010170af21d84cd898d00c6336993dba_I20181228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="i3d7219d185874a2188412be82a05f1ee_D20181229-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="i1aaa1630501a4eb1839161674cac9e08_D20181229-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="i7b32b70c60b14ff19391f59a6db9dd0e_D20181229-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="i6dab0b7d12c64bcfa11c169e3789d3bf_D20181229-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="if5e8e1669be6453aa3ae0fc322692c38_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ResultingFromDiscoveryEffortsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="ibe41da152065437483e7469fa266c06d_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductsDerivedFromCabozantinibMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="ie9df0cd737b54a18828c9607339f712f_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductsDerivedFromOtherCompoundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i6b8fc82f50494df690850a723f567147_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">exel:NewInformationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i53d5d16c99e24b1685ffd6417b746dc5_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i988d96d56fc8488e825029b9ae6e78da_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="ib4f8f5605ff6401098c5e709f8d70e2f_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:MckessonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i1d8dbceba046414c9646347dd14f559d_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:MckessonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="i6b8d3dbc1c5648e68dcec00585f82d14_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i458bde72c5d5486cb34c5d501fb3ca84_D20190629-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="ie5535b1b3b1a487ea1ac2f456daeae47_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i7500a3b3560547179833f5e227db7a5c_D20181229-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="i2148af2d149c45dbb0c184eb9a166068_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i5ed764ccd2a94897aeb76c66da22a057_D20190629-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="ifbbf27901590404f947e7e8da56664d3_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="ib6d312e664d54a13a0bb0c707a911341_D20181229-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="id85db556f50145f28ee780d1a8a89976_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="ib1234ea649134872b48e4dbb76f2d830_D20190629-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="i53da4333857a41c596e180b7605fb101_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i0d89b0fff8f440c5a47f0e0cbadc2d30_D20181229-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="ide4bbab6cf384b57a9b8addbd0e12d37_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="iad9dc86bff5e482395fb34a230d3bce2_D20190629-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="i97faf5b0431f41eeafdc9b84f69366b6_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="icdccf6af360349f19712f9f78dc3b258_D20181229-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="ide08272d8494485aa3f67140ad87e288_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i0c63f161b29d440b983b8d7886c07431_D20190629-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="if80a8f9a26734cc1a3ab10698b7d38d1_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="ic2a58f6e8634467fbb6096248e57b129_D20181229-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="ia60d29d213b7423f8b44089dbc426396_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i84172e8ba8944bff9097e2420fc4a71d_D20190629-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="i386a27a71d1b4955bcbcf10ffefe4dc9_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="icc5620147c964216bca8a91f88f53db3_D20181229-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="ib86d0fb1dcd542688f1f82783390f7d7_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i73d4427b07944bb4a39082c52e7e3993_D20190629-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="i5702087f6d044b2f8cb91e6d9e024981_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i185156eb44914a05b07e512b521ee175_D20181229-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="i1a1a12d3a1e34e64be6756a38f99157b_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i7fe0056abef84c0fb63cfb73f2dbaf5e_D20190629-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="i70fe222147914251b9dc10ce75948cf9_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="iacd7fc12f88842b1924368fbbf75cc1f_D20181229-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="i14e1a35d582a44a0a5026811d269e717_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="iced8dcb1cd6a410d8111f8781e04944b_D20190629-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="id929db05799d4a7ea908997e18680ab8_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="iaabc597e0f5940e89c79670faf29f78e_D20181229-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="i3d6b1d115ff4494fb1233255cd7c2c19_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofOptumSpecialtyPharmacyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i54ae6ae3ffc442a5b7b73749a9ee7058_D20190629-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofOptumSpecialtyPharmacyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="iff89a893303e4fa882dc5129bcbfb868_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofOptumSpecialtyPharmacyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="ief5d2999265b4a7ba5bbc8848a958c41_D20181229-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofOptumSpecialtyPharmacyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="i586e46eec28e45cc9e06428a8195d748_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:TakedaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i7d79b47a315146babea975fec8dce552_D20190629-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:TakedaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="i3cb1cfcba4a24a5a95475dcd23a6d6a7_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:TakedaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i3a9ff92761624c878e628676f2c878f8_D20181229-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:TakedaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="iec0582c68f2e45809336de61a7ef2ffe_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i71b0e797d9454761a9c3b48ce0cd6dc7_D20190629-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="i0e8cff04ca5040a68e2a49c6e3601c97_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i62c0d9fe6a22430782ddc2b6e95e7fea_D20181229-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="if3a34af32f82425db5a92b122c952662_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="iec35a82156214e73aba68b440656efba_D20190629-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="id6b900d2f20e47d098b552ec62a9e8d6_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="ie38bb019719d40208f85caefe75b164d_D20181229-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="i3b85521d483a41f38d661425a8820625_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i2db6d59506ab40b9822586497086d157_D20190629-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="i477ac2490d6a414281cc99f9812014e7_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i65978d0dcb28411cb73d35911d6e8d6c_D20181229-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="i67b11a0135a641a4bd4d22e09f7bfbcf_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="i504cbdf3907f4152872efaf0c542118f_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="i2b422997cdc1458bb19aa47286284ef0_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="i5bb996de5a5f41699a6974a3f048c443_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="ic9fee7c5808d4690b34490b6ca50b8db_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i8b664d4199b94af5a11e4871fd387735_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="ie771b9f5649b4d37b25de019253cf120_I20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-02</instant>
        </period>
    </context>
    <context id="i07e441c2da394ce2b81f3584524ba9a1_I20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-02</instant>
        </period>
    </context>
    <context id="if2f14853d41346db96816c2397b0613f_I20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-02</instant>
        </period>
    </context>
    <context id="icef64ef981c4433ab4d95dd86f4c12ae_I20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-02</instant>
        </period>
    </context>
    <context id="i0813edb6dc1f42149871864785a370b0_I20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:TakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-02</instant>
        </period>
    </context>
    <context id="ic563e3038d034910b191aa2e402f2d54_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i306ec623b7da464887c212d6bbb0c3b9_D20190629-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="ie769fec28ac9424ab1612b636240244f_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i2b97daa6c5714e879d52e0f5818a13e5_D20181229-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="i625c660e5c2c47ffba3e54c798ef1200_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="icb1de3b33b4e4d3ea045adf1503e5b39_D20190629-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="ie8fed9d02b6e436ebb1928ac49eccab8_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i39ac5c13a0c242ad9f5edee49b33dee7_D20181229-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="i911b510538cf4e2e9af50c7bbb5b99af_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i7142efd22e1049f7852952c299c3d936_D20190629-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="ib2cd405124b14735b901658a7069f2a6_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="iccf5e837fe3f43d6856e3b446cd61ef1_D20181229-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="ia423630adad04538bc955c381c570336_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i5df4d5352b0b4f0ba481cb03390bc3df_D20190629-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="ibcb0ee440b7e4dc0b3ff4215f20b3b2d_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="ie6551575ad754a52ade8c9bd7ebfa664_D20181229-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="i17097e4a7b2744f3bb555de0fd06a162_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i6130e6433ae14ecf9e3154f44ad89dcd_D20190629-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="ia4048c98f09848dc973a93054bfd645e_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="ieffdd922a5584f5fb2c96d614a69b68c_D20181229-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="ieb095da3afbd4daa9861c6249817cea0_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i16a003aa5aa5428887c9c411dbc420fc_D20190629-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="i32bf9affdda745209b77e77dfc211f15_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i350a22df21c64d1c93c2524af875b962_D20181229-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="i0b512ec06edc41c18dbe1037421ea9bb_I20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-02</instant>
        </period>
    </context>
    <context id="ia8670170a5094b3b904e1504aafbac8c_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:GlaxoSmithKlineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="if6d4cedf8c084744ba29969039e3b2e9_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i8dbb49564117496fb5290d851754b098_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i681117f1aebd445288c3a111845dc5c8_D20190629-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="i71974296a61b4d89993136d3ef36daed_D20181229-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="id774200cb5964ec7a9f457d6f01d6879_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CotellicMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i3042085c439a4f33a184caed0a43f26b_D20190629-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CotellicMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="i435fea9408f448279983514e753b98c2_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CotellicMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i54179f4a09954324b9f756384579283e_D20181229-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CotellicMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="i02e9b643d49a417e9373b15e166ba536_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementWithCatalentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i4f29e6a4d7e4442a814e495bb866df20_I20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementWithCatalentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-02</instant>
        </period>
    </context>
    <context id="i6b107f2541f144959f65cffe2682f793_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementWithNBETherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i9dc3e9657668420dbfcde5f6032f0548_I20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementWithNBETherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-02</instant>
        </period>
    </context>
    <context id="i5d1bc4ca714746459025e3f4409d9cd3_I20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-02</instant>
        </period>
    </context>
    <context id="i51a81230a1d74e55a2566c55413e2b2a_I20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-02</instant>
        </period>
    </context>
    <context id="i9ba278ad76ca4fcd841ffefc73154898_I20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-02</instant>
        </period>
    </context>
    <context id="id17bab0418ae471988fdfa84040140f1_I20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-02</instant>
        </period>
    </context>
    <context id="ifac6d9b9d2944e76a0f5c167b3983bc0_I20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-02</instant>
        </period>
    </context>
    <context id="ideca50ba198246c68d0bffddd169057c_I20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-02</instant>
        </period>
    </context>
    <context id="i58a13023c0dd450eb2ee0d861f56e766_I20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-02</instant>
        </period>
    </context>
    <context id="i0f9a560b1450471a9fb3a5226dea5132_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="ic27aa82f118547bcaca2790c33dd963b_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="i7f0bf831f83f4af59172086b8a97f3c4_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="i785b48358c27484689107bc80f7a2cbb_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="i28526894a4b14f39b408ab8db78be75d_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="i1800b81e21784d189946618c1ae33956_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="ieadeb951ef494630818c3cc30b3da393_I20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-02</instant>
        </period>
    </context>
    <context id="i0aad2b7015eb477c88c1ea01262ba619_I20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-02</instant>
        </period>
    </context>
    <context id="ia338dcf4e5144bef8ca2ebd43f622d04_I20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-02</instant>
        </period>
    </context>
    <context id="i214b7f1c98384cd7ae5d32548266b97b_I20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-02</instant>
        </period>
    </context>
    <context id="i2e427409ff9d4828a3b7640315fdf49b_I20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-02</instant>
        </period>
    </context>
    <context id="i7ea639c496fd491897fbb9c377110819_I20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-02</instant>
        </period>
    </context>
    <context id="i14689612fde84c3c940d88d417602b2a_I20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-02</instant>
        </period>
    </context>
    <context id="i105a4d34d1764fab907327463ccad490_I20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-02</instant>
        </period>
    </context>
    <context id="i5b6ffe686868432ab9437a164687d998_I20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-02</instant>
        </period>
    </context>
    <context id="i5c82661404c1488b9aa5b0c3a43ca9f4_I20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-02</instant>
        </period>
    </context>
    <context id="ic69aa2cb176f4a9aa647d6c00a697fb9_I20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-02</instant>
        </period>
    </context>
    <context id="ibbb5a720eff3482091e3be625d787981_I20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-02</instant>
        </period>
    </context>
    <context id="i8d11a44c584e4c27b4cd486045540585_I20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-02</instant>
        </period>
    </context>
    <context id="i6891e843a55d40c9a8f7f81e029810ef_I20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-02</instant>
        </period>
    </context>
    <context id="ia145ea6fe2c34f45a3f0710801bc6531_I20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-02</instant>
        </period>
    </context>
    <context id="i295ed1efaf864ae9b0abe578705aae7c_I20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-02</instant>
        </period>
    </context>
    <context id="i8b2d74b62bf14b7399c48b032c3050fa_I20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-02</instant>
        </period>
    </context>
    <context id="iecc5d76d94114b538c7cc261d3d7dbb9_I20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-02</instant>
        </period>
    </context>
    <context id="i7eec7f6e4801439489ec8ab44f13dca5_I20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-02</instant>
        </period>
    </context>
    <context id="ife2cb38c2462497fb4f2be87aacfcbe9_I20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-02</instant>
        </period>
    </context>
    <context id="i3e13458d32e445e6a3bdc3140700b3ef_I20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-02</instant>
        </period>
    </context>
    <context id="i727f7c37fa244a2d96022ada5bf8347f_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="ie98bf240c97e447183ba8f88a167242d_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="i4d639ed777ff435ea5b6c19441e7ecff_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="i8d9829f5158045228bedb41708d21afd_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="i7facc890253843839cb983e5f0c5d14c_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="i77e3015ed1f944988e83d686ba77f015_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="ie5fb7e2d38294fdaa468d8855b980731_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="ia2b721b19a1d4ee8a556e85a2c797759_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="i7b010574af4c409fa174a0bc4c2b34e1_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="icefaee59f19a40b0bbd4de9922c8c59c_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="if4060e618697434cad36b5db4d7c6111_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="ifd8e36118a87443ca78892462d27bfab_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="i09f2281bdf9349038431afc18379805b_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="ie9c4cc15650340169d2372d82bde6360_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="i362da4b860134a89851c683e142464ef_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="ic072d7bdc3a747c3aa29c10bd5bd37e7_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="i76745aad80e54832855f5e01889a5b33_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="i4c5d87cfd74f40ccabd0feeeecbb37cd_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="i6de1a52cb79c40518135c31ed1ad1ba2_I20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-02</instant>
        </period>
    </context>
    <context id="i24f6503be5494081a0dbe6c993e81397_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="ifbece5f4cfff4192b62909c119134d4d_I20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:OtherLongtermAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-02</instant>
        </period>
    </context>
    <context id="i91d78c6281004d5e860e9762ede7f244_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:OtherLongtermAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="id8807e50c23c4d31ab20dcdcebd143c7_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i6d73a25521cd47598eec943fc3e67f0b_D20190629-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="id10dbcb3d9244b64b3c0a11867e5072c_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i2730b1b9796c4aaaa8efe5695e985946_D20181229-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="i94716cdf2585476f8d2241789b25429d_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="ia84c18733f11427b85d537694ee6b742_D20190629-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="ife7f80399bf046279aeacfddc3d5cb35_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="ifb17c6080fe0476e875c10f986a8b090_D20181229-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="i6084a0d4002647d69b2148895c55cbd9_D20200520-20200520">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2020-05-20</startDate>
            <endDate>2020-05-20</endDate>
        </period>
    </context>
    <context id="i6c137f0c3b874241af6cdf35240fc6c4_I20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-02</instant>
        </period>
    </context>
    <context id="ie7840df292b24b97a39df16ab6f9e94c_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="ib477ff76a01e469abd582edacf5f60b7_I20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-02</instant>
        </period>
    </context>
    <context id="i2fa39753eebb4b2da55065a78f952a39_D20180101-20181228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:PerformanceShareOptionsPSOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="i91d293b87e5445f5b5b67e1a9c37b9d2_I20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-02</instant>
        </period>
    </context>
    <context id="i4972ebe551a741e48565ab4e7bcd8df1_I20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:StatusAxis">exel:AchievedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-02</instant>
        </period>
    </context>
    <context id="i1e5cec7e0ab144f59216d279d7df965d_I20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:StatusAxis">exel:ProbableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-02</instant>
        </period>
    </context>
    <context id="i21aab8a484c04ec2a5cff2d96ab82dbd_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i7550f0f67bcf428b9b1a23a22d59a795_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i41f51136e2dd4492aea05277671e9389_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="if970e9016fc3406ea7bb57cbb0786e20_D20190629-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="ib0cf80d622b4495e8ba855ad5bbe6234_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i01d75cb9987e4a6e9148d6e76b57e666_D20181229-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="product">
        <measure>exel:product</measure>
    </unit>
    <unit id="segment">
        <measure>exel:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="investment">
        <measure>exel:investment</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80L2ZyYWc6MzhmYWFlNjhmMzU5NDQ3NGJmMWJmZDZmNzNiMzA5ZTkvdGFibGU6MmYwYWE3NTg5ZGE2NDM0YWIxOWQzMDE0ODE0MDRmNzcvdGFibGVyYW5nZToyZjBhYTc1ODlkYTY0MzRhYjE5ZDMwMTQ4MTQwNGY3N18yLTEtMS0xLTA_1500a88a-62f6-4d42-88e2-e654a21e24cc">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80L2ZyYWc6MzhmYWFlNjhmMzU5NDQ3NGJmMWJmZDZmNzNiMzA5ZTkvdGFibGU6MmYwYWE3NTg5ZGE2NDM0YWIxOWQzMDE0ODE0MDRmNzcvdGFibGVyYW5nZToyZjBhYTc1ODlkYTY0MzRhYjE5ZDMwMTQ4MTQwNGY3N180LTEtMS0xLTA_9e5d612d-7c74-44e3-838a-4271a91fa74e">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80L2ZyYWc6MzhmYWFlNjhmMzU5NDQ3NGJmMWJmZDZmNzNiMzA5ZTkvdGFibGU6MmYwYWE3NTg5ZGE2NDM0YWIxOWQzMDE0ODE0MDRmNzcvdGFibGVyYW5nZToyZjBhYTc1ODlkYTY0MzRhYjE5ZDMwMTQ4MTQwNGY3N181LTEtMS0xLTA_2291d85b-ecb9-47c9-9d8d-df4628e80f37">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80L2ZyYWc6MzhmYWFlNjhmMzU5NDQ3NGJmMWJmZDZmNzNiMzA5ZTkvdGFibGU6MmYwYWE3NTg5ZGE2NDM0YWIxOWQzMDE0ODE0MDRmNzcvdGFibGVyYW5nZToyZjBhYTc1ODlkYTY0MzRhYjE5ZDMwMTQ4MTQwNGY3N182LTEtMS0xLTA_c2684032-71f4-48d1-a4be-cf0dc4b0a31b">0000939767</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80L2ZyYWc6MzhmYWFlNjhmMzU5NDQ3NGJmMWJmZDZmNzNiMzA5ZTkvdGFibGU6MmYwYWE3NTg5ZGE2NDM0YWIxOWQzMDE0ODE0MDRmNzcvdGFibGVyYW5nZToyZjBhYTc1ODlkYTY0MzRhYjE5ZDMwMTQ4MTQwNGY3N183LTEtMS0xLTA_1a1509a8-facf-4724-88ed-5be04108837d">--01-01</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xL2ZyYWc6NzYyMWE0NTkyM2ExNDQ2Mzg0N2JiYjk0N2RjMmZiMDMvdGFibGU6YjBkNmYxMzliZDIzNDE1MmI5M2ZhNzUzODA4OTYzY2MvdGFibGVyYW5nZTpiMGQ2ZjEzOWJkMjM0MTUyYjkzZmE3NTM4MDg5NjNjY18wLTEtMS0xLTA_f399f45b-7de3-492e-8d3a-bf5ddfb505b1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xL2ZyYWc6NzYyMWE0NTkyM2ExNDQ2Mzg0N2JiYjk0N2RjMmZiMDMvdGFibGU6OGUxZjgzZWE4ZTkxNDY5ZmE1NDMxYTQxNDIxODk3ZDgvdGFibGVyYW5nZTo4ZTFmODNlYThlOTE0NjlmYTU0MzFhNDE0MjE4OTdkOF8wLTAtMS0xLTA_c48fbd04-6583-4df2-832f-4de5c4e1134e">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xL2ZyYWc6NzYyMWE0NTkyM2ExNDQ2Mzg0N2JiYjk0N2RjMmZiMDMvdGV4dHJlZ2lvbjo3NjIxYTQ1OTIzYTE0NDYzODQ3YmJiOTQ3ZGMyZmIwM18xMTQ_f5106220-a284-4728-8b7e-900129e272fb">2020-10-02</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xL2ZyYWc6NzYyMWE0NTkyM2ExNDQ2Mzg0N2JiYjk0N2RjMmZiMDMvdGFibGU6Yjg4YmQ4MWM3OWMxNDUzZGI3YWQ0MGQzYmUxMzNhNWMvdGFibGVyYW5nZTpiODhiZDgxYzc5YzE0NTNkYjdhZDQwZDNiZTEzM2E1Y18wLTAtMS0xLTA_53bb0400-c872-438b-8a16-017dfeb9301e">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xL2ZyYWc6NzYyMWE0NTkyM2ExNDQ2Mzg0N2JiYjk0N2RjMmZiMDMvdGV4dHJlZ2lvbjo3NjIxYTQ1OTIzYTE0NDYzODQ3YmJiOTQ3ZGMyZmIwM18xODc0_c991cace-a6ee-42d4-9094-e3eeb7f3a0c1">000-30235</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xL2ZyYWc6NzYyMWE0NTkyM2ExNDQ2Mzg0N2JiYjk0N2RjMmZiMDMvdGFibGU6MWI5YWExMDRjYTE3NGRiYThmOGU3NDA4ZDM1ZjY1MzcvdGFibGVyYW5nZToxYjlhYTEwNGNhMTc0ZGJhOGY4ZTc0MDhkMzVmNjUzN18xLTAtMS0xLTA_8df3c23f-7598-4947-8c9f-d363f8b8bfa1">EXELIXIS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xL2ZyYWc6NzYyMWE0NTkyM2ExNDQ2Mzg0N2JiYjk0N2RjMmZiMDMvdGFibGU6MWY3NmU2ZDYzNTBiNDhiNzk2MTMzZDBiOWZmYjRiYTIvdGFibGVyYW5nZToxZjc2ZTZkNjM1MGI0OGI3OTYxMzNkMGI5ZmZiNGJhMl8wLTAtMS0xLTA_006dbb54-f120-496a-89aa-87aeaf7be800">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xL2ZyYWc6NzYyMWE0NTkyM2ExNDQ2Mzg0N2JiYjk0N2RjMmZiMDMvdGFibGU6MWY3NmU2ZDYzNTBiNDhiNzk2MTMzZDBiOWZmYjRiYTIvdGFibGVyYW5nZToxZjc2ZTZkNjM1MGI0OGI3OTYxMzNkMGI5ZmZiNGJhMl8wLTEtMS0xLTA_5174f5d8-7902-4bf7-b6b2-e05c9fb75032">04-3257395</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xL2ZyYWc6NzYyMWE0NTkyM2ExNDQ2Mzg0N2JiYjk0N2RjMmZiMDMvdGV4dHJlZ2lvbjo3NjIxYTQ1OTIzYTE0NDYzODQ3YmJiOTQ3ZGMyZmIwM18xODc1_fc054253-3249-4434-bd7f-de762dc6f98a">1851 Harbor Bay Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xL2ZyYWc6NzYyMWE0NTkyM2ExNDQ2Mzg0N2JiYjk0N2RjMmZiMDMvdGV4dHJlZ2lvbjo3NjIxYTQ1OTIzYTE0NDYzODQ3YmJiOTQ3ZGMyZmIwM18xODgx_94f19f27-5134-4ee1-b237-83d30183ca00">Alameda,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xL2ZyYWc6NzYyMWE0NTkyM2ExNDQ2Mzg0N2JiYjk0N2RjMmZiMDMvdGV4dHJlZ2lvbjo3NjIxYTQ1OTIzYTE0NDYzODQ3YmJiOTQ3ZGMyZmIwM18xODc2_00fe4bac-f355-4aeb-b89e-2623be49c91e">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xL2ZyYWc6NzYyMWE0NTkyM2ExNDQ2Mzg0N2JiYjk0N2RjMmZiMDMvdGV4dHJlZ2lvbjo3NjIxYTQ1OTIzYTE0NDYzODQ3YmJiOTQ3ZGMyZmIwM18xODc3_6f453961-101e-4dc2-a97c-8e1bd1bd6034">94502</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xL2ZyYWc6NzYyMWE0NTkyM2ExNDQ2Mzg0N2JiYjk0N2RjMmZiMDMvdGV4dHJlZ2lvbjo3NjIxYTQ1OTIzYTE0NDYzODQ3YmJiOTQ3ZGMyZmIwM18xODgy_a7a7aaa7-d512-415a-aad5-153bf58b543c">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xL2ZyYWc6NzYyMWE0NTkyM2ExNDQ2Mzg0N2JiYjk0N2RjMmZiMDMvdGV4dHJlZ2lvbjo3NjIxYTQ1OTIzYTE0NDYzODQ3YmJiOTQ3ZGMyZmIwM18xODgz_8bddab05-3792-429c-b2f6-251a5cb91ddf">837-7000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xL2ZyYWc6NzYyMWE0NTkyM2ExNDQ2Mzg0N2JiYjk0N2RjMmZiMDMvdGFibGU6OTkxNjgxMjE4MmZhNGJjNjhiN2JmMWZkOTY3MDY1OTMvdGFibGVyYW5nZTo5OTE2ODEyMTgyZmE0YmM2OGI3YmYxZmQ5NjcwNjU5M18xLTAtMS0xLTA_11fedd6d-336c-4e80-926f-7f1954a006c5">Common Stock $.001 Par Value per Share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xL2ZyYWc6NzYyMWE0NTkyM2ExNDQ2Mzg0N2JiYjk0N2RjMmZiMDMvdGFibGU6OTkxNjgxMjE4MmZhNGJjNjhiN2JmMWZkOTY3MDY1OTMvdGFibGVyYW5nZTo5OTE2ODEyMTgyZmE0YmM2OGI3YmYxZmQ5NjcwNjU5M18xLTEtMS0xLTA_814dbcc7-9a1b-48b8-9315-c7a960021705">EXEL</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xL2ZyYWc6NzYyMWE0NTkyM2ExNDQ2Mzg0N2JiYjk0N2RjMmZiMDMvdGFibGU6OTkxNjgxMjE4MmZhNGJjNjhiN2JmMWZkOTY3MDY1OTMvdGFibGVyYW5nZTo5OTE2ODEyMTgyZmE0YmM2OGI3YmYxZmQ5NjcwNjU5M18xLTItMS0xLTA_445ec0bb-7bfb-4d50-a4e3-72c1f721d76b">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xL2ZyYWc6NzYyMWE0NTkyM2ExNDQ2Mzg0N2JiYjk0N2RjMmZiMDMvdGV4dHJlZ2lvbjo3NjIxYTQ1OTIzYTE0NDYzODQ3YmJiOTQ3ZGMyZmIwM18xODc4_a12baf35-c5ac-490b-a759-a5f9faf342a3">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xL2ZyYWc6NzYyMWE0NTkyM2ExNDQ2Mzg0N2JiYjk0N2RjMmZiMDMvdGV4dHJlZ2lvbjo3NjIxYTQ1OTIzYTE0NDYzODQ3YmJiOTQ3ZGMyZmIwM18xODc5_2b86d76e-917b-4f9a-bcb4-a14ff1c664ba">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xL2ZyYWc6NzYyMWE0NTkyM2ExNDQ2Mzg0N2JiYjk0N2RjMmZiMDMvdGFibGU6ZGIzMzQzNzk5MDliNGYxYjkzZWM3NzAzOTcwMjE3YjkvdGFibGVyYW5nZTpkYjMzNDM3OTkwOWI0ZjFiOTNlYzc3MDM5NzAyMTdiOV8wLTAtMS0xLTA_3445ea10-09be-4d23-9346-2b413d204152">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xL2ZyYWc6NzYyMWE0NTkyM2ExNDQ2Mzg0N2JiYjk0N2RjMmZiMDMvdGFibGU6ZGIzMzQzNzk5MDliNGYxYjkzZWM3NzAzOTcwMjE3YjkvdGFibGVyYW5nZTpkYjMzNDM3OTkwOWI0ZjFiOTNlYzc3MDM5NzAyMTdiOV8xLTQtMS0xLTA_ce339056-25cf-42e7-916e-b6ab21ac4a10">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xL2ZyYWc6NzYyMWE0NTkyM2ExNDQ2Mzg0N2JiYjk0N2RjMmZiMDMvdGFibGU6ZGIzMzQzNzk5MDliNGYxYjkzZWM3NzAzOTcwMjE3YjkvdGFibGVyYW5nZTpkYjMzNDM3OTkwOWI0ZjFiOTNlYzc3MDM5NzAyMTdiOV8yLTEtMS0xLTA_a0ae8ddc-138e-4eed-ab35-7282b5642dae">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xL2ZyYWc6NzYyMWE0NTkyM2ExNDQ2Mzg0N2JiYjk0N2RjMmZiMDMvdGV4dHJlZ2lvbjo3NjIxYTQ1OTIzYTE0NDYzODQ3YmJiOTQ3ZGMyZmIwM18xODgw_e733ed17-0c3b-4ec4-b439-8dc69b91fb21">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i889d2f8991ef4018930cd672e669b490_I20201026"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xL2ZyYWc6NzYyMWE0NTkyM2ExNDQ2Mzg0N2JiYjk0N2RjMmZiMDMvdGV4dHJlZ2lvbjo3NjIxYTQ1OTIzYTE0NDYzODQ3YmJiOTQ3ZGMyZmIwM18xODE5_80dddb64-6428-493e-9aa8-67971b82fc59"
      unitRef="shares">310243961</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfNy0xLTEtMS0w_edaafdff-accb-4a66-b9e3-aac9c8e44aec"
      unitRef="usd">334046000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfNy0zLTEtMS0w_e7e1a5fe-b5b6-4b14-9829-b36d5e6358c1"
      unitRef="usd">266501000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfOC0xLTEtMS0w_6aa44340-f734-4d18-8e34-e4d0ecac75b5"
      unitRef="usd">853835000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfOC0zLTEtMS0w_3d67b824-eba2-4e52-add4-6452b67a5d0e"
      unitRef="usd">585742000</us-gaap:ShortTermInvestments>
    <us-gaap:ReceivablesNetCurrent
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfOS0xLTEtMS0w_254ff3c5-4760-4238-aaef-9ce3f616d5e0"
      unitRef="usd">166138000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfOS0zLTEtMS0w_227f2625-72a8-43b5-9382-4296ff98e577"
      unitRef="usd">119073000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:InventoryNet
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMTAtMS0xLTEtMA_c7ce7cf2-e265-4bac-87fc-fff50d81e140"
      unitRef="usd">19319000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMTAtMy0xLTEtMA_384c74b0-eff7-433a-a3d1-8bc270be3054"
      unitRef="usd">12886000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMTItMS0xLTEtMA_9c5f9341-200e-4ca4-907e-048189321a83"
      unitRef="usd">34470000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMTItMy0xLTEtMA_62300794-6ea8-4f64-8e44-9f31308d5191"
      unitRef="usd">26988000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMTMtMS0xLTEtMA_b7ae591e-7bd9-4eff-b0d6-a5063351c16f"
      unitRef="usd">1407808000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMTMtMy0xLTEtMA_ac891fa4-39a3-484b-850e-4c0845c23f11"
      unitRef="usd">1011190000</us-gaap:AssetsCurrent>
    <us-gaap:LongTermInvestments
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMTQtMS0xLTEtMA_85c51585-4e73-45c0-a2e0-62e7a4aeb3b2"
      unitRef="usd">358079000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMTQtMy0xLTEtMA_3abf92e8-e92b-4fb3-b206-4c8065569eea"
      unitRef="usd">536385000</us-gaap:LongTermInvestments>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMTUtMS0xLTEtMA_2b9046d3-1b4b-4f80-bc6e-8b3705c78223"
      unitRef="usd">56385000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMTUtMy0xLTEtMA_76b670d3-8a00-41f2-b0f8-44c4f863e573"
      unitRef="usd">48892000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMTYtMS0xLTEtMA_8735999c-da2f-4323-a10a-93bb40a754a3"
      unitRef="usd">155678000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMTYtMy0xLTEtMA_634414dc-a874-4349-bc86-d53a09a31910"
      unitRef="usd">172374000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:Goodwill
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMTctMS0xLTEtMA_0fd1d683-a696-42b0-8bb3-603d88194c8c"
      unitRef="usd">63684000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMTctMy0xLTEtMA_ec483cfc-b607-4c6d-9448-4cf39df7812c"
      unitRef="usd">63684000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMTgtMS0xLTEtMA_0e76a723-d58e-4384-a5fa-f0650ff59b5c"
      unitRef="usd">69409000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMTgtMy0xLTEtMA_1bd791ff-37ba-4ec1-92c0-c0544fb531a8"
      unitRef="usd">53145000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMTktMS0xLTEtMA_611471a4-780f-41fb-b039-7728b72d16a1"
      unitRef="usd">2111043000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMTktMy0xLTEtMA_294c412d-a287-4ed4-b031-c6120b1b37ff"
      unitRef="usd">1885670000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMjItMS0xLTEtMA_43867823-f91f-4c1c-b5f3-868a75bc59a2"
      unitRef="usd">47927000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMjItMy0xLTEtMA_c412d07a-0cd7-4f9d-b3ab-707c0a814562"
      unitRef="usd">11581000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMjMtMS0xLTEtMA_bf1fa1a3-0bb1-49c6-bc84-ec32dccf1ca6"
      unitRef="usd">40782000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMjMtMy0xLTEtMA_cba198c9-afa5-4511-8f34-b0a6187a6339"
      unitRef="usd">37364000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <exel:AccruedClinicalLiabilitiesCurrent
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMjQtMS0xLTEtMA_4ef9b0be-1aa9-41f3-81b2-adc6ccd8f5a0"
      unitRef="usd">47074000</exel:AccruedClinicalLiabilitiesCurrent>
    <exel:AccruedClinicalLiabilitiesCurrent
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMjQtMy0xLTEtMA_bc2de38e-ea4f-4200-b01b-4f691f2a702c"
      unitRef="usd">38777000</exel:AccruedClinicalLiabilitiesCurrent>
    <us-gaap:CustomerRefundLiabilityCurrent
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMjUtMS0xLTEtMA_2d718176-9d6a-4040-b71b-4b16be8eee80"
      unitRef="usd">19129000</us-gaap:CustomerRefundLiabilityCurrent>
    <us-gaap:CustomerRefundLiabilityCurrent
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMjUtMy0xLTEtMA_511bb0de-d224-4cb6-b55e-0704ec825af1"
      unitRef="usd">18719000</us-gaap:CustomerRefundLiabilityCurrent>
    <exel:AccruedCollaborationLiabilityCurrent
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMjYtMS0xLTEtMA_67c284c9-f86e-4f36-bb65-5939b20f51a5"
      unitRef="usd">11102000</exel:AccruedCollaborationLiabilityCurrent>
    <exel:AccruedCollaborationLiabilityCurrent
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMjYtMy0xLTEtMA_26d376d1-4f69-4f5a-9e45-fbfa58a0ad93"
      unitRef="usd">11856000</exel:AccruedCollaborationLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMjgtMS0xLTEtMA_535bd695-9999-4cf9-97c2-e1f15480c358"
      unitRef="usd">35329000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMjgtMy0xLTEtMA_7ea7eb5f-e386-482c-8c2c-a8d8e435400a"
      unitRef="usd">24449000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMjktMS0xLTEtMA_b4e0768d-edd3-46f0-9c18-e92063f0ceec"
      unitRef="usd">201343000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMjktMy0xLTEtMA_e52b0b2a-f57a-4f7f-a41f-f16fea458c56"
      unitRef="usd">142746000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMzAtMS0xLTEtMA_0705bc8c-c1b8-4ae4-b64c-2eea9d990b24"
      unitRef="usd">9322000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMzAtMy0xLTEtMA_d5535281-53dd-437e-a96a-a035bb7652fe"
      unitRef="usd">6596000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMzEtMS0xLTEtMA_9fa7f815-84ed-45d5-b999-e4b2d7d1fdd5"
      unitRef="usd">47626000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMzEtMy0xLTEtMA_91d2912f-d279-44b6-b7d8-849f1030a237"
      unitRef="usd">48011000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMzItMS0xLTEtMA_aa885db0-b803-4b18-977a-9b2d65d11b86"
      unitRef="usd">721000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMzItMy0xLTEtMA_adefb194-a1d3-4db7-91d2-64910ed5b9d8"
      unitRef="usd">2347000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMzMtMS0xLTEtMA_20f8f94d-1e4d-4ee9-a894-dfaaa461c025"
      unitRef="usd">259012000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMzMtMy0xLTEtMA_1f225ad5-140a-4831-957d-66fa57ec32e2"
      unitRef="usd">199700000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMzQtMS0xLTEtMA_74655d0c-3585-49f4-ac81-af58f627eeba"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMzQtMy0xLTEtMA_105a787c-0330-40f6-a7e5-e6da596bc0b8"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjdiNjJiZDZiNWE1ZTQwMmJhMGUyMzQwOGM3M2I2Y2JiXzEwOTk1MTE2Mjc4Njc_d76b876a-1318-4e9b-8efb-8fdbc0393108"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjdiNjJiZDZiNWE1ZTQwMmJhMGUyMzQwOGM3M2I2Y2JiXzEwOTk1MTE2Mjc4Njc_eef76bad-25da-4e5e-a08b-0220a27e1f7a"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjdiNjJiZDZiNWE1ZTQwMmJhMGUyMzQwOGM3M2I2Y2JiXzEwOTk1MTE2Mjc4Nzc_1862a00e-7c62-44e4-84af-bb0548d793ce"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjdiNjJiZDZiNWE1ZTQwMmJhMGUyMzQwOGM3M2I2Y2JiXzEwOTk1MTE2Mjc4Nzc_1f599f06-63c7-49d8-b75d-d250032817d5"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjdiNjJiZDZiNWE1ZTQwMmJhMGUyMzQwOGM3M2I2Y2JiXzEwOTk1MTE2Mjc4ODI_3aea053a-caf6-446f-b42a-0d8a9432223b"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjdiNjJiZDZiNWE1ZTQwMmJhMGUyMzQwOGM3M2I2Y2JiXzEwOTk1MTE2Mjc4ODI_472a1818-f0bc-47f9-83e0-6ff9da400efc"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMzYtMS0xLTEtMA_ad18083a-a3aa-4180-a0f8-6a93ad6cdc36"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMzYtMy0xLTEtMA_51c9e082-78d7-40b7-9123-bb53daf926a0"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjY4ZDY4NTQ5YjQ2NTRkYzBhODQ4YmU2NDhlNDM2MDRhXzEwOTk1MTE2Mjc5NzY_8712d35c-e19b-472c-9809-0c9bb956640e"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjY4ZDY4NTQ5YjQ2NTRkYzBhODQ4YmU2NDhlNDM2MDRhXzEwOTk1MTE2Mjc5NzY_f37b90b6-608b-4249-a87f-a7a20a416707"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjY4ZDY4NTQ5YjQ2NTRkYzBhODQ4YmU2NDhlNDM2MDRhXzEwOTk1MTE2Mjc5ODY_0730b9a4-ad42-4c54-877b-651ea944834d"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjY4ZDY4NTQ5YjQ2NTRkYzBhODQ4YmU2NDhlNDM2MDRhXzEwOTk1MTE2Mjc5ODY_4ef0b4bc-b1da-446f-80eb-4f9a476938a6"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjY4ZDY4NTQ5YjQ2NTRkYzBhODQ4YmU2NDhlNDM2MDRhXzEwOTk1MTE2Mjc5NTE_69523b6a-c663-4e03-ab06-6bfd99d5f069"
      unitRef="shares">309402000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjY4ZDY4NTQ5YjQ2NTRkYzBhODQ4YmU2NDhlNDM2MDRhXzEwOTk1MTE2Mjc5NTE_ba3779ff-f600-48ad-b09a-7a900d2f6171"
      unitRef="shares">309402000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjY4ZDY4NTQ5YjQ2NTRkYzBhODQ4YmU2NDhlNDM2MDRhXzEwOTk1MTE2Mjc5NjI_8f2221b6-c4e0-421a-a077-facd7ecccf1b"
      unitRef="shares">304831000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMzctMC0xLTEtMC90ZXh0cmVnaW9uOjY4ZDY4NTQ5YjQ2NTRkYzBhODQ4YmU2NDhlNDM2MDRhXzEwOTk1MTE2Mjc5NjI_9f5ab816-98a0-4645-96eb-64c27caf80b4"
      unitRef="shares">304831000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMzctMS0xLTEtMA_984945a9-eb25-4d64-a5f9-ea45cb52fca0"
      unitRef="usd">309000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMzctMy0xLTEtMA_e429110f-f9db-426c-aab8-16293ff2993d"
      unitRef="usd">305000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMzgtMS0xLTEtMA_3532ea22-2edf-47df-ad20-a05c1e0dca14"
      unitRef="usd">2321441000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMzgtMy0xLTEtMA_b68ab873-0853-4e9c-9d86-23db985d0cc6"
      unitRef="usd">2241947000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMzktMS0xLTEtMA_b834c722-9e42-46db-92ad-1fd3e04b29b3"
      unitRef="usd">6239000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfMzktMy0xLTEtMA_fc2277f4-5e40-445a-9382-18eff30a0d45"
      unitRef="usd">3069000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfNDAtMS0xLTEtMA_522a6152-6e63-4dae-b02d-de69446842f5"
      unitRef="usd">-475958000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfNDAtMy0xLTEtMA_5936b155-f7ee-464f-a86b-0cc006da851e"
      unitRef="usd">-559351000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfNDEtMS0xLTEtMA_f477b16c-8040-45f9-8ccd-e825ecc95703"
      unitRef="usd">1852031000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfNDEtMy0xLTEtMA_32504f6b-e594-4ff5-a5bd-a89b57bf7e19"
      unitRef="usd">1685970000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfNDItMS0xLTEtMA_612a5478-4057-4952-afad-1cec6a99e47f"
      unitRef="usd">2111043000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8xNi9mcmFnOjE4NzU0YTAzNGU2ZDQzMjFiZTY4NmM0ZmY3YWE3Y2YwL3RhYmxlOmYwZDdhOGI1MDk3ZjRmOTk5ZWRhNjdjZDgwMjQxZDkxL3RhYmxlcmFuZ2U6ZjBkN2E4YjUwOTdmNGY5OTllZGE2N2NkODAyNDFkOTFfNDItMy0xLTEtMA_4b147253-29ef-4015-926f-17585d594c0c"
      unitRef="usd">1885670000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia527955beb274c50967751e32dc17dff_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMy0xLTEtMS0w_3d02242e-90d7-43a7-a7b3-c4c1edfb3bb3"
      unitRef="usd">168587000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i663049bc589a41de99b922b6fb02f1bc_D20190629-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMy0zLTEtMS0w_fd819f17-a8c5-4a8b-a9bc-685488fb8b99"
      unitRef="usd">191768000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iefbb93ab12054c04a4d0d55ad1aaf502_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMy01LTEtMS0w_1d3efd23-055c-4446-a217-f43399b9d307"
      unitRef="usd">541197000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i75b81eceef094c2d86c24a00c59294e1_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMy03LTEtMS0w_615778d9-fa15-4ef0-8eaa-441ec490a96c"
      unitRef="usd">565024000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie72938b556dd42ada9b416a6b60b47fa_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfNC0xLTEtMS0w_6703c1b4-4147-4871-a2d7-8a09d86fd89d"
      unitRef="usd">33205000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic55505ff13f844188fb0751728d84cce_D20190629-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfNC0zLTEtMS0w_6f130490-08cf-4313-a2a0-aa497f6b24b6"
      unitRef="usd">69137000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i47085b4d4dbd42ac8d6b0c47740109da_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfNC01LTEtMS0w_79ff62aa-c761-40eb-8130-ecb165967708"
      unitRef="usd">113318000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i98f01433b4094674bd5e812d8d00d234_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfNC03LTEtMS0w_7ae6e83b-58d8-46a3-81de-e5d792000ad9"
      unitRef="usd">132443000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="i25bf6a1fad8f41f8b3dd9743b6494697_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfNS0xLTEtMS0w_db9876f8-23df-4efd-a3cf-8c3930714713"
      unitRef="usd">29300000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="i88aea9011a624e6ab196817bcb69590c_D20190629-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfNS0zLTEtMS0w_0f050580-54fc-4b47-b2c6-68d7784d122c"
      unitRef="usd">10798000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="iced2a1e2c6a1480d8302a1285f8e233c_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfNS01LTEtMS0w_d9893e92-456b-4aa0-aa42-4b799ab0a0ce"
      unitRef="usd">62971000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="i43a6c75a975a475a8220f03f17c813e5_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfNS03LTEtMS0w_49e693e5-97b7-47ca-874a-e97e9f598797"
      unitRef="usd">29998000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:Revenues
      contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfNi0xLTEtMS0w_ff19af56-07e7-4ec7-b06f-d81185f6e3d2"
      unitRef="usd">231092000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfNi0zLTEtMS0w_e0886dd0-db54-4615-8aaf-2c5811affafc"
      unitRef="usd">271703000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfNi01LTEtMS0w_f494c235-1440-49bb-83b5-2829fc0f5eb6"
      unitRef="usd">717486000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfNi03LTEtMS0w_0e30034c-5aab-4718-934e-923558b32ec6"
      unitRef="usd">727465000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfOC0xLTEtMS0w_3ff76d75-62a3-4677-b6dd-1e5e3ffda2f2"
      unitRef="usd">8725000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfOC0zLTEtMS0w_bb2df2f9-1b6c-4ed0-b0c4-2e47de7bbec3"
      unitRef="usd">7537000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfOC01LTEtMS0w_dcf4d975-b23b-4a53-bfbb-82a1294c9c67"
      unitRef="usd">27235000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfOC03LTEtMS0w_538040e9-e7bc-4c84-802f-370e4e9384c6"
      unitRef="usd">22577000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfOS0xLTEtMS0w_6a6f355f-65cf-4c97-9b39-5ae17cd07bde"
      unitRef="usd">176762000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfOS0zLTEtMS0w_13665dd9-3a9f-4e58-ab46-878ba0a48c8d"
      unitRef="usd">97295000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfOS01LTEtMS0w_7a57a545-fc53-4624-ab75-1f0dc6f11d74"
      unitRef="usd">393572000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfOS03LTEtMS0w_b63022a7-20db-4a94-b6fe-22b65549f1b0"
      unitRef="usd">242516000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTAtMS0xLTEtMA_3ebc7dc8-af6a-4d1b-9385-6b3cb3ab2980"
      unitRef="usd">88185000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTAtMy0xLTEtMA_c5d75a84-056e-4b4c-800c-f353d2b6bddd"
      unitRef="usd">51265000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTAtNS0xLTEtMA_7417b59f-48d0-49af-953e-6b154e8c6ba1"
      unitRef="usd">210916000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTAtNy0xLTEtMA_48792d91-b1c2-47ca-9b27-96bb04808da8"
      unitRef="usd">170218000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTEtMS0xLTEtMA_67fbff87-5435-4713-a578-8eb191a007d3"
      unitRef="usd">273672000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTEtMy0xLTEtMA_059b2542-ed4f-4fce-a94f-08a5c8d5e8cc"
      unitRef="usd">156097000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTEtNS0xLTEtMA_498ee8b8-b6a5-495c-b9ed-02fce8d2d5d4"
      unitRef="usd">631723000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTEtNy0xLTEtMA_47983846-40c4-47d6-bc25-1bd9cb711ddd"
      unitRef="usd">435311000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTItMS0xLTEtMA_8afa3ce3-ce85-4117-b4be-434e8e2c4ff9"
      unitRef="usd">-42580000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTItMy0xLTEtMA_09dc68ab-f302-46bf-a234-da72ae971a82"
      unitRef="usd">115606000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTItNS0xLTEtMA_00c77dfc-beac-4311-86d2-923e9fbaead3"
      unitRef="usd">85763000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTItNy0xLTEtMA_42aa19ba-2c99-47d3-81a0-49a078cf66b7"
      unitRef="usd">292154000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOther
      contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTMtMS0xLTEtMA_964fc70a-8bc5-4918-aa27-3c2c608dd7d6"
      unitRef="usd">3994000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTMtMy0xLTEtMA_364219f4-e474-4baa-899b-111409844ea9"
      unitRef="usd">7191000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTMtNS0xLTEtMA_1792c516-b575-429b-9f6e-9f5f562f4feb"
      unitRef="usd">16376000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTMtNy0xLTEtMA_0c148e8d-e02b-4c3e-addf-76c9d11345cf"
      unitRef="usd">20253000</us-gaap:InterestIncomeOther>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTQtMS0xLTEtMA_6c0b7bfd-bbe3-4976-b0a3-89a56a08b9e6"
      unitRef="usd">565000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTQtMy0xLTEtMA_fbd0aa1b-0820-48e4-a161-c774976cee39"
      unitRef="usd">-140000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTQtNS0xLTEtMA_04396dbc-7bc8-49cf-9ed1-d9e23f94488c"
      unitRef="usd">571000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTQtNy0xLTEtMA_c8992384-8e39-40f0-a5bd-5644ef31181f"
      unitRef="usd">688000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTUtMS0xLTEtMA_40adb407-3a86-477c-9957-bf6122bfedbf"
      unitRef="usd">-38021000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTUtMy0xLTEtMA_f7d0a351-bd2f-4eba-a377-e13ce3c0ecf2"
      unitRef="usd">122657000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTUtNS0xLTEtMA_25d16113-3172-4bd1-82f1-01d7a00b3cf1"
      unitRef="usd">102710000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTUtNy0xLTEtMA_238884d7-1371-4b1f-8c5c-095b783f9898"
      unitRef="usd">313095000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTYtMS0xLTEtMA_1739398f-2e30-41eb-99d5-eda949cc55f9"
      unitRef="usd">-5981000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTYtMy0xLTEtMA_a3ff79e0-71d5-4c8a-a804-a7994c6f6156"
      unitRef="usd">25205000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTYtNS0xLTEtMA_e1c359b4-3057-4de6-9da6-e841565d597e"
      unitRef="usd">19317000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTYtNy0xLTEtMA_54180849-8d76-4f81-8ba1-6e025e9a8d6f"
      unitRef="usd">60826000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTctMS0xLTEtMA_e14fdd44-f91f-4aa8-8680-c1ce4c535495"
      unitRef="usd">-32040000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTctMy0xLTEtMA_c230d74c-b0e6-47c5-b0c6-2fc1d389f218"
      unitRef="usd">97452000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTctNS0xLTEtMA_abfa2d1e-5ccf-42b5-84d6-40e96d4bcd40"
      unitRef="usd">83393000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTctNy0xLTEtMA_9bcc5c2b-55a6-4d0e-b747-be683cc26c85"
      unitRef="usd">252269000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTktMS0xLTEtMA_7a3147de-aef6-4bfa-95f9-00cc4ada70f9"
      unitRef="usdPerShare">-0.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTktMy0xLTEtMA_d6849b2a-127a-4ef8-bca4-87bb5574df34"
      unitRef="usdPerShare">0.32</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTktNS0xLTEtMA_0ce389e6-f463-4470-9f6f-0c0f57c77414"
      unitRef="usdPerShare">0.27</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMTktNy0xLTEtMA_2a713e4f-985b-45b8-92d1-f77166c3ab6c"
      unitRef="usdPerShare">0.84</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMjAtMS0xLTEtMA_7f9a4c55-e401-442f-8fa4-105892c23951"
      unitRef="usdPerShare">-0.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMjAtMy0xLTEtMA_19789304-e307-47ab-b0c5-170978039f50"
      unitRef="usdPerShare">0.31</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMjAtNS0xLTEtMA_7572123f-74b1-484b-8639-040d6b395680"
      unitRef="usdPerShare">0.26</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMjAtNy0xLTEtMA_f7ec4ab4-79db-4afc-8e6d-1c9da65693e3"
      unitRef="usdPerShare">0.80</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMjItMS0xLTEtMA_ad71f298-fb89-4ea2-b645-546a307bf799"
      unitRef="shares">309116000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMjItMy0xLTEtMA_383b0a50-bc8b-4cab-8407-0ed04091d0ff"
      unitRef="shares">303268000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMjItNS0xLTEtMA_5deb2c6c-2f08-4e8c-af99-133a8fd8a946"
      unitRef="shares">307437000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMjItNy0xLTEtMA_0b59a1e4-7c19-4daf-b7a4-3eda28981bce"
      unitRef="shares">301999000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMjMtMS0xLTEtMA_fcb6fbba-e5c5-420c-8a09-7c56dcf33bbc"
      unitRef="shares">309116000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMjMtMy0xLTEtMA_c3338bce-f879-430e-8cb2-db360f2f7110"
      unitRef="shares">315453000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMjMtNS0xLTEtMA_9f5610da-8468-45b6-9380-b8894e2003c2"
      unitRef="shares">317495000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yMi9mcmFnOjk4NDEyNmJkMDQ2YjQwMTU4YzJmZWMwM2YyZTFjNzRjL3RhYmxlOjcwMWYyZGRkNGRmODRkMzA5NzY2MTE5NmEyMTZiOTRjL3RhYmxlcmFuZ2U6NzAxZjJkZGQ0ZGY4NGQzMDk3NjYxMTk2YTIxNmI5NGNfMjMtNy0xLTEtMA_800cc155-a1ef-4247-98e3-c11eac534e2b"
      unitRef="shares">315046000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yNS9mcmFnOjRiMDI4MTFlZDYxYzRmZTNhYjc0YmZiYTMxMjMxZTAzL3RhYmxlOjIxNmE4NzZkZjY1YTQwNTA4MGU1ZTczYmU4YjA4MWNkL3RhYmxlcmFuZ2U6MjE2YTg3NmRmNjVhNDA1MDgwZTVlNzNiZThiMDgxY2RfMi0xLTEtMS0w_e14fdd44-f91f-4aa8-8680-c1ce4c535495"
      unitRef="usd">-32040000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yNS9mcmFnOjRiMDI4MTFlZDYxYzRmZTNhYjc0YmZiYTMxMjMxZTAzL3RhYmxlOjIxNmE4NzZkZjY1YTQwNTA4MGU1ZTczYmU4YjA4MWNkL3RhYmxlcmFuZ2U6MjE2YTg3NmRmNjVhNDA1MDgwZTVlNzNiZThiMDgxY2RfMi0zLTEtMS0w_c230d74c-b0e6-47c5-b0c6-2fc1d389f218"
      unitRef="usd">97452000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yNS9mcmFnOjRiMDI4MTFlZDYxYzRmZTNhYjc0YmZiYTMxMjMxZTAzL3RhYmxlOjIxNmE4NzZkZjY1YTQwNTA4MGU1ZTczYmU4YjA4MWNkL3RhYmxlcmFuZ2U6MjE2YTg3NmRmNjVhNDA1MDgwZTVlNzNiZThiMDgxY2RfMi01LTEtMS0w_abfa2d1e-5ccf-42b5-84d6-40e96d4bcd40"
      unitRef="usd">83393000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yNS9mcmFnOjRiMDI4MTFlZDYxYzRmZTNhYjc0YmZiYTMxMjMxZTAzL3RhYmxlOjIxNmE4NzZkZjY1YTQwNTA4MGU1ZTczYmU4YjA4MWNkL3RhYmxlcmFuZ2U6MjE2YTg3NmRmNjVhNDA1MDgwZTVlNzNiZThiMDgxY2RfMi03LTEtMS0w_9bcc5c2b-55a6-4d0e-b747-be683cc26c85"
      unitRef="usd">252269000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yNS9mcmFnOjRiMDI4MTFlZDYxYzRmZTNhYjc0YmZiYTMxMjMxZTAzL3RhYmxlOjIxNmE4NzZkZjY1YTQwNTA4MGU1ZTczYmU4YjA4MWNkL3RhYmxlcmFuZ2U6MjE2YTg3NmRmNjVhNDA1MDgwZTVlNzNiZThiMDgxY2RfNC0wLTEtMS0wL3RleHRyZWdpb246MWVjYmUzOGQ1NDljNDgyYWEwODlkMzJkMTJhZTRjOTRfNTQ5NzU1ODEzOTAyMw_63dcde30-4207-4506-8859-6f040741e95d"
      unitRef="usd">453000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yNS9mcmFnOjRiMDI4MTFlZDYxYzRmZTNhYjc0YmZiYTMxMjMxZTAzL3RhYmxlOjIxNmE4NzZkZjY1YTQwNTA4MGU1ZTczYmU4YjA4MWNkL3RhYmxlcmFuZ2U6MjE2YTg3NmRmNjVhNDA1MDgwZTVlNzNiZThiMDgxY2RfNC0wLTEtMS0wL3RleHRyZWdpb246MWVjYmUzOGQ1NDljNDgyYWEwODlkMzJkMTJhZTRjOTRfNTQ5NzU1ODEzOTAzMw_34055de9-1da2-4cd4-9a19-b84c16b1f8a6"
      unitRef="usd">-129000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yNS9mcmFnOjRiMDI4MTFlZDYxYzRmZTNhYjc0YmZiYTMxMjMxZTAzL3RhYmxlOjIxNmE4NzZkZjY1YTQwNTA4MGU1ZTczYmU4YjA4MWNkL3RhYmxlcmFuZ2U6MjE2YTg3NmRmNjVhNDA1MDgwZTVlNzNiZThiMDgxY2RfNC0wLTEtMS0wL3RleHRyZWdpb246MWVjYmUzOGQ1NDljNDgyYWEwODlkMzJkMTJhZTRjOTRfNTQ5NzU1ODEzOTA0Mw_ff3cea69-a05e-4a7a-953e-3a2b5f9620d0"
      unitRef="usd">-893000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yNS9mcmFnOjRiMDI4MTFlZDYxYzRmZTNhYjc0YmZiYTMxMjMxZTAzL3RhYmxlOjIxNmE4NzZkZjY1YTQwNTA4MGU1ZTczYmU4YjA4MWNkL3RhYmxlcmFuZ2U6MjE2YTg3NmRmNjVhNDA1MDgwZTVlNzNiZThiMDgxY2RfNC0wLTEtMS0wL3RleHRyZWdpb246MWVjYmUzOGQ1NDljNDgyYWEwODlkMzJkMTJhZTRjOTRfNTQ5NzU1ODEzOTA1Mw_045a1430-e92a-4af1-9623-939cd9c9b731"
      unitRef="usd">-936000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yNS9mcmFnOjRiMDI4MTFlZDYxYzRmZTNhYjc0YmZiYTMxMjMxZTAzL3RhYmxlOjIxNmE4NzZkZjY1YTQwNTA4MGU1ZTczYmU4YjA4MWNkL3RhYmxlcmFuZ2U6MjE2YTg3NmRmNjVhNDA1MDgwZTVlNzNiZThiMDgxY2RfNC0xLTEtMS0w_ca4be55d-65f3-4301-be7a-6feead480ae3"
      unitRef="usd">-1601000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yNS9mcmFnOjRiMDI4MTFlZDYxYzRmZTNhYjc0YmZiYTMxMjMxZTAzL3RhYmxlOjIxNmE4NzZkZjY1YTQwNTA4MGU1ZTczYmU4YjA4MWNkL3RhYmxlcmFuZ2U6MjE2YTg3NmRmNjVhNDA1MDgwZTVlNzNiZThiMDgxY2RfNC0zLTEtMS0w_df59e7d2-0dd5-442d-8891-e383b7f2411f"
      unitRef="usd">461000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yNS9mcmFnOjRiMDI4MTFlZDYxYzRmZTNhYjc0YmZiYTMxMjMxZTAzL3RhYmxlOjIxNmE4NzZkZjY1YTQwNTA4MGU1ZTczYmU4YjA4MWNkL3RhYmxlcmFuZ2U6MjE2YTg3NmRmNjVhNDA1MDgwZTVlNzNiZThiMDgxY2RfNC01LTEtMS0w_b869689c-6c48-4b9f-a279-8b7cc4e2b058"
      unitRef="usd">3170000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yNS9mcmFnOjRiMDI4MTFlZDYxYzRmZTNhYjc0YmZiYTMxMjMxZTAzL3RhYmxlOjIxNmE4NzZkZjY1YTQwNTA4MGU1ZTczYmU4YjA4MWNkL3RhYmxlcmFuZ2U6MjE2YTg3NmRmNjVhNDA1MDgwZTVlNzNiZThiMDgxY2RfNC03LTEtMS0w_add737e4-48fe-42a9-8767-4051927f5b51"
      unitRef="usd">3369000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yNS9mcmFnOjRiMDI4MTFlZDYxYzRmZTNhYjc0YmZiYTMxMjMxZTAzL3RhYmxlOjIxNmE4NzZkZjY1YTQwNTA4MGU1ZTczYmU4YjA4MWNkL3RhYmxlcmFuZ2U6MjE2YTg3NmRmNjVhNDA1MDgwZTVlNzNiZThiMDgxY2RfNi0xLTEtMS0w_1fefd1ae-e074-49f2-97d3-8b2794303963"
      unitRef="usd">-33641000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yNS9mcmFnOjRiMDI4MTFlZDYxYzRmZTNhYjc0YmZiYTMxMjMxZTAzL3RhYmxlOjIxNmE4NzZkZjY1YTQwNTA4MGU1ZTczYmU4YjA4MWNkL3RhYmxlcmFuZ2U6MjE2YTg3NmRmNjVhNDA1MDgwZTVlNzNiZThiMDgxY2RfNi0zLTEtMS0w_88c9d98e-91d6-4a8d-9192-cb60294b59ca"
      unitRef="usd">97913000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yNS9mcmFnOjRiMDI4MTFlZDYxYzRmZTNhYjc0YmZiYTMxMjMxZTAzL3RhYmxlOjIxNmE4NzZkZjY1YTQwNTA4MGU1ZTczYmU4YjA4MWNkL3RhYmxlcmFuZ2U6MjE2YTg3NmRmNjVhNDA1MDgwZTVlNzNiZThiMDgxY2RfNi01LTEtMS0w_39aa7fa5-3fda-4b07-ab7b-39a8c76ea291"
      unitRef="usd">86563000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8yNS9mcmFnOjRiMDI4MTFlZDYxYzRmZTNhYjc0YmZiYTMxMjMxZTAzL3RhYmxlOjIxNmE4NzZkZjY1YTQwNTA4MGU1ZTczYmU4YjA4MWNkL3RhYmxlcmFuZ2U6MjE2YTg3NmRmNjVhNDA1MDgwZTVlNzNiZThiMDgxY2RfNi03LTEtMS0w_ebe005ee-bb78-46dd-8d8a-31d069d22e3e"
      unitRef="usd">255638000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i316676d09b8a43edb69e0d908574a669_I20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOmJjNDJlOGY4OTBhYTQ5NjJiYTdhZjk5OTgwZjczZTEyL3RhYmxlcmFuZ2U6YmM0MmU4Zjg5MGFhNDk2MmJhN2FmOTk5ODBmNzNlMTJfMjMtMS0xLTEtMA_b6c56174-e168-454b-a4bb-47c3b8cd0dfe"
      unitRef="shares">308886000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i316676d09b8a43edb69e0d908574a669_I20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOmJjNDJlOGY4OTBhYTQ5NjJiYTdhZjk5OTgwZjczZTEyL3RhYmxlcmFuZ2U6YmM0MmU4Zjg5MGFhNDk2MmJhN2FmOTk5ODBmNzNlMTJfMjMtMy0xLTEtMA_1da14fb5-2fb0-49f2-9f32-76829fc6860c"
      unitRef="usd">309000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i02f1924710584639831de419a08af15c_I20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOmJjNDJlOGY4OTBhYTQ5NjJiYTdhZjk5OTgwZjczZTEyL3RhYmxlcmFuZ2U6YmM0MmU4Zjg5MGFhNDk2MmJhN2FmOTk5ODBmNzNlMTJfMjMtNS0xLTEtMA_7833a383-7d9d-4ebe-bdbd-84642912877b"
      unitRef="usd">2269093000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i46f2d57ee3234492ae78920271a99b39_I20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOmJjNDJlOGY4OTBhYTQ5NjJiYTdhZjk5OTgwZjczZTEyL3RhYmxlcmFuZ2U6YmM0MmU4Zjg5MGFhNDk2MmJhN2FmOTk5ODBmNzNlMTJfMjMtNy0xLTEtMA_19b56244-a6d5-42c9-aca2-d5e706f3ea5f"
      unitRef="usd">7840000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i49c13447908e420384b91c447fbe71a9_I20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOmJjNDJlOGY4OTBhYTQ5NjJiYTdhZjk5OTgwZjczZTEyL3RhYmxlcmFuZ2U6YmM0MmU4Zjg5MGFhNDk2MmJhN2FmOTk5ODBmNzNlMTJfMjMtOS0xLTEtMA_1082d5d4-1561-47ca-874b-d99ff78881a3"
      unitRef="usd">-443918000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4e76b251fbeb42f3a7cc3df6ca3a4230_I20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOmJjNDJlOGY4OTBhYTQ5NjJiYTdhZjk5OTgwZjczZTEyL3RhYmxlcmFuZ2U6YmM0MmU4Zjg5MGFhNDk2MmJhN2FmOTk5ODBmNzNlMTJfMjMtMTEtMS0xLTA_98980725-66f3-4ce2-8940-7c124e391ea2"
      unitRef="usd">1833324000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ic40a4137775f410490cca3ab2ec24c82_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOmJjNDJlOGY4OTBhYTQ5NjJiYTdhZjk5OTgwZjczZTEyL3RhYmxlcmFuZ2U6YmM0MmU4Zjg5MGFhNDk2MmJhN2FmOTk5ODBmNzNlMTJfMjQtOS0xLTEtMA_a334065c-4ac4-4d96-aa87-ce8e04be0742"
      unitRef="usd">-32040000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOmJjNDJlOGY4OTBhYTQ5NjJiYTdhZjk5OTgwZjczZTEyL3RhYmxlcmFuZ2U6YmM0MmU4Zjg5MGFhNDk2MmJhN2FmOTk5ODBmNzNlMTJfMjQtMTEtMS0xLTA_234ae639-050e-4885-b1df-ea698571936e"
      unitRef="usd">-32040000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ie823ac87cfcf453da0d0ee469a5208a4_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOmJjNDJlOGY4OTBhYTQ5NjJiYTdhZjk5OTgwZjczZTEyL3RhYmxlcmFuZ2U6YmM0MmU4Zjg5MGFhNDk2MmJhN2FmOTk5ODBmNzNlMTJfMjUtNy0xLTEtMA_1b5d1a32-5a22-439c-abca-f130a24e49c0"
      unitRef="usd">-1601000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOmJjNDJlOGY4OTBhYTQ5NjJiYTdhZjk5OTgwZjczZTEyL3RhYmxlcmFuZ2U6YmM0MmU4Zjg5MGFhNDk2MmJhN2FmOTk5ODBmNzNlMTJfMjUtMTEtMS0xLTA_43161a5f-2254-4c2d-be7d-f240545cf07b"
      unitRef="usd">-1601000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i0f63bc8277444a159ea4d49770eaf477_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOmJjNDJlOGY4OTBhYTQ5NjJiYTdhZjk5OTgwZjczZTEyL3RhYmxlcmFuZ2U6YmM0MmU4Zjg5MGFhNDk2MmJhN2FmOTk5ODBmNzNlMTJfMjYtMS0xLTEtMA_49354f7d-3621-424a-953d-0913f17fc749"
      unitRef="shares">516000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i97e9d031387d43198b6f05ff2861f3ab_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOmJjNDJlOGY4OTBhYTQ5NjJiYTdhZjk5OTgwZjczZTEyL3RhYmxlcmFuZ2U6YmM0MmU4Zjg5MGFhNDk2MmJhN2FmOTk5ODBmNzNlMTJfMjYtNS0xLTEtMA_f89cbef3-de11-436e-9996-5d1fd6b535f9"
      unitRef="usd">1872000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOmJjNDJlOGY4OTBhYTQ5NjJiYTdhZjk5OTgwZjczZTEyL3RhYmxlcmFuZ2U6YmM0MmU4Zjg5MGFhNDk2MmJhN2FmOTk5ODBmNzNlMTJfMjYtMTEtMS0xLTA_b30b761f-323e-4fe4-a475-1937340503f6"
      unitRef="usd">1872000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i97e9d031387d43198b6f05ff2861f3ab_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOmJjNDJlOGY4OTBhYTQ5NjJiYTdhZjk5OTgwZjczZTEyL3RhYmxlcmFuZ2U6YmM0MmU4Zjg5MGFhNDk2MmJhN2FmOTk5ODBmNzNlMTJfMjctNS0xLTEtMA_215ab77e-c542-41bb-98e3-903ecdffdd80"
      unitRef="usd">5179000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOmJjNDJlOGY4OTBhYTQ5NjJiYTdhZjk5OTgwZjczZTEyL3RhYmxlcmFuZ2U6YmM0MmU4Zjg5MGFhNDk2MmJhN2FmOTk5ODBmNzNlMTJfMjctMTEtMS0xLTA_bfb29a85-50f8-44d0-82b4-39ffdced8fe3"
      unitRef="usd">5179000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i97e9d031387d43198b6f05ff2861f3ab_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOmJjNDJlOGY4OTBhYTQ5NjJiYTdhZjk5OTgwZjczZTEyL3RhYmxlcmFuZ2U6YmM0MmU4Zjg5MGFhNDk2MmJhN2FmOTk5ODBmNzNlMTJfMjgtNS0xLTEtMA_a3f64efe-c993-4ba8-b928-7640ac1d023e"
      unitRef="usd">55655000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOmJjNDJlOGY4OTBhYTQ5NjJiYTdhZjk5OTgwZjczZTEyL3RhYmxlcmFuZ2U6YmM0MmU4Zjg5MGFhNDk2MmJhN2FmOTk5ODBmNzNlMTJfMjgtMTEtMS0xLTA_fa1912ca-353e-4ef7-b857-203cd66e7a95"
      unitRef="usd">55655000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ida20c4eb650547409d09265abf22aef1_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOmJjNDJlOGY4OTBhYTQ5NjJiYTdhZjk5OTgwZjczZTEyL3RhYmxlcmFuZ2U6YmM0MmU4Zjg5MGFhNDk2MmJhN2FmOTk5ODBmNzNlMTJfMjktMS0xLTEtMA_3954f4e8-42e9-4d68-9517-f217255ac1e3"
      unitRef="shares">309402000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ida20c4eb650547409d09265abf22aef1_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOmJjNDJlOGY4OTBhYTQ5NjJiYTdhZjk5OTgwZjczZTEyL3RhYmxlcmFuZ2U6YmM0MmU4Zjg5MGFhNDk2MmJhN2FmOTk5ODBmNzNlMTJfMjktMy0xLTEtMA_2a4e81be-05ec-45aa-a949-63ddc249d719"
      unitRef="usd">309000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9a1eac7bffc9475a9bbdda86813fd7ee_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOmJjNDJlOGY4OTBhYTQ5NjJiYTdhZjk5OTgwZjczZTEyL3RhYmxlcmFuZ2U6YmM0MmU4Zjg5MGFhNDk2MmJhN2FmOTk5ODBmNzNlMTJfMjktNS0xLTEtMA_e4239190-006e-4ab5-87b2-49829c6cdb8a"
      unitRef="usd">2321441000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic7bf961275044b01a0c4a9ccebad588f_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOmJjNDJlOGY4OTBhYTQ5NjJiYTdhZjk5OTgwZjczZTEyL3RhYmxlcmFuZ2U6YmM0MmU4Zjg5MGFhNDk2MmJhN2FmOTk5ODBmNzNlMTJfMjktNy0xLTEtMA_b006b6df-aff2-4b56-a73b-50442693667f"
      unitRef="usd">6239000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8a5031970ae845a8b4d0e06e3e6e4934_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOmJjNDJlOGY4OTBhYTQ5NjJiYTdhZjk5OTgwZjczZTEyL3RhYmxlcmFuZ2U6YmM0MmU4Zjg5MGFhNDk2MmJhN2FmOTk5ODBmNzNlMTJfMjktOS0xLTEtMA_4875605d-bc3f-4382-b573-c0b8b338c1d9"
      unitRef="usd">-475958000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOmJjNDJlOGY4OTBhYTQ5NjJiYTdhZjk5OTgwZjczZTEyL3RhYmxlcmFuZ2U6YmM0MmU4Zjg5MGFhNDk2MmJhN2FmOTk5ODBmNzNlMTJfMjktMTEtMS0xLTA_dcdce783-81a8-4cca-9fbb-ff0dcd2df208"
      unitRef="usd">1852031000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i6c1980f2c4f24d4baa81b1ccba73febb_I20190628"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjFhYzJmMjE2ZTUxNjQyMDg4OGUzZTI1ODdmY2Y2NzljL3RhYmxlcmFuZ2U6MWFjMmYyMTZlNTE2NDIwODg4ZTNlMjU4N2ZjZjY3OWNfMjMtMS0xLTEtMA_daec6fc7-d8bf-4680-8194-d60ed13a8c5f"
      unitRef="shares">302785000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i6c1980f2c4f24d4baa81b1ccba73febb_I20190628"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjFhYzJmMjE2ZTUxNjQyMDg4OGUzZTI1ODdmY2Y2NzljL3RhYmxlcmFuZ2U6MWFjMmYyMTZlNTE2NDIwODg4ZTNlMjU4N2ZjZjY3OWNfMjMtMy0xLTEtMA_e2f996d6-0583-490a-826e-c2f129896436"
      unitRef="usd">303000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i013e4989ee6443b9afcc82a956f959f9_I20190628"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjFhYzJmMjE2ZTUxNjQyMDg4OGUzZTI1ODdmY2Y2NzljL3RhYmxlcmFuZ2U6MWFjMmYyMTZlNTE2NDIwODg4ZTNlMjU4N2ZjZjY3OWNfMjMtNS0xLTEtMA_059d6d41-587d-4911-a790-c8b66ddf88a8"
      unitRef="usd">2211668000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib0dbb32931e346bfae3a3ca347f978ab_I20190628"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjFhYzJmMjE2ZTUxNjQyMDg4OGUzZTI1ODdmY2Y2NzljL3RhYmxlcmFuZ2U6MWFjMmYyMTZlNTE2NDIwODg4ZTNlMjU4N2ZjZjY3OWNfMjMtNy0xLTEtMA_774e747f-0605-4e20-9a04-765af53b80db"
      unitRef="usd">2207000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7ad7ce0b72c9496489178748e0770609_I20190628"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjFhYzJmMjE2ZTUxNjQyMDg4OGUzZTI1ODdmY2Y2NzljL3RhYmxlcmFuZ2U6MWFjMmYyMTZlNTE2NDIwODg4ZTNlMjU4N2ZjZjY3OWNfMjMtOS0xLTEtMA_ffe26ae2-963d-4b4b-9fa1-78ba23a5ee17"
      unitRef="usd">-725546000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if77bb429cb9c49c7a19d55f3f313ee70_I20190628"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjFhYzJmMjE2ZTUxNjQyMDg4OGUzZTI1ODdmY2Y2NzljL3RhYmxlcmFuZ2U6MWFjMmYyMTZlNTE2NDIwODg4ZTNlMjU4N2ZjZjY3OWNfMjMtMTEtMS0xLTA_2856e9ec-0552-4df8-a465-cab1523b5650"
      unitRef="usd">1488632000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ifd7f360120b34b36ae5e37843a1f7fd3_D20190629-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjFhYzJmMjE2ZTUxNjQyMDg4OGUzZTI1ODdmY2Y2NzljL3RhYmxlcmFuZ2U6MWFjMmYyMTZlNTE2NDIwODg4ZTNlMjU4N2ZjZjY3OWNfMjQtOS0xLTEtMA_12998603-4406-4d97-af95-620b0b7d442c"
      unitRef="usd">97452000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjFhYzJmMjE2ZTUxNjQyMDg4OGUzZTI1ODdmY2Y2NzljL3RhYmxlcmFuZ2U6MWFjMmYyMTZlNTE2NDIwODg4ZTNlMjU4N2ZjZjY3OWNfMjQtMTEtMS0xLTA_a6cafd49-45d7-4e62-a7c2-787f2174432d"
      unitRef="usd">97452000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ib60dcfd8f46a44b6b0c8dfc25001dd5e_D20190629-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjFhYzJmMjE2ZTUxNjQyMDg4OGUzZTI1ODdmY2Y2NzljL3RhYmxlcmFuZ2U6MWFjMmYyMTZlNTE2NDIwODg4ZTNlMjU4N2ZjZjY3OWNfMjUtNy0xLTEtMA_08ba4f02-5843-47de-8506-006d67a47734"
      unitRef="usd">461000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjFhYzJmMjE2ZTUxNjQyMDg4OGUzZTI1ODdmY2Y2NzljL3RhYmxlcmFuZ2U6MWFjMmYyMTZlNTE2NDIwODg4ZTNlMjU4N2ZjZjY3OWNfMjUtMTEtMS0xLTA_247f524e-d9f9-4496-b5d4-d30f0144b57d"
      unitRef="usd">461000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i8ab198a265ed4c0494a01c26fc2f82c7_D20190629-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjFhYzJmMjE2ZTUxNjQyMDg4OGUzZTI1ODdmY2Y2NzljL3RhYmxlcmFuZ2U6MWFjMmYyMTZlNTE2NDIwODg4ZTNlMjU4N2ZjZjY3OWNfMjYtMS0xLTEtMA_9f54dd95-8942-4a67-a6e0-13d58f51939b"
      unitRef="shares">991000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i8ab198a265ed4c0494a01c26fc2f82c7_D20190629-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjFhYzJmMjE2ZTUxNjQyMDg4OGUzZTI1ODdmY2Y2NzljL3RhYmxlcmFuZ2U6MWFjMmYyMTZlNTE2NDIwODg4ZTNlMjU4N2ZjZjY3OWNfMjYtMy0xLTEtMA_20603cc5-91c9-460a-b0b5-5a08cc08a2ae"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i1082fd4f150346c182b846e3072e0c3f_D20190629-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjFhYzJmMjE2ZTUxNjQyMDg4OGUzZTI1ODdmY2Y2NzljL3RhYmxlcmFuZ2U6MWFjMmYyMTZlNTE2NDIwODg4ZTNlMjU4N2ZjZjY3OWNfMjYtNS0xLTEtMA_66e8a85b-229e-4d72-8450-c4609087c7af"
      unitRef="usd">4967000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjFhYzJmMjE2ZTUxNjQyMDg4OGUzZTI1ODdmY2Y2NzljL3RhYmxlcmFuZ2U6MWFjMmYyMTZlNTE2NDIwODg4ZTNlMjU4N2ZjZjY3OWNfMjYtMTEtMS0xLTA_b09ad653-b64c-4b60-9418-097ee3a4a0e2"
      unitRef="usd">4968000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i1082fd4f150346c182b846e3072e0c3f_D20190629-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjFhYzJmMjE2ZTUxNjQyMDg4OGUzZTI1ODdmY2Y2NzljL3RhYmxlcmFuZ2U6MWFjMmYyMTZlNTE2NDIwODg4ZTNlMjU4N2ZjZjY3OWNfMjctNS0xLTEtMA_94d0a2ac-8062-4600-bf6a-588d4e2b8c16"
      unitRef="usd">935000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjFhYzJmMjE2ZTUxNjQyMDg4OGUzZTI1ODdmY2Y2NzljL3RhYmxlcmFuZ2U6MWFjMmYyMTZlNTE2NDIwODg4ZTNlMjU4N2ZjZjY3OWNfMjctMTEtMS0xLTA_9d7741c8-160f-45e8-bc83-88a890a0eb9f"
      unitRef="usd">935000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1082fd4f150346c182b846e3072e0c3f_D20190629-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjFhYzJmMjE2ZTUxNjQyMDg4OGUzZTI1ODdmY2Y2NzljL3RhYmxlcmFuZ2U6MWFjMmYyMTZlNTE2NDIwODg4ZTNlMjU4N2ZjZjY3OWNfMjgtNS0xLTEtMA_bedfe1cc-6197-4006-970b-e94907944d7e"
      unitRef="usd">13139000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjFhYzJmMjE2ZTUxNjQyMDg4OGUzZTI1ODdmY2Y2NzljL3RhYmxlcmFuZ2U6MWFjMmYyMTZlNTE2NDIwODg4ZTNlMjU4N2ZjZjY3OWNfMjgtMTEtMS0xLTA_e5eb2484-c8ed-4e51-a97c-1a830694bdbc"
      unitRef="usd">13139000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i05f14b5dcf314304b309c5e87df9f50a_I20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjFhYzJmMjE2ZTUxNjQyMDg4OGUzZTI1ODdmY2Y2NzljL3RhYmxlcmFuZ2U6MWFjMmYyMTZlNTE2NDIwODg4ZTNlMjU4N2ZjZjY3OWNfMjktMS0xLTEtMA_df5add31-4497-478d-bc14-07cbbef61a6d"
      unitRef="shares">303776000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i05f14b5dcf314304b309c5e87df9f50a_I20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjFhYzJmMjE2ZTUxNjQyMDg4OGUzZTI1ODdmY2Y2NzljL3RhYmxlcmFuZ2U6MWFjMmYyMTZlNTE2NDIwODg4ZTNlMjU4N2ZjZjY3OWNfMjktMy0xLTEtMA_95ef1792-5b75-4ec2-aff1-08e9dbb36626"
      unitRef="usd">304000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1c6f2cb1dfbd41acbc289114955cd416_I20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjFhYzJmMjE2ZTUxNjQyMDg4OGUzZTI1ODdmY2Y2NzljL3RhYmxlcmFuZ2U6MWFjMmYyMTZlNTE2NDIwODg4ZTNlMjU4N2ZjZjY3OWNfMjktNS0xLTEtMA_7dd3c7fd-a8ce-441a-aa27-e786c9a3e51d"
      unitRef="usd">2228839000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3dac2e6ea3d14a2e8cc5b92c6af71211_I20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjFhYzJmMjE2ZTUxNjQyMDg4OGUzZTI1ODdmY2Y2NzljL3RhYmxlcmFuZ2U6MWFjMmYyMTZlNTE2NDIwODg4ZTNlMjU4N2ZjZjY3OWNfMjktNy0xLTEtMA_68ac871f-f5ac-4e5c-9fcd-4ae244fe9b94"
      unitRef="usd">2668000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic827287aa3294c6a883bc9d0b8a0623f_I20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjFhYzJmMjE2ZTUxNjQyMDg4OGUzZTI1ODdmY2Y2NzljL3RhYmxlcmFuZ2U6MWFjMmYyMTZlNTE2NDIwODg4ZTNlMjU4N2ZjZjY3OWNfMjktOS0xLTEtMA_6718163b-6d06-45bb-bc3d-35651d81e2f6"
      unitRef="usd">-628094000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i34bbe41183cc4f96afa896c1d7f86bb3_I20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjFhYzJmMjE2ZTUxNjQyMDg4OGUzZTI1ODdmY2Y2NzljL3RhYmxlcmFuZ2U6MWFjMmYyMTZlNTE2NDIwODg4ZTNlMjU4N2ZjZjY3OWNfMjktMTEtMS0xLTA_62661179-25c1-4da4-a110-04941df5c1c7"
      unitRef="usd">1603717000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i1f39a5eecfd64bbdb16dc650b0f43744_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjdjYzQyNDI1NjMzOTRhOGY4OWM5NjkyOTg2Mjc0MGI4L3RhYmxlcmFuZ2U6N2NjNDI0MjU2MzM5NGE4Zjg5Yzk2OTI5ODYyNzQwYjhfMTEtMS0xLTEtMA_8d9bc777-8f5b-40df-8dfb-ea850744577c"
      unitRef="shares">304831000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i1f39a5eecfd64bbdb16dc650b0f43744_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjdjYzQyNDI1NjMzOTRhOGY4OWM5NjkyOTg2Mjc0MGI4L3RhYmxlcmFuZ2U6N2NjNDI0MjU2MzM5NGE4Zjg5Yzk2OTI5ODYyNzQwYjhfMTEtMy0xLTEtMA_0d55f348-6a68-4090-9841-9223f1bb333a"
      unitRef="usd">305000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia8909ade88d7423e92687245874b7f72_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjdjYzQyNDI1NjMzOTRhOGY4OWM5NjkyOTg2Mjc0MGI4L3RhYmxlcmFuZ2U6N2NjNDI0MjU2MzM5NGE4Zjg5Yzk2OTI5ODYyNzQwYjhfMTEtNS0xLTEtMA_9a35e950-988c-4922-bf3b-884e8934435d"
      unitRef="usd">2241947000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic6b255ea4abe49edafb55d811bcad05b_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjdjYzQyNDI1NjMzOTRhOGY4OWM5NjkyOTg2Mjc0MGI4L3RhYmxlcmFuZ2U6N2NjNDI0MjU2MzM5NGE4Zjg5Yzk2OTI5ODYyNzQwYjhfMTEtNy0xLTEtMA_874a494c-1c2e-4f20-8bbd-5e8fb929239e"
      unitRef="usd">3069000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2614e82c41c1401c802f3cfcc0fa0efe_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjdjYzQyNDI1NjMzOTRhOGY4OWM5NjkyOTg2Mjc0MGI4L3RhYmxlcmFuZ2U6N2NjNDI0MjU2MzM5NGE4Zjg5Yzk2OTI5ODYyNzQwYjhfMTEtOS0xLTEtMA_cf9ca389-2cba-42ff-9fdc-17299a419b9c"
      unitRef="usd">-559351000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjdjYzQyNDI1NjMzOTRhOGY4OWM5NjkyOTg2Mjc0MGI4L3RhYmxlcmFuZ2U6N2NjNDI0MjU2MzM5NGE4Zjg5Yzk2OTI5ODYyNzQwYjhfMTEtMTEtMS0xLTA_24f43b4a-7fa0-4ca9-b45b-541c8906a70d"
      unitRef="usd">1685970000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ia5ea39c6afc94359bbe264fb14b43e10_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjdjYzQyNDI1NjMzOTRhOGY4OWM5NjkyOTg2Mjc0MGI4L3RhYmxlcmFuZ2U6N2NjNDI0MjU2MzM5NGE4Zjg5Yzk2OTI5ODYyNzQwYjhfMTItOS0xLTEtMA_2c2f6b99-d271-4ff9-a722-be8b85be4247"
      unitRef="usd">83393000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjdjYzQyNDI1NjMzOTRhOGY4OWM5NjkyOTg2Mjc0MGI4L3RhYmxlcmFuZ2U6N2NjNDI0MjU2MzM5NGE4Zjg5Yzk2OTI5ODYyNzQwYjhfMTItMTEtMS0xLTA_dd1e5e9c-9eab-4c28-b62a-65996cf9347a"
      unitRef="usd">83393000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="icdb2053635ce46b7b040cfe89917a2b4_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjdjYzQyNDI1NjMzOTRhOGY4OWM5NjkyOTg2Mjc0MGI4L3RhYmxlcmFuZ2U6N2NjNDI0MjU2MzM5NGE4Zjg5Yzk2OTI5ODYyNzQwYjhfMTMtNy0xLTEtMA_7f0930ee-968a-4d01-b168-4c433d920cf9"
      unitRef="usd">3170000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjdjYzQyNDI1NjMzOTRhOGY4OWM5NjkyOTg2Mjc0MGI4L3RhYmxlcmFuZ2U6N2NjNDI0MjU2MzM5NGE4Zjg5Yzk2OTI5ODYyNzQwYjhfMTMtMTEtMS0xLTA_4f3110dc-8d21-4317-a59a-db37b65880b7"
      unitRef="usd">3170000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="id485c543ae654a6fa7b0799bc9c76368_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjdjYzQyNDI1NjMzOTRhOGY4OWM5NjkyOTg2Mjc0MGI4L3RhYmxlcmFuZ2U6N2NjNDI0MjU2MzM5NGE4Zjg5Yzk2OTI5ODYyNzQwYjhfMTQtMS0xLTEtMA_b846d63c-a140-4261-88da-20aaf799d37c"
      unitRef="shares">4571000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="id485c543ae654a6fa7b0799bc9c76368_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjdjYzQyNDI1NjMzOTRhOGY4OWM5NjkyOTg2Mjc0MGI4L3RhYmxlcmFuZ2U6N2NjNDI0MjU2MzM5NGE4Zjg5Yzk2OTI5ODYyNzQwYjhfMTQtMy0xLTEtMA_c98c83df-2a37-4bd4-aa9b-682c11807d68"
      unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i168c5944094040729529b381e8529300_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjdjYzQyNDI1NjMzOTRhOGY4OWM5NjkyOTg2Mjc0MGI4L3RhYmxlcmFuZ2U6N2NjNDI0MjU2MzM5NGE4Zjg5Yzk2OTI5ODYyNzQwYjhfMTQtNS0xLTEtMA_07a85213-4243-4fb0-8205-9b18ea43501f"
      unitRef="usd">19823000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjdjYzQyNDI1NjMzOTRhOGY4OWM5NjkyOTg2Mjc0MGI4L3RhYmxlcmFuZ2U6N2NjNDI0MjU2MzM5NGE4Zjg5Yzk2OTI5ODYyNzQwYjhfMTQtMTEtMS0xLTA_b7132eba-a666-4cb0-a734-9572fb878ef4"
      unitRef="usd">19827000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i168c5944094040729529b381e8529300_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjdjYzQyNDI1NjMzOTRhOGY4OWM5NjkyOTg2Mjc0MGI4L3RhYmxlcmFuZ2U6N2NjNDI0MjU2MzM5NGE4Zjg5Yzk2OTI5ODYyNzQwYjhfMTUtNS0xLTEtMA_48a0eff1-6417-4fae-a475-d02181994aa1"
      unitRef="usd">26120000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjdjYzQyNDI1NjMzOTRhOGY4OWM5NjkyOTg2Mjc0MGI4L3RhYmxlcmFuZ2U6N2NjNDI0MjU2MzM5NGE4Zjg5Yzk2OTI5ODYyNzQwYjhfMTUtMTEtMS0xLTA_5d8a0860-c4a4-406a-b4e3-ced19ffa14b1"
      unitRef="usd">26120000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i168c5944094040729529b381e8529300_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjdjYzQyNDI1NjMzOTRhOGY4OWM5NjkyOTg2Mjc0MGI4L3RhYmxlcmFuZ2U6N2NjNDI0MjU2MzM5NGE4Zjg5Yzk2OTI5ODYyNzQwYjhfMTYtNS0xLTEtMA_9e9186b2-36c2-44b6-9be4-6775a6e08684"
      unitRef="usd">85791000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjdjYzQyNDI1NjMzOTRhOGY4OWM5NjkyOTg2Mjc0MGI4L3RhYmxlcmFuZ2U6N2NjNDI0MjU2MzM5NGE4Zjg5Yzk2OTI5ODYyNzQwYjhfMTYtMTEtMS0xLTA_f89ab3a2-7fbc-47ca-aee6-ea0c410181e3"
      unitRef="usd">85791000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ida20c4eb650547409d09265abf22aef1_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjdjYzQyNDI1NjMzOTRhOGY4OWM5NjkyOTg2Mjc0MGI4L3RhYmxlcmFuZ2U6N2NjNDI0MjU2MzM5NGE4Zjg5Yzk2OTI5ODYyNzQwYjhfMTctMS0xLTEtMA_d725fcb5-968b-43cc-9c73-04baccf2a442"
      unitRef="shares">309402000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ida20c4eb650547409d09265abf22aef1_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjdjYzQyNDI1NjMzOTRhOGY4OWM5NjkyOTg2Mjc0MGI4L3RhYmxlcmFuZ2U6N2NjNDI0MjU2MzM5NGE4Zjg5Yzk2OTI5ODYyNzQwYjhfMTctMy0xLTEtMA_2fe1f7f1-c0e6-4827-99e8-d21e055b4cfe"
      unitRef="usd">309000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9a1eac7bffc9475a9bbdda86813fd7ee_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjdjYzQyNDI1NjMzOTRhOGY4OWM5NjkyOTg2Mjc0MGI4L3RhYmxlcmFuZ2U6N2NjNDI0MjU2MzM5NGE4Zjg5Yzk2OTI5ODYyNzQwYjhfMTctNS0xLTEtMA_b2b4b382-35cc-4948-a568-5d175f2fddc6"
      unitRef="usd">2321441000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic7bf961275044b01a0c4a9ccebad588f_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjdjYzQyNDI1NjMzOTRhOGY4OWM5NjkyOTg2Mjc0MGI4L3RhYmxlcmFuZ2U6N2NjNDI0MjU2MzM5NGE4Zjg5Yzk2OTI5ODYyNzQwYjhfMTctNy0xLTEtMA_7fdb961c-d8bd-4c09-a6a4-dad3865f3720"
      unitRef="usd">6239000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8a5031970ae845a8b4d0e06e3e6e4934_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjdjYzQyNDI1NjMzOTRhOGY4OWM5NjkyOTg2Mjc0MGI4L3RhYmxlcmFuZ2U6N2NjNDI0MjU2MzM5NGE4Zjg5Yzk2OTI5ODYyNzQwYjhfMTctOS0xLTEtMA_fd2c555e-50e9-4485-8503-9b94d5d65595"
      unitRef="usd">-475958000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjdjYzQyNDI1NjMzOTRhOGY4OWM5NjkyOTg2Mjc0MGI4L3RhYmxlcmFuZ2U6N2NjNDI0MjU2MzM5NGE4Zjg5Yzk2OTI5ODYyNzQwYjhfMTctMTEtMS0xLTA_6b8e45d0-0eef-450c-82e3-de78dc68b2b3"
      unitRef="usd">1852031000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ifad3e2a4eb5e4ee8a6ee49d932419d11_I20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjYzMjRjZjJlNWYwNjRjOWNiNTJjM2U1NTc2YTUxMDhiL3RhYmxlcmFuZ2U6NjMyNGNmMmU1ZjA2NGM5Y2I1MmMzZTU1NzZhNTEwOGJfMTEtMS0xLTEtMA_d50416fc-cb3b-4f81-a85c-ad634253c547"
      unitRef="shares">299876000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ifad3e2a4eb5e4ee8a6ee49d932419d11_I20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjYzMjRjZjJlNWYwNjRjOWNiNTJjM2U1NTc2YTUxMDhiL3RhYmxlcmFuZ2U6NjMyNGNmMmU1ZjA2NGM5Y2I1MmMzZTU1NzZhNTEwOGJfMTEtMy0xLTEtMA_b9a91200-a6e5-42db-9d7e-a0c573a85291"
      unitRef="usd">300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i13b4a5caa8a046bb9f6cc3529e516e24_I20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjYzMjRjZjJlNWYwNjRjOWNiNTJjM2U1NTc2YTUxMDhiL3RhYmxlcmFuZ2U6NjMyNGNmMmU1ZjA2NGM5Y2I1MmMzZTU1NzZhNTEwOGJfMTEtNS0xLTEtMA_67f200b6-7f03-4a44-9ef3-9b2a7b1e74ad"
      unitRef="usd">2168217000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1277e0158f8545d28d0907eafd290af9_I20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjYzMjRjZjJlNWYwNjRjOWNiNTJjM2U1NTc2YTUxMDhiL3RhYmxlcmFuZ2U6NjMyNGNmMmU1ZjA2NGM5Y2I1MmMzZTU1NzZhNTEwOGJfMTEtNy0xLTEtMA_d941e194-d90e-480e-a89f-e4d2d6549e3b"
      unitRef="usd">-701000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i18bb90a064a742e5b5735480b882cb98_I20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjYzMjRjZjJlNWYwNjRjOWNiNTJjM2U1NTc2YTUxMDhiL3RhYmxlcmFuZ2U6NjMyNGNmMmU1ZjA2NGM5Y2I1MmMzZTU1NzZhNTEwOGJfMTEtOS0xLTEtMA_3645918e-c910-4e6d-8b5b-5de10c2a737a"
      unitRef="usd">-880363000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i010170af21d84cd898d00c6336993dba_I20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjYzMjRjZjJlNWYwNjRjOWNiNTJjM2U1NTc2YTUxMDhiL3RhYmxlcmFuZ2U6NjMyNGNmMmU1ZjA2NGM5Y2I1MmMzZTU1NzZhNTEwOGJfMTEtMTEtMS0xLTA_a78d14ed-5bd3-4060-aa82-cdd689186153"
      unitRef="usd">1287453000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i3d7219d185874a2188412be82a05f1ee_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjYzMjRjZjJlNWYwNjRjOWNiNTJjM2U1NTc2YTUxMDhiL3RhYmxlcmFuZ2U6NjMyNGNmMmU1ZjA2NGM5Y2I1MmMzZTU1NzZhNTEwOGJfMTItOS0xLTEtMA_b0f1f760-1c88-431e-a17f-fde89dc8d511"
      unitRef="usd">252269000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjYzMjRjZjJlNWYwNjRjOWNiNTJjM2U1NTc2YTUxMDhiL3RhYmxlcmFuZ2U6NjMyNGNmMmU1ZjA2NGM5Y2I1MmMzZTU1NzZhNTEwOGJfMTItMTEtMS0xLTA_e8d111de-e06d-4c44-a1f8-2402b5e4c128"
      unitRef="usd">252269000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i1aaa1630501a4eb1839161674cac9e08_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjYzMjRjZjJlNWYwNjRjOWNiNTJjM2U1NTc2YTUxMDhiL3RhYmxlcmFuZ2U6NjMyNGNmMmU1ZjA2NGM5Y2I1MmMzZTU1NzZhNTEwOGJfMTMtNy0xLTEtMA_325b8cff-6109-4831-ac75-c81c845e20c3"
      unitRef="usd">3369000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjYzMjRjZjJlNWYwNjRjOWNiNTJjM2U1NTc2YTUxMDhiL3RhYmxlcmFuZ2U6NjMyNGNmMmU1ZjA2NGM5Y2I1MmMzZTU1NzZhNTEwOGJfMTMtMTEtMS0xLTA_4fae4f42-b4dc-4d86-ba2f-67bbf6d1a0b2"
      unitRef="usd">3369000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i7b32b70c60b14ff19391f59a6db9dd0e_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjYzMjRjZjJlNWYwNjRjOWNiNTJjM2U1NTc2YTUxMDhiL3RhYmxlcmFuZ2U6NjMyNGNmMmU1ZjA2NGM5Y2I1MmMzZTU1NzZhNTEwOGJfMTQtMS0xLTEtMA_69c2963f-8310-479d-9d64-e00f0e47bc77"
      unitRef="shares">3900000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i7b32b70c60b14ff19391f59a6db9dd0e_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjYzMjRjZjJlNWYwNjRjOWNiNTJjM2U1NTc2YTUxMDhiL3RhYmxlcmFuZ2U6NjMyNGNmMmU1ZjA2NGM5Y2I1MmMzZTU1NzZhNTEwOGJfMTQtMy0xLTEtMA_a550ae68-9576-4619-9606-fdb4034ac7bc"
      unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i6dab0b7d12c64bcfa11c169e3789d3bf_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjYzMjRjZjJlNWYwNjRjOWNiNTJjM2U1NTc2YTUxMDhiL3RhYmxlcmFuZ2U6NjMyNGNmMmU1ZjA2NGM5Y2I1MmMzZTU1NzZhNTEwOGJfMTQtNS0xLTEtMA_002cf30f-e360-4a9a-bd1f-2e3346be09ab"
      unitRef="usd">23244000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjYzMjRjZjJlNWYwNjRjOWNiNTJjM2U1NTc2YTUxMDhiL3RhYmxlcmFuZ2U6NjMyNGNmMmU1ZjA2NGM5Y2I1MmMzZTU1NzZhNTEwOGJfMTQtMTEtMS0xLTA_882ea346-9757-400b-9f6f-c44928f45b71"
      unitRef="usd">23248000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i6dab0b7d12c64bcfa11c169e3789d3bf_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjYzMjRjZjJlNWYwNjRjOWNiNTJjM2U1NTc2YTUxMDhiL3RhYmxlcmFuZ2U6NjMyNGNmMmU1ZjA2NGM5Y2I1MmMzZTU1NzZhNTEwOGJfMTUtNS0xLTEtMA_4704483e-5362-4f1f-8f20-72a4cf9435a0"
      unitRef="usd">3369000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjYzMjRjZjJlNWYwNjRjOWNiNTJjM2U1NTc2YTUxMDhiL3RhYmxlcmFuZ2U6NjMyNGNmMmU1ZjA2NGM5Y2I1MmMzZTU1NzZhNTEwOGJfMTUtMTEtMS0xLTA_1fe7408f-114e-40cf-9fae-4bd23393c320"
      unitRef="usd">3369000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6dab0b7d12c64bcfa11c169e3789d3bf_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjYzMjRjZjJlNWYwNjRjOWNiNTJjM2U1NTc2YTUxMDhiL3RhYmxlcmFuZ2U6NjMyNGNmMmU1ZjA2NGM5Y2I1MmMzZTU1NzZhNTEwOGJfMTYtNS0xLTEtMA_eb48381b-db25-43f1-bc07-d0576751911d"
      unitRef="usd">40747000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjYzMjRjZjJlNWYwNjRjOWNiNTJjM2U1NTc2YTUxMDhiL3RhYmxlcmFuZ2U6NjMyNGNmMmU1ZjA2NGM5Y2I1MmMzZTU1NzZhNTEwOGJfMTYtMTEtMS0xLTA_65705e0f-7c8f-4eb1-a06c-908a8b7c88a8"
      unitRef="usd">40747000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i05f14b5dcf314304b309c5e87df9f50a_I20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjYzMjRjZjJlNWYwNjRjOWNiNTJjM2U1NTc2YTUxMDhiL3RhYmxlcmFuZ2U6NjMyNGNmMmU1ZjA2NGM5Y2I1MmMzZTU1NzZhNTEwOGJfMTctMS0xLTEtMA_f0c2c5f0-4ad2-4114-a666-12477da9aa94"
      unitRef="shares">303776000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i05f14b5dcf314304b309c5e87df9f50a_I20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjYzMjRjZjJlNWYwNjRjOWNiNTJjM2U1NTc2YTUxMDhiL3RhYmxlcmFuZ2U6NjMyNGNmMmU1ZjA2NGM5Y2I1MmMzZTU1NzZhNTEwOGJfMTctMy0xLTEtMA_98e4cbe3-8ffe-4a95-baf9-5cf5409482b5"
      unitRef="usd">304000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1c6f2cb1dfbd41acbc289114955cd416_I20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjYzMjRjZjJlNWYwNjRjOWNiNTJjM2U1NTc2YTUxMDhiL3RhYmxlcmFuZ2U6NjMyNGNmMmU1ZjA2NGM5Y2I1MmMzZTU1NzZhNTEwOGJfMTctNS0xLTEtMA_741cb046-ddb8-4354-a765-7c26f22142f1"
      unitRef="usd">2228839000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3dac2e6ea3d14a2e8cc5b92c6af71211_I20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjYzMjRjZjJlNWYwNjRjOWNiNTJjM2U1NTc2YTUxMDhiL3RhYmxlcmFuZ2U6NjMyNGNmMmU1ZjA2NGM5Y2I1MmMzZTU1NzZhNTEwOGJfMTctNy0xLTEtMA_6d0d66f7-f197-427c-bdff-16fe0c113ee7"
      unitRef="usd">2668000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic827287aa3294c6a883bc9d0b8a0623f_I20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjYzMjRjZjJlNWYwNjRjOWNiNTJjM2U1NTc2YTUxMDhiL3RhYmxlcmFuZ2U6NjMyNGNmMmU1ZjA2NGM5Y2I1MmMzZTU1NzZhNTEwOGJfMTctOS0xLTEtMA_03ff8834-a84a-437c-8d6b-73133ae13c4e"
      unitRef="usd">-628094000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i34bbe41183cc4f96afa896c1d7f86bb3_I20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zMS9mcmFnOjFkYWNjM2U3YmY4MTQ1YTY4ZTI0MjZjM2Q2MThhNTUzL3RhYmxlOjYzMjRjZjJlNWYwNjRjOWNiNTJjM2U1NTc2YTUxMDhiL3RhYmxlcmFuZ2U6NjMyNGNmMmU1ZjA2NGM5Y2I1MmMzZTU1NzZhNTEwOGJfMTctMTEtMS0xLTA_77d24c7a-ad35-405e-a6b5-e9102d9bc215"
      unitRef="usd">1603717000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMi0xLTEtMS0w_abfa2d1e-5ccf-42b5-84d6-40e96d4bcd40"
      unitRef="usd">83393000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMi0zLTEtMS0w_9bcc5c2b-55a6-4d0e-b747-be683cc26c85"
      unitRef="usd">252269000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfNC0xLTEtMS0w_eb644498-84ec-41b0-986c-e55f61a54746"
      unitRef="usd">6731000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfNC0zLTEtMS0w_10969b3b-61da-4100-9fc4-a439c0738cc8"
      unitRef="usd">6088000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfNS0xLTEtMS0w_6ebddb28-5062-40e0-8e20-ba1605868b44"
      unitRef="usd">85791000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfNS0zLTEtMS0w_81374cf9-17f3-4505-baa5-4fc05c7b06f2"
      unitRef="usd">40747000</us-gaap:ShareBasedCompensation>
    <exel:NoncashLeaseExpense
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfNi0xLTEtMS0w_250f89d1-fdb6-454a-a173-1df167b07757"
      unitRef="usd">3607000</exel:NoncashLeaseExpense>
    <exel:NoncashLeaseExpense
      contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfNi0zLTEtMS0w_2e02eba3-6283-43ce-b319-66fe9a744ce1"
      unitRef="usd">1803000</exel:NoncashLeaseExpense>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfNy0xLTEtMS0w_ef9d2b90-fd64-49b6-8be5-447e2a4b2298"
      unitRef="usd">15803000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfNy0zLTEtMS0w_365a8300-ff87-4347-84c4-7b561f6bb4b2"
      unitRef="usd">56339000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfOC0xLTEtMS0w_9229cbc9-6b41-457b-a003-03e90ab94f4f"
      unitRef="usd">-1609000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfOC0zLTEtMS0w_82f83531-612a-44e0-b1ab-c5acd42e81ba"
      unitRef="usd">621000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMTAtMS0xLTEtMA_e00457fc-11b9-4d20-ad52-cdcbece5afe7"
      unitRef="usd">47074000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMTAtMy0xLTEtMA_01b8bab6-e16c-428b-96ff-9780370e3129"
      unitRef="usd">7017000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMTEtMS0xLTEtMA_2e17b392-0275-44ae-b7e9-8118f0891b42"
      unitRef="usd">13466000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMTEtMy0xLTEtMA_41e74bfa-0270-463e-bd93-fd2a55c714a6"
      unitRef="usd">3528000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMTMtMS0xLTEtMA_f4a2952f-b181-47c4-a6c1-49d0fc299f27"
      unitRef="usd">15868000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMTMtMy0xLTEtMA_7dd91519-93b2-4bed-ae7b-a8b171abee5d"
      unitRef="usd">14108000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMTUtMS0xLTEtMA_c36dcde0-799f-4961-988f-b70c2a11db9b"
      unitRef="usd">4012000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMTUtMy0xLTEtMA_d10b4069-f8bc-4a38-b881-52620ecb93ae"
      unitRef="usd">3592000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMTYtMS0xLTEtMA_8584fece-2084-4995-9007-3d12f77cbb88"
      unitRef="usd">51151000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMTYtMy0xLTEtMA_c7210eb7-4a11-47ee-b6a4-13ae44f0dfec"
      unitRef="usd">33371000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMTctMS0xLTEtMA_edd23108-967d-429f-866f-590f61dcc25b"
      unitRef="usd">175689000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMTctMy0xLTEtMA_e2a91981-b360-4c77-9b1e-93d0b0200bae"
      unitRef="usd">368935000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMTktMS0xLTEtMA_648a9347-2030-4067-b56a-fe78121b2ae7"
      unitRef="usd">16055000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMTktMy0xLTEtMA_bd9c65a5-09dd-46cb-ba93-da7dd95a8c77"
      unitRef="usd">5575000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMjEtMS0xLTEtMA_edf2d4c2-8420-42cc-b490-7fe870f98c4e"
      unitRef="usd">866975000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMjEtMy0xLTEtMA_85e62d78-963a-40b8-88c2-80d0053b8ce8"
      unitRef="usd">887698000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMjItMS0xLTEtMA_16892b03-7ba3-4b99-bdf7-ea0e317f0784"
      unitRef="usd">781324000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMjItMy0xLTEtMA_bd2eec96-7a92-42bb-a525-965124e03dab"
      unitRef="usd">436227000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMjMtMS0xLTEtMA_6460daa9-0df2-4659-a5b0-acb8f34e3df5"
      unitRef="usd">-101706000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMjMtMy0xLTEtMA_13db9700-44d7-4ab5-aea2-ce4ba6360aef"
      unitRef="usd">-457046000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMjUtMS0xLTEtMA_49398a1e-7a9d-44bf-a829-afea4355a1f3"
      unitRef="usd">19682000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMjUtMy0xLTEtMA_49d9bebe-3cf7-4827-bac9-72a0d49f5f89"
      unitRef="usd">18956000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMjYtMS0xLTEtMA_772fdf84-6b61-45c3-b00f-5ae15172723d"
      unitRef="usd">26120000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMjYtMy0xLTEtMA_078b0a7a-a6a0-4bd0-a549-62ed90c5e4b7"
      unitRef="usd">3369000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMjgtMS0xLTEtMA_4da6190b-5a60-4865-814c-9522efaec118"
      unitRef="usd">0</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMjgtMy0xLTEtMA_eb9221cf-5bbc-41e7-ae1d-d5f262f0b119"
      unitRef="usd">-34000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMjktMS0xLTEtMA_99a5269a-fb2a-43d9-a18f-b29824b2f8a0"
      unitRef="usd">-6438000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMjktMy0xLTEtMA_8d3df574-fda8-4091-938e-c3eef484fd83"
      unitRef="usd">15553000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMzAtMS0xLTEtMA_05eefc28-ea79-410e-81c6-3a11595fbef1"
      unitRef="usd">67545000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMzAtMy0xLTEtMA_b1484be9-26a8-4455-a1e3-60258b5e6761"
      unitRef="usd">-72558000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMzEtMS0xLTEtMA_d403bd0e-5ca4-47be-8070-50a862b75e7e"
      unitRef="usd">268137000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i010170af21d84cd898d00c6336993dba_I20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMzEtMy0xLTEtMA_b1a2d24b-80cb-4638-9059-4d21bca3a4c8"
      unitRef="usd">315875000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMzItMS0xLTEtMA_e7188730-b966-4b39-90f0-7b2959141580"
      unitRef="usd">335682000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i34bbe41183cc4f96afa896c1d7f86bb3_I20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMzItMy0xLTEtMA_6c212593-0644-413d-8098-c34f492d76c0"
      unitRef="usd">243317000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <exel:RightOfUseAssetObtainedInExchangeForLeaseLiability
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMzctMS0xLTEtMA_5c5df418-8c77-4189-a3d6-a1189d44b9ca"
      unitRef="usd">1824000</exel:RightOfUseAssetObtainedInExchangeForLeaseLiability>
    <exel:RightOfUseAssetObtainedInExchangeForLeaseLiability
      contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMzctMy0xLTEtMA_82ae9e14-3c30-4123-bb1f-9b8784fd59c0"
      unitRef="usd">12944000</exel:RightOfUseAssetObtainedInExchangeForLeaseLiability>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMzgtMS0xLTEtMA_03912f5a-f9d4-418c-8c64-d7e6bda74134"
      unitRef="usd">843000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMzgtMy0xLTEtMA_4d248689-efa3-4e89-86ee-106b45ff51ba"
      unitRef="usd">159000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <exel:LiabilitiesExpendituresIncurredButNotYetPaidToRelatedPartyTransactions
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMzktMS0xLTEtMA_79794ea1-f0f0-49ef-9186-56b037b3a72a"
      unitRef="usd">0</exel:LiabilitiesExpendituresIncurredButNotYetPaidToRelatedPartyTransactions>
    <exel:LiabilitiesExpendituresIncurredButNotYetPaidToRelatedPartyTransactions
      contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF8zNC9mcmFnOmM2MDg5NWRlY2EwMzRhYjQ5NDg1YmM1YmFhZGFhNzZlL3RhYmxlOjRjNmNhMmRhMzhiZjRlMGZhNGMyZTYwYTBmNWZmMmEzL3RhYmxlcmFuZ2U6NGM2Y2EyZGEzOGJmNGUwZmE0YzJlNjBhMGY1ZmYyYTNfMzktMy0xLTEtMA_586191b5-5f2a-4aa0-b2e7-83d4d19f0e4c"
      unitRef="usd">8961000</exel:LiabilitiesExpendituresIncurredButNotYetPaidToRelatedPartyTransactions>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80MC9mcmFnOjIwZjk1ZGUyZGQ0YzQ1MWZiZWU3MjM2ODkyNmFlNmE3L3RleHRyZWdpb246MjBmOTVkZTJkZDRjNDUxZmJlZTcyMzY4OTI2YWU2YTdfMjA3MzI_656ebf6e-d53b-4d36-a5fa-ecd702c0b96d">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Organization&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exelixis, Inc. (Exelixis, we, our or us) is an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our drug discovery and development capabilities and commercialization platform are the foundations upon which we intend to bring to market novel, effective and tolerable therapies to provide cancer patients with additional treatment options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since we were founded in 1994, four products resulting from our discovery efforts&#160;have progressed through clinical development, received regulatory approval and established a commercial presence in various geographies around the world. Two are derived from cabozantinib, our flagship molecule, an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. Our cabozantinib products are: CABOMETYX&#xae; (cabozantinib) tablets approved for advanced renal cell carcinoma (RCC) and previously treated hepatocellular carcinoma; and COMETRIQ&#xae;&#160;(cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer. For these types of cancer, cabozantinib has become or is becoming a standard of care. Beyond these approved indications, cabozantinib is currently the focus of a broad clinical development program and is being investigated both alone and in combination with other therapies in a wide variety of cancers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The other two products resulting from our discovery efforts are: COTELLIC&#xae; (cobimetinib), an inhibitor of MEK, approved as part of multiple combination regimens to treat specific forms of advanced melanoma and marketed under a collaboration with Genentech, Inc. (a member of the Roche Group) (Genentech); and MINNEBRO&#xae; (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor, approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo Company, Limited (Daiichi Sankyo).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also remain committed to building our product pipeline by discovering and developing new therapies for cancer patients. Using our in-house drug discovery expertise, specifically in medicinal chemistry, tumor biology and pharmacology, we are advancing small molecule drug candidates toward and through preclinical development. In addition, we have augmented our internal drug discovery activities with multiple partnerships, including several that enable us to discover and advance various biologics, such as bispecific antibodies and antibody-drug conjugates (ADCs), and we continue to engage in business development initiatives aimed at identifying and in-licensing promising, early-stage oncology assets, which we can further develop utilizing our established clinical development infrastructure.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Condensed Consolidated Financial Statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&#x2019; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of our financial statements for the periods presented have been included. Operating results for the three and nine months ended September&#160;30, 2020 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2020 or for any future period. The accompanying Condensed Consolidated Financial Statements and Notes thereto should be read in conjunction with our Consolidated Financial Statements and Notes thereto for the year ended December&#160;31, 2019, included in our Annual Report on Form 10-K filed with the SEC on February&#160;25, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;st&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Fiscal year 2020, which is a 52-week fiscal year, will end on January 1, 2021 and fiscal year 2019, which was a 53-week fiscal year, ended on January 3, 2020. For convenience, references in this report as of and for the fiscal periods ended October 2, 2020 and September 27, 2019, and as of and for the fiscal years ending January 1, 2021, and ended January 3, 2020, are indicated as being as of and for the fiscal periods ended September 30, 2020 and September 30, 2019 and the years ending &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2020 and ended December&#160;31, 2019, respectively. Similarly, references in this report to the first day of the fiscal year ending January 1, 2021 are indicated as being as of January 1, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain prior period amounts in the accompanying Condensed Consolidated Financial Statements have been reclassified to conform to the current period presentation. Such reclassifications did not impact previously reported total revenues, income from operations, net income, total assets, total liabilities or total stockholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate in one business segment that focuses on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of our long-lived assets are located in the U.S. See &#x201c;Note 2. Revenues&#x201d; for enterprise-wide disclosures about product sales, revenues from major customers and revenues by geographic region.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the accompanying Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, we received the Preliminary Calculation of our Branded Prescription Drug Fee for 2020, and in August 2020, the Final Calculation of our Branded Prescription Drug Fee for 2020 from the Internal Revenue Service for the 2018 sales year, which resulted in an increase in our estimate of such fees for the 2018 and 2019 sales years. Accordingly, we recorded an adjustment to increase selling, general and administrative expenses and our accrual for these fees by&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; $5.1&#160;million du&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ring t&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;he nine months ended September 30, 2020. This adjustment resulted in a $0.02 decrease in basic and diluted earnings per share for the nine months ended September&#160;30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2020, we adopted Accounting Standards Update (ASU) No.&#160;201&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8-18,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASU 2018-18). ASU 2018-18 clarifies that certain transactions between collaborative arrangement participants should be accounted for as part of revenues under Accounting Standards Codification (ASC) Topic 606,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Revenue from Contracts with Customers &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Topic 606) when the counterparty is a customer for a distinct good or service (i.e. a unit of account). For units of account that are in the scope of Topic 606, all of the guidance in Topic 606 should be applied, including the guidance on recognition, measurement, presentation and disclosure. ASU 2018-18 precludes entities from presenting amounts related to transactions with a counterparty in a collaborative arrangement that is not a customer together with revenue from contracts with customers. If a portion of a distinct bundle of goods or services within an arrangement is not with a customer, then the unit of account is not within the scope of Topic 606, and the recognition and measurement of that unit of account shall be based on analogy to authoritative accounting literature or, if there is no appropriate analogy, a reasonable, rational, and consistently applied accounting policy election. Upon adoption of ASU 2018-18, we have presented revenues from performance obligations associated with our collaboration arrangements that are within the scope of Topic 606 (license revenues) separately from revenues from performance obligations that are not subject to Topic 606 (collaboration services revenues). The adoption of ASU 2018-18 was applied retrospectively, and prior periods have been restated to conform to the presentation prescribed by ASU 2018-18. The adoption of ASU 2018-18 did not impact total revenues for the prior period presented in the accompanying Condensed Consolidated Statements of Income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2020, we adopted ASU No.&#160;2017-04,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Intangibles&#x2014;Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASU 2017-04)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ASU 2017-04 simplifies goodwill impairment testing by eliminating the second &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;step of the impairment test. The amended guidance requires an impairment charge to be recognized for the amount by which the carrying amount of a reporting unit exceeds its fair value under a one-step impairment test. The adoption of ASU 2017-04 did not impact the accompanying Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2020, we adopted ASU No.&#160;2016-13,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Financial Instruments&#x2014;Credit Losses (Topic 326) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASU 2016-13)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU 2016-13 implements an impairment model, known as the current expected credit loss model, that is based on expected losses rather than incurred losses. Under the new guidance, we will recognize our estimate of current expected credit losses as an allowance on financial assets measured at amortized cost, including accounts receivable, unbilled collaboration revenues, and investments classified as available for sale. Current expected credit losses were immaterial as of the date of adoption, and the adoption of ASU 2016-13 did not have a significant impact on the accompanying Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Investment Impairment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Quarterly, we assess each of our investments in debt securities available-for-sale whose fair value is below its cost basis to determine if the investment&#x2019;s impairment is due to credit-related factors or noncredit-related factors. Factors considered in determining whether an impairment is credit-related include the extent to which the investment&#x2019;s fair value is less than its cost basis, declines in published credit ratings, issuer default on interest or principal payments, and declines in the financial condition and near-term prospects of the issuer. If we determine a credit-related impairment exists, we will measure the credit loss based on a discounted cash flows model. Credit-related impairments on debt securities available-for-sale are recognized as an allowance for credit losses with a corresponding adjustment to other income, net in the accompanying Condensed Consolidated Statements of Income. The portion of the impairment that is not credit-related is recorded, net of applicable taxes, as a reduction of other comprehensive income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have elected to exclude accrued interest from both the fair value and the amortized cost basis of debt securities available-for-sale for the purposes of identifying and measuring an impairment. We write-off accrued interest as a reduction of interest income when an issuer has defaulted on interest payments due on a security.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade receivables, net contain amounts billed to our customers for product sales, and amounts billed to our collaboration partners for development, regulatory and sales-based milestone payments, royalties on the sale of licensed products, profit-sharing arrangements, development cost reimbursements, and payments for product supply services. Our customers are primarily pharmaceutical and biotechnology companies that are located in the U.S., and collaboration partners that are located in Europe and Japan. As of September 30, 2020 and December 31, 2019, 47% and 38%, respectively, of our trade receivables were from our collaboration partner Ipsen Pharma SAS (Ipsen), and 12% and 14% were from affiliates of McKesson Corporation. We record trade receivables net of allowances for credit losses and chargebacks, and cash discounts for prompt payment. We apply an aging method to estimate credit losses and consider our historical loss information, adjusted to account for current conditions, and reasonable and supportable forecasts of future economic conditions affecting our customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recorded goodwill amounts as the excess purchase price over tangible assets, liabilities and intangible assets acquired based on their estimated fair value. We review the carrying amount of goodwill for impairment annually and whenever events or changes in circumstance indicate that the carrying value may not be recoverable. We perform our annual assessment of the recoverability of our goodwill as of the first day of our fourth quarter. The assessment of recoverability may first consider qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. We perform a quantitative assessment if the qualitative assessment results in a more likely than not determination or if a qualitative assessment is not performed. The quantitative assessment determines whether the carrying amount of a reporting unit exceeds its fair value, in which case an impairment charge is recognized for the amount by which the carrying amount of a reporting unit exceeds its fair value, limited to the goodwill balance. We operate in one business segment, which is also considered to be our sole reporting unit and therefore, goodwill is tested for impairment at the enterprise level. We did not recognize any impairment charges in any of the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Collaboration Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess whether our collaboration agreements are subject to ASC Topic 808,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;(Topic 808) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic&#160;808, we apply by analogy the unit of account guidance under Topic 606 to identify distinct performance obligations, and then determine whether a customer relationship exists for each distinct performance obligation. If we determine a performance obligation within the arrangement is with a customer, we apply the guidance in Topic 606. If a portion of a distinct bundle of goods or services within an arrangement is not with a customer, then the unit of account is not within the scope of Topic&#160;606, and the recognition and measurement of that unit of account shall be based on analogy to authoritative accounting literature or, if there is no appropriate analogy, a reasonable, rational, and consistently applied accounting policy election. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We enter into collaboration arrangements, under which we license certain rights to our intellectual property to third parties. The terms of these arrangements typically include payments to us for one or more of the following: nonrefundable up-front license fees; development, regulatory and sales-based milestone payments; product supply services; development cost reimbursements; profit-sharing arrangements; and royalties on net sales of licensed products. As part of the accounting for these arrangements, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include forecasted revenues, clinical development timelines and costs, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Up-front License Fees: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from nonrefundable up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license, which generally occurs at or near the inception of the contract. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenues from nonrefundable up-front fees. We evaluate the measure of progress at the end of each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Regulatory and Development Milestone Payments: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of each arrangement that includes development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our or the licensee&#x2019;s control, such as regulatory approvals, are not considered probable of being achieved until uncertainty associated with the approvals has been resolved. The transaction price is then allocated to each performance obligation, on a relative standalone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achieving such development and regulatory milestones and any related variable consideration constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Supply Services:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Arrangements that include a promise for the future supply of drug product for either clinical development or commercial supply at the licensee&#x2019;s discretion are generally considered as options. We assess if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Development Cost Reimbursements:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Our collaboration arrangements may include promises of future clinical development and drug safety services, as well as participation on certain joint committees. When such services are provided to a customer, and they are distinct from the licenses provided to our collaboration partners, these promises are accounted for as a separate performance obligation which we estimate using internal development costs incurred and projections through the term of the arrangements. We record revenues for these services as the performance obligations are satisfied over time based on measure of progress. However, if we conclude that our collaboration partner is not a customer for those collaborative research and development activities, we present such payments as a reduction of research and development expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Profit-sharing Arrangements: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of our collaboration agreement with Genentech for cobimetinib, we are entitled to a share of U.S. profits and losses received in connection with the commercialization of cobimetinib. We &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;account for this arrangement in accordance with Topic 606. We have determined that we are an agent under the agreement and therefore revenues are recorded net of costs incurred. We record revenues for the variable consideration associated with the profits and losses under the collaboration agreement when it is probable that a significant reversal in the amount of cumulative revenues recognized will not occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalty and Sales-based Milestone Payments:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; For arrangements that include royalties and sales-based milestone payments, including milestone payments earned for the first commercial sale of a product, the license is deemed to be the predominant item to which such payments relate and we recognize revenues at the later of when the related sales occur or when the performance obligation to which the royalty has been allocated has been satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the Financial Accounting Standards Board issued&#160;ASU 2019-12,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740)-Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASU 2019-12). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in ASC Topic 740, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and clarifying and amending existing guidance. ASU 2019-12 will be effective for us in the first quarter of 2021 with early adoption permitted. We are currently assessing the impact of ASU 2019-12 on our financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <exel:NumberofProductsinCommercialMarket
      contextRef="if5e8e1669be6453aa3ae0fc322692c38_D20200104-20201002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80MC9mcmFnOjIwZjk1ZGUyZGQ0YzQ1MWZiZWU3MjM2ODkyNmFlNmE3L3RleHRyZWdpb246MjBmOTVkZTJkZDRjNDUxZmJlZTcyMzY4OTI2YWU2YTdfNTcw_d71d1502-0ed3-4694-a886-61eac96bdeb1"
      unitRef="product">4</exel:NumberofProductsinCommercialMarket>
    <exel:NumberofProductsinCommercialMarket
      contextRef="ibe41da152065437483e7469fa266c06d_D20200104-20201002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80MC9mcmFnOjIwZjk1ZGUyZGQ0YzQ1MWZiZWU3MjM2ODkyNmFlNmE3L3RleHRyZWdpb246MjBmOTVkZTJkZDRjNDUxZmJlZTcyMzY4OTI2YWU2YTdfNzcz_5f73edec-0a1b-4d46-9e46-91fe294af023"
      unitRef="product">2</exel:NumberofProductsinCommercialMarket>
    <exel:NumberofProductsinCommercialMarket
      contextRef="ie9df0cd737b54a18828c9607339f712f_D20200104-20201002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80MC9mcmFnOjIwZjk1ZGUyZGQ0YzQ1MWZiZWU3MjM2ODkyNmFlNmE3L3RleHRyZWdpb246MjBmOTVkZTJkZDRjNDUxZmJlZTcyMzY4OTI2YWU2YTdfMTQ4OA_89ad324d-f7d4-4109-b7aa-48a3b79781b9"
      unitRef="product">2</exel:NumberofProductsinCommercialMarket>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80MC9mcmFnOjIwZjk1ZGUyZGQ0YzQ1MWZiZWU3MjM2ODkyNmFlNmE3L3RleHRyZWdpb246MjBmOTVkZTJkZDRjNDUxZmJlZTcyMzY4OTI2YWU2YTdfMjA3NTk_2f151e08-3984-4f96-879f-896a78dbef04">The accompanying Condensed Consolidated Financial Statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&#x2019; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80MC9mcmFnOjIwZjk1ZGUyZGQ0YzQ1MWZiZWU3MjM2ODkyNmFlNmE3L3RleHRyZWdpb246MjBmOTVkZTJkZDRjNDUxZmJlZTcyMzY4OTI2YWU2YTdfMjA3NjI_be16dd2a-925e-41e7-8d2a-eb5bdc493bf1">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of our financial statements for the periods presented have been included. Operating results for the three and nine months ended September&#160;30, 2020 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2020 or for any future period. The accompanying Condensed Consolidated Financial Statements and Notes thereto should be read in conjunction with our Consolidated Financial Statements and Notes thereto for the year ended December&#160;31, 2019, included in our Annual Report on Form 10-K filed with the SEC on February&#160;25, 2020.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:FiscalPeriod
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80MC9mcmFnOjIwZjk1ZGUyZGQ0YzQ1MWZiZWU3MjM2ODkyNmFlNmE3L3RleHRyZWdpb246MjBmOTVkZTJkZDRjNDUxZmJlZTcyMzY4OTI2YWU2YTdfMjA3Mzc_32188ed7-b967-4c42-8c26-921fbe987890">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;st&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Fiscal year 2020, which is a 52-week fiscal year, will end on January 1, 2021 and fiscal year 2019, which was a 53-week fiscal year, ended on January 3, 2020. For convenience, references in this report as of and for the fiscal periods ended October 2, 2020 and September 27, 2019, and as of and for the fiscal years ending January 1, 2021, and ended January 3, 2020, are indicated as being as of and for the fiscal periods ended September 30, 2020 and September 30, 2019 and the years ending &lt;/span&gt;December&#160;31, 2020 and ended December&#160;31, 2019, respectively. Similarly, references in this report to the first day of the fiscal year ending January 1, 2021 are indicated as being as of January 1, 2020.</us-gaap:FiscalPeriod>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80MC9mcmFnOjIwZjk1ZGUyZGQ0YzQ1MWZiZWU3MjM2ODkyNmFlNmE3L3RleHRyZWdpb246MjBmOTVkZTJkZDRjNDUxZmJlZTcyMzY4OTI2YWU2YTdfMjA3NTY_53b1ef88-1d39-41a1-9a20-8d92b78c9b30">Certain prior period amounts in the accompanying Condensed Consolidated Financial Statements have been reclassified to conform to the current period presentation. Such reclassifications did not impact previously reported total revenues, income from operations, net income, total assets, total liabilities or total stockholders&#x2019; equity.</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80MC9mcmFnOjIwZjk1ZGUyZGQ0YzQ1MWZiZWU3MjM2ODkyNmFlNmE3L3RleHRyZWdpb246MjBmOTVkZTJkZDRjNDUxZmJlZTcyMzY4OTI2YWU2YTdfMjA3NzU_ea659790-5807-4f51-ba0b-5bb8dba0cfef">We operate in one business segment that focuses on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80MC9mcmFnOjIwZjk1ZGUyZGQ0YzQ1MWZiZWU3MjM2ODkyNmFlNmE3L3RleHRyZWdpb246MjBmOTVkZTJkZDRjNDUxZmJlZTcyMzY4OTI2YWU2YTdfNDU2MA_6e88aa5a-64b7-4f8a-a7ed-daa9bcee4d3b"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:UseOfEstimates
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80MC9mcmFnOjIwZjk1ZGUyZGQ0YzQ1MWZiZWU3MjM2ODkyNmFlNmE3L3RleHRyZWdpb246MjBmOTVkZTJkZDRjNDUxZmJlZTcyMzY4OTI2YWU2YTdfMjA3NTc_7770d901-6909-4ae4-b752-4de766bb35e9">The preparation of the accompanying Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.In March 2020, we received the Preliminary Calculation of our Branded Prescription Drug Fee for 2020, and in August 2020, the Final Calculation of our Branded Prescription Drug Fee for 2020 from the Internal Revenue Service for the 2018 sales year, which resulted in an increase in our estimate of such fees for the 2018 and 2019 sales years.</us-gaap:UseOfEstimates>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i6b8fc82f50494df690850a723f567147_D20200104-20201002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80MC9mcmFnOjIwZjk1ZGUyZGQ0YzQ1MWZiZWU3MjM2ODkyNmFlNmE3L3RleHRyZWdpb246MjBmOTVkZTJkZDRjNDUxZmJlZTcyMzY4OTI2YWU2YTdfMTA0NDUzNjA0ODYxODA_e698a617-738a-4411-b4b5-eb700a07f77b"
      unitRef="usd">5100000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i6b8fc82f50494df690850a723f567147_D20200104-20201002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80MC9mcmFnOjIwZjk1ZGUyZGQ0YzQ1MWZiZWU3MjM2ODkyNmFlNmE3L3RleHRyZWdpb246MjBmOTVkZTJkZDRjNDUxZmJlZTcyMzY4OTI2YWU2YTdfNjUwNA_60ac4cfd-1be1-4bc5-b091-98fa9b4c4945"
      unitRef="usdPerShare">-0.02</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80MC9mcmFnOjIwZjk1ZGUyZGQ0YzQ1MWZiZWU3MjM2ODkyNmFlNmE3L3RleHRyZWdpb246MjBmOTVkZTJkZDRjNDUxZmJlZTcyMzY4OTI2YWU2YTdfMjA3Njc_b1659d10-cb08-4074-bbe7-893492d11301">&lt;div style="margin-top:9pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2020, we adopted Accounting Standards Update (ASU) No.&#160;201&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8-18,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASU 2018-18). ASU 2018-18 clarifies that certain transactions between collaborative arrangement participants should be accounted for as part of revenues under Accounting Standards Codification (ASC) Topic 606,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Revenue from Contracts with Customers &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Topic 606) when the counterparty is a customer for a distinct good or service (i.e. a unit of account). For units of account that are in the scope of Topic 606, all of the guidance in Topic 606 should be applied, including the guidance on recognition, measurement, presentation and disclosure. ASU 2018-18 precludes entities from presenting amounts related to transactions with a counterparty in a collaborative arrangement that is not a customer together with revenue from contracts with customers. If a portion of a distinct bundle of goods or services within an arrangement is not with a customer, then the unit of account is not within the scope of Topic 606, and the recognition and measurement of that unit of account shall be based on analogy to authoritative accounting literature or, if there is no appropriate analogy, a reasonable, rational, and consistently applied accounting policy election. Upon adoption of ASU 2018-18, we have presented revenues from performance obligations associated with our collaboration arrangements that are within the scope of Topic 606 (license revenues) separately from revenues from performance obligations that are not subject to Topic 606 (collaboration services revenues). The adoption of ASU 2018-18 was applied retrospectively, and prior periods have been restated to conform to the presentation prescribed by ASU 2018-18. The adoption of ASU 2018-18 did not impact total revenues for the prior period presented in the accompanying Condensed Consolidated Statements of Income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2020, we adopted ASU No.&#160;2017-04,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Intangibles&#x2014;Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASU 2017-04)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ASU 2017-04 simplifies goodwill impairment testing by eliminating the second &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;step of the impairment test. The amended guidance requires an impairment charge to be recognized for the amount by which the carrying amount of a reporting unit exceeds its fair value under a one-step impairment test. The adoption of ASU 2017-04 did not impact the accompanying Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2020, we adopted ASU No.&#160;2016-13,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Financial Instruments&#x2014;Credit Losses (Topic 326) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASU 2016-13)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU 2016-13 implements an impairment model, known as the current expected credit loss model, that is based on expected losses rather than incurred losses. Under the new guidance, we will recognize our estimate of current expected credit losses as an allowance on financial assets measured at amortized cost, including accounts receivable, unbilled collaboration revenues, and investments classified as available for sale. Current expected credit losses were immaterial as of the date of adoption, and the adoption of ASU 2016-13 did not have a significant impact on the accompanying Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Investment Impairment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Quarterly, we assess each of our investments in debt securities available-for-sale whose fair value is below its cost basis to determine if the investment&#x2019;s impairment is due to credit-related factors or noncredit-related factors. Factors considered in determining whether an impairment is credit-related include the extent to which the investment&#x2019;s fair value is less than its cost basis, declines in published credit ratings, issuer default on interest or principal payments, and declines in the financial condition and near-term prospects of the issuer. If we determine a credit-related impairment exists, we will measure the credit loss based on a discounted cash flows model. Credit-related impairments on debt securities available-for-sale are recognized as an allowance for credit losses with a corresponding adjustment to other income, net in the accompanying Condensed Consolidated Statements of Income. The portion of the impairment that is not credit-related is recorded, net of applicable taxes, as a reduction of other comprehensive income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have elected to exclude accrued interest from both the fair value and the amortized cost basis of debt securities available-for-sale for the purposes of identifying and measuring an impairment. We write-off accrued interest as a reduction of interest income when an issuer has defaulted on interest payments due on a security.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade receivables, net contain amounts billed to our customers for product sales, and amounts billed to our collaboration partners for development, regulatory and sales-based milestone payments, royalties on the sale of licensed products, profit-sharing arrangements, development cost reimbursements, and payments for product supply services. Our customers are primarily pharmaceutical and biotechnology companies that are located in the U.S., and collaboration partners that are located in Europe and Japan. As of September 30, 2020 and December 31, 2019, 47% and 38%, respectively, of our trade receivables were from our collaboration partner Ipsen Pharma SAS (Ipsen), and 12% and 14% were from affiliates of McKesson Corporation. We record trade receivables net of allowances for credit losses and chargebacks, and cash discounts for prompt payment. We apply an aging method to estimate credit losses and consider our historical loss information, adjusted to account for current conditions, and reasonable and supportable forecasts of future economic conditions affecting our customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recorded goodwill amounts as the excess purchase price over tangible assets, liabilities and intangible assets acquired based on their estimated fair value. We review the carrying amount of goodwill for impairment annually and whenever events or changes in circumstance indicate that the carrying value may not be recoverable. We perform our annual assessment of the recoverability of our goodwill as of the first day of our fourth quarter. The assessment of recoverability may first consider qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. We perform a quantitative assessment if the qualitative assessment results in a more likely than not determination or if a qualitative assessment is not performed. The quantitative assessment determines whether the carrying amount of a reporting unit exceeds its fair value, in which case an impairment charge is recognized for the amount by which the carrying amount of a reporting unit exceeds its fair value, limited to the goodwill balance. We operate in one business segment, which is also considered to be our sole reporting unit and therefore, goodwill is tested for impairment at the enterprise level. We did not recognize any impairment charges in any of the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Collaboration Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess whether our collaboration agreements are subject to ASC Topic 808,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;(Topic 808) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic&#160;808, we apply by analogy the unit of account guidance under Topic 606 to identify distinct performance obligations, and then determine whether a customer relationship exists for each distinct performance obligation. If we determine a performance obligation within the arrangement is with a customer, we apply the guidance in Topic 606. If a portion of a distinct bundle of goods or services within an arrangement is not with a customer, then the unit of account is not within the scope of Topic&#160;606, and the recognition and measurement of that unit of account shall be based on analogy to authoritative accounting literature or, if there is no appropriate analogy, a reasonable, rational, and consistently applied accounting policy election. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We enter into collaboration arrangements, under which we license certain rights to our intellectual property to third parties. The terms of these arrangements typically include payments to us for one or more of the following: nonrefundable up-front license fees; development, regulatory and sales-based milestone payments; product supply services; development cost reimbursements; profit-sharing arrangements; and royalties on net sales of licensed products. As part of the accounting for these arrangements, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include forecasted revenues, clinical development timelines and costs, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Up-front License Fees: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from nonrefundable up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license, which generally occurs at or near the inception of the contract. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenues from nonrefundable up-front fees. We evaluate the measure of progress at the end of each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Regulatory and Development Milestone Payments: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of each arrangement that includes development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our or the licensee&#x2019;s control, such as regulatory approvals, are not considered probable of being achieved until uncertainty associated with the approvals has been resolved. The transaction price is then allocated to each performance obligation, on a relative standalone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achieving such development and regulatory milestones and any related variable consideration constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Supply Services:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Arrangements that include a promise for the future supply of drug product for either clinical development or commercial supply at the licensee&#x2019;s discretion are generally considered as options. We assess if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Development Cost Reimbursements:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Our collaboration arrangements may include promises of future clinical development and drug safety services, as well as participation on certain joint committees. When such services are provided to a customer, and they are distinct from the licenses provided to our collaboration partners, these promises are accounted for as a separate performance obligation which we estimate using internal development costs incurred and projections through the term of the arrangements. We record revenues for these services as the performance obligations are satisfied over time based on measure of progress. However, if we conclude that our collaboration partner is not a customer for those collaborative research and development activities, we present such payments as a reduction of research and development expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Profit-sharing Arrangements: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of our collaboration agreement with Genentech for cobimetinib, we are entitled to a share of U.S. profits and losses received in connection with the commercialization of cobimetinib. We &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;account for this arrangement in accordance with Topic 606. We have determined that we are an agent under the agreement and therefore revenues are recorded net of costs incurred. We record revenues for the variable consideration associated with the profits and losses under the collaboration agreement when it is probable that a significant reversal in the amount of cumulative revenues recognized will not occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalty and Sales-based Milestone Payments:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; For arrangements that include royalties and sales-based milestone payments, including milestone payments earned for the first commercial sale of a product, the license is deemed to be the predominant item to which such payments relate and we recognize revenues at the later of when the related sales occur or when the performance obligation to which the royalty has been allocated has been satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the Financial Accounting Standards Board issued&#160;ASU 2019-12,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740)-Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASU 2019-12). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in ASC Topic 740, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and clarifying and amending existing guidance. ASU 2019-12 will be effective for us in the first quarter of 2021 with early adoption permitted. We are currently assessing the impact of ASU 2019-12 on our financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i53d5d16c99e24b1685ffd6417b746dc5_D20200104-20201002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80MC9mcmFnOjIwZjk1ZGUyZGQ0YzQ1MWZiZWU3MjM2ODkyNmFlNmE3L3RleHRyZWdpb246MjBmOTVkZTJkZDRjNDUxZmJlZTcyMzY4OTI2YWU2YTdfMTA0NDUzNjA0ODgwMTA_98a3bb96-b4c6-459f-8f23-c58cd2f0b117"
      unitRef="number">0.47</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i988d96d56fc8488e825029b9ae6e78da_D20181229-20200103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80MC9mcmFnOjIwZjk1ZGUyZGQ0YzQ1MWZiZWU3MjM2ODkyNmFlNmE3L3RleHRyZWdpb246MjBmOTVkZTJkZDRjNDUxZmJlZTcyMzY4OTI2YWU2YTdfMTA0NDUzNjA0ODgwMTU_6066c1a8-49c4-48c9-b0a1-38bac8a98899"
      unitRef="number">0.38</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib4f8f5605ff6401098c5e709f8d70e2f_D20200104-20201002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80MC9mcmFnOjIwZjk1ZGUyZGQ0YzQ1MWZiZWU3MjM2ODkyNmFlNmE3L3RleHRyZWdpb246MjBmOTVkZTJkZDRjNDUxZmJlZTcyMzY4OTI2YWU2YTdfMTA0NDUzNjA0ODgwMjA_1d9da526-374b-4424-85d8-08aed2f02c24"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i1d8dbceba046414c9646347dd14f559d_D20181229-20200103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80MC9mcmFnOjIwZjk1ZGUyZGQ0YzQ1MWZiZWU3MjM2ODkyNmFlNmE3L3RleHRyZWdpb246MjBmOTVkZTJkZDRjNDUxZmJlZTcyMzY4OTI2YWU2YTdfMTA0NDUzNjA0ODgwMjU_63331217-b5cb-4fbd-a396-340fc58fb330"
      unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80MC9mcmFnOjIwZjk1ZGUyZGQ0YzQ1MWZiZWU3MjM2ODkyNmFlNmE3L3RleHRyZWdpb246MjBmOTVkZTJkZDRjNDUxZmJlZTcyMzY4OTI2YWU2YTdfMTM1NDU_6e88aa5a-64b7-4f8a-a7ed-daa9bcee4d3b"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80MC9mcmFnOjIwZjk1ZGUyZGQ0YzQ1MWZiZWU3MjM2ODkyNmFlNmE3L3RleHRyZWdpb246MjBmOTVkZTJkZDRjNDUxZmJlZTcyMzY4OTI2YWU2YTdfMTM3MDI_613fe927-1eb6-41f0-8b9f-1f458f8f7c13"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RleHRyZWdpb246MGE4MmQ4MjNlMWM0NDg1OWFkNTUzYmNhNmNhMTE1ZTdfNDg1MQ_963a1031-8c63-4ae5-9723-f78fd30f75bc">REVENUES&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross product revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;702,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;704,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discounts and allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51,814)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48,148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(161,668)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(139,060)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net product revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;541,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;565,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total collaboration revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;727,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net product revenues and license revenues are recorded in accordance with Topic 606. License revenues include the recognition of the portion of milestones payments allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the milestone would be achieved and a significant reversal of revenues would not occur, as well as royalty revenues and our share of profits under our collaboration agreement with Genentech. Collaboration services revenues were recorded in accordance with Topic 808 and by analogy to Topic 606. Collaboration services revenues include the recognition of deferred revenues for the portion of upfront and milestone payments allocated to our research and development services performance obligations, development cost reimbursements earned under our collaboration agreements, product supply revenues, net of product supply costs, and the royalties we paid to GlaxoSmithKline (GSK) on sales of products containing cabozantinib by our collaboration partners.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net product revenues by product were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CABOMETYX&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;522,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;552,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;COMETRIQ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net product revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;541,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;565,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The percentage of total revenues by customer who individually accounted for&#160;10%&#160;or more of our total revenues were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ipsen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of CVS Health Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of Optum Specialty Pharmacy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Takeda Pharmaceutical Company Limited (Takeda)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues by geographic region were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;549,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;572,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;727,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net product revenues are attributed to geographic region based on the ship-to location. License and collaboration services revenues are attributed to geographic region based on the location of our collaboration partners&#x2019; headquarters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Product Sales Discounts and Allowances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.590%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Chargebacks and Discounts for Prompt Payment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other Customer Credits/Fees and Co-pay Assistance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Rebates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision related to sales made in:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(352)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments and customer credits issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(107,118)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,513)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41,546)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(160,177)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September&#160;30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The allowance for chargebacks and discounts for prompt payment is recorded as a reduction of trade receivables, net and the remaining reserves are recorded as rebates and fees due to customers in the accompanying Condensed Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contract Assets and Liabilities &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We receive payments from our collaboration partners based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. We may also recognize revenues in advance of the contractual billing schedule and such amounts are recorded, net of any allowance for credit losses, as a contract asset when recognized. Contract assets, which are presented in prepaid expenses and other current assets in the accompanying Condensed Consolidated Balance Sheets, we&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;re $0 and&#160;$1.1 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;as of&#160;September&#160;30, 2020 and December&#160;31, 2019, respectively. We may be required to defer recognition of revenues for upfront and milestone payments until we perform our obligations under these arrangements, and such amounts are recorded as deferred revenues upon receipt or when due. Contract liabilities we&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;re $10.6 million and&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$6.6 million&#160;as of&#160;September&#160;30, 2020 and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2019, respectively. The current portion of th&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;e contract liabilities totaling $1.3 million and $0 as of&#160;September&#160;30, 2020 and December&#160;31, 2019, respectively, are presented in other current liabilities and the remainder of the contract liabilities are presented in long-term portion of deferred revenues as of those dates in the accompanyi&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ng Condensed Consolidated Balance Sheets. For those contracts that have multiple performance obligations, contract&#160;assets and liabilities are reported on a&#160;net&#160;basis&#160;at the&#160;contract&#160;level. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant changes in contract assets during the nine months ended September&#160;30, 2020 include the impact of a $20.0 million development milestone from Ipsen we determined was probable of achievement, which was offset by the impact of a $10.0 million milestone from Takeda which was recognized as revenues during the year ended December 31, 2019 and was achieved, invoiced and collected in the first quarter of 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended September&#160;30, 2020 and 2019, we recognized $6.8 million and $2.7 million, respectively, in revenues that were included in the beginning deferred revenues balance for those periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and nine months ended September&#160;30, 2020, we recognized $33.1 million and $115.3 million, respectively, in revenues for performance obligations satisfied in previous periods as compared to $67.7 million and $129.0 million during the comparable periods in 2019. Such revenues primarily related to milestone and royalty payments allocated to the license performance obligations for our collaborations with Ipsen, Takeda, Daiichi Sankyo and Genentech.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, $88.9 million of t&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;he combined transaction prices for our Ipsen and Takeda collaborations were allocated to performance obligations that had not yet been satisfied. See &#x201c;Note 3. Collaboration Agreements - Cabozantinib Commercial Collaborations - Performance Obligations and Transaction Prices for our Ipsen and Takeda Collaborations&#x201d; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2019 for information about the expected timing to satisfy these performance obligations.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RleHRyZWdpb246MGE4MmQ4MjNlMWM0NDg1OWFkNTUzYmNhNmNhMTE1ZTdfNDg0Ng_77c0074a-3ffc-4852-bf67-4b5fe074dde1">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross product revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;702,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;704,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discounts and allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51,814)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48,148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(161,668)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(139,060)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net product revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;541,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;565,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total collaboration revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;727,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net product revenues by product were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CABOMETYX&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;522,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;552,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;COMETRIQ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net product revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;541,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;565,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The percentage of total revenues by customer who individually accounted for&#160;10%&#160;or more of our total revenues were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ipsen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of CVS Health Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of Optum Specialty Pharmacy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Takeda Pharmaceutical Company Limited (Takeda)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues by geographic region were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;549,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;572,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;727,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6b8d3dbc1c5648e68dcec00585f82d14_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmIxMDRjYzQ2ODk0ODQzNDQ4YzdiMTFjYmNmMmU3MDUzL3RhYmxlcmFuZ2U6YjEwNGNjNDY4OTQ4NDM0NDhjN2IxMWNiY2YyZTcwNTNfMy0xLTEtMS0w_2874c770-08cb-40e2-8a9d-0a6441a07673"
      unitRef="usd">220401000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i458bde72c5d5486cb34c5d501fb3ca84_D20190629-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmIxMDRjYzQ2ODk0ODQzNDQ4YzdiMTFjYmNmMmU3MDUzL3RhYmxlcmFuZ2U6YjEwNGNjNDY4OTQ4NDM0NDhjN2IxMWNiY2YyZTcwNTNfMy0zLTEtMS0w_38b7be91-6557-4d91-a664-f2e21d158e8a"
      unitRef="usd">239916000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie5535b1b3b1a487ea1ac2f456daeae47_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmIxMDRjYzQ2ODk0ODQzNDQ4YzdiMTFjYmNmMmU3MDUzL3RhYmxlcmFuZ2U6YjEwNGNjNDY4OTQ4NDM0NDhjN2IxMWNiY2YyZTcwNTNfMy01LTEtMS0w_3befb086-a11e-4b1f-ae1c-7cdb1490c7cd"
      unitRef="usd">702865000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7500a3b3560547179833f5e227db7a5c_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmIxMDRjYzQ2ODk0ODQzNDQ4YzdiMTFjYmNmMmU3MDUzL3RhYmxlcmFuZ2U6YjEwNGNjNDY4OTQ4NDM0NDhjN2IxMWNiY2YyZTcwNTNfMy03LTEtMS0w_31686d66-e81e-4493-a6df-a723663c8a21"
      unitRef="usd">704084000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2148af2d149c45dbb0c184eb9a166068_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmIxMDRjYzQ2ODk0ODQzNDQ4YzdiMTFjYmNmMmU3MDUzL3RhYmxlcmFuZ2U6YjEwNGNjNDY4OTQ4NDM0NDhjN2IxMWNiY2YyZTcwNTNfNC0xLTEtMS0w_3f9dba84-ca75-40e1-a134-59d00919be82"
      unitRef="usd">-51814000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5ed764ccd2a94897aeb76c66da22a057_D20190629-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmIxMDRjYzQ2ODk0ODQzNDQ4YzdiMTFjYmNmMmU3MDUzL3RhYmxlcmFuZ2U6YjEwNGNjNDY4OTQ4NDM0NDhjN2IxMWNiY2YyZTcwNTNfNC0zLTEtMS0w_bc1b5fec-e2f2-4a9d-b1b4-182dc9bc57ce"
      unitRef="usd">-48148000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifbbf27901590404f947e7e8da56664d3_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmIxMDRjYzQ2ODk0ODQzNDQ4YzdiMTFjYmNmMmU3MDUzL3RhYmxlcmFuZ2U6YjEwNGNjNDY4OTQ4NDM0NDhjN2IxMWNiY2YyZTcwNTNfNC01LTEtMS0w_16b99c33-2e67-4226-b53c-6b79d5853068"
      unitRef="usd">-161668000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib6d312e664d54a13a0bb0c707a911341_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmIxMDRjYzQ2ODk0ODQzNDQ4YzdiMTFjYmNmMmU3MDUzL3RhYmxlcmFuZ2U6YjEwNGNjNDY4OTQ4NDM0NDhjN2IxMWNiY2YyZTcwNTNfNC03LTEtMS0w_6727c8b9-0f41-4639-b9e2-df80baceddaf"
      unitRef="usd">-139060000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia527955beb274c50967751e32dc17dff_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmIxMDRjYzQ2ODk0ODQzNDQ4YzdiMTFjYmNmMmU3MDUzL3RhYmxlcmFuZ2U6YjEwNGNjNDY4OTQ4NDM0NDhjN2IxMWNiY2YyZTcwNTNfNS0xLTEtMS0w_3d02242e-90d7-43a7-a7b3-c4c1edfb3bb3"
      unitRef="usd">168587000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i663049bc589a41de99b922b6fb02f1bc_D20190629-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmIxMDRjYzQ2ODk0ODQzNDQ4YzdiMTFjYmNmMmU3MDUzL3RhYmxlcmFuZ2U6YjEwNGNjNDY4OTQ4NDM0NDhjN2IxMWNiY2YyZTcwNTNfNS0zLTEtMS0w_fd819f17-a8c5-4a8b-a9bc-685488fb8b99"
      unitRef="usd">191768000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iefbb93ab12054c04a4d0d55ad1aaf502_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmIxMDRjYzQ2ODk0ODQzNDQ4YzdiMTFjYmNmMmU3MDUzL3RhYmxlcmFuZ2U6YjEwNGNjNDY4OTQ4NDM0NDhjN2IxMWNiY2YyZTcwNTNfNS01LTEtMS0w_1d3efd23-055c-4446-a217-f43399b9d307"
      unitRef="usd">541197000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i75b81eceef094c2d86c24a00c59294e1_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmIxMDRjYzQ2ODk0ODQzNDQ4YzdiMTFjYmNmMmU3MDUzL3RhYmxlcmFuZ2U6YjEwNGNjNDY4OTQ4NDM0NDhjN2IxMWNiY2YyZTcwNTNfNS03LTEtMS0w_615778d9-fa15-4ef0-8eaa-441ec490a96c"
      unitRef="usd">565024000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie72938b556dd42ada9b416a6b60b47fa_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmIxMDRjYzQ2ODk0ODQzNDQ4YzdiMTFjYmNmMmU3MDUzL3RhYmxlcmFuZ2U6YjEwNGNjNDY4OTQ4NDM0NDhjN2IxMWNiY2YyZTcwNTNfNy0xLTEtMS0w_6703c1b4-4147-4871-a2d7-8a09d86fd89d"
      unitRef="usd">33205000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic55505ff13f844188fb0751728d84cce_D20190629-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmIxMDRjYzQ2ODk0ODQzNDQ4YzdiMTFjYmNmMmU3MDUzL3RhYmxlcmFuZ2U6YjEwNGNjNDY4OTQ4NDM0NDhjN2IxMWNiY2YyZTcwNTNfNy0zLTEtMS0w_6f130490-08cf-4313-a2a0-aa497f6b24b6"
      unitRef="usd">69137000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i47085b4d4dbd42ac8d6b0c47740109da_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmIxMDRjYzQ2ODk0ODQzNDQ4YzdiMTFjYmNmMmU3MDUzL3RhYmxlcmFuZ2U6YjEwNGNjNDY4OTQ4NDM0NDhjN2IxMWNiY2YyZTcwNTNfNy01LTEtMS0w_79ff62aa-c761-40eb-8130-ecb165967708"
      unitRef="usd">113318000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i98f01433b4094674bd5e812d8d00d234_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmIxMDRjYzQ2ODk0ODQzNDQ4YzdiMTFjYmNmMmU3MDUzL3RhYmxlcmFuZ2U6YjEwNGNjNDY4OTQ4NDM0NDhjN2IxMWNiY2YyZTcwNTNfNy03LTEtMS0w_7ae6e83b-58d8-46a3-81de-e5d792000ad9"
      unitRef="usd">132443000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="i25bf6a1fad8f41f8b3dd9743b6494697_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmIxMDRjYzQ2ODk0ODQzNDQ4YzdiMTFjYmNmMmU3MDUzL3RhYmxlcmFuZ2U6YjEwNGNjNDY4OTQ4NDM0NDhjN2IxMWNiY2YyZTcwNTNfOC0xLTEtMS0w_db9876f8-23df-4efd-a3cf-8c3930714713"
      unitRef="usd">29300000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="i88aea9011a624e6ab196817bcb69590c_D20190629-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmIxMDRjYzQ2ODk0ODQzNDQ4YzdiMTFjYmNmMmU3MDUzL3RhYmxlcmFuZ2U6YjEwNGNjNDY4OTQ4NDM0NDhjN2IxMWNiY2YyZTcwNTNfOC0zLTEtMS0w_0f050580-54fc-4b47-b2c6-68d7784d122c"
      unitRef="usd">10798000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="iced2a1e2c6a1480d8302a1285f8e233c_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmIxMDRjYzQ2ODk0ODQzNDQ4YzdiMTFjYmNmMmU3MDUzL3RhYmxlcmFuZ2U6YjEwNGNjNDY4OTQ4NDM0NDhjN2IxMWNiY2YyZTcwNTNfOC01LTEtMS0w_d9893e92-456b-4aa0-aa42-4b799ab0a0ce"
      unitRef="usd">62971000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="i43a6c75a975a475a8220f03f17c813e5_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmIxMDRjYzQ2ODk0ODQzNDQ4YzdiMTFjYmNmMmU3MDUzL3RhYmxlcmFuZ2U6YjEwNGNjNDY4OTQ4NDM0NDhjN2IxMWNiY2YyZTcwNTNfOC03LTEtMS0w_49e693e5-97b7-47ca-874a-e97e9f598797"
      unitRef="usd">29998000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:Revenues
      contextRef="id85db556f50145f28ee780d1a8a89976_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmIxMDRjYzQ2ODk0ODQzNDQ4YzdiMTFjYmNmMmU3MDUzL3RhYmxlcmFuZ2U6YjEwNGNjNDY4OTQ4NDM0NDhjN2IxMWNiY2YyZTcwNTNfOS0xLTEtMS0w_d3a07a9b-cb7f-4cda-a7cf-522420a1cb2b"
      unitRef="usd">62505000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib1234ea649134872b48e4dbb76f2d830_D20190629-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmIxMDRjYzQ2ODk0ODQzNDQ4YzdiMTFjYmNmMmU3MDUzL3RhYmxlcmFuZ2U6YjEwNGNjNDY4OTQ4NDM0NDhjN2IxMWNiY2YyZTcwNTNfOS0zLTEtMS0w_ff7c2597-0455-4919-94d3-18b27a538ca3"
      unitRef="usd">79935000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i53da4333857a41c596e180b7605fb101_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmIxMDRjYzQ2ODk0ODQzNDQ4YzdiMTFjYmNmMmU3MDUzL3RhYmxlcmFuZ2U6YjEwNGNjNDY4OTQ4NDM0NDhjN2IxMWNiY2YyZTcwNTNfOS01LTEtMS0w_3c654001-f7b6-4cdf-9211-aec464843800"
      unitRef="usd">176289000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0d89b0fff8f440c5a47f0e0cbadc2d30_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmIxMDRjYzQ2ODk0ODQzNDQ4YzdiMTFjYmNmMmU3MDUzL3RhYmxlcmFuZ2U6YjEwNGNjNDY4OTQ4NDM0NDhjN2IxMWNiY2YyZTcwNTNfOS03LTEtMS0w_2d8ae740-cc88-4501-8215-4182ffc10fca"
      unitRef="usd">162441000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmIxMDRjYzQ2ODk0ODQzNDQ4YzdiMTFjYmNmMmU3MDUzL3RhYmxlcmFuZ2U6YjEwNGNjNDY4OTQ4NDM0NDhjN2IxMWNiY2YyZTcwNTNfMTAtMS0xLTEtMA_ff19af56-07e7-4ec7-b06f-d81185f6e3d2"
      unitRef="usd">231092000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmIxMDRjYzQ2ODk0ODQzNDQ4YzdiMTFjYmNmMmU3MDUzL3RhYmxlcmFuZ2U6YjEwNGNjNDY4OTQ4NDM0NDhjN2IxMWNiY2YyZTcwNTNfMTAtMy0xLTEtMA_e0886dd0-db54-4615-8aaf-2c5811affafc"
      unitRef="usd">271703000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmIxMDRjYzQ2ODk0ODQzNDQ4YzdiMTFjYmNmMmU3MDUzL3RhYmxlcmFuZ2U6YjEwNGNjNDY4OTQ4NDM0NDhjN2IxMWNiY2YyZTcwNTNfMTAtNS0xLTEtMA_f494c235-1440-49bb-83b5-2829fc0f5eb6"
      unitRef="usd">717486000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmIxMDRjYzQ2ODk0ODQzNDQ4YzdiMTFjYmNmMmU3MDUzL3RhYmxlcmFuZ2U6YjEwNGNjNDY4OTQ4NDM0NDhjN2IxMWNiY2YyZTcwNTNfMTAtNy0xLTEtMA_0e30034c-5aab-4718-934e-923558b32ec6"
      unitRef="usd">727465000</us-gaap:Revenues>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RleHRyZWdpb246MGE4MmQ4MjNlMWM0NDg1OWFkNTUzYmNhNmNhMTE1ZTdfNDgyMA_48501c8f-036f-40fe-acc5-1f364755276a">Net product revenues and license revenues are recorded in accordance with Topic 606. License revenues include the recognition of the portion of milestones payments allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the milestone would be achieved and a significant reversal of revenues would not occur, as well as royalty revenues and our share of profits under our collaboration agreement with Genentech. Collaboration services revenues were recorded in accordance with Topic 808 and by analogy to Topic 606. Collaboration services revenues include the recognition of deferred revenues for the portion of upfront and milestone payments allocated to our research and development services performance obligations, development cost reimbursements earned under our collaboration agreements, product supply revenues, net of product supply costs, and the royalties we paid to GlaxoSmithKline (GSK) on sales of products containing cabozantinib by our collaboration partners.Net product revenues are attributed to geographic region based on the ship-to location. License and collaboration services revenues are attributed to geographic region based on the location of our collaboration partners&#x2019; headquarters.&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The allowance for chargebacks and discounts for prompt payment is recorded as a reduction of trade receivables, net and the remaining reserves are recorded as rebates and fees due to customers in the accompanying Condensed Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contract Assets and Liabilities &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We receive payments from our collaboration partners based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. We may also recognize revenues in advance of the contractual billing schedule and such amounts are recorded, net of any allowance for credit losses, as a contract asset when recognized. Contract assets, which are presented in prepaid expenses and other current assets in the accompanying Condensed Consolidated Balance Sheets, we&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;re $0 and&#160;$1.1 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;as of&#160;September&#160;30, 2020 and December&#160;31, 2019, respectively. We may be required to defer recognition of revenues for upfront and milestone payments until we perform our obligations under these arrangements, and such amounts are recorded as deferred revenues upon receipt or when due. Contract liabilities we&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;re $10.6 million and&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$6.6 million&#160;as of&#160;September&#160;30, 2020 and &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2019, respectively. The current portion of th&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;e contract liabilities totaling $1.3 million and $0 as of&#160;September&#160;30, 2020 and December&#160;31, 2019, respectively, are presented in other current liabilities and the remainder of the contract liabilities are presented in long-term portion of deferred revenues as of those dates in the accompanyi&lt;/span&gt;ng Condensed Consolidated Balance Sheets. For those contracts that have multiple performance obligations, contract&#160;assets and liabilities are reported on a&#160;net&#160;basis&#160;at the&#160;contract&#160;level.</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ide4bbab6cf384b57a9b8addbd0e12d37_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmZjMjQwNWQ1NzBmYTQwOTM4NTkzNmM2NGQzMTc5NmZlL3RhYmxlcmFuZ2U6ZmMyNDA1ZDU3MGZhNDA5Mzg1OTM2YzY0ZDMxNzk2ZmVfMi0xLTEtMS0w_f306d664-8e82-44b9-842d-8044e87d01b0"
      unitRef="usd">159555000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iad9dc86bff5e482395fb34a230d3bce2_D20190629-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmZjMjQwNWQ1NzBmYTQwOTM4NTkzNmM2NGQzMTc5NmZlL3RhYmxlcmFuZ2U6ZmMyNDA1ZDU3MGZhNDA5Mzg1OTM2YzY0ZDMxNzk2ZmVfMi0zLTEtMS0w_8ce226b8-d36e-49e5-bb59-3b97af45290d"
      unitRef="usd">187410000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i97faf5b0431f41eeafdc9b84f69366b6_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmZjMjQwNWQ1NzBmYTQwOTM4NTkzNmM2NGQzMTc5NmZlL3RhYmxlcmFuZ2U6ZmMyNDA1ZDU3MGZhNDA5Mzg1OTM2YzY0ZDMxNzk2ZmVfMi01LTEtMS0w_65d9b115-4f5c-45fe-a1ab-71ead92ee2d8"
      unitRef="usd">522381000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icdccf6af360349f19712f9f78dc3b258_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmZjMjQwNWQ1NzBmYTQwOTM4NTkzNmM2NGQzMTc5NmZlL3RhYmxlcmFuZ2U6ZmMyNDA1ZDU3MGZhNDA5Mzg1OTM2YzY0ZDMxNzk2ZmVfMi03LTEtMS0w_c522b6d7-c7bd-4131-9146-185dd1a61d8b"
      unitRef="usd">552315000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ide08272d8494485aa3f67140ad87e288_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmZjMjQwNWQ1NzBmYTQwOTM4NTkzNmM2NGQzMTc5NmZlL3RhYmxlcmFuZ2U6ZmMyNDA1ZDU3MGZhNDA5Mzg1OTM2YzY0ZDMxNzk2ZmVfMy0xLTEtMS0w_12389131-32ef-4f8f-97d4-9e1115e68112"
      unitRef="usd">9032000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0c63f161b29d440b983b8d7886c07431_D20190629-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmZjMjQwNWQ1NzBmYTQwOTM4NTkzNmM2NGQzMTc5NmZlL3RhYmxlcmFuZ2U6ZmMyNDA1ZDU3MGZhNDA5Mzg1OTM2YzY0ZDMxNzk2ZmVfMy0zLTEtMS0w_bd2c2f7d-315e-4225-bb90-cf09874bbc12"
      unitRef="usd">4358000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if80a8f9a26734cc1a3ab10698b7d38d1_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmZjMjQwNWQ1NzBmYTQwOTM4NTkzNmM2NGQzMTc5NmZlL3RhYmxlcmFuZ2U6ZmMyNDA1ZDU3MGZhNDA5Mzg1OTM2YzY0ZDMxNzk2ZmVfMy01LTEtMS0w_1d6079d7-8642-4696-914c-4176dd690990"
      unitRef="usd">18816000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic2a58f6e8634467fbb6096248e57b129_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmZjMjQwNWQ1NzBmYTQwOTM4NTkzNmM2NGQzMTc5NmZlL3RhYmxlcmFuZ2U6ZmMyNDA1ZDU3MGZhNDA5Mzg1OTM2YzY0ZDMxNzk2ZmVfMy03LTEtMS0w_8ff1b662-1d01-4cb8-8a79-3959d25decbb"
      unitRef="usd">12709000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia527955beb274c50967751e32dc17dff_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmZjMjQwNWQ1NzBmYTQwOTM4NTkzNmM2NGQzMTc5NmZlL3RhYmxlcmFuZ2U6ZmMyNDA1ZDU3MGZhNDA5Mzg1OTM2YzY0ZDMxNzk2ZmVfNC0xLTEtMS0w_4da31165-14d6-4ccd-add7-ec824a5df747"
      unitRef="usd">168587000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i663049bc589a41de99b922b6fb02f1bc_D20190629-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmZjMjQwNWQ1NzBmYTQwOTM4NTkzNmM2NGQzMTc5NmZlL3RhYmxlcmFuZ2U6ZmMyNDA1ZDU3MGZhNDA5Mzg1OTM2YzY0ZDMxNzk2ZmVfNC0zLTEtMS0w_f70c46ac-bb5a-413f-b6a3-9524c7f44777"
      unitRef="usd">191768000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iefbb93ab12054c04a4d0d55ad1aaf502_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmZjMjQwNWQ1NzBmYTQwOTM4NTkzNmM2NGQzMTc5NmZlL3RhYmxlcmFuZ2U6ZmMyNDA1ZDU3MGZhNDA5Mzg1OTM2YzY0ZDMxNzk2ZmVfNC01LTEtMS0w_2b671381-43a2-4a56-a2ca-4bf476fc80c0"
      unitRef="usd">541197000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i75b81eceef094c2d86c24a00c59294e1_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmZjMjQwNWQ1NzBmYTQwOTM4NTkzNmM2NGQzMTc5NmZlL3RhYmxlcmFuZ2U6ZmMyNDA1ZDU3MGZhNDA5Mzg1OTM2YzY0ZDMxNzk2ZmVfNC03LTEtMS0w_b40a7679-cf64-4dbd-9df0-ba28bbc816f0"
      unitRef="usd">565024000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia60d29d213b7423f8b44089dbc426396_D20200704-20201002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjk3NDcwZDRlZTY2MDRiMTlhYjdjMGRlMGU5YzU1M2MwL3RhYmxlcmFuZ2U6OTc0NzBkNGVlNjYwNGIxOWFiN2MwZGUwZTljNTUzYzBfMi0xLTEtMS0w_027860d7-a419-44e1-920a-5ea784e2c350"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i84172e8ba8944bff9097e2420fc4a71d_D20190629-20190927"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjk3NDcwZDRlZTY2MDRiMTlhYjdjMGRlMGU5YzU1M2MwL3RhYmxlcmFuZ2U6OTc0NzBkNGVlNjYwNGIxOWFiN2MwZGUwZTljNTUzYzBfMi0zLTEtMS0w_50c8ad72-d85a-4fbd-bd65-6873de8a8a1e"
      unitRef="number">0.28</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i386a27a71d1b4955bcbcf10ffefe4dc9_D20200104-20201002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjk3NDcwZDRlZTY2MDRiMTlhYjdjMGRlMGU5YzU1M2MwL3RhYmxlcmFuZ2U6OTc0NzBkNGVlNjYwNGIxOWFiN2MwZGUwZTljNTUzYzBfMi01LTEtMS0w_2a107627-b137-4528-9c03-8ff7e1120968"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="icc5620147c964216bca8a91f88f53db3_D20181229-20190927"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjk3NDcwZDRlZTY2MDRiMTlhYjdjMGRlMGU5YzU1M2MwL3RhYmxlcmFuZ2U6OTc0NzBkNGVlNjYwNGIxOWFiN2MwZGUwZTljNTUzYzBfMi03LTEtMS0w_02e2d44e-e869-4468-88aa-029082e65df7"
      unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib86d0fb1dcd542688f1f82783390f7d7_D20200704-20201002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjk3NDcwZDRlZTY2MDRiMTlhYjdjMGRlMGU5YzU1M2MwL3RhYmxlcmFuZ2U6OTc0NzBkNGVlNjYwNGIxOWFiN2MwZGUwZTljNTUzYzBfMy0xLTEtMS0w_f7e5d41d-15eb-44c5-8711-73e4a761462b"
      unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i73d4427b07944bb4a39082c52e7e3993_D20190629-20190927"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjk3NDcwZDRlZTY2MDRiMTlhYjdjMGRlMGU5YzU1M2MwL3RhYmxlcmFuZ2U6OTc0NzBkNGVlNjYwNGIxOWFiN2MwZGUwZTljNTUzYzBfMy0zLTEtMS0w_f862174c-af75-447d-93d7-90afa5a74bf7"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i5702087f6d044b2f8cb91e6d9e024981_D20200104-20201002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjk3NDcwZDRlZTY2MDRiMTlhYjdjMGRlMGU5YzU1M2MwL3RhYmxlcmFuZ2U6OTc0NzBkNGVlNjYwNGIxOWFiN2MwZGUwZTljNTUzYzBfMy01LTEtMS0w_8f62bfb7-0e15-4fc7-a9d9-7d2ca098c35a"
      unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i185156eb44914a05b07e512b521ee175_D20181229-20190927"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjk3NDcwZDRlZTY2MDRiMTlhYjdjMGRlMGU5YzU1M2MwL3RhYmxlcmFuZ2U6OTc0NzBkNGVlNjYwNGIxOWFiN2MwZGUwZTljNTUzYzBfMy03LTEtMS0w_58f049f1-6245-44c4-b8da-7c9cedfab388"
      unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i1a1a12d3a1e34e64be6756a38f99157b_D20200704-20201002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjk3NDcwZDRlZTY2MDRiMTlhYjdjMGRlMGU5YzU1M2MwL3RhYmxlcmFuZ2U6OTc0NzBkNGVlNjYwNGIxOWFiN2MwZGUwZTljNTUzYzBfNC0xLTEtMS0w_af81039b-efed-4762-a168-8483e6bab405"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i7fe0056abef84c0fb63cfb73f2dbaf5e_D20190629-20190927"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjk3NDcwZDRlZTY2MDRiMTlhYjdjMGRlMGU5YzU1M2MwL3RhYmxlcmFuZ2U6OTc0NzBkNGVlNjYwNGIxOWFiN2MwZGUwZTljNTUzYzBfNC0zLTEtMS0w_7fe22524-8ad0-4e36-821b-305b8dbb99bf"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i70fe222147914251b9dc10ce75948cf9_D20200104-20201002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjk3NDcwZDRlZTY2MDRiMTlhYjdjMGRlMGU5YzU1M2MwL3RhYmxlcmFuZ2U6OTc0NzBkNGVlNjYwNGIxOWFiN2MwZGUwZTljNTUzYzBfNC01LTEtMS0w_588ef121-77b8-4e7e-9421-c4e031cb593d"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iacd7fc12f88842b1924368fbbf75cc1f_D20181229-20190927"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjk3NDcwZDRlZTY2MDRiMTlhYjdjMGRlMGU5YzU1M2MwL3RhYmxlcmFuZ2U6OTc0NzBkNGVlNjYwNGIxOWFiN2MwZGUwZTljNTUzYzBfNC03LTEtMS0w_188fa74f-4e35-4b62-8b6d-9c5ed6d20108"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i14e1a35d582a44a0a5026811d269e717_D20200704-20201002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjk3NDcwZDRlZTY2MDRiMTlhYjdjMGRlMGU5YzU1M2MwL3RhYmxlcmFuZ2U6OTc0NzBkNGVlNjYwNGIxOWFiN2MwZGUwZTljNTUzYzBfNS0xLTEtMS0w_22b7168c-3933-4d6e-a943-210f44508afb"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iced8dcb1cd6a410d8111f8781e04944b_D20190629-20190927"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjk3NDcwZDRlZTY2MDRiMTlhYjdjMGRlMGU5YzU1M2MwL3RhYmxlcmFuZ2U6OTc0NzBkNGVlNjYwNGIxOWFiN2MwZGUwZTljNTUzYzBfNS0zLTEtMS0w_9783d827-1944-433b-92ef-1e4a82e5445a"
      unitRef="number">0.09</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id929db05799d4a7ea908997e18680ab8_D20200104-20201002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjk3NDcwZDRlZTY2MDRiMTlhYjdjMGRlMGU5YzU1M2MwL3RhYmxlcmFuZ2U6OTc0NzBkNGVlNjYwNGIxOWFiN2MwZGUwZTljNTUzYzBfNS01LTEtMS0w_330d8a10-5b54-4d5d-ba43-847d9519886a"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iaabc597e0f5940e89c79670faf29f78e_D20181229-20190927"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjk3NDcwZDRlZTY2MDRiMTlhYjdjMGRlMGU5YzU1M2MwL3RhYmxlcmFuZ2U6OTc0NzBkNGVlNjYwNGIxOWFiN2MwZGUwZTljNTUzYzBfNS03LTEtMS0w_53fbcac5-4491-4bea-aa05-375c4a36deaf"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i3d6b1d115ff4494fb1233255cd7c2c19_D20200704-20201002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjk3NDcwZDRlZTY2MDRiMTlhYjdjMGRlMGU5YzU1M2MwL3RhYmxlcmFuZ2U6OTc0NzBkNGVlNjYwNGIxOWFiN2MwZGUwZTljNTUzYzBfNi0xLTEtMS0w_45229d3d-1bf3-41e5-925a-a83eaf64bccd"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i54ae6ae3ffc442a5b7b73749a9ee7058_D20190629-20190927"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjk3NDcwZDRlZTY2MDRiMTlhYjdjMGRlMGU5YzU1M2MwL3RhYmxlcmFuZ2U6OTc0NzBkNGVlNjYwNGIxOWFiN2MwZGUwZTljNTUzYzBfNi0zLTEtMS0w_67f501c0-4c04-474b-aa4b-37d4db9d3779"
      unitRef="number">0.07</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iff89a893303e4fa882dc5129bcbfb868_D20200104-20201002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjk3NDcwZDRlZTY2MDRiMTlhYjdjMGRlMGU5YzU1M2MwL3RhYmxlcmFuZ2U6OTc0NzBkNGVlNjYwNGIxOWFiN2MwZGUwZTljNTUzYzBfNi01LTEtMS0w_5a9ecaa1-31e1-42ab-bbbb-b8aca3deda6c"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ief5d2999265b4a7ba5bbc8848a958c41_D20181229-20190927"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjk3NDcwZDRlZTY2MDRiMTlhYjdjMGRlMGU5YzU1M2MwL3RhYmxlcmFuZ2U6OTc0NzBkNGVlNjYwNGIxOWFiN2MwZGUwZTljNTUzYzBfNi03LTEtMS0w_1b36af8c-deca-4ff8-a385-a6b8f9bf4c4e"
      unitRef="number">0.08</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i586e46eec28e45cc9e06428a8195d748_D20200704-20201002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjk3NDcwZDRlZTY2MDRiMTlhYjdjMGRlMGU5YzU1M2MwL3RhYmxlcmFuZ2U6OTc0NzBkNGVlNjYwNGIxOWFiN2MwZGUwZTljNTUzYzBfNy0xLTEtMS0w_53804a20-6c4f-42f6-a009-aeda89a4546d"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i7d79b47a315146babea975fec8dce552_D20190629-20190927"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjk3NDcwZDRlZTY2MDRiMTlhYjdjMGRlMGU5YzU1M2MwL3RhYmxlcmFuZ2U6OTc0NzBkNGVlNjYwNGIxOWFiN2MwZGUwZTljNTUzYzBfNy0zLTEtMS0w_f382dd79-81d4-4b10-99eb-efb6563dbfa6"
      unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i3cb1cfcba4a24a5a95475dcd23a6d6a7_D20200104-20201002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjk3NDcwZDRlZTY2MDRiMTlhYjdjMGRlMGU5YzU1M2MwL3RhYmxlcmFuZ2U6OTc0NzBkNGVlNjYwNGIxOWFiN2MwZGUwZTljNTUzYzBfNy01LTEtMS0w_5c35cd91-f61e-4fc4-83d7-9d7da0e15502"
      unitRef="number">0.07</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i3a9ff92761624c878e628676f2c878f8_D20181229-20190927"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjk3NDcwZDRlZTY2MDRiMTlhYjdjMGRlMGU5YzU1M2MwL3RhYmxlcmFuZ2U6OTc0NzBkNGVlNjYwNGIxOWFiN2MwZGUwZTljNTUzYzBfNy03LTEtMS0w_c676824e-28b8-4e58-9372-4fae229e32da"
      unitRef="number">0.02</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iec0582c68f2e45809336de61a7ef2ffe_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmE4MzdkZjM4ZWIxMDRlYTViMzI5N2M5OGI1YTlkZjI2L3RhYmxlcmFuZ2U6YTgzN2RmMzhlYjEwNGVhNWIzMjk3Yzk4YjVhOWRmMjZfMi0xLTEtMS0w_440af340-c842-4ff5-9913-c1f65cec2c61"
      unitRef="usd">171552000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i71b0e797d9454761a9c3b48ce0cd6dc7_D20190629-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmE4MzdkZjM4ZWIxMDRlYTViMzI5N2M5OGI1YTlkZjI2L3RhYmxlcmFuZ2U6YTgzN2RmMzhlYjEwNGVhNWIzMjk3Yzk4YjVhOWRmMjZfMi0zLTEtMS0w_4c33272d-36a8-4a30-a4e6-329ad9d4a3cf"
      unitRef="usd">194484000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0e8cff04ca5040a68e2a49c6e3601c97_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmE4MzdkZjM4ZWIxMDRlYTViMzI5N2M5OGI1YTlkZjI2L3RhYmxlcmFuZ2U6YTgzN2RmMzhlYjEwNGVhNWIzMjk3Yzk4YjVhOWRmMjZfMi01LTEtMS0w_e4d1e087-5dd9-4c96-9073-5d26f112c6d5"
      unitRef="usd">549379000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i62c0d9fe6a22430782ddc2b6e95e7fea_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmE4MzdkZjM4ZWIxMDRlYTViMzI5N2M5OGI1YTlkZjI2L3RhYmxlcmFuZ2U6YTgzN2RmMzhlYjEwNGVhNWIzMjk3Yzk4YjVhOWRmMjZfMi03LTEtMS0w_95e904c7-bda3-49bd-9599-a33cabdb6752"
      unitRef="usd">572957000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if3a34af32f82425db5a92b122c952662_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmE4MzdkZjM4ZWIxMDRlYTViMzI5N2M5OGI1YTlkZjI2L3RhYmxlcmFuZ2U6YTgzN2RmMzhlYjEwNGVhNWIzMjk3Yzk4YjVhOWRmMjZfMy0xLTEtMS0w_364d4b81-c12b-4414-a7e1-85b3ef776864"
      unitRef="usd">36006000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iec35a82156214e73aba68b440656efba_D20190629-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmE4MzdkZjM4ZWIxMDRlYTViMzI5N2M5OGI1YTlkZjI2L3RhYmxlcmFuZ2U6YTgzN2RmMzhlYjEwNGVhNWIzMjk3Yzk4YjVhOWRmMjZfMy0zLTEtMS0w_fb8568b7-3600-48ab-bae9-9b4011dcb2f0"
      unitRef="usd">76017000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id6b900d2f20e47d098b552ec62a9e8d6_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmE4MzdkZjM4ZWIxMDRlYTViMzI5N2M5OGI1YTlkZjI2L3RhYmxlcmFuZ2U6YTgzN2RmMzhlYjEwNGVhNWIzMjk3Yzk4YjVhOWRmMjZfMy01LTEtMS0w_b4896630-e904-4008-938b-6909dc0d092e"
      unitRef="usd">117959000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie38bb019719d40208f85caefe75b164d_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmE4MzdkZjM4ZWIxMDRlYTViMzI5N2M5OGI1YTlkZjI2L3RhYmxlcmFuZ2U6YTgzN2RmMzhlYjEwNGVhNWIzMjk3Yzk4YjVhOWRmMjZfMy03LTEtMS0w_6a747156-08b9-4236-ab37-86a017c2b4b8"
      unitRef="usd">120134000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3b85521d483a41f38d661425a8820625_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmE4MzdkZjM4ZWIxMDRlYTViMzI5N2M5OGI1YTlkZjI2L3RhYmxlcmFuZ2U6YTgzN2RmMzhlYjEwNGVhNWIzMjk3Yzk4YjVhOWRmMjZfNC0xLTEtMS0w_351b21df-bd51-4b5c-8c04-8920ff1a9099"
      unitRef="usd">23534000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2db6d59506ab40b9822586497086d157_D20190629-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmE4MzdkZjM4ZWIxMDRlYTViMzI5N2M5OGI1YTlkZjI2L3RhYmxlcmFuZ2U6YTgzN2RmMzhlYjEwNGVhNWIzMjk3Yzk4YjVhOWRmMjZfNC0zLTEtMS0w_9b841086-f62b-4964-9302-fd04dc8d4e59"
      unitRef="usd">1202000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i477ac2490d6a414281cc99f9812014e7_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmE4MzdkZjM4ZWIxMDRlYTViMzI5N2M5OGI1YTlkZjI2L3RhYmxlcmFuZ2U6YTgzN2RmMzhlYjEwNGVhNWIzMjk3Yzk4YjVhOWRmMjZfNC01LTEtMS0w_d5c46123-cf71-439f-866b-ab75f06fcf76"
      unitRef="usd">50148000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i65978d0dcb28411cb73d35911d6e8d6c_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmE4MzdkZjM4ZWIxMDRlYTViMzI5N2M5OGI1YTlkZjI2L3RhYmxlcmFuZ2U6YTgzN2RmMzhlYjEwNGVhNWIzMjk3Yzk4YjVhOWRmMjZfNC03LTEtMS0w_64c07323-ccd1-4288-bb1f-0edfbc7304c1"
      unitRef="usd">34374000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmE4MzdkZjM4ZWIxMDRlYTViMzI5N2M5OGI1YTlkZjI2L3RhYmxlcmFuZ2U6YTgzN2RmMzhlYjEwNGVhNWIzMjk3Yzk4YjVhOWRmMjZfNS0xLTEtMS0w_240c95aa-376c-4f38-b30a-86cacfaaaadc"
      unitRef="usd">231092000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmE4MzdkZjM4ZWIxMDRlYTViMzI5N2M5OGI1YTlkZjI2L3RhYmxlcmFuZ2U6YTgzN2RmMzhlYjEwNGVhNWIzMjk3Yzk4YjVhOWRmMjZfNS0zLTEtMS0w_e5d2f128-e0a4-4874-b440-9a0ca49abe2e"
      unitRef="usd">271703000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmE4MzdkZjM4ZWIxMDRlYTViMzI5N2M5OGI1YTlkZjI2L3RhYmxlcmFuZ2U6YTgzN2RmMzhlYjEwNGVhNWIzMjk3Yzk4YjVhOWRmMjZfNS01LTEtMS0w_4bcf8ec1-b466-474e-b079-696f41257773"
      unitRef="usd">717486000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOmE4MzdkZjM4ZWIxMDRlYTViMzI5N2M5OGI1YTlkZjI2L3RhYmxlcmFuZ2U6YTgzN2RmMzhlYjEwNGVhNWIzMjk3Yzk4YjVhOWRmMjZfNS03LTEtMS0w_54a924c0-3cfb-4403-969f-f858a93c37f2"
      unitRef="usd">727465000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RleHRyZWdpb246MGE4MmQ4MjNlMWM0NDg1OWFkNTUzYmNhNmNhMTE1ZTdfNDgyNw_eec01f03-b633-4f29-a0de-bf7f5e99c05d">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.590%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Chargebacks and Discounts for Prompt Payment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other Customer Credits/Fees and Co-pay Assistance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Rebates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision related to sales made in:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(352)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments and customer credits issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(107,118)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,513)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41,546)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(160,177)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September&#160;30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i67b11a0135a641a4bd4d22e09f7bfbcf_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjEwOGFmODMyOTY3ZDQxMTRiYmFmNzI0ZThjOGUxNzkzL3RhYmxlcmFuZ2U6MTA4YWY4MzI5NjdkNDExNGJiYWY3MjRlOGM4ZTE3OTNfMS0xLTEtMS0w_dfe11480-ddfa-42d6-8393-c6ce2e3d2d33"
      unitRef="usd">7514000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i504cbdf3907f4152872efaf0c542118f_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjEwOGFmODMyOTY3ZDQxMTRiYmFmNzI0ZThjOGUxNzkzL3RhYmxlcmFuZ2U6MTA4YWY4MzI5NjdkNDExNGJiYWY3MjRlOGM4ZTE3OTNfMS0zLTEtMS0w_ad15f1c7-d722-4bf5-95d0-0ea7db752cc6"
      unitRef="usd">3497000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i2b422997cdc1458bb19aa47286284ef0_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjEwOGFmODMyOTY3ZDQxMTRiYmFmNzI0ZThjOGUxNzkzL3RhYmxlcmFuZ2U6MTA4YWY4MzI5NjdkNDExNGJiYWY3MjRlOGM4ZTE3OTNfMS01LTEtMS0w_58a63fab-1868-4a17-ac12-7fa50205d535"
      unitRef="usd">15222000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjEwOGFmODMyOTY3ZDQxMTRiYmFmNzI0ZThjOGUxNzkzL3RhYmxlcmFuZ2U6MTA4YWY4MzI5NjdkNDExNGJiYWY3MjRlOGM4ZTE3OTNfMS05LTEtMS0w_3c575f1a-21ee-474d-b111-7e17ba28571e"
      unitRef="usd">26233000</us-gaap:ValuationAllowancesAndReservesBalance>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="i5bb996de5a5f41699a6974a3f048c443_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjEwOGFmODMyOTY3ZDQxMTRiYmFmNzI0ZThjOGUxNzkzL3RhYmxlcmFuZ2U6MTA4YWY4MzI5NjdkNDExNGJiYWY3MjRlOGM4ZTE3OTNfMy0xLTEtMS0w_1344a60e-8725-48fa-8e8b-ebbe035b7166"
      unitRef="usd">108166000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="ic9fee7c5808d4690b34490b6ca50b8db_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjEwOGFmODMyOTY3ZDQxMTRiYmFmNzI0ZThjOGUxNzkzL3RhYmxlcmFuZ2U6MTA4YWY4MzI5NjdkNDExNGJiYWY3MjRlOGM4ZTE3OTNfMy0zLTEtMS0w_30d22b56-53a8-470e-8be7-7cb19d9ad723"
      unitRef="usd">11718000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="i8b664d4199b94af5a11e4871fd387735_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjEwOGFmODMyOTY3ZDQxMTRiYmFmNzI0ZThjOGUxNzkzL3RhYmxlcmFuZ2U6MTA4YWY4MzI5NjdkNDExNGJiYWY3MjRlOGM4ZTE3OTNfMy01LTEtMS0w_0f907195-2cb1-47a0-b4cd-25978b26f03d"
      unitRef="usd">41351000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjEwOGFmODMyOTY3ZDQxMTRiYmFmNzI0ZThjOGUxNzkzL3RhYmxlcmFuZ2U6MTA4YWY4MzI5NjdkNDExNGJiYWY3MjRlOGM4ZTE3OTNfMy05LTEtMS0w_5c147fa0-bd32-41aa-afb1-d3d555b74385"
      unitRef="usd">161235000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="i5bb996de5a5f41699a6974a3f048c443_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjEwOGFmODMyOTY3ZDQxMTRiYmFmNzI0ZThjOGUxNzkzL3RhYmxlcmFuZ2U6MTA4YWY4MzI5NjdkNDExNGJiYWY3MjRlOGM4ZTE3OTNfNC0xLTEtMS0w_56e869b2-3b7e-472e-b63e-b60c98da5e58"
      unitRef="usd">33000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="ic9fee7c5808d4690b34490b6ca50b8db_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjEwOGFmODMyOTY3ZDQxMTRiYmFmNzI0ZThjOGUxNzkzL3RhYmxlcmFuZ2U6MTA4YWY4MzI5NjdkNDExNGJiYWY3MjRlOGM4ZTE3OTNfNC0zLTEtMS0w_c33c9887-61ff-4acb-bfef-367b8e2d8955"
      unitRef="usd">-352000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="i8b664d4199b94af5a11e4871fd387735_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjEwOGFmODMyOTY3ZDQxMTRiYmFmNzI0ZThjOGUxNzkzL3RhYmxlcmFuZ2U6MTA4YWY4MzI5NjdkNDExNGJiYWY3MjRlOGM4ZTE3OTNfNC01LTEtMS0w_6fdd08dc-045b-45a0-8613-fa1c6ee97f2e"
      unitRef="usd">752000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjEwOGFmODMyOTY3ZDQxMTRiYmFmNzI0ZThjOGUxNzkzL3RhYmxlcmFuZ2U6MTA4YWY4MzI5NjdkNDExNGJiYWY3MjRlOGM4ZTE3OTNfNC05LTEtMS0w_358e8807-f51e-4335-9c5a-772ca4749a57"
      unitRef="usd">433000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i5bb996de5a5f41699a6974a3f048c443_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjEwOGFmODMyOTY3ZDQxMTRiYmFmNzI0ZThjOGUxNzkzL3RhYmxlcmFuZ2U6MTA4YWY4MzI5NjdkNDExNGJiYWY3MjRlOGM4ZTE3OTNfNS0xLTEtMS0w_8f5110ab-2834-4c91-a151-cebc68cc6619"
      unitRef="usd">107118000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="ic9fee7c5808d4690b34490b6ca50b8db_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjEwOGFmODMyOTY3ZDQxMTRiYmFmNzI0ZThjOGUxNzkzL3RhYmxlcmFuZ2U6MTA4YWY4MzI5NjdkNDExNGJiYWY3MjRlOGM4ZTE3OTNfNS0zLTEtMS0w_30cb7a29-1f85-43f2-957a-2cf6f80e6587"
      unitRef="usd">11513000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i8b664d4199b94af5a11e4871fd387735_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjEwOGFmODMyOTY3ZDQxMTRiYmFmNzI0ZThjOGUxNzkzL3RhYmxlcmFuZ2U6MTA4YWY4MzI5NjdkNDExNGJiYWY3MjRlOGM4ZTE3OTNfNS01LTEtMS0w_866785b0-6d8f-4de4-8262-9fa1bac65618"
      unitRef="usd">41546000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjEwOGFmODMyOTY3ZDQxMTRiYmFmNzI0ZThjOGUxNzkzL3RhYmxlcmFuZ2U6MTA4YWY4MzI5NjdkNDExNGJiYWY3MjRlOGM4ZTE3OTNfNS05LTEtMS0w_ab686636-646f-490a-bc06-8a39e7011041"
      unitRef="usd">160177000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ie771b9f5649b4d37b25de019253cf120_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjEwOGFmODMyOTY3ZDQxMTRiYmFmNzI0ZThjOGUxNzkzL3RhYmxlcmFuZ2U6MTA4YWY4MzI5NjdkNDExNGJiYWY3MjRlOGM4ZTE3OTNfNi0xLTEtMS0w_9a9d7ed9-de66-486f-85dd-3b2f935b3e82"
      unitRef="usd">8595000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i07e441c2da394ce2b81f3584524ba9a1_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjEwOGFmODMyOTY3ZDQxMTRiYmFmNzI0ZThjOGUxNzkzL3RhYmxlcmFuZ2U6MTA4YWY4MzI5NjdkNDExNGJiYWY3MjRlOGM4ZTE3OTNfNi0zLTEtMS0w_84d5a033-9b62-4f4f-b446-a8dd60158217"
      unitRef="usd">3350000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="if2f14853d41346db96816c2397b0613f_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjEwOGFmODMyOTY3ZDQxMTRiYmFmNzI0ZThjOGUxNzkzL3RhYmxlcmFuZ2U6MTA4YWY4MzI5NjdkNDExNGJiYWY3MjRlOGM4ZTE3OTNfNi01LTEtMS0w_18ab6b39-8f23-4c62-b483-63bd62e738f9"
      unitRef="usd">15779000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RhYmxlOjEwOGFmODMyOTY3ZDQxMTRiYmFmNzI0ZThjOGUxNzkzL3RhYmxlcmFuZ2U6MTA4YWY4MzI5NjdkNDExNGJiYWY3MjRlOGM4ZTE3OTNfNi05LTEtMS0w_1a66f85c-1918-400f-808d-22bbcf92ac78"
      unitRef="usd">27724000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RleHRyZWdpb246MGE4MmQ4MjNlMWM0NDg1OWFkNTUzYmNhNmNhMTE1ZTdfMjY0Ng_27f0bcd9-f954-4514-b169-25b059c19330"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RleHRyZWdpb246MGE4MmQ4MjNlMWM0NDg1OWFkNTUzYmNhNmNhMTE1ZTdfMjY1NA_fccb6730-386a-424a-90c0-4c60554c8966"
      unitRef="usd">1100000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RleHRyZWdpb246MGE4MmQ4MjNlMWM0NDg1OWFkNTUzYmNhNmNhMTE1ZTdfMjkzOA_86546085-39dc-4c0c-8992-ae84f5e36615"
      unitRef="usd">10600000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RleHRyZWdpb246MGE4MmQ4MjNlMWM0NDg1OWFkNTUzYmNhNmNhMTE1ZTdfMjk0Ng_772ffe66-7bfe-4db4-873a-7014fda99929"
      unitRef="usd">6600000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RleHRyZWdpb246MGE4MmQ4MjNlMWM0NDg1OWFkNTUzYmNhNmNhMTE1ZTdfMzAzOA_9a0e26af-7748-4504-b518-15b04e115564"
      unitRef="usd">1300000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RleHRyZWdpb246MGE4MmQ4MjNlMWM0NDg1OWFkNTUzYmNhNmNhMTE1ZTdfMzA0Ng_e0774037-7bf9-41ce-912e-a2444cda550c"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <exel:EligiblePaymentFromCollaborationForDevelopmentMilestoneAchievementUnderCollaborationsAgreement
      contextRef="icef64ef981c4433ab4d95dd86f4c12ae_I20201002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RleHRyZWdpb246MGE4MmQ4MjNlMWM0NDg1OWFkNTUzYmNhNmNhMTE1ZTdfMzUzMA_2cab4d54-ae79-40e2-b2de-6810144b6488"
      unitRef="usd">20000000.0</exel:EligiblePaymentFromCollaborationForDevelopmentMilestoneAchievementUnderCollaborationsAgreement>
    <exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement
      contextRef="i0813edb6dc1f42149871864785a370b0_I20201002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RleHRyZWdpb246MGE4MmQ4MjNlMWM0NDg1OWFkNTUzYmNhNmNhMTE1ZTdfMzY0NQ_db913dfc-d4c2-4b29-8f96-bcd05747a95e"
      unitRef="usd">10000000.0</exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RleHRyZWdpb246MGE4MmQ4MjNlMWM0NDg1OWFkNTUzYmNhNmNhMTE1ZTdfMzg1Mw_da981f4e-bd56-4092-8574-4dcaabeb32aa"
      unitRef="usd">6800000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RleHRyZWdpb246MGE4MmQ4MjNlMWM0NDg1OWFkNTUzYmNhNmNhMTE1ZTdfMzg1OQ_02522412-630a-463d-91ee-6c4d040dc91f"
      unitRef="usd">2700000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RleHRyZWdpb246MGE4MmQ4MjNlMWM0NDg1OWFkNTUzYmNhNmNhMTE1ZTdfNDAwMw_ffc7ab45-fd05-4561-95db-1b355b9fe311"
      unitRef="usd">33100000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RleHRyZWdpb246MGE4MmQ4MjNlMWM0NDg1OWFkNTUzYmNhNmNhMTE1ZTdfNDAxMg_6e02dc17-f0f9-4057-a002-1c881f1cb77a"
      unitRef="usd">115300000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RleHRyZWdpb246MGE4MmQ4MjNlMWM0NDg1OWFkNTUzYmNhNmNhMTE1ZTdfNDExNg_da7ecaf2-6a64-477b-bbc8-e12754f8e5ff"
      unitRef="usd">67700000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RleHRyZWdpb246MGE4MmQ4MjNlMWM0NDg1OWFkNTUzYmNhNmNhMTE1ZTdfNDEyMw_da8c858f-039e-4b8b-894b-8b5bd55e6f79"
      unitRef="usd">129000000.0</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80Ni9mcmFnOjBhODJkODIzZTFjNDQ4NTlhZDU1M2JjYTZjYTExNWU3L3RleHRyZWdpb246MGE4MmQ4MjNlMWM0NDg1OWFkNTUzYmNhNmNhMTE1ZTdfNDM2MQ_86414fa2-c7ad-44b3-a6e1-c640da01e06f"
      unitRef="usd">88900000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RleHRyZWdpb246YWFhZjI4ZTg2ZTI3NDdhNjk4ODc4MTA3NmE5YzhjZTNfMTA0NDUzNjA0NzYwNzg_66fa4588-d6ae-4ff1-abf5-d34eacf97341">COLLABORATION AGREEMENTS&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have established multiple collaborations with leading pharmaceutical companies for the commercialization and further development of cabozantinib. Additionally, consistent with our business strategy prior to the commercialization of cabozantinib, we entered into other collaborations with leading pharmaceutical companies for other compounds and programs in our portfolio. Under these collaborations, we are generally entitled to receive milestone and royalty payments, and for certain collaborations receive payments for product supply services, development cost reimbursements, and/or profit-sharing payments. See &#x201c;Note 2. Revenues&#x201d; for additional information on revenues recognized under our collaboration agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have also established multiple collaborations with smaller, discovery-focused biotechnology companies to expand our product pipeline. Under these collaborations, we may be required to make milestone and royalty payments, and for certain collaborations make payments for development cost reimbursements and/or option exercise fees. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See &#x201c;Note 3. Collaboration Agreements&#x201d; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2019, or as further described below, for a description of each of our collaboration agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cabozantinib Collaborations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Ipsen Collaboration &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In February 2016, we entered into a collaboration agreement with Ipsen for the commercialization and further development of cabozantinib. Under the terms of the collaboration agreement, as amended, Ipsen received exclusive commercialization rights for current and potential future cabozantinib indications outside of the U.S. and Japan. We have also agreed to collaborate with Ipsen on the development of cabozantinib for current and potential future indications. The parties&#x2019; efforts are governed through a joint steering committee and appropriate subcommittees established to guide and oversee the collaboration&#x2019;s operation and strategic direction; provided, however, that we retain final decision-making authority with respect to cabozantinib&#x2019;s ongoing development. During the second quarter of 2020, Ipsen opted into and is now co-funding the development costs for CONTACT-01 and CONTACT-02, two phase 3 pivotal trials of cabozantinib in combination with atezolizumab in patients with previously treated, metastatic non-small cell lung cancer and metastatic castration-resistant prostate cancer, respectively, and the four remaining cohorts of COSMIC-021 it had not previously opted into. COSMIC-021 is a broad phase 1b study evaluating the safety and tolerability of cabozantinib in combination with atezolizumab in patients with locally advanced or metastatic solid tumors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues under the collaboration agreement with Ipsen were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September 30, 2020, we are eligible to receive additional regulatory and development milestone payments from Ipsen totaling an aggregate of $59.0 million, as well as sales-based milestones, including milestone payments earned for the first commercial sale of a product, of up to $469.9 million. We excluded these milestones from the transaction price as of September 30, 2020 because we determined such payments to be fully constrained under Topic 606 due to the fact that it was not probable that a significant reversal of cumulative revenue would not occur, given the inherent uncertainty of success with these milestones. We will re-evaluate the transaction price at each reporting period and as uncertain events are resolved or other changes in circumstances occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, $42.6 million of the tr&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ansaction price was allocated to our research and development services performance obligation that has not yet been satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Takeda Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2017, we entered into a collaboration agreement with Takeda. Under this collaboration agreement, as amended, Takeda has exclusive commercialization rights for current and potential future cabozantinib indications in Japan, and the parties have agreed to collaborate on the clinical development of cabozantinib in Japan. The operation and strategic direction of the parties&#x2019; collaboration is governed through a joint executive committee and appropriate subcommittees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues under the collaboration agreement with Takeda were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Milestone revenues for the three and nine months ended September&#160;30, 2020 included $9.2&#160;million in revenues recognized in connection with a $10.0&#160;million milestone we expect to achieve upon Takeda&#x2019;s and Ono Pharmaceutical Co., Ltd.&#x2019;s supplemental application to the Japanese Ministry of Health, Labour and Welfare for Manufacturing and Marketing Approval of CABOMETYX in combination with Opdivo for the treatment of patients with unresectable, advanced or metastatic RCC. At September 30, 2020, we have not yet received this milestone payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the third quarter of 2020, Takeda opted into and is now co-funding the development costs for CONTACT-01, CONTACT-02 and certain cohorts of COSMIC-021. Concurrently, we entered into the third amendment to the collaboration agreement with Takeda (the Amendment), which modified certain cost sharing obligations related to the Japan-specific development costs associated with CONTACT-01 and CONTACT-02. We determined the Amendment represented a contract modification that was treated as a termination of an existing contract and the creation of a new contract under Topic 606. As a result, we allocated the remaining transaction price to the performance obligations identified in the contract. The two remaining performance obligations are the research and development services associated with committed studies described in &#x201c;Note 3. Collaboration Agreements&#x201d; of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, and the research and development services associated with CONTACT-01, CONTACT-02, and certain cohorts of COSMIC-021 studies. In allocating the transaction price for the modified contract we estimated the standalone selling price for the performance obligations. We utilized development costs incurred for these obligations in process and the projections of costs through the term of the arrangement. Revenue is recognized when, or as, we satisfy our performance obligations by transferring the promised services to Takeda. Revenue is being recognized using the cost proportional performance method, based on costs incurred to perform the research and development services, since the level of costs incurred over time is thought to best reflect the transfer of services to Takeda.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are eligible to receive additional regulatory and development milestone payments, without contractual limit, for additional potential future indications. We are further eligible to receive sales-based milestones, including milestone payments earned for the first commercial sale of a product, of up to $124.0&#160;million. We excluded these milestones from the transaction price as of September 30, 2020 because we determined such payments to be fully constrained under Topic 606 due to the fact that it was not probable that a significant reversal of cumulative revenue would not occur, given the inherent uncertainty of success with these milestones. We will re-evaluate the transaction price at each reporting period and as uncertain events are resolved or other changes in circumstances occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, $46.3 million of the trans&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;action price was allocated to our research and development services performance obligations that has not yet been satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;GSK&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2002, we established a product development and commercialization collaboration agreement with GSK. We are required to pay a 3% royalty to GSK on the net sales of any product incorporating cabozantinib by us and our collaboration partners. Royalties earned by GSK in connection with the sales of cabozantinib are included in cost of goods sold for sales by us and as a reduction of collaboration services revenues for sales by our collaboration partners. Such royalties were $7.9 million and $23.7 million during the three and nine months ended September&#160;30, 2020, respectively, as compared to $8.0 million and $23.1 million during the comparable periods in 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Genentech Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2006, we out-licensed the development and commercialization of cobimetinib to Genentech under a worldwide collaboration agreement. In&#160;November&#160;2015, the U.S. Food and Drug Administration (FDA) approved cobimetinib, under the brand name COTELLIC, in combination with Genentech&#x2019;s ZELBORAF&#xae;  (vemurafenib) for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma. COTELLIC in combination with ZELBORAF has also been approved in the European Union and multiple additional countries for use in the same indication. In July 2020, the FDA also approved COTELLIC for use in combination with ZELBORAF and TECENTRIQ&#xae; (atezolizumab) for the treatment of patients with BRAF V600 mutation-positive advanced melanoma in previously untreated patients. License revenues under the collaboration agreement with Genentech were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.981%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.424%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.460%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Profits on U.S. commercialization&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty revenues on ex-U.S. sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;In-Licensing Collaborations &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC, Catalent Pharma Solution LLC Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020, we entered into a collaboration and license agreement with Catalent, Inc.&#x2019;s wholly owned subsidiaries Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC and Catalent Pharma Solutions, Inc., (individually and collectively referred to as Catalent). Under the terms of the agreement, we made an upfront payment of $10.0&#160;million in exchange to nominate and have the exclusive option to license four targets using Catalent&#x2019;s ADC platform over a three-year period. In addition, we have a right to extend the target selection term to five years and nominate up to two additional targets for an additional payment of $4.0&#160;million. We will also contribute research funding to Catalent for discovery and preclinical development work. For each option we decide to exercise, we will pay an exercise fee of $2.0&#160;million, and would assume responsibilities for all subsequent clinical development, commercialization and global manufacturing of that program. Catalent would then become eligible to receive up to $44.0&#160;million per compound in potential development milestone payments, $60.0&#160;million per product in potential commercial milestone payments, as well as royalties on potential sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;NBE Therapeutics AG (NBE) Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020, we entered into a collaboration and license agreement with NBE. Under the terms of the agreement, we made an upfront payment of $25.0&#160;million in exchange for exclusive options to nominate four targets using NBE&#x2019;s ADC platform over a two-year period. In addition, within the first eighteen months of the agreement, we also have a right to extend the target selection term to three years for an additional payment of $2.0&#160;million. We will also contribute research funding to NBE for discovery and preclinical development work. For each option we decide to exercise, we will be &lt;/span&gt;&lt;/div&gt;required to pay an exercise fee of $10.0&#160;million, and would assume responsibilities for all subsequent clinical development, commercialization and global manufacturing of that program. NBE would then become eligible to receive up to $90.0&#160;million per program in potential development milestone payments, $135.0&#160;million per program in potential commercial milestone payments, as well as royalties on potential sales.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RleHRyZWdpb246YWFhZjI4ZTg2ZTI3NDdhNjk4ODc4MTA3NmE5YzhjZTNfNTU0NQ_51c51eb6-c3ea-4154-a1d3-0850a35a2ea0">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues under the collaboration agreement with Ipsen were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues under the collaboration agreement with Takeda were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;License revenues under the collaboration agreement with Genentech were as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.981%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.424%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.460%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Profits on U.S. commercialization&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty revenues on ex-U.S. sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic563e3038d034910b191aa2e402f2d54_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RhYmxlOjFhNTdhNmNiZGNmYTRhNmJhZmI0YjhhYjU4YmYxZjUzL3RhYmxlcmFuZ2U6MWE1N2E2Y2JkY2ZhNGE2YmFmYjRiOGFiNThiZjFmNTNfMi0xLTEtMS0w_afec674b-cb2a-4975-b831-2a1ee4567cea"
      unitRef="usd">19910000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i306ec623b7da464887c212d6bbb0c3b9_D20190629-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RhYmxlOjFhNTdhNmNiZGNmYTRhNmJhZmI0YjhhYjU4YmYxZjUzL3RhYmxlcmFuZ2U6MWE1N2E2Y2JkY2ZhNGE2YmFmYjRiOGFiNThiZjFmNTNfMi0zLTEtMS0w_0fc33a16-c1d4-44e7-b717-a7e092ca24b5"
      unitRef="usd">66409000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie769fec28ac9424ab1612b636240244f_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RhYmxlOjFhNTdhNmNiZGNmYTRhNmJhZmI0YjhhYjU4YmYxZjUzL3RhYmxlcmFuZ2U6MWE1N2E2Y2JkY2ZhNGE2YmFmYjRiOGFiNThiZjFmNTNfMi01LTEtMS0w_9f849b53-d2b2-44f2-944a-baefefe9b94c"
      unitRef="usd">71456000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2b97daa6c5714e879d52e0f5818a13e5_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RhYmxlOjFhNTdhNmNiZGNmYTRhNmJhZmI0YjhhYjU4YmYxZjUzL3RhYmxlcmFuZ2U6MWE1N2E2Y2JkY2ZhNGE2YmFmYjRiOGFiNThiZjFmNTNfMi03LTEtMS0w_36a87fa3-186e-4a93-958d-d16a9bf00bc1"
      unitRef="usd">95318000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="i625c660e5c2c47ffba3e54c798ef1200_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RhYmxlOjFhNTdhNmNiZGNmYTRhNmJhZmI0YjhhYjU4YmYxZjUzL3RhYmxlcmFuZ2U6MWE1N2E2Y2JkY2ZhNGE2YmFmYjRiOGFiNThiZjFmNTNfMy0xLTEtMS0w_72c7bfc6-ae66-41b2-a94d-06aeee27db52"
      unitRef="usd">16096000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="icb1de3b33b4e4d3ea045adf1503e5b39_D20190629-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RhYmxlOjFhNTdhNmNiZGNmYTRhNmJhZmI0YjhhYjU4YmYxZjUzL3RhYmxlcmFuZ2U6MWE1N2E2Y2JkY2ZhNGE2YmFmYjRiOGFiNThiZjFmNTNfMy0zLTEtMS0w_5de003e4-a8cc-4d15-8e1c-cffdd0a15455"
      unitRef="usd">9607000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="ie8fed9d02b6e436ebb1928ac49eccab8_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RhYmxlOjFhNTdhNmNiZGNmYTRhNmJhZmI0YjhhYjU4YmYxZjUzL3RhYmxlcmFuZ2U6MWE1N2E2Y2JkY2ZhNGE2YmFmYjRiOGFiNThiZjFmNTNfMy01LTEtMS0w_82217340-3ffd-4023-a89e-5196d6a4718f"
      unitRef="usd">46503000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="i39ac5c13a0c242ad9f5edee49b33dee7_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RhYmxlOjFhNTdhNmNiZGNmYTRhNmJhZmI0YjhhYjU4YmYxZjUzL3RhYmxlcmFuZ2U6MWE1N2E2Y2JkY2ZhNGE2YmFmYjRiOGFiNThiZjFmNTNfMy03LTEtMS0w_57dbbbc3-0627-4c3b-945f-7c370451f258"
      unitRef="usd">24815000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:Revenues
      contextRef="i911b510538cf4e2e9af50c7bbb5b99af_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RhYmxlOjFhNTdhNmNiZGNmYTRhNmJhZmI0YjhhYjU4YmYxZjUzL3RhYmxlcmFuZ2U6MWE1N2E2Y2JkY2ZhNGE2YmFmYjRiOGFiNThiZjFmNTNfNC0xLTEtMS0w_cd425d71-2425-4cef-9b67-54fc5a56e4b6"
      unitRef="usd">36006000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7142efd22e1049f7852952c299c3d936_D20190629-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RhYmxlOjFhNTdhNmNiZGNmYTRhNmJhZmI0YjhhYjU4YmYxZjUzL3RhYmxlcmFuZ2U6MWE1N2E2Y2JkY2ZhNGE2YmFmYjRiOGFiNThiZjFmNTNfNC0zLTEtMS0w_32274bcb-3c3f-4e84-84ed-48e09fd1671b"
      unitRef="usd">76016000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib2cd405124b14735b901658a7069f2a6_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RhYmxlOjFhNTdhNmNiZGNmYTRhNmJhZmI0YjhhYjU4YmYxZjUzL3RhYmxlcmFuZ2U6MWE1N2E2Y2JkY2ZhNGE2YmFmYjRiOGFiNThiZjFmNTNfNC01LTEtMS0w_fb9edcd0-9e4f-4b9c-ac71-b925fab87fe4"
      unitRef="usd">117959000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iccf5e837fe3f43d6856e3b446cd61ef1_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RhYmxlOjFhNTdhNmNiZGNmYTRhNmJhZmI0YjhhYjU4YmYxZjUzL3RhYmxlcmFuZ2U6MWE1N2E2Y2JkY2ZhNGE2YmFmYjRiOGFiNThiZjFmNTNfNC03LTEtMS0w_fd82c477-8c2f-40b2-b32f-b7f394565f99"
      unitRef="usd">120133000</us-gaap:Revenues>
    <exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement
      contextRef="icef64ef981c4433ab4d95dd86f4c12ae_I20201002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RleHRyZWdpb246YWFhZjI4ZTg2ZTI3NDdhNjk4ODc4MTA3NmE5YzhjZTNfMTA5OTUxMTY0MDI3Mw_94f8da91-d264-4671-8b46-cc82cf3ab34f"
      unitRef="usd">59000000.0</exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement>
    <exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement
      contextRef="icef64ef981c4433ab4d95dd86f4c12ae_I20201002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RleHRyZWdpb246YWFhZjI4ZTg2ZTI3NDdhNjk4ODc4MTA3NmE5YzhjZTNfMTA5OTUxMTY0MDI5NQ_ef24dcf4-b555-446b-95cf-97426b90ae35"
      unitRef="usd">469900000</exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="icef64ef981c4433ab4d95dd86f4c12ae_I20201002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RleHRyZWdpb246YWFhZjI4ZTg2ZTI3NDdhNjk4ODc4MTA3NmE5YzhjZTNfMjgwNw_e49339cc-26b6-4e9a-9477-f779845e8e9c"
      unitRef="usd">42600000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia423630adad04538bc955c381c570336_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RhYmxlOmI2MGYxODk0MTk5MDQzMDA5N2RjNDRjN2JhMjAyMDYxL3RhYmxlcmFuZ2U6YjYwZjE4OTQxOTkwNDMwMDk3ZGM0NGM3YmEyMDIwNjFfMi0xLTEtMS0w_30516fa6-bbf6-4a44-ae42-bebf7c6f7638"
      unitRef="usd">9780000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5df4d5352b0b4f0ba481cb03390bc3df_D20190629-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RhYmxlOmI2MGYxODk0MTk5MDQzMDA5N2RjNDRjN2JhMjAyMDYxL3RhYmxlcmFuZ2U6YjYwZjE4OTQxOTkwNDMwMDk3ZGM0NGM3YmEyMDIwNjFfMi0zLTEtMS0w_9081fa59-7dcb-4569-bb0f-0ffc78178933"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibcb0ee440b7e4dc0b3ff4215f20b3b2d_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RhYmxlOmI2MGYxODk0MTk5MDQzMDA5N2RjNDRjN2JhMjAyMDYxL3RhYmxlcmFuZ2U6YjYwZjE4OTQxOTkwNDMwMDk3ZGM0NGM3YmEyMDIwNjFfMi01LTEtMS0w_aa9cc672-8315-486a-bb90-a2a07d538cbe"
      unitRef="usd">32726000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie6551575ad754a52ade8c9bd7ebfa664_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RhYmxlOmI2MGYxODk0MTk5MDQzMDA5N2RjNDRjN2JhMjAyMDYxL3RhYmxlcmFuZ2U6YjYwZjE4OTQxOTkwNDMwMDk3ZGM0NGM3YmEyMDIwNjFfMi03LTEtMS0w_9e293d57-7961-4de1-aad0-f966eb13028b"
      unitRef="usd">9056000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="i17097e4a7b2744f3bb555de0fd06a162_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RhYmxlOmI2MGYxODk0MTk5MDQzMDA5N2RjNDRjN2JhMjAyMDYxL3RhYmxlcmFuZ2U6YjYwZjE4OTQxOTkwNDMwMDk3ZGM0NGM3YmEyMDIwNjFfMy0xLTEtMS0w_792cc6b1-b528-4d73-8eb9-ae5fdc634094"
      unitRef="usd">13204000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="i6130e6433ae14ecf9e3154f44ad89dcd_D20190629-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RhYmxlOmI2MGYxODk0MTk5MDQzMDA5N2RjNDRjN2JhMjAyMDYxL3RhYmxlcmFuZ2U6YjYwZjE4OTQxOTkwNDMwMDk3ZGM0NGM3YmEyMDIwNjFfMy0zLTEtMS0w_99f42c92-a9d8-409f-9d21-83f4d2224160"
      unitRef="usd">1187000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="ia4048c98f09848dc973a93054bfd645e_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RhYmxlOmI2MGYxODk0MTk5MDQzMDA5N2RjNDRjN2JhMjAyMDYxL3RhYmxlcmFuZ2U6YjYwZjE4OTQxOTkwNDMwMDk3ZGM0NGM3YmEyMDIwNjFfMy01LTEtMS0w_1c8ae7b6-bd11-4d07-b87d-d62ffe00bc2d"
      unitRef="usd">16468000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="ieffdd922a5584f5fb2c96d614a69b68c_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RhYmxlOmI2MGYxODk0MTk5MDQzMDA5N2RjNDRjN2JhMjAyMDYxL3RhYmxlcmFuZ2U6YjYwZjE4OTQxOTkwNDMwMDk3ZGM0NGM3YmEyMDIwNjFfMy03LTEtMS0w_f1433497-db46-41d4-9ff0-fdf5a63aa596"
      unitRef="usd">5189000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:Revenues
      contextRef="ieb095da3afbd4daa9861c6249817cea0_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RhYmxlOmI2MGYxODk0MTk5MDQzMDA5N2RjNDRjN2JhMjAyMDYxL3RhYmxlcmFuZ2U6YjYwZjE4OTQxOTkwNDMwMDk3ZGM0NGM3YmEyMDIwNjFfNC0xLTEtMS0w_65fd313a-0590-4943-ba57-42c3bab51bff"
      unitRef="usd">22984000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i16a003aa5aa5428887c9c411dbc420fc_D20190629-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RhYmxlOmI2MGYxODk0MTk5MDQzMDA5N2RjNDRjN2JhMjAyMDYxL3RhYmxlcmFuZ2U6YjYwZjE4OTQxOTkwNDMwMDk3ZGM0NGM3YmEyMDIwNjFfNC0zLTEtMS0w_2cb5bc0e-9314-4db2-80ad-3d7371ac1ce7"
      unitRef="usd">1187000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i32bf9affdda745209b77e77dfc211f15_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RhYmxlOmI2MGYxODk0MTk5MDQzMDA5N2RjNDRjN2JhMjAyMDYxL3RhYmxlcmFuZ2U6YjYwZjE4OTQxOTkwNDMwMDk3ZGM0NGM3YmEyMDIwNjFfNC01LTEtMS0w_aecf1dfb-27e0-4bed-84ad-5e6c70127788"
      unitRef="usd">49194000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i350a22df21c64d1c93c2524af875b962_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RhYmxlOmI2MGYxODk0MTk5MDQzMDA5N2RjNDRjN2JhMjAyMDYxL3RhYmxlcmFuZ2U6YjYwZjE4OTQxOTkwNDMwMDk3ZGM0NGM3YmEyMDIwNjFfNC03LTEtMS0w_ff8d9137-50dd-4b8d-b8f9-a7aaf26f3951"
      unitRef="usd">14245000</us-gaap:Revenues>
    <exel:MilestonePaymentsEarned
      contextRef="ieb095da3afbd4daa9861c6249817cea0_D20200704-20201002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RleHRyZWdpb246YWFhZjI4ZTg2ZTI3NDdhNjk4ODc4MTA3NmE5YzhjZTNfMTA0NDUzNjA0ODE4MDQ_04f83aac-5ec3-49bc-b912-bb5e87a57d7d"
      unitRef="usd">9200000</exel:MilestonePaymentsEarned>
    <exel:MilestonePaymentsEarned
      contextRef="i32bf9affdda745209b77e77dfc211f15_D20200104-20201002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RleHRyZWdpb246YWFhZjI4ZTg2ZTI3NDdhNjk4ODc4MTA3NmE5YzhjZTNfMTA0NDUzNjA0ODE4MDQ_544a3994-1e7a-4c56-8ff0-9fd0ec538947"
      unitRef="usd">9200000</exel:MilestonePaymentsEarned>
    <exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement
      contextRef="i0b512ec06edc41c18dbe1037421ea9bb_I20201002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RleHRyZWdpb246YWFhZjI4ZTg2ZTI3NDdhNjk4ODc4MTA3NmE5YzhjZTNfMTA0NDUzNjA0ODE4MTg_b21cbc85-aeeb-45cc-a78f-0e89b1043344"
      unitRef="usd">10000000.0</exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement>
    <exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement
      contextRef="i0b512ec06edc41c18dbe1037421ea9bb_I20201002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RleHRyZWdpb246YWFhZjI4ZTg2ZTI3NDdhNjk4ODc4MTA3NmE5YzhjZTNfMTA0NDUzNjA0NzU5MTk_7e38c49a-68a5-4318-acad-da0eaab89109"
      unitRef="usd">124000000.0</exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i0b512ec06edc41c18dbe1037421ea9bb_I20201002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RleHRyZWdpb246YWFhZjI4ZTg2ZTI3NDdhNjk4ODc4MTA3NmE5YzhjZTNfMTA5OTUxMTYzMzM0Mg_9127515e-f9ea-45f6-bc9f-494b93960e51"
      unitRef="usd">46300000</us-gaap:RevenueRemainingPerformanceObligation>
    <exel:CollaborationAgreementPercentOfRoyaltyOnNetSale
      contextRef="ia8670170a5094b3b904e1504aafbac8c_D20200104-20201002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RleHRyZWdpb246YWFhZjI4ZTg2ZTI3NDdhNjk4ODc4MTA3NmE5YzhjZTNfNDE5Mg_e030c443-c16b-4f52-83ea-1396b026ced8"
      unitRef="number">0.03</exel:CollaborationAgreementPercentOfRoyaltyOnNetSale>
    <us-gaap:RoyaltyExpense
      contextRef="if6d4cedf8c084744ba29969039e3b2e9_D20200704-20201002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RleHRyZWdpb246YWFhZjI4ZTg2ZTI3NDdhNjk4ODc4MTA3NmE5YzhjZTNfNDU0Mw_2fd8bb9d-f868-439e-87d7-d4ee5ab0fa7a"
      unitRef="usd">7900000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="i8dbb49564117496fb5290d851754b098_D20200104-20201002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RleHRyZWdpb246YWFhZjI4ZTg2ZTI3NDdhNjk4ODc4MTA3NmE5YzhjZTNfNDU1Mg_77d4c530-af04-411b-ab37-6f20237e77f7"
      unitRef="usd">23700000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="i681117f1aebd445288c3a111845dc5c8_D20190629-20190927"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RleHRyZWdpb246YWFhZjI4ZTg2ZTI3NDdhNjk4ODc4MTA3NmE5YzhjZTNfNDYwMw_1b2bf86e-5025-482e-8f32-e68b449fc0f3"
      unitRef="usd">8000000.0</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="i71974296a61b4d89993136d3ef36daed_D20181229-20190927"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RleHRyZWdpb246YWFhZjI4ZTg2ZTI3NDdhNjk4ODc4MTA3NmE5YzhjZTNfNDYxMA_14d33bb8-b893-452a-9077-7fab15684492"
      unitRef="usd">23100000</us-gaap:RoyaltyExpense>
    <exel:CollaborativeArrangementIncomeLossFromAgreement
      contextRef="id774200cb5964ec7a9f457d6f01d6879_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RhYmxlOmU3NWRhMjE2NTg5NjQ3ZDJiYWQzNmZhMDk2ZDMxZjlkL3RhYmxlcmFuZ2U6ZTc1ZGEyMTY1ODk2NDdkMmJhZDM2ZmEwOTZkMzFmOWRfMi0xLTEtMS0w_998010f6-f985-4ce8-958b-f09748a6620b"
      unitRef="usd">1595000</exel:CollaborativeArrangementIncomeLossFromAgreement>
    <exel:CollaborativeArrangementIncomeLossFromAgreement
      contextRef="i3042085c439a4f33a184caed0a43f26b_D20190629-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RhYmxlOmU3NWRhMjE2NTg5NjQ3ZDJiYWQzNmZhMDk2ZDMxZjlkL3RhYmxlcmFuZ2U6ZTc1ZGEyMTY1ODk2NDdkMmJhZDM2ZmEwOTZkMzFmOWRfMi0zLTEtMS0w_e847e362-b91e-4467-9a06-8399aa6f0c01"
      unitRef="usd">1102000</exel:CollaborativeArrangementIncomeLossFromAgreement>
    <exel:CollaborativeArrangementIncomeLossFromAgreement
      contextRef="i435fea9408f448279983514e753b98c2_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RhYmxlOmU3NWRhMjE2NTg5NjQ3ZDJiYWQzNmZhMDk2ZDMxZjlkL3RhYmxlcmFuZ2U6ZTc1ZGEyMTY1ODk2NDdkMmJhZDM2ZmEwOTZkMzFmOWRfMi01LTEtMS0w_fd3bf188-9684-4cdd-bba6-188f376a0e52"
      unitRef="usd">4378000</exel:CollaborativeArrangementIncomeLossFromAgreement>
    <exel:CollaborativeArrangementIncomeLossFromAgreement
      contextRef="i54179f4a09954324b9f756384579283e_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RhYmxlOmU3NWRhMjE2NTg5NjQ3ZDJiYWQzNmZhMDk2ZDMxZjlkL3RhYmxlcmFuZ2U6ZTc1ZGEyMTY1ODk2NDdkMmJhZDM2ZmEwOTZkMzFmOWRfMi03LTEtMS0w_a0c6c5d1-c37e-4863-8f12-50f4b2387b19"
      unitRef="usd">3507000</exel:CollaborativeArrangementIncomeLossFromAgreement>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id774200cb5964ec7a9f457d6f01d6879_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RhYmxlOmU3NWRhMjE2NTg5NjQ3ZDJiYWQzNmZhMDk2ZDMxZjlkL3RhYmxlcmFuZ2U6ZTc1ZGEyMTY1ODk2NDdkMmJhZDM2ZmEwOTZkMzFmOWRfMy0xLTEtMS0w_cbb238b4-e1ce-4c14-8d8d-29f1e2a2ae95"
      unitRef="usd">1370000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3042085c439a4f33a184caed0a43f26b_D20190629-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RhYmxlOmU3NWRhMjE2NTg5NjQ3ZDJiYWQzNmZhMDk2ZDMxZjlkL3RhYmxlcmFuZ2U6ZTc1ZGEyMTY1ODk2NDdkMmJhZDM2ZmEwOTZkMzFmOWRfMy0zLTEtMS0w_5f88e7c0-f7a9-4c64-a2ef-d444ef9f2a78"
      unitRef="usd">1614000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i435fea9408f448279983514e753b98c2_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RhYmxlOmU3NWRhMjE2NTg5NjQ3ZDJiYWQzNmZhMDk2ZDMxZjlkL3RhYmxlcmFuZ2U6ZTc1ZGEyMTY1ODk2NDdkMmJhZDM2ZmEwOTZkMzFmOWRfMy01LTEtMS0w_7d086d7d-df8f-40e2-b5dd-d174f506e214"
      unitRef="usd">3804000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i54179f4a09954324b9f756384579283e_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RhYmxlOmU3NWRhMjE2NTg5NjQ3ZDJiYWQzNmZhMDk2ZDMxZjlkL3RhYmxlcmFuZ2U6ZTc1ZGEyMTY1ODk2NDdkMmJhZDM2ZmEwOTZkMzFmOWRfMy03LTEtMS0w_44a4ad32-2eae-4d23-a226-3d4ab9f66cc8"
      unitRef="usd">4426000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <exel:CollaborativeAgreementsUpfrontPayments
      contextRef="i02e9b643d49a417e9373b15e166ba536_D20200104-20201002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RleHRyZWdpb246YWFhZjI4ZTg2ZTI3NDdhNjk4ODc4MTA3NmE5YzhjZTNfMTA0NDUzNjA0NzU5MzU_7de06246-2bdc-463b-9ffe-d0c5bf5a67fe"
      unitRef="usd">10000000.0</exel:CollaborativeAgreementsUpfrontPayments>
    <exel:CollaborationAndLicenseAgreementTargetSelectionTerm
      contextRef="i02e9b643d49a417e9373b15e166ba536_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RleHRyZWdpb246YWFhZjI4ZTg2ZTI3NDdhNjk4ODc4MTA3NmE5YzhjZTNfNTQ5NzU1ODE1NzM2Mg_ca076b21-c61e-4874-8671-b5852eff58b1">P3Y</exel:CollaborationAndLicenseAgreementTargetSelectionTerm>
    <exel:CollaborationAndLicenseAgreementExtendedTargetSelectionTerm
      contextRef="i02e9b643d49a417e9373b15e166ba536_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RleHRyZWdpb246YWFhZjI4ZTg2ZTI3NDdhNjk4ODc4MTA3NmE5YzhjZTNfMTA0NDUzNjA0NzYxMDc_a37c307f-d05b-40f4-a107-2212dd597c3a">P5Y</exel:CollaborationAndLicenseAgreementExtendedTargetSelectionTerm>
    <exel:CollaborationAgreementsAdditionalUpfrontPayments
      contextRef="i02e9b643d49a417e9373b15e166ba536_D20200104-20201002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RleHRyZWdpb246YWFhZjI4ZTg2ZTI3NDdhNjk4ODc4MTA3NmE5YzhjZTNfMTA0NDUzNjA0NzU5NTA_14732698-364a-40cc-9e00-945d18704b48"
      unitRef="usd">4000000.0</exel:CollaborationAgreementsAdditionalUpfrontPayments>
    <exel:CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption
      contextRef="i4f29e6a4d7e4442a814e495bb866df20_I20201002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RleHRyZWdpb246YWFhZjI4ZTg2ZTI3NDdhNjk4ODc4MTA3NmE5YzhjZTNfMTA0NDUzNjA0NzU5NjI_7228a497-be7f-4603-89df-8932920cf559"
      unitRef="usd">2000000.0</exel:CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption>
    <exel:CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones
      contextRef="i4f29e6a4d7e4442a814e495bb866df20_I20201002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RleHRyZWdpb246YWFhZjI4ZTg2ZTI3NDdhNjk4ODc4MTA3NmE5YzhjZTNfMTA0NDUzNjA0NzU5NzY_9e04fb3c-0f05-4600-a641-3156f572cc5a"
      unitRef="usd">44000000.0</exel:CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones>
    <exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement
      contextRef="i4f29e6a4d7e4442a814e495bb866df20_I20201002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RleHRyZWdpb246YWFhZjI4ZTg2ZTI3NDdhNjk4ODc4MTA3NmE5YzhjZTNfMTA0NDUzNjA0NzU5OTE_f5705eb0-d1e3-485b-8572-6ab54b65f289"
      unitRef="usd">60000000.0</exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement>
    <exel:CollaborativeAgreementsUpfrontPayments
      contextRef="i6b107f2541f144959f65cffe2682f793_D20200104-20201002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RleHRyZWdpb246YWFhZjI4ZTg2ZTI3NDdhNjk4ODc4MTA3NmE5YzhjZTNfMTA0NDUzNjA0NzYwMzM_5b1b3fd8-36e4-4088-98e9-83625611760d"
      unitRef="usd">25000000.0</exel:CollaborativeAgreementsUpfrontPayments>
    <exel:CollaborationAndLicenseAgreementTargetSelectionTerm
      contextRef="i6b107f2541f144959f65cffe2682f793_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RleHRyZWdpb246YWFhZjI4ZTg2ZTI3NDdhNjk4ODc4MTA3NmE5YzhjZTNfNjA0NzMxMzk3MzQ0NA_8f21665e-9301-4741-9e8c-e63b99842f63">P2Y</exel:CollaborationAndLicenseAgreementTargetSelectionTerm>
    <exel:CollaborationAndLicenseAgreementTargetSelectionExtensionOptionTerm
      contextRef="i6b107f2541f144959f65cffe2682f793_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RleHRyZWdpb246YWFhZjI4ZTg2ZTI3NDdhNjk4ODc4MTA3NmE5YzhjZTNfOTg5NTYwNDY2ODU2Mw_52aff017-93a7-4442-9dab-e72b25e373bc">P18M</exel:CollaborationAndLicenseAgreementTargetSelectionExtensionOptionTerm>
    <exel:CollaborationAndLicenseAgreementExtendedTargetSelectionTerm
      contextRef="i6b107f2541f144959f65cffe2682f793_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RleHRyZWdpb246YWFhZjI4ZTg2ZTI3NDdhNjk4ODc4MTA3NmE5YzhjZTNfMTA0NDUzNjA0NzYxODQ_ec5e7aab-7b1a-4a06-82b8-da4488e276ba">P3Y</exel:CollaborationAndLicenseAgreementExtendedTargetSelectionTerm>
    <exel:CollaborationAgreementsAdditionalUpfrontPayments
      contextRef="i6b107f2541f144959f65cffe2682f793_D20200104-20201002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RleHRyZWdpb246YWFhZjI4ZTg2ZTI3NDdhNjk4ODc4MTA3NmE5YzhjZTNfMTA0NDUzNjA0NzYwMDY_f52e7d40-881a-465c-90ca-f489126b62da"
      unitRef="usd">2000000.0</exel:CollaborationAgreementsAdditionalUpfrontPayments>
    <exel:CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption
      contextRef="i9dc3e9657668420dbfcde5f6032f0548_I20201002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RleHRyZWdpb246YWFhZjI4ZTg2ZTI3NDdhNjk4ODc4MTA3NmE5YzhjZTNfMTA0NDUzNjA0NzYwMTg_0ebcc930-fe37-407a-989e-28a67e1f4d59"
      unitRef="usd">10000000.0</exel:CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption>
    <exel:CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones
      contextRef="i9dc3e9657668420dbfcde5f6032f0548_I20201002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RleHRyZWdpb246YWFhZjI4ZTg2ZTI3NDdhNjk4ODc4MTA3NmE5YzhjZTNfMTA0NDUzNjA0NzYwNjQ_dbb1a67e-7073-40b1-a73b-f3aa0b222cc7"
      unitRef="usd">90000000.0</exel:CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones>
    <exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement
      contextRef="i9dc3e9657668420dbfcde5f6032f0548_I20201002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF80OS9mcmFnOmFhYWYyOGU4NmUyNzQ3YTY5ODg3ODEwNzZhOWM4Y2UzL3RleHRyZWdpb246YWFhZjI4ZTg2ZTI3NDdhNjk4ODc4MTA3NmE5YzhjZTNfMTA0NDUzNjA0NzYwNDg_e31b9348-57b3-4253-95bf-6d2ac5a8acd6"
      unitRef="usd">135000000.0</exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement>
    <exel:CashCashEquivalentsAndInvestmentsTextBlock
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RleHRyZWdpb246OGZhODczZDFjZDY5NGI4YmE5NzUwZTE4NjFmNGMwMGFfMjI0NQ_387b2675-7acb-4ba6-bbca-6f9b56de9770">CASH AND INVESTMENTS&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Restricted Cash Equivalents &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;334,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash equivalents included in long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;335,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash equivalents consisted of certificates of deposit with original maturities of 90 days or less used to collateralize letters of credit. The long-term classification of restricted cash equivalents is based upon the remaining term of the underlying restriction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash and Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and investments consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;466,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;466,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;629,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;636,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,329,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,337,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,537,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,545,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;752,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;756,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,308,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,312,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,384,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,388,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest receivable was $4.5 million and $6.2 million as of September&#160;30, 2020 and December&#160;31, 2019, respectively, and is included in prepaid expenses and other current assets in the accompanying Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Realized gains and losses on the sales of investments were insignificant during the three and nine months ended September&#160;30, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We manage credit risk associated with our investment portfolio through our investment policy, which limits purchases to high-quality issuers and limits the amount of our portfolio that can be invested in a single issuer. The fair value and gross unrealized losses on debt securities available-for-sale in an unrealized loss position were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.459%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.459%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All securities presented have been in an unrealized loss position less than 12 months. There were 16 and 9 investments in an unrealized loss position as of September&#160;30, 2020 and December&#160;31, 2019, respectively. During the nine months ended September&#160;30, 2020 and 2019, we did not record an allowance for credit losses or other impairment charges on our investment securities. Based upon our quarterly impairment review, we determined that the unrealized losses were not attributed to credit risk but were primarily associated with changes in interest rates and market liquidity. Based on the scheduled maturities of our investments, we determined that it was more likely than not that we will hold these investments for a period of time sufficient for a recovery of our cost basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of debt securities available-for-sale by contractual maturity was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;789,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;522,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,337,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,312,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</exel:CashCashEquivalentsAndInvestmentsTextBlock>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RleHRyZWdpb246OGZhODczZDFjZDY5NGI4YmE5NzUwZTE4NjFmNGMwMGFfMjIzOQ_9add4554-6db9-463b-8673-4ec8649e1fb6">A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;334,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash equivalents included in long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;335,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RleHRyZWdpb246OGZhODczZDFjZDY5NGI4YmE5NzUwZTE4NjFmNGMwMGFfMjI0MA_d320285c-5c98-4b49-bcf8-25835e9ef95d">A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;334,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash equivalents included in long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;335,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOjgzNGU2OWJhYzY0OTQ2YmE5NmY1YWI5NGYxY2Q0YjM2L3RhYmxlcmFuZ2U6ODM0ZTY5YmFjNjQ5NDZiYTk2ZjVhYjk0ZjFjZDRiMzZfMS0xLTEtMS0w_edaafdff-accb-4a66-b9e3-aac9c8e44aec"
      unitRef="usd">334046000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOjgzNGU2OWJhYzY0OTQ2YmE5NmY1YWI5NGYxY2Q0YjM2L3RhYmxlcmFuZ2U6ODM0ZTY5YmFjNjQ5NDZiYTk2ZjVhYjk0ZjFjZDRiMzZfMS0zLTEtMS0w_e7e1a5fe-b5b6-4b14-9829-b36d5e6358c1"
      unitRef="usd">266501000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashEquivalentsNoncurrent
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOjgzNGU2OWJhYzY0OTQ2YmE5NmY1YWI5NGYxY2Q0YjM2L3RhYmxlcmFuZ2U6ODM0ZTY5YmFjNjQ5NDZiYTk2ZjVhYjk0ZjFjZDRiMzZfMy0xLTEtMS0w_83dcb8e0-4cbc-4fa0-88b2-94d1e66fdd6c"
      unitRef="usd">1636000</us-gaap:RestrictedCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashEquivalentsNoncurrent
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOjgzNGU2OWJhYzY0OTQ2YmE5NmY1YWI5NGYxY2Q0YjM2L3RhYmxlcmFuZ2U6ODM0ZTY5YmFjNjQ5NDZiYTk2ZjVhYjk0ZjFjZDRiMzZfMy0zLTEtMS0w_414eafba-76c1-4e8d-8236-9f7830e8e8f7"
      unitRef="usd">1636000</us-gaap:RestrictedCashEquivalentsNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOjgzNGU2OWJhYzY0OTQ2YmE5NmY1YWI5NGYxY2Q0YjM2L3RhYmxlcmFuZ2U6ODM0ZTY5YmFjNjQ5NDZiYTk2ZjVhYjk0ZjFjZDRiMzZfNC0xLTEtMS0w_e086c422-f102-4dd1-ae70-a445f7da7a08"
      unitRef="usd">335682000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOjgzNGU2OWJhYzY0OTQ2YmE5NmY1YWI5NGYxY2Q0YjM2L3RhYmxlcmFuZ2U6ODM0ZTY5YmFjNjQ5NDZiYTk2ZjVhYjk0ZjFjZDRiMzZfNC0zLTEtMS0w_6afd40fb-c135-47b1-9fd3-88a02c31e869"
      unitRef="usd">268137000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RleHRyZWdpb246OGZhODczZDFjZDY5NGI4YmE5NzUwZTE4NjFmNGMwMGFfMjI1NA_73dd51a7-f71d-43ac-bcd1-ba5e5b813eaf">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and investments consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;466,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;466,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;629,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;636,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,329,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,337,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,537,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,545,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;752,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;756,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,308,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,312,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,384,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,388,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5d1bc4ca714746459025e3f4409d9cd3_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfMy0xLTEtMS0w_fdf4ef6e-87b8-4a31-b1cd-fd7c60e0ccca"
      unitRef="usd">466141000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5d1bc4ca714746459025e3f4409d9cd3_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfMy0zLTEtMS0w_9d598546-69fa-44b4-8cec-e1a725c54716"
      unitRef="usd">225000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5d1bc4ca714746459025e3f4409d9cd3_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfMy01LTEtMS0w_206d427c-a0e6-4ee4-b6e2-bd1292c25802"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5d1bc4ca714746459025e3f4409d9cd3_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfMy03LTEtMS0w_f66fe802-2faf-4b0b-95ce-d7d7482e86cc"
      unitRef="usd">466366000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i51a81230a1d74e55a2566c55413e2b2a_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfNC0xLTEtMS0w_191190b6-19a8-4d23-a95b-906c43f75961"
      unitRef="usd">629309000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i51a81230a1d74e55a2566c55413e2b2a_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfNC0zLTEtMS0w_5b81bfcd-1c16-4c15-8bdb-9f65b0779db5"
      unitRef="usd">7526000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i51a81230a1d74e55a2566c55413e2b2a_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfNC01LTEtMS0w_d885fb9c-de1c-419a-8b82-412af33ff572"
      unitRef="usd">20000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i51a81230a1d74e55a2566c55413e2b2a_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfNC03LTEtMS0w_21099f7f-15d6-4f73-853f-2567bf86ec40"
      unitRef="usd">636815000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9ba278ad76ca4fcd841ffefc73154898_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfNS0xLTEtMS0w_4426b0a4-62bd-471c-850e-45de08fdaa23"
      unitRef="usd">213449000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9ba278ad76ca4fcd841ffefc73154898_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfNS0zLTEtMS0w_e220d3b3-4c52-4d33-ac00-0a33e9ce29c6"
      unitRef="usd">354000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9ba278ad76ca4fcd841ffefc73154898_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfNS01LTEtMS0w_b5582b4e-2318-45b9-9582-bc9d104fe01b"
      unitRef="usd">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9ba278ad76ca4fcd841ffefc73154898_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfNS03LTEtMS0w_7645e90f-2aaf-4e74-8fcc-5c9fd60ad91c"
      unitRef="usd">213793000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id17bab0418ae471988fdfa84040140f1_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfNi0xLTEtMS0w_2a1c7ee8-ded6-4c8f-ba26-4c835ae43e27"
      unitRef="usd">20326000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id17bab0418ae471988fdfa84040140f1_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfNi0zLTEtMS0w_2c0ce464-8cbb-4239-a6b6-bcd85974a306"
      unitRef="usd">105000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id17bab0418ae471988fdfa84040140f1_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfNi01LTEtMS0w_55f69f7b-385d-4ec0-8c47-21a64971a850"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id17bab0418ae471988fdfa84040140f1_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfNi03LTEtMS0w_c0628c00-ade9-4e10-a523-c8e8e650d78d"
      unitRef="usd">20431000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfNy0xLTEtMS0w_1edd6462-6c54-496d-9dbc-b64ad9fc248d"
      unitRef="usd">1329225000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfNy0zLTEtMS0w_6a83c44d-249b-4cc2-be30-d95d9a5c5d6d"
      unitRef="usd">8210000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfNy01LTEtMS0w_b7335511-b5ec-46e4-8a62-78e3572b8f49"
      unitRef="usd">30000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfNy03LTEtMS0w_f7df6f0f-d03d-499c-8325-c973f12ac410"
      unitRef="usd">1337405000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="ifac6d9b9d2944e76a0f5c167b3983bc0_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfOC0xLTEtMS0w_304800d5-e3cc-42a1-8049-3c93ba05aa34"
      unitRef="usd">55979000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="ifac6d9b9d2944e76a0f5c167b3983bc0_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfOC0zLTEtMS0w_e7c738ec-e8af-47ab-b6c7-dca8de77c2b0"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="ifac6d9b9d2944e76a0f5c167b3983bc0_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfOC01LTEtMS0w_32e59a52-7112-4fee-b6f3-d8462ed75e03"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="ifac6d9b9d2944e76a0f5c167b3983bc0_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfOC03LTEtMS0w_37418c80-7190-46fa-8f85-03f190544695"
      unitRef="usd">55979000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="ideca50ba198246c68d0bffddd169057c_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfOS0xLTEtMS0w_b8e6ecb7-704c-45b0-b993-d7763aa54df4"
      unitRef="usd">96992000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="ideca50ba198246c68d0bffddd169057c_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfOS0zLTEtMS0w_d0850d3b-1169-414a-8277-2f5cc188cdb1"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="ideca50ba198246c68d0bffddd169057c_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfOS01LTEtMS0w_50b40f3d-9caa-44ea-9508-271be5436625"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="ideca50ba198246c68d0bffddd169057c_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfOS03LTEtMS0w_d37d9672-1b5f-4db8-a484-01d68818fb8f"
      unitRef="usd">96992000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="i58a13023c0dd450eb2ee0d861f56e766_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfMTAtMS0xLTEtMA_1b1e8be2-d118-495e-977a-eace41a2d55a"
      unitRef="usd">55583000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="i58a13023c0dd450eb2ee0d861f56e766_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfMTAtMy0xLTEtMA_08107a74-39c1-4de6-a9d6-61578304036a"
      unitRef="usd">1000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="i58a13023c0dd450eb2ee0d861f56e766_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfMTAtNS0xLTEtMA_c37fe11e-a30d-4c57-9550-8edb708617d2"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="i58a13023c0dd450eb2ee0d861f56e766_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfMTAtNy0xLTEtMA_f85fd61f-61ea-472b-8bcd-879fae01a8d5"
      unitRef="usd">55584000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfMTEtMS0xLTEtMA_614f5f06-c394-4764-8823-7d68ad685adb"
      unitRef="usd">1537779000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfMTEtMy0xLTEtMA_cbae2520-fbfa-4897-969c-8b4c9c9accf2"
      unitRef="usd">8211000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfMTEtNS0xLTEtMA_808493ee-2403-4347-8e5c-c41ced0b9d76"
      unitRef="usd">30000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmNhYWY2N2U1YjJiZTQ3NjY4MmFiOGFlNjQ4NDY0OGJkL3RhYmxlcmFuZ2U6Y2FhZjY3ZTViMmJlNDc2NjgyYWI4YWU2NDg0NjQ4YmRfMTEtNy0xLTEtMA_04be8def-930b-41ab-9536-69d68835b4b3"
      unitRef="usd">1545960000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i0f9a560b1450471a9fb3a5226dea5132_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmYxZWQ5YzU5MGI3YzRjNTZhODBhMTUxNGNiOWJhMGMyL3RhYmxlcmFuZ2U6ZjFlZDljNTkwYjdjNGM1NmE4MGExNTE0Y2I5YmEwYzJfMy0xLTEtMS0w_6559794c-9353-4330-9a4d-850a8ea9a6b3"
      unitRef="usd">389573000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0f9a560b1450471a9fb3a5226dea5132_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmYxZWQ5YzU5MGI3YzRjNTZhODBhMTUxNGNiOWJhMGMyL3RhYmxlcmFuZ2U6ZjFlZDljNTkwYjdjNGM1NmE4MGExNTE0Y2I5YmEwYzJfMy0zLTEtMS0w_87b743b2-74de-4023-9c66-d46222d73b63"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0f9a560b1450471a9fb3a5226dea5132_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmYxZWQ5YzU5MGI3YzRjNTZhODBhMTUxNGNiOWJhMGMyL3RhYmxlcmFuZ2U6ZjFlZDljNTkwYjdjNGM1NmE4MGExNTE0Y2I5YmEwYzJfMy01LTEtMS0w_27ac9ac1-c6c5-43f4-8c9f-89dd23a17e18"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0f9a560b1450471a9fb3a5226dea5132_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmYxZWQ5YzU5MGI3YzRjNTZhODBhMTUxNGNiOWJhMGMyL3RhYmxlcmFuZ2U6ZjFlZDljNTkwYjdjNGM1NmE4MGExNTE0Y2I5YmEwYzJfMy03LTEtMS0w_bdea8798-b2af-4002-a345-cf1a87c6775e"
      unitRef="usd">389573000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic27aa82f118547bcaca2790c33dd963b_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmYxZWQ5YzU5MGI3YzRjNTZhODBhMTUxNGNiOWJhMGMyL3RhYmxlcmFuZ2U6ZjFlZDljNTkwYjdjNGM1NmE4MGExNTE0Y2I5YmEwYzJfNC0xLTEtMS0w_b3e46530-ea7a-41aa-93c5-e6bcf32c4f21"
      unitRef="usd">752295000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic27aa82f118547bcaca2790c33dd963b_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmYxZWQ5YzU5MGI3YzRjNTZhODBhMTUxNGNiOWJhMGMyL3RhYmxlcmFuZ2U6ZjFlZDljNTkwYjdjNGM1NmE4MGExNTE0Y2I5YmEwYzJfNC0zLTEtMS0w_28205767-c75e-4441-a618-bdcfd718723a"
      unitRef="usd">3934000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic27aa82f118547bcaca2790c33dd963b_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmYxZWQ5YzU5MGI3YzRjNTZhODBhMTUxNGNiOWJhMGMyL3RhYmxlcmFuZ2U6ZjFlZDljNTkwYjdjNGM1NmE4MGExNTE0Y2I5YmEwYzJfNC01LTEtMS0w_948c15c9-de67-4ce8-9662-c441e7941add"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic27aa82f118547bcaca2790c33dd963b_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmYxZWQ5YzU5MGI3YzRjNTZhODBhMTUxNGNiOWJhMGMyL3RhYmxlcmFuZ2U6ZjFlZDljNTkwYjdjNGM1NmE4MGExNTE0Y2I5YmEwYzJfNC03LTEtMS0w_fbf99b58-4841-41ab-b01c-6a7807a205ba"
      unitRef="usd">756226000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i7f0bf831f83f4af59172086b8a97f3c4_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmYxZWQ5YzU5MGI3YzRjNTZhODBhMTUxNGNiOWJhMGMyL3RhYmxlcmFuZ2U6ZjFlZDljNTkwYjdjNGM1NmE4MGExNTE0Y2I5YmEwYzJfNS0xLTEtMS0w_fd5114fc-acf3-4c13-9096-65bd5c896a55"
      unitRef="usd">166483000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7f0bf831f83f4af59172086b8a97f3c4_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmYxZWQ5YzU5MGI3YzRjNTZhODBhMTUxNGNiOWJhMGMyL3RhYmxlcmFuZ2U6ZjFlZDljNTkwYjdjNGM1NmE4MGExNTE0Y2I5YmEwYzJfNS0zLTEtMS0w_f05700c3-35af-4357-89c4-cc378173519f"
      unitRef="usd">187000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7f0bf831f83f4af59172086b8a97f3c4_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmYxZWQ5YzU5MGI3YzRjNTZhODBhMTUxNGNiOWJhMGMyL3RhYmxlcmFuZ2U6ZjFlZDljNTkwYjdjNGM1NmE4MGExNTE0Y2I5YmEwYzJfNS01LTEtMS0w_3463a017-dbb4-4e64-bbb9-13bfd74574f2"
      unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7f0bf831f83f4af59172086b8a97f3c4_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmYxZWQ5YzU5MGI3YzRjNTZhODBhMTUxNGNiOWJhMGMyL3RhYmxlcmFuZ2U6ZjFlZDljNTkwYjdjNGM1NmE4MGExNTE0Y2I5YmEwYzJfNS03LTEtMS0w_eaf12556-dc76-485d-b95a-a8d454a282cc"
      unitRef="usd">166665000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmYxZWQ5YzU5MGI3YzRjNTZhODBhMTUxNGNiOWJhMGMyL3RhYmxlcmFuZ2U6ZjFlZDljNTkwYjdjNGM1NmE4MGExNTE0Y2I5YmEwYzJfNi0xLTEtMS0w_022f54a3-6fd7-4f77-b2b8-2ceadba4e73e"
      unitRef="usd">1308351000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmYxZWQ5YzU5MGI3YzRjNTZhODBhMTUxNGNiOWJhMGMyL3RhYmxlcmFuZ2U6ZjFlZDljNTkwYjdjNGM1NmE4MGExNTE0Y2I5YmEwYzJfNi0zLTEtMS0w_d33244e9-5a8f-4105-b168-33de6263cd8d"
      unitRef="usd">4121000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmYxZWQ5YzU5MGI3YzRjNTZhODBhMTUxNGNiOWJhMGMyL3RhYmxlcmFuZ2U6ZjFlZDljNTkwYjdjNGM1NmE4MGExNTE0Y2I5YmEwYzJfNi01LTEtMS0w_b798c70a-9064-474f-9a03-dc62c03b8f1d"
      unitRef="usd">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmYxZWQ5YzU5MGI3YzRjNTZhODBhMTUxNGNiOWJhMGMyL3RhYmxlcmFuZ2U6ZjFlZDljNTkwYjdjNGM1NmE4MGExNTE0Y2I5YmEwYzJfNi03LTEtMS0w_7e93af25-c6fd-4511-ac92-89c9d192a1e4"
      unitRef="usd">1312464000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="i785b48358c27484689107bc80f7a2cbb_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmYxZWQ5YzU5MGI3YzRjNTZhODBhMTUxNGNiOWJhMGMyL3RhYmxlcmFuZ2U6ZjFlZDljNTkwYjdjNGM1NmE4MGExNTE0Y2I5YmEwYzJfNy0xLTEtMS0w_56c4b3d6-6d12-4b0e-ab7d-030fb0bfa823"
      unitRef="usd">40964000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="i785b48358c27484689107bc80f7a2cbb_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmYxZWQ5YzU5MGI3YzRjNTZhODBhMTUxNGNiOWJhMGMyL3RhYmxlcmFuZ2U6ZjFlZDljNTkwYjdjNGM1NmE4MGExNTE0Y2I5YmEwYzJfNy0zLTEtMS0w_1dc8c8bc-35b1-4ff4-987a-4e4565173630"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="i785b48358c27484689107bc80f7a2cbb_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmYxZWQ5YzU5MGI3YzRjNTZhODBhMTUxNGNiOWJhMGMyL3RhYmxlcmFuZ2U6ZjFlZDljNTkwYjdjNGM1NmE4MGExNTE0Y2I5YmEwYzJfNy01LTEtMS0w_f7bab996-8d3e-4b64-a975-a2103e073e3c"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="i785b48358c27484689107bc80f7a2cbb_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmYxZWQ5YzU5MGI3YzRjNTZhODBhMTUxNGNiOWJhMGMyL3RhYmxlcmFuZ2U6ZjFlZDljNTkwYjdjNGM1NmE4MGExNTE0Y2I5YmEwYzJfNy03LTEtMS0w_db86d582-7713-4256-89f7-0885f0bfcb33"
      unitRef="usd">40964000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="i28526894a4b14f39b408ab8db78be75d_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmYxZWQ5YzU5MGI3YzRjNTZhODBhMTUxNGNiOWJhMGMyL3RhYmxlcmFuZ2U6ZjFlZDljNTkwYjdjNGM1NmE4MGExNTE0Y2I5YmEwYzJfOC0xLTEtMS0w_78080aa4-6122-48f5-88f1-85203bb685b0"
      unitRef="usd">2467000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="i28526894a4b14f39b408ab8db78be75d_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmYxZWQ5YzU5MGI3YzRjNTZhODBhMTUxNGNiOWJhMGMyL3RhYmxlcmFuZ2U6ZjFlZDljNTkwYjdjNGM1NmE4MGExNTE0Y2I5YmEwYzJfOC0zLTEtMS0w_12988e84-69d1-441b-863f-20686d1efcc1"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="i28526894a4b14f39b408ab8db78be75d_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmYxZWQ5YzU5MGI3YzRjNTZhODBhMTUxNGNiOWJhMGMyL3RhYmxlcmFuZ2U6ZjFlZDljNTkwYjdjNGM1NmE4MGExNTE0Y2I5YmEwYzJfOC01LTEtMS0w_d57b2163-3554-4d3a-aceb-d523b319c2e0"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="i28526894a4b14f39b408ab8db78be75d_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmYxZWQ5YzU5MGI3YzRjNTZhODBhMTUxNGNiOWJhMGMyL3RhYmxlcmFuZ2U6ZjFlZDljNTkwYjdjNGM1NmE4MGExNTE0Y2I5YmEwYzJfOC03LTEtMS0w_e72ffe85-a542-4f54-b30d-d8c70384fcca"
      unitRef="usd">2467000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="i1800b81e21784d189946618c1ae33956_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmYxZWQ5YzU5MGI3YzRjNTZhODBhMTUxNGNiOWJhMGMyL3RhYmxlcmFuZ2U6ZjFlZDljNTkwYjdjNGM1NmE4MGExNTE0Y2I5YmEwYzJfOS0xLTEtMS0w_c7e0b148-d83a-4bf5-b8d5-932b26108bbc"
      unitRef="usd">32728000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="i1800b81e21784d189946618c1ae33956_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmYxZWQ5YzU5MGI3YzRjNTZhODBhMTUxNGNiOWJhMGMyL3RhYmxlcmFuZ2U6ZjFlZDljNTkwYjdjNGM1NmE4MGExNTE0Y2I5YmEwYzJfOS0zLTEtMS0w_2ef0e9e4-aac8-40aa-a29d-ffc64f2f1187"
      unitRef="usd">5000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="i1800b81e21784d189946618c1ae33956_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmYxZWQ5YzU5MGI3YzRjNTZhODBhMTUxNGNiOWJhMGMyL3RhYmxlcmFuZ2U6ZjFlZDljNTkwYjdjNGM1NmE4MGExNTE0Y2I5YmEwYzJfOS01LTEtMS0w_3e283fdf-4e00-4606-9858-cf7b238d0ea0"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="i1800b81e21784d189946618c1ae33956_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmYxZWQ5YzU5MGI3YzRjNTZhODBhMTUxNGNiOWJhMGMyL3RhYmxlcmFuZ2U6ZjFlZDljNTkwYjdjNGM1NmE4MGExNTE0Y2I5YmEwYzJfOS03LTEtMS0w_3d4603d8-7b51-44e3-9d86-77adfacebfe4"
      unitRef="usd">32733000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmYxZWQ5YzU5MGI3YzRjNTZhODBhMTUxNGNiOWJhMGMyL3RhYmxlcmFuZ2U6ZjFlZDljNTkwYjdjNGM1NmE4MGExNTE0Y2I5YmEwYzJfMTAtMS0xLTEtMA_5e721370-8bd1-4fd8-8992-cb5cf3667279"
      unitRef="usd">1384510000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmYxZWQ5YzU5MGI3YzRjNTZhODBhMTUxNGNiOWJhMGMyL3RhYmxlcmFuZ2U6ZjFlZDljNTkwYjdjNGM1NmE4MGExNTE0Y2I5YmEwYzJfMTAtMy0xLTEtMA_57d53d7e-269d-4952-982d-56c879b5f2fd"
      unitRef="usd">4126000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmYxZWQ5YzU5MGI3YzRjNTZhODBhMTUxNGNiOWJhMGMyL3RhYmxlcmFuZ2U6ZjFlZDljNTkwYjdjNGM1NmE4MGExNTE0Y2I5YmEwYzJfMTAtNS0xLTEtMA_505eb758-483f-456e-ab97-6671b098ffc8"
      unitRef="usd">8000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmYxZWQ5YzU5MGI3YzRjNTZhODBhMTUxNGNiOWJhMGMyL3RhYmxlcmFuZ2U6ZjFlZDljNTkwYjdjNGM1NmE4MGExNTE0Y2I5YmEwYzJfMTAtNy0xLTEtMA_04d497f2-929e-41fc-8c52-5cbb24321543"
      unitRef="usd">1388628000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities>
    <us-gaap:InterestReceivable
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RleHRyZWdpb246OGZhODczZDFjZDY5NGI4YmE5NzUwZTE4NjFmNGMwMGFfNzUz_f9d08229-590c-45aa-8be9-a796171b0c3d"
      unitRef="usd">4500000</us-gaap:InterestReceivable>
    <us-gaap:InterestReceivable
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RleHRyZWdpb246OGZhODczZDFjZDY5NGI4YmE5NzUwZTE4NjFmNGMwMGFfNzYw_aea0efad-9cd8-4624-897c-a5d6947f9fa8"
      unitRef="usd">6200000</us-gaap:InterestReceivable>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RleHRyZWdpb246OGZhODczZDFjZDY5NGI4YmE5NzUwZTE4NjFmNGMwMGFfMjIxNw_5ccaf71d-0e13-4b12-b8e7-9316a21ed2ce">The fair value and gross unrealized losses on debt securities available-for-sale in an unrealized loss position were as follows (in thousands):&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.459%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.459%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i51a81230a1d74e55a2566c55413e2b2a_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOjBjNDRiYmMxNDA0ZDQ0Y2E5NjkxMzhjZDlhYTI4OWMzL3RhYmxlcmFuZ2U6MGM0NGJiYzE0MDRkNDRjYTk2OTEzOGNkOWFhMjg5YzNfMi05LTEtMS0w_1fdf8f10-bcb5-4426-aec6-b3886755c9cd"
      unitRef="usd">29627000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i51a81230a1d74e55a2566c55413e2b2a_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOjBjNDRiYmMxNDA0ZDQ0Y2E5NjkxMzhjZDlhYTI4OWMzL3RhYmxlcmFuZ2U6MGM0NGJiYzE0MDRkNDRjYTk2OTEzOGNkOWFhMjg5YzNfMi0xMS0xLTEtMA_ae6a03ab-57e3-4c29-9878-f480d52f535f"
      unitRef="usd">20000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i9ba278ad76ca4fcd841ffefc73154898_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOjBjNDRiYmMxNDA0ZDQ0Y2E5NjkxMzhjZDlhYTI4OWMzL3RhYmxlcmFuZ2U6MGM0NGJiYzE0MDRkNDRjYTk2OTEzOGNkOWFhMjg5YzNfMy05LTEtMS0w_6bc27a80-681e-4745-b049-9c6697490dbf"
      unitRef="usd">70465000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i9ba278ad76ca4fcd841ffefc73154898_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOjBjNDRiYmMxNDA0ZDQ0Y2E5NjkxMzhjZDlhYTI4OWMzL3RhYmxlcmFuZ2U6MGM0NGJiYzE0MDRkNDRjYTk2OTEzOGNkOWFhMjg5YzNfMy0xMS0xLTEtMA_fba1f4b5-e301-42ef-a6a6-d92418412fc8"
      unitRef="usd">10000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOjBjNDRiYmMxNDA0ZDQ0Y2E5NjkxMzhjZDlhYTI4OWMzL3RhYmxlcmFuZ2U6MGM0NGJiYzE0MDRkNDRjYTk2OTEzOGNkOWFhMjg5YzNfNi05LTEtMS0w_5ef5a47a-f553-4928-9e38-2bfe2b697eca"
      unitRef="usd">100092000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOjBjNDRiYmMxNDA0ZDQ0Y2E5NjkxMzhjZDlhYTI4OWMzL3RhYmxlcmFuZ2U6MGM0NGJiYzE0MDRkNDRjYTk2OTEzOGNkOWFhMjg5YzNfNi0xMS0xLTEtMA_d9512807-59ed-45d9-b9ae-8d205d66c826"
      unitRef="usd">30000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ic27aa82f118547bcaca2790c33dd963b_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmVhODRhN2I4MjY4NTQ1MGZhMWI2MTAzMTZlMzczNDg3L3RhYmxlcmFuZ2U6ZWE4NGE3YjgyNjg1NDUwZmExYjYxMDMxNmUzNzM0ODdfMi05LTEtMS0w_a1215e37-0b37-407a-9b96-ea4e0856f07b"
      unitRef="usd">14529000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="ic27aa82f118547bcaca2790c33dd963b_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmVhODRhN2I4MjY4NTQ1MGZhMWI2MTAzMTZlMzczNDg3L3RhYmxlcmFuZ2U6ZWE4NGE3YjgyNjg1NDUwZmExYjYxMDMxNmUzNzM0ODdfMi0xMS0xLTEtMA_731f4575-af92-4cb0-a613-5f2745dc56f1"
      unitRef="usd">3000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i7f0bf831f83f4af59172086b8a97f3c4_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmVhODRhN2I4MjY4NTQ1MGZhMWI2MTAzMTZlMzczNDg3L3RhYmxlcmFuZ2U6ZWE4NGE3YjgyNjg1NDUwZmExYjYxMDMxNmUzNzM0ODdfMy05LTEtMS0w_3332fabb-a451-4d43-84cb-9be109c5d2b3"
      unitRef="usd">2848000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i7f0bf831f83f4af59172086b8a97f3c4_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmVhODRhN2I4MjY4NTQ1MGZhMWI2MTAzMTZlMzczNDg3L3RhYmxlcmFuZ2U6ZWE4NGE3YjgyNjg1NDUwZmExYjYxMDMxNmUzNzM0ODdfMy0xMS0xLTEtMA_1d8512eb-cf5e-4959-8e4d-3ed34b6c4ed1"
      unitRef="usd">5000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmVhODRhN2I4MjY4NTQ1MGZhMWI2MTAzMTZlMzczNDg3L3RhYmxlcmFuZ2U6ZWE4NGE3YjgyNjg1NDUwZmExYjYxMDMxNmUzNzM0ODdfNS05LTEtMS0w_a7cda02c-dd8f-4456-aee4-c821c67800bc"
      unitRef="usd">17377000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOmVhODRhN2I4MjY4NTQ1MGZhMWI2MTAzMTZlMzczNDg3L3RhYmxlcmFuZ2U6ZWE4NGE3YjgyNjg1NDUwZmExYjYxMDMxNmUzNzM0ODdfNS0xMS0xLTEtMA_781179c2-ccbb-44c4-8c40-da63300e76d9"
      unitRef="usd">8000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RleHRyZWdpb246OGZhODczZDFjZDY5NGI4YmE5NzUwZTE4NjFmNGMwMGFfMTQ4MQ_aca373f9-749d-49ec-946c-dd5a7e2edf1b"
      unitRef="investment">16</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RleHRyZWdpb246OGZhODczZDFjZDY5NGI4YmE5NzUwZTE4NjFmNGMwMGFfMTQ4OQ_17b6e2a7-cd79-4012-8fa3-4dda97f8e33c"
      unitRef="investment">9</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RleHRyZWdpb246OGZhODczZDFjZDY5NGI4YmE5NzUwZTE4NjFmNGMwMGFfMTY0OTI2NzQ0Mzk3MQ_baf5c35f-07b3-426b-9902-dd67b0fe3278"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i34bbe41183cc4f96afa896c1d7f86bb3_I20190927"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RleHRyZWdpb246OGZhODczZDFjZDY5NGI4YmE5NzUwZTE4NjFmNGMwMGFfMTY0OTI2NzQ0Mzk3MQ_d69aae4d-ea94-49a5-955e-f272fb16d1e4"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RleHRyZWdpb246OGZhODczZDFjZDY5NGI4YmE5NzUwZTE4NjFmNGMwMGFfMjI0Nw_71c51f97-46e6-48d9-a93f-48813e3247f4">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of debt securities available-for-sale by contractual maturity was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;789,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;522,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,337,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,312,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOjg5NDNjN2IzMWU1YTQ3YmY4YjlkMjJjMjcyMjQxYzI1L3RhYmxlcmFuZ2U6ODk0M2M3YjMxZTVhNDdiZjhiOWQyMmMyNzIyNDFjMjVfMS0xLTEtMS0w_0a1fbb6b-5db4-4e03-be3e-32304f2e79b3"
      unitRef="usd">993211000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOjg5NDNjN2IzMWU1YTQ3YmY4YjlkMjJjMjcyMjQxYzI1L3RhYmxlcmFuZ2U6ODk0M2M3YjMxZTVhNDdiZjhiOWQyMmMyNzIyNDFjMjVfMS0zLTEtMS0w_145f389f-809c-4de2-a454-6d93cfec814b"
      unitRef="usd">789913000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOjg5NDNjN2IzMWU1YTQ3YmY4YjlkMjJjMjcyMjQxYzI1L3RhYmxlcmFuZ2U6ODk0M2M3YjMxZTVhNDdiZjhiOWQyMmMyNzIyNDFjMjVfMi0xLTEtMS0w_e96dd969-cf15-4083-9f1a-f8852059276c"
      unitRef="usd">344194000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOjg5NDNjN2IzMWU1YTQ3YmY4YjlkMjJjMjcyMjQxYzI1L3RhYmxlcmFuZ2U6ODk0M2M3YjMxZTVhNDdiZjhiOWQyMmMyNzIyNDFjMjVfMi0zLTEtMS0w_cbf4bd58-cd1f-4f6d-b652-a0aa31c0bdc8"
      unitRef="usd">522551000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOjg5NDNjN2IzMWU1YTQ3YmY4YjlkMjJjMjcyMjQxYzI1L3RhYmxlcmFuZ2U6ODk0M2M3YjMxZTVhNDdiZjhiOWQyMmMyNzIyNDFjMjVfMy0xLTEtMS0w_a068b0ea-9a50-441b-bc3e-0ad7839e870b"
      unitRef="usd">1337405000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF81NS9mcmFnOjhmYTg3M2QxY2Q2OTRiOGJhOTc1MGUxODYxZjRjMDBhL3RhYmxlOjg5NDNjN2IzMWU1YTQ3YmY4YjlkMjJjMjcyMjQxYzI1L3RhYmxlcmFuZ2U6ODk0M2M3YjMxZTVhNDdiZjhiOWQyMmMyNzIyNDFjMjVfMy0zLTEtMS0w_7390248e-674a-4827-abfe-905d0a3aec06"
      unitRef="usd">1312464000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RleHRyZWdpb246OGY1NzI5NjEwZmQ1NDVjMDhjYzhiMmRhNWNjMmVhYzlfMTU0Mg_035895a5-f7a6-46e7-8e84-3c97f3c9ec86">FAIR VALUE MEASUREMENTS&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value reflects the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy has the following three levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt"&gt;Level 1 -&#160;quoted prices (unadjusted) in active markets for identical assets and liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt"&gt;Level 2 -&#160;inputs other than level 1 that are observable either directly or indirectly, such as quoted prices in active markets for similar instruments or on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt"&gt;Level 3 -&#160;unobservable inputs that are supported by little or no market activity that are significant to the fair value measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;466,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;466,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;636,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;636,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,337,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,337,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets carried at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,392,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,489,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;756,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;756,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,312,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,312,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets carried at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,345,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,347,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When available, we value investments based on quoted prices for those financial instruments, which is a Level 1 input. Our remaining investments are valued using third-party pricing sources, which use observable market prices, interest rates and yield curves observable at commonly quoted intervals for similar assets as observable inputs for pricing, which is a Level 2 input.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount of our remaining financial assets and liabilities, which include cash, receivables and payables, approximate their fair values due to their short-term nature.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RleHRyZWdpb246OGY1NzI5NjEwZmQ1NDVjMDhjYzhiMmRhNWNjMmVhYzlfMTU0Mw_07b9f471-e652-4e45-ab1c-3434a904bdbe">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;466,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;466,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;636,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;636,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,337,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,337,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets carried at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,392,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,489,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;756,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;756,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,312,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,312,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets carried at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,345,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,347,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ieadeb951ef494630818c3cc30b3da393_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjEyYWUyN2FkOTk4MjQwNzM5YzBhMjFkZjNkODYzYTNhL3RhYmxlcmFuZ2U6MTJhZTI3YWQ5OTgyNDA3MzljMGEyMWRmM2Q4NjNhM2FfMi0xLTEtMS0w_b23d1e7b-98f5-485b-9bfb-36882d74fdae"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0aad2b7015eb477c88c1ea01262ba619_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjEyYWUyN2FkOTk4MjQwNzM5YzBhMjFkZjNkODYzYTNhL3RhYmxlcmFuZ2U6MTJhZTI3YWQ5OTgyNDA3MzljMGEyMWRmM2Q4NjNhM2FfMi0zLTEtMS0w_790c74c6-3327-46e4-a5f5-ed6ad420abf0"
      unitRef="usd">466366000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia338dcf4e5144bef8ca2ebd43f622d04_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjEyYWUyN2FkOTk4MjQwNzM5YzBhMjFkZjNkODYzYTNhL3RhYmxlcmFuZ2U6MTJhZTI3YWQ5OTgyNDA3MzljMGEyMWRmM2Q4NjNhM2FfMi01LTEtMS0w_16bc5bb1-7ce5-469f-9257-87baf856e7e5"
      unitRef="usd">466366000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i214b7f1c98384cd7ae5d32548266b97b_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjEyYWUyN2FkOTk4MjQwNzM5YzBhMjFkZjNkODYzYTNhL3RhYmxlcmFuZ2U6MTJhZTI3YWQ5OTgyNDA3MzljMGEyMWRmM2Q4NjNhM2FfMy0xLTEtMS0w_4fdaf91f-7296-4016-ade0-93282687e308"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2e427409ff9d4828a3b7640315fdf49b_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjEyYWUyN2FkOTk4MjQwNzM5YzBhMjFkZjNkODYzYTNhL3RhYmxlcmFuZ2U6MTJhZTI3YWQ5OTgyNDA3MzljMGEyMWRmM2Q4NjNhM2FfMy0zLTEtMS0w_0604b246-0416-4cb6-85c1-e47a850984b7"
      unitRef="usd">636815000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7ea639c496fd491897fbb9c377110819_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjEyYWUyN2FkOTk4MjQwNzM5YzBhMjFkZjNkODYzYTNhL3RhYmxlcmFuZ2U6MTJhZTI3YWQ5OTgyNDA3MzljMGEyMWRmM2Q4NjNhM2FfMy01LTEtMS0w_c3cca474-c295-4ba6-afc3-b0c4c613c141"
      unitRef="usd">636815000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i14689612fde84c3c940d88d417602b2a_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjEyYWUyN2FkOTk4MjQwNzM5YzBhMjFkZjNkODYzYTNhL3RhYmxlcmFuZ2U6MTJhZTI3YWQ5OTgyNDA3MzljMGEyMWRmM2Q4NjNhM2FfNC0xLTEtMS0w_dd2f761e-dfc4-4643-afe2-79240d449903"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i105a4d34d1764fab907327463ccad490_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjEyYWUyN2FkOTk4MjQwNzM5YzBhMjFkZjNkODYzYTNhL3RhYmxlcmFuZ2U6MTJhZTI3YWQ5OTgyNDA3MzljMGEyMWRmM2Q4NjNhM2FfNC0zLTEtMS0w_62f133f5-bb48-4e5d-b8d7-aebf2c111add"
      unitRef="usd">213793000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5b6ffe686868432ab9437a164687d998_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjEyYWUyN2FkOTk4MjQwNzM5YzBhMjFkZjNkODYzYTNhL3RhYmxlcmFuZ2U6MTJhZTI3YWQ5OTgyNDA3MzljMGEyMWRmM2Q4NjNhM2FfNC01LTEtMS0w_4cf48fe3-cabb-46d1-853c-364bb0c01190"
      unitRef="usd">213793000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5c82661404c1488b9aa5b0c3a43ca9f4_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjEyYWUyN2FkOTk4MjQwNzM5YzBhMjFkZjNkODYzYTNhL3RhYmxlcmFuZ2U6MTJhZTI3YWQ5OTgyNDA3MzljMGEyMWRmM2Q4NjNhM2FfNS0xLTEtMS0w_186a1777-a6ca-419e-addc-d4f213272585"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic69aa2cb176f4a9aa647d6c00a697fb9_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjEyYWUyN2FkOTk4MjQwNzM5YzBhMjFkZjNkODYzYTNhL3RhYmxlcmFuZ2U6MTJhZTI3YWQ5OTgyNDA3MzljMGEyMWRmM2Q4NjNhM2FfNS0zLTEtMS0w_5702290f-9eba-4fd4-897a-9921a7dcc636"
      unitRef="usd">20431000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibbb5a720eff3482091e3be625d787981_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjEyYWUyN2FkOTk4MjQwNzM5YzBhMjFkZjNkODYzYTNhL3RhYmxlcmFuZ2U6MTJhZTI3YWQ5OTgyNDA3MzljMGEyMWRmM2Q4NjNhM2FfNS01LTEtMS0w_c7dd70df-d45a-4e06-869b-80ca0a3f67fb"
      unitRef="usd">20431000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8d11a44c584e4c27b4cd486045540585_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjEyYWUyN2FkOTk4MjQwNzM5YzBhMjFkZjNkODYzYTNhL3RhYmxlcmFuZ2U6MTJhZTI3YWQ5OTgyNDA3MzljMGEyMWRmM2Q4NjNhM2FfNi0xLTEtMS0w_1670d7d0-c7ef-4306-8dab-303c59d0bcd3"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6891e843a55d40c9a8f7f81e029810ef_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjEyYWUyN2FkOTk4MjQwNzM5YzBhMjFkZjNkODYzYTNhL3RhYmxlcmFuZ2U6MTJhZTI3YWQ5OTgyNDA3MzljMGEyMWRmM2Q4NjNhM2FfNi0zLTEtMS0w_29a14425-d16e-4f0c-bf57-991f5f421995"
      unitRef="usd">1337405000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia145ea6fe2c34f45a3f0710801bc6531_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjEyYWUyN2FkOTk4MjQwNzM5YzBhMjFkZjNkODYzYTNhL3RhYmxlcmFuZ2U6MTJhZTI3YWQ5OTgyNDA3MzljMGEyMWRmM2Q4NjNhM2FfNi01LTEtMS0w_f5c4bb5b-ffb2-4a2b-b754-616ba1a4137b"
      unitRef="usd">1337405000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i295ed1efaf864ae9b0abe578705aae7c_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjEyYWUyN2FkOTk4MjQwNzM5YzBhMjFkZjNkODYzYTNhL3RhYmxlcmFuZ2U6MTJhZTI3YWQ5OTgyNDA3MzljMGEyMWRmM2Q4NjNhM2FfNy0xLTEtMS0w_07f85f9b-ae83-4053-a638-b0538303e383"
      unitRef="usd">96992000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8b2d74b62bf14b7399c48b032c3050fa_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjEyYWUyN2FkOTk4MjQwNzM5YzBhMjFkZjNkODYzYTNhL3RhYmxlcmFuZ2U6MTJhZTI3YWQ5OTgyNDA3MzljMGEyMWRmM2Q4NjNhM2FfNy0zLTEtMS0w_dd471a85-30e5-4c1c-8670-824747674204"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iecc5d76d94114b538c7cc261d3d7dbb9_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjEyYWUyN2FkOTk4MjQwNzM5YzBhMjFkZjNkODYzYTNhL3RhYmxlcmFuZ2U6MTJhZTI3YWQ5OTgyNDA3MzljMGEyMWRmM2Q4NjNhM2FfNy01LTEtMS0w_1b4cb321-fbac-48e6-954e-4ffb73dd0ec8"
      unitRef="usd">96992000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i7eec7f6e4801439489ec8ab44f13dca5_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjEyYWUyN2FkOTk4MjQwNzM5YzBhMjFkZjNkODYzYTNhL3RhYmxlcmFuZ2U6MTJhZTI3YWQ5OTgyNDA3MzljMGEyMWRmM2Q4NjNhM2FfOC0xLTEtMS0w_139d1926-5c3d-4632-a153-a861f7180472"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ife2cb38c2462497fb4f2be87aacfcbe9_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjEyYWUyN2FkOTk4MjQwNzM5YzBhMjFkZjNkODYzYTNhL3RhYmxlcmFuZ2U6MTJhZTI3YWQ5OTgyNDA3MzljMGEyMWRmM2Q4NjNhM2FfOC0zLTEtMS0w_aa568325-f6dc-425e-bb53-987c5cb2b5a2"
      unitRef="usd">55584000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3e13458d32e445e6a3bdc3140700b3ef_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjEyYWUyN2FkOTk4MjQwNzM5YzBhMjFkZjNkODYzYTNhL3RhYmxlcmFuZ2U6MTJhZTI3YWQ5OTgyNDA3MzljMGEyMWRmM2Q4NjNhM2FfOC01LTEtMS0w_e7482307-8264-4fac-82a1-c5c102a67ed7"
      unitRef="usd">55584000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8d11a44c584e4c27b4cd486045540585_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjEyYWUyN2FkOTk4MjQwNzM5YzBhMjFkZjNkODYzYTNhL3RhYmxlcmFuZ2U6MTJhZTI3YWQ5OTgyNDA3MzljMGEyMWRmM2Q4NjNhM2FfOS0xLTEtMS0w_05aaef1c-5510-4065-8797-c045e3f5bfa2"
      unitRef="usd">96992000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6891e843a55d40c9a8f7f81e029810ef_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjEyYWUyN2FkOTk4MjQwNzM5YzBhMjFkZjNkODYzYTNhL3RhYmxlcmFuZ2U6MTJhZTI3YWQ5OTgyNDA3MzljMGEyMWRmM2Q4NjNhM2FfOS0zLTEtMS0w_eef03668-1588-472e-9225-c03fcdbc6877"
      unitRef="usd">1392989000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia145ea6fe2c34f45a3f0710801bc6531_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjEyYWUyN2FkOTk4MjQwNzM5YzBhMjFkZjNkODYzYTNhL3RhYmxlcmFuZ2U6MTJhZTI3YWQ5OTgyNDA3MzljMGEyMWRmM2Q4NjNhM2FfOS01LTEtMS0w_71d73a5c-54ca-4894-8474-45246f87aeb6"
      unitRef="usd">1489981000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i727f7c37fa244a2d96022ada5bf8347f_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjFkNmVkOGY4ZDFjYTRjYWY4ODUxODI5OWVmODQwMDkyL3RhYmxlcmFuZ2U6MWQ2ZWQ4ZjhkMWNhNGNhZjg4NTE4Mjk5ZWY4NDAwOTJfMi0xLTEtMS0w_e452bf87-b7bc-4df6-a05b-0e0b2e21d973"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie98bf240c97e447183ba8f88a167242d_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjFkNmVkOGY4ZDFjYTRjYWY4ODUxODI5OWVmODQwMDkyL3RhYmxlcmFuZ2U6MWQ2ZWQ4ZjhkMWNhNGNhZjg4NTE4Mjk5ZWY4NDAwOTJfMi0zLTEtMS0w_c6868dc4-51d8-4d4a-a7a3-de559a51c5ea"
      unitRef="usd">389573000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4d639ed777ff435ea5b6c19441e7ecff_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjFkNmVkOGY4ZDFjYTRjYWY4ODUxODI5OWVmODQwMDkyL3RhYmxlcmFuZ2U6MWQ2ZWQ4ZjhkMWNhNGNhZjg4NTE4Mjk5ZWY4NDAwOTJfMi01LTEtMS0w_b1fdee45-38a4-4a54-b01d-243000ea0f1d"
      unitRef="usd">389573000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8d9829f5158045228bedb41708d21afd_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjFkNmVkOGY4ZDFjYTRjYWY4ODUxODI5OWVmODQwMDkyL3RhYmxlcmFuZ2U6MWQ2ZWQ4ZjhkMWNhNGNhZjg4NTE4Mjk5ZWY4NDAwOTJfMy0xLTEtMS0w_703c79d4-503b-43fb-90ff-24b7767d66d6"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7facc890253843839cb983e5f0c5d14c_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjFkNmVkOGY4ZDFjYTRjYWY4ODUxODI5OWVmODQwMDkyL3RhYmxlcmFuZ2U6MWQ2ZWQ4ZjhkMWNhNGNhZjg4NTE4Mjk5ZWY4NDAwOTJfMy0zLTEtMS0w_c9f66f13-ea50-4cbe-b6b6-a1d484c35fcc"
      unitRef="usd">756226000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i77e3015ed1f944988e83d686ba77f015_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjFkNmVkOGY4ZDFjYTRjYWY4ODUxODI5OWVmODQwMDkyL3RhYmxlcmFuZ2U6MWQ2ZWQ4ZjhkMWNhNGNhZjg4NTE4Mjk5ZWY4NDAwOTJfMy01LTEtMS0w_80386749-4391-4d73-bb1a-47fe36b36725"
      unitRef="usd">756226000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie5fb7e2d38294fdaa468d8855b980731_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjFkNmVkOGY4ZDFjYTRjYWY4ODUxODI5OWVmODQwMDkyL3RhYmxlcmFuZ2U6MWQ2ZWQ4ZjhkMWNhNGNhZjg4NTE4Mjk5ZWY4NDAwOTJfNC0xLTEtMS0w_40ed2ef1-59fc-483e-a3be-27be5f5a9faf"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia2b721b19a1d4ee8a556e85a2c797759_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjFkNmVkOGY4ZDFjYTRjYWY4ODUxODI5OWVmODQwMDkyL3RhYmxlcmFuZ2U6MWQ2ZWQ4ZjhkMWNhNGNhZjg4NTE4Mjk5ZWY4NDAwOTJfNC0zLTEtMS0w_22654339-aa27-4ecc-9281-af6ae79b508f"
      unitRef="usd">166665000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7b010574af4c409fa174a0bc4c2b34e1_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjFkNmVkOGY4ZDFjYTRjYWY4ODUxODI5OWVmODQwMDkyL3RhYmxlcmFuZ2U6MWQ2ZWQ4ZjhkMWNhNGNhZjg4NTE4Mjk5ZWY4NDAwOTJfNC01LTEtMS0w_6d213a14-6687-46a2-a7f2-46bc28479eef"
      unitRef="usd">166665000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icefaee59f19a40b0bbd4de9922c8c59c_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjFkNmVkOGY4ZDFjYTRjYWY4ODUxODI5OWVmODQwMDkyL3RhYmxlcmFuZ2U6MWQ2ZWQ4ZjhkMWNhNGNhZjg4NTE4Mjk5ZWY4NDAwOTJfNS0xLTEtMS0w_88f14cf8-9b71-42cb-8ed9-88cc4d0e0080"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if4060e618697434cad36b5db4d7c6111_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjFkNmVkOGY4ZDFjYTRjYWY4ODUxODI5OWVmODQwMDkyL3RhYmxlcmFuZ2U6MWQ2ZWQ4ZjhkMWNhNGNhZjg4NTE4Mjk5ZWY4NDAwOTJfNS0zLTEtMS0w_718cc587-a646-4955-988c-29b87ac3d1c7"
      unitRef="usd">1312464000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifd8e36118a87443ca78892462d27bfab_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjFkNmVkOGY4ZDFjYTRjYWY4ODUxODI5OWVmODQwMDkyL3RhYmxlcmFuZ2U6MWQ2ZWQ4ZjhkMWNhNGNhZjg4NTE4Mjk5ZWY4NDAwOTJfNS01LTEtMS0w_b0cc0d9e-c625-48cf-9adc-ff94536652c9"
      unitRef="usd">1312464000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i09f2281bdf9349038431afc18379805b_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjFkNmVkOGY4ZDFjYTRjYWY4ODUxODI5OWVmODQwMDkyL3RhYmxlcmFuZ2U6MWQ2ZWQ4ZjhkMWNhNGNhZjg4NTE4Mjk5ZWY4NDAwOTJfNi0xLTEtMS0w_5dae037a-0648-4b48-b1ab-95673748c568"
      unitRef="usd">2467000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie9c4cc15650340169d2372d82bde6360_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjFkNmVkOGY4ZDFjYTRjYWY4ODUxODI5OWVmODQwMDkyL3RhYmxlcmFuZ2U6MWQ2ZWQ4ZjhkMWNhNGNhZjg4NTE4Mjk5ZWY4NDAwOTJfNi0zLTEtMS0w_25c613b8-e0f5-4a53-a16f-9cbfd01b718e"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i362da4b860134a89851c683e142464ef_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjFkNmVkOGY4ZDFjYTRjYWY4ODUxODI5OWVmODQwMDkyL3RhYmxlcmFuZ2U6MWQ2ZWQ4ZjhkMWNhNGNhZjg4NTE4Mjk5ZWY4NDAwOTJfNi01LTEtMS0w_f8fa745d-d10c-4c77-9f5c-fa9532b8abf9"
      unitRef="usd">2467000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic072d7bdc3a747c3aa29c10bd5bd37e7_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjFkNmVkOGY4ZDFjYTRjYWY4ODUxODI5OWVmODQwMDkyL3RhYmxlcmFuZ2U6MWQ2ZWQ4ZjhkMWNhNGNhZjg4NTE4Mjk5ZWY4NDAwOTJfNy0xLTEtMS0w_a94cabc6-ba13-4f22-abc6-e263b50bab93"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i76745aad80e54832855f5e01889a5b33_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjFkNmVkOGY4ZDFjYTRjYWY4ODUxODI5OWVmODQwMDkyL3RhYmxlcmFuZ2U6MWQ2ZWQ4ZjhkMWNhNGNhZjg4NTE4Mjk5ZWY4NDAwOTJfNy0zLTEtMS0w_6723dc85-b670-410f-a45d-5744fab578e2"
      unitRef="usd">32733000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4c5d87cfd74f40ccabd0feeeecbb37cd_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjFkNmVkOGY4ZDFjYTRjYWY4ODUxODI5OWVmODQwMDkyL3RhYmxlcmFuZ2U6MWQ2ZWQ4ZjhkMWNhNGNhZjg4NTE4Mjk5ZWY4NDAwOTJfNy01LTEtMS0w_31cc7f5e-1195-4c93-a007-17e9f934ea79"
      unitRef="usd">32733000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="icefaee59f19a40b0bbd4de9922c8c59c_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjFkNmVkOGY4ZDFjYTRjYWY4ODUxODI5OWVmODQwMDkyL3RhYmxlcmFuZ2U6MWQ2ZWQ4ZjhkMWNhNGNhZjg4NTE4Mjk5ZWY4NDAwOTJfOC0xLTEtMS0w_f4e89418-5305-4977-a0db-5edcde2af0c4"
      unitRef="usd">2467000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if4060e618697434cad36b5db4d7c6111_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjFkNmVkOGY4ZDFjYTRjYWY4ODUxODI5OWVmODQwMDkyL3RhYmxlcmFuZ2U6MWQ2ZWQ4ZjhkMWNhNGNhZjg4NTE4Mjk5ZWY4NDAwOTJfOC0zLTEtMS0w_464715d0-8b9a-488d-baa1-f209b2a474a1"
      unitRef="usd">1345197000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ifd8e36118a87443ca78892462d27bfab_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82MS9mcmFnOjhmNTcyOTYxMGZkNTQ1YzA4Y2M4YjJkYTVjYzJlYWM5L3RhYmxlOjFkNmVkOGY4ZDFjYTRjYWY4ODUxODI5OWVmODQwMDkyL3RhYmxlcmFuZ2U6MWQ2ZWQ4ZjhkMWNhNGNhZjg4NTE4Mjk5ZWY4NDAwOTJfOC01LTEtMS0w_bd3d087a-7ba1-4633-8861-7bc5dfd2f60e"
      unitRef="usd">1347664000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82NC9mcmFnOmJkNjVhZGFjMzM3NDRiYWViNmNiMWRmZWJiMWUwMTgyL3RleHRyZWdpb246YmQ2NWFkYWMzMzc0NGJhZWI2Y2IxZGZlYmIxZTAxODJfMTkw_7ddb5c4d-ca87-4aa6-b622-52c16995a9c5">INVENTORY&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance Sheet classification:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion included in inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion included in other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Write-downs related to excess and expiring inventory were $2.2 million and $0.4 million for the nine months ended September&#160;30, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82NC9mcmFnOmJkNjVhZGFjMzM3NDRiYWViNmNiMWRmZWJiMWUwMTgyL3RleHRyZWdpb246YmQ2NWFkYWMzMzc0NGJhZWI2Y2IxZGZlYmIxZTAxODJfMTg2_57aa0087-0b4c-48a8-8163-e978e89d7489">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance Sheet classification:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion included in inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion included in other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82NC9mcmFnOmJkNjVhZGFjMzM3NDRiYWViNmNiMWRmZWJiMWUwMTgyL3RhYmxlOmEzYjdjNzI5NWIwNTQ0NTQ4MmNlMTFjNWI4ODc3OGJjL3RhYmxlcmFuZ2U6YTNiN2M3Mjk1YjA1NDQ1NDgyY2UxMWM1Yjg4Nzc4YmNfMS0xLTEtMS0w_063d91bc-1c6c-4867-9d06-091c2b74ef25"
      unitRef="usd">5298000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82NC9mcmFnOmJkNjVhZGFjMzM3NDRiYWViNmNiMWRmZWJiMWUwMTgyL3RhYmxlOmEzYjdjNzI5NWIwNTQ0NTQ4MmNlMTFjNWI4ODc3OGJjL3RhYmxlcmFuZ2U6YTNiN2M3Mjk1YjA1NDQ1NDgyY2UxMWM1Yjg4Nzc4YmNfMS0zLTEtMS0w_c7f4a2f3-476f-4bcf-9502-f6a2b88f889d"
      unitRef="usd">2709000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82NC9mcmFnOmJkNjVhZGFjMzM3NDRiYWViNmNiMWRmZWJiMWUwMTgyL3RhYmxlOmEzYjdjNzI5NWIwNTQ0NTQ4MmNlMTFjNWI4ODc3OGJjL3RhYmxlcmFuZ2U6YTNiN2M3Mjk1YjA1NDQ1NDgyY2UxMWM1Yjg4Nzc4YmNfMi0xLTEtMS0w_6244f32b-05d2-455d-8e15-772f42e24a63"
      unitRef="usd">17911000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82NC9mcmFnOmJkNjVhZGFjMzM3NDRiYWViNmNiMWRmZWJiMWUwMTgyL3RhYmxlOmEzYjdjNzI5NWIwNTQ0NTQ4MmNlMTFjNWI4ODc3OGJjL3RhYmxlcmFuZ2U6YTNiN2M3Mjk1YjA1NDQ1NDgyY2UxMWM1Yjg4Nzc4YmNfMi0zLTEtMS0w_27b05cb0-a714-43a9-8c05-adf8b728806e"
      unitRef="usd">9447000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82NC9mcmFnOmJkNjVhZGFjMzM3NDRiYWViNmNiMWRmZWJiMWUwMTgyL3RhYmxlOmEzYjdjNzI5NWIwNTQ0NTQ4MmNlMTFjNWI4ODc3OGJjL3RhYmxlcmFuZ2U6YTNiN2M3Mjk1YjA1NDQ1NDgyY2UxMWM1Yjg4Nzc4YmNfMy0xLTEtMS0w_5f4e30de-ab42-441a-bd28-4bfb6306fee2"
      unitRef="usd">4535000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82NC9mcmFnOmJkNjVhZGFjMzM3NDRiYWViNmNiMWRmZWJiMWUwMTgyL3RhYmxlOmEzYjdjNzI5NWIwNTQ0NTQ4MmNlMTFjNWI4ODc3OGJjL3RhYmxlcmFuZ2U6YTNiN2M3Mjk1YjA1NDQ1NDgyY2UxMWM1Yjg4Nzc4YmNfMy0zLTEtMS0w_bd185a3b-451b-47a4-a3d2-2ecd0a4b11d7"
      unitRef="usd">4367000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryGross
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82NC9mcmFnOmJkNjVhZGFjMzM3NDRiYWViNmNiMWRmZWJiMWUwMTgyL3RhYmxlOmEzYjdjNzI5NWIwNTQ0NTQ4MmNlMTFjNWI4ODc3OGJjL3RhYmxlcmFuZ2U6YTNiN2M3Mjk1YjA1NDQ1NDgyY2UxMWM1Yjg4Nzc4YmNfNC0xLTEtMS0w_ca93adb2-ccd1-41a0-bf41-78c16fb9e085"
      unitRef="usd">27744000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82NC9mcmFnOmJkNjVhZGFjMzM3NDRiYWViNmNiMWRmZWJiMWUwMTgyL3RhYmxlOmEzYjdjNzI5NWIwNTQ0NTQ4MmNlMTFjNWI4ODc3OGJjL3RhYmxlcmFuZ2U6YTNiN2M3Mjk1YjA1NDQ1NDgyY2UxMWM1Yjg4Nzc4YmNfNC0zLTEtMS0w_2f7ff407-ed20-4105-b9b6-ee1a9a85fabe"
      unitRef="usd">16523000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i6de1a52cb79c40518135c31ed1ad1ba2_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82NC9mcmFnOmJkNjVhZGFjMzM3NDRiYWViNmNiMWRmZWJiMWUwMTgyL3RhYmxlOmEzYjdjNzI5NWIwNTQ0NTQ4MmNlMTFjNWI4ODc3OGJjL3RhYmxlcmFuZ2U6YTNiN2M3Mjk1YjA1NDQ1NDgyY2UxMWM1Yjg4Nzc4YmNfNi0xLTEtMS0w_97a5ce56-8b3d-453b-97ca-e0bbaadeaa11"
      unitRef="usd">19319000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i24f6503be5494081a0dbe6c993e81397_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82NC9mcmFnOmJkNjVhZGFjMzM3NDRiYWViNmNiMWRmZWJiMWUwMTgyL3RhYmxlOmEzYjdjNzI5NWIwNTQ0NTQ4MmNlMTFjNWI4ODc3OGJjL3RhYmxlcmFuZ2U6YTNiN2M3Mjk1YjA1NDQ1NDgyY2UxMWM1Yjg4Nzc4YmNfNi0zLTEtMS0w_bb02ce03-1360-4986-86c0-336575edce2d"
      unitRef="usd">12886000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="ifbece5f4cfff4192b62909c119134d4d_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82NC9mcmFnOmJkNjVhZGFjMzM3NDRiYWViNmNiMWRmZWJiMWUwMTgyL3RhYmxlOmEzYjdjNzI5NWIwNTQ0NTQ4MmNlMTFjNWI4ODc3OGJjL3RhYmxlcmFuZ2U6YTNiN2M3Mjk1YjA1NDQ1NDgyY2UxMWM1Yjg4Nzc4YmNfNy0xLTEtMS0w_7ea9852c-8fa6-46e2-ad20-d67a8888d4c8"
      unitRef="usd">8425000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i91d78c6281004d5e860e9762ede7f244_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82NC9mcmFnOmJkNjVhZGFjMzM3NDRiYWViNmNiMWRmZWJiMWUwMTgyL3RhYmxlOmEzYjdjNzI5NWIwNTQ0NTQ4MmNlMTFjNWI4ODc3OGJjL3RhYmxlcmFuZ2U6YTNiN2M3Mjk1YjA1NDQ1NDgyY2UxMWM1Yjg4Nzc4YmNfNy0zLTEtMS0w_82d91373-367a-4a3f-9707-c1e827885cb9"
      unitRef="usd">3637000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82NC9mcmFnOmJkNjVhZGFjMzM3NDRiYWViNmNiMWRmZWJiMWUwMTgyL3RhYmxlOmEzYjdjNzI5NWIwNTQ0NTQ4MmNlMTFjNWI4ODc3OGJjL3RhYmxlcmFuZ2U6YTNiN2M3Mjk1YjA1NDQ1NDgyY2UxMWM1Yjg4Nzc4YmNfOC0xLTEtMS0w_fab94578-9d10-448c-9c9e-1535ed59ff9e"
      unitRef="usd">27744000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="ie736426c8e19488ea872e8da8ebb6578_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82NC9mcmFnOmJkNjVhZGFjMzM3NDRiYWViNmNiMWRmZWJiMWUwMTgyL3RhYmxlOmEzYjdjNzI5NWIwNTQ0NTQ4MmNlMTFjNWI4ODc3OGJjL3RhYmxlcmFuZ2U6YTNiN2M3Mjk1YjA1NDQ1NDgyY2UxMWM1Yjg4Nzc4YmNfOC0zLTEtMS0w_d57b59dd-e054-4e0a-b0f3-8f33261e8aba"
      unitRef="usd">16523000</us-gaap:InventoryGross>
    <us-gaap:InventoryWriteDown
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82NC9mcmFnOmJkNjVhZGFjMzM3NDRiYWViNmNiMWRmZWJiMWUwMTgyL3RleHRyZWdpb246YmQ2NWFkYWMzMzc0NGJhZWI2Y2IxZGZlYmIxZTAxODJfMTM5_164dc53b-c697-4bfd-b9b1-6074ad328e9c"
      unitRef="usd">2200000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82NC9mcmFnOmJkNjVhZGFjMzM3NDRiYWViNmNiMWRmZWJiMWUwMTgyL3RleHRyZWdpb246YmQ2NWFkYWMzMzc0NGJhZWI2Y2IxZGZlYmIxZTAxODJfMTQ2_badc0db0-5216-4489-96dd-5499db05cc06"
      unitRef="usd">400000</us-gaap:InventoryWriteDown>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RleHRyZWdpb246MGVjNTZiZTkxYWVmNGEyYmFhZTkyNGYwYmE2NTdhNDFfMTA0NDUzNjA0NzAzNTY_ac7b9ebf-811f-4102-bd8b-2f9d6fe68167">STOCK-BASED COMPENSATION&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We allocated the stock-based compensation expense for our equity incentive plans and our 2000 Employee Stock Purchase Plan (ESPP) as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, 16,900,406 sh&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ares were available for grant under the Exelixis, Inc. 2017 Equity Incentive Plan (as amended and restated, the 2017 Plan). The share reserve is reduced by 1 share for each share issued pursuant to a stock option or stock appreciation award and 1.5 shares for full value awards granted in the form of restricted stock units (RSUs). On May&#160;20, 2020, at our 2020 Annual Meeting of Stockholders, our stockholders approved the amendment and restatement of the 2017 Plan. The amendment and restatement increased the share reserve under the 2017 Plan by 21,000,000 shares, subject to adjustment for certain changes in our capitalization, which became effective immediately upon stockholder approval.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended September&#160;30, 2020, we granted 1,189,888 stock options with a weighted average exercise price of $21.84 per share and a weighted average grant&#160;date fair&#160;value of $9.61&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; per s&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;hare. As of September&#160;30, 2020, there were 16,219,326 stock options outstanding and $28.4 million unrecognized compensation expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended September&#160;30, 2020, we granted 2,813,888 service-based RSUs with a weighted average grant&#160;date fair&#160;value of $23.56 per share. As of September&#160;30, 2020, there were 6,554,909 RSUs outstanding and $111.9 million unrecognized compensation expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options and RSUs granted to employees during the nine months ended September&#160;30, 2020 have vesting conditions and contractual lives of a similar nature to those described in &#x201c;Note 8. Employee Benefit Plans&#x201d; of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;year ended &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2018, in connection with our long-term incentive compensation program, we granted 308,365 performance-based stock options (PSOs) to our President and Chief Executive Officer. In addition to the standard service-based vesting conditions included in our other stock options, these PSOs contain a market vesting condition such that they may not be exercised until, at any time after the grant date, the closing market price of our Common Stock is equal to or greater than 125% of the per share exercise price of the PSOs over a period of at least 30 consecutive calendar days. This market vesting condition was achieved during the three months ended June&#160;30, 2020. The stock-based compensation expense for the PSOs is being recognized on an accelerated basis over the service period of the award, which commenced on the date of grant. The achievement of the market vesting condition did not impact the compensation expense recognized during the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of&#160;September&#160;30, 2020, there were&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,186,977&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; performance-based restricted stock units (PSUs) outstanding with $129.7 million in related unrecognized compensation expense. Expense recognition for PSUs commences when it is determined that achievement of the performance target is probable. Of the outstanding PSUs, 188,624 relate to awards for which we achieved the performance target during 2019 or had determined during 2019 that it was probable that we would achieve the performance target during 2020. During 2020, we determined that it had become probable that we would achieve additional performance targets for 2,947,563 additional PSUs granted during 2018 and 2019. Total stock-based compensation expense for PSUs was $41.2 million and $43.2 million during the three and nine months ended September&#160;30, 2020, respectively. For more information about our PSUs, see &#x201c;Note 8. Employee Benefit Plans&#x201d; of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020, in connection with our long-term incentive compensation program, we awarded 1,951,830 PSUs (the target amount) that will vest upon the achievement of certain performance targets related to clinical trial positive top-line results and product approvals by the FDA (the 2020 PSUs). Employees may earn up to 200% of the target amount or 3,903,660 shares, depending on the volume and the timing of achievement of the&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;performance targets. The 2020 PSUs &lt;/span&gt;&lt;/div&gt;were designed to drive the performance of our management team and employees toward the achievement of key corporate objectives and will be forfeited if the performance targets are not met by December 31, 2024.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RleHRyZWdpb246MGVjNTZiZTkxYWVmNGEyYmFhZTkyNGYwYmE2NTdhNDFfMzY5MQ_b36e070d-178b-4d71-85e8-1f563ea3e73a">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We allocated the stock-based compensation expense for our equity incentive plans and our 2000 Employee Stock Purchase Plan (ESPP) as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id8807e50c23c4d31ab20dcdcebd143c7_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RhYmxlOjliYjIzZTg3MzhjZTQxM2JiNDAwYzc1YWZhOTJmNGNmL3RhYmxlcmFuZ2U6OWJiMjNlODczOGNlNDEzYmI0MDBjNzVhZmE5MmY0Y2ZfMi0xLTEtMS0w_6cf7d895-c7bf-47d6-bcca-1099b296b01c"
      unitRef="usd">18936000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6d73a25521cd47598eec943fc3e67f0b_D20190629-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RhYmxlOjliYjIzZTg3MzhjZTQxM2JiNDAwYzc1YWZhOTJmNGNmL3RhYmxlcmFuZ2U6OWJiMjNlODczOGNlNDEzYmI0MDBjNzVhZmE5MmY0Y2ZfMi0zLTEtMS0w_1fbecb53-c987-4014-801e-e862193461e3"
      unitRef="usd">4301000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id10dbcb3d9244b64b3c0a11867e5072c_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RhYmxlOjliYjIzZTg3MzhjZTQxM2JiNDAwYzc1YWZhOTJmNGNmL3RhYmxlcmFuZ2U6OWJiMjNlODczOGNlNDEzYmI0MDBjNzVhZmE5MmY0Y2ZfMi01LTEtMS0w_c9874ad9-db38-40ff-ac97-b50baa35515e"
      unitRef="usd">30134000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2730b1b9796c4aaaa8efe5695e985946_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RhYmxlOjliYjIzZTg3MzhjZTQxM2JiNDAwYzc1YWZhOTJmNGNmL3RhYmxlcmFuZ2U6OWJiMjNlODczOGNlNDEzYmI0MDBjNzVhZmE5MmY0Y2ZfMi03LTEtMS0w_bbfaccde-3afa-4e35-b5eb-1ccfc800b2ec"
      unitRef="usd">13745000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i94716cdf2585476f8d2241789b25429d_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RhYmxlOjliYjIzZTg3MzhjZTQxM2JiNDAwYzc1YWZhOTJmNGNmL3RhYmxlcmFuZ2U6OWJiMjNlODczOGNlNDEzYmI0MDBjNzVhZmE5MmY0Y2ZfMy0xLTEtMS0w_2eda64cb-304f-4908-9cc3-3c9e2fb6d8e8"
      unitRef="usd">36719000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia84c18733f11427b85d537694ee6b742_D20190629-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RhYmxlOjliYjIzZTg3MzhjZTQxM2JiNDAwYzc1YWZhOTJmNGNmL3RhYmxlcmFuZ2U6OWJiMjNlODczOGNlNDEzYmI0MDBjNzVhZmE5MmY0Y2ZfMy0zLTEtMS0w_09bf5d47-c5f6-4098-b257-43db1fa61089"
      unitRef="usd">8838000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ife7f80399bf046279aeacfddc3d5cb35_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RhYmxlOjliYjIzZTg3MzhjZTQxM2JiNDAwYzc1YWZhOTJmNGNmL3RhYmxlcmFuZ2U6OWJiMjNlODczOGNlNDEzYmI0MDBjNzVhZmE5MmY0Y2ZfMy01LTEtMS0w_c23a0599-5261-41ff-a75b-ca8caa699a43"
      unitRef="usd">55657000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ifb17c6080fe0476e875c10f986a8b090_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RhYmxlOjliYjIzZTg3MzhjZTQxM2JiNDAwYzc1YWZhOTJmNGNmL3RhYmxlcmFuZ2U6OWJiMjNlODczOGNlNDEzYmI0MDBjNzVhZmE5MmY0Y2ZfMy03LTEtMS0w_0a5d648a-0924-496e-bf7c-c3a3cbada506"
      unitRef="usd">27002000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RhYmxlOjliYjIzZTg3MzhjZTQxM2JiNDAwYzc1YWZhOTJmNGNmL3RhYmxlcmFuZ2U6OWJiMjNlODczOGNlNDEzYmI0MDBjNzVhZmE5MmY0Y2ZfNC0xLTEtMS0w_fe4b38ed-474a-4eb6-b53c-08ea66399aa4"
      unitRef="usd">55655000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RhYmxlOjliYjIzZTg3MzhjZTQxM2JiNDAwYzc1YWZhOTJmNGNmL3RhYmxlcmFuZ2U6OWJiMjNlODczOGNlNDEzYmI0MDBjNzVhZmE5MmY0Y2ZfNC0zLTEtMS0w_858ccb36-44f2-428e-82db-13d26f9fe3bf"
      unitRef="usd">13139000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RhYmxlOjliYjIzZTg3MzhjZTQxM2JiNDAwYzc1YWZhOTJmNGNmL3RhYmxlcmFuZ2U6OWJiMjNlODczOGNlNDEzYmI0MDBjNzVhZmE5MmY0Y2ZfNC01LTEtMS0w_605a3b06-1280-43c6-a0e8-b26ea5200e31"
      unitRef="usd">85791000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RhYmxlOjliYjIzZTg3MzhjZTQxM2JiNDAwYzc1YWZhOTJmNGNmL3RhYmxlcmFuZ2U6OWJiMjNlODczOGNlNDEzYmI0MDBjNzVhZmE5MmY0Y2ZfNC03LTEtMS0w_79109854-4967-4129-9588-2c862782097a"
      unitRef="usd">40747000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RleHRyZWdpb246MGVjNTZiZTkxYWVmNGEyYmFhZTkyNGYwYmE2NTdhNDFfMjEw_eb7688b3-e4d1-4d8e-b9c1-7fb642d5f4c2"
      unitRef="shares">16900406</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RleHRyZWdpb246MGVjNTZiZTkxYWVmNGEyYmFhZTkyNGYwYmE2NTdhNDFfMzcx_ca5bb823-ce59-4064-8fc3-ac2e830a0480"
      unitRef="shares">1</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward>
    <exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RleHRyZWdpb246MGVjNTZiZTkxYWVmNGEyYmFhZTkyNGYwYmE2NTdhNDFfNDYx_aeddf999-263a-4213-b7c2-d63bebcc1998"
      unitRef="shares">1.5</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i6084a0d4002647d69b2148895c55cbd9_D20200520-20200520"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RleHRyZWdpb246MGVjNTZiZTkxYWVmNGEyYmFhZTkyNGYwYmE2NTdhNDFfNzYz_07a12001-8db9-44be-9881-26c5fc49a0f9"
      unitRef="shares">21000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RleHRyZWdpb246MGVjNTZiZTkxYWVmNGEyYmFhZTkyNGYwYmE2NTdhNDFfMTAyOA_5b2b3bc5-6662-4fa9-8fbb-a14dcad50109"
      unitRef="shares">1189888</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RleHRyZWdpb246MGVjNTZiZTkxYWVmNGEyYmFhZTkyNGYwYmE2NTdhNDFfMTA4Nw_cdbe7ad4-cfa4-4f57-84a3-919d89e16e80"
      unitRef="usdPerShare">21.84</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RleHRyZWdpb246MGVjNTZiZTkxYWVmNGEyYmFhZTkyNGYwYmE2NTdhNDFfMTE0OA_cb86e085-9f65-41e0-97be-9c1327826ffa"
      unitRef="usdPerShare">9.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="iccc3837038f342898d73d67395904bae_I20201002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RleHRyZWdpb246MGVjNTZiZTkxYWVmNGEyYmFhZTkyNGYwYmE2NTdhNDFfMTE4Mw_332cfd40-2d61-4140-b112-498e9c3ff63c"
      unitRef="shares">16219326</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i6c137f0c3b874241af6cdf35240fc6c4_I20201002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RleHRyZWdpb246MGVjNTZiZTkxYWVmNGEyYmFhZTkyNGYwYmE2NTdhNDFfMTIxOQ_c767a5ab-d4e7-47e7-9918-9afc52c67513"
      unitRef="usd">28400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ie7840df292b24b97a39df16ab6f9e94c_D20200104-20201002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RleHRyZWdpb246MGVjNTZiZTkxYWVmNGEyYmFhZTkyNGYwYmE2NTdhNDFfMTI4Nw_ef54e3cf-3dd0-4f17-9b30-e85f43a8f8af"
      unitRef="shares">2813888</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ie7840df292b24b97a39df16ab6f9e94c_D20200104-20201002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RleHRyZWdpb246MGVjNTZiZTkxYWVmNGEyYmFhZTkyNGYwYmE2NTdhNDFfMTM0NQ_f40d2f68-429a-4737-b97a-4aa4b757eec3"
      unitRef="usdPerShare">23.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ib477ff76a01e469abd582edacf5f60b7_I20201002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RleHRyZWdpb246MGVjNTZiZTkxYWVmNGEyYmFhZTkyNGYwYmE2NTdhNDFfMTM4MQ_a2c15494-8d62-49c4-a10d-9a5ea83ee25d"
      unitRef="shares">6554909</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ib477ff76a01e469abd582edacf5f60b7_I20201002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RleHRyZWdpb246MGVjNTZiZTkxYWVmNGEyYmFhZTkyNGYwYmE2NTdhNDFfMTQwNg_aad5c485-77b2-4be9-b802-13e8b966bd07"
      unitRef="usd">111900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i2fa39753eebb4b2da55065a78f952a39_D20180101-20181228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RleHRyZWdpb246MGVjNTZiZTkxYWVmNGEyYmFhZTkyNGYwYmE2NTdhNDFfMTg4Mg_69618f02-5cd5-4ac3-a39d-d00d26a026ab"
      unitRef="shares">308365</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <exel:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises
      contextRef="i2fa39753eebb4b2da55065a78f952a39_D20180101-20181228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RleHRyZWdpb246MGVjNTZiZTkxYWVmNGEyYmFhZTkyNGYwYmE2NTdhNDFfMjI2NA_b928c64e-ac78-42ff-a25f-20c9e9bab499"
      unitRef="number">1.25</exel:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i91d293b87e5445f5b5b67e1a9c37b9d2_I20201002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RleHRyZWdpb246MGVjNTZiZTkxYWVmNGEyYmFhZTkyNGYwYmE2NTdhNDFfMjc2NA_a81d5fb9-19a3-44f8-98e6-e6272e2d32b4"
      unitRef="shares">8186977</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i91d293b87e5445f5b5b67e1a9c37b9d2_I20201002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RleHRyZWdpb246MGVjNTZiZTkxYWVmNGEyYmFhZTkyNGYwYmE2NTdhNDFfMjgzMg_273b8feb-67db-4380-a620-bb85be8e9531"
      unitRef="usd">129700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i4972ebe551a741e48565ab4e7bcd8df1_I20201002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RleHRyZWdpb246MGVjNTZiZTkxYWVmNGEyYmFhZTkyNGYwYmE2NTdhNDFfMzAyMw_02725c05-08ee-49e3-a150-13d94d0ab818"
      unitRef="shares">188624</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i1e5cec7e0ab144f59216d279d7df965d_I20201002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RleHRyZWdpb246MGVjNTZiZTkxYWVmNGEyYmFhZTkyNGYwYmE2NTdhNDFfMzM1NQ_a9b5af16-f68d-45e8-b98b-4f7db8eb8e57"
      unitRef="shares">2947563</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i21aab8a484c04ec2a5cff2d96ab82dbd_D20200704-20201002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RleHRyZWdpb246MGVjNTZiZTkxYWVmNGEyYmFhZTkyNGYwYmE2NTdhNDFfMTA5OTUxMTYzNzM1Nw_f486f550-44c4-44f4-84d1-e479af97a28d"
      unitRef="usd">41200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7550f0f67bcf428b9b1a23a22d59a795_D20200104-20201002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RleHRyZWdpb246MGVjNTZiZTkxYWVmNGEyYmFhZTkyNGYwYmE2NTdhNDFfMTA5OTUxMTYzNzM2NQ_bc09bff2-adb8-4bd0-b453-c2dfcb56ed2c"
      unitRef="usd">43200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i7550f0f67bcf428b9b1a23a22d59a795_D20200104-20201002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RleHRyZWdpb246MGVjNTZiZTkxYWVmNGEyYmFhZTkyNGYwYmE2NTdhNDFfODI0NjMzNzIxNTk4MQ_0b553c03-fe02-4b5a-ab37-8daff717ed92"
      unitRef="shares">1951830</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest
      contextRef="ie7840df292b24b97a39df16ab6f9e94c_D20200104-20201002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RleHRyZWdpb246MGVjNTZiZTkxYWVmNGEyYmFhZTkyNGYwYmE2NTdhNDFfMTA0NDUzNjA0NzAzNTg_c94bce6b-af88-4bf8-ac36-f60bd8898681"
      unitRef="number">2</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest>
    <exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumNumberOfSharesToVest
      contextRef="ie7840df292b24b97a39df16ab6f9e94c_D20200104-20201002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF82Ny9mcmFnOjBlYzU2YmU5MWFlZjRhMmJhYWU5MjRmMGJhNjU3YTQxL3RleHRyZWdpb246MGVjNTZiZTkxYWVmNGEyYmFhZTkyNGYwYmE2NTdhNDFfMTA5OTUxMTYzNjg0NQ_41ac798c-9fec-4af0-ad27-748a5d0ea946"
      unitRef="shares">3903660</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumNumberOfSharesToVest>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83MC9mcmFnOmNkMGQ3MmFhOTAwZTRmODFhZWJkZDQwYjAyOTZkOWJiL3RleHRyZWdpb246Y2QwZDcyYWE5MDBlNGY4MWFlYmRkNDBiMDI5NmQ5YmJfMzcy_effe1ce6-2ee8-4d47-8dd0-0bb11535e163">INCOME TAXESOur effective income tax rate was 15.7% and 18.8% during the three and nine months ended September&#160;30, 2020, respectively, as compared to 20.5% and 19.4% for the comparable periods in 2019. The effective tax rate for the three and nine months ended September 30, 2020 differed from U.S. federal statutory tax rate of 21% primarily due to excess tax benefits related to the exercise of certain stock options and federal tax credits, offset by the non-deductible executive compensation during the periods. The effective tax rate for the three and nine months ended September&#160;30, 2019 differed from the U.S. federal statutory rate of&#160;21%&#160;primarily due to excess tax benefits related to the exercise of certain stock options and federal tax credits during the periods.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83MC9mcmFnOmNkMGQ3MmFhOTAwZTRmODFhZWJkZDQwYjAyOTZkOWJiL3RleHRyZWdpb246Y2QwZDcyYWE5MDBlNGY4MWFlYmRkNDBiMDI5NmQ5YmJfNjE_d23cf9d4-4b52-4dea-81bd-d9366cdca430"
      unitRef="number">0.157</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83MC9mcmFnOmNkMGQ3MmFhOTAwZTRmODFhZWJkZDQwYjAyOTZkOWJiL3RleHRyZWdpb246Y2QwZDcyYWE5MDBlNGY4MWFlYmRkNDBiMDI5NmQ5YmJfNzA_3364d063-1c6e-43e7-8655-c9cfd9a00f83"
      unitRef="number">0.188</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83MC9mcmFnOmNkMGQ3MmFhOTAwZTRmODFhZWJkZDQwYjAyOTZkOWJiL3RleHRyZWdpb246Y2QwZDcyYWE5MDBlNGY4MWFlYmRkNDBiMDI5NmQ5YmJfMTIy_4b645030-62aa-4e53-abf6-32c6c270feeb"
      unitRef="number">0.205</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83MC9mcmFnOmNkMGQ3MmFhOTAwZTRmODFhZWJkZDQwYjAyOTZkOWJiL3RleHRyZWdpb246Y2QwZDcyYWE5MDBlNGY4MWFlYmRkNDBiMDI5NmQ5YmJfMTI5_99368446-6774-4e88-a333-26e1c9dbd245"
      unitRef="number">0.194</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83My9mcmFnOjY2MTU0MTc0NzE4ODQ1ZmVhNmE3Zjc2NDM1Yjk4YjQyL3RleHRyZWdpb246NjYxNTQxNzQ3MTg4NDVmZWE2YTdmNzY0MzViOThiNDJfNjIw_e4f39f40-1fbb-442b-bbf1-789c8f9bd465">NET INCOME (LOSS) PER SHARE&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income (loss) per share - basic and diluted, were computed as follows (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,040)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding &#x2014; basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding &#x2014; diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;315,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;315,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) per share &#x2014; basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) per share &#x2014; diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dilutive securities included stock options, RSUs, PSUs, PSOs and ESPP contributions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain potential common shares were excluded from our calculation of weighted-average common shares outstanding - diluted because either they would have had an anti-dilutive effect on net income per share or they were related to shares from PSUs for which the contingent vesting condition had not been achieved. The weighted-average potential common shares excluded from our calculation were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive securities and contingently issuable shares excluded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83My9mcmFnOjY2MTU0MTc0NzE4ODQ1ZmVhNmE3Zjc2NDM1Yjk4YjQyL3RleHRyZWdpb246NjYxNTQxNzQ3MTg4NDVmZWE2YTdmNzY0MzViOThiNDJfNjM1_c8e54b7b-769b-474a-bae0-e57512fc282e">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income (loss) per share - basic and diluted, were computed as follows (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,040)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding &#x2014; basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding &#x2014; diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;315,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;315,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) per share &#x2014; basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) per share &#x2014; diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83My9mcmFnOjY2MTU0MTc0NzE4ODQ1ZmVhNmE3Zjc2NDM1Yjk4YjQyL3RhYmxlOjc4OGRlODBiYTA5NzRmM2Q4ZmE0OGNiOTcyOThhMmYzL3RhYmxlcmFuZ2U6Nzg4ZGU4MGJhMDk3NGYzZDhmYTQ4Y2I5NzI5OGEyZjNfMy0xLTEtMS0w_e14fdd44-f91f-4aa8-8680-c1ce4c535495"
      unitRef="usd">-32040000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83My9mcmFnOjY2MTU0MTc0NzE4ODQ1ZmVhNmE3Zjc2NDM1Yjk4YjQyL3RhYmxlOjc4OGRlODBiYTA5NzRmM2Q4ZmE0OGNiOTcyOThhMmYzL3RhYmxlcmFuZ2U6Nzg4ZGU4MGJhMDk3NGYzZDhmYTQ4Y2I5NzI5OGEyZjNfMy0zLTEtMS0w_c230d74c-b0e6-47c5-b0c6-2fc1d389f218"
      unitRef="usd">97452000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83My9mcmFnOjY2MTU0MTc0NzE4ODQ1ZmVhNmE3Zjc2NDM1Yjk4YjQyL3RhYmxlOjc4OGRlODBiYTA5NzRmM2Q4ZmE0OGNiOTcyOThhMmYzL3RhYmxlcmFuZ2U6Nzg4ZGU4MGJhMDk3NGYzZDhmYTQ4Y2I5NzI5OGEyZjNfMy01LTEtMS0w_abfa2d1e-5ccf-42b5-84d6-40e96d4bcd40"
      unitRef="usd">83393000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83My9mcmFnOjY2MTU0MTc0NzE4ODQ1ZmVhNmE3Zjc2NDM1Yjk4YjQyL3RhYmxlOjc4OGRlODBiYTA5NzRmM2Q4ZmE0OGNiOTcyOThhMmYzL3RhYmxlcmFuZ2U6Nzg4ZGU4MGJhMDk3NGYzZDhmYTQ4Y2I5NzI5OGEyZjNfMy03LTEtMS0w_9bcc5c2b-55a6-4d0e-b747-be683cc26c85"
      unitRef="usd">252269000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83My9mcmFnOjY2MTU0MTc0NzE4ODQ1ZmVhNmE3Zjc2NDM1Yjk4YjQyL3RhYmxlOjc4OGRlODBiYTA5NzRmM2Q4ZmE0OGNiOTcyOThhMmYzL3RhYmxlcmFuZ2U6Nzg4ZGU4MGJhMDk3NGYzZDhmYTQ4Y2I5NzI5OGEyZjNfNS0xLTEtMS0w_ad71f298-fb89-4ea2-b645-546a307bf799"
      unitRef="shares">309116000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83My9mcmFnOjY2MTU0MTc0NzE4ODQ1ZmVhNmE3Zjc2NDM1Yjk4YjQyL3RhYmxlOjc4OGRlODBiYTA5NzRmM2Q4ZmE0OGNiOTcyOThhMmYzL3RhYmxlcmFuZ2U6Nzg4ZGU4MGJhMDk3NGYzZDhmYTQ4Y2I5NzI5OGEyZjNfNS0zLTEtMS0w_383b0a50-bc8b-4cab-8407-0ed04091d0ff"
      unitRef="shares">303268000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83My9mcmFnOjY2MTU0MTc0NzE4ODQ1ZmVhNmE3Zjc2NDM1Yjk4YjQyL3RhYmxlOjc4OGRlODBiYTA5NzRmM2Q4ZmE0OGNiOTcyOThhMmYzL3RhYmxlcmFuZ2U6Nzg4ZGU4MGJhMDk3NGYzZDhmYTQ4Y2I5NzI5OGEyZjNfNS01LTEtMS0w_5deb2c6c-2f08-4e8c-af99-133a8fd8a946"
      unitRef="shares">307437000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83My9mcmFnOjY2MTU0MTc0NzE4ODQ1ZmVhNmE3Zjc2NDM1Yjk4YjQyL3RhYmxlOjc4OGRlODBiYTA5NzRmM2Q4ZmE0OGNiOTcyOThhMmYzL3RhYmxlcmFuZ2U6Nzg4ZGU4MGJhMDk3NGYzZDhmYTQ4Y2I5NzI5OGEyZjNfNS03LTEtMS0w_0b59a1e4-7c19-4daf-b7a4-3eda28981bce"
      unitRef="shares">301999000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83My9mcmFnOjY2MTU0MTc0NzE4ODQ1ZmVhNmE3Zjc2NDM1Yjk4YjQyL3RhYmxlOjc4OGRlODBiYTA5NzRmM2Q4ZmE0OGNiOTcyOThhMmYzL3RhYmxlcmFuZ2U6Nzg4ZGU4MGJhMDk3NGYzZDhmYTQ4Y2I5NzI5OGEyZjNfNi0xLTEtMS0w_ad887d7f-671e-4374-a827-52a8817b1af3"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83My9mcmFnOjY2MTU0MTc0NzE4ODQ1ZmVhNmE3Zjc2NDM1Yjk4YjQyL3RhYmxlOjc4OGRlODBiYTA5NzRmM2Q4ZmE0OGNiOTcyOThhMmYzL3RhYmxlcmFuZ2U6Nzg4ZGU4MGJhMDk3NGYzZDhmYTQ4Y2I5NzI5OGEyZjNfNi0zLTEtMS0w_d660de6f-4abf-49cb-84e9-14de39dadfe6"
      unitRef="shares">12185000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83My9mcmFnOjY2MTU0MTc0NzE4ODQ1ZmVhNmE3Zjc2NDM1Yjk4YjQyL3RhYmxlOjc4OGRlODBiYTA5NzRmM2Q4ZmE0OGNiOTcyOThhMmYzL3RhYmxlcmFuZ2U6Nzg4ZGU4MGJhMDk3NGYzZDhmYTQ4Y2I5NzI5OGEyZjNfNi01LTEtMS0w_0d827cb5-513c-48be-86f6-522d1b51c3e2"
      unitRef="shares">10058000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83My9mcmFnOjY2MTU0MTc0NzE4ODQ1ZmVhNmE3Zjc2NDM1Yjk4YjQyL3RhYmxlOjc4OGRlODBiYTA5NzRmM2Q4ZmE0OGNiOTcyOThhMmYzL3RhYmxlcmFuZ2U6Nzg4ZGU4MGJhMDk3NGYzZDhmYTQ4Y2I5NzI5OGEyZjNfNi03LTEtMS0w_ae1efd41-0137-46a7-a078-7c6ea4e50130"
      unitRef="shares">13047000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83My9mcmFnOjY2MTU0MTc0NzE4ODQ1ZmVhNmE3Zjc2NDM1Yjk4YjQyL3RhYmxlOjc4OGRlODBiYTA5NzRmM2Q4ZmE0OGNiOTcyOThhMmYzL3RhYmxlcmFuZ2U6Nzg4ZGU4MGJhMDk3NGYzZDhmYTQ4Y2I5NzI5OGEyZjNfNy0xLTEtMS0w_803f0d2a-bbdc-4ef4-bffb-d803c0103b39"
      unitRef="shares">309116000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83My9mcmFnOjY2MTU0MTc0NzE4ODQ1ZmVhNmE3Zjc2NDM1Yjk4YjQyL3RhYmxlOjc4OGRlODBiYTA5NzRmM2Q4ZmE0OGNiOTcyOThhMmYzL3RhYmxlcmFuZ2U6Nzg4ZGU4MGJhMDk3NGYzZDhmYTQ4Y2I5NzI5OGEyZjNfNy0zLTEtMS0w_67b9574c-6450-49ee-919c-f49b4b4803bc"
      unitRef="shares">315453000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83My9mcmFnOjY2MTU0MTc0NzE4ODQ1ZmVhNmE3Zjc2NDM1Yjk4YjQyL3RhYmxlOjc4OGRlODBiYTA5NzRmM2Q4ZmE0OGNiOTcyOThhMmYzL3RhYmxlcmFuZ2U6Nzg4ZGU4MGJhMDk3NGYzZDhmYTQ4Y2I5NzI5OGEyZjNfNy01LTEtMS0w_4e8b08e6-3bf8-4021-9776-f7d4824624af"
      unitRef="shares">317495000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83My9mcmFnOjY2MTU0MTc0NzE4ODQ1ZmVhNmE3Zjc2NDM1Yjk4YjQyL3RhYmxlOjc4OGRlODBiYTA5NzRmM2Q4ZmE0OGNiOTcyOThhMmYzL3RhYmxlcmFuZ2U6Nzg4ZGU4MGJhMDk3NGYzZDhmYTQ4Y2I5NzI5OGEyZjNfNy03LTEtMS0w_e597c94f-7aaa-4a7c-a731-1c6ad536fba0"
      unitRef="shares">315046000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83My9mcmFnOjY2MTU0MTc0NzE4ODQ1ZmVhNmE3Zjc2NDM1Yjk4YjQyL3RhYmxlOjc4OGRlODBiYTA5NzRmM2Q4ZmE0OGNiOTcyOThhMmYzL3RhYmxlcmFuZ2U6Nzg4ZGU4MGJhMDk3NGYzZDhmYTQ4Y2I5NzI5OGEyZjNfOC0xLTEtMS0w_7a3147de-aef6-4bfa-95f9-00cc4ada70f9"
      unitRef="usdPerShare">-0.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83My9mcmFnOjY2MTU0MTc0NzE4ODQ1ZmVhNmE3Zjc2NDM1Yjk4YjQyL3RhYmxlOjc4OGRlODBiYTA5NzRmM2Q4ZmE0OGNiOTcyOThhMmYzL3RhYmxlcmFuZ2U6Nzg4ZGU4MGJhMDk3NGYzZDhmYTQ4Y2I5NzI5OGEyZjNfOC0zLTEtMS0w_d6849b2a-127a-4ef8-bca4-87bb5574df34"
      unitRef="usdPerShare">0.32</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83My9mcmFnOjY2MTU0MTc0NzE4ODQ1ZmVhNmE3Zjc2NDM1Yjk4YjQyL3RhYmxlOjc4OGRlODBiYTA5NzRmM2Q4ZmE0OGNiOTcyOThhMmYzL3RhYmxlcmFuZ2U6Nzg4ZGU4MGJhMDk3NGYzZDhmYTQ4Y2I5NzI5OGEyZjNfOC01LTEtMS0w_0ce389e6-f463-4470-9f6f-0c0f57c77414"
      unitRef="usdPerShare">0.27</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83My9mcmFnOjY2MTU0MTc0NzE4ODQ1ZmVhNmE3Zjc2NDM1Yjk4YjQyL3RhYmxlOjc4OGRlODBiYTA5NzRmM2Q4ZmE0OGNiOTcyOThhMmYzL3RhYmxlcmFuZ2U6Nzg4ZGU4MGJhMDk3NGYzZDhmYTQ4Y2I5NzI5OGEyZjNfOC03LTEtMS0w_2a713e4f-985b-45b8-92d1-f77166c3ab6c"
      unitRef="usdPerShare">0.84</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83My9mcmFnOjY2MTU0MTc0NzE4ODQ1ZmVhNmE3Zjc2NDM1Yjk4YjQyL3RhYmxlOjc4OGRlODBiYTA5NzRmM2Q4ZmE0OGNiOTcyOThhMmYzL3RhYmxlcmFuZ2U6Nzg4ZGU4MGJhMDk3NGYzZDhmYTQ4Y2I5NzI5OGEyZjNfOS0xLTEtMS0w_7f9a4c55-e401-442f-8fa4-105892c23951"
      unitRef="usdPerShare">-0.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i60a0619ccaec4eb98059215818a245c3_D20190629-20190927"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83My9mcmFnOjY2MTU0MTc0NzE4ODQ1ZmVhNmE3Zjc2NDM1Yjk4YjQyL3RhYmxlOjc4OGRlODBiYTA5NzRmM2Q4ZmE0OGNiOTcyOThhMmYzL3RhYmxlcmFuZ2U6Nzg4ZGU4MGJhMDk3NGYzZDhmYTQ4Y2I5NzI5OGEyZjNfOS0zLTEtMS0w_19789304-e307-47ab-b0c5-170978039f50"
      unitRef="usdPerShare">0.31</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83My9mcmFnOjY2MTU0MTc0NzE4ODQ1ZmVhNmE3Zjc2NDM1Yjk4YjQyL3RhYmxlOjc4OGRlODBiYTA5NzRmM2Q4ZmE0OGNiOTcyOThhMmYzL3RhYmxlcmFuZ2U6Nzg4ZGU4MGJhMDk3NGYzZDhmYTQ4Y2I5NzI5OGEyZjNfOS01LTEtMS0w_7572123f-74b1-484b-8639-040d6b395680"
      unitRef="usdPerShare">0.26</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie46bdd6b0da74934a72f09a508c2536f_D20181229-20190927"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83My9mcmFnOjY2MTU0MTc0NzE4ODQ1ZmVhNmE3Zjc2NDM1Yjk4YjQyL3RhYmxlOjc4OGRlODBiYTA5NzRmM2Q4ZmE0OGNiOTcyOThhMmYzL3RhYmxlcmFuZ2U6Nzg4ZGU4MGJhMDk3NGYzZDhmYTQ4Y2I5NzI5OGEyZjNfOS03LTEtMS0w_f7ec4ab4-79db-4afc-8e6d-1c9da65693e3"
      unitRef="usdPerShare">0.80</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83My9mcmFnOjY2MTU0MTc0NzE4ODQ1ZmVhNmE3Zjc2NDM1Yjk4YjQyL3RleHRyZWdpb246NjYxNTQxNzQ3MTg4NDVmZWE2YTdmNzY0MzViOThiNDJfNjQ2_43d53379-2056-4d0d-9daa-fe58a9c8a5c5">The weighted-average potential common shares excluded from our calculation were as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive securities and contingently issuable shares excluded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i41f51136e2dd4492aea05277671e9389_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83My9mcmFnOjY2MTU0MTc0NzE4ODQ1ZmVhNmE3Zjc2NDM1Yjk4YjQyL3RhYmxlOmNjYTZjZmNhYmNmMTQwZjViMGY1YTZkOGFkZDQ2ZTAxL3RhYmxlcmFuZ2U6Y2NhNmNmY2FiY2YxNDBmNWIwZjVhNmQ4YWRkNDZlMDFfMi0xLTEtMS0w_b0ff8aaa-fca1-45d3-97a9-6b671a4df1e7"
      unitRef="shares">27033000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if970e9016fc3406ea7bb57cbb0786e20_D20190629-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83My9mcmFnOjY2MTU0MTc0NzE4ODQ1ZmVhNmE3Zjc2NDM1Yjk4YjQyL3RhYmxlOmNjYTZjZmNhYmNmMTQwZjViMGY1YTZkOGFkZDQ2ZTAxL3RhYmxlcmFuZ2U6Y2NhNmNmY2FiY2YxNDBmNWIwZjVhNmQ4YWRkNDZlMDFfMi0zLTEtMS0w_99352eac-f920-4118-b6ba-bc70daaca6a9"
      unitRef="shares">6153000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib0cf80d622b4495e8ba855ad5bbe6234_D20200104-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83My9mcmFnOjY2MTU0MTc0NzE4ODQ1ZmVhNmE3Zjc2NDM1Yjk4YjQyL3RhYmxlOmNjYTZjZmNhYmNmMTQwZjViMGY1YTZkOGFkZDQ2ZTAxL3RhYmxlcmFuZ2U6Y2NhNmNmY2FiY2YxNDBmNWIwZjVhNmQ4YWRkNDZlMDFfMi01LTEtMS0w_0cc4bf38-5de0-4d43-93e1-4bd3f889c366"
      unitRef="shares">10224000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i01d75cb9987e4a6e9148d6e76b57e666_D20181229-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83My9mcmFnOjY2MTU0MTc0NzE4ODQ1ZmVhNmE3Zjc2NDM1Yjk4YjQyL3RhYmxlOmNjYTZjZmNhYmNmMTQwZjViMGY1YTZkOGFkZDQ2ZTAxL3RhYmxlcmFuZ2U6Y2NhNmNmY2FiY2YxNDBmNWIwZjVhNmQ4YWRkNDZlMDFfMi03LTEtMS0w_eaa53e2f-7958-4117-86c4-45399f364fd7"
      unitRef="shares">5740000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyODNjNmY1MTdiNDQ3ZWM5MmYxNTRlZTY5MWY0MDI4L3NlYzowMjgzYzZmNTE3YjQ0N2VjOTJmMTU0ZWU2OTFmNDAyOF83Ni9mcmFnOmIzMDczNGMwOWNiZjQ5N2FiZGFkYzEwZjFjNTM1ZDQyL3RleHRyZWdpb246YjMwNzM0YzA5Y2JmNDk3YWJkYWRjMTBmMWM1MzVkNDJfMzEzMg_97b2e19e-f31d-47db-a874-8417dcd55a22">COMMITMENTS AND CONTINGENCIES&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2019, we received a notice letter regarding an Abbreviated New Drug Application (ANDA) submitted to the FDA by MSN Pharmaceuticals, Inc. (MSN), requesting approval to market a generic version of CABOMETYX tablets.&#160;MSN&#x2019;s initial notice letter included a Paragraph IV certification with respect to our&#160;U.S. Patent Nos.&#160;8,877,776, 9,724,342, 10,034,873 and 10,039,757, which are&#160;listed in the Approved Drug Products with Therapeutic Equivalence Evaluations, also referred to as the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Orange Book.&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;MSN&#x2019;s initial notice letter did not provide a Paragraph IV certification against U.S. Patent No. 7,579,473, the composition of matter patent, or U.S. Patent No. 8,497,284, a method of use patent. On October 29, 2019, we filed a complaint in the United States District Court for the District of Delaware for patent infringement against MSN asserting U.S. Patent No. 8,877,776 arising from MSN&#x2019;s ANDA filing with the FDA. On November 20, 2019, MSN filed its response to the complaint, alleging that U.S. Patent No. 8,877,776 is invalid and not infringed. On May 5, 2020, we received notice from MSN that it had amended its ANDA to assert additional Paragraph IV certifications. The ANDA now requests approval to market a generic version of CABOMETYX tablets&#160;prior to&#160;expiration of the two previously-unasserted CABOMETYX patents: U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284.&#160;On May 11, 2020, we &lt;/span&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;filed a complaint in the United States District Court for the District of Delaware for patent infringement against MSN asserting U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284 arising from MSN&#x2019;s amended ANDA filing with the FDA. On May 22, 2020, MSN filed its response to the complaint, alleging that each of U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284 is invalid and not infringed. Neither of our complaints alleges infringement of U.S. Patent Nos. 9,724,342, 10,034,873 and 10,039,757. In our complaints, we are seeking, among other relief, an order that the effective date of any FDA approval of the ANDA would be a date no earlier than the expiration of all of U.S. Patent No. 7,579,473, U.S. Patent No. 8,497,284 and U.S. Patent No. 8,877,776, the latest of which expires on October 8, 2030, and equitable relief enjoining MSN from infringing these patents. These two lawsuits against MSN have been consolidated, and a bench trial has been scheduled for May 2022. The sale of a generic version of CABOMETYX earlier than its patent expiration could significantly decrease our revenues and thereby materially harm our business, financial condition and results of operations. It is not possible at this time to determine the likelihood of an unfavorable outcome or estimate of the amount or range of any potential loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may also from time to time become a party or subject to various other legal proceedings and claims, either asserted or unasserted, which arise in the ordinary course of business. Some of these proceedings have involved, and may involve in the future, claims that are subject to substantial uncertainties and unascertainable damages.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139923437988616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Oct. 26, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct.  02,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EXELIXIS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">04-3257395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1851 Harbor Bay Parkway<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Alameda,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">837-7000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock $.001 Par Value per Share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EXEL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">310,243,961<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000939767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--01-01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139923437514152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 334,046<span></span>
</td>
<td class="nump">$ 266,501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">853,835<span></span>
</td>
<td class="nump">585,742<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Trade receivables, net</a></td>
<td class="nump">166,138<span></span>
</td>
<td class="nump">119,073<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">19,319<span></span>
</td>
<td class="nump">12,886<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">34,470<span></span>
</td>
<td class="nump">26,988<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,407,808<span></span>
</td>
<td class="nump">1,011,190<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">358,079<span></span>
</td>
<td class="nump">536,385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">56,385<span></span>
</td>
<td class="nump">48,892<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets, net</a></td>
<td class="nump">155,678<span></span>
</td>
<td class="nump">172,374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">63,684<span></span>
</td>
<td class="nump">63,684<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">69,409<span></span>
</td>
<td class="nump">53,145<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">2,111,043<span></span>
</td>
<td class="nump">1,885,670<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">47,927<span></span>
</td>
<td class="nump">11,581<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">40,782<span></span>
</td>
<td class="nump">37,364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_AccruedClinicalLiabilitiesCurrent', window );">Accrued clinical trial liabilities</a></td>
<td class="nump">47,074<span></span>
</td>
<td class="nump">38,777<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CustomerRefundLiabilityCurrent', window );">Rebates and fees due to customers</a></td>
<td class="nump">19,129<span></span>
</td>
<td class="nump">18,719<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_AccruedCollaborationLiabilityCurrent', window );">Accrued collaboration liabilities</a></td>
<td class="nump">11,102<span></span>
</td>
<td class="nump">11,856<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">35,329<span></span>
</td>
<td class="nump">24,449<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">201,343<span></span>
</td>
<td class="nump">142,746<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term portion of deferred revenues</a></td>
<td class="nump">9,322<span></span>
</td>
<td class="nump">6,596<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion of operating lease liabilities</a></td>
<td class="nump">47,626<span></span>
</td>
<td class="nump">48,011<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">721<span></span>
</td>
<td class="nump">2,347<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">259,012<span></span>
</td>
<td class="nump">199,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 309,402 and 304,831 at September&#160;30, 2020 and December&#160;31, 2019, respectively</a></td>
<td class="nump">309<span></span>
</td>
<td class="nump">305<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">2,321,441<span></span>
</td>
<td class="nump">2,241,947<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">6,239<span></span>
</td>
<td class="nump">3,069<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(475,958)<span></span>
</td>
<td class="num">(559,351)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">1,852,031<span></span>
</td>
<td class="nump">1,685,970<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 2,111,043<span></span>
</td>
<td class="nump">$ 1,885,670<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AccruedClinicalLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AccruedClinicalLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AccruedCollaborationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Collaboration Liability, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AccruedCollaborationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CustomerRefundLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CustomerRefundLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139923437987864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares issued (in shares)</a></td>
<td class="nump">309,402,000<span></span>
</td>
<td class="nump">304,831,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">309,402,000<span></span>
</td>
<td class="nump">304,831,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139923438024376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Income (Loss) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">$ 231,092<span></span>
</td>
<td class="nump">$ 271,703<span></span>
</td>
<td class="nump">$ 717,486<span></span>
</td>
<td class="nump">$ 727,465<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">231,092<span></span>
</td>
<td class="nump">271,703<span></span>
</td>
<td class="nump">717,486<span></span>
</td>
<td class="nump">727,465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">8,725<span></span>
</td>
<td class="nump">7,537<span></span>
</td>
<td class="nump">27,235<span></span>
</td>
<td class="nump">22,577<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">176,762<span></span>
</td>
<td class="nump">97,295<span></span>
</td>
<td class="nump">393,572<span></span>
</td>
<td class="nump">242,516<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">88,185<span></span>
</td>
<td class="nump">51,265<span></span>
</td>
<td class="nump">210,916<span></span>
</td>
<td class="nump">170,218<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">273,672<span></span>
</td>
<td class="nump">156,097<span></span>
</td>
<td class="nump">631,723<span></span>
</td>
<td class="nump">435,311<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="num">(42,580)<span></span>
</td>
<td class="nump">115,606<span></span>
</td>
<td class="nump">85,763<span></span>
</td>
<td class="nump">292,154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="nump">3,994<span></span>
</td>
<td class="nump">7,191<span></span>
</td>
<td class="nump">16,376<span></span>
</td>
<td class="nump">20,253<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">565<span></span>
</td>
<td class="num">(140)<span></span>
</td>
<td class="nump">571<span></span>
</td>
<td class="nump">688<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income (loss) before income taxes</a></td>
<td class="num">(38,021)<span></span>
</td>
<td class="nump">122,657<span></span>
</td>
<td class="nump">102,710<span></span>
</td>
<td class="nump">313,095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for (benefit from) income taxes</a></td>
<td class="num">(5,981)<span></span>
</td>
<td class="nump">25,205<span></span>
</td>
<td class="nump">19,317<span></span>
</td>
<td class="nump">60,826<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (32,040)<span></span>
</td>
<td class="nump">$ 97,452<span></span>
</td>
<td class="nump">$ 83,393<span></span>
</td>
<td class="nump">$ 252,269<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income (loss) per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="nump">$ 0.32<span></span>
</td>
<td class="nump">$ 0.27<span></span>
</td>
<td class="nump">$ 0.84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="nump">$ 0.31<span></span>
</td>
<td class="nump">$ 0.26<span></span>
</td>
<td class="nump">$ 0.80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted-average common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">309,116<span></span>
</td>
<td class="nump">303,268<span></span>
</td>
<td class="nump">307,437<span></span>
</td>
<td class="nump">301,999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">309,116<span></span>
</td>
<td class="nump">315,453<span></span>
</td>
<td class="nump">317,495<span></span>
</td>
<td class="nump">315,046<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">$ 168,587<span></span>
</td>
<td class="nump">$ 191,768<span></span>
</td>
<td class="nump">$ 541,197<span></span>
</td>
<td class="nump">$ 565,024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">33,205<span></span>
</td>
<td class="nump">69,137<span></span>
</td>
<td class="nump">113,318<span></span>
</td>
<td class="nump">132,443<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Revenue not from contract with customer</a></td>
<td class="nump">$ 29,300<span></span>
</td>
<td class="nump">$ 10,798<span></span>
</td>
<td class="nump">$ 62,971<span></span>
</td>
<td class="nump">$ 29,998<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueNotFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue that is not accounted for under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueNotFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139923437005864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income (Loss) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (32,040)<span></span>
</td>
<td class="nump">$ 97,452<span></span>
</td>
<td class="nump">$ 83,393<span></span>
</td>
<td class="nump">$ 252,269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized gains (losses) on available-for-sale debt securities, net of tax impact of $453, $(129), $(893) and $(936), respectively</a></td>
<td class="num">(1,601)<span></span>
</td>
<td class="nump">461<span></span>
</td>
<td class="nump">3,170<span></span>
</td>
<td class="nump">3,369<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss)</a></td>
<td class="num">$ (33,641)<span></span>
</td>
<td class="nump">$ 97,913<span></span>
</td>
<td class="nump">$ 86,563<span></span>
</td>
<td class="nump">$ 255,638<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139923432494504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax', window );">Net unrealized gains (losses) on available-for-sale debt securities, net of tax impact of $453, $(129), $(893) and $(936), respectively</a></td>
<td class="nump">$ 453<span></span>
</td>
<td class="num">$ (129)<span></span>
</td>
<td class="num">$ (893)<span></span>
</td>
<td class="num">$ (936)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139923510577304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 28, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">299,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 28, 2018</a></td>
<td class="nump">$ 1,287,453<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 2,168,217<span></span>
</td>
<td class="num">$ (701)<span></span>
</td>
<td class="num">$ (880,363)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">252,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">252,269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">3,369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans</a></td>
<td class="nump">23,248<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">23,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Stock transactions associated with taxes withheld on equity awards</a></td>
<td class="num">(3,369)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,369)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">40,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 27, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">303,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 27, 2019</a></td>
<td class="nump">1,603,717<span></span>
</td>
<td class="nump">$ 304<span></span>
</td>
<td class="nump">2,228,839<span></span>
</td>
<td class="nump">2,668<span></span>
</td>
<td class="num">(628,094)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Jun. 28, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">302,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Jun. 28, 2019</a></td>
<td class="nump">1,488,632<span></span>
</td>
<td class="nump">$ 303<span></span>
</td>
<td class="nump">2,211,668<span></span>
</td>
<td class="nump">2,207<span></span>
</td>
<td class="num">(725,546)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">97,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,452<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans</a></td>
<td class="nump">4,968<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">4,967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Stock transactions associated with taxes withheld on equity awards</a></td>
<td class="num">(935)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(935)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">13,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 27, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">303,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 27, 2019</a></td>
<td class="nump">$ 1,603,717<span></span>
</td>
<td class="nump">$ 304<span></span>
</td>
<td class="nump">2,228,839<span></span>
</td>
<td class="nump">2,668<span></span>
</td>
<td class="num">(628,094)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Jan. 03, 2020</a></td>
<td class="nump">304,831<span></span>
</td>
<td class="nump">304,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Jan. 03, 2020</a></td>
<td class="nump">$ 1,685,970<span></span>
</td>
<td class="nump">$ 305<span></span>
</td>
<td class="nump">2,241,947<span></span>
</td>
<td class="nump">3,069<span></span>
</td>
<td class="num">(559,351)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">83,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,393<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">3,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans</a></td>
<td class="nump">19,827<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">19,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Stock transactions associated with taxes withheld on equity awards</a></td>
<td class="num">(26,120)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26,120)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 85,791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Oct. 02, 2020</a></td>
<td class="nump">309,402<span></span>
</td>
<td class="nump">309,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Oct. 02, 2020</a></td>
<td class="nump">$ 1,852,031<span></span>
</td>
<td class="nump">$ 309<span></span>
</td>
<td class="nump">2,321,441<span></span>
</td>
<td class="nump">6,239<span></span>
</td>
<td class="num">(475,958)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Jul. 03, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">308,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Jul. 03, 2020</a></td>
<td class="nump">1,833,324<span></span>
</td>
<td class="nump">$ 309<span></span>
</td>
<td class="nump">2,269,093<span></span>
</td>
<td class="nump">7,840<span></span>
</td>
<td class="num">(443,918)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(32,040)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32,040)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">(1,601)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,601)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans</a></td>
<td class="nump">1,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Stock transactions associated with taxes withheld on equity awards</a></td>
<td class="num">(5,179)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,179)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 55,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Oct. 02, 2020</a></td>
<td class="nump">309,402<span></span>
</td>
<td class="nump">309,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Oct. 02, 2020</a></td>
<td class="nump">$ 1,852,031<span></span>
</td>
<td class="nump">$ 309<span></span>
</td>
<td class="nump">$ 2,321,441<span></span>
</td>
<td class="nump">$ 6,239<span></span>
</td>
<td class="num">$ (475,958)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139923516983176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 83,393<span></span>
</td>
<td class="nump">$ 252,269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation</a></td>
<td class="nump">6,731<span></span>
</td>
<td class="nump">6,088<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">85,791<span></span>
</td>
<td class="nump">40,747<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_NoncashLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">3,607<span></span>
</td>
<td class="nump">1,803<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred taxes</a></td>
<td class="nump">15,803<span></span>
</td>
<td class="nump">56,339<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other, net</a></td>
<td class="nump">1,609<span></span>
</td>
<td class="num">(621)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Trade receivables, net</a></td>
<td class="num">(47,074)<span></span>
</td>
<td class="num">(7,017)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(13,466)<span></span>
</td>
<td class="num">(3,528)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(15,868)<span></span>
</td>
<td class="num">(14,108)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">4,012<span></span>
</td>
<td class="nump">3,592<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable and other liabilities</a></td>
<td class="nump">51,151<span></span>
</td>
<td class="nump">33,371<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">175,689<span></span>
</td>
<td class="nump">368,935<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, equipment and other</a></td>
<td class="num">(16,055)<span></span>
</td>
<td class="num">(5,575)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(866,975)<span></span>
</td>
<td class="num">(887,698)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Proceeds from maturities and sales of investments</a></td>
<td class="nump">781,324<span></span>
</td>
<td class="nump">436,227<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(101,706)<span></span>
</td>
<td class="num">(457,046)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from issuance of common stock under equity incentive and stock purchase plans</a></td>
<td class="nump">19,682<span></span>
</td>
<td class="nump">18,956<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="num">(26,120)<span></span>
</td>
<td class="num">(3,369)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(6,438)<span></span>
</td>
<td class="nump">15,553<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">67,545<span></span>
</td>
<td class="num">(72,558)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">268,137<span></span>
</td>
<td class="nump">315,875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">335,682<span></span>
</td>
<td class="nump">243,317<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow disclosure:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability', window );">Right-of-use assets obtained in exchange for lease obligations</a></td>
<td class="nump">1,824<span></span>
</td>
<td class="nump">12,944<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Unpaid liabilities incurred for purchases of property and equipment</a></td>
<td class="nump">843<span></span>
</td>
<td class="nump">159<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LiabilitiesExpendituresIncurredButNotYetPaidToRelatedPartyTransactions', window );">Unpaid liabilities incurred to acquire investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 8,961<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LiabilitiesExpendituresIncurredButNotYetPaidToRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liabilities Expenditures Incurred But Not Yet Paid To Related Party Transactions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LiabilitiesExpendituresIncurredButNotYetPaidToRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_NoncashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash Lease Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_NoncashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right-Of-Use Asset Obtained In Exchange For Lease Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RightOfUseAssetObtainedInExchangeForLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139923430300104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 02, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Organization</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exelixis, Inc. (Exelixis, we, our or us) is an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our drug discovery and development capabilities and commercialization platform are the foundations upon which we intend to bring to market novel, effective and tolerable therapies to provide cancer patients with additional treatment options.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since we were founded in 1994, four products resulting from our discovery efforts&#160;have progressed through clinical development, received regulatory approval and established a commercial presence in various geographies around the world. Two are derived from cabozantinib, our flagship molecule, an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. Our cabozantinib products are: CABOMETYX&#174; (cabozantinib) tablets approved for advanced renal cell carcinoma (RCC) and previously treated hepatocellular carcinoma; and COMETRIQ&#174;&#160;(cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer. For these types of cancer, cabozantinib has become or is becoming a standard of care. Beyond these approved indications, cabozantinib is currently the focus of a broad clinical development program and is being investigated both alone and in combination with other therapies in a wide variety of cancers.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other two products resulting from our discovery efforts are: COTELLIC&#174; (cobimetinib), an inhibitor of MEK, approved as part of multiple combination regimens to treat specific forms of advanced melanoma and marketed under a collaboration with Genentech, Inc. (a member of the Roche Group) (Genentech); and MINNEBRO&#174; (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor, approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo Company, Limited (Daiichi Sankyo).</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also remain committed to building our product pipeline by discovering and developing new therapies for cancer patients. Using our in-house drug discovery expertise, specifically in medicinal chemistry, tumor biology and pharmacology, we are advancing small molecule drug candidates toward and through preclinical development. In addition, we have augmented our internal drug discovery activities with multiple partnerships, including several that enable us to discover and advance various biologics, such as bispecific antibodies and antibody-drug conjugates (ADCs), and we continue to engage in business development initiatives aimed at identifying and in-licensing promising, early-stage oncology assets, which we can further develop utilizing our established clinical development infrastructure.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&#8217; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of our financial statements for the periods presented have been included. Operating results for the three and nine months ended September&#160;30, 2020 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2020 or for any future period. The accompanying Condensed Consolidated Financial Statements and Notes thereto should be read in conjunction with our Consolidated Financial Statements and Notes thereto for the year ended December&#160;31, 2019, included in our Annual Report on Form 10-K filed with the SEC on February&#160;25, 2020.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Fiscal year 2020, which is a 52-week fiscal year, will end on January 1, 2021 and fiscal year 2019, which was a 53-week fiscal year, ended on January 3, 2020. For convenience, references in this report as of and for the fiscal periods ended October 2, 2020 and September 27, 2019, and as of and for the fiscal years ending January 1, 2021, and ended January 3, 2020, are indicated as being as of and for the fiscal periods ended September 30, 2020 and September 30, 2019 and the years ending </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2020 and ended December&#160;31, 2019, respectively. Similarly, references in this report to the first day of the fiscal year ending January 1, 2021 are indicated as being as of January 1, 2020.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior period amounts in the accompanying Condensed Consolidated Financial Statements have been reclassified to conform to the current period presentation. Such reclassifications did not impact previously reported total revenues, income from operations, net income, total assets, total liabilities or total stockholders&#8217; equity.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in one business segment that focuses on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our long-lived assets are located in the U.S. See &#8220;Note 2. Revenues&#8221; for enterprise-wide disclosures about product sales, revenues from major customers and revenues by geographic region.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the accompanying Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, we received the Preliminary Calculation of our Branded Prescription Drug Fee for 2020, and in August 2020, the Final Calculation of our Branded Prescription Drug Fee for 2020 from the Internal Revenue Service for the 2018 sales year, which resulted in an increase in our estimate of such fees for the 2018 and 2019 sales years. Accordingly, we recorded an adjustment to increase selling, general and administrative expenses and our accrual for these fees by</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $5.1&#160;million du</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ring t</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he nine months ended September 30, 2020. This adjustment resulted in a $0.02 decrease in basic and diluted earnings per share for the nine months ended September&#160;30, 2020.</span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2020, we adopted Accounting Standards Update (ASU) No.&#160;201</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8-18,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2018-18). ASU 2018-18 clarifies that certain transactions between collaborative arrangement participants should be accounted for as part of revenues under Accounting Standards Codification (ASC) Topic 606,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 606) when the counterparty is a customer for a distinct good or service (i.e. a unit of account). For units of account that are in the scope of Topic 606, all of the guidance in Topic 606 should be applied, including the guidance on recognition, measurement, presentation and disclosure. ASU 2018-18 precludes entities from presenting amounts related to transactions with a counterparty in a collaborative arrangement that is not a customer together with revenue from contracts with customers. If a portion of a distinct bundle of goods or services within an arrangement is not with a customer, then the unit of account is not within the scope of Topic 606, and the recognition and measurement of that unit of account shall be based on analogy to authoritative accounting literature or, if there is no appropriate analogy, a reasonable, rational, and consistently applied accounting policy election. Upon adoption of ASU 2018-18, we have presented revenues from performance obligations associated with our collaboration arrangements that are within the scope of Topic 606 (license revenues) separately from revenues from performance obligations that are not subject to Topic 606 (collaboration services revenues). The adoption of ASU 2018-18 was applied retrospectively, and prior periods have been restated to conform to the presentation prescribed by ASU 2018-18. The adoption of ASU 2018-18 did not impact total revenues for the prior period presented in the accompanying Condensed Consolidated Statements of Income. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2020, we adopted ASU No.&#160;2017-04,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Intangibles&#8212;Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2017-04)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ASU 2017-04 simplifies goodwill impairment testing by eliminating the second </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">step of the impairment test. The amended guidance requires an impairment charge to be recognized for the amount by which the carrying amount of a reporting unit exceeds its fair value under a one-step impairment test. The adoption of ASU 2017-04 did not impact the accompanying Condensed Consolidated Financial Statements.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2020, we adopted ASU No.&#160;2016-13,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Financial Instruments&#8212;Credit Losses (Topic 326) </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASU 2016-13)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2016-13 implements an impairment model, known as the current expected credit loss model, that is based on expected losses rather than incurred losses. Under the new guidance, we will recognize our estimate of current expected credit losses as an allowance on financial assets measured at amortized cost, including accounts receivable, unbilled collaboration revenues, and investments classified as available for sale. Current expected credit losses were immaterial as of the date of adoption, and the adoption of ASU 2016-13 did not have a significant impact on the accompanying Condensed Consolidated Financial Statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investment Impairment</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quarterly, we assess each of our investments in debt securities available-for-sale whose fair value is below its cost basis to determine if the investment&#8217;s impairment is due to credit-related factors or noncredit-related factors. Factors considered in determining whether an impairment is credit-related include the extent to which the investment&#8217;s fair value is less than its cost basis, declines in published credit ratings, issuer default on interest or principal payments, and declines in the financial condition and near-term prospects of the issuer. If we determine a credit-related impairment exists, we will measure the credit loss based on a discounted cash flows model. Credit-related impairments on debt securities available-for-sale are recognized as an allowance for credit losses with a corresponding adjustment to other income, net in the accompanying Condensed Consolidated Statements of Income. The portion of the impairment that is not credit-related is recorded, net of applicable taxes, as a reduction of other comprehensive income.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected to exclude accrued interest from both the fair value and the amortized cost basis of debt securities available-for-sale for the purposes of identifying and measuring an impairment. We write-off accrued interest as a reduction of interest income when an issuer has defaulted on interest payments due on a security.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade receivables, net contain amounts billed to our customers for product sales, and amounts billed to our collaboration partners for development, regulatory and sales-based milestone payments, royalties on the sale of licensed products, profit-sharing arrangements, development cost reimbursements, and payments for product supply services. Our customers are primarily pharmaceutical and biotechnology companies that are located in the U.S., and collaboration partners that are located in Europe and Japan. As of September 30, 2020 and December 31, 2019, 47% and 38%, respectively, of our trade receivables were from our collaboration partner Ipsen Pharma SAS (Ipsen), and 12% and 14% were from affiliates of McKesson Corporation. We record trade receivables net of allowances for credit losses and chargebacks, and cash discounts for prompt payment. We apply an aging method to estimate credit losses and consider our historical loss information, adjusted to account for current conditions, and reasonable and supportable forecasts of future economic conditions affecting our customers.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded goodwill amounts as the excess purchase price over tangible assets, liabilities and intangible assets acquired based on their estimated fair value. We review the carrying amount of goodwill for impairment annually and whenever events or changes in circumstance indicate that the carrying value may not be recoverable. We perform our annual assessment of the recoverability of our goodwill as of the first day of our fourth quarter. The assessment of recoverability may first consider qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. We perform a quantitative assessment if the qualitative assessment results in a more likely than not determination or if a qualitative assessment is not performed. The quantitative assessment determines whether the carrying amount of a reporting unit exceeds its fair value, in which case an impairment charge is recognized for the amount by which the carrying amount of a reporting unit exceeds its fair value, limited to the goodwill balance. We operate in one business segment, which is also considered to be our sole reporting unit and therefore, goodwill is tested for impairment at the enterprise level. We did not recognize any impairment charges in any of the periods presented.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration Agreements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess whether our collaboration agreements are subject to ASC Topic 808,&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(Topic 808) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic&#160;808, we apply by analogy the unit of account guidance under Topic 606 to identify distinct performance obligations, and then determine whether a customer relationship exists for each distinct performance obligation. If we determine a performance obligation within the arrangement is with a customer, we apply the guidance in Topic 606. If a portion of a distinct bundle of goods or services within an arrangement is not with a customer, then the unit of account is not within the scope of Topic&#160;606, and the recognition and measurement of that unit of account shall be based on analogy to authoritative accounting literature or, if there is no appropriate analogy, a reasonable, rational, and consistently applied accounting policy election. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into collaboration arrangements, under which we license certain rights to our intellectual property to third parties. The terms of these arrangements typically include payments to us for one or more of the following: nonrefundable up-front license fees; development, regulatory and sales-based milestone payments; product supply services; development cost reimbursements; profit-sharing arrangements; and royalties on net sales of licensed products. As part of the accounting for these arrangements, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include forecasted revenues, clinical development timelines and costs, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Up-front License Fees: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from nonrefundable up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license, which generally occurs at or near the inception of the contract. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenues from nonrefundable up-front fees. We evaluate the measure of progress at the end of each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulatory and Development Milestone Payments: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of being achieved until uncertainty associated with the approvals has been resolved. The transaction price is then allocated to each performance obligation, on a relative standalone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achieving such development and regulatory milestones and any related variable consideration constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Supply Services:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Arrangements that include a promise for the future supply of drug product for either clinical development or commercial supply at the licensee&#8217;s discretion are generally considered as options. We assess if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Development Cost Reimbursements:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our collaboration arrangements may include promises of future clinical development and drug safety services, as well as participation on certain joint committees. When such services are provided to a customer, and they are distinct from the licenses provided to our collaboration partners, these promises are accounted for as a separate performance obligation which we estimate using internal development costs incurred and projections through the term of the arrangements. We record revenues for these services as the performance obligations are satisfied over time based on measure of progress. However, if we conclude that our collaboration partner is not a customer for those collaborative research and development activities, we present such payments as a reduction of research and development expenses.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Profit-sharing Arrangements: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of our collaboration agreement with Genentech for cobimetinib, we are entitled to a share of U.S. profits and losses received in connection with the commercialization of cobimetinib. We </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">account for this arrangement in accordance with Topic 606. We have determined that we are an agent under the agreement and therefore revenues are recorded net of costs incurred. We record revenues for the variable consideration associated with the profits and losses under the collaboration agreement when it is probable that a significant reversal in the amount of cumulative revenues recognized will not occur.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty and Sales-based Milestone Payments:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For arrangements that include royalties and sales-based milestone payments, including milestone payments earned for the first commercial sale of a product, the license is deemed to be the predominant item to which such payments relate and we recognize revenues at the later of when the related sales occur or when the performance obligation to which the royalty has been allocated has been satisfied.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Financial Accounting Standards Board issued&#160;ASU 2019-12,&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740)-Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2019-12). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in ASC Topic 740, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and clarifying and amending existing guidance. ASU 2019-12 will be effective for us in the first quarter of 2021 with early adoption permitted. We are currently assessing the impact of ASU 2019-12 on our financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139923431754024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 02, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">REVENUES</a></td>
<td class="text">REVENUES<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.715%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product revenues</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239,916&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">702,865&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">704,084&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounts and allowances</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,814)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48,148)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(161,668)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(139,060)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,587&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,768&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541,197&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565,024&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,318&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,443&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,798&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,971&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,505&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,935&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,289&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,441&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,092&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,703&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717,486&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727,465&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues and license revenues are recorded in accordance with Topic 606. License revenues include the recognition of the portion of milestones payments allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the milestone would be achieved and a significant reversal of revenues would not occur, as well as royalty revenues and our share of profits under our collaboration agreement with Genentech. Collaboration services revenues were recorded in accordance with Topic 808 and by analogy to Topic 606. Collaboration services revenues include the recognition of deferred revenues for the portion of upfront and milestone payments allocated to our research and development services performance obligations, development cost reimbursements earned under our collaboration agreements, product supply revenues, net of product supply costs, and the royalties we paid to GlaxoSmithKline (GSK) on sales of products containing cabozantinib by our collaboration partners.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues by product were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.715%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CABOMETYX</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,555&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,410&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522,381&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">552,315&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COMETRIQ</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,032&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,816&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,709&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,587&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,768&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541,197&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565,024&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The percentage of total revenues by customer who individually accounted for&#160;10%&#160;or more of our total revenues were as follows:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ipsen</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of CVS Health Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of McKesson Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of AmerisourceBergen Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of Optum Specialty Pharmacy</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Takeda Pharmaceutical Company Limited (Takeda)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by geographic region were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,552&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194,484&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549,379&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572,957&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,006&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,017&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,959&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,092&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,703&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717,486&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727,465&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues are attributed to geographic region based on the ship-to location. License and collaboration services revenues are attributed to geographic region based on the location of our collaboration partners&#8217; headquarters.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Sales Discounts and Allowances</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.742%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Chargebacks and Discounts for Prompt Payment</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Customer Credits/Fees and Co-pay Assistance</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Rebates</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2019</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,514&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,497&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,222&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,233&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to sales made in:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,718&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,235&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(352)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">752&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and customer credits issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107,118)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,513)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,546)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(160,177)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September&#160;30, 2020</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,595&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,350&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,779&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,724&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowance for chargebacks and discounts for prompt payment is recorded as a reduction of trade receivables, net and the remaining reserves are recorded as rebates and fees due to customers in the accompanying Condensed Consolidated Balance Sheets. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Assets and Liabilities </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive payments from our collaboration partners based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. We may also recognize revenues in advance of the contractual billing schedule and such amounts are recorded, net of any allowance for credit losses, as a contract asset when recognized. Contract assets, which are presented in prepaid expenses and other current assets in the accompanying Condensed Consolidated Balance Sheets, we</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">re $0 and&#160;$1.1 million</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;as of&#160;September&#160;30, 2020 and December&#160;31, 2019, respectively. We may be required to defer recognition of revenues for upfront and milestone payments until we perform our obligations under these arrangements, and such amounts are recorded as deferred revenues upon receipt or when due. Contract liabilities we</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">re $10.6 million and&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$6.6 million&#160;as of&#160;September&#160;30, 2020 and </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2019, respectively. The current portion of th</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e contract liabilities totaling $1.3 million and $0 as of&#160;September&#160;30, 2020 and December&#160;31, 2019, respectively, are presented in other current liabilities and the remainder of the contract liabilities are presented in long-term portion of deferred revenues as of those dates in the accompanyi</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ng Condensed Consolidated Balance Sheets. For those contracts that have multiple performance obligations, contract&#160;assets and liabilities are reported on a&#160;net&#160;basis&#160;at the&#160;contract&#160;level. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant changes in contract assets during the nine months ended September&#160;30, 2020 include the impact of a $20.0 million development milestone from Ipsen we determined was probable of achievement, which was offset by the impact of a $10.0 million milestone from Takeda which was recognized as revenues during the year ended December 31, 2019 and was achieved, invoiced and collected in the first quarter of 2020.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2020 and 2019, we recognized $6.8 million and $2.7 million, respectively, in revenues that were included in the beginning deferred revenues balance for those periods.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2020, we recognized $33.1 million and $115.3 million, respectively, in revenues for performance obligations satisfied in previous periods as compared to $67.7 million and $129.0 million during the comparable periods in 2019. Such revenues primarily related to milestone and royalty payments allocated to the license performance obligations for our collaborations with Ipsen, Takeda, Daiichi Sankyo and Genentech.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, $88.9 million of t</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he combined transaction prices for our Ipsen and Takeda collaborations were allocated to performance obligations that had not yet been satisfied. See &#8220;Note 3. Collaboration Agreements - Cabozantinib Commercial Collaborations - Performance Obligations and Transaction Prices for our Ipsen and Takeda Collaborations&#8221; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2019 for information about the expected timing to satisfy these performance obligations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139923433310232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 02, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">COLLABORATION AGREEMENTS</a></td>
<td class="text">COLLABORATION AGREEMENTS<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established multiple collaborations with leading pharmaceutical companies for the commercialization and further development of cabozantinib. Additionally, consistent with our business strategy prior to the commercialization of cabozantinib, we entered into other collaborations with leading pharmaceutical companies for other compounds and programs in our portfolio. Under these collaborations, we are generally entitled to receive milestone and royalty payments, and for certain collaborations receive payments for product supply services, development cost reimbursements, and/or profit-sharing payments. See &#8220;Note 2. Revenues&#8221; for additional information on revenues recognized under our collaboration agreements.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also established multiple collaborations with smaller, discovery-focused biotechnology companies to expand our product pipeline. Under these collaborations, we may be required to make milestone and royalty payments, and for certain collaborations make payments for development cost reimbursements and/or option exercise fees. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Note 3. Collaboration Agreements&#8221; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2019, or as further described below, for a description of each of our collaboration agreements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cabozantinib Collaborations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ipsen Collaboration </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In February 2016, we entered into a collaboration agreement with Ipsen for the commercialization and further development of cabozantinib. Under the terms of the collaboration agreement, as amended, Ipsen received exclusive commercialization rights for current and potential future cabozantinib indications outside of the U.S. and Japan. We have also agreed to collaborate with Ipsen on the development of cabozantinib for current and potential future indications. The parties&#8217; efforts are governed through a joint steering committee and appropriate subcommittees established to guide and oversee the collaboration&#8217;s operation and strategic direction; provided, however, that we retain final decision-making authority with respect to cabozantinib&#8217;s ongoing development. During the second quarter of 2020, Ipsen opted into and is now co-funding the development costs for CONTACT-01 and CONTACT-02, two phase 3 pivotal trials of cabozantinib in combination with atezolizumab in patients with previously treated, metastatic non-small cell lung cancer and metastatic castration-resistant prostate cancer, respectively, and the four remaining cohorts of COSMIC-021 it had not previously opted into. COSMIC-021 is a broad phase 1b study evaluating the safety and tolerability of cabozantinib in combination with atezolizumab in patients with locally advanced or metastatic solid tumors.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under the collaboration agreement with Ipsen were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,910&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,409&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,456&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,318&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,096&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,607&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,503&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,815&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,006&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,016&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,959&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,133&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2020, we are eligible to receive additional regulatory and development milestone payments from Ipsen totaling an aggregate of $59.0 million, as well as sales-based milestones, including milestone payments earned for the first commercial sale of a product, of up to $469.9 million. We excluded these milestones from the transaction price as of September 30, 2020 because we determined such payments to be fully constrained under Topic 606 due to the fact that it was not probable that a significant reversal of cumulative revenue would not occur, given the inherent uncertainty of success with these milestones. We will re-evaluate the transaction price at each reporting period and as uncertain events are resolved or other changes in circumstances occur. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, $42.6 million of the tr</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ansaction price was allocated to our research and development services performance obligation that has not yet been satisfied.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, we entered into a collaboration agreement with Takeda. Under this collaboration agreement, as amended, Takeda has exclusive commercialization rights for current and potential future cabozantinib indications in Japan, and the parties have agreed to collaborate on the clinical development of cabozantinib in Japan. The operation and strategic direction of the parties&#8217; collaboration is governed through a joint executive committee and appropriate subcommittees.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under the collaboration agreement with Takeda were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,780&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,726&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,056&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,468&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,189&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,984&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,187&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,194&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestone revenues for the three and nine months ended September&#160;30, 2020 included $9.2&#160;million in revenues recognized in connection with a $10.0&#160;million milestone we expect to achieve upon Takeda&#8217;s and Ono Pharmaceutical Co., Ltd.&#8217;s supplemental application to the Japanese Ministry of Health, Labour and Welfare for Manufacturing and Marketing Approval of CABOMETYX in combination with Opdivo for the treatment of patients with unresectable, advanced or metastatic RCC. At September 30, 2020, we have not yet received this milestone payment.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2020, Takeda opted into and is now co-funding the development costs for CONTACT-01, CONTACT-02 and certain cohorts of COSMIC-021. Concurrently, we entered into the third amendment to the collaboration agreement with Takeda (the Amendment), which modified certain cost sharing obligations related to the Japan-specific development costs associated with CONTACT-01 and CONTACT-02. We determined the Amendment represented a contract modification that was treated as a termination of an existing contract and the creation of a new contract under Topic 606. As a result, we allocated the remaining transaction price to the performance obligations identified in the contract. The two remaining performance obligations are the research and development services associated with committed studies described in &#8220;Note 3. Collaboration Agreements&#8221; of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, and the research and development services associated with CONTACT-01, CONTACT-02, and certain cohorts of COSMIC-021 studies. In allocating the transaction price for the modified contract we estimated the standalone selling price for the performance obligations. We utilized development costs incurred for these obligations in process and the projections of costs through the term of the arrangement. Revenue is recognized when, or as, we satisfy our performance obligations by transferring the promised services to Takeda. Revenue is being recognized using the cost proportional performance method, based on costs incurred to perform the research and development services, since the level of costs incurred over time is thought to best reflect the transfer of services to Takeda.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are eligible to receive additional regulatory and development milestone payments, without contractual limit, for additional potential future indications. We are further eligible to receive sales-based milestones, including milestone payments earned for the first commercial sale of a product, of up to $124.0&#160;million. We excluded these milestones from the transaction price as of September 30, 2020 because we determined such payments to be fully constrained under Topic 606 due to the fact that it was not probable that a significant reversal of cumulative revenue would not occur, given the inherent uncertainty of success with these milestones. We will re-evaluate the transaction price at each reporting period and as uncertain events are resolved or other changes in circumstances occur. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, $46.3 million of the trans</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">action price was allocated to our research and development services performance obligations that has not yet been satisfied. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">GSK</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2002, we established a product development and commercialization collaboration agreement with GSK. We are required to pay a 3% royalty to GSK on the net sales of any product incorporating cabozantinib by us and our collaboration partners. Royalties earned by GSK in connection with the sales of cabozantinib are included in cost of goods sold for sales by us and as a reduction of collaboration services revenues for sales by our collaboration partners. Such royalties were $7.9 million and $23.7 million during the three and nine months ended September&#160;30, 2020, respectively, as compared to $8.0 million and $23.1 million during the comparable periods in 2019. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Genentech Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2006, we out-licensed the development and commercialization of cobimetinib to Genentech under a worldwide collaboration agreement. In&#160;November&#160;2015, the U.S. Food and Drug Administration (FDA) approved cobimetinib, under the brand name COTELLIC, in combination with Genentech&#8217;s ZELBORAF&#174;  (vemurafenib) for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma. COTELLIC in combination with ZELBORAF has also been approved in the European Union and multiple additional countries for use in the same indication. In July 2020, the FDA also approved COTELLIC for use in combination with ZELBORAF and TECENTRIQ&#174; (atezolizumab) for the treatment of patients with BRAF V600 mutation-positive advanced melanoma in previously untreated patients. License revenues under the collaboration agreement with Genentech were as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.849%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.981%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.750%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.424%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.750%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.015%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.460%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Profits on U.S. commercialization</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,595&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,102&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,378&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,507&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenues on ex-U.S. sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,804&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,426&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">In-Licensing Collaborations </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC, Catalent Pharma Solution LLC Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we entered into a collaboration and license agreement with Catalent, Inc.&#8217;s wholly owned subsidiaries Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC and Catalent Pharma Solutions, Inc., (individually and collectively referred to as Catalent). Under the terms of the agreement, we made an upfront payment of $10.0&#160;million in exchange to nominate and have the exclusive option to license four targets using Catalent&#8217;s ADC platform over a three-year period. In addition, we have a right to extend the target selection term to five years and nominate up to two additional targets for an additional payment of $4.0&#160;million. We will also contribute research funding to Catalent for discovery and preclinical development work. For each option we decide to exercise, we will pay an exercise fee of $2.0&#160;million, and would assume responsibilities for all subsequent clinical development, commercialization and global manufacturing of that program. Catalent would then become eligible to receive up to $44.0&#160;million per compound in potential development milestone payments, $60.0&#160;million per product in potential commercial milestone payments, as well as royalties on potential sales.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NBE Therapeutics AG (NBE) Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we entered into a collaboration and license agreement with NBE. Under the terms of the agreement, we made an upfront payment of $25.0&#160;million in exchange for exclusive options to nominate four targets using NBE&#8217;s ADC platform over a two-year period. In addition, within the first eighteen months of the agreement, we also have a right to extend the target selection term to three years for an additional payment of $2.0&#160;million. We will also contribute research funding to NBE for discovery and preclinical development work. For each option we decide to exercise, we will be </span></div>required to pay an exercise fee of $10.0&#160;million, and would assume responsibilities for all subsequent clinical development, commercialization and global manufacturing of that program. NBE would then become eligible to receive up to $90.0&#160;million per program in potential development milestone payments, $135.0&#160;million per program in potential commercial milestone payments, as well as royalties on potential sales.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139923431702824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 02, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsAndInvestmentsTextBlock', window );">CASH AND INVESTMENTS</a></td>
<td class="text">CASH AND INVESTMENTS<div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash Equivalents </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334,046&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,501&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash equivalents included in long-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,636&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,636&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335,682&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268,137&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash equivalents consisted of certificates of deposit with original maturities of 90 days or less used to collateralize letters of credit. The long-term classification of restricted cash equivalents is based upon the remaining term of the underlying restriction.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Investments</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and investments consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466,141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466,366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">629,309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,526&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636,815&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,449&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,793&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,326&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,431&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,329,225&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,210&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,337,405&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,979&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,979&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,583&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,537,779&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,211&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,545,960&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389,573&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389,573&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">752,295&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,934&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">756,226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,483&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,308,351&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,121&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,312,464&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,964&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,964&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,728&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,384,510&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,126&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,388,628&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest receivable was $4.5 million and $6.2 million as of September&#160;30, 2020 and December&#160;31, 2019, respectively, and is included in prepaid expenses and other current assets in the accompanying Condensed Consolidated Balance Sheets.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains and losses on the sales of investments were insignificant during the three and nine months ended September&#160;30, 2020 and 2019.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage credit risk associated with our investment portfolio through our investment policy, which limits purchases to high-quality issuers and limits the amount of our portfolio that can be invested in a single issuer. The fair value and gross unrealized losses on debt securities available-for-sale in an unrealized loss position were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.459%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.822%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.824%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,627&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,465&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,092&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.459%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.822%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.824%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,529&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,848&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,377&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All securities presented have been in an unrealized loss position less than 12 months. There were 16 and 9 investments in an unrealized loss position as of September&#160;30, 2020 and December&#160;31, 2019, respectively. During the nine months ended September&#160;30, 2020 and 2019, we did not record an allowance for credit losses or other impairment charges on our investment securities. Based upon our quarterly impairment review, we determined that the unrealized losses were not attributed to credit risk but were primarily associated with changes in interest rates and market liquidity. Based on the scheduled maturities of our investments, we determined that it was more likely than not that we will hold these investments for a period of time sufficient for a recovery of our cost basis.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of debt securities available-for-sale by contractual maturity was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993,211&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">789,913&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344,194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522,551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,337,405&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,312,464&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsAndInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, and Investments [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsAndInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139923520549128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 02, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value reflects the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy has the following three levels:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Level 1 -&#160;quoted prices (unadjusted) in active markets for identical assets and liabilities;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Level 2 -&#160;inputs other than level 1 that are observable either directly or indirectly, such as quoted prices in active markets for similar instruments or on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Level 3 -&#160;unobservable inputs that are supported by little or no market activity that are significant to the fair value measurement</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466,366&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466,366&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636,815&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636,815&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,793&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,793&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,337,405&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,337,405&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,992&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,392,989&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,489,981&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389,573&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389,573&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">756,226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">756,226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,665&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,665&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,312,464&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,312,464&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,467&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,345,197&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,347,664&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When available, we value investments based on quoted prices for those financial instruments, which is a Level 1 input. Our remaining investments are valued using third-party pricing sources, which use observable market prices, interest rates and yield curves observable at commonly quoted intervals for similar assets as observable inputs for pricing, which is a Level 2 input.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of our remaining financial assets and liabilities, which include cash, receivables and payables, approximate their fair values due to their short-term nature.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139923437195384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 02, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORY</a></td>
<td class="text">INVENTORY<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,298&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,709&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,535&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,744&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,523&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet classification:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion included in inventory</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion included in other long-term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,425&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,637&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,744&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,523&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Write-downs related to excess and expiring inventory were $2.2 million and $0.4 million for the nine months ended September&#160;30, 2020 and 2019, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139923430110136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 02, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text">STOCK-BASED COMPENSATION<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated the stock-based compensation expense for our equity incentive plans and our 2000 Employee Stock Purchase Plan (ESPP) as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,936&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,301&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,134&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,745&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,838&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,002&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,655&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,139&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,791&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,747&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 16,900,406 sh</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ares were available for grant under the Exelixis, Inc. 2017 Equity Incentive Plan (as amended and restated, the 2017 Plan). The share reserve is reduced by 1 share for each share issued pursuant to a stock option or stock appreciation award and 1.5 shares for full value awards granted in the form of restricted stock units (RSUs). On May&#160;20, 2020, at our 2020 Annual Meeting of Stockholders, our stockholders approved the amendment and restatement of the 2017 Plan. The amendment and restatement increased the share reserve under the 2017 Plan by 21,000,000 shares, subject to adjustment for certain changes in our capitalization, which became effective immediately upon stockholder approval.&#160;</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2020, we granted 1,189,888 stock options with a weighted average exercise price of $21.84 per share and a weighted average grant&#160;date fair&#160;value of $9.61</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> per s</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hare. As of September&#160;30, 2020, there were 16,219,326 stock options outstanding and $28.4 million unrecognized compensation expense. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2020, we granted 2,813,888 service-based RSUs with a weighted average grant&#160;date fair&#160;value of $23.56 per share. As of September&#160;30, 2020, there were 6,554,909 RSUs outstanding and $111.9 million unrecognized compensation expense.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options and RSUs granted to employees during the nine months ended September&#160;30, 2020 have vesting conditions and contractual lives of a similar nature to those described in &#8220;Note 8. Employee Benefit Plans&#8221; of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year ended </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2018, in connection with our long-term incentive compensation program, we granted 308,365 performance-based stock options (PSOs) to our President and Chief Executive Officer. In addition to the standard service-based vesting conditions included in our other stock options, these PSOs contain a market vesting condition such that they may not be exercised until, at any time after the grant date, the closing market price of our Common Stock is equal to or greater than 125% of the per share exercise price of the PSOs over a period of at least 30 consecutive calendar days. This market vesting condition was achieved during the three months ended June&#160;30, 2020. The stock-based compensation expense for the PSOs is being recognized on an accelerated basis over the service period of the award, which commenced on the date of grant. The achievement of the market vesting condition did not impact the compensation expense recognized during the period.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of&#160;September&#160;30, 2020, there were&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,186,977</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> performance-based restricted stock units (PSUs) outstanding with $129.7 million in related unrecognized compensation expense. Expense recognition for PSUs commences when it is determined that achievement of the performance target is probable. Of the outstanding PSUs, 188,624 relate to awards for which we achieved the performance target during 2019 or had determined during 2019 that it was probable that we would achieve the performance target during 2020. During 2020, we determined that it had become probable that we would achieve additional performance targets for 2,947,563 additional PSUs granted during 2018 and 2019. Total stock-based compensation expense for PSUs was $41.2 million and $43.2 million during the three and nine months ended September&#160;30, 2020, respectively. For more information about our PSUs, see &#8220;Note 8. Employee Benefit Plans&#8221; of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, in connection with our long-term incentive compensation program, we awarded 1,951,830 PSUs (the target amount) that will vest upon the achievement of certain performance targets related to clinical trial positive top-line results and product approvals by the FDA (the 2020 PSUs). Employees may earn up to 200% of the target amount or 3,903,660 shares, depending on the volume and the timing of achievement of the</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">performance targets. The 2020 PSUs </span></div>were designed to drive the performance of our management team and employees toward the achievement of key corporate objectives and will be forfeited if the performance targets are not met by December 31, 2024.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139923430022280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 02, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">INCOME TAXESOur effective income tax rate was 15.7% and 18.8% during the three and nine months ended September&#160;30, 2020, respectively, as compared to 20.5% and 19.4% for the comparable periods in 2019. The effective tax rate for the three and nine months ended September 30, 2020 differed from U.S. federal statutory tax rate of 21% primarily due to excess tax benefits related to the exercise of certain stock options and federal tax credits, offset by the non-deductible executive compensation during the periods. The effective tax rate for the three and nine months ended September&#160;30, 2019 differed from the U.S. federal statutory rate of&#160;21%&#160;primarily due to excess tax benefits related to the exercise of certain stock options and federal tax credits during the periods.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139923430110136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 02, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET INCOME (LOSS) PER SHARE</a></td>
<td class="text">NET INCOME (LOSS) PER SHARE<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss) per share - basic and diluted, were computed as follows (in thousands, except per share amounts):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,040)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252,269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding &#8212; basic</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309,116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303,268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301,999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,058&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,047&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding &#8212; diluted</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309,116&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315,453&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317,495&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315,046&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share &#8212; basic</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.10)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.32&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.27&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.84&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share &#8212; diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dilutive securities included stock options, RSUs, PSUs, PSOs and ESPP contributions.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain potential common shares were excluded from our calculation of weighted-average common shares outstanding - diluted because either they would have had an anti-dilutive effect on net income per share or they were related to shares from PSUs for which the contingent vesting condition had not been achieved. The weighted-average potential common shares excluded from our calculation were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive securities and contingently issuable shares excluded</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,033&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,153&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,224&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,740&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139923430208968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 02, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, we received a notice letter regarding an Abbreviated New Drug Application (ANDA) submitted to the FDA by MSN Pharmaceuticals, Inc. (MSN), requesting approval to market a generic version of CABOMETYX tablets.&#160;MSN&#8217;s initial notice letter included a Paragraph IV certification with respect to our&#160;U.S. Patent Nos.&#160;8,877,776, 9,724,342, 10,034,873 and 10,039,757, which are&#160;listed in the Approved Drug Products with Therapeutic Equivalence Evaluations, also referred to as the </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Orange Book.&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSN&#8217;s initial notice letter did not provide a Paragraph IV certification against U.S. Patent No. 7,579,473, the composition of matter patent, or U.S. Patent No. 8,497,284, a method of use patent. On October 29, 2019, we filed a complaint in the United States District Court for the District of Delaware for patent infringement against MSN asserting U.S. Patent No. 8,877,776 arising from MSN&#8217;s ANDA filing with the FDA. On November 20, 2019, MSN filed its response to the complaint, alleging that U.S. Patent No. 8,877,776 is invalid and not infringed. On May 5, 2020, we received notice from MSN that it had amended its ANDA to assert additional Paragraph IV certifications. The ANDA now requests approval to market a generic version of CABOMETYX tablets&#160;prior to&#160;expiration of the two previously-unasserted CABOMETYX patents: U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284.&#160;On May 11, 2020, we </span><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">filed a complaint in the United States District Court for the District of Delaware for patent infringement against MSN asserting U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284 arising from MSN&#8217;s amended ANDA filing with the FDA. On May 22, 2020, MSN filed its response to the complaint, alleging that each of U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284 is invalid and not infringed. Neither of our complaints alleges infringement of U.S. Patent Nos. 9,724,342, 10,034,873 and 10,039,757. In our complaints, we are seeking, among other relief, an order that the effective date of any FDA approval of the ANDA would be a date no earlier than the expiration of all of U.S. Patent No. 7,579,473, U.S. Patent No. 8,497,284 and U.S. Patent No. 8,877,776, the latest of which expires on October 8, 2030, and equitable relief enjoining MSN from infringing these patents. These two lawsuits against MSN have been consolidated, and a bench trial has been scheduled for May 2022. The sale of a generic version of CABOMETYX earlier than its patent expiration could significantly decrease our revenues and thereby materially harm our business, financial condition and results of operations. It is not possible at this time to determine the likelihood of an unfavorable outcome or estimate of the amount or range of any potential loss. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also from time to time become a party or subject to various other legal proceedings and claims, either asserted or unasserted, which arise in the ordinary course of business. Some of these proceedings have involved, and may involve in the future, claims that are subject to substantial uncertainties and unascertainable damages.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139923517079704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 02, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of Consolidation</a></td>
<td class="text">The accompanying Condensed Consolidated Financial Statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&#8217; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of our financial statements for the periods presented have been included. Operating results for the three and nine months ended September&#160;30, 2020 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2020 or for any future period. The accompanying Condensed Consolidated Financial Statements and Notes thereto should be read in conjunction with our Consolidated Financial Statements and Notes thereto for the year ended December&#160;31, 2019, included in our Annual Report on Form 10-K filed with the SEC on February&#160;25, 2020.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiscalPeriod', window );">Fiscal Period</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Fiscal year 2020, which is a 52-week fiscal year, will end on January 1, 2021 and fiscal year 2019, which was a 53-week fiscal year, ended on January 3, 2020. For convenience, references in this report as of and for the fiscal periods ended October 2, 2020 and September 27, 2019, and as of and for the fiscal years ending January 1, 2021, and ended January 3, 2020, are indicated as being as of and for the fiscal periods ended September 30, 2020 and September 30, 2019 and the years ending </span>December&#160;31, 2020 and ended December&#160;31, 2019, respectively. Similarly, references in this report to the first day of the fiscal year ending January 1, 2021 are indicated as being as of January 1, 2020.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text">Certain prior period amounts in the accompanying Condensed Consolidated Financial Statements have been reclassified to conform to the current period presentation. Such reclassifications did not impact previously reported total revenues, income from operations, net income, total assets, total liabilities or total stockholders&#8217; equity.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text">We operate in one business segment that focuses on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">The preparation of the accompanying Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.In March 2020, we received the Preliminary Calculation of our Branded Prescription Drug Fee for 2020, and in August 2020, the Final Calculation of our Branded Prescription Drug Fee for 2020 from the Internal Revenue Service for the 2018 sales year, which resulted in an increase in our estimate of such fees for the 2018 and 2019 sales years.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2020, we adopted Accounting Standards Update (ASU) No.&#160;201</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8-18,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2018-18). ASU 2018-18 clarifies that certain transactions between collaborative arrangement participants should be accounted for as part of revenues under Accounting Standards Codification (ASC) Topic 606,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 606) when the counterparty is a customer for a distinct good or service (i.e. a unit of account). For units of account that are in the scope of Topic 606, all of the guidance in Topic 606 should be applied, including the guidance on recognition, measurement, presentation and disclosure. ASU 2018-18 precludes entities from presenting amounts related to transactions with a counterparty in a collaborative arrangement that is not a customer together with revenue from contracts with customers. If a portion of a distinct bundle of goods or services within an arrangement is not with a customer, then the unit of account is not within the scope of Topic 606, and the recognition and measurement of that unit of account shall be based on analogy to authoritative accounting literature or, if there is no appropriate analogy, a reasonable, rational, and consistently applied accounting policy election. Upon adoption of ASU 2018-18, we have presented revenues from performance obligations associated with our collaboration arrangements that are within the scope of Topic 606 (license revenues) separately from revenues from performance obligations that are not subject to Topic 606 (collaboration services revenues). The adoption of ASU 2018-18 was applied retrospectively, and prior periods have been restated to conform to the presentation prescribed by ASU 2018-18. The adoption of ASU 2018-18 did not impact total revenues for the prior period presented in the accompanying Condensed Consolidated Statements of Income. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2020, we adopted ASU No.&#160;2017-04,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Intangibles&#8212;Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2017-04)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ASU 2017-04 simplifies goodwill impairment testing by eliminating the second </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">step of the impairment test. The amended guidance requires an impairment charge to be recognized for the amount by which the carrying amount of a reporting unit exceeds its fair value under a one-step impairment test. The adoption of ASU 2017-04 did not impact the accompanying Condensed Consolidated Financial Statements.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2020, we adopted ASU No.&#160;2016-13,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Financial Instruments&#8212;Credit Losses (Topic 326) </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASU 2016-13)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2016-13 implements an impairment model, known as the current expected credit loss model, that is based on expected losses rather than incurred losses. Under the new guidance, we will recognize our estimate of current expected credit losses as an allowance on financial assets measured at amortized cost, including accounts receivable, unbilled collaboration revenues, and investments classified as available for sale. Current expected credit losses were immaterial as of the date of adoption, and the adoption of ASU 2016-13 did not have a significant impact on the accompanying Condensed Consolidated Financial Statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investment Impairment</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quarterly, we assess each of our investments in debt securities available-for-sale whose fair value is below its cost basis to determine if the investment&#8217;s impairment is due to credit-related factors or noncredit-related factors. Factors considered in determining whether an impairment is credit-related include the extent to which the investment&#8217;s fair value is less than its cost basis, declines in published credit ratings, issuer default on interest or principal payments, and declines in the financial condition and near-term prospects of the issuer. If we determine a credit-related impairment exists, we will measure the credit loss based on a discounted cash flows model. Credit-related impairments on debt securities available-for-sale are recognized as an allowance for credit losses with a corresponding adjustment to other income, net in the accompanying Condensed Consolidated Statements of Income. The portion of the impairment that is not credit-related is recorded, net of applicable taxes, as a reduction of other comprehensive income.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected to exclude accrued interest from both the fair value and the amortized cost basis of debt securities available-for-sale for the purposes of identifying and measuring an impairment. We write-off accrued interest as a reduction of interest income when an issuer has defaulted on interest payments due on a security.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade receivables, net contain amounts billed to our customers for product sales, and amounts billed to our collaboration partners for development, regulatory and sales-based milestone payments, royalties on the sale of licensed products, profit-sharing arrangements, development cost reimbursements, and payments for product supply services. Our customers are primarily pharmaceutical and biotechnology companies that are located in the U.S., and collaboration partners that are located in Europe and Japan. As of September 30, 2020 and December 31, 2019, 47% and 38%, respectively, of our trade receivables were from our collaboration partner Ipsen Pharma SAS (Ipsen), and 12% and 14% were from affiliates of McKesson Corporation. We record trade receivables net of allowances for credit losses and chargebacks, and cash discounts for prompt payment. We apply an aging method to estimate credit losses and consider our historical loss information, adjusted to account for current conditions, and reasonable and supportable forecasts of future economic conditions affecting our customers.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded goodwill amounts as the excess purchase price over tangible assets, liabilities and intangible assets acquired based on their estimated fair value. We review the carrying amount of goodwill for impairment annually and whenever events or changes in circumstance indicate that the carrying value may not be recoverable. We perform our annual assessment of the recoverability of our goodwill as of the first day of our fourth quarter. The assessment of recoverability may first consider qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. We perform a quantitative assessment if the qualitative assessment results in a more likely than not determination or if a qualitative assessment is not performed. The quantitative assessment determines whether the carrying amount of a reporting unit exceeds its fair value, in which case an impairment charge is recognized for the amount by which the carrying amount of a reporting unit exceeds its fair value, limited to the goodwill balance. We operate in one business segment, which is also considered to be our sole reporting unit and therefore, goodwill is tested for impairment at the enterprise level. We did not recognize any impairment charges in any of the periods presented.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration Agreements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess whether our collaboration agreements are subject to ASC Topic 808,&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(Topic 808) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic&#160;808, we apply by analogy the unit of account guidance under Topic 606 to identify distinct performance obligations, and then determine whether a customer relationship exists for each distinct performance obligation. If we determine a performance obligation within the arrangement is with a customer, we apply the guidance in Topic 606. If a portion of a distinct bundle of goods or services within an arrangement is not with a customer, then the unit of account is not within the scope of Topic&#160;606, and the recognition and measurement of that unit of account shall be based on analogy to authoritative accounting literature or, if there is no appropriate analogy, a reasonable, rational, and consistently applied accounting policy election. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into collaboration arrangements, under which we license certain rights to our intellectual property to third parties. The terms of these arrangements typically include payments to us for one or more of the following: nonrefundable up-front license fees; development, regulatory and sales-based milestone payments; product supply services; development cost reimbursements; profit-sharing arrangements; and royalties on net sales of licensed products. As part of the accounting for these arrangements, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include forecasted revenues, clinical development timelines and costs, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Up-front License Fees: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from nonrefundable up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license, which generally occurs at or near the inception of the contract. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenues from nonrefundable up-front fees. We evaluate the measure of progress at the end of each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulatory and Development Milestone Payments: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of being achieved until uncertainty associated with the approvals has been resolved. The transaction price is then allocated to each performance obligation, on a relative standalone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achieving such development and regulatory milestones and any related variable consideration constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Supply Services:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Arrangements that include a promise for the future supply of drug product for either clinical development or commercial supply at the licensee&#8217;s discretion are generally considered as options. We assess if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Development Cost Reimbursements:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our collaboration arrangements may include promises of future clinical development and drug safety services, as well as participation on certain joint committees. When such services are provided to a customer, and they are distinct from the licenses provided to our collaboration partners, these promises are accounted for as a separate performance obligation which we estimate using internal development costs incurred and projections through the term of the arrangements. We record revenues for these services as the performance obligations are satisfied over time based on measure of progress. However, if we conclude that our collaboration partner is not a customer for those collaborative research and development activities, we present such payments as a reduction of research and development expenses.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Profit-sharing Arrangements: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of our collaboration agreement with Genentech for cobimetinib, we are entitled to a share of U.S. profits and losses received in connection with the commercialization of cobimetinib. We </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">account for this arrangement in accordance with Topic 606. We have determined that we are an agent under the agreement and therefore revenues are recorded net of costs incurred. We record revenues for the variable consideration associated with the profits and losses under the collaboration agreement when it is probable that a significant reversal in the amount of cumulative revenues recognized will not occur.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty and Sales-based Milestone Payments:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For arrangements that include royalties and sales-based milestone payments, including milestone payments earned for the first commercial sale of a product, the license is deemed to be the predominant item to which such payments relate and we recognize revenues at the later of when the related sales occur or when the performance obligation to which the royalty has been allocated has been satisfied.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Financial Accounting Standards Board issued&#160;ASU 2019-12,&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740)-Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2019-12). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in ASC Topic 740, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and clarifying and amending existing guidance. ASU 2019-12 will be effective for us in the first quarter of 2021 with early adoption permitted. We are currently assessing the impact of ASU 2019-12 on our financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenues</a></td>
<td class="text">Net product revenues and license revenues are recorded in accordance with Topic 606. License revenues include the recognition of the portion of milestones payments allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the milestone would be achieved and a significant reversal of revenues would not occur, as well as royalty revenues and our share of profits under our collaboration agreement with Genentech. Collaboration services revenues were recorded in accordance with Topic 808 and by analogy to Topic 606. Collaboration services revenues include the recognition of deferred revenues for the portion of upfront and milestone payments allocated to our research and development services performance obligations, development cost reimbursements earned under our collaboration agreements, product supply revenues, net of product supply costs, and the royalties we paid to GlaxoSmithKline (GSK) on sales of products containing cabozantinib by our collaboration partners.Net product revenues are attributed to geographic region based on the ship-to location. License and collaboration services revenues are attributed to geographic region based on the location of our collaboration partners&#8217; headquarters.<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowance for chargebacks and discounts for prompt payment is recorded as a reduction of trade receivables, net and the remaining reserves are recorded as rebates and fees due to customers in the accompanying Condensed Consolidated Balance Sheets. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Assets and Liabilities </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive payments from our collaboration partners based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. We may also recognize revenues in advance of the contractual billing schedule and such amounts are recorded, net of any allowance for credit losses, as a contract asset when recognized. Contract assets, which are presented in prepaid expenses and other current assets in the accompanying Condensed Consolidated Balance Sheets, we</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">re $0 and&#160;$1.1 million</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;as of&#160;September&#160;30, 2020 and December&#160;31, 2019, respectively. We may be required to defer recognition of revenues for upfront and milestone payments until we perform our obligations under these arrangements, and such amounts are recorded as deferred revenues upon receipt or when due. Contract liabilities we</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">re $10.6 million and&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$6.6 million&#160;as of&#160;September&#160;30, 2020 and </span></div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2019, respectively. The current portion of th</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e contract liabilities totaling $1.3 million and $0 as of&#160;September&#160;30, 2020 and December&#160;31, 2019, respectively, are presented in other current liabilities and the remainder of the contract liabilities are presented in long-term portion of deferred revenues as of those dates in the accompanyi</span>ng Condensed Consolidated Balance Sheets. For those contracts that have multiple performance obligations, contract&#160;assets and liabilities are reported on a&#160;net&#160;basis&#160;at the&#160;contract&#160;level.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiscalPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining an entity's fiscal year or other fiscal period. This disclosure may include identification of the fiscal period end-date, the length of the fiscal period, any reporting period lag between the entity and its subsidiaries, or equity investees. If a reporting lag exists, the closing date of the entity having a different period end is generally noted, along with an explanation of the necessity for using different closing dates. Any intervening events that materially affect the entity's financial position or results of operations are generally also disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=d3e5291-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiscalPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139923431843128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 02, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Disaggregation of Revenue</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.715%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product revenues</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239,916&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">702,865&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">704,084&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounts and allowances</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,814)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48,148)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(161,668)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(139,060)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,587&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,768&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541,197&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565,024&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,318&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,443&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,798&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,971&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,505&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,935&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,289&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,441&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,092&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,703&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717,486&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727,465&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues by product were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.715%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CABOMETYX</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,555&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,410&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522,381&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">552,315&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COMETRIQ</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,032&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,816&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,709&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,587&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,768&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541,197&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565,024&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The percentage of total revenues by customer who individually accounted for&#160;10%&#160;or more of our total revenues were as follows:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ipsen</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of CVS Health Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of McKesson Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of AmerisourceBergen Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of Optum Specialty Pharmacy</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Takeda Pharmaceutical Company Limited (Takeda)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by geographic region were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,552&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194,484&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549,379&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572,957&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,006&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,017&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,959&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,092&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,703&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717,486&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727,465&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock', window );">Schedule of Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.742%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Chargebacks and Discounts for Prompt Payment</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Customer Credits/Fees and Co-pay Assistance</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Rebates</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2019</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,514&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,497&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,222&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,233&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to sales made in:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,718&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,235&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(352)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">752&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and customer credits issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107,118)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,513)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,546)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(160,177)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September&#160;30, 2020</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,595&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,350&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,779&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,724&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139923430257864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 02, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Schedule of Collaborative Revenues Under Collaboration Agreement</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under the collaboration agreement with Ipsen were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,910&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,409&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,456&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,318&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,096&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,607&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,503&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,815&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,006&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,016&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,959&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,133&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under the collaboration agreement with Takeda were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,780&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,726&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,056&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,468&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,189&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,984&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,187&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,194&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div>License revenues under the collaboration agreement with Genentech were as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.849%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.981%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.750%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.424%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.750%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.015%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.460%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Profits on U.S. commercialization</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,595&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,102&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,378&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,507&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenues on ex-U.S. sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,804&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,426&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139923437214440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 02, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text">A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334,046&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,501&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash equivalents included in long-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,636&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,636&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335,682&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268,137&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text">A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334,046&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,501&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash equivalents included in long-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,636&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,636&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335,682&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268,137&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock', window );">Schedule of Investments by Security Type</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and investments consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466,141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466,366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">629,309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,526&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636,815&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,449&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,793&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,326&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,431&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,329,225&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,210&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,337,405&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,979&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,979&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,583&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,537,779&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,211&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,545,960&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389,573&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389,573&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">752,295&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,934&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">756,226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,483&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,308,351&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,121&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,312,464&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,964&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,964&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,728&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,384,510&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,126&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,388,628&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Schedule of Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position</a></td>
<td class="text">The fair value and gross unrealized losses on debt securities available-for-sale in an unrealized loss position were as follows (in thousands):<div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.459%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.822%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.824%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,627&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,465&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,092&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.459%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.822%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.824%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,529&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,848&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,377&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Schedule of Fair Value of Cash Equivalents and Investments by Contractual Maturity</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of debt securities available-for-sale by contractual maturity was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993,211&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">789,913&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344,194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522,551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,337,405&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,312,464&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27290-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of unrealized gains and losses on investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139923432323752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 02, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Classification of Financial Assets Measured and Recorded at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466,366&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466,366&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636,815&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636,815&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,793&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,793&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,337,405&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,337,405&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,992&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,392,989&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,489,981&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389,573&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389,573&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">756,226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">756,226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,665&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,665&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,312,464&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,312,464&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,467&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,345,197&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,347,664&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139923431584696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 02, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventory</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,298&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,709&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,535&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,744&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,523&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet classification:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion included in inventory</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion included in other long-term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,425&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,637&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,744&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,523&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139923431884808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 02, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Allocated Employee Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated the stock-based compensation expense for our equity incentive plans and our 2000 Employee Stock Purchase Plan (ESPP) as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,936&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,301&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,134&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,745&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,838&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,002&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,655&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,139&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,791&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,747&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139923431892088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 02, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Computation of Basic and Diluted Net Income (Loss) Per Share</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss) per share - basic and diluted, were computed as follows (in thousands, except per share amounts):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,040)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252,269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding &#8212; basic</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309,116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303,268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301,999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,058&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,047&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding &#8212; diluted</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309,116&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315,453&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317,495&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315,046&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share &#8212; basic</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.10)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.32&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.27&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.84&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share &#8212; diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income (Loss) Per Share</a></td>
<td class="text">The weighted-average potential common shares excluded from our calculation were as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive securities and contingently issuable shares excluded</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,033&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,153&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,224&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,740&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139923437046040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 02, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 27, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 02, 2020 </div>
<div>USD ($) </div>
<div>segment </div>
<div>product </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 27, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jan. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of business segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative | $</a></td>
<td class="nump">$ 88,185,000<span></span>
</td>
<td class="nump">$ 51,265,000<span></span>
</td>
<td class="nump">$ 210,916,000<span></span>
</td>
<td class="nump">$ 170,218,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | Customer Concentration Risk | Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | Customer Concentration Risk | Mckesson</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ResultingFromDiscoveryEffortsMember', window );">Resulting from discovery efforts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_NumberofProductsinCommercialMarket', window );">Number of products that entered in the commercial marketplace | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ProductsDerivedFromCabozantinibMember', window );">Products derived from cabozantinib</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_NumberofProductsinCommercialMarket', window );">Number of products that entered in the commercial marketplace | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ProductsDerivedFromOtherCompoundsMember', window );">Products derived from other compounds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_NumberofProductsinCommercialMarket', window );">Number of products that entered in the commercial marketplace | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateByTypeAxis=exel_NewInformationMember', window );">New information</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Decrease in earnings per share due to change in accounting estimate (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_NumberofProductsinCommercialMarket">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Products in Commercial Market</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_NumberofProductsinCommercialMarket</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization And Summary Of Significant Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_OrganizationAndSummaryOfSignificantPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_IpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_IpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_MckessonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_MckessonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ResultingFromDiscoveryEffortsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ResultingFromDiscoveryEffortsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ProductsDerivedFromCabozantinibMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ProductsDerivedFromCabozantinibMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ProductsDerivedFromOtherCompoundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ProductsDerivedFromOtherCompoundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingEstimateByTypeAxis=exel_NewInformationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingEstimateByTypeAxis=exel_NewInformationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139923437460680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Revenues by Disaggregated Category (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">$ 231,092<span></span>
</td>
<td class="nump">$ 271,703<span></span>
</td>
<td class="nump">$ 717,486<span></span>
</td>
<td class="nump">$ 727,465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">231,092<span></span>
</td>
<td class="nump">271,703<span></span>
</td>
<td class="nump">717,486<span></span>
</td>
<td class="nump">727,465<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">168,587<span></span>
</td>
<td class="nump">191,768<span></span>
</td>
<td class="nump">541,197<span></span>
</td>
<td class="nump">565,024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ProductGrossMember', window );">Gross product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">220,401<span></span>
</td>
<td class="nump">239,916<span></span>
</td>
<td class="nump">702,865<span></span>
</td>
<td class="nump">704,084<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ProductSalesDiscountsAndAllowancesMember', window );">Discounts and allowances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="num">(51,814)<span></span>
</td>
<td class="num">(48,148)<span></span>
</td>
<td class="num">(161,668)<span></span>
</td>
<td class="num">(139,060)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_CollaborationMember', window );">Total collaboration revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">62,505<span></span>
</td>
<td class="nump">79,935<span></span>
</td>
<td class="nump">176,289<span></span>
</td>
<td class="nump">162,441<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">33,205<span></span>
</td>
<td class="nump">69,137<span></span>
</td>
<td class="nump">113,318<span></span>
</td>
<td class="nump">132,443<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Revenue not from contract with customer</a></td>
<td class="nump">$ 29,300<span></span>
</td>
<td class="nump">$ 10,798<span></span>
</td>
<td class="nump">$ 62,971<span></span>
</td>
<td class="nump">$ 29,998<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueNotFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue that is not accounted for under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueNotFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ProductGrossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ProductGrossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ProductSalesDiscountsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ProductSalesDiscountsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139923510624472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Net Product Revenues Disaggregated by Product (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenues</a></td>
<td class="nump">$ 231,092<span></span>
</td>
<td class="nump">$ 271,703<span></span>
</td>
<td class="nump">$ 717,486<span></span>
</td>
<td class="nump">$ 727,465<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenues</a></td>
<td class="nump">168,587<span></span>
</td>
<td class="nump">191,768<span></span>
</td>
<td class="nump">541,197<span></span>
</td>
<td class="nump">565,024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_CabometyxMember', window );">CABOMETYX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenues</a></td>
<td class="nump">159,555<span></span>
</td>
<td class="nump">187,410<span></span>
</td>
<td class="nump">522,381<span></span>
</td>
<td class="nump">552,315<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_CometriqMember', window );">COMETRIQ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenues</a></td>
<td class="nump">$ 9,032<span></span>
</td>
<td class="nump">$ 4,358<span></span>
</td>
<td class="nump">$ 18,816<span></span>
</td>
<td class="nump">$ 12,709<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CabometyxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CabometyxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CometriqMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CometriqMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139923438028040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Revenues Disaggregated by Significant Customer (Details) - Revenue - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_IpsenMember', window );">Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesofCVSHealthCorporationMember', window );">Affiliates of CVS Health Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember', window );">Affiliates of McKesson Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesOfAmerisourceBergenCorporationMember', window );">Affiliates of AmerisourceBergen Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesofOptumSpecialtyPharmacyMember', window );">Affiliates of Optum Specialty Pharmacy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_TakedaMember', window );">Takeda Pharmaceutical Company Limited (Takeda)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_IpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_IpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_AffiliatesofCVSHealthCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_AffiliatesofCVSHealthCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_AffiliatesOfAmerisourceBergenCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_AffiliatesOfAmerisourceBergenCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_AffiliatesofOptumSpecialtyPharmacyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_AffiliatesofOptumSpecialtyPharmacyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_TakedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_TakedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139923432387128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Revenues Disaggregated by Geographic Region (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">$ 231,092<span></span>
</td>
<td class="nump">$ 271,703<span></span>
</td>
<td class="nump">$ 717,486<span></span>
</td>
<td class="nump">$ 727,465<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">171,552<span></span>
</td>
<td class="nump">194,484<span></span>
</td>
<td class="nump">549,379<span></span>
</td>
<td class="nump">572,957<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">36,006<span></span>
</td>
<td class="nump">76,017<span></span>
</td>
<td class="nump">117,959<span></span>
</td>
<td class="nump">120,134<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_JP', window );">Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">$ 23,534<span></span>
</td>
<td class="nump">$ 1,202<span></span>
</td>
<td class="nump">$ 50,148<span></span>
</td>
<td class="nump">$ 34,374<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139923437630344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Oct. 02, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at December&#160;31, 2019</a></td>
<td class="nump">$ 26,233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">161,235<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="nump">433<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(160,177)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at September&#160;30, 2020</a></td>
<td class="nump">27,724<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_ChargebacksAndDiscountsForPromptPaymentMember', window );">Chargebacks and Discounts for Prompt Payment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at December&#160;31, 2019</a></td>
<td class="nump">7,514<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">108,166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(107,118)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at September&#160;30, 2020</a></td>
<td class="nump">8,595<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember', window );">Other Customer Credits/Fees and Co-pay Assistance</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at December&#160;31, 2019</a></td>
<td class="nump">3,497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">11,718<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="num">(352)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(11,513)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at September&#160;30, 2020</a></td>
<td class="nump">3,350<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForProductRebatesMember', window );">Rebates</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at December&#160;31, 2019</a></td>
<td class="nump">15,222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">41,351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="nump">752<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(41,546)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at September&#160;30, 2020</a></td>
<td class="nump">$ 15,779<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowances And Reserves, Additions For Sales In Current Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowances And Reserves, Additions For Sales In Prior Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowances And Reserves, Additions To Provision [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_ChargebacksAndDiscountsForPromptPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_ChargebacksAndDiscountsForPromptPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForProductRebatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForProductRebatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139923437660888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Contract Assets and Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with customer, liability</a></td>
<td class="nump">10.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract with customer, liability, current</a></td>
<td class="nump">1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Amount of revenues recognized included in the beginning contract liability balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.8<span></span>
</td>
<td class="nump">$ 2.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod', window );">Revenues recognized for performance obligations satisfied in previous periods</a></td>
<td class="nump">33.1<span></span>
</td>
<td class="nump">$ 67.7<span></span>
</td>
<td class="nump">115.3<span></span>
</td>
<td class="nump">$ 129.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">88.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative Arrangement with Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_EligiblePaymentFromCollaborationForDevelopmentMilestoneAchievementUnderCollaborationsAgreement', window );">Eligible development milestone under collaborative agreement</a></td>
<td class="nump">20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement', window );">Reduction related to a milestone</a></td>
<td class="nump">59.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">42.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_TakedaMember', window );">Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement', window );">Reduction related to a milestone</a></td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Eligible Payment From Collaboration For Development And Regulatory Milestone Achievement Under Collaborations Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_EligiblePaymentFromCollaborationForDevelopmentMilestoneAchievementUnderCollaborationsAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Eligible Payment From Collaboration For Development Milestone Achievement Under Collaborations Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_EligiblePaymentFromCollaborationForDevelopmentMilestoneAchievementUnderCollaborationsAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12A<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL108322424-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_TakedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_TakedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139923437550456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">$ 231,092<span></span>
</td>
<td class="nump">$ 271,703<span></span>
</td>
<td class="nump">$ 717,486<span></span>
</td>
<td class="nump">$ 727,465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">231,092<span></span>
</td>
<td class="nump">271,703<span></span>
</td>
<td class="nump">717,486<span></span>
</td>
<td class="nump">727,465<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative Arrangement with Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">36,006<span></span>
</td>
<td class="nump">76,016<span></span>
</td>
<td class="nump">117,959<span></span>
</td>
<td class="nump">120,133<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">33,205<span></span>
</td>
<td class="nump">69,137<span></span>
</td>
<td class="nump">113,318<span></span>
</td>
<td class="nump">132,443<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues | Collaborative Arrangement with Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">19,910<span></span>
</td>
<td class="nump">66,409<span></span>
</td>
<td class="nump">71,456<span></span>
</td>
<td class="nump">95,318<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Revenue not from contract with customer</a></td>
<td class="nump">29,300<span></span>
</td>
<td class="nump">10,798<span></span>
</td>
<td class="nump">62,971<span></span>
</td>
<td class="nump">29,998<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues | Collaborative Arrangement with Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Revenue not from contract with customer</a></td>
<td class="nump">$ 16,096<span></span>
</td>
<td class="nump">$ 9,607<span></span>
</td>
<td class="nump">$ 46,503<span></span>
</td>
<td class="nump">$ 24,815<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueNotFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue that is not accounted for under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueNotFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139923430037592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration Agreements - Ipsen Collaboration (Details)<br></strong></div></th>
<th class="th">
<div>Oct. 02, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">$ 88,900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative Arrangement with Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement', window );">Eligible payment from collaboration for development and regulatory milestone achievement under collaborations agreement</a></td>
<td class="nump">59,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement', window );">Maximum amount eligible for commercial milestones under collaborations agreement</a></td>
<td class="nump">469,900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">$ 42,600,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Eligible Payment From Collaboration For Development And Regulatory Milestone Achievement Under Collaborations Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum Amount Eligible For Commercial Milestones Under Collaborations Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139923437549848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Takeda (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">$ 231,092<span></span>
</td>
<td class="nump">$ 271,703<span></span>
</td>
<td class="nump">$ 717,486<span></span>
</td>
<td class="nump">$ 727,465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">231,092<span></span>
</td>
<td class="nump">271,703<span></span>
</td>
<td class="nump">717,486<span></span>
</td>
<td class="nump">727,465<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative Arrangement with Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">22,984<span></span>
</td>
<td class="nump">1,187<span></span>
</td>
<td class="nump">49,194<span></span>
</td>
<td class="nump">14,245<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">33,205<span></span>
</td>
<td class="nump">69,137<span></span>
</td>
<td class="nump">113,318<span></span>
</td>
<td class="nump">132,443<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues | Collaborative Arrangement with Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">9,780<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">32,726<span></span>
</td>
<td class="nump">9,056<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Revenue not from contract with customer</a></td>
<td class="nump">29,300<span></span>
</td>
<td class="nump">10,798<span></span>
</td>
<td class="nump">62,971<span></span>
</td>
<td class="nump">29,998<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues | Collaborative Arrangement with Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Revenue not from contract with customer</a></td>
<td class="nump">$ 13,204<span></span>
</td>
<td class="nump">$ 1,187<span></span>
</td>
<td class="nump">$ 16,468<span></span>
</td>
<td class="nump">$ 5,189<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueNotFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue that is not accounted for under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueNotFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139923433145320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Takeda Collaboration (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 02, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 02, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">$ 88,900,000<span></span>
</td>
<td class="nump">$ 88,900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative Arrangement with Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MilestonePaymentsEarned', window );">Milestone payments earned</a></td>
<td class="nump">9,200,000<span></span>
</td>
<td class="nump">9,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement', window );">Eligible payment from collaboration for development and regulatory milestone achievement under collaborations agreement</a></td>
<td class="nump">10,000,000.0<span></span>
</td>
<td class="nump">10,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement', window );">Maximum amount eligible for commercial milestones under collaborations agreement</a></td>
<td class="nump">124,000,000.0<span></span>
</td>
<td class="nump">124,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">$ 46,300,000<span></span>
</td>
<td class="nump">$ 46,300,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Eligible Payment From Collaboration For Development And Regulatory Milestone Achievement Under Collaborations Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum Amount Eligible For Commercial Milestones Under Collaborations Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MilestonePaymentsEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments Earned</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MilestonePaymentsEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139923532057176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - GSK (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementswithGlaxoSmithKlineMember', window );">Collaboration Agreement with GlaxoSmithKline</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense</a></td>
<td class="nump">$ 7.9<span></span>
</td>
<td class="nump">$ 8.0<span></span>
</td>
<td class="nump">$ 23.7<span></span>
</td>
<td class="nump">$ 23.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_GlaxoSmithKlineMember', window );">GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Percent Of Royalty On Net Sale</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementPercentOfRoyaltyOnNetSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementswithGlaxoSmithKlineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementswithGlaxoSmithKlineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_GlaxoSmithKlineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_GlaxoSmithKlineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139923436946216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Royalty Revenues under the Collaboration Agreement with Genentech (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Royalty revenues on ex-U.S. sales</a></td>
<td class="nump">$ 231,092<span></span>
</td>
<td class="nump">$ 271,703<span></span>
</td>
<td class="nump">$ 717,486<span></span>
</td>
<td class="nump">$ 727,465<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_CotellicMember', window );">Cotellic | Collaborative Arrangement with Genentech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementIncomeLossFromAgreement', window );">Profits on U.S. commercialization</a></td>
<td class="nump">1,595<span></span>
</td>
<td class="nump">1,102<span></span>
</td>
<td class="nump">4,378<span></span>
</td>
<td class="nump">3,507<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Royalty revenues on ex-U.S. sales</a></td>
<td class="nump">$ 1,370<span></span>
</td>
<td class="nump">$ 1,614<span></span>
</td>
<td class="nump">$ 3,804<span></span>
</td>
<td class="nump">$ 4,426<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementIncomeLossFromAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Income (Loss) from Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementIncomeLossFromAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CotellicMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CotellicMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139923520350264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - In-Licensing Collaborations (Details) - Collaborative Arrangement With Catalent<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Oct. 02, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeAgreementsUpfrontPayments', window );">Upfront payment</a></td>
<td class="nump">$ 10.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAndLicenseAgreementTargetSelectionTerm', window );">Collaboration term</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAndLicenseAgreementExtendedTargetSelectionTerm', window );">Collaboration target selection extended, term</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementsAdditionalUpfrontPayments', window );">Additional payments</a></td>
<td class="nump">$ 4.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption', window );">Option exercise fee payment, if exercised</a></td>
<td class="nump">2.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones', window );">Maximum amount eligible for development and regulatory milestones</a></td>
<td class="nump">44.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement', window );">Maximum amount eligible for commercial milestones under collaborations agreement</a></td>
<td class="nump">$ 60.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Option Exercise Fee Payment, Upon Exercising Option</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementsAdditionalUpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreements, Additional Upfront Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementsAdditionalUpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAndLicenseAgreementExtendedTargetSelectionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration And License Agreement, Extended Target Selection Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAndLicenseAgreementExtendedTargetSelectionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAndLicenseAgreementTargetSelectionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration And License Agreement, Target Selection Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAndLicenseAgreementTargetSelectionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeAgreementsUpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreements, Upfront Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeAgreementsUpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount eligible for development and regulatory milestones under collaborations agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum Amount Eligible For Commercial Milestones Under Collaborations Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementWithCatalentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementWithCatalentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139923520586424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - NBE Therapeutics AG (NBE) Collaboration (Details) - Collaborative Arrangement With NBE Therapeutics<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Oct. 02, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeAgreementsUpfrontPayments', window );">Upfront payment</a></td>
<td class="nump">$ 25.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAndLicenseAgreementTargetSelectionTerm', window );">Collaboration term</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAndLicenseAgreementTargetSelectionExtensionOptionTerm', window );">Collaboration extension option</a></td>
<td class="text">18 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAndLicenseAgreementExtendedTargetSelectionTerm', window );">Collaboration target selection extended, term</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementsAdditionalUpfrontPayments', window );">Additional payments</a></td>
<td class="nump">$ 2.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption', window );">Option exercise fee payment, if exercised</a></td>
<td class="nump">10.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones', window );">Maximum amount eligible for development and regulatory milestones</a></td>
<td class="nump">90.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement', window );">Maximum amount eligible for commercial milestones under collaborations agreement</a></td>
<td class="nump">$ 135.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Option Exercise Fee Payment, Upon Exercising Option</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementsAdditionalUpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreements, Additional Upfront Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementsAdditionalUpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAndLicenseAgreementExtendedTargetSelectionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration And License Agreement, Extended Target Selection Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAndLicenseAgreementExtendedTargetSelectionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAndLicenseAgreementTargetSelectionExtensionOptionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration And License Agreement, Target Selection, Extension Option Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAndLicenseAgreementTargetSelectionExtensionOptionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAndLicenseAgreementTargetSelectionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration And License Agreement, Target Selection Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAndLicenseAgreementTargetSelectionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeAgreementsUpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreements, Upfront Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeAgreementsUpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount eligible for development and regulatory milestones under collaborations agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum Amount Eligible For Commercial Milestones Under Collaborations Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementWithNBETherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementWithNBETherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139923436954440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 334,046<span></span>
</td>
<td class="nump">$ 266,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashEquivalentsNoncurrent', window );">Restricted cash equivalents included in long-term investments</a></td>
<td class="nump">1,636<span></span>
</td>
<td class="nump">1,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows</a></td>
<td class="nump">$ 335,682<span></span>
</td>
<td class="nump">$ 268,137<span></span>
</td>
<td class="nump">$ 243,317<span></span>
</td>
<td class="nump">$ 315,875<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139923432458808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments - Investments by Security Type (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Investments, available-for-sale, amortized cost</a></td>
<td class="nump">$ 1,329,225<span></span>
</td>
<td class="nump">$ 1,308,351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Investments available-for-sale, gross unrealized gains</a></td>
<td class="nump">8,210<span></span>
</td>
<td class="nump">4,121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Investments available-for-sale, gross unrealized losses</a></td>
<td class="num">(30)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments available-for-sale, fair value</a></td>
<td class="nump">1,337,405<span></span>
</td>
<td class="nump">1,312,464<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cash, cash equivalents, restricted cash and restricted cash equivalents and available-for-sale debt securities, amortized cost</a></td>
<td class="nump">1,537,779<span></span>
</td>
<td class="nump">1,384,510<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Cash, cash equivalents, restricted cash and restricted cash equivalents and available-for-sale debt securities, gross unrealized gains</a></td>
<td class="nump">8,211<span></span>
</td>
<td class="nump">4,126<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Cash, cash equivalents, restricted cash and restricted cash equivalents and available-for-sale debt securities, gross unrealized losses</a></td>
<td class="num">(30)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities', window );">Cash, cash equivalents, restricted cash and restricted cash equivalents and available-for-sale debt securities</a></td>
<td class="nump">1,545,960<span></span>
</td>
<td class="nump">1,388,628<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Investments, available-for-sale, amortized cost</a></td>
<td class="nump">466,141<span></span>
</td>
<td class="nump">389,573<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Investments available-for-sale, gross unrealized gains</a></td>
<td class="nump">225<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Investments available-for-sale, gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments available-for-sale, fair value</a></td>
<td class="nump">466,366<span></span>
</td>
<td class="nump">389,573<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Investments, available-for-sale, amortized cost</a></td>
<td class="nump">629,309<span></span>
</td>
<td class="nump">752,295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Investments available-for-sale, gross unrealized gains</a></td>
<td class="nump">7,526<span></span>
</td>
<td class="nump">3,934<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Investments available-for-sale, gross unrealized losses</a></td>
<td class="num">(20)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments available-for-sale, fair value</a></td>
<td class="nump">636,815<span></span>
</td>
<td class="nump">756,226<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Investments, available-for-sale, amortized cost</a></td>
<td class="nump">213,449<span></span>
</td>
<td class="nump">166,483<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Investments available-for-sale, gross unrealized gains</a></td>
<td class="nump">354<span></span>
</td>
<td class="nump">187<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Investments available-for-sale, gross unrealized losses</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments available-for-sale, fair value</a></td>
<td class="nump">213,793<span></span>
</td>
<td class="nump">166,665<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember', window );">Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Investments, available-for-sale, amortized cost</a></td>
<td class="nump">20,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Investments available-for-sale, gross unrealized gains</a></td>
<td class="nump">105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Investments available-for-sale, gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments available-for-sale, fair value</a></td>
<td class="nump">20,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashMember', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost', window );">Cash, cash equivalents, restricted cash and restricted cash equivalents, amortized cost</a></td>
<td class="nump">55,979<span></span>
</td>
<td class="nump">40,964<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain', window );">Cash, cash equivalents, restricted cash and restricted cash equivalents, gross unrealized gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss', window );">Cash, cash equivalents, restricted cash and restricted cash equivalents, gross unrealized loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure', window );">Cash, cash equivalents, restricted cash and restricted cash equivalents</a></td>
<td class="nump">55,979<span></span>
</td>
<td class="nump">40,964<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost', window );">Cash, cash equivalents, restricted cash and restricted cash equivalents, amortized cost</a></td>
<td class="nump">96,992<span></span>
</td>
<td class="nump">2,467<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain', window );">Cash, cash equivalents, restricted cash and restricted cash equivalents, gross unrealized gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss', window );">Cash, cash equivalents, restricted cash and restricted cash equivalents, gross unrealized loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure', window );">Cash, cash equivalents, restricted cash and restricted cash equivalents</a></td>
<td class="nump">96,992<span></span>
</td>
<td class="nump">2,467<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost', window );">Cash, cash equivalents, restricted cash and restricted cash equivalents, amortized cost</a></td>
<td class="nump">55,583<span></span>
</td>
<td class="nump">32,728<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain', window );">Cash, cash equivalents, restricted cash and restricted cash equivalents, gross unrealized gain</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss', window );">Cash, cash equivalents, restricted cash and restricted cash equivalents, gross unrealized loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure', window );">Cash, cash equivalents, restricted cash and restricted cash equivalents</a></td>
<td class="nump">$ 55,584<span></span>
</td>
<td class="nump">$ 32,733<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139923430170936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments - Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Oct. 02, 2020 </div>
<div>USD ($) </div>
<div>investment</div>
</th>
<th class="th">
<div>Jan. 03, 2020 </div>
<div>USD ($) </div>
<div>investment</div>
</th>
<th class="th">
<div>Sep. 27, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Interest receivable</a></td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="nump">$ 6,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of investments in an unrealized loss position | investment</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for credit losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922900-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922900-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139923437874904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">$ 100,092<span></span>
</td>
<td class="nump">$ 17,377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">(30)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">29,627<span></span>
</td>
<td class="nump">14,529<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">(20)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">70,465<span></span>
</td>
<td class="nump">2,848<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">$ (10)<span></span>
</td>
<td class="num">$ (5)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139923436756888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Maturing in one year or less</a></td>
<td class="nump">$ 993,211<span></span>
</td>
<td class="nump">$ 789,913<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Maturing after one year through five years</a></td>
<td class="nump">344,194<span></span>
</td>
<td class="nump">522,551<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">$ 1,337,405<span></span>
</td>
<td class="nump">$ 1,312,464<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139923436343096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">$ 1,337,405<span></span>
</td>
<td class="nump">$ 1,312,464<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">1,337,405<span></span>
</td>
<td class="nump">1,312,464<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets carried at fair value</a></td>
<td class="nump">1,489,981<span></span>
</td>
<td class="nump">1,347,664<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets carried at fair value</a></td>
<td class="nump">96,992<span></span>
</td>
<td class="nump">2,467<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">1,337,405<span></span>
</td>
<td class="nump">1,312,464<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets carried at fair value</a></td>
<td class="nump">1,392,989<span></span>
</td>
<td class="nump">1,345,197<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">466,366<span></span>
</td>
<td class="nump">389,573<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">466,366<span></span>
</td>
<td class="nump">389,573<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level&#160;2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">466,366<span></span>
</td>
<td class="nump">389,573<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">636,815<span></span>
</td>
<td class="nump">756,226<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">636,815<span></span>
</td>
<td class="nump">756,226<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Level&#160;2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">636,815<span></span>
</td>
<td class="nump">756,226<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">213,793<span></span>
</td>
<td class="nump">166,665<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">213,793<span></span>
</td>
<td class="nump">166,665<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises | Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises | Level&#160;2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">213,793<span></span>
</td>
<td class="nump">166,665<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember', window );">Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">20,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember', window );">Municipal bonds | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">20,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember', window );">Municipal bonds | Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember', window );">Municipal bonds | Level&#160;2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">20,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">96,992<span></span>
</td>
<td class="nump">2,467<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">96,992<span></span>
</td>
<td class="nump">2,467<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Level&#160;2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">55,584<span></span>
</td>
<td class="nump">32,733<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level&#160;2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 55,584<span></span>
</td>
<td class="nump">$ 32,733<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139923437547528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 5,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,709<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">17,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,447<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">4,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,367<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total</a></td>
<td class="nump">27,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,523<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-down</a></td>
<td class="nump">2,200<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_InventoriesMember', window );">Current portion included in inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total</a></td>
<td class="nump">19,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,886<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=exel_OtherLongtermAssetsMember', window );">Long-term portion included in other long-term assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total</a></td>
<td class="nump">$ 8,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,637<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_InventoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_InventoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=exel_OtherLongtermAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=exel_OtherLongtermAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139923437546936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Allocated Employee Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 55,655<span></span>
</td>
<td class="nump">$ 13,139<span></span>
</td>
<td class="nump">$ 85,791<span></span>
</td>
<td class="nump">$ 40,747<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">18,936<span></span>
</td>
<td class="nump">4,301<span></span>
</td>
<td class="nump">30,134<span></span>
</td>
<td class="nump">13,745<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 36,719<span></span>
</td>
<td class="nump">$ 8,838<span></span>
</td>
<td class="nump">$ 55,657<span></span>
</td>
<td class="nump">$ 27,002<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139923510973416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 20, 2020</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based compensation arrangement by share-based payment award, number of shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,900,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,900,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward', window );">Reduction in share reserve after stock option or stock appreciation award (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards', window );">Reduction in share reserve after all other awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in share reserve under 2017 plan (in shares)</a></td>
<td class="nump">21,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted in the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,189,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted in the period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,219,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,219,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,655<span></span>
</td>
<td class="nump">$ 13,139<span></span>
</td>
<td class="nump">$ 85,791<span></span>
</td>
<td class="nump">$ 40,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 111,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 111,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSUs awarded (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,813,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, awarded (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of awards outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,554,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,554,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest', window );">Maximum potential to vest, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumNumberOfSharesToVest', window );">Additional shares to be earned (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,903,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=exel_PerformanceShareOptionsPSOMember', window );">Performance Share Options (PSO)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted in the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">308,365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises', window );">Share-based compensation arrangement by share-based payment award, options, percent of common stock share price triggering PSO exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 129,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 129,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSUs awarded (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,951,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of awards outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,186,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,186,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares | Achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of awards outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">188,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">188,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares | Probable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of awards outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,947,563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,947,563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumNumberOfSharesToVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Maximum Number of Shares to Vest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumNumberOfSharesToVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Maximum Potential To Vest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award,Reduction of Number of Shares in Share Reserve</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award,Reduction of Number of Shares in Share Reserve After Stock Option or Stock Appreciation Award</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Percent Of Common Stock Share Price Triggering PSO Exercises</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=exel_PerformanceShareOptionsPSOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=exel_PerformanceShareOptionsPSOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_StatusAxis=exel_AchievedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_StatusAxis=exel_AchievedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_StatusAxis=exel_ProbableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_StatusAxis=exel_ProbableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139923432373240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">15.70%<span></span>
</td>
<td class="nump">20.50%<span></span>
</td>
<td class="nump">18.80%<span></span>
</td>
<td class="nump">19.40%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139923437607512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share - Computation of Basic and Diluted Net Income Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_EarningsPerShareNumeratorAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (32,040)<span></span>
</td>
<td class="nump">$ 97,452<span></span>
</td>
<td class="nump">$ 83,393<span></span>
</td>
<td class="nump">$ 252,269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_EarningsPerShareDenominatorAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding - basic (in shares)</a></td>
<td class="nump">309,116<span></span>
</td>
<td class="nump">303,268<span></span>
</td>
<td class="nump">307,437<span></span>
</td>
<td class="nump">301,999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive securities (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,185<span></span>
</td>
<td class="nump">10,058<span></span>
</td>
<td class="nump">13,047<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding - diluted (in shares)</a></td>
<td class="nump">309,116<span></span>
</td>
<td class="nump">315,453<span></span>
</td>
<td class="nump">317,495<span></span>
</td>
<td class="nump">315,046<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share - basic (in dollars per share)</a></td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="nump">$ 0.32<span></span>
</td>
<td class="nump">$ 0.27<span></span>
</td>
<td class="nump">$ 0.84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) per share - diluted (in dollars per share)</a></td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="nump">$ 0.31<span></span>
</td>
<td class="nump">$ 0.26<span></span>
</td>
<td class="nump">$ 0.80<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_EarningsPerShareDenominatorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Earnings Per Share, Denominator [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_EarningsPerShareDenominatorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_EarningsPerShareNumeratorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Earnings Per Share, Numerator [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_EarningsPerShareNumeratorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139923431657112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share - Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income (Loss) Per Share (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">Anti-dilutive securities and contingently issuable shares excluded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares (in shares)</a></td>
<td class="nump">27,033<span></span>
</td>
<td class="nump">6,153<span></span>
</td>
<td class="nump">10,224<span></span>
</td>
<td class="nump">5,740<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>66
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M@=/-#0MX :'*!L#UC93F>6*/N.Z5)OT'4$L#!!0    ( +:"95%'Q5L@2@8
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M]&([U5U8R"DDNT7;A?D\X)3BM*G7NPEOE/B+4\AKIU O$JT*X"Y0+^ Y([F
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M[^C5C"+/Y_1JT7S5Z,,W'UD^)>4Z*S3)Y0JZ\BX%)$;9?+=H;HS:U0?SC\J
MMO7E1B:I+"L _'^EE'FYJ3KHOA[=_@M02P,$%     @ MH)E42\9\UU* P
M>@D  !@   !X;"]W;W)K<VAE971S+W-H965T-2YX;6RE5EMOVS84_BN$D(<$
M2"*)NEF!;2"Q7:S N@;UNCT4?: EVB)*B1I)V^E^_0XI6;-EV2VV%_'V?><N
M'H[W0GY3!:4:O96\4A.GT+I^<EV5%;0DZE'4M(*3M9 ET;"4&U?5DI+<DDKN
M8L^+W9*PRIF.[=ZKG([%5G-6T5>)U+8LB?S^0KG83QS?.6Q\8IM"FPUW.J[)
MABZI_ER_2EBYG92<E;123%1(TO7$>?:?%HG!6\ ?C.[5T1P93U9"?#.+]_G$
M\8Q!E--,&PD$AAV=4<Z-(##CKU:FTZDTQ./Y0?H[ZSOXLB**S@3_D^6ZF#@C
M!^5T3;9<?Q+[7VCK3V3D98(K^T7[%NLY*-LJ+<J6#!:4K&I&\M;&X8@ <H8)
MN"7@/B&\0 A:0O"S&L*6$/ZLAJ@E6-?=QG<;N#G19#J68H^D08,T,['1MVR(
M%ZM,G2RUA%,&/#V=B2J'K-,<P4P)SG*B8;'4,$ Y:(7$&HY**,+"5,>.HO=5
M)DJ*;G\52MVA!_1Y.4>W-W?H!K$*_5Z(K2)5KL:N!O.,$C=K37EI3,$73 G0
M!U'I0J$%F)0/\.?7^>D5O@MAZ6*##[%YP5<%?LST(_+P/<(>]@;LF5VG+VG]
MB'!BZ'XZY,[_T[[XS]I/@A%TA1)8><$E>8>*N%@07YY72DOX\[]>41=VZD*K
M+KR@[C>X(EE;:-P4VE ]-2)B*\)<B+OI0X"]$**U.T[3.2Q-P@B?HN;GJ%$0
MI,$I:G&.PA'&<=K!3KR-.F^CJ\']J LJ4782U1/OGZZ$-.Z4Q#\,Z;:"9L+9
MW_"+;Z")J$8\A?_87-H[PCA9<?H _>=!$4[AREUII&BVE4PSJNY116T!:/*&
M6%E#LLWJ)HR">W1SZ^/TSHRC-+A#< G - UBV))4U=2V!/Y]*)&-X=%Q(OW8
M\WMY/$>%<0\S/\<$?M(KB,4 *+B4PJ2+;G(UNK/+R1OR.!DHW2 .^RZ?P](D
M]7M%.3]'C>(H[I?N.0I'@!KU_':/FDE)Y<9V<07%N:UT<UUTN]U#X=GVQ][^
MB_\T\P?VY_"P:-X!_XIO7B4?B-R8HN1T#:J\QP12))M.WRRTJ&TK6PD-C=%.
M"W@<46D <+X60A\61D'WW)K^ U!+ P04    " "V@F51)S>0\M,"   M!P
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MQ@"YC<%)Y@69&D\QCK">I#&8RE&: >0V T\R+\A4=@SUM;0:0ZF,I0% SV,
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MFJ,?-Q_0VS<GZ VJ&O1]*PZ*-:4Z6VA 8^9<%-W*5^W*9&+E)?HL&KU5Z ]
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M^#XILHPG<@\].LD+-WX_&IO=CPI^$\0'V[@8%?:^&M)Z25]&>I5R6\$\'I]
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M,B<#90KR UAN]7&V29+_#,;H/Y_1/%V5EC%HWK-7NZ#'*:>2"6[,^;X+/K5
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MUNV%\$ZMX9Y<9;P',\%TACXR2;3=5CK>9WDB":'/2Q#+L!A]B_IPLY9O0@[
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M0AOW 79V'9O,AHHLZ,=_@V@D.> ].OE:.5NH -#C)DU5$7OO 1"'S6Z-[D;
MP!';ADL)<I3C5G<<LGJ'C?X79-P?QSJO8Q.$-$#0K+'+<?0(T2M'WZKB/IW"
MMUI^.STZGFAWE?E(35"^;O+LR>'!=+>Q^V28DQN^EPP9CU71K[2M>R2SIXU$
MW()%=8K&KAV#7N_WJ>KF4WM:8-.#>LEY73KD&&I#('YG59Q!BV?&I!5(/Y7
M)0CZPV?^A]1+)<\FG]!<\ =)8\L@B;46K$F4^'L+;#[XFU2QQ75#QJ_KU#1Q
M"!R^#RBPT#/:M[@N!I2X^M8/W\S&/A_[*/G4+W1NR1\T;N4HDGSU-UPU_IO)
M)_*IX/BX?'#Y;=8LRYJ*U N\>CA[]O2!P%/_HW,;_G#PW'5PT/SGRF8PD_0
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MEX+C@D@;L#Y7RFY>Z(#MU]?S_P!02P,$%     @ MH)E42BN?$?%!0  X T
M !D   !X;"]W;W)K<VAE971S+W-H965T,3,N>&ULI5?;;MLX$/T5PELLMH#B
MBR3?TB1 DJ9H@69;)$W[L-@'6J(M;B52)2F[_OL]0UVLW%IL]\4B9<[,F9DS
M,]3)3INO-A/"L>]%KNSI('.N/!Z-;)*)@MNA+H7"/VMM"NZP-9N1+8W@J1<J
M\E$X'L]&!9=J<';BWWTT9R>Z<KE4XJ-AMBH*;O87(M>[T\%DT+ZXD9O,T8O1
MV4G)-^)6N+ORH\%NU&E)92&4E5HQ(]:G@_/)\45,Y_V!SU+L;&_-R).5UE]I
M\RX]'8P)D,A%XD@#QV,K+D6>DR+ ^-;H''0F2;"_;K6_\;[#EQ6WXE+G7V3J
MLM/!8L!2L>95[F[T[JUH_)F2OD3GUO^R77TVB@<LJ:S312,,!(54]9-_;^+0
M$UB,GQ$(&X'0XZX->92ON>-G)T;OF*'3T$8+[ZJ7!CBI*"FWSN!?"3EW]H9+
MPS[SO!+L6G!;&8&(.WLR<E!.1T9)H^BB5A0^HVC)KK5RF657*A7I??D10'7(
MPA;91?A#A1\2-V3C,&#A.!S_0%_4>1IY?='//7TM;9)K<M:RO\Y7UAF0X^\?
MV(@[&[&W$3]GX_S=#?M\_O[NBEU?G=_>W5Q=7_WYZ?:I:/Z2(N:=V'HGP%ZB
MMF4N$XP7NE)^S1WJH,I3MJ(CB0#G4U:5* #+<\'TFG'4@K6H=VU8R67*G&:(
M@+)K81AGN>0KF4NW9U+166U28?)]?837M;02;B>$ A'-5R@JN7$RD24G" !
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M =TW@_H9@W,[@(NE:&-9^%A6Y*;Q;EZZLRM2X#*#3!2UQ2R$+=(,V5>N"]S
M6A5T2PU<" DV5[4A<Q,"OJ18V2,T7JI:6O/A"C[G&O%-V&%)MEBNR#B)0G@@
MK\[-N\A2$8^/6@]UB9I;I:_>\>EGN$A8&/4BUQP/PUZ?46.4A,DXH0;KLY -
MQO 1I:+[TJ!\]9<3LTO^3, ;[W1);X+WQ@ ]5L:2JW0TX)>?1BQFO[9R)=$X
MC.,!U0FACJBF#9,AU7$X'M,N3DIZ5L!@6FMA!:'M$&(6QJ,^Q%$8]4<0)\1Y
M^%^8M.$Z<(G[Y'1"-7$9]WT_Z@W.AO^M5R1AU(F]@%$G8;YB0U^->C^$L^/T
M%BEND 8-4O2N.H1<U.X8T-.6?@-5N<>9SMC3\@N5B[9\-/ZDSI>+!2DDK1:K
MVAMVX!:UI60#E;(HK>#%OR3TAYI.;+/+6JN25-60\B*M"^Y3@5J3U0_'X7+O
M[0I37AM"%S8G2:AXI:13%QGD!$,%72)*-,3J,MNYCNLU)2 @:'G0]2"HVL$X
MUAJ)(.UCU8Z'I^]$H:NI89N+-'?V7A/B1@+ ,QK7=$.9\.XY'E)9HHLN[>4"
MGS'KT%7%[]T^I>)Y 3W;4^_%__4J7+_1]>A(N9-R$*1X!6%,S5<%?N<,&X91
MDL @C.G^T,5DK ?]<-B+X+W'OWN45NE!VOC/@Z&MZ.UK,NQ^=/\_N6[2\L&\
M^=S<<[T1TD"!:UH:=8;] '3S86@Z5E4^2:^4I93OFSG]L5 [ YI?*PI4VW$;
M[']MLW\ 4$L#!!0    ( +:"95':8C=)P@8  +00   9    >&PO=V]R:W-H
M965T<R]S:&5E=#$X+GAM;,U8VV[C.!+]%<(++&8 K>THSCCI30(XEYG-0YQ@
MG)[9Q6(?:*EL<2*1:I**.W^_ITJ7)-,=H]'[LB^Q)))5ITZ=*I(YW3G_& JB
MJ#Y7I0UGHR+&^L-D$K*"*AW&KB:+D8WSE8YX]=M)J#WI7!95Y22=3G^:5-K8
MT?FI?+OWYZ>NB:6Q=.]5:*I*^^<+*MWN;'0PZC_\:K9%Y ^3\]-:;VE%\6-]
M[_$V&:SDIB(;C+/*T^9LM#CX<#'C^3+A-T.[\.I9<21KYQ[YY28_&TT9$)64
M1;:@\?-$EU26; @P/G4V1X-+7OCZN;?^L\2.6-8ZT*4K?S=Y+,Y&QR.5TT8W
M9?S5[?Y!73Q';"]S99"_:M?./4I'*FM"=%6W& @J8]M?_;GCX=6"X^D["])N
M02JX6T>"\DI'?7[JW4YYG@UK_""ARFJ ,Y:3LHH>HP;KXOFEJRH3P7(,2MM<
M73H;C=V2S0R%TTF$"YXXR3IS%ZVY]!US)^H6!HJ@KFU.^=OU$T ;\*4]OHMT
MK\&[+([5-$U4.DVG>^P=#O$>BKW#[XE779F0E2XTGM2_%^L0/43SGSU>9X/7
MF7B=O>?U[O;VYN'V>OFP4HOEE;J\6S[<+'^Y7E[>7*^^QO+_8$[=6+6B.E*U
M)@_:#DX2M2,44$;0?ZZTLBZ:C%1),6*&IZWV.3@ 'VJQ7GMZ,CIBXA(E=>6;
MK5K4=6DR+57T _PM?D0-KT$CSXI.Q8+4SU<+M7Y6MZNENB\TRB6C!EYT&1(
MRL;J!PS]F,#;IX9"%'=U[=V3+MD$&L(C.I!6R 1YDZDG\E+W;J,N%Q=WM]</
M__JGBGH-T&',;O[ZE^/T8/[WH(PUT<#*VZB,S<HFEW#OM==;K^M"W?RF,O+1
M;/IH=B86@!1J] B&X1JO/HY78ZR)D(A:.C@[3H[G\V0^_RE1)\D\G26',^CQ
M8)I,#V<8.A0=R2N&C^9@NS!9H31$5)K '!DK'"TD8+P+J_?>Y4T&&0J(AX(
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MH;P;EM,DKT^/!+*$'=LI$<4TP- %L<@Z!G6-;<9_)*2N3R6E5]Z2T ".4J#
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M(0FH]$*$:9;%_VGE>:77)E.O3?YPKUW0B*><DD/+P'A1][L96B5<B7KH'Y2
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MI1U&P9-;O")*0PSX?ZVUVW_0!M.E\_(W4$L#!!0    ( +:"95'9IF/S; ,
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M)2A"RC<@E1VD_^58V]J')QV<C 4.EIPID H*KFVDLXQVVU2"53X+Z'H"FV!
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M!$GB+"&/OTJCC<JG ^X^;ZW?Y9/'R<RX@9%*?A>Q75XU^@T2PYRO$OND-K]
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M)W[\G=4)N86_B*>R_ 7'&@LM$.VEXEEMK&>0)7GU3[_51'0,M!^S :X-<-_
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ME[M1"[?V"T\L6QF[$(R':Y+19VJ^KA\5O 65EI3E5&@F!5)T.6K=X.L9[EF
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MQX6Y0)C^@BBFV.+/[3#]46PN$ US.F&V<'YN]OD/S]Y*AE<7E%?8\UXNJ)U
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M0>0( 8?<.@2*CQ5< N<."&G\Z#&#(:1SW%ROT3]Z[:AE00U<*OZ5%;::!TE
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M"M+=N.XV5M5^1"Z4Q8'KEQ7><*"= ;Y?*F77&S=UASLS^PE02P,$%     @
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M#9[LKIGBY0N4#<#W*RG-KF,GJ*YST]]02P,$%     @ MH)E490_<=G2 @
MG @  !D   !X;"]W;W)K<VAE971S+W-H965T,S@N>&ULS5;;;MLP#/T5P>B
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MV" RGX6YH<7:7O8+H7%TV&6"GP\@C0,^7PJA#X81*#](PA]02P,$%     @
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M:D4O>/SJA<>CE[='N%>V*&ONB[.A/(355+"NM_L 6#1E[VEZ\_5P32>$$Y3
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M2 . _940^FUB&FWS<H_^ 5!+ P04    " "V@F51[XM19T &   K)P  &0
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M3@V%;*=<:VA1NWN?"6VFB%N6YL. TCJ8\Y40^MFPHZ3_U"3_ 5!+ P04
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MCP0W7.,[#I1UP/6EE.;9L"^%ZF4X_@U02P,$%     @ MH)E48/[ 4.@ @
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M<EC=H'&! @3.W 1>!Z6?EC'@739(UX8##?/3N3:\\WU7#JS+W:S; DT_%>+
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M0Y9I)?3C>RUJ-38U\?CYH/[:!(_!W%,)<YY]88E*)];0(@FLZ393=WS_!NJ
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M*P,+DFY.4I?Y]27V0LMR+&\\6M>3Y0##QC@XVW%PC./PC46KHHJ_$ 5%D$S
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MC,-V0'KMFJPKK<!FL= 1*02>]>I5Z:J9%=C>*UBX$@7\,ZJ =E3AK$'T,'G
M;7T@]M#=4UM)I0G$K E?MJO7<G7T"G$@[9(/E=8)K=TR>H!ADWXE#<0L#9_I
M4YRN4K3D"J9$3!.D.%HSJ<[T>,Z@#:+0-9X]?HEE#2WK%].6I[;G,5?QJRB*
M]?P!<N4. 3A.&6)49/W)6CJOCYT=6K;G[9DRI-("8M[[3)C(#YVR&2OJRXO2
MH)/)_==34]^KXDZ<MU'?2%6[B;EV'[/4O2M]-Z)A!;:W9W] *B$@YAW"_[ 1
M+39G<IOY>E*#JQ2<%+NU8N>Q%#$$7(EX/H<NPRR'8$-I!TPL6=?IRET/=4S<
MOKE2B0\QBT\K)TTR2RIU(,$;2<-**HA9*GY*9DN?#?DDH=^2V7Z[YFE))1>V
M62Y>([-VQXX@='%@[V-157W;7)V/$:W2=9U5@ ,O]/W=HY9^PR;]2A#L Y;U
M!^YG2E>-K04FK8!WF=ED;[QKQV.OU B)_D57LT7,UBPRG;]5"F&_$86P*X6P
MS0IQ5'JU!0('@4><W8#UVC7)5T)BFZMQ9\0F@D_UB:1I>*H:;?MO)&)5?;?-
MJ_^C(M:Q&P@=W_7LW9#U&Q;T1[47)_K-VV<JYC&L.!+V"$AKZ(,+4;S,*FX4
M7^;O4J9<*9[FEPM&(R:T ?S^R&%Y6][HUS/;5XJ7_P%02P,$%     @ MH)E
M4>3G)O=6 @  O@8  !D   !X;"]W;W)K<VAE971S+W-H965T-3$N>&ULI97;
MCILP$(9?Q4*JU$H5$"#-9I5$RJGJ7JP:[?9P4?7"@2%8:VQJ3YKT[6L;0M.(
M):OV!NRQO__WV'B8'*1ZT@4 DF/)A9YZ!6)U&P0Z+:"DVI<5"#.22U52-%VU
M"W2E@&8.*GD0A>&[H*1,>+.)BVW4;"+WR)F C2)Z7Y94_5H EX>I-_!.@0>V
M*] &@MFDHCMX!/Q<;93I!:U*QDH0FDE!%.13;SZX72=VOIOPA<%!G[6)S60K
MY9/MW&53+[0+ @XI6@5J7C]A"9Q;(;.,'XVFUUI:\+Q]4G_O<C>Y;*F&I>1?
M68;%U+OQ2 8YW7-\D(</T.0SM'JIY-H]R:&>&\<>2?<:9=G 9@4E$_6;'IM]
M. .,3C<0-4!T"23/ '$#Q"]U2!H@>:G#L %<ZD&=N]NX%44ZFRAY(,K.-FJV
MX7;?T6:_F+#?R2,J,\H,A[,[D<H2R"=Z!$U>KP IX_K-)$"C;6<$::.SJ'6B
M9W1B<B\%%IJL1099![_JY\<]?&!R:A.+3HDMHE[!CRGZ)(S>DBB,PH[U+/OQ
M1ZA\$HTL/AAWI?-_[NM_=O]K,^+VE&.G%U\]9;)B.N52[Q60;_.M1F6NZO<>
MBZ2U2)Q%\HS%.L_!77K":C,T9HHB='U+_5*#H3\*7W6=63\7A?ZPDUM=\;OQ
M;SJY]15N[">77+UWP=F%+$'M7"74))5[@?6IM=&VV,Y=C;F(+P:WRT%'?&6*
M<UU+_\C7E?V>JAT3FG#(C57HCTR]4'6UK#LH*U<.MA)-<7'-POQ@0-D)9CR7
M$D\=:]#^LF:_ 5!+ P04    " "V@F51-3(AP*H#  "/#   &0   'AL+W=O
M<FMS:&5E=',O<VAE970U,BYX;6RM5]&.FS@4_14+S<-4Z@1C(, HB=2$K+92
MNSMJ.NVS!YQ@%7#6-I/NWZ]M""'$DYG=[DN"[7..?0_7]F5V8/R'* B1X&=5
MUF+N%%+N[UU79 6IL)BP/:G5R);Q"DO5Y#M7[#G!N2%5I8L@G+H5IK6SF)F^
M![Z8L4:6M"8/'(BFJC#_>TE*=I@[GG/L^$)WA=0=[F*VQSNR(?)Q_\!5R^U5
M<EJ16E!6 TZV<^>#=[_VH"88Q#=*#F+P#'0H3XS]T(V/^=R!>D6D))G4$EC]
M/9,5*4NMI-;Q5R?J]'-JXO#YJ/Z;"5X%\X0%6;'R.\UE,7=B!^1DBYM2?F&'
MWTD74*CU,E8*\PL.'18Z(&N$9%5'5BNH:-W^XY^=$0."TK$34$= 8T+P L'O
M"/Y;9P@Z0O#6&<*.8$)WV]B-<2F6>#'C[ "X1BLU_6#<-VSE%ZUUHFPD5Z-4
M\>3B#Y6+'^N,503<?F)"O ,/A(--@3D!=V#%JGTCL7FE; N66- ,X#H'*2T;
M27(PH)]XMRF1F)9*ZPX\;E)P>_,.W  7"#TJ *W!8TVE>#_H^%JP1BAAU7ES
MUIZY4D6IU^IF743+-B+T0D0^^,QJ60BPKG.26_CI=7YRA>\J=WN+T='B);HJ
M^&<F)P"B]P!!!"WK65VG;\A^ E"DZ5YB"^?79E__Y]G/S/#[?/.-GO]2OC45
MX5@R?G]%+.C% B,67$E>VB5OJ9/7EBVMQ-1(Z&/S>7'G(Q@H+YZ'+^$2ED1!
MB,Y1Z24J]OW$/T>M+U$H1&B:]+"S:,,^VO"J=2FIF3H!7C-OVLM-KYKWW9RA
M)+_#S^J-[ A0/E9JGW>;4ETJ0JH=2.N=VL9/9N??TN.PU>EVOG 0M@\3SYN.
MG+;!?#2-1U;;8%'@1R.O;3 O25[P.NK-B:Z:8\XW=8,!0;*&4TF5(Z]$'UTL
M9)QBEP@/>7$XBMN"@C <N;.VH'P81/:HXS[J^/]+B;R[ EZQ)7Y;4EA@7AB$
MHYV5VF!1D(P\7%O58#"UVY/T]B3_[K@!>W7GB>ZN/&V1G)4EYN(T:C6FG2L>
MGDMPXHULN03!B3\^E&P@--XG-E <V WQX*EZ@+]@R3!%WF9*-]TKKEA0RI81
M*K6BT"CQUE94//+%'118ZO[:F<I6J.W1U+*]^_K>OGK^8&K&4?_2NU]YEOY4
M5]NFH#O)MZ7Z9\QWM!:@)%LU%9Q$*JMY6_VV#<GVIKQ[8E(5B^:Q4%\,A&N
M&M\R)H\-/4'_#;+X!U!+ P04    " "V@F51S@5<..("  #*!P  &0   'AL
M+W=O<FMS:&5E=',O<VAE970U,RYX;6RE56U/VS 0_BM6/H$TFC1IZ4!M)?HR
M#0E81??R8=H'-[DV%G[);(?"O]_924.!$K'M2V.?[WGNN?/5-]PJ?6=R $L>
M!)=F%.36%N=A:-(<!#4=58#$D[72@EK<ZDUH"@TT\R#!PSB*3D-!F0S&0V];
MZ/%0E98S"0M-3"D$U8\3X&H["KK!SG#+-KEUAG \+.@&EF"_%0N-N[!AR9@
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M.WPS/X&45$PONF2$>_L')+3BG[I9]_9%M+-Z^[M]O&#>%.SOZO%?4$L#!!0
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M(7N1G""0DR$A<P!YCD">#PE9 ,@/".2'(2$G /(C OF1%O*G77,MG]L#C.N
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M$,HU][ 4@FDG)]8.BMFOV&#:R8FU S O8\50^I#ZM&/IFZXD3'!S3#PYL7@
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M;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ MH)E41F+Z&CN    *P(  !$
M             ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @
MMH)E49E<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H
M96UE,2YX;6Q02P$"% ,4    " "V@F51"AY7%#8%  !@%0  &
M    @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @
MMH)E4?'=X1OJ!@  _AL  !@              ("!>0T  'AL+W=O<FMS:&5E
M=',O<VAE970R+GAM;%!+ 0(4 Q0    ( +:"95&60D,%J@(  -X(   8
M          " @9D4  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M    " "V@F511\5;($H&  !)&@  &               @(%Y%P  >&PO=V]R
M:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ MH)E42\9\UU* P  >@D
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M965T.2YX;6Q02P$"% ,4    " "V@F51W(-6Z,@+  #B'P  &0
M    @(%$40  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    (
M +:"95&^QTU,9A   )<S   9              " @4-=  !X;"]W;W)K<VAE
M971S+W-H965T,3$N>&UL4$L! A0#%     @ MH)E49#%\\KP!P  B14  !D
M             ("!X&T  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"
M% ,4    " "V@F51**Y\1\4%  #@#0  &0              @($'=@  >&PO
M=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( +:"95&7]0Y+!0,
M $\&   9              " @0-\  !X;"]W;W)K<VAE971S+W-H965T,30N
M>&UL4$L! A0#%     @ MH)E4;K-QK;1"   L!8  !D              ("!
M/W\  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " "V@F51
M4M>^*@,#  !5!P  &0              @(%'B   >&PO=V]R:W-H965T<R]S
M:&5E=#$V+GAM;%!+ 0(4 Q0    ( +:"95$P:LC'& 0  ,$)   9
M      " @8&+  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%
M  @ MH)E4=IB-TG"!@  M!   !D              ("!T(\  'AL+W=O<FMS
M:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " "V@F51!PZ%$!$<   \6P
M&0              @(')E@  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+
M 0(4 Q0    ( +:"95%X11#T%@8  ( .   9              " @1&S  !X
M;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ MH)E4=FF8_-L
M P  *0@  !D              ("!7KD  'AL+W=O<FMS:&5E=',O<VAE970R
M,2YX;6Q02P$"% ,4    " "V@F510TR\1O\%  !]%   &0
M@($!O0  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( +:"
M95&/H?Q:O@,  /D(   9              " @3?#  !X;"]W;W)K<VAE971S
M+W-H965T,C,N>&UL4$L! A0#%     @ MH)E4907QS#! @  QP4  !D
M         ("!+,<  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
M    " "V@F51D\9>9O$"  !$!@  &0              @($DR@  >&PO=V]R
M:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( +:"95%AZWL:KP,  $H)
M   9              " @4S-  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL
M4$L! A0#%     @ MH)E42&L^VBW!   :Q,  !D              ("!,M$
M 'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " "V@F51^>J9
ME3X$  !@$@  &0              @($@U@  >&PO=V]R:W-H965T<R]S:&5E
M=#(X+GAM;%!+ 0(4 Q0    ( +:"95$@. %H0P,  ,T+   9
M  " @97:  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @
MMH)E43YOWR;F P  N1(  !D              ("!#]X  'AL+W=O<FMS:&5E
M=',O<VAE970S,"YX;6Q02P$"% ,4    " "V@F51,S1%$TL#  #P"P  &0
M            @($LX@  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4
M Q0    ( +:"95$/,[ANC@0  %X3   9              " @:[E  !X;"]W
M;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ MH)E4879T3I'!
MQ \  !D              ("!<^H  'AL+W=O<FMS:&5E=',O<VAE970S,RYX
M;6Q02P$"% ,4    " "V@F51-DC-^0P$   +$@  &0              @('Q
M[@  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( +:"95'.
M?44PHP(  #\'   9              " @33S  !X;"]W;W)K<VAE971S+W-H
M965T,S4N>&UL4$L! A0#%     @ MH)E46K\QU\"!   !1(  !D
M     ("!#O8  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4
M" "V@F51@ Y5M1,#  #:"0  &0              @(%'^@  >&PO=V]R:W-H
M965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( +:"95&4/W'9T@(  )P(   9
M              " @9']  !X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L!
M A0#%     @ MH)E48X$F(<T P  $@H  !D              ("!F@ ! 'AL
M+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " "V@F512, ?H@<#
M  !M"   &0              @($%! $ >&PO=V]R:W-H965T<R]S:&5E=#0P
M+GAM;%!+ 0(4 Q0    ( +:"95&OSSGF*P,  "()   9              "
M@4,' 0!X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ MH)E
M4;8>+Q[: @  Q0<  !D              ("!I0H! 'AL+W=O<FMS:&5E=',O
M<VAE970T,BYX;6Q02P$"% ,4    " "V@F51[XM19T &   K)P  &0
M        @(&V#0$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0
M   ( +:"95$N !;"BP(  '8&   9              " @2T4 0!X;"]W;W)K
M<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ MH)E48ZSX%P2 P  )0H
M !D              ("![Q8! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q0
M2P$"% ,4    " "V@F51@_L!0Z "  !%!@  &0              @($X&@$
M>&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( +:"95%4$==R
MG 8  #HR   9              " @0\= 0!X;"]W;W)K<VAE971S+W-H965T
M-#<N>&UL4$L! A0#%     @ MH)E45XN?G!" P  D@H  !D
M ("!XB,! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    " "V
M@F51T%W3#$X#   +"P  &0              @(%;)P$ >&PO=V]R:W-H965T
M<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( +:"95%CWP@.! 8  %X<   9
M          " @> J 0!X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#
M%     @ MH)E4>3G)O=6 @  O@8  !D              ("!&S$! 'AL+W=O
M<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    " "V@F51-3(AP*H#  "/
M#   &0              @(&H,P$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM
M;%!+ 0(4 Q0    ( +:"95'.!5PXX@(  ,H'   9              " @8DW
M 0!X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ MH)E49;H
M+-A) @  N L   T              ( !HCH! 'AL+W-T>6QE<RYX;6Q02P$"
M% ,4    " "V@F51EXJ[',     3 @  "P              @ $6/0$ 7W)E
M;',O+G)E;'-02P$"% ,4    " "V@F51^9 G7S@$  !J(P  #P
M    @ '_/0$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ MH)E47Q^Z1O4
M 0  QA\  !H              ( !9$(! 'AL+U]R96QS+W=O<FMB;V]K+GAM
M;"YR96QS4$L! A0#%     @ MH)E42IDTJ;* 0  FQ\  !,
M ( !<$0! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     #T /0"B$   :T8!
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>254</ContextCount>
  <ElementCount>288</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>61</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="exel-20201002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="exel-20201002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="exel-20201002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="exel-20201002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss</Role>
      <ShortName>Condensed Consolidated Statements of Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="exel-20201002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="exel-20201002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Comprehensive Income (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="exel-20201002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Condensed Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="exel-20201002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1007008 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="exel-20201002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="exel-20201002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2104102 - Disclosure - Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/Revenues</Role>
      <ShortName>Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="exel-20201002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2112103 - Disclosure - Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreements</Role>
      <ShortName>Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="exel-20201002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2122104 - Disclosure - Cash and Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestments</Role>
      <ShortName>Cash and Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="exel-20201002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2129105 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="exel-20201002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2132106 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="exel-20201002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2135107 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="exel-20201002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2139108 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="exel-20201002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2141109 - Disclosure - Net Income (Loss) Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomeLossPerShare</Role>
      <ShortName>Net Income (Loss) Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="exel-20201002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2145110 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="exel-20201002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="exel-20201002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesTables</Role>
      <ShortName>Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/Revenues</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="exel-20201002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2313302 - Disclosure - Collaboration Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsTables</Role>
      <ShortName>Collaboration Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreements</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="exel-20201002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2323303 - Disclosure - Cash and Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestmentsTables</Role>
      <ShortName>Cash and Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CashandInvestments</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="exel-20201002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2330304 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/FairValueMeasurements</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="exel-20201002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2333305 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/Inventory</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="exel-20201002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2336306 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/StockBasedCompensation</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="exel-20201002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2342307 - Disclosure - Net Income (Loss) Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomeLossPerShareTables</Role>
      <ShortName>Net Income (Loss) Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/NetIncomeLossPerShare</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="exel-20201002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2403401 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="exel-20201002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Revenues - Revenues by Disaggregated Category (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails</Role>
      <ShortName>Revenues - Revenues by Disaggregated Category (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="exel-20201002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Revenues - Net Product Revenues Disaggregated by Product (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails</Role>
      <ShortName>Revenues - Net Product Revenues Disaggregated by Product (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="exel-20201002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Revenues - Revenues Disaggregated by Significant Customer (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails</Role>
      <ShortName>Revenues - Revenues Disaggregated by Significant Customer (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="exel-20201002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - Revenues - Revenues Disaggregated by Geographic Region (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails</Role>
      <ShortName>Revenues - Revenues Disaggregated by Geographic Region (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="exel-20201002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2410406 - Disclosure - Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails</Role>
      <ShortName>Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="exel-20201002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2411407 - Disclosure - Revenues - Contract Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails</Role>
      <ShortName>Revenues - Contract Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="exel-20201002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2414408 - Disclosure - Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails</Role>
      <ShortName>Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="exel-20201002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2415409 - Disclosure - Collaboration Agreements - Ipsen Collaboration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails</Role>
      <ShortName>Collaboration Agreements - Ipsen Collaboration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="exel-20201002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2416410 - Disclosure - Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails</Role>
      <ShortName>Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="exel-20201002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2417411 - Disclosure - Collaboration Agreements - Takeda Collaboration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails</Role>
      <ShortName>Collaboration Agreements - Takeda Collaboration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="exel-20201002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2418412 - Disclosure - Collaboration Agreements - GSK (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsGSKDetails</Role>
      <ShortName>Collaboration Agreements - GSK (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreementsTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="exel-20201002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2419413 - Disclosure - Collaboration Agreements - Royalty Revenues under the Collaboration Agreement with Genentech (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails</Role>
      <ShortName>Collaboration Agreements - Royalty Revenues under the Collaboration Agreement with Genentech (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="exel-20201002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2420414 - Disclosure - Collaboration Agreements - In-Licensing Collaborations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsInLicensingCollaborationsDetails</Role>
      <ShortName>Collaboration Agreements - In-Licensing Collaborations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="exel-20201002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2421415 - Disclosure - Collaboration Agreements - NBE Therapeutics AG (NBE) Collaboration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsNBETherapeuticsAGNBECollaborationDetails</Role>
      <ShortName>Collaboration Agreements - NBE Therapeutics AG (NBE) Collaboration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="exel-20201002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2424416 - Disclosure - Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails</Role>
      <ShortName>Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="exel-20201002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2425417 - Disclosure - Cash and Investments - Investments by Security Type (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails</Role>
      <ShortName>Cash and Investments - Investments by Security Type (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="exel-20201002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2426418 - Disclosure - Cash and Investments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails</Role>
      <ShortName>Cash and Investments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="exel-20201002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2427419 - Disclosure - Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails</Role>
      <ShortName>Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="exel-20201002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2428420 - Disclosure - Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails</Role>
      <ShortName>Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="exel-20201002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2431421 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="exel-20201002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2434422 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/InventoryTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="exel-20201002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2437423 - Disclosure - Stock-Based Compensation - Allocated Employee Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Allocated Employee Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="exel-20201002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2438424 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="exel-20201002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2440425 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/IncomeTaxes</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="exel-20201002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2443426 - Disclosure - Net Income (Loss) Per Share - Computation of Basic and Diluted Net Income Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomeLossPerShareComputationofBasicandDilutedNetIncomePerShareDetails</Role>
      <ShortName>Net Income (Loss) Per Share - Computation of Basic and Diluted Net Income Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/NetIncomeLossPerShareTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="exel-20201002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2444427 - Disclosure - Net Income (Loss) Per Share - Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income (Loss) Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomeLossPerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails</Role>
      <ShortName>Net Income (Loss) Per Share - Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income (Loss) Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/NetIncomeLossPerShareTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="exel-20201002.htm">exel-20201002.htm</File>
    <File>exel-20201002.xsd</File>
    <File>exel-20201002_cal.xml</File>
    <File>exel-20201002_def.xml</File>
    <File>exel-20201002_lab.xml</File>
    <File>exel-20201002_pre.xml</File>
    <File>exel20200930exhibit101.htm</File>
    <File>exel20200930exhibit311.htm</File>
    <File>exel20200930exhibit312.htm</File>
    <File>exel20200930exhibit321.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>exel-20201002_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>71
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "exel-20201002.htm": {
   "axisCustom": 1,
   "axisStandard": 16,
   "contextCount": 254,
   "dts": {
    "calculationLink": {
     "local": [
      "exel-20201002_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "exel-20201002_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "exel-20201002.htm"
     ]
    },
    "labelLink": {
     "local": [
      "exel-20201002_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "exel-20201002_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "exel-20201002.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 378,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 5
   },
   "keyCustom": 36,
   "keyStandard": 252,
   "memberCustom": 31,
   "memberStandard": 30,
   "nsprefix": "exel",
   "nsuri": "http://www.exelixis.com/20201002",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.exelixis.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104102 - Disclosure - Revenues",
     "role": "http://www.exelixis.com/role/Revenues",
     "shortName": "Revenues",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112103 - Disclosure - Collaboration Agreements",
     "role": "http://www.exelixis.com/role/CollaborationAgreements",
     "shortName": "Collaboration Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "exel:CashCashEquivalentsAndInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2122104 - Disclosure - Cash and Investments",
     "role": "http://www.exelixis.com/role/CashandInvestments",
     "shortName": "Cash and Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "exel:CashCashEquivalentsAndInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129105 - Disclosure - Fair Value Measurements",
     "role": "http://www.exelixis.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2132106 - Disclosure - Inventory",
     "role": "http://www.exelixis.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135107 - Disclosure - Stock-Based Compensation",
     "role": "http://www.exelixis.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2139108 - Disclosure - Income Taxes",
     "role": "http://www.exelixis.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2141109 - Disclosure - Net Income (Loss) Per Share",
     "role": "http://www.exelixis.com/role/NetIncomeLossPerShare",
     "shortName": "Net Income (Loss) Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2145110 - Disclosure - Commitments and Contingencies",
     "role": "http://www.exelixis.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "iccc3837038f342898d73d67395904bae_I20201002",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "iccc3837038f342898d73d67395904bae_I20201002",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Revenues (Tables)",
     "role": "http://www.exelixis.com/role/RevenuesTables",
     "shortName": "Revenues (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313302 - Disclosure - Collaboration Agreements (Tables)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsTables",
     "shortName": "Collaboration Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2323303 - Disclosure - Cash and Investments (Tables)",
     "role": "http://www.exelixis.com/role/CashandInvestmentsTables",
     "shortName": "Cash and Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2330304 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.exelixis.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2333305 - Disclosure - Inventory (Tables)",
     "role": "http://www.exelixis.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2336306 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.exelixis.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2342307 - Disclosure - Net Income (Loss) Per Share (Tables)",
     "role": "http://www.exelixis.com/role/NetIncomeLossPerShareTables",
     "shortName": "Net Income (Loss) Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403401 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)",
     "role": "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Organization and Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Revenues - Revenues by Disaggregated Category (Details)",
     "role": "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails",
     "shortName": "Revenues - Revenues by Disaggregated Category (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i6b8d3dbc1c5648e68dcec00585f82d14_D20200704-20201002",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Revenues - Net Product Revenues Disaggregated by Product (Details)",
     "role": "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
     "shortName": "Revenues - Net Product Revenues Disaggregated by Product (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "ide4bbab6cf384b57a9b8addbd0e12d37_D20200704-20201002",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "iccc3837038f342898d73d67395904bae_I20201002",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "iccc3837038f342898d73d67395904bae_I20201002",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "ia60d29d213b7423f8b44089dbc426396_D20200704-20201002",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Revenues - Revenues Disaggregated by Significant Customer (Details)",
     "role": "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails",
     "shortName": "Revenues - Revenues Disaggregated by Significant Customer (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "ia60d29d213b7423f8b44089dbc426396_D20200704-20201002",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409405 - Disclosure - Revenues - Revenues Disaggregated by Geographic Region (Details)",
     "role": "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails",
     "shortName": "Revenues - Revenues Disaggregated by Geographic Region (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "iec0582c68f2e45809336de61a7ef2ffe_D20200704-20201002",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "ie736426c8e19488ea872e8da8ebb6578_I20200103",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410406 - Disclosure - Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)",
     "role": "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails",
     "shortName": "Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "ie736426c8e19488ea872e8da8ebb6578_I20200103",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "iccc3837038f342898d73d67395904bae_I20201002",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411407 - Disclosure - Revenues - Contract Assets and Liabilities (Details)",
     "role": "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails",
     "shortName": "Revenues - Contract Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "ie736426c8e19488ea872e8da8ebb6578_I20200103",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414408 - Disclosure - Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
     "shortName": "Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i911b510538cf4e2e9af50c7bbb5b99af_D20200704-20201002",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "iccc3837038f342898d73d67395904bae_I20201002",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415409 - Disclosure - Collaboration Agreements - Ipsen Collaboration (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails",
     "shortName": "Collaboration Agreements - Ipsen Collaboration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "icef64ef981c4433ab4d95dd86f4c12ae_I20201002",
      "decimals": "INF",
      "lang": "en-US",
      "name": "exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416410 - Disclosure - Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
     "shortName": "Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "ieb095da3afbd4daa9861c6249817cea0_D20200704-20201002",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "iccc3837038f342898d73d67395904bae_I20201002",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417411 - Disclosure - Collaboration Agreements - Takeda Collaboration (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails",
     "shortName": "Collaboration Agreements - Takeda Collaboration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "ieb095da3afbd4daa9861c6249817cea0_D20200704-20201002",
      "decimals": "-5",
      "lang": "en-US",
      "name": "exel:MilestonePaymentsEarned",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "if6d4cedf8c084744ba29969039e3b2e9_D20200704-20201002",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RoyaltyExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418412 - Disclosure - Collaboration Agreements - GSK (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsGSKDetails",
     "shortName": "Collaboration Agreements - GSK (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "if6d4cedf8c084744ba29969039e3b2e9_D20200704-20201002",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RoyaltyExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419413 - Disclosure - Collaboration Agreements - Royalty Revenues under the Collaboration Agreement with Genentech (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails",
     "shortName": "Collaboration Agreements - Royalty Revenues under the Collaboration Agreement with Genentech (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "id774200cb5964ec7a9f457d6f01d6879_D20200704-20201002",
      "decimals": "-3",
      "lang": "en-US",
      "name": "exel:CollaborativeArrangementIncomeLossFromAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Income (Loss)",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss",
     "shortName": "Condensed Consolidated Statements of Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i02e9b643d49a417e9373b15e166ba536_D20200104-20201002",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "exel:CollaborativeAgreementsUpfrontPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420414 - Disclosure - Collaboration Agreements - In-Licensing Collaborations (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsInLicensingCollaborationsDetails",
     "shortName": "Collaboration Agreements - In-Licensing Collaborations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i02e9b643d49a417e9373b15e166ba536_D20200104-20201002",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "exel:CollaborativeAgreementsUpfrontPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i6b107f2541f144959f65cffe2682f793_D20200104-20201002",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "exel:CollaborativeAgreementsUpfrontPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421415 - Disclosure - Collaboration Agreements - NBE Therapeutics AG (NBE) Collaboration (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsNBETherapeuticsAGNBECollaborationDetails",
     "shortName": "Collaboration Agreements - NBE Therapeutics AG (NBE) Collaboration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i6b107f2541f144959f65cffe2682f793_D20200104-20201002",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "exel:CollaborativeAgreementsUpfrontPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "iccc3837038f342898d73d67395904bae_I20201002",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424416 - Disclosure - Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)",
     "role": "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails",
     "shortName": "Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "iccc3837038f342898d73d67395904bae_I20201002",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashEquivalentsNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "iccc3837038f342898d73d67395904bae_I20201002",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425417 - Disclosure - Cash and Investments - Investments by Security Type (Details)",
     "role": "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
     "shortName": "Cash and Investments - Investments by Security Type (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "iccc3837038f342898d73d67395904bae_I20201002",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "iccc3837038f342898d73d67395904bae_I20201002",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426418 - Disclosure - Cash and Investments - Narrative (Details)",
     "role": "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails",
     "shortName": "Cash and Investments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "iccc3837038f342898d73d67395904bae_I20201002",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "iccc3837038f342898d73d67395904bae_I20201002",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427419 - Disclosure - Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)",
     "role": "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
     "shortName": "Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "iccc3837038f342898d73d67395904bae_I20201002",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "iccc3837038f342898d73d67395904bae_I20201002",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428420 - Disclosure - Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)",
     "role": "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails",
     "shortName": "Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "iccc3837038f342898d73d67395904bae_I20201002",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "iccc3837038f342898d73d67395904bae_I20201002",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431421 - Disclosure - Fair Value Measurements (Details)",
     "role": "http://www.exelixis.com/role/FairValueMeasurementsDetails",
     "shortName": "Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "ia145ea6fe2c34f45a3f0710801bc6531_I20201002",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "iccc3837038f342898d73d67395904bae_I20201002",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434422 - Disclosure - Inventory (Details)",
     "role": "http://www.exelixis.com/role/InventoryDetails",
     "shortName": "Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "iccc3837038f342898d73d67395904bae_I20201002",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437423 - Disclosure - Stock-Based Compensation - Allocated Employee Stock-Based Compensation Expense (Details)",
     "role": "http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Allocated Employee Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "id8807e50c23c4d31ab20dcdcebd143c7_D20200704-20201002",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss)",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "iccc3837038f342898d73d67395904bae_I20201002",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438424 - Disclosure - Stock-Based Compensation - Narrative (Details)",
     "role": "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails",
     "shortName": "Stock-Based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002",
      "decimals": "INF",
      "lang": "en-US",
      "name": "exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440425 - Disclosure - Income Taxes (Details)",
     "role": "http://www.exelixis.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443426 - Disclosure - Net Income (Loss) Per Share - Computation of Basic and Diluted Net Income Per Share (Details)",
     "role": "http://www.exelixis.com/role/NetIncomeLossPerShareComputationofBasicandDilutedNetIncomePerShareDetails",
     "shortName": "Net Income (Loss) Per Share - Computation of Basic and Diluted Net Income Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i41f51136e2dd4492aea05277671e9389_D20200704-20201002",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444427 - Disclosure - Net Income (Loss) Per Share - Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income (Loss) Per Share (Details)",
     "role": "http://www.exelixis.com/role/NetIncomeLossPerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails",
     "shortName": "Net Income (Loss) Per Share - Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income (Loss) Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i41f51136e2dd4492aea05277671e9389_D20200704-20201002",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Comprehensive Income (Parenthetical)",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i719734989c4e4074bec2e9a0b8932dcf_D20200704-20201002",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "ifad3e2a4eb5e4ee8a6ee49d932419d11_I20181228",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Condensed Consolidated Statements of Stockholders' Equity",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "ifad3e2a4eb5e4ee8a6ee49d932419d11_I20181228",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007008 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Summary of Significant Accounting Policies",
     "role": "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20201002.htm",
      "contextRef": "i3b5e25de499543c0a3aa2563a31fef4c_D20200104-20201002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 61,
   "tag": {
    "country_JP": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "JAPAN",
        "terseLabel": "Japan"
       }
      }
     },
     "localname": "JP",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S."
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "exel_AccruedClinicalLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued Clinical Liabilities, Current",
        "label": "Accrued Clinical Liabilities, Current",
        "terseLabel": "Accrued clinical trial liabilities"
       }
      }
     },
     "localname": "AccruedClinicalLiabilitiesCurrent",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_AccruedCollaborationLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued Collaboration Liability, Current",
        "label": "Accrued Collaboration Liability, Current",
        "terseLabel": "Accrued collaboration liabilities"
       }
      }
     },
     "localname": "AccruedCollaborationLiabilityCurrent",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_AchievedMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Achieved [Member]",
        "label": "Achieved [Member]",
        "terseLabel": "Achieved"
       }
      }
     },
     "localname": "AchievedMember",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AffiliatesOfAmerisourceBergenCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Affiliates Of Amerisource Bergen Corporation [Member]",
        "label": "Affiliates Of Amerisource Bergen Corporation [Member]",
        "terseLabel": "Affiliates of AmerisourceBergen Corporation"
       }
      }
     },
     "localname": "AffiliatesOfAmerisourceBergenCorporationMember",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AffiliatesofCVSHealthCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Affiliates of CVS Health Corporation [Member]",
        "label": "Affiliates of CVS Health Corporation [Member]",
        "terseLabel": "Affiliates of CVS Health Corporation"
       }
      }
     },
     "localname": "AffiliatesofCVSHealthCorporationMember",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AffiliatesofMcKessonCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Affiliates of McKesson Corporation [Member]",
        "label": "Affiliates of McKesson Corporation [Member]",
        "terseLabel": "Affiliates of McKesson Corporation"
       }
      }
     },
     "localname": "AffiliatesofMcKessonCorporationMember",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AffiliatesofOptumSpecialtyPharmacyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Affiliates of Optum Specialty Pharmacy [Member]",
        "label": "Affiliates of Optum Specialty Pharmacy [Member]",
        "terseLabel": "Affiliates of Optum Specialty Pharmacy"
       }
      }
     },
     "localname": "AffiliatesofOptumSpecialtyPharmacyMember",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member]",
        "label": "Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member]",
        "terseLabel": "Other Customer Credits/Fees and Co-pay Assistance"
       }
      }
     },
     "localname": "AllowanceForCustomerCreditsFeesandCoPayAssistanceMember",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AllowanceForProductRebatesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Allowance For Product Rebates [Member]",
        "label": "Allowance For Product Rebates [Member]",
        "terseLabel": "Rebates"
       }
      }
     },
     "localname": "AllowanceForProductRebatesMember",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CabometyxMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cabometyx [Member]",
        "label": "Cabometyx [Member]",
        "terseLabel": "CABOMETYX"
       }
      }
     },
     "localname": "CabometyxMember",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CashCashEquivalentsAndInvestmentsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash, Cash Equivalents, and Investments [Text Block]",
        "label": "Cash, Cash Equivalents, and Investments [Text Block]",
        "terseLabel": "CASH AND INVESTMENTS"
       }
      }
     },
     "localname": "CashCashEquivalentsAndInvestmentsTextBlock",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 1.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost",
        "totalLabel": "Cash, cash equivalents, restricted cash and restricted cash equivalents, amortized cost"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1": {
       "order": 1.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities",
        "totalLabel": "Cash, cash equivalents, restricted cash and restricted cash equivalents and available-for-sale debt securities"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1": {
       "order": 3.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax",
        "totalLabel": "Cash, cash equivalents, restricted cash and restricted cash equivalents and available-for-sale debt securities, gross unrealized gains"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1": {
       "order": 2.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax",
        "negatedTotalLabel": "Cash, cash equivalents, restricted cash and restricted cash equivalents and available-for-sale debt securities, gross unrealized losses"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis",
        "totalLabel": "Cash, cash equivalents, restricted cash and restricted cash equivalents and available-for-sale debt securities, amortized cost"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 2.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash, cash equivalents, restricted cash and restricted cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 1.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain",
        "terseLabel": "Cash, cash equivalents, restricted cash and restricted cash equivalents, gross unrealized gain"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 3.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss",
        "negatedTerseLabel": "Cash, cash equivalents, restricted cash and restricted cash equivalents, gross unrealized loss"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ChargebacksAndDiscountsForPromptPaymentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Chargebacks And Discounts For Prompt Payment [Member]",
        "label": "Chargebacks And Discounts For Prompt Payment [Member]",
        "terseLabel": "Chargebacks and Discounts for Prompt Payment"
       }
      }
     },
     "localname": "ChargebacksAndDiscountsForPromptPaymentMember",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement, Option Exercise Fee Payment, Upon Exercising Option",
        "label": "Collaboration Agreement, Option Exercise Fee Payment, Upon Exercising Option",
        "terseLabel": "Option exercise fee payment, if exercised"
       }
      }
     },
     "localname": "CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingCollaborationsDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsNBETherapeuticsAGNBECollaborationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborationAgreementPercentOfRoyaltyOnNetSale": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement, Percent Of Royalty On Net Sale",
        "label": "Collaboration Agreement, Percent Of Royalty On Net Sale",
        "terseLabel": "Percent of royalty on net sale"
       }
      }
     },
     "localname": "CollaborationAgreementPercentOfRoyaltyOnNetSale",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsGSKDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exel_CollaborationAgreementsAdditionalUpfrontPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreements, Additional Upfront Payments",
        "label": "Collaboration Agreements, Additional Upfront Payments",
        "terseLabel": "Additional payments"
       }
      }
     },
     "localname": "CollaborationAgreementsAdditionalUpfrontPayments",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingCollaborationsDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsNBETherapeuticsAGNBECollaborationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborationAndLicenseAgreementExtendedTargetSelectionTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration And License Agreement, Extended Target Selection Term",
        "label": "Collaboration And License Agreement, Extended Target Selection Term",
        "terseLabel": "Collaboration target selection extended, term"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementExtendedTargetSelectionTerm",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingCollaborationsDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsNBETherapeuticsAGNBECollaborationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "exel_CollaborationAndLicenseAgreementTargetSelectionExtensionOptionTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration And License Agreement, Target Selection, Extension Option Term",
        "label": "Collaboration And License Agreement, Target Selection, Extension Option Term",
        "terseLabel": "Collaboration extension option"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementTargetSelectionExtensionOptionTerm",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsNBETherapeuticsAGNBECollaborationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "exel_CollaborationAndLicenseAgreementTargetSelectionTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration And License Agreement, Target Selection Term",
        "label": "Collaboration And License Agreement, Target Selection Term",
        "terseLabel": "Collaboration term"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementTargetSelectionTerm",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingCollaborationsDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsNBETherapeuticsAGNBECollaborationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "exel_CollaborationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration [Member]",
        "label": "Collaboration [Member]",
        "verboseLabel": "Total collaboration revenues"
       }
      }
     },
     "localname": "CollaborationMember",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeAgreementsUpfrontPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Agreements, Upfront Payments",
        "label": "Collaborative Agreements, Upfront Payments",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "localname": "CollaborativeAgreementsUpfrontPayments",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingCollaborationsDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsNBETherapeuticsAGNBECollaborationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementIncomeLossFromAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Income (Loss) from Agreement",
        "label": "Collaborative Arrangement, Income (Loss) From Agreement",
        "terseLabel": "Profits on U.S. commercialization"
       }
      }
     },
     "localname": "CollaborativeArrangementIncomeLossFromAgreement",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum amount eligible for development and regulatory milestones under collaborations agreement.",
        "label": "Collaborative Arrangement, Maximum Amount Eligible For Development And Regulatory Milestones",
        "terseLabel": "Maximum amount eligible for development and regulatory milestones"
       }
      }
     },
     "localname": "CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingCollaborationsDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsNBETherapeuticsAGNBECollaborationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementWithCatalentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement With Catalent",
        "label": "Collaborative Arrangement With Catalent [Member]",
        "terseLabel": "Collaborative Arrangement With Catalent"
       }
      }
     },
     "localname": "CollaborativeArrangementWithCatalentMember",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeArrangementWithNBETherapeuticsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement With NBE Therapeutics",
        "label": "Collaborative Arrangement With NBE Therapeutics [Member]",
        "terseLabel": "Collaborative Arrangement With NBE Therapeutics"
       }
      }
     },
     "localname": "CollaborativeArrangementWithNBETherapeuticsMember",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsNBETherapeuticsAGNBECollaborationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeArrangementswithGlaxoSmithKlineMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangements with Glaxo Smith Kline",
        "label": "Collaborative Arrangements with Glaxo Smith Kline [Member]",
        "terseLabel": "Collaboration Agreement with GlaxoSmithKline"
       }
      }
     },
     "localname": "CollaborativeArrangementswithGlaxoSmithKlineMember",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsGSKDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeArrangementwithGenentechMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement with Genentech [Member]",
        "label": "Collaborative Arrangement with Genentech [Member]",
        "terseLabel": "Collaborative Arrangement with Genentech"
       }
      }
     },
     "localname": "CollaborativeArrangementwithGenentechMember",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeArrangementwithIpsenMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement with Ipsen [Member]",
        "label": "Collaborative Arrangement with Ipsen [Member]",
        "terseLabel": "Collaborative Arrangement with Ipsen"
       }
      }
     },
     "localname": "CollaborativeArrangementwithIpsenMember",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails",
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeArrangementwithTakedaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement with Takeda [Member]",
        "label": "Collaborative Arrangement with Takeda [Member]",
        "terseLabel": "Collaborative Arrangement with Takeda"
       }
      }
     },
     "localname": "CollaborativeArrangementwithTakedaMember",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CometriqMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cometriq [Member]",
        "label": "Cometriq [Member]",
        "terseLabel": "COMETRIQ"
       }
      }
     },
     "localname": "CometriqMember",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CotellicMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cotellic [Member]",
        "label": "Cotellic [Member]",
        "terseLabel": "Cotellic"
       }
      }
     },
     "localname": "CotellicMember",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_EarningsPerShareDenominatorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Earnings Per Share, Denominator [Abstract]",
        "label": "Earnings Per Share, Denominator [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "EarningsPerShareDenominatorAbstract",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomeLossPerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_EarningsPerShareNumeratorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Earnings Per Share, Numerator [Abstract]",
        "label": "Earnings Per Share, Numerator [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "EarningsPerShareNumeratorAbstract",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomeLossPerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Eligible Payment From Collaboration For Development And Regulatory Milestone Achievement Under Collaborations Agreement",
        "label": "Eligible Payment From Collaboration For Development And Regulatory Milestone Achievement Under Collaborations Agreement",
        "terseLabel": "Reduction related to a milestone",
        "verboseLabel": "Eligible payment from collaboration for development and regulatory milestone achievement under collaborations agreement"
       }
      }
     },
     "localname": "EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails",
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_EligiblePaymentFromCollaborationForDevelopmentMilestoneAchievementUnderCollaborationsAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Eligible Payment From Collaboration For Development Milestone Achievement Under Collaborations Agreement",
        "label": "Eligible Payment From Collaboration For Development Milestone Achievement Under Collaborations Agreement",
        "terseLabel": "Eligible development milestone under collaborative agreement"
       }
      }
     },
     "localname": "EligiblePaymentFromCollaborationForDevelopmentMilestoneAchievementUnderCollaborationsAgreement",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_GlaxoSmithKlineMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Glaxo Smith Kline [Member].",
        "label": "Glaxo Smith Kline [Member]",
        "terseLabel": "GSK"
       }
      }
     },
     "localname": "GlaxoSmithKlineMember",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsGSKDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_IpsenMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ipsen [Member]",
        "label": "Ipsen [Member]",
        "terseLabel": "Ipsen"
       }
      }
     },
     "localname": "IpsenMember",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_LiabilitiesExpendituresIncurredButNotYetPaidToRelatedPartyTransactions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Liabilities Expenditures Incurred But Not Yet Paid To Related Party Transactions",
        "label": "Liabilities Expenditures Incurred But Not Yet Paid To Related Party Transactions",
        "terseLabel": "Unpaid liabilities incurred to acquire investments"
       }
      }
     },
     "localname": "LiabilitiesExpendituresIncurredButNotYetPaidToRelatedPartyTransactions",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum Amount Eligible For Commercial Milestones Under Collaborations Agreement",
        "label": "Maximum Amount Eligible For Commercial Milestones Under Collaborations Agreement",
        "terseLabel": "Maximum amount eligible for commercial milestones under collaborations agreement"
       }
      }
     },
     "localname": "MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingCollaborationsDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsNBETherapeuticsAGNBECollaborationDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_MckessonMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Mckesson",
        "label": "Mckesson [Member]",
        "terseLabel": "Mckesson"
       }
      }
     },
     "localname": "MckessonMember",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_MilestonePaymentsEarned": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Milestone Payments Earned",
        "label": "Milestone Payments Earned",
        "terseLabel": "Milestone payments earned"
       }
      }
     },
     "localname": "MilestonePaymentsEarned",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_NewInformationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "New Information [Member]",
        "label": "New Information [Member]",
        "terseLabel": "New information"
       }
      }
     },
     "localname": "NewInformationMember",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_NoncashLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Noncash Lease Expense",
        "label": "Noncash Lease Expense",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "NoncashLeaseExpense",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_NumberofProductsinCommercialMarket": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of Products in Commercial Market",
        "label": "Number of Products in Commercial Market",
        "terseLabel": "Number of products that entered in the commercial marketplace"
       }
      }
     },
     "localname": "NumberofProductsinCommercialMarket",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "exel_OrganizationAndSummaryOfSignificantPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Organization And Summary Of Significant Policies [Line Items]",
        "label": "Organization And Summary Of Significant Policies [Line Items]",
        "terseLabel": "Organization And Summary Of Significant Policies [Line Items]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantPoliciesLineItems",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_OrganizationAndSummaryOfSignificantPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Organization And Summary Of Significant Policies [Table]",
        "label": "Organization And Summary Of Significant Policies [Table]",
        "terseLabel": "Organization And Summary Of Significant Policies [Table]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantPoliciesTable",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_OtherLongtermAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Long-term Assets [Member]",
        "label": "Other Long-term Assets [Member]",
        "terseLabel": "Long-term portion included in other long-term assets"
       }
      }
     },
     "localname": "OtherLongtermAssetsMember",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_PerformanceShareOptionsPSOMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Performance Share Options (PSO) [Member]",
        "label": "Performance Share Options (PSO) [Member]",
        "terseLabel": "Performance Share Options (PSO)"
       }
      }
     },
     "localname": "PerformanceShareOptionsPSOMember",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProbableMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Probable [Member]",
        "label": "Probable [Member]",
        "terseLabel": "Probable"
       }
      }
     },
     "localname": "ProbableMember",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProductGrossMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Product, Gross [Member]",
        "label": "Product, Gross [Member]",
        "terseLabel": "Gross product revenues"
       }
      }
     },
     "localname": "ProductGrossMember",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProductSalesDiscountsAndAllowancesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Product, Sales Discounts And Allowances [Member]",
        "label": "Product, Sales Discounts And Allowances [Member]",
        "terseLabel": "Discounts and allowances"
       }
      }
     },
     "localname": "ProductSalesDiscountsAndAllowancesMember",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProductsDerivedFromCabozantinibMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Products Derived from Cabozantinib [Member]",
        "label": "Products Derived From Cabozantinib [Member]",
        "terseLabel": "Products derived from cabozantinib"
       }
      }
     },
     "localname": "ProductsDerivedFromCabozantinibMember",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProductsDerivedFromOtherCompoundsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Products Derived From Other Compounds [Member]",
        "label": "Products Derived From Other Compounds [Member]",
        "terseLabel": "Products derived from other compounds"
       }
      }
     },
     "localname": "ProductsDerivedFromOtherCompoundsMember",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]",
        "label": "Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]",
        "terseLabel": "Schedule of Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances"
       }
      }
     },
     "localname": "ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "exel_ResultingFromDiscoveryEffortsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Resulting From Discovery Efforts [Member]",
        "label": "Resulting From Discovery Efforts [Member]",
        "terseLabel": "Resulting from discovery efforts"
       }
      }
     },
     "localname": "ResultingFromDiscoveryEffortsMember",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_RightOfUseAssetObtainedInExchangeForLeaseLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Right-Of-Use Asset Obtained In Exchange For Lease Liability",
        "label": "Right-Of-Use Asset Obtained In Exchange For Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForLeaseLiability",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumNumberOfSharesToVest": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Maximum Number of Shares to Vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Maximum Number of Shares to Vest",
        "terseLabel": "Additional shares to be earned (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumNumberOfSharesToVest",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Maximum Potential To Vest",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Maximum Potential To Vest",
        "terseLabel": "Maximum potential to vest, percentage"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award,Reduction of Number of Shares in Share Reserve",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Other Awards",
        "terseLabel": "Reduction in share reserve after all other awards (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award,Reduction of Number of Shares in Share Reserve After Stock Option or Stock Appreciation Award",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Stock Option Or Stock Appreciation Award",
        "terseLabel": "Reduction in share reserve after stock option or stock appreciation award (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Percent Of Common Stock Share Price Triggering PSO Exercises",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Percent Of Common Stock Share Price Triggering PSO Exercises",
        "terseLabel": "Share-based compensation arrangement by share-based payment award, options, percent of common stock share price triggering PSO exercises"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exel_StatusAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Status [Axis]",
        "label": "Status [Axis]",
        "terseLabel": "Status [Axis]"
       }
      }
     },
     "localname": "StatusAxis",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_StatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Status [Axis]",
        "label": "Status [Domain]",
        "terseLabel": "Status [Domain]"
       }
      }
     },
     "localname": "StatusDomain",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_TakedaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Takeda [Member]",
        "label": "Takeda [Member]",
        "terseLabel": "Takeda Pharmaceutical Company Limited (Takeda)",
        "verboseLabel": "Takeda"
       }
      }
     },
     "localname": "TakedaMember",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Valuation Allowances And Reserves, Additions For Sales In Current Period",
        "label": "Valuation Allowances And Reserves, Additions For Sales In Current Period",
        "terseLabel": "Current period"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Valuation Allowances And Reserves, Additions For Sales In Prior Period",
        "label": "Valuation Allowances And Reserves, Additions For Sales In Prior Period",
        "terseLabel": "Prior periods"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Valuation Allowances And Reserves, Additions To Provision [Abstract]",
        "label": "Valuation Allowances And Reserves, Additions To Provision [Abstract]",
        "terseLabel": "Provision related to sales made in:"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesAdditionsToProvisionAbstract",
     "nsuri": "http://www.exelixis.com/20201002",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r165",
      "r239",
      "r245",
      "r400"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsGSKDetails",
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r165",
      "r239",
      "r245",
      "r400"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsGSKDetails",
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r162",
      "r239",
      "r243",
      "r367",
      "r397",
      "r398"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss",
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r162",
      "r239",
      "r243",
      "r367",
      "r397",
      "r398"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss",
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r163",
      "r164",
      "r239",
      "r244",
      "r399",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r163",
      "r164",
      "r239",
      "r244",
      "r399",
      "r410",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r37"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits, Current",
        "terseLabel": "Accrued compensation and benefits"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r22",
      "r51",
      "r53",
      "r54",
      "r387",
      "r405",
      "r406"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r50",
      "r54",
      "r55",
      "r101",
      "r102",
      "r103",
      "r312",
      "r401",
      "r402"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r20",
      "r279"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r101",
      "r102",
      "r103",
      "r276",
      "r277",
      "r278"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedTerseLabel": "Stock transactions associated with taxes withheld on equity awards"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r260",
      "r262",
      "r281",
      "r282"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r262",
      "r272",
      "r280"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation",
        "verboseLabel": "Total stock-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails",
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive shares (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomeLossPerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomeLossPerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomeLossPerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomeLossPerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsGSKDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingCollaborationsDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsNBETherapeuticsAGNBECollaborationDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails",
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r90",
      "r145",
      "r154",
      "r160",
      "r183",
      "r308",
      "r313",
      "r328",
      "r370",
      "r385"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r47",
      "r90",
      "r183",
      "r308",
      "r313",
      "r328"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r318"
     ],
     "calculation": {
      "http://www.exelixis.com/role/FairValueMeasurementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total financial assets carried at fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r171"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Investments available-for-sale, gross unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r172"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 2.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Investments available-for-sale, gross unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r168",
      "r190"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 2.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Investments, available-for-sale, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]",
        "terseLabel": "Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r173",
      "r175",
      "r382"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Maturing after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r173",
      "r174",
      "r381"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Maturing in one year or less"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r167",
      "r169",
      "r190",
      "r374"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 1.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/FairValueMeasurementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Investments available-for-sale, fair value",
        "totalLabel": "Total debt securities available-for-sale",
        "verboseLabel": "Total debt securities available-for-sale"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r264",
      "r274"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r316",
      "r317"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r84",
      "r85",
      "r86"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Unpaid liabilities incurred for purchases of property and equipment"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]",
        "terseLabel": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r32",
      "r83"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/FairValueMeasurementsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r78",
      "r83",
      "r87"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "totalLabel": "Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r78",
      "r329"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash [Member]",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ChangeInAccountingEstimateByTypeAxis": {
     "auth_ref": [
      "r109",
      "r127"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of change in accounting estimate.",
        "label": "Change in Accounting Estimate by Type [Axis]",
        "terseLabel": "Change in Accounting Estimate by Type [Axis]"
       }
      }
     },
     "localname": "ChangeInAccountingEstimateByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ChangeInAccountingEstimateTypeDomain": {
     "auth_ref": [
      "r109",
      "r127"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the accounting estimate that was changed that had the effect of adjusting the carrying amount of an existing asset or liability, or that will alter the subsequent accounting for existing or future assets or liabilities.",
        "label": "Change in Accounting Estimate, Type [Domain]",
        "terseLabel": "Change in Accounting Estimate, Type [Domain]"
       }
      }
     },
     "localname": "ChangeInAccountingEstimateTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r301",
      "r302",
      "r304"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "COLLABORATION AGREEMENTS"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsGSKDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingCollaborationsDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsNBETherapeuticsAGNBECollaborationDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r40",
      "r212",
      "r375",
      "r392"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r213"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r101",
      "r102"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "verboseLabel": "Shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r18",
      "r215"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "verboseLabel": "Shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 309,402 and 304,831 at September\u00a030, 2020 and December\u00a031, 2019, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r58",
      "r60",
      "r61",
      "r64",
      "r377",
      "r394"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income (loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r134",
      "r135",
      "r165",
      "r326",
      "r327"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r134",
      "r135",
      "r165",
      "r326",
      "r327",
      "r408"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r134",
      "r135",
      "r165",
      "r326",
      "r327",
      "r408"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r134",
      "r135",
      "r165",
      "r326",
      "r327"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Percent of total revenues"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r134",
      "r135",
      "r165",
      "r326",
      "r327"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r88",
      "r310"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Basis of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetCurrent": {
     "auth_ref": [
      "r217",
      "r219",
      "r240"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current",
        "verboseLabel": "Contract assets"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r217",
      "r218",
      "r240"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Contract with customer, liability"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r217",
      "r218",
      "r240"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Contract with customer, liability, current"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r217",
      "r218",
      "r240"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Long-term portion of deferred revenues"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r241"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Amount of revenues recognized included in the beginning contract liability balance"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": {
     "auth_ref": [
      "r226"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.",
        "label": "Contract with Customer, Performance Obligation Satisfied in Previous Period",
        "terseLabel": "Revenues recognized for performance obligations satisfied in previous periods"
       }
      }
     },
     "localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r67",
      "r367"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r133",
      "r165"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRefundLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment.",
        "label": "Customer Refund Liability, Current",
        "terseLabel": "Rebates and fees due to customers"
       }
      }
     },
     "localname": "CustomerRefundLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "auth_ref": [
      "r170",
      "r190",
      "r196",
      "r197"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Allowance for Credit Loss",
        "terseLabel": "Allowance for credit losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r179",
      "r191",
      "r199"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "auth_ref": [
      "r180",
      "r192"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "auth_ref": [
      "r178",
      "r194",
      "r199"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "terseLabel": "Schedule of Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r181",
      "r193"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Number of investments in an unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r285",
      "r286"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.",
        "label": "Deferred Income Taxes and Tax Credits",
        "terseLabel": "Deferred taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r81",
      "r143"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r239",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "STOCK-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Net income (loss) per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r65",
      "r106",
      "r107",
      "r108",
      "r109",
      "r110",
      "r114",
      "r116",
      "r118",
      "r119",
      "r120",
      "r124",
      "r125",
      "r378",
      "r395"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in dollars per share)",
        "verboseLabel": "Net income (loss) per share - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss",
      "http://www.exelixis.com/role/NetIncomeLossPerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "negatedTerseLabel": "Decrease in earnings per share due to change in accounting estimate (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r65",
      "r106",
      "r107",
      "r108",
      "r109",
      "r110",
      "r116",
      "r118",
      "r119",
      "r120",
      "r124",
      "r125",
      "r378",
      "r395"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (in dollars per share)",
        "verboseLabel": "Net income (loss) per share - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss",
      "http://www.exelixis.com/role/NetIncomeLossPerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r121",
      "r122",
      "r123",
      "r126"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "NET INCOME (LOSS) PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomeLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r273"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r101",
      "r102",
      "r103",
      "r105",
      "r111",
      "r113",
      "r128",
      "r184",
      "r215",
      "r216",
      "r276",
      "r277",
      "r278",
      "r292",
      "r293",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r401",
      "r402",
      "r403"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r318",
      "r319",
      "r320",
      "r324"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r318",
      "r319"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Classification of Financial Assets Measured and Recorded at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r319",
      "r340",
      "r341",
      "r342"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r318",
      "r319",
      "r321",
      "r322",
      "r325"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r252",
      "r253",
      "r258",
      "r259",
      "r319",
      "r340"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r252",
      "r253",
      "r258",
      "r259",
      "r319",
      "r341"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level\u00a02"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r340",
      "r341",
      "r342"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r323",
      "r325"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r176",
      "r177",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r194",
      "r195",
      "r198",
      "r199",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiscalPeriod": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining an entity's fiscal year or other fiscal period. This disclosure may include identification of the fiscal period end-date, the length of the fiscal period, any reporting period lag between the entity and its subsidiaries, or equity investees. If a reporting lag exists, the closing date of the entity having a different period end is generally noted, along with an explanation of the necessity for using different closing dates. Any intervening events that materially affect the entity's financial position or results of operations are generally also disclosed.",
        "label": "Fiscal Period, Policy [Policy Text Block]",
        "terseLabel": "Fiscal Period"
       }
      }
     },
     "localname": "FiscalPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r202",
      "r204",
      "r369"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r81",
      "r203",
      "r205",
      "r206"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Goodwill impairment"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r92",
      "r145",
      "r153",
      "r156",
      "r159",
      "r161"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income (loss) before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r289",
      "r290",
      "r291",
      "r294",
      "r296",
      "r298",
      "r299",
      "r300"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r91",
      "r112",
      "r113",
      "r144",
      "r287",
      "r295",
      "r297",
      "r396"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for (benefit from) income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Trade receivables, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestIncomeOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of interest income earned from interest bearing assets classified as other.",
        "label": "Interest Income, Other",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivable": {
     "auth_ref": [
      "r46"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.",
        "label": "Interest Receivable",
        "terseLabel": "Interest receivable"
       }
      }
     },
     "localname": "InterestReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoriesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tangible personal property held for sale in the ordinary course of business, or in process of, or to be consumed in, production for sale.",
        "label": "Inventories [Member]",
        "terseLabel": "Current portion included in inventory"
       }
      }
     },
     "localname": "InventoriesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryCurrentTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Current [Table]",
        "terseLabel": "Inventory, Current [Table]"
       }
      }
     },
     "localname": "InventoryCurrentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "INVENTORY"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.exelixis.com/role/InventoryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.exelixis.com/role/InventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Inventory [Line Items]",
        "terseLabel": "Inventory [Line Items]"
       }
      }
     },
     "localname": "InventoryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r4",
      "r45"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.exelixis.com/role/InventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.exelixis.com/role/InventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r200"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down",
        "terseLabel": "Inventory write-down"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Cash Equivalents and Investments by Contractual Maturity"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r36",
      "r90",
      "r155",
      "r183",
      "r309",
      "r313",
      "r314",
      "r328"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r25",
      "r90",
      "r183",
      "r328",
      "r371",
      "r389"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r38",
      "r90",
      "r183",
      "r309",
      "r313",
      "r314",
      "r328"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "License revenues",
        "verboseLabel": "License revenues"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-term Investments",
        "terseLabel": "Long-term investments"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MovementInValuationAllowancesAndReservesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "terseLabel": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]"
       }
      }
     },
     "localname": "MovementInValuationAllowancesAndReservesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash (used in) provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r78",
      "r79",
      "r82"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r56",
      "r59",
      "r63",
      "r82",
      "r90",
      "r104",
      "r106",
      "r107",
      "r108",
      "r109",
      "r112",
      "r113",
      "r117",
      "r145",
      "r153",
      "r156",
      "r159",
      "r161",
      "r183",
      "r328",
      "r376",
      "r393"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income (loss)",
        "totalLabel": "Net income (loss)"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.exelixis.com/role/NetIncomeLossPerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of business segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r145",
      "r153",
      "r156",
      "r159",
      "r161"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income (loss) from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r336"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "verboseLabel": "Long-term portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r2",
      "r100",
      "r139",
      "r315"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r10",
      "r37"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "verboseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r57",
      "r60",
      "r306",
      "r307",
      "r311"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "verboseLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r48",
      "r51"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Net unrealized gains (losses) on available-for-sale debt securities, net of tax impact of $453, $(129), $(893) and $(936), respectively"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": {
     "auth_ref": [
      "r49",
      "r52"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax",
        "terseLabel": "Net unrealized gains (losses) on available-for-sale debt securities, net of tax impact of $453, $(129), $(893) and $(936), respectively"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other, net"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedTerseLabel": "Taxes paid related to net share settlement of equity awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, equipment and other"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance Shares"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred Stock, Par or Stated Value Per Share",
        "verboseLabel": "Par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "verboseLabel": "Shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "verboseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r5",
      "r30",
      "r31"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "verboseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassifications"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r74",
      "r275"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Proceeds from issuance of common stock under equity incentive and stock purchase plans"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r75",
      "r77",
      "r93"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "terseLabel": "Proceeds from maturities and sales of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Net product revenues",
        "verboseLabel": "Net product revenues"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r13",
      "r14",
      "r207",
      "r391"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r19",
      "r26",
      "r390",
      "r409"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "terseLabel": "Trade receivables, net"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r284",
      "r421"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r7",
      "r15",
      "r87",
      "r411"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash Equivalents, Noncurrent",
        "verboseLabel": "Restricted cash equivalents included in long-term investments"
       }
      }
     },
     "localname": "RestrictedCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r21",
      "r216",
      "r279",
      "r388",
      "r404",
      "r406"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r101",
      "r102",
      "r103",
      "r105",
      "r111",
      "r113",
      "r184",
      "r276",
      "r277",
      "r278",
      "r292",
      "r293",
      "r401",
      "r403"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r141",
      "r142",
      "r152",
      "r157",
      "r158",
      "r162",
      "r163",
      "r165",
      "r238",
      "r239",
      "r367"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "netLabel": "Net product revenues",
        "terseLabel": "Revenue from contract with customer",
        "verboseLabel": "Royalty revenues on ex-U.S. sales"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [
      "r134",
      "r165"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r89",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r251"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r228",
      "r229",
      "r242",
      "r251"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "REVENUES"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/Revenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Initial Application Period Cumulative Effect Transition [Line Items]",
        "terseLabel": "Revenue, Initial Application Period Cumulative Effect Transition [Line Items]"
       }
      }
     },
     "localname": "RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information when using transition method for cumulative effect in initial period of application for revenue from contract with customer.",
        "label": "Revenue, Initial Application Period Cumulative Effect Transition [Table]",
        "terseLabel": "Revenue, Initial Application Period Cumulative Effect Transition [Table]"
       }
      }
     },
     "localname": "RevenueInitialApplicationPeriodCumulativeEffectTransitionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueNotFromContractWithCustomer": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue that is not accounted for under Topic 606.",
        "label": "Revenue Not from Contract with Customer",
        "terseLabel": "Revenue not from contract with customer"
       }
      }
     },
     "localname": "RevenueNotFromContractWithCustomer",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r227"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Remaining performance obligation"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails",
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r62",
      "r90",
      "r141",
      "r142",
      "r152",
      "r157",
      "r158",
      "r162",
      "r163",
      "r165",
      "r183",
      "r328",
      "r379"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenues",
        "totalLabel": "Total revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r68"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royalty Expense",
        "verboseLabel": "Royalty expense"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsGSKDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomeLossPerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income (Loss) Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomeLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsGSKDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingCollaborationsDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsNBETherapeuticsAGNBECollaborationDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
        "terseLabel": "Schedule of Collaborative Revenues Under Collaboration Agreement"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Computation of Basic and Diluted Net Income (Loss) Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomeLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r262",
      "r271",
      "r280"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r262",
      "r271",
      "r280"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "verboseLabel": "Allocated Employee Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r11",
      "r27",
      "r28",
      "r29"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r12",
      "r87",
      "r368",
      "r386"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r264",
      "r274"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r88",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r163"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "verboseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss",
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "verboseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ServiceMember": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.",
        "label": "Service [Member]",
        "terseLabel": "Collaboration services revenues"
       }
      }
     },
     "localname": "ServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "RSUs awarded (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Weighted average grant date fair value, awarded (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "terseLabel": "Number of awards outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Increase in share reserve under 2017 plan (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Share-based compensation arrangement by share-based payment award, number of shares available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Options granted in the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant-date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r266",
      "r274"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "terseLabel": "Options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r261",
      "r265"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Options granted in the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r16",
      "r372",
      "r373",
      "r384"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r41",
      "r101",
      "r102",
      "r103",
      "r105",
      "r111",
      "r113",
      "r128",
      "r184",
      "r215",
      "r216",
      "r276",
      "r277",
      "r278",
      "r292",
      "r293",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r401",
      "r402",
      "r403"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r101",
      "r102",
      "r103",
      "r128",
      "r367"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockCompensationPlanMember": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.",
        "label": "Share-based Payment Arrangement [Member]",
        "terseLabel": "Anti-dilutive securities and contingently issuable shares excluded"
       }
      }
     },
     "localname": "StockCompensationPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomeLossPerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r17",
      "r18",
      "r215",
      "r216"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock under equity incentive and stock purchase plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r17",
      "r18",
      "r216",
      "r263",
      "r269"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock under equity incentive and stock purchase plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r18",
      "r23",
      "r24",
      "r90",
      "r166",
      "r183",
      "r328"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental cash flow disclosure:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r176",
      "r177",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsGSKDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingCollaborationsDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsNBETherapeuticsAGNBECollaborationDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails",
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USStatesAndPoliticalSubdivisionsMember": {
     "auth_ref": [
      "r252",
      "r407"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bonds or similar securities issued by state, city, or local US governments or the agencies operated by state, city, or local governments. Debt securities issued by state governments may include bond issuances of US state authorities including, for example, but not limited to, housing authorities, dormitory authorities, and general obligations while debt securities issued by political subdivisions of US states would include, for example, debt issuances by county, borough, city, or municipal governments.",
        "label": "US States and Political Subdivisions Debt Securities [Member]",
        "terseLabel": "Municipal bonds"
       }
      }
     },
     "localname": "USStatesAndPoliticalSubdivisionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "auth_ref": [
      "r252",
      "r380",
      "r407"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Treasury and Government [Member]",
        "terseLabel": "U.S. Treasury and government-sponsored enterprises"
       }
      }
     },
     "localname": "USTreasuryAndGovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of unrealized gains and losses on investments.",
        "label": "Unrealized Gain (Loss) on Investments [Table Text Block]",
        "terseLabel": "Schedule of Investments by Security Type"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r129",
      "r130",
      "r131",
      "r132",
      "r136",
      "r137",
      "r138"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r94",
      "r98"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "periodEndLabel": "Balance at September\u00a030, 2020",
        "periodStartLabel": "Balance at December\u00a031, 2019"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "auth_ref": [
      "r97"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction",
        "negatedTerseLabel": "Payments and customer credits issued"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDeductions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r97",
      "r98"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r97",
      "r98"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r120"
     ],
     "calculation": {
      "http://www.exelixis.com/role/NetIncomeLossPerShareComputationofBasicandDilutedNetIncomePerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "terseLabel": "Dilutive securities (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomeLossPerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r115",
      "r120"
     ],
     "calculation": {
      "http://www.exelixis.com/role/NetIncomeLossPerShareComputationofBasicandDilutedNetIncomePerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Weighted-average common shares outstanding - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss",
      "http://www.exelixis.com/role/NetIncomeLossPerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r114",
      "r120"
     ],
     "calculation": {
      "http://www.exelixis.com/role/NetIncomeLossPerShareComputationofBasicandDilutedNetIncomePerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Weighted-average common shares outstanding - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss",
      "http://www.exelixis.com/role/NetIncomeLossPerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Weighted-average common shares outstanding:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e777-108305"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(i)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130533-203044"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL108322424-203045"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)(1)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=d3e5291-111683"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=SL120269850-112803"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=SL120269850-112803"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r422": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r423": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r424": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r425": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r426": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r427": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e640-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>72
<FILENAME>0000939767-20-000150-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000939767-20-000150-xbrl.zip
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M.9D<88FZD3VFADAFBM$'PU1%OUOIEP.JLF#F'O3+I^)\JBG0+R;G#+>.,B+
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MB10X%X%2S;V'9%"2K#:(/- QU-(Y/COZS$WW)VZLB!$])HF3$1R5P4M!'$G
M%<#L:MHLAUE^7+&=FV5G-'*>#5'KH(#Q:)C4BH'0"IQ*BBT-:>:4,SPE,OF<
MWBBB!8NJQ,1@DQ,B:$J=MX$(MSQDFOMZZ;1(QB2%J)D'ZBD0ZC5AB?OD/4F6
MQ!27AF2SSAF>EN9#<>(F UMO@ N#1II)2 X=2."1DA)L^%PX0LU_&Z@/CA'!
M)1<^[_!2C@#Q*>;ZC,HR!\M'U;D'9N=#Z !:> '<CNJMRV21U,H8]'R\DESJ
MY2/T3#-F9T]0*K47!G+Y$I19Q8Q@QG%-H\8/G"RA/IY;QNSLB9MLX)%9B$Y$
MB%%;&1''!L,94!,F8:6\V[;LZ_2S"LR.]_Y.8X&:<@=6>&NU)6@QG4G2>XXR
M%P65D<'2D&8>@=DIDHDI%0D5.FD!(C =B"$JVA28(7:20[849)IS8':*)-,H
M3;D\ U@%+ HG%!>@B=/H%CJCEX9D,PW,3H\^B"&H0MEA-)<H#+G:."%><BZ-
MX<'9V=%G7C/ @V+9_NH<[[.,:@V4N:B9S2NI,9:@:,["L>K\2W10:RV5G A"
M,^*BFALJJ53@K3>1Z.6CZMQ]X#G53'*<.84JBS@**5&<?YJ$L3(X$P)90O&=
M77+27 @J@W7$J4"9E^!\LI1Z*DU.&#6!NWD4)5H64#X7XE[VM3@>EW7[2Z^4
MW!OH]>3@Q3WNW2PEB:@CS7UFH@3!K>4VDN0Y8](PS\L0 KN[Y-UH9K;CX*0]
M1#O]MM_KK+<&OO<E]L\V4NKUATL9OLZ) L%2P8@4>6E<\ZA FF29E)[(4'Z2
M3@X-UG%2OL20"?O&NMXY(MA6M^66D:C1A$1\4%PY 19!-M/>2*(X-SFI*BTE
M42]Q6.^D&Y9%5J\ZB8U'>KL^GQS\:7TNG4Y>LR1RFGE(,A?5(U8QGH14%%0)
M^.02IQW8[CXB;P3FN5,U:O"-P;#5P9G^_2RW4;[&.XWX=;-[V8QZV1BE>Y('
M?D?+N6/\^--<(G@0@4IO3&3@J-0BY;0JJAQ:BN!%";@D:Y.Z/>SUWYP,ANB;
M]0?7^&'S>!!_Q ;WY\->U\?<537SUG9K</3[V>^QZP\ZMG_T%Q<R<^I@._K8
M^F)=^T<>XV/&<"4"ER=-9N(O)R^)0'S3JT '(X.0J.YRCSO-!&'&&1ME5'K<
M:^+2S5G,')F*A1>%A7_"F?LV>^@Q0!V21K.<2SK)48<4[454Q"0=%(FEP'3/
MAL$>)\QU?Q0'@Z5!)C<CQ4$'EXON$$ $ >B5@.2@0J"0A#"A!(JXXN(%XN+Y
MZ&+TFP)'/J9>2-!1ZN"C)T3DWAT,6;D$M?;NYU^_Z_<&2UGG%(1V(2KF11"@
MI7<<\D="D^/>:BC!IMR%H>"<VBD(P86CCCMJ0:MHJ?4L@9#!1AM+$;M8& K.
MJX$J(98[GD$M**J,YCR)R)@*3EGA2[#VM# 4G%,+.0K:IFSQC <1G".>ZMP3
MQE(IR65*=/GMX(YMQ\%H.2CCN+5N6&NW>U\MXJFEM(XB!B7!^\"L 6V4C4Y)
M+U&ULIRH4X8:) M.U_G8S.1<8LH0*@P! LF BBKJ8(64$L:EH9;"9LY57N>P
MB"L#IRQF&N;U/FY)5L6**&LHY5#N5N0+0=?YV->@T:@*(1,Z)B 2TS$J30*U
MVFJ#,U]^^_JFUVY;U^O/:"EN]J;44<8A6@D&!5$KYD!'0*2D<D\FS4GY3>D,
M23@?JYG;H #G7 ME@7IA9*2:( 6)2(X26GZK.6,IG+V!)$$;1U)*.@$0GQNV
M)A*)=S9X%B926&H#.4LIG(\MC."<==*GW P-13'W@PS!!1(IDK ,#6M^1$*D
M7R<.STZ7T0[:8(+7TJ4D(FC&#>I.#I9Q$KCSD2V!'9P-^>9C XU*-@E'@-,$
M-.9=@!X%$)(T7$HGE\ &SD[ZYE&DPOLD;:X+S<$D:G(6J$E*!\\=$V78H+,8
MY)N7[2.YY%[08 "TL):GG)]);- J,KT$<=8WF7C]UG^6T?3E'9Z)2NJ8"8@^
MG='<Z:"TEIXH5*A+8/IF0KTYQ4PUL3H9RZ3BX#W-/4XID48[%;@.2^']S4KV
MYF#XF!4ZR:@E!Y J.2>)D0QT%,I19I; \,U&]N9B]ZPD 94FH]SE6I%).]2?
MV@3G@4ENRA+_7+2TW>WX)79/XF@G5"]?X8>?6\.#BQ&6(CFME$A  U4L:F<U
MXCATA5'?('X#1I('JV@H"1*H^'GA^'D^V(AK:9G*G$M=KJOOO/.)DI1BBA"\
M*0DVJOAYX?AY3FC1"XEL"BKGI3,JG;?:&IJT3H('QTN"%BM^7CA^G@]^=EH&
MDAP-/@A$S,C&R,M,:<X-22J48<WD>7+;X\1\+:56NX4\,^BE-W_L_#/:-KY_
MKW^\Q'D6B@< -BK)B]#:@446U\P+%E7DQI2IZV'%ZF5A]3GEHR@4'*T2ZG9D
M=9:T=X9&&4PD#(PN0T2R8O6RL?J<MHMJ086,#L!0L$2@>H^",B<8C9$J40)
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M!HZ"XBBLA$JAK2+2)&;+L%^G!+2=5V]SM.2:JQ1Y AZD%A(]#@#I@Z3HJI;
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MF8O5,^'DW!_.*D9B2APT(X9&[J)D(BBMC*[RH"OF^5XY*$HM@!<:(GBF'/@
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M@YK427#<$TNIEEFL%?,3"::5!$]%@NG,)9@I3AQU1AGIP>(_.J8HI!'1:&%
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MU_?-C6%]AYR^;Z[]F;@Q"80K5(B\ ,-BH0.WA4LBA.0$$0X!.3J+'T>@_HJ
MJS=X^A;S_52*>G*7IU+"WT?PW\/+["75=R/FAR)M(U\*=K_;/AQIC\EP)]:^
MIYI8Z[=LN_:IV_*]$&OUG;OT!;D'JGT"?3$*ZP_Q:GSM0?3X>KVVL^UV;^AZ
MI[>IDX\GZ"<CE#[;CL>]_K#$FF7KW:?3/7S6WN<-V&L>X36[ C4#;:S73W>;
M'_'[YNG6^A'?6]__1K/T\/RW'7RO]F[SH+W5Q.<>MCN[.+[Z^=L#U%"D?KB!
M6BD<X1A1LZQ=:A8/.KF %)!"HV8)B16:LX2?HO 0*>6 )NB__V84R%^_JURF
MZSA.Q^9]R\-_L7DC'O[OOU%)?KW^]\=/:]O-C>WWN[7MC0];V\W:AT_;.Y_6
M&LU:<ZN&T+V)^+Q&>6UKNT;%+^'OM:VWM>8_-VK74/TEHE][T\R'J>%P#V4\
MI3<W/Q)>=ON+C_]^V^O7A@>Q]I\+T:J-(TJUB$YKJ#VES+\..0T:[W@0[-E9
MM/W8O4WH/XS&LS&.>Y52Y/^ \,]_M?=8^XL[[/'&X686<;K5W#S?S>*[OHM
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M&KT'O?8]]W3=]^TG>WU^(D)4#H5:RXH%=4JG-1RB*HIMU"W]7C>#FO99+2+
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MC?-"&XLT1&.<8<S)Y A+U/E"4-00R0PT'PQ3E:#:2U ?/Q-4"IJ:1#,M:2\
MK79@LYQ!:H%:)Z>=*:'+AG:5O)X*60FJ$E0[""HFYPRWCC(BT!.T&$@0P@9J
M;1*$76I0M&I0:T%0]#-!T<!C"HP#$<(#(DJP+/-50L[++A1XZ40DD':IJ1I4
M):BV$I023M-8/"G$H&=!2\_0$N*%808C;30H35G5H-:"H/AG@I)4**6#R2N+
M9@TJRQ=T+-UQ,8L;#;%&^DQ04G0)P]835"M<YJUWSOW2\R6>]4;'W#P)KH\U
MAY49KIT0,@1D-F2C JFTTDGB4"5;/5KK0W?[SV<\6E(1[JE#0(H*4"N:];&@
M0%M2RHAF>]*4JN.\RUI5>+S6Y5M6GJ(0@HB4*$\Z;W'%1T"4H(KIH#&_>?4$
MK16PIYX@F45*LKX"1/L$R"G/P+8$K$6CDG0,G=S:EJ9+^<)V5@5V^X"-BFCA
M,&!P9<?V.DA'/"J%>7<VP58/REH!>^I!*4W]),L6B5>2 I;>ICI#':)W5(IR
MU$CTUC:EO,OIPB[>BNSV(=OH1"AR[I 8E I=$%%3%G0HC1TY5M?#6B%[ZGI0
M-LJHN0.1E2] :7E&=H@015 F<S6QH1S><-;%Q4L.W#NR:US0;7#_O.0ON<M\
MPDY^R%\]'T>+>2+6K^#G'.S'A$O2TF2#3DB3=CP$HY [B9D-C;H'3\3^8'P3
M 5:RFX?L7LTX'DIW$B63+HU*4O&S!K \6RK:<\.)HJ@HW]IFILN_TJ:];6[6
M6KAW;AQK;:,UA%(K&49I'3524^6\DZ5&TGV$H%0<+PW'4S\#2400H0D(3![0
MH0+'O 2I@U(:0]9#2YD/TE7F$0:<5!S[&)BE,8O<4M0D:$[ROYD624?&N;\'
M/T/%\=)P/'4K!*,-CX8!"ND [<15F/_IE#'6$4M\UHTEZQI5N_\]0APCM](K
M84W^?\S_KQG+U,X355Y3'L4]>!4JCI>&XZD3 4V4&<@"C'(*4'D+6J&%:%0T
M262EVZA&KS9KL!^W)WR!X1/55A_"I.#M,H(7-K ZMZ)&<<R;G\>(1*&+GD5C
MB<O;(0O^/G)U1I7=YF&WWHS7("5J;!(2B(J9W:+/U@:1"8*F-*N<,O+ ,KMQ
MVLT;U+H4YJYE^%>2\Y)56$F-]S9FJ#NCB3","DVU92@\OP>'0P7ZG$"?NA4B
MT5J&0" X@8"2"M#6)F ^2XS:E&SR&>B*=A59UEE(!?JC #IW(C(1(AHCD'MB
MN;5,2&XY33'A?7@D*M#G!/K4[Y"PQ,]S 11+:QWC'.@L06":F>1)$K'$*2FJ
MNJAE!7H%^DQ0,DH72EA3L H-1ZM8(L8*HCT37*9[<%E4H,\)]*EC@D1."$</
MPEH'J*B&++,()H-?:,=9] 7H+ -=+BO4^(& WHK0AU:Z*@[.8PEUZ+_IQ/?G
M)>?BCB6+KE9[OX=".[?U%]=!KN$@V^-6;'=HTJ@I^O]F, BC,MFAYD4]I/>P
MR.,@_52D49J57(:*O<IRJ4K)'$K)P6SZ$T])R: $2&8YH%0*G P!:!0Q7PN6
M);:UK;N*U>RG1PC?5?H$*WR7!=^IE] Y%A)+!JB3'C & B7)!5A$%:)RF8YY
MMBFZHN8X/4;XKM+35^&[+/C.Q!SYA,'DW=<Q7F*.! >7B@.P1) 9],;+$JN@
MNHS7[?<1XG>5#KR*WV7A=^K2$UP3)-% WFKS]NLU@B8L 5<D8C1<8W'I,=85
MJOW[;RN<=JUW"KR,HVB'_KCIJ1WB7_%T<%XZ_=5$I8<-+)I()3/;SE0FNQ,7
M:^6W>?AM-D=)6IFX$ FD*#44O%%@'#<@;*3*!Z)<R/BC2G:57#C:J 9%MP_#
MJXT9JAA>&H:G+@+*I10A&.#6E#Q#H<$ZE*"5=I98U%Z'K6V3;0RSL(U1(=P^
M"*\V&JA">&D0GJEX8D7^'PI(7A0G/<,,826 )A*\3)0&A5O;W/!L9]1M^!%B
M>+6!/A7#2\/PU%7@)">,694%%(JKSR XF2*4K@-"H$G4D:UMAJPKZ,)A?AN4
ME]1F7\&K>)I_^:;;>1/[<6A/&Y^!#6>]?F\T+F% ?\4:4?"0;H-+ ?TT$4]F
MO&=7A%-)[PZUI ^?%<*;^!">_<FC\RKX;',D:0$#=6"X%B =]XY;Q[))N;6M
M=9?J>L+Q"-&\2@="1?/]H/G#9S1[$4IF/ (1,I9:)QXT(1X2%SQD128KJ6%K
M6] N6UH$<T5SB]"\2E]"1?.]H'E_NC<KI,J)XA34H60>V01&\)CW9BHP:B^=
MI=DDH:1K%C=)*IS;!^=5NA4JG.\'SM/-&;4R+!@*CGHV*7QB'%-@I',$-='!
MEKK(BG39&M1%;D\T0OLKGPRN)14M$HVP@8F4J\YB*!%8EXQ7$RKGH[S=6>^"
M5,FEI!5D;524E$H.5B@-.CIJJ,T2"Z6&JN)=N;2#D=;D3B_QU&0#(;_JS(<*
M^44@/]5RLI@<$\@@!LR62_(1K,F?B+;"Z]()P)=RJT)VR=+Z9U;(/PK(KSI;
MHD)^ <C/^"FR8A:C=AJ<M'F7-\*#,S$ 81G].K @ FYM2TZ[BBU<"JE"_C%!
M?M4)%A7RBT!^QI>AC.8:)6#)9D05)+@L,: N&.\4I<U!0U;ZNYPNJQKS9M1*
M^;KCII7.C1=]/SB+G7^<#D:C[SII.#C[Y.D8]&N5USQ!_UBMBV.47S1_FH,2
M/U>[F8CRERS(RHISL>*+67>'MLER'SEDM2<K0I0J<%F0@!RCCLQC2B:S(NL*
M?;UES'=K4CNJ%HE;7T='Q?L2\#[CZS#!2VT=)$X89%4V@64<(2NSS$:CJ-6L
M=+H474EJ:<B*^@?R=534+X[Z&7<'(5ZID#RX:'UI7$U!R\!*G<AHDK/1ED,-
M+;I*UL+/%?0/Y.VHH%\"Z&<<'LQ::IP%YHTI#H_2^M8V45E$:9^D=$W7&M:E
M M<;]:V([&BIPV,<AW$T[O0:3-62$@\9I_%)&!-^.Q@?UZ9<<Q+<WJSOPDA,
M7A$+VOERB$,U9(U4 ??,2Z)#4$%N;?.N,0O36\U@;1]R5^F%J,A= G*GJ@F7
MR*A)"!$5 CJ;,6R, THI$J,1HS6EQB0UM2_F(T3N*CT)%;F+(W?&DT"585Y0
M"4ZHO.>R#%J39,P_1!*2)4S1;6U3V>6J_2GG%;JM]@=4Z"X!NC.N?T]11QT@
M$N8 /8^0EV@");T)E/*L,Z6M;4:Z69"MAVX-<;BQ'4S!R:6YW_G'9?;&=]U.
M/]ZMH.2C3E=;@O7_A0^SS/[^H#^XZLNLN6AWH:_?KB1F>.*42P&<BSQ;^RKK
M(%ESS(:#%=(2[4S,UKZH6>)K@]-Y8HV68.Q_CC6JB+U/Q$X5CN0"L98Z()H1
MR+H'@J62@E>JP#>O5YZM_&SQ+QY85,':HDUU">9]A>@]0G0V, "YD<%Y4,[K
MO*GZ!"8&"L%$QI-!U-KG354M[(:K.&T?3I=@RU><WB=.9ZHD:6,8+[T@\IX)
M2!(!*UP (1%CXC2+*=ON4M<B#.M\5#^;F^!B&@SC)SM^;-_7"@QKD9\PC5WZ
M<3@X>Y['T^M?Y,D]^)QF\J]&LI/[#HM<]WK]P; W_O#)W_FL'ZX^9?=_+_+E
MO3@^'N0K?^5;2OW<&APU'Z'^/NM-0&*#RXL"N-424"D/65M5X)+,&YY+,;A,
MJ%QW";NN^]S>/*FIGZUGE-9&'%0>:2V/S/@X5,CVK:#@ BNM,)P%RY6"2$M6
ME2?1EV:WF5*Z4M3:$95-'BP*HK))6]EDQAV3EP.5E'+@5#% %RAHEB@0&I0E
MQ'&?:&83PKJ*7O>:5C;98#99;6!&99/6LLE4-V%<:XU! >6*9C:A";07'H@1
M3FF>LF6LLXU#>9<LK4_79B2 K%$XR*_#P5^]42&/C,C./USLQ]0;-Z4OOEO<
MN[1^_O$U<2!ETKQTF_]K(K%*A',1X=&LLX<J;KC1"5CD!)!&!\8$ 3%8@]F<
M%Z(4N1!=HQ?Q]=0CKO9I1:OWV%3@+@S<J09C>4K*1 **9KBBUQ:LSFQKE3'H
M99)4E&;HHLM(#?MZA/!=O8NDPG=1^,ZX,R+U7!B'P(E0@"%*,,%*B!HS<$40
M1I5>WZ;+Z<*^T0K?]L%W]3Z)"M^%X3O=?052330:T$%)P*0I:&<IR$B8R':0
M#K($G9"N9NWOY5/C3FX"]'X<?TX7:6)/[LWG\U5F^]H\/ BQ_??]O7<[F;SU
MKI"\,FLIH#LRN9]U@$2**01$2(8F0&LU:*D)>.HC>L$%&K&US5F7+!2,OV8G
M2I77'B>OM=0_5-EL(3:;"89FG 2%'AR))7;/B_S)2V#)T\"U28SJK6VCNB@V
MK4-3I;2-I[15^LPJI2U":3.>,NN298%&$-YG!8TY 1I#Z541C0SH?,#2TYYW
MN=FT=C25TC:>TE;I1ZR4MA"E3;4TX[P7GCD0PF8B"R2"4ZC 1:FY]TQZ+<K9
M'>LR:=:;T]8B^NA!0'[-M]@YC\/.Z-@.X],; XYN\>XS@N99E&%PX4[C-4G?
M>"*SC%.=.LKU'&4K#@(FJ@AKZ8G O^RHYQ>I]?7(5*TUT*:^Z<O_-0Y?%<I=
MKD^?W5A29]<.^WF^1I_^;K.>/NM2I.I2M]"EWL[Z[U4VWE&%"#:FK$ME8Q&,
M2 8(\1YMUHI)"6 D3[Z2%#*W]WZ-3+]*.6TUX&Y@G 7=[:P2S;T0S=1H"U*C
M<<P"9<H"QJ3!>8N@E7-"* R)8R$:OBS'>F6;RC;WQ38+>L(KV]P+V\Q6'_.1
M:Q,E))0<$!4IQ<03$$^24*5,(&W8ABTK<[ZR366;^V*;!9W4E6WNAVUFTF&M
MHCQB J.% Q1.@V&!0E**2NFY==(7MM'M[Q;4"H?SA)3H$R9:ZL;:Z9U>C&-8
M) ;YL3#OUUZMG<S;:D?6Y8JJ+#P/"Y\\N^+*2L:B%P*RI&C6^5@"G;*%28G0
MAGG&C: +N[+:EPQ42:?-I--"5U:EFCM2S53AR[M"W@ RZ4=.%*"RKL2)"J"*
MY"N$FR1(X\QZA-6M*]\\,KZY;V=6Y9N[\<V,.TL)Q2CC";(&FE4;C0ZTY 8(
MDB!=5FRD;OAF#;(E*]]L.M_<MSNK\LT=^6:V]FQ6/:U#4"8X0)L\Z"@#4%^J
M+ AI>.2-0VOA4I$U._O!G%A_-/^( 6P>C7T3\PN>G64(-S&4H\[@8CP:VW[S
M&G<*J/R;8XKZC+5Y1G4*WSFV\?,+;TBIE@EY+#_%_]99%I]8[=F$U/8OSEP<
M'J1&,Q@=3#GMZJ%7S<*XC8[P8M;=:H.BB1D-*8L1,%H&3J( @=)RHEQ2QFQM
M<V*ZE#Y"LZ0">\5)[A78]PKLJ?+/-7<DFV/@O"[=O*T#7?K9D!@($D,#2:6!
M#>%=)MO?%:P"^R[ 7F6J=P7V?0)[QHN8Y>F8EQY8(CKOV-J#3<8 Y=SJ%+0U
M* NP51=YK9KX.(&]RH3G"NQ[!?9TQR9.&$LC@O(TJ^+!)G#*(O 8+--&4^=C
M 3;M&K-P0O1F>.Q:[VVX(03M5B1WVT#@=26Y%O@;+L5SC>LJS<U%<WNS'H?D
MG4S.68C""T!&/&A+3&8](;-4.7?.+\WCT+ZX_@KM=G@<*K27!>V9PGN<<YVU
M%$A:90V&DPC:.P;!<4D22XI24AI*B2Z*996IJM!N%[1;X'.HT%X2M&>\#B8)
M2;.Y"1JE+LDQ$@S7!)S6!F,6*/>L0%MU<6F]XBJTVP7M%G@=*K27!>WIKJU+
ME1 J!%@:2VU)5&!TY. IC=8+GN'M)KLVP?8KY/?J=UCLX?7.>Q#6]V/K3F/^
M;^C]M?W/_./3-\[L\$VOWQ0$,U?YU\?29'9U5,L*U1X>QX[U?G"6_^:'O/0[
M_<$XCCJ9QSIY$+T\HC=#>]HYM\-Q9Y ZX^,XBIWG@WXHS6I"^=14*[29_3H_
M]OJV[WOY]E?C_(NF$>Z3SQ#\/!$-$1*FN9=)4.405?2&)2HP1FEHPGSQ3R:V
MVC1[ZJNSM_N?W5]>_.?%JV[GQ?[SK[SJY3 >>IC/#S+G[[_:W>GD3Z\.?GFQ
M\^PP_^/58?[/WN[^X:O.P8_YTMZO+W?_)]_WXM^[Y7T.]G8[__CEX-6K[UK[
M8O_H]?.2'%SD9X11BX=YT;<7H9<Q<O,8;[&R&TKYO(=-"@OFH9_:\U%\^NG#
M#Y\HJ==O!M)\Z<L=*_^5'][UPOBX*%Q/R$3INMQ?+I]_>?E)<^F+_7-R#<D3
M1<6-E\D3>N.U;SV6LB>*FSL]]MO7N%F;P=(GR.6Z#/;^9A;9;1^[:HWK;PTR
M<^W6KUA<$V3?K\EE;L50A\?#&#M[^;[C46<W[^ZA\RJ>YST\FS<=3KJWB-%^
M;%.RGW]SVQE9=+7,N #F* 7=SGDK[K/;A/3?YD4W9,*H60:^'M><U$5T'XNH
M%<D6?Q?RD,6P8H?CW7M)7B_SO1G=/.9^[W9ZFFLOR3NYD_=??7(GO^R59^P=
M_GCZ>N?H_=''EV>O#_>/CTX\.3I[W3LZW'N_=[+W_O7ALX]3=W)Q^>[B_L?7
M;U^?'-&CP]_>[1\^P[V??J>O#_W'H[/?\>@D__N/_;=?NI/W3G;9T>$;OG_V
M\FS_Y-_'>3QT;^?-N]>'_S[=_[C?>WUXG,?SYOT1>YGV>I>NY%?DW:HZ2<Z+
MBI9GOU=66T]6JYTD'Q^7??S,9:OL(UD)K1):"UZX]I%\?(1&/Q/:*KM(5D*K
MA-:"%ZY=)!\?H?'/A+;2'I(/RVBMR*=J):<=C(_CL)0].A_&X]@?]?Z*5WV,
MM?#19C]C+7SQGZ$S$ZIR^0@H]S\MW2 ?P%M_T1_&_*R/,73>V%Y_-,%4''W7
MR;NI_<OV3DO<"^2=#T9Y$\L;HLND&/W%L#?NQ5&WTX^3@#;[OM,[.\_46_[U
MWZMU!U_=?!O">#[+%Y.]^/?/K_H_@],R\3_E%RX;]$'_U><7>C;LC?*EG?S/
M_IM?\[P.PJ%]7[?P.;;P_>?DW:<M/#_G-/[/RP^O_PCGCJ'<^^/?)_GO?#SX
MZ3>ZOW-ZLK_SYL/1'[OO#G9.W^Y]_/GMWN'/QZ\/7^;WS\\Y_$WL?_R='NSL
M?CPX?/9A[]V?D@<?(B<EKU !"B)!:V% )E*6#HU&A*WMKV4?=3O_/<\9Q1+<
M>3?T%*BK\U&NSH]Y=7(D0H1H@ ;+ +.Y#<92 TZCI]+1I*W<VJ;LNJKZW9S+
M<PG.F;H\-VEYDKP\4^(^6FG $A$AV[^EBRR/P"US(AG)2"CNH:_XAK[KV'Z8
M;X4NP=JN*W235BC-*Y2@L!3S]AX-LZ6B,86\+#D8;GPPWCC%Z=:VX=?3E#*!
M#N/H/.9__15//UR-#G_DM85:'WNQ;,1FN^4@5=C.#=MI&(>W6?)95P$I$B^9
M_!1<S/N!3#':@)K84CJ<=B6YWAMEG=LP/5(&6*UA4\'=1G!/XQI"$B:JP("$
M($J+M9"-9$,AEIJA*C&D-&4C63["MD<5WZL\MJ_0;P?TIQ$ 3DLCLW('TJ,&
M=":!9<J =LK[DNA/A-[:YEVJVM\3I(*_U4?<%?SM /_TM#PO:<551$"=(B"S
M&?=**D B:)9T$JZT5N5=OK2S\C4]#F]?J8M-OG-%L0NK3X9Z?G/(PKSU="Z#
M4B;(><HSU,+@HA0Q**._.63E44:N+7-*VKGCM]ZA]Y5MOV[?=]F^9U.KBGT6
MJ(T0LQ@!36)@5.!9=\\:/'+"C>1Y^^9=B8LXY98(GP<NVG=/KUAY<S/B@5>9
ML54)<VF$.?5S:NU-,#J"H27)P>J0/QD&WDG"##IAO&WRMPQ=5C7B)8'G<1)G
M9<VUU#9;ZERNE+DTRISZA[FQ5B4K@*=@ 1U18)URD'^OO9+1,D.WMK7L9J$^
M+&5N %]6RMP,17.57OG*FDMCS:EC/;I(B(@1G%,:4(8 .F@+G 8B36 L\EC2
MT$17\H5[;;99TZSUG.^SGO/EFUT.0V >Y_E@U"N+Z.DPGMH2VCBM-OO_7<TE
MNEPH9/H5Z_((+L8W?Z5E,XY?!&W._+Q]M>L2'WKYI>/A-,_J3<;N,-JW8%-^
ML:?V])W],-KZ_NITY+F8G?M;3!L5W\K92FF>6=*WF*2)C#+U#X:VD7'FC3@L
M=^51V(<>0N=X6/:[__I[*:F,KZ8&<T;.\[)59D#\\WN[_;45T*+RTX^I2OFK
MPX/G_^]_#G[9V7WYZO_\EV94_=#9_>WW%X='K7VO6J3</V"1<OZ$$[7TZM3J
MB51WK9;]K6N,ZSK6-1FK?H+W4DU]T^<UCU7??'7VJ0N7W;Y^;UN+_)+;5&GO
M7"N;?#E#7^CH3#;SL7 =][4NF_PIUN5LT,_VS<"_746]Z>'@W;58S[6?Q&=Y
MC$6GMJ?_=,/OMW^UO0"]?O/YN3WOC?/OZ]3><6J]OSB[.&W,\4E!F:O161-7
M69W>Q:>W6:X[,?5\;USG\ZX;U&!\20(-HQX/3O,+C2[MM.;WN_][T1M_N,4>
M17&1/>J1E/9O)G725;)V0Y@'UV>#B_YM8#S'K*SPUAH'ON%WU@6PX7?6!;#A
M=]8%L.%WU@6PX7?6!;#A=]8%L.%WU@6PX7?6!;#A=]8%L.%WU@6PX7?6!;#A
M=]8%L.%WU@6PX7?6!;#A=]8%L.%WU@6PX7?6!;#A=]8%L.%WU@6PX7>NJ-_C
MI-QHD_=7_L2GQ_M[+DOQ+WMJ^SYV[+CS\T4_3FH/7,MHN7-7G,5JF:Q!]8Y1
M$R/\9=DC*J62@1BG+?(8G#21!$.T4&BE-'^^N*RQR1>IVW$VZ#?!WI,PY8.+
M\6AL^V5"MUI2N./CWN?"'3^^/?IC_V2/_<Z/SHYP[_ W>G1XA*\/7Y"]D]?Y
M][^QO</CX_W#WZ>%.\Y^/MG?^?GTX*<C/#C\U_%1Z?YT\G/OZ# <OSYY*PX.
MW[Q[?>(_OC[<_?!EX8ZCLSVR=_8[OCYY(_9^^O%X?^<MVSO[^7B?_7AV<)B_
MN_.OL_V/^Z=[AS^GO9.]4K1C4E;SV9].>B&I0HA4:D"!#BPZ!Z@\=]H'$E)F
M!DYT5^OK7:76JH/TW/7R[Q?L:UBX:.[W7C-R^TI!MSLSVU7ZFLU2F62F5-*:
ME[0^?"8M&BS%Y 2PY,AE)>#$&2BIF4E>:DE\(:TU;WE?":L2UKR$15BBAJ&B
M1&B4W&A.0T1J+-$V4>&7H(I5+EN8R_:G"IC2G%NN.:A@ F!T$5QP ;+TD!G*
MM%)N:YMUF31=\I76LY71*J,]:D9#F5@0*D;..*)A-BIM,HDI:HUQ?!G&966T
MQ1EM1CLS3DB&"%:6]HK,&[#>,@@B*B(3CU:DK6W5U;BL'FN5S2J;K4L_&C2>
M9AY3V8:,R C7Z SU^1?)Q4)I-]/9_&UH*J\MS&L'4TV-$ITWHH! A:3%069!
M*W00C$E)::VIY5O;B+QKZ/4JMW-WA:ZD5DEM752TJ*1C@F8*<\@2M\I['I+T
MEEMDG%05K0U4MC<IUYWI[-F?1AM-%!,@9>EO[R,#;9" \I1AY(9&RTI_^VR<
M=CG#=='35M0J\4'PN!_'G=(;\<9B,]\ZGOS*>[;\!+*IY<1^N%MQ^!;UQJCB
MJ>*IXJGBJ>)9'_',8\][)!8I5TJ)A)2@(;ZHO8Y%S]!K=B_]9;,N,"G(6?K&
M5T5X+D7XMUF;WG*.1 H/:#T"!B/!6JW 1QT)NM)I-NO!G'7)5YR5<_>4K<AM
M$W(?I#-T1>XBR)TU81E'&R4W0 2)@%H+<#0DB%8:+;)PN8SM@NZ*(FL?!'B3
MFM'^2LWH.UNK7WGOEO/.W12ZK\OW(9VY53Q5/%4\53QW5JJB9MQZK7SR"04/
ME@02(TIC!2/:XKTH5<WF\Y7.GD7'^M3=\]?!L(S]V7@\[+F+I@_4X>!7.XS]
M<57#YE+#?K\2[.%$H)8S$)8Q0&X\6.<M),J)95FQ-IZ4@P1)Z.)'HA7JE8DW
M6CRM-V\K$Z^6B6<-8N144BL2,"80T+, +JH B2$1*'PB)9*X153\F$]K7XQ&
M%TVBZ2 5J[CT_AJ5$(9.TPZV$YL0ADZO7UJ9%%O9]L/E#><70W]L1[%S?IK_
M_H:<]LZ7;TJ2Y,YKIA0B6BI,M!C0*$6B3:C4+:CM*]$E160Q[%P,\YS]FE]C
M$":9ILW/?V6)A$)LF=6:OKZ5JN:BJJ/9I%,T7&#*U,0EHX ,+9AL*P QE">J
MDE=HMK8%73CAM/K=6ZTW5O$\-+U>5QN-BB803KE6(6L41CN9B$B):4D3M^X6
MW#I?4-]UVOVW/;V(E767PKHSF68IFP(N)@XATLRZ7$8PQDC(!GP*T@DNDFEB
M_A2KO+LFP*Z\6\53Q;.";7$)WI2Z+;9G6YSUFSA.G,K*#7#&(V"*"!:5 &IX
M%CD1A"?9OGWQ,0<3- #HC(?Y$9-Y'G7L:#3PO:8]];O>^+@SMN_CJ/EX'$]#
M)X/WTJ5BW]EAJ&$'U5U?Q5/%L[S3E%6:Q<_"R<5H?!;[X]'+V/2,/QP<VO=_
M%+(;G);9_7$PK(K $A0!/VL?,RJL4RJ"%\@ J7-@=.1@"(\^I!2")EO;HDO5
M];I2]2B[=>BNY%O%4\6S)I$&=6]LX=YXQ4A.CAFK!0B2-" & IHY!&[RQNAC
MT"GR5FV.CSFXH+&/P94%WH3<?UKA&Q(L4+VJ53Q5/(_L+'AF8S\</,NS609G
M3W^UO?"B_]R>]\;VM-G7W9?[^LOB^1OUQO%5'/[5\W'B+7\9_>!-OWE*XSBO
MN_]<N_^;6<O8\B0QIFP9&\,!G=7@#-.@)!+K:2",Q[SYBZX4HD4N\LH#E::K
M>*IX-NCHN.ZB+=M%9VWH9*FAS%O@HAPTQZ3 ::&RU+D/4D9EC6CA-KHQ#:%>
MQ?-Q/'-Q>$]=H2;3^I1G.83!A3N-GVO?;6;;J& 9R9SHI" "%9)L:Q@FA76)
M,1L3G92-7(@/:]NHI7'9V]D(?FX$)HP:,&]E@$%J,((J2(PJ)D0V"HH[D!/3
M1;)PU,S24;0>%7/OBRY:X\:\:TG=94S,FO'G=:WR[N19"^LNFQ>GZ?#,9E*D
M+@(1T0,*:\$:-"!Y")ZA"=D8N(?.5)43*R=63NP92Z/URJ7D#2IAC7,A6"TU
MY2FH&)>@4%:Z7)@N9QS+$1DWU! @1&:+V#H!6CD&:#0S7OK@M"W-KSBC7<3K
M:>N5-"MI5M)<C#0+7QI)F1($T1%JLUII39XH9X/0.E72; 5I3G5,E\G2R9#
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M(!HT1!G$H$I0!^]2;EKDZ*X\4&FZBJ>*9X,.@.LNVK)==-:"CB(ZAAK!ZQ@
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M:)4!W95&HIF7I+",E:9,+B8&4IGJE^+&=46[G(KU!Y2USZGHH&6]H:65S,I
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MU8+U2WTB.W/ #X+7=UP9*UL"?E^>LZ_"^,&X+I/XAP5MY6 "JU!-H@L8N![
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MS6'[8U M3ON@KWZ*PW'VSV=O/3;&C!-$BWH=D8^/XDGO* 8 A!$\#]W]89
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MT[F;#L( %0'@$P=9GT&40(C,87+J5Z#RD:\-D)42XT]1&\$WOM[<W^P%E%A
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M.1RKZL&\K);Q-KG@W3*FYP.T7E7=4GY"]K/SV;\K.-,Z!H7%61417G"B/9?
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M%(1IQY4M"^UML?%$@4Q3='3>T7F[Z%01K"B*0I?*"N9+(R/3%,B<ELDQRN[
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MKS-'8GZ<)G#&\R"6VW'QZ<#UF<1IM!/8<;PAP(.'X^.\0(NAP29GB0)G.G;
M#/+0I_V5J_UXBALZ.'+SR316[X+GCN!%7]T+>%1#5-/Y\?%PN<']W@@HKMK7
M]N_X-O@1AYS7*9^+0=XEF.H@3^[%T/X]WC^"K?D7XG7OEQ?[_WK4PS4'46?:
M>N@T@X(=C( I]CR,[[-%C!@XW,3SPSZVD]D(SNWF.>[4</',NN"W&FNJVS(D
MNU(51>*A-(&)TI6&T61IX=%T;Q)S9_')2*X+I8,& 4Z4W!HF;>E#H4 T3#J(
MC35FB1=B):QH\UTF*(MG&/M_3GN_9&P9S^&=8?KH\>IJ?F66E8CBD98G,,TL
M0RRDJ$H6RIMX/(V/FP^_-C+(8)0'GV\Z*_7 6WX]&839(0KRF[02YFO?<_W\
M^N?-_-,9":[Z3=!-Q<I+?Z:;[-+?OO18QC=58;[IL5_^K3 /9K!L4Q3RH0SV
M[E96\*L^]GM'8WPU=,N<N_0"TT9%V7>KRILSJ*8N1+6#0V!:O1VX[G#:VQZA
M++ ?CV?QR &/*VC_"O5L?[0EV47N>L45N>EI:5GGKJ'BKN>ZH;)WE?+'MU6;
M]P=8,&9N@[Y^K#7I#M%='**U"%%<R\C$IUN_[>UL'[SYSS=:+6_1NW$O\_]6
M[\9M."_N9<+7216-PCGKI$^%%J#L6N,T3- %&AD'M;4KB7T;?HZW'W8^_'FR
M^]>?;/?S;T=O#OX\V3O8@?L^?MX]VN&[+_[\O'/@R]VCM\.S?HZW1SNG, 8&
MSR]V7KP]A,_ESN?W#.[G;SZ_H6^?[?R]^_DC?WOT[[0S:&65IH+*(*4@.FI.
MA'"&:,$#T52(J%6@S&$62FGZ97G+7H[;=&+<22OD#O=^>MRSP02OI4NIC$)S
M4/.3*X3E!0V%\Y%W%<,?%.XMLVPU;!Z73I-0R$B$B25QKC2D<$;9)$IN: #<
MTZHOV&V5Y.MPK\.]!X)[1B6;2D=%P9)@,=H4/(A\(DE32.ED5U#]0>'>,NM8
MEL$XAMF'"=LXENA,9]81Q2+P.AXC#WKC2<EYO]"W5?JLP[T.]QX([OG@?9(V
M%9(6PB1F%./))*6#+QPO=5=N_D'AWC()VY?8F3PHXI4+1+""$<.$)$R7(3 K
M6= .<*\$W&,/7,]=BSIR:XE\3]&^^>KEG]^_Y=VZXUZ(5',%O%\8(71I;9&D
M8H+:H%7D6G?VO0>$>^V6=XP7VB#:%3PF$/IT(D8%04QD( 5&J1GC&T],GQ8W
MSBR^49.-;Q/H[KU]SKK3-?6R2$PRQTT0@CJC"Z>#TEIZJD"YZ^Q7#XJNE_8K
M%[CG204"XDHD@G.T7QE*?*)&*^&<1[H6_:*\W[98'5W?"5TG3:U.QG*I"N$]
MLX5UC$JCG0J%#G=1ZJVCZ[NCZZ5]A@5)E<&>M!+KT4LC44_QH+$H&8($A#;H
MC]-]S6Z<IMD1]OH1MN>VU$E&+0LAI$K.26HD%SJ6RC%N.@/$@R+LI0%"I\2<
ME)RP0!D1WFFBK3*D,*4)F$7FG0/"YGU%;ZO:XP]C8KAYN[M[(?N+$B4>0,&W
M!V64_BZIY>O.-&S)E2E+%QU7PI<4^^*6+&*Q-Z9"NHN";QW3N".FL=ON&RB"
M+1B36+4C8(U@'P@<7$6BUUS8,B0E%)8.U?U2W[BQ^3WFH-^G.Z^#U@Y:OU 9
M3A94&.=+;:Q@(1KC#'J2DJ,<!+J[Z-S80>O=06NKS8*B7DCK,>S+HD,P$8=-
MJ$W)A5=)"*406@WK*WE;O:,Z:.V@M8/614&DY)Q!NR6GI?!46!%H*$L;F+6I
MI+RS83XH:%W:,($]*E9H1D1A.0$Y51++/8"L2T+)Y#7U=.-)*5B?F4YJ[:"U
M@]9;KP!?.LTBK@O%LH]!2P_Z(J6^--R(R#HK\H."UJ45V0EJE52&^"0%$<$%
M8D*BQ%FNG?.:R830*LL^Y>('A]8[*4K7+NUST3>M>C4U<98"J/=X/,W5G!Y/
MXA"N_!27Q67^9[663[V,='F+=;!B\]GEMURA,,[WK/_#^&H)G_;_'TZ6R?KO
M(W&3:#\2FV"0C^WPQ)Y.-_ZQ.C685WL=K[ $K/Q2Q:.4KC-C?84)5^L=L$!8
M/@./<]DKO I&8>]["+W#"2+^?PTHUX67J63*@>X:O>&)E2)&:5@2\.,[T&8/
M<OFD<>HA4&-]KO_]AWURT69>6..*6Q6$B8ZYQ$5*W$13NLA<*8L@+4UG:US9
M%%V,P41:),%%=(434HL28Q7*'&Y[\7L><FVL ZS9%B=(EW#^<V&_E7X_6"?+
MUYRQ=W(X[L%0!Y\&86Z'P]-<>6X^PAINP'TKL&;T?ZH/XTGO:%S5PL/296<>
M>Z;FU@]69$LP]7!*095"/)3!/K B6W>ULEV1K:[(5E=DZ\&5^^GJ(W5%MKI#
MM):':"WBP];2K/D29.?1-^6?W4H2\@/HG#&:(^\[&^$D:> F<%8X$->*I$')
MI=H$YP67A9%?B7 Z5W<?%& DJDJ=?C68?OQCH;2QA762\(=LGOSPL=A]YD_>
M/LOCX#O/7@UVX)XW'\*'G1>OACLO7I=O/N/].R=GS9-[!Y[N?O[MX^Z+?P]W
M/[PYV7WQ\N^]OYX/=N':MR]>G[P]&'[(!?L__[9:38IRI6&G%+&"&2)$9,1P
M:DD9K=(B<E^4&+U^RPV&OM'PN#9M=?[G*BSHNGZD#E.^ABE:,,6C=E8;(5Q*
MAAH5N> T>6$5"U\)[>DPY2XQ91FH4U*O;5"<!(V!.LD%XH(LB=2J"%%;;1DP
M<7[+,3H=IG28\@V84FAIN4+T8$Y@2+9W/C&:4DQ1!&^^$M/28<I=8DHK0L4R
MJB17Q+%"$5%R38RG!=$IJ<A U3%2=W)*AREK@2G>EQ*@0BAOI.!,.@\\S["D
M=2J+X(JO!'-TF'*7F%*T=)_( Z@\)&J)NH_41&MK">6&:AXE9FL IMQRP-O/
M@"E=0:/+5F\KI<%P8&=5VZNG_][O_5^TP]EA[^EX<EP'"WS_8D</ %.=EH$F
MQX(/I> 2H!3PE"M=%(8F%;Y6S[S#U+O#U';U(I#&RB!8(*R,#C#5ET0KQH@J
M(JCHD@G),6GZQI%N5TV8?E"PN8;5%QX ,J@"F#A7CBJT"CEA"V3?ON11Q<*8
MHK,*W2,RM-*WM.1,"4]L4B4@@PK$%$$10VVRI578YA60H>B0H4.&6T*&4H$D
MH%4"R0&0@2?MG6%18H C%T9_K>92APQWB0RL56@%A(+D%*$QE[GVBE@3#%&!
M>TN-]D5IL:-)APP=,MP2,C!=LE)&)X1APM(2A(=8,NY*SF)DJNPL-/>(#$L+
M3:D3Q:+>1'*!,H,7Q.E@B?+&QY"L*[3ND&$]C# /**1GU0BSX_\5IU. C)N:
M8"Y8@1\+-"W\CX?"LEB(*(6+4I72%CH9PTKE.A/,?8'F2@DBFS2CA7$DIAB(
M4)(3R]"V+701I;-.T++*";L5L_:/!9IWZ@W[89%!I4@I0(&+20M/DY.%!X&^
M2#PXF\K8F6#N$1F6)AC8)LY++HBV@1(1"TDT9XX4( #KX)PQ+G7(T"'#;2(#
MQ3/'F5"@:/&2.1,\HSZJT@CM4Q=><Y_(P%J*EHZ)<4:4<AJ0045B!/SI1:0%
M\ZXT1;@-XVR'#!TR- D"/JCD&4]::\$=,UP44B?GDBJ]9ZDSP=PC,BQ-,$SK
M9)5(*"Z41#C0)K23@1A?QB #0K;N9(;U,,'\_^R]:5-;2;8N_%<4G'MO=$<H
MZ9R'JA-$4 ;[N$XARC9NO_B+(T<0!HG68 R__EV96Q,S,@($[.XJ2B!I[]R9
M:SUKR)7/>K9U,.M'<)5^=P@*^T?L[<7[YV)>? *;1V*9"$)3R[G%5F":6T,%
M*DU4I"Z'>3KT_#23BZ'4*2*U1\PPAGB0$5G#&:($)\X%UC;E<IA[]VU]D0GL
M>FOKEXJ/8]#!.^*#M)S@ *! DE::1)Q;!;HZ%_.$R##-Q1BE6=!4(0*+@CAC
M#IG<\(]$;C6- M#!KJP]6F.1&AA>/# $0TUP6"AC K<J6H.U,2H2+36V3M>I
MF"<$AFDJAC' ;$LP$DYDPD@1D+/@,FBN@A'$:"UM[3+4R+#(5(QU7@ 2X"0,
MQU$;KXQ4.-E$<R?U6*=BGA 99JIA6'+>^EP(8PCB+EID+1:(*>&Y93)$F[=O
M<(T,3Y^*>;;5,-O'@^%1X],Q:+<]')PV_MZWO2/K3^N*F*L.CP?I2"!$)(CF
M#4^.4,:H$#XH3STQ=1;FR8!SEN2&"S!=@05$7&*(DR@@UA* GIH!9$KNO ^+
M ,X7F<.N=[=^Z>@!MU':R%+RG%,KG'***6ZLB5%AH>LLS!,BPS0+(U42F'B,
M<CL;Q!5WX%+!#Z8"#\YD"FNSLK:H$^ U,-3 D)(V5AN(\EGDR6I-@Q>$&N==
M<EK669BG!(:9@A@ :F\M08Q$B+6H=<C!_Y#3UEL68K#2+R(+4R-#C0R3[FHB
M4&,,E<)QJQPX#<YKS;4U0GM^6PN@&AD>$AEF"F(<DS9IG[M[9':[I)%E6B K
MG4[&)>XY1/"+(K=[6<!0U\-<-WL[]CO8E'&V)0[+@!IOND<PAM/&7^VC=FXR
M\H_J8_^L2V*N"KFTC%S&Z*F.7'AO(I:<:JN)$4%Q72=CG@P_9QEB!-.86XJ1
M]+FJD":)+,8&61#LW+)9<+F09,R+S&+7^UN_= @A*..XLHP(PO,)N&B-$BEZ
M'7P4@M;)F"=$AAF&& ;!,"P5TB1PQ!W!R)B8SS$ZF5N6N63EREH-##4P+&S_
M)M?))>\L&"1N(>877(G@ V56!FE5G8QY0F"82<9X)GPP!"5)8B:(X4@7ZJB@
M@LVD,0+6Y?Y9VAH8:F 8 X,U*8$;((FDW&NEHZ1:*IEH_B7I.A?SA, PS<5X
M6!)->414EV.+0B/#% 6(L!'6)C(:[,K:O<\FO4A@>-!<S/TN7G_R 1;K?.?L
MI>W'^W&F[^Y>[.[U[/%^VS=Z<2^C]H6NN8U_M#N-P7YW"'<,_7_6371?7JO7
MNHENW43WTM6?6<?8NHENW42W[G^ZU/U/7]F<U$+T:IOH/DE ^GGUT^J#]<NY
M,O.T-(_^?Q[NN9]9IFW8#Q=+GCP6FGJI$XU<:&Q8/L4DB54QT93B+5OV"+0C
M=7M'=@#7^CGXK3,\"MW!Z/V+*;A18/FVUSUZT\VI.#_XTA[LOQGV88IB;_.G
M/QSFJ5WO]R/\$W;LSTEFCCWGQ-S1)M\Z"]^_'FSQKU_>_]S:^'BXN_/O]M;9
M>]&B6V+[W7NRNW,([[^G%Q-SNSM[9RWZ\6CK;/]P]V#SI/7NW_NM+^_/M@Z^
ML]VS[WSWX-_[VU_@_8.OY]L*<XYM8APCKWE.QR6!C"$,>9*D\-'#FI/<6HLT
MA5@4==#]^FO=K#^++':L<>_5XYXB#D=E5#!<< 5X9SQS7/N(?9#!JUL*$FK<
M6R[<FY8P<,\8530@)JU&W#*,+(\2,6ILR+0+S.<CNH8WN;YW#ZP:]VK<6X('
MG@/W<-0^)<R]%1@\!*DCM=QX&9G$Q)O;ZBUJW%LNW)M6:$0>2,1:(1&"0=P;
MB0Q6#'ZE,A$"[EX0*VN"FR93]^8TJG&OQKTE>. Y<$]2CX-)45I*.<,JUSEZ
MZF0T(JH4[2WE)#7N+1?N30M08/T,F#.%7+ ,<>,",L(89!GSU@4GE:" >XHV
MC5B./M*_C'O/XNS.DP#!YK#7/8ZO_4S.9=1+S#)N$Z-)4TY%<,(:Z@#EO!%4
M2EIG]YX1ZLT>X6&2!^XT09[0W.29<&15)$@+QV)22FK)5]:8;&(L'ZOV;H'^
M7%T@>VO:G@FK*1&2$AX5LPY".<<YED+&Y&R=OGI6BCUS L=I 2NI$,3C&'&=
M60]L-,@XC@D)WM&$5]84*#9YM&K[6K$?3[&#= ;C0!/%D:N C79"T.@EM2;J
M(.O\S+-2[&E^QG%MI&08Y7 %@9SD0GGMD 1P#A"; D3'3&>B($YY-,[I6K,?
MT63#:CNPQ8J8P'-7]*2%MS%%)1P!=Z[.0#PKS9YF(*157($GAK!V!G'*)+*.
M*:2E!2/MJ0-'/??GP4W"[KWC].":75=07:?K?UJXV6LG8;V,:PP\5D%)X)I9
M3A(#)T7F1H.96 T"$%'G&)X/KIWK8LP$<;"N";D@,MFU\$AGCD9M*$Z)6#!1
M9F6-LJ:X/ZS=E6OI\?:,:L6FP<D@C, R-ZQV1E,JM.1&82T#$76)S/-2[)G&
M-TYS HN(DLS)0R,YA"*8HA0P#UX''@4H-FD"7-=Z_?+TFBME/>4&E_94G&KB
MO3')0.R!<S*Q3C$\*[V>IAB"\%P2RI!/"@PV,PEB$.D@&E$B89G@SW)E34 <
MPA^-'+%6[$>L<1!&Z8!SDA@ GGBG6&#"$!)D3AWZ.L/PK!1[)L/ /58L*[8/
MF0I9:^0<20C'D)Q7#'-/5M88;S*U_)[X4E0Q5#I/5JE8TF3#3G=@#QN]$17#
MO.FA48%*-?+?&#QOZ XSN<)XP*^NXFWQ$_/LS84B1C%NM/$\<JRXBYY&8['3
MAM'@4YVX>4;FXES+8XZ]$=8BIJ1'/#$P%PQ;< :]]<G"_X+/B1O2!!=@00GI
MQ2G6$V]4U=!:0^O]/7%LL23&>QL!7)W16!A*A";:4BX\JU-GSPI:IZFS* )-
MA&H4L>6(:\51KKI"8#:]Y<:ZF'?QJ2)-A5D-K36TUM"Z\.U&$:D(D1LC.//8
M,FNID,PRDF+BOLY>/BMHG68ON?-)1T\ 4*7,C> B<E@9)(U,G%"AE&(K:XJH
M)M>+JFFNH;6&UAI:)Q5J7+H0I,/!*FX8MXHF;*S VE/!9*KSQ\\*6F?:EG-K
M*/<8,9_R:1',D)$FH:2%MH9YIE)F;Z< K5*\<&A=.(]OGJZL1NW.L'"++S&S
M[W]?&&JE1L0Q0IE4V!H,9A<;310UT3+!75*!5"@!WXEA/:NVD(;*F$B2/''G
MO&/.1I*<C]18'_C*6BL.&L>];ACZP22%W;"9-W@PZ+7=,#?2&G2O(!=V%E2]
MT<V,PK'1WV\?P\PU#KN^C':U\5?;QTX?+M,I"W9H08:J!X$)^0%O]N]QN_%M
M<@OV[K!WX0;'MC?HQ%[___V7ID3]WMB/-OQG"'^$OZU>(0-WHT%^L/6_FD3O
M[]&:? (8[3<VVGT/BCOHE_E<SW3.MN-G-AO*V"LP: T!E&'B[N^*5V8@_HR'
M8 /@<KYTOH<YVTYE6.-1K7?"=$@?8U[@^(<]++_N9/W;@7'\ 8OV_7E:@\/X
M/Q]/OWX)QXYRN?4.K,+1![YUT#K<^K*%6QM[9/O+V^^%<O^HM=^"?[=V-LG7
MG9#@O=/6R;<8/28)D-Q)QA!/8)0M#N S)Y5$-,9C ?8]@LD\AOD>](89PY86
MF79  ;.Y^=$>M&,ED+&3+0"H:EEZT-5J[;.+T8C6[S?Z /GM!/#?&31 =>->
MMW>:E3><DVL[$:)FXP1T?S_+<'_0'@ L-'[87KN0CN>_M<$<%4ELOB:2<[)J
ML'@(=FMAKG_[UZFXF7F0P3X,;_A+'>S"W:H'(DY?'&WUKYY/F,&&J\#@<0AT
M"S*\V0=LBME=KW!Q:OTSH()G< 1N]M_V] C&=A[?%L/9_/QG<!N\Q%YC'*$V
MWO1B: _Z_WH;1P;K31<=V],&1*SM_B!;G'H:KYK&CR"$@XM>YF(FYR&ZN3S_
M"2^E1%=,]R.=U0(WI9J.Q\U[C6(%B $;&]&7M@95(H.19N,<F_@Y :RIPFJJ
M,.4(L9@P824GEKO  Z41FZ1<<CY]>S\*:]DO9S__;0^K1,$TQ(5X=Q3E]D>B
M^S+RG0>;)]OOWAYM;VR=;N_LLJ\;'WYN[7QL[Q[!]<_>XZ\[^P?;[S[_;)U]
M/[N8[]S:6>>[7W9YR8T>A.^M#;CVNS_;\#>V=?#Q</O=%O\*X]_>::6MV0*H
MD"(A7&,40K*(TR"19H8A+WVDD04:6-Y*:@I2,\#6\/;*X$U@[EU(S&"5.!%4
M*QJ33=@+3@G1-;PM*;Q-BY!L("(1KU!0E"+N,K6_"!CA:%5P2E#OY<H::W+S
MS D/:WBKX6WN4\N.4VJ,\L$3+K1SQ%C+%=62:AX3KN%M.>%MIM>XMI(EZQ#1
M,C/X$X6L)Q2I9 4LG0B"B94U(IJ4OK;&)0^8>*TQ\_5B9E1,<BJ]CL1PK:/-
M/J$.5D?GI%"ZQLSEQ$PQY6KQ0H%/:!$E,>;BR8 <(02I2)2S5 M%<EVZ;%)V
M[[+TQ\+,UW+4\^]>]T>[GU6T%P_MJ%BE7THTCFR(C7;GMVM9IQ;!R%=?XR&O
M\1![$O.-:T%Y_J)'E*^J9=6C-\->+W8&C6/X>C?41&V7$C_.&2-#%%8D3J0Q
M5AK%+4N8:\\Y6\3)B5+7=;.M7X>YS6_VWW9[I>+K?6>T<G^7A:N=@'F<@%E2
M>,(XMQ)'!.Z;0%PGBW34#H$7%S$33A$I(7#"N@DOEIXGHB: F5O#O4DQ*B\T
MUH%+@QT(!/R4N=F7T\'5&OXL-7R:^64X4.J$1(+EYH8JZ[J+"BGOB G&!D59
M)I%N*E(S/+U !==.YL8?Q!AGN$W"$A*Y5B0%II5BHE;P9ZG@T]PG3@8K8@2B
MH-&@X!8CQWU -%-[.2H39F%EC9,F$^0%*_A#A$^O%C0>X\1T#1J/#AK3Y)_P
MA*N4H2(PBCBQ%MD$\!%8$ +<?LYTWC"1I$G9O8_W+1 U%IG@6^;$Q-\@WKU1
M6N(2E=N=\.E%-\980%[B/B!45J>&H+DAZ!Q7O)!12^,H8D[E_0<:\[FT_ -[
MHX,54>B5M?OO/=2-;1Y)?__QN&F'?)8/7M6:_$2:/$TQ>,9 8[5"DJ2$N/4.
M.7 3$9/*Z4B#-@*<"28NEU[\L];B9=/BQTTMU+K[)+H[S1[(% )@L$>8"X>X
M@)! 2\) IHB7,1J5,CN=ND)W7XX9?NS4P8L&A06D#FI0>!)0F"D-$CIJC15*
M@H!KSIA Q@N+E*+><L6-%6IEC2^5;[[(DH6E+OVISEM7YX?]^&2QKTX6-]K]
M_C"^ED*&>0*.QZADN%OAXD;,A#H9M6J F@>@9D_K:0 F@JU#5#..N#<$62((
M\M%YJ;V7DN1V5%@UR16[FG>/.I9XO^/UJO)CE"S4JORPJCQ;G^"=LM0@DK0
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MKW_:CW'07VTL9WNW<2/-W((DCHH*_VI;USZLNFK-U;;JZ03KRWCAXUA80(!
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M)E#-5='EB9X-W?J+[13V<([!\^P4]NB8>;!WTCKY%KEAS'B/ !4EXM%89'+
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MZ?@2L]29OML?<7F^V6[MK+_909@TIZ]IN<R8C]IW][N]02%L?K/]:>O]&_@
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MA4O%,5<'4L5;=.VC6+F@V5^>S$N5M;2-DV[O,)RTP[4U+GF#O;('K>Z/&>L
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MF22%3RE2J6E2AM69NR>)@T^VSK:^"4<<2R%'*Y%#M)*/QNAHD&:2"DF(DCB
M>R?FRMQE1^YBDJY_+I]W19H.Q/*7,W2_)&%UAFY1&;HB3UL_M\Z^LZTS&-OZ
M-YTHD5)$9!@FB"MPH$S4'D7)G#&:TR39RMK@I#M/?@[ :\1*6;7_>B8241)Q
M?7A119>O4$"V\^;YSNY):V.7;F]\IELGWP2U*6&B0$"L0MEU1298AZ*BCHJ8
M,UM^9:T8P4QK6G&)7Y*3*ZU6R9<L.I/[E/)49W*OR^1N;WSX%KV(RH+H*$<L
MXN7P.G4:!<NYUI$JZ>QH,^":5.["$K1/X>C4"=JY7)Z-78B^:%2!8Z1U%AA8
M(F2PMRAQ;0B53M)@[Y#1FB]!FP.2!\[-NGBATJ3N$'Q5AV!9=PA^X1V"'[\F
M[&I1NYH^^_;6PY=ZC]UOP\4$SZ*10DD)CC<.+OD019*8T80%U_6&R_*8IYV]
M;S@Z[R%L0@F\8(C(E86(W$1$M94J@CJ$O.%R>RW-TNRX9-/W4)LMCRC;]6;+
M8F6]=?#A6W#@LX-4(X45 UEW!%F(_%!BUF)'*?4>@-_<.1&>!>[A]EH>6MCJ
MO99%B]C&WK?(B#.,:R24 Q&C@B$C7$(R4.N%U=8'"7#*;L]P7BMC"]MLN;U1
M1UG.6YTE(5:6K3Z^M;VSV>"K-^98F!.1BA!Y.=/BL044H$(RRTB*B5_=,W46
MK&U_/_^[">[3C[+)WP<0?M_Y 4M2UF(';O7'8==_?UJ](*VQ7ASL'^WN[+$M
M^N'G+OT G_G8WG[WY_[VCB=;[S[_W-[8_?GUX./!UL8?^Q?U8OL=Z,R&/_NZ
M\?;@Z\:N:+U[SW=!%UIGGT^^[FSRU@'<[]W6R=:[MVGKX#UN??B6^5ZH5 (I
MZQWBF??*.0A\93).R!"-4OAB YL8'!?:P0^1N#/1:4J-5)XGGR@G\/D(8',,
M2S#H#2&F>+/^Z7\:ZZV-QOO6OS<_[6QMMG8^74RXG!?K*YWDVV][H<].D#K1
MD#AGEN=^NZ /*FBF%(3V"N1D>30A2V@^(-'?;\P(:O&G/H*@P@3E1D27WG\F
M6Y4/I>#CLVCYI$,8'L;M-)VL/%>@Z!=4_Q4K^]GVAV_&A@#:P\'0.5.5Y&N9
MG:SHM>0& @DG+VJ1]Y%)3%A41'')I0LD. VF1J; @@@7E?W1UOJ:%<X)@5>\
MS'AK_5M@,'M:>"2\T8#IW"#GDT94:":BB<F(2TW)A&<!%@*'%"TWC%AJ#0V,
M!*$( 8?HXC*OYP"MV_$0-4Z;_Q44RS\;<;HB5<S9F\+8Q0_ >\?=WF#:G\[Z
MT@&R<UJ=F\NXE9L0PJM"'5::LOUA#W/[ML:G_9BWBW.E=?YF<9.G%YS9'KS+
M13\-X#_%*R@II3S.MZ5]VDGNIW=S-[5SMNPFVS9?&O1*2WBK3E[SO5L7>>FZ
MM$F^"@"U^/9<8E7]8M>OF]]CY@%ZB>7!JCM==K'=D8[:(1S&Y>^.-'<KELF#
M/6(KEG,MK1IW[&0S1[.:9S$)DS:SC#0;EYK3O.1&,L68E%.T%ZQ?W4"FYMR]
MD%/TWC,(4S'3B7&JC0X*[+8"VV(P1.CQFISB//0=5SO/ZX,WMM?+'M*_[>$P
M+@MAQZ_ZT15A!]RG]0ZN]^7/_=VS7;R]\X$6_QG&NOOE/?C3N_E:>/=@BUXD
M[-C>V,)Y[+M';P]:!Q]$:^-K>W?G._UZ\._]W8/O^.M!]LD_MK?.OJ:M3S-L
MC#%8FT)*"+Q.A[B5$CD3&;+6&Z\CYS:"L\48;V)^;\J.FE2\!K@E>. Y "XJ
M)CF5H G$Y'HLJQ6-.E@=G9-"C39- .%8#7#+!' S+6)4)%:DB)QP$G%'.#*:
M&N28#")*)K0G*VM4RJ; Y+D W"W^Y_V8BVJ.\CDYRF](&+4[F5VL2A@==CM[
MJ%3KMJ>;.M>&5G2^R;G2Q#Q+R'T$G_)\\GT&=5O=CA_V>DO4M>%Y .XLO[=F
MP3L=,>+>><23S:6JCB+# XE2IA"D+P2Z;/DIX.9FJ*S5]Q$\IEI]%ZZ^4W^)
M$QYM<A8IZ0GBL'1(4R:124HS''7422V?^BXH(5=I(5FE8DE]C3>_N'%E?VWO
MZKIMIE]TB$?U]PPF.G2'>?MF/%.O/)1>Q,0\>\OQ2,G$"S;C4B'&M=:EMBES
MV)36F]DD(];2<TI1(I@B'@)!-BJ,+.<BJ6"5Q3HG&453Z@4W:EV 9CV/+&2-
MK36V/GD>L\;61\+6J;\N;3Z(E1SRA G$E2/@J@<&,;?%U#,2M<P,9U(W"5MP
MF\0GQ-;;V-7GY5M_ZL+3FW*(/A]ZZN>W<N5:GI4$\S*(Q2</L9QEK;AQNC!S
M[4XYTY2/,U6E^JEA<"/84WC9:QS&?F8LJ4[GE2*I0>SE8U$1WAK Z_(%WXNA
M/5C-'$0S64M_:/O]ZMZC,KJ;(HYVO^%LOM'PN%L%'+UX9-N=<J(X7V[$?E =
MIRQ!R/AR^7CR'2O1GJ#ZN<1:[Z_(X([KP1^PIO1SIQ?+:H5W,)6YU>QV9_:$
MP"LO*26M]6\0,P1!K$))D8 XLQXY#PZGLR(*IPF+-EVJ!%Y:7)@(W,R6P7E
M*(0RI=HSJ]"E>L]?K^=<LOI*;E;Y0Y0LXE6-^7.IKZP'^Y"#U8NL7+U^9X#\
M>B7D8L.,A92#WG<Z9B+C.9S&.T>H,YCW8-P==RL57C_JPA#/2HJU/[ASR?"=
M9J6>W7<]<(8:4_^HD1VD?CW+#SS+V06-]30O>)K?VG:O4>J^KIC9EUQ[OA%=
MIK;SX^#5_K#MP^Q2HM3MH7S0_+<[G$6X7UW67<1OWAQN/<CG,<@%E:DM_S;R
ME//A&.+@WKVZD;Z078.7V6@U$.>YMXKP?/Y2&)SI21/GV 3C UO GNKZ&*/?
M=GN? *$SAG^:0/C$Z\U.[Q^VWWXAJ?ZC5N:$H2WZF>P>_-G^NO.!M0YV^=;1
M6_CNV\/6P0?>VMC%<)U+S55W:>:$V65?=_[=WCKZ\["UX6GK8.]T]\M[O@MC
M;&WLX?S]W:./YROK4D@\)AF15DXC;AE!COB 4E!>XHB]][FY@Y1-PN]=RKQ\
MM74U*+UZ4)H+>;P?'F4"LQA*V'(^=_Y'!("+2]3K^;G T73GT01AM. 229,L
MXMQQI'WT*!*KJ/""*R)7UB@5-1354/3BH&C6/SJ+O6ZP_?U% 53.JM0 ]8L
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MN]SVN8[Y%Z.[TYB?$FQ,4@D1$< $)\60%BPA6$OEDI;1<PQ>-I--3>Z]2[)
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M0LRG[\7A,!Y:X'3QQV'LCW(O!;AF,&['80&T?@B !D\?Q7'^5@%_75CO!SW
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MY@O'9PQSTJ5K9GNX]J5@C+FY96\ P^MV#@#?*XZ9WZB\ +YSW 'RVAYT\U>
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M$1)4UECV&@NGE,^F?%4M=+KDDU6N?"U.VWN_]](#[7-2HP_#06UWW0M@+[3
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M!ZI3''9A'"6ARA^#4.+B3."*S_FNQ9]'0]^&.Q=_PJ7%+QN?__SS'[F6?%5
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M27GDF67>V6!%SF*DJ@& O/"ZO! A4 M?I+&LM71CXL0#O49U89$GG)BEWS'
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MJIUQQ%)F*0W"6&5N+?)>2\13200%^'$^]V!(%%E &\1= %K+<]-0&I)W0L9
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M. T'"$*++Y&KJ$O8G(3M LTNP19W*W-HUH#*1ELO[%>YFEJPE.]\./4W7L3
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MHL?0C,+0/*5U<,[@E>WY,E$LL3.="4190I!9MJZE0"I06': *NJ@\V<, -H
MWBO\AL \M1S2F/ ,? (R,E'O5CRD[CW471AQ $L(O$@Y/#L_.3YL=+#N@]*,
M)-'-I\ACG=*:*WB$$DW3&,G4$6/DT9)4CFS7"[W0Q5NTO<\'Q_N-2$PBRLC0
M\G2XQ+%\4_3^XG!?MWQ+>C2=D_*Y#HM7< WVY86;<R+YD\J64W1+MPHR,8%3
MH/F2'BT89,+L'."'NN&,S$8X7@ZV3"DY80/X>(9Q N 4#M=B4BNE("+59TGG
M=/>[=_;Y\[[,]0W8+?)F^5Y0L:E+M3!H3+"[;)Q&5UAP:.Q]^G"^#X(-7LUR
M4 1T_;7)+?]S*S8I=5$&X>6U'9&E@Q$&58HI^8:H/%2DMX)U=/]V621CI+R8
M,>RI9%/MMW'F;X-Q31:]3!N.5;V#QUE3[U+/)^,ZI(N#C.<Y0U;^$8X!,%?*
M2YC2I;S&,9C0!2^9A9@T! 8?IC%1M+\QQRW25:J1I#/,6 ZNO"@,6"QHDB"_
MSZ0SY^)5Y;)5A0.68)/EW-(E:::R5W%ZU1(V>5R"7XBP;AJ'>&5Q@NAJC(X^
M8^WDK0*EPD4LO)GJ)^!A/YW98\ZND-6U,78K4;NKO&E:;0>:VC0%><NP4E&6
M[A_XB@#1%,X;2.!9#IYVD4;>6*S2OO#7*L>+[O'$Y8+OJQD<,YP+@2GY%8($
M>!Y3X#%PY&=RHI0A1WTW0[P.SY_EU'IL[0^_RD7(&4@03)-&@#7D%;2*S^B"
MB+R,SY]94L73\%K=O-R&+R*-'&'%M$7 7,IW.()R2O%IUXO)L-/D'N++!11.
M<WQSB"/#^-[4_HZ7_X0IX__^^OG__:W5[%EOC5'O)Y0@$S!R.8$D07;TC?][
M>/S_WAC8>1])I]7L=]\:\__C)V^IC;_%'BS[DH4=2YD P#@W>?N*:+/]TT;!
M1.BV?EJ]WU\_PP;!S#-&P^9P])-Q>$R[:?%NAB-M-U9KOX!?5X""8K*1SI@@
M)Q+0@^_O]7]2BK@]^(GH.GMOTWB?62I%WN3,($ZTH743BITCV$B>GB^H8CJ=
M&<>&Q'H6]SD/'6)[<O30J(;?GZF0WM[1^<G9OO$O+Z(4UT/0K8A5XHGE6!23
M%Z"(4RCP-6,;Z4^I5^UZ4Y9+Q;*05UU#W'Z5>8?[23(:R/*0$5PE%Q1J42;
M^AI06]T6%8NC<&XXX93<+9)^UL_M6PRIJEWG/+3*Y2 /I?2SN>=[,_ISR1JK
MN.PNY@I4",Y?BZ)25>PK=0</S8 BX#R3-$]G7B:M^KJV?%W;J:]KZ^O:)R&U
M ^K,HXEMW+LR5Y78SC,Z#LX/S]1?^\8O8#-%:$Y0HYC,#8\U_5!(TFG+ LK,
M4>JL;03"AW-?)#<9%^9J:2<U8(5U<B<!62$*R93 &!)\W"#)&8*_25: 4AA<
MG<-^Y@P/@RY:!+HCN]7(X8*O%^3^X-6RNHN4F>I+IJ4,SE#Y0,/%'%?EP*H1
M85GL1L7_L$*4Z__ Y9Z)G:EEQ-"G"F:2]^91/>MD0=H?0.R'>=UPP8_+G+[\
M\IJT-VLM1&9^M<>1JDWT\8>F\6LXF<S $VA\M&5&)0;<<]ZASW+F@:T ]2?B
M>^A[WY'D]!N:C!+::W'([=Z8]A[%#=F5X.T>TJ\5/I'R>+P\Z0U--JZ0S^GZ
MFNYJF=[= OL#89M9$%3:0N 2)*F[*'-_#!M-%I(-,$]^#'RZIB];./H25_LA
M&RHKG$%N-$@N-SJPV<8-*F7A8#FE/E!2,7B$\1NLD ICT< ^:7(*&AU.5< 6
M ,*W<];PK8KY4 IEO/00!G\X"-?$6DNN@\TXN_P^V#P7+6L;+O@)E;[:M?0J
M&@QBOB_+W#MPF(##[$N^L0$CEN,065AA";)%@_F"B_KULY4V*$/>(+':7<!R
M0D7A:"?'\H(7B$M^L&F$H$ "?(M.[OS28L7\D*CT8"QC_0V.]6LQQ'>J=%,+
M3^D $UB,83M,P9*8*4HL*R:SO>3)ITB'-M[D9P$HE5VKRPD^/3^[Y+)01O8,
M/7PJ!_!3.B$'4$_/#S_J(=0;$UZ!+D%:\2UDSAN.K;*.&^@;4B4U^NE4*96]
M:';X^=/:+Q+!=\!% @K#I;#+SXB#,78@$!'FR=J.2+BBSN5T$D]PT0.&DKD
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M9(/QU^^%PS/5:)Z[L\8P[%V9&WH,!P!BX?'V"+TK3UQ[<D1W>< N@O[VV;R
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M:"/"I3!"A<.1V1QN: 1A8BQ$8GP-PFL27E/XWQDX(7R&,"X\B0^10X6KSN!
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MM5,X,%"N%M4$F>6"Y5\)*F!!Q6/2*42@1%[\-2YB.0]N #KGDB)N=&)SO[$
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M0_'VH?%EU>C414W;5]3T1/5'@(8GOF<[%3*R1C<4*%+&"\T1SPV4NOCH=:2
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M,\.$&CT5#G[&I\+L)L"%G[J<I"U/!]\#<0,M@&R(U3EBSOZEW*E"IN+<CI)
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MU\URQ(PH,%94,L#B5^+0<20@M1U:>9$!"2:<Q[&[1W4!9UBT>A<D*5>DY!:
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MCZ6#U;H+?D6PC><<<9Q*Y\^I?JV5- #--UQ(XG$M4<PWWW-P47F+_!(Y8?7
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M3 Y%6\0[_&BI9]^U^3PIVHYW2Y*=TQ*D3[-/<A[:/G^"6K2BYQN6(PM6,"1
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M64D8H]DUCNRA1O)S3Y3$6:7,W+XJ\;I[-1.J5M]:RO$N^,Y2_$&'N$LX,LE
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MP$:3PT.'E?E P[T3GM#%<#:\1C 8Z7$7-GY[30HDU5BI@R)FZB]%1.($[G<
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MT+ *8Q1YZJ@51H)8"(9KN]/8S*Y?J1&M93\!%WY7)](60HW#&\3U;80"_Q(
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M:NW6[Z#N#[=(*FT\=U*W /C/_V#*;^)DHPG3J0ER_B&_0,W+)J=4-_V$++O
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M4RG3IPGU+=:Z*4 $FV_:FKD^8UON=M$0E6&8[KX!DZCR$].6JK="W=KR@Y#
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MQ0A&!5I=VW.43;A@ 6WB(%]JIXP5T8Y5TVSSKH-/7$6V^N#5TK5*,^ DE^3
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M-NNH8ZE)"@FB%?9583>IU[.70?+(I\&JKQKK-3+7IAZLD5@]$VBJM?NHRNV
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M918N9L&;?R+!@ WP0+0'ZRX($(/2[-W%>[#P](6)A W.WK\ZHS>)"FR]/HT
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M/T.],M\."1IR+[M-Q6"FV+KDI)OB>[LZTL0$HZ!QF "\R9-4#FT$8T24WS'
M*<1RV8RY)6D G2^\6H?*C@1Y"RWTW+GCO+%!OW"0$Y+8^#:)NNIXK6-<WGB_
MKMR0RW"@5R^:J37C+@^EWKM8'=<!G1U)+8(W:)@+635HAF A7IE!<"9I.<4C
M;6/7SH8)[IC-XU3I84I*,:)'<MZVVXW]'&T>4\E.S\8E4R3YI(2RO$?LPH,G
MPHTVF@H&.[REL+A1(!3:O.%:2>2#GT;<6(^JW'/$T4F64K3U-2++G;!2QX8;
M]V\T3_--%><E[+#KYN7.Q.<.2<0;JB&$ CGVC]U3G '7TV M&=HO1$=$A4G&
M^NR E8>DZ@XAI;U;A=[:+9CC3E,LFT76[>3T7J=PD!U'?^21XV""B\NL$V!3
MB(.Y J7B(&%E]WJRS6FF8M-H"+2P;(':])Y.&0W!"WF%R _+2XIM@JP>YRV/
MEOEX%JFO7K5%2I$81)2<Q=CDK-2*P<(4?1&DOJGQ4@J+#7V/UE(YA+M%TM1O
MGMHS7??Z'8\I$71$R1^U*2H[.*D]=*FK1/LY78F<8DL$$8X-,;!#L:-UTF46
MSJL=C<V^%5^Q8M-[O.TT6QCQDOQG%70*L]?\)$-]Y"5$KR&U[@;G#HP9>8L*
M#'01\LR:2MN:?:]QK-=BE<4)IM!P^<GQ<]>-T?-$,AP1B81CJ7G.+T&4)'ZX
M$46^BTKJ!A<$<HU7G08--6XHDH"K9]CHN5:. N2G@OB15[;;W?X&5USVJJGF
M-9A=(/.):PS23-F(#F,#P9K0FU_@@60IP>&;(NZ7J4>X&S7]F.Q/"CA#WG"'
MI.\-E1LBLITM28)P1.&!#)@%+!-;.B;;FGCO0B(9 L*P* _S@OQ[+J4)"Z#Y
M HZ@,078=VB&KL5CZ&TZ^8/Z7B$"XRP.Y]@X YZ@-T42A2 4D%#?5NA=Z$'^
M M8QD,D&/^M=<Z9-4L>0-F4;3A](V(\^:QZS A$GN1[#3(_DBX'.FP_T4\46
M%\5#D'W>]@[!$(L54$G*-"GC* S6N]B[HIEM0)K- ^."FM6"<!VR ;QPYC02
MGV0:I^G$Q&NX*!KKOOR6@!/H;80C="9Z0DV0F*4/"R(\_;](KQ3QI73*]';"
MM*JOC[)Q%DX+.]+@J=,#6XNW;P"1-:%B;P<@@]4\_+V"+-5W!?4(O>GU44FS
M*)^3Y<&% #C'[%6 I+!+QDMB. ],M:CK>])ZPG#@[;B)%MS'G+<K:94.![/3
M9#/"QVWZNIR^?M:FK]OT]=U4FAORUZ(L_HW7#;?&?%/'2_O$*^8.*2A4@+XA
M .2D=Y\?*9/6!FRR@0TNY"H(U/?L*]M,FEF+ D<B:BGZA_X7TPBR5+1FL_$'
M2B2@GC*QYH 16#L4J]\]4^P7:0=9)7H"_>"RB+DQJR9N,Y@AP^[F,N7BI.W0
M-*UO=<;="[\<D!=40/UM6'N8&-I&>T*HE/3.,]POC)!34P"0:6>QP+"<5R*\
MHAAUF3RPCA[;=2C#-=S:KDUD3I#;-!&8PRSXW7D!MKCX><U.ZQ_+R'9A@X)Q
MM]6,<[_%;)6;A'2^&L\0S#=VR,'JLN7"%-BTS[P\\4X<[7M/PR5?HRS%*B..
M17WD2,=;F;7=.7TWAZLL<9W_$V83) >&QO5CB(0C;61D]I3L :.1+$4"'&J&
M*Y"I20E]3)$LL(0OF<28(\D+;2U<"B^FMC;#V**([!.,'D40+Q:JS"6 #^GV
M>+4O\N[#NI-N>+X-LQ@1.V*^)&;6+ST]=G7,%'FUG-<NF<VF.:$!R -)%VW[
MA"O0[$Z Z%^F,$A!V6&"S@Q0!>A3@O[FF/AMZ<@7ED&%T24SX#3NB%@F.8 =
MG9/?EUK2.OBXTFB]#J EAD^GJR]6I$I?7+XI)YWL6#S)21[O,A."5K2/B%ZM
MF;C6&C\E"K;*YG58D.VPX4W4-Z!=X2BF>(YHJ<&)D 4J4A0R*/6K3/0U:$38
MVW-M-*X=O4%4 I^?"UW$5Y)Q4@0CHGK/I0F/>XU!;>@X=:H;>1]Q"^8DX6(]
MP^?I]]$T0<ZY6]S(U7R88>6N!DXC9^4)X5J*5YX<POMK=Y=60O+'@&*DVA/_
M5N4[. D;.;B=2F]4IVNYQ)AW1R#=7 7@(;/@- GDV_UK.)6G(09T8"_G)I4C
M]<C5;;U#LW)=&HMWSTS%$WSQ& E80*K(=! *;\TI:T8] 3]([HBG"&364@X@
M\_T V!:?RS$R>6ZA&&'@]1'O,)<,<U!!K7"YQ *+*S!] )$K;.]'!$V=FB4N
M55\(TFVBA,R8D!LH:[W*9N<\>*D??EMC[MHN*7"@)UEX1<K?\%D;P>PS<^=V
MM-JSQ<(G%WX'589DM%_I5Z_A%Y#J-2^MZZ^/L\H6<8E.&J^H5[PF3.X\8R;$
MCCTSJ80=R$Q6;+A@')52)>,P\[J$-\%(+?&X;6N=R3XH97 $\D.X;& AX]-8
M7>(:M2.K69KR4M[(%?N5U!S/33B'HG)8T/\:]+H]/2UZX' Z(.AI,PUP8_\"
M^;WT9W 8/7U=*8'Q3$7S$39[HO[SM70R% AQ+I1<'\'B)0CK1]-==02T2M7Y
MHD!W3BA_1]-<U6+R34"X3N$7V-O(P/'!KB5(K_L6-*M><?K2JG-^!P[TF(7N
M!A\2F/,PQ^,&I"!2D(F'!#8)F&7ZF\FE(4_0VQG\\+'A>-?B2.A?<*./4 SH
M+XG\ <\)T'XM$]LR :+E$R&/+1LPL,S7HJMK4JS<%)7QU4+/VZEO7^*&T*19
M[#R,!1KFH'H!".O ;!I$(@I7E;&Q)U-1*1;9D'^?3%NBD5<.QDFO%48D5 8H
MA#UQC,&Y.=="0K_C19&.O^R.LK^A"82<U_ & %<94QOE-3R_(P-XT5Z;7N-X
M;^P<P#X5W!Z 7M70:. RTB28UR^]I7',1MH75.RN7G\[A*)D"H1A^8YF@J?0
M#1DS93Z/ XLV[B5LVF%1V3& '\0P<GD=C<O*KO2+359G"!DSD%7)Y4&LIK0\
MWGH=])_?^8(ABN'9R[OG1O7GHC_L]@;P\JBI]=P"_Z= J'S*Q4PKP>1 _MTA
MBC2W23-<SK2K' "YAHFQV>*&V>F?O*PQ/_46Q9()0P> CNE\)!$!?&+I,6+;
MF\J<YMN_;'?4-G>48VERGV#IQHAMZ"PI*(B+<_C[TYM_.*R5V%0%;3FR#0JA
M8$94(.U%AW/3"^$+.X+>5-&$XTO5'4=$N4Q):PAVVFVPM6U@*(3! @:BV7B)
M'%0F<Y!Y<L=#+F)@<YUG+@>Y[.649%.*3IUW2?,*/UJDQ4F+M'B42(M6CFVJ
MSHIHSI2)-6!SBS'FR',*8'"65&C-EH#O%*/7XU;:G$[J(C"2\Y[Z8&S"B]02
M#[:*:VL+7D+I(?"9_43J<>>P4RHJ]A"R<PSD10L%3S(<F ;A#E$63*%1"S(O
MBE"?DFE7];96U9)K.%EJHO^DBA.O[LMO>D54GDO3$0F.JC%)<9'YHHZ-@->U
MC05C!9BZ,'(X'JL%)0O0[VZ7_E8D. )P3%S;1(^1C0K2KU,/]U/*$7K9FG)C
MAG:]MN<YC+G#)_*Z(I>NZ%7#O6SZF1M>;EI;9)SOK(T_! T9DK(6?KE1'_!V
M23=94C^CX*YG>:TEH!3FF$V1:MOQC%M;8P^20J\UY@8I52DUXJ5V)M(*:-J0
MS33BG4-;B%E4H3;$%7;+O90,08T\@,I>V&.0F569$Y;BWL:<1@4),V%J;QA,
M*]9O-W*94 S2,'276D)3J^Y5.2S8+LJM+HI[W+T&*!+\?W?QG@,Z.?;VZ52[
M#.G;;-R!IUW.K2TGUUA!@B=DA+:!BS:'UVO!P>VJ;&U54!DJLQ 4H]13/(L6
M>0-$ST1.7<5'%-"9B_"<IQ/;-HP/F V/VZ[M7#O'R,RI/M0"M,&&:I8E<'W\
MUC'+(:FH_TZ8K)TU:H<;8HE_U0F:BY\;@$N D1)JY G7S\S;W7BK(C\$A(R=
M]"I_-& PH'^ANH0B_/$?RXBBY^VZ;&U=+"[&/?,;= 5PCY'%S@B J,/8=N(Y
M;==KJ^>(L,KF%(T9%7Z9IA,$7=CP,0'*V^F_#:6J?4!P(O, \)ESTB'([P&J
M1WN>S'5I"@$)E!K&JYQ5I*V:NEQJ>0>I;Q,)=$B>"A7.;?6Y0\G+608B=2A7
M!L+9_!U)[!J& "-@)Z?TL':[;/6T*FQ(AATWP/'D50=[)LM"EJ;M$=W>G#L!
M&)-_^0YR7T:?KMJ5V=K*8&,SZE4.,.11G(Z_Y+780:YLJ/^2I1;32@$&'GN;
M@]=",/R46UVYF&#\*74R:0_;-O$[A/)F)F0%KANR6-:Q0XU2:#7$A'#M(FQ5
MRU!=;62Z\5A@0+ES+81BH BI78$M2C9'T@BF6:)@F-G7-F*0B8UHFM!2=0S6
MB*)=29<@>5F[-MM:&ZX;X0AP)] &>I+.A=4OC2.IPDI<44;^$P/0/4(LQJ0O
MDS(4T?(1NV#6K&2?EY"NI>!HQ\.Z"]]"(X]LXC@1]'Z[5)%Z74U"KJI3[9++
MK.&?($@&O'!S!4)-&1(9$#Q37E&1H(KE.\CS>E9C7842WLZT]Z/6JUR?-(N
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M$=JSD92]C.PE:-]QV)MJOZ9Q;(\1K1U!_*R*ST5VM&!+I3@!8T;(6;2:Z!G
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M->VXF@D,';,WF7YH<=:?A@R =Q>+^6R%!UMN5OO0Z8]&JA0K5VN^6K^HJM:
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M-C0A9XT]V241U5_@4Y>B>=8$N^CS#_\'4$L#!!0    ( +:"95',@#/RTQT
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M9E)=D35O?EO/<.D%=C(M[<9'R2B>5$[E<L=,I ^2!$@*@:%#4DFI:)J4V6U
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MS;G<WI(B6C?*K"X-\:^NU^TY8'V8%:GAH[F>Z=@>$/M:-K@N*2N\-0)M6=
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M<GDU2DQF&JRT8@!"_=\2_NR&^HH[R56!\R-E7Y"!13"&"%MN9;94HP04$.5
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MN9<E<S:;RH^ 2?4__O8_4$L#!!0    ( +:"95'T,3U,'E   *>6 P 5
M97AE;"TR,#(P,3 P,E]D968N>&UL[+U9=UNYDB;Z7K\B;_;KQ4G,PUEUJI=S
M;'=EIGUM9YV^3UP!(&"S4B)=).6TZ]=W@!HL4:2T-[E!4L-954I9HO;^$%\
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MQ_$\G4SG9[/S=?&K9$(]L+&*2:G(6 W2,\^=8H*C$$E+74"WT)EAX#_X+>8
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M03]&ZF\4<QZ$^3[";6!B7@#[;6E C4ST(M?4&%K.R.@(-A 8R$QHF6B[RT%
MDTCR#13[,P\'9&8ZE%@;E)G\2H.:S/$"C-!1>LDC@PR1:6,E\]9X!LA-M68Q
MQR8<WT#Q&#C>7JP-YO'%N"[ ..--PIJE(G)F6A;+8A*1.>5I2,9G&G:;G-!K
M*!X#Q]N+=:-/]J_?K<B#G(P_FY7$_C ]_3C##W6_^X2-ZV,WO6L?Q;*=QKE2
M.:NRE;[00JQMTL67H"TFGJ,%I4DW\/[*V0XC;L]GFP+U7B\]$,,]BMA+ N]*
M0NYICM9_J"A!>,#L7')R*ZKW5=;^=C%-?WZ8GM J,C]/R6G"\IK7[(/7^T:W
MPB1$JX6/W$H(NF@;'"K+0_'&T>1%=S^3:UXX>-E[4-X6R(J!YF3Q&4B,=B!#
M^Z61(6?M'+;9@ <O>R=5GR',\4<\_^_+R6WYO9F>G/P\G?T%LSQ*QL<<LF,\
M!/*0)"@6@[-,R$2\A:*B]8V2L/K@/(JX6A\M69.<U8R7!CX(+9^GTW.(M\^Z
M@_$6@4:?<D#RJJL5S4D.1D6C52X14VE3I;(9U/X5I"FCM^I8!J*CA2MS:]0C
MK2(WH#4K3A,B'C3SBNQPIX5263@739-%9=.6^%C58D?1-XA#W4Q,+!!K)5UA
MR3K%M,V>16LSDRIZ+9S4*C0I;3IPLN<^56![@3>H9UR68&QPL@CHJ_(./K^>
MSI;27RQFXWBVJ&&9=]-STWP4:".502%3VI#R1N#,9Z_):[=2<OH"I4D>QHZX
M'[>&[9/4!O5W2\&\G,_/,/]X-J/]\C7.QM.+"/YE"F7U/DYKTORR]&(D$P;G
M%3_/I-0%/0-R7^B+!E29YT;GZEM@?=RZUYJ\!L5_&R#_!YR<X0;$(<44<D)6
M,G=,!UJZ(>;(O!0D/ $ZF49-U_I"?9+:-A1U#:H*7^3_/+NH\GJ#)_7DY-V4
MEN/:%*M*B(9 <MD$/5L3H=2NU;0:Z[HD@R-+L9!WZQTHBS*UT+H=,#]N]=L7
MF0U*_*Y!?S=]D?.2%3AY#>/\<O(#?!POX&2)/*XB?X,DP_EX@1>AF_,I]P;3
M]/TYM\O9-_+9^1!M9$+4ZETA @M6 W,\125CS-HW295L/; GH]&'5XL&I8UW
M'LM$,G=-R,A<":YFA!;FDU$,04<DN[=>)W#84[)!SGI2MD58@A%%II4'>!TF
M9): 1U3%H51-?/S[SGIVSJ$UJ*/W,C">2F;:1,.\#HF<EQ1C57X;VK;"/70.
M[2['W3O(\M YM+>&<*Y==76:3NI2MLPL*S:JVC&(<:"U44M:?FB7%2PG&V-)
M"BUO4J9T)ZHCR;+MQ?8FQ=E9ZBWJ'&]BNDQ8Z0"J1\IM;Y58BVJ_J;<-V%LM
M>AQ,]'O3"R #Q&A/:#P933HM#[ZD8Q*"*FBRC*Z)S;I'?=B0CWLH=>@C\09J
M<,WRNLA (^>+QN@\4RJ;NA(ZYJ7)M159 0XNB38M3FXA.4#I\^X,;0Z";B'>
M!D'R#1[-98:I(!L_T09JO:AM5U"RX$C1419CI2@JF":MX.]$]1CT8#BQ-U@#
M7J1T=GJV/+W9%#BYS#(/LI2*,4I)(N#)LZAX(J,I*)#%A6":!!DZ(WP4NM*$
MC@:!\S>XH+%BOFSN<)G"[((U0DE"5</Y)@D& :LH5(Q">I-=H_LDUL%Y#!HQ
M@* W1L[WG"L.\P\_GTS_:I0=?O7TO60+KQ_+:@8X9%D4>9'*94TK.7C,$JU1
MBF=N3(=DTK6CZL?+J]E[F(S_>WE,"9/\]NST%&9?IN7M^/UD7,8))@M:=:9G
MM:/?^]<$(HUQ*XJV>]$ ; TPPM5\;BM<2:78H'VMNJU5-CPK<);[(-".=A[K
M'CC<.Y<'Y[03M\!5*JBCS0$T65@^<8DH3<JFDERVX_9 '/]8=X>3_5%\^;Y#
M,;QVO"L$H_52T/]G99U&8:,QH)6I2?S.NYBW(_CRS=N9377X-][[XNJ]KZZ_
M]_)M7T^U,R]1&H],@>9,%XLL>IN9$](H@<7HPN^C>NNW;VLE+E]XWH-D6BY+
MY\:3ZA'C+(W)^8'9G[@8J6"ES2(QVA-==8,%"PDD@\Q#P'K:$DVGP=W_KOW9
M@OOA^M).;"'J!F</EPUIKCK>OSV/>LQ'+IJ4#!(F(SS39"JSL+PY03FE50*:
MOTWB5AL1/59-&9:*)D7&'2]!\>3H"LE$\N1-*06UC:1B0A<?(8<D;9MF04=V
M(\UAM*<!20V.)]:V':W7,%WTGE0:R!6'PA!\9!H@LAC0,Q-<C1/KR-MT;;P'
MUV-7GB%I:7*_T23A9''>T/[->/XGX:P_@/<H1@9K4S1.&VA(M6.:KU?QU-HE
MQ1&]E]*51ODQFT$]=GT9C) &B?KUKK^_QB<G+T\_PGBV3$6I)2W"< TI(1,E
MT\*GK6)!^\Q 2YF$,N26-%E9UL-Y[ HR  D#YM3WE<%Y^DE4RDEPP# B$-B:
MD>9J7#GFXKRV)A<]M(>WEURM SA"385_+)E>/WR R7M\.?EZ2/'3?#$^A05^
M_^4=/6.9K8 EY1!*9(4KVDHQ.1:<"DS8H%T.)A79)!+3!=R^\[[VH!JK&]?0
M%+5(_]B(L2*\"%UUP=@R6:P+R,/DC@U/<6<=VI&?0^E2QL2]JA%0(>NJ+C6+
M(EAF9;!)V0S"V\>E0_?DFQV'"O6A94#5.3^XQ+]>3LIT=KI<EB]BVS(5!2#)
MG(\T;!T49T%$ F1IZ_=.>Q.['7FO>_K^<P*&)V$ZI 0'/.S=V-?48DK>DC=O
MN+.DPS7#FKPV5C0Y:4FE +)+[M"#:>>\/X-C$)$/> !W=Z_$+J">6K?G7D1U
MZOF[C93WUNTY*Q^SXX&V,\'KK?>9^> R*UEZ(=# K9#?@Z&^;[?GX9GO(]RA
MM_(W."=]JE6_-/)ZQ<7T$\Z^_%1H;UI<9JTI0F=M#(S^$VBKRX7%C)$XRUH;
MR367HM/.WN%EQ](?MA<GTX8"'7"C7^*['/*/.!M_PKR\%Q;B]+^AVCCC>)G?
M3*,F0[5VQJTY[UQ'%C+M;):^FF0(IHB=*._TN@=/^O!"'7J>KT%XE:I,]FV^
M5$W2/N&E480LU-6-1A]%K@G**!V6+&3IEMO1\86/D?J=!=L@M'HK)O/]E^]Q
MDCZ0<?OG<EO3.@NKI&5>$BI-O@PA]9Y):<'XXELE=-P'[/$Z 4VHV4=\]0K=
MQ=SI@J_I:>,]  ]TTC@HK??JS "<-"E6O >G*:Z&]RSCLB:X.47K;JR%FI;7
MZFX)X!MU>3V$SMQWLGA0E>E#19N:MGK0-G^#"<>?ZJIZN7/:* 6HQ 2OO3^2
M"\P7Z^J@O<=8R*)JDL*Q"= !SB('I>YV\=KN<F_2'/K69/AZNNZ5QD130 &0
M \6+8]$B#9\[@6B*S[%).Y@[,#U).V4K0AID]=R"=CW6U@':7JV3@X= A^+Q
M/OW8D81]F"/7(&I#VZ=U@IDD:&^-2C*(A1B%X(TCH,GN9TTY='CS .K11_8M
MU.)LOIB>5I]]!>+E>9W/ $HF9KRL][P2,O!1,>$TEI \>FRC&G?C.@)#9%L.
M5W5C0 (&CHS^!O\YG5WB.V\I4ZLK>):%92X(C0:RQ\$I%E&BT!*$T5W4H5,P
MY/;K'Z^A,8"X!TP+K6A^AU-\56Y@NM#V+J"&CHEN1+/_F.BN-$U;R7C@B.AF
M<(C<UWOA6'3U,#_PR()(AKGH/)+#Q:/MTG?K&(F_(R*Z%][[B';H.,G+CW.\
MS,=!'M!%GEG"2-:.E)E%KVGK,<YZ-$G[N'(DOB$6<NVA^XUW#"3CZ0 "&CJ.
M^5OZ$^?SJ]PIM$:3\6D(2K4^A JU(9-E]:[UD*(LTJ=.7-U\[H.G:P<Q;9Q:
M@S:@>8.?<'*V7;^+J[\=H+'!>APK30J$+\Z \2['2(X0#PHX49!S44%SE4;K
M$&TGCZ49M9-4+IXPH&S685J1D,\Y\QB"16YU,#YDU#R2=,A^=P XVHQN.SE=
M_C=^^7$\A_?O9_B^MN/Y@;Z\G\Z^[-!JH^<;!I3S-F-:Y<%$&576$GW0GL=H
MH\,<(2,6#[R,>KYK-P?[VJ-)**_*Q4M_O2H=*CH UMND!/>2:5JDF"_ 68D@
MLPH9M&I2]W(?L-T;KBV?MTP(F5;'-BWJ30N7J_M/G]/)66V9_F(^IV4:\SOX
M/ H^Q1"+)5L*21:<3*L(-C-++F_0SDGGFUP3N@76_9] #*I)M[NVM66K093D
M O+OT\4FU*- 5EKB1C,C'5EI]8C& YGJ/)B(,1M'FU=#?;H#VN-4GZ&X:'#0
M>;G8C[RWNEAI&1I-JAL=9Y%S1TX_UT$%&X5LTHWCIGWTV)CO)]<&65X;!GE^
M),=S,B&*7*^-$DRG+!GHFNQ&OAI/)D;5*8=[J#UVKQ=/-&5_,*D?NE1Y8\X[
M.9G*(.UJ(@@@]Y-6+,@F,0PZ@PHJ2C[8B?<Q5 (-S^Q]A3]])+RWJH\NH)Y:
MX4\OHCJ5?VPCY;VI -DJTH0:=-.%E+Q>L!*3T[4G,H3HK$FZR_U]QTA]W\*?
MX9GO(]P&UN %L,L8:PF!+^]V1]H&M:-MT!?IF$(E$O<FTZK6PCRX@>)8R@%Z
M,3,=2JR-:GU^F4WGEV4(J?#B(GI6$A*F&K<!+B6+KL@L@5"MMGJ_N[[CVK/W
M;]/O(.DU)1S;BJE1J<Y;."%UK 5D-3NSMNP[.9G^!1-2T@N005D9:A<MGP4Y
MDY!H03*>,[)7BT@^D*MI^W!Y[QL?.L/#BG1 _VT)\H?I"?UH.KO>$D!8'HWC
MDAD5:3&J7?5(*PF9E[0)H0:?NI5>KGGX0UYK!Q%8@RWU5QK79'Z90>T4) ##
MR6)0GO25!P;H"[,N 1<ZU:S]%EOJ#11[;B:W,RG3H23:I-?M4G,O^W70 @0.
M%.,J2=HD!+(@%.T4B,$HER'')K4K-U \<'JWE^C&Y;=)>/IW7%RL8)<_N1$N
MBU\N?CM O+'OJP8,/.XTRI4(I"OH(RA!6J"T]S$:&QW0-IV=T^#4:-N7-@Y%
MIECO8HJ!":@Z*%-F4:O(G+8YBVPQ([:8U<<8BA2BY.2%9\J%7*] BBQ:;Q@1
M*K).5O$V8=G'$8KLHTE#A"+[L-4@%'GG82E$S4T6EAFN"],Q"Q:-1&:D51&*
M+BCV&> _KN##+HHRF-2/-O@0O5$6;&'1NUJ':($%@X+9H((J*0D7NO1F?ES!
MAU[,WA=\Z"/AO9T\=P'UU((/O8CJ= 2]C93WI@( A6L?#,LJRWHRP!G($)D5
MQ6?/LT<8.NQXK,&'X9GO(]SFP0<D-T&@1N9BO<@&:XL#K$G.R?"B5##Y"04?
M>C%S9_"ACUB'#C[4!EBGN/CR^0)+ULH0%LY\\()ISC/SFGS[0O^+02H97;>&
M^2L//O2A="\93P<2T- QAQ\JDMGXORZAJ&*#DYX5C;6O+4&)(=H:[^3"!@&P
M>M'.QF/GZ\]]N%1M+Y[]'E-M.$&Y5J9Y55@R7&)\]Y<UR)'?<J0KAU5:<Q=(
M"6A:<,UKQ8+EN?B -IKB,MY*E^_^VD%.;5Y64<')BX\?3^@E56JO<3:>YA_.
M[QVO5WB5@FGQ;@9D8%Q(]<*[!'(ET7/."&AF.EO+8J[7>X44K#=%2M$EA6/;
M0YP=H#>]&:IXI9,OF:&I33@#^5)!1,EXT#G1BB!D)[=R]WX/![D9ZD#ZU>NJ
MJ#X,M4NM[R^:"P_=9B,-N?KH/6TV4BCF370,74CU=P2_2X'P_J;=7L_$#JQW
M>^3V&,[5UI1M:V.CPB"8(V&10XDUN:7>R*:2L<+HQ#L=R#Z0)A:'X/WNKA9]
MY+^WI@9=0#VMKA:]:.K4W6 ;&>]- 8(+H8;SR0?EAM947E@ [9A1(A5E:??U
M@UWY<=1=+8;GO8]H6W:U\(I;KIQ@26.H.#SS'@03L7B07F2W>JO+P^EJT4O&
MF[I:]!'0T(=F+TH9GXS)IYQ/RP__\?9_(9PL/OPPG7V\F7%CO1(V1LYH6#5E
M3M;6G-JP[#C7!;BX5<JU@<-N[WOP]#80Z]!3]#K$W]*_+YMVW$;H"9WB9'N0
MR4O+$HV; 2U3+"7DVGDDN71K2=/I=8^*]V&$.G32[U>$K\H+&O%X/CTC#_A[
MG+W'-5!)#R5*<HD3T<FTX, (7V <HP(GDXFB+_]=WON(%&%P,0_8<?^6SK[Z
MN#@[??L1$SDKBR^O/\#L%-*7RU/HF$KBW#(4#IAV 5C4F&O&).DQ^2FEA-YK
MP5UO?$1:,*!H!VQGO 3Y#O[$#)= @@_.V,*\JE<J*U^O)=&Q]EJ+)($@N.Q6
MXG']J0^>QZU%-&![R#O:Y=[LV2^YU_6TDKP?G6DM29IY;@6S$JRL5V)KT>;^
MU".[6.6 1S!-N-K+)3TK??Z[X'N^:64W6OM>F[$-)X>X:<6#4=J'Q$(LJ=X^
M5ABX# R+I5]8*4)N$H]XF#>M-%69/E2TZP*T*;?\R@:2R;GB6*IY9MK;5.^:
M42R@E#D+XXUH4MW4"=T1M#[?B=1^V?Y;,++G"UE$\@*2DDSX:.M%V&2$^41?
MLE$6D\?(]Q-,/]R%+,=IWVS%T#XND;MV<T 7:,\WM&S#8X\K.+8A8<\WM*0L
MLP)AR"OG]?81<"RBT2PY5#)J'[/=SQ651WQ#2ROUZ"/[ ]S08F1*$CAGA39!
MII%L-M!.,HS)\)AER+I)I?V#NJ&E%X<];VCI0\!&VV2?*;&_X/3]##Y^&*<W
M^)Y>U2X?=M.;VB?#=AKC2B8L%E=OD?3)**=UB@ 8B;MD)*W]8.)]F;";WMFZ
M@;0,-D I3-IZ,Z:O/0@*",81:4DLNMY<U6(!.,JJ;1"A<.-94)%DD95G$*UE
M18J4D\KH4Y-]\G%4;??1I$&JMGNPM>^J[0CD4@)P$D-U1D1MN"2D8-8'$XVN
M_FX337H05=N[*,I@4C^&[-*W"UKZZT.^KOWD^%9K--DD.9#W&D@6K-Y>S*+4
ML@;:A=9>1%C--=H^G6PCBJ.LW^[%\71H60^<3_CV7(>N0[HT.3N &CJA=".:
M_2>4#L36M)6H]Z<'1A:EA*1=3>N:4*&JND?FG0Y"!%,\= F"'B/_=^25[I7^
M'A(>D/9E*\79E]$?;T=66PD*#$N!IQJ(!^9K+[ <@\W6Q9S,FH#!_%+,<TQ_
M>S_]]-W%$\]YOOC'*LU?W[K?7(:!Q#_=278#&H%U3#^=S:8?+QNPZ<*%@&*9
M2ZFVV:0!!3)"6<P@ XB,$ =K]WS]Q0^9QIV$V& J_N_7(\Y+DB@-"\43@IIC
M \DG9F0@+\-:D?C04_%_OW[('&XIN_T6=[](B_$G>AK.89)_FE1'\@W.<?8)
MOX>391?;,IU=KT0^O\-K7-/=KKK>PO6NMP,<>K4#->#YV)XDMW*4QFT($(U5
M-.NU<"(63#8#_5BCMJ!'[>%MORW\!YR<75[W_/^=P<FX?*D'%^G\9?6MY%V>
MS:[YPX'+Y'P.RW@T^369,P]*L:S 8=)*H!O,QNN-;M=CDM^FGY:6W,O)UU=?
M29M 7/ U?S,].?EY.OL+9GDDLPV\N,1\U)YI0YN!3VB9"C$6%47P!EJ<GFR!
M=;]K=UO=6CUK:4U=@T.YNX%>+ HC68KT-=Q"BW(U&FG/(D/1L6))*+[DE(IK
MH5^=T.W_9+<YS]/6) U=4W0WPA<Y+QF9OYN^GDT_C:L[^R+.EZ?6(U.4$Y8<
M$D.0F8Z>S-<8.!-2B1B=C\IV*R[8'L/CU:!]DC-TP5)'V"2>Y6T++R<_G,UF
M)-/S[*=1R;)8GPMY1 +KE>'(0LR2654;N"NGI1]4KS;@V'/7]'UQO85^#4'4
M@=:MK]!?$^39!?"$49#CS9GCY+5I)X"1$:Z80YN$BT#OZG83_"XHGO5K.)(:
M%%K<C?U'K#WC*OA10)/(Y(P,K<E,AQ*9-[[0%LXY6&.4:=,[JRO Q[M'-J6J
M08)K-VLP.F6\PL(R]Y'I'$CON? L)W T$Z/GZ5A,]C;'!>?1SQ(R1M1D!:.A
M10>\H,U%*U9**%"XT)9WR2L8]*A@+\D%^_-^VY)RZ+2#;GI]E14;0XCH-"T[
MDF2GG:2AV<)9-M*"BA9I#NY_VAVJ4J&Q:O1:P+>BJ$&"\3W;S$6S] X86Q8J
M= %YF(J%%B3W,P2V9^A0VL3)QI6*;"'C(3!M'?E:4246R!30QM*"KYH<#Q].
MB^ZI:S@6)>I#S."-N#_ [#U&2']68%?!';*DR74[_;AX#5_JOGD1:09(H"RY
MYE8J<M(#9 9$%L.:-QH31[Y:=K>I3W>?U^[?Z1B>MNE>9#YX>[#+X?_\M9G&
M#S,D5WO^,RZCAS],">V+^7P\7]3/7=ZK9X2S0!LVUONKM2$KTB=3&QZ)Z%'G
M))3OI"=; GAL&K,/'@9O,'8-\]5]>[$VP[F\^Y9C-%$69HH%IGF]A]5:\DU=
MHI_: J9T6TSN>]-CUH:=);O?E)++*H5:D+!,(?AU#'%\LLQ%&" YI,OC!TSS
MZ#V:E80-$VPJUF--_]$ &,C+CER -XA97;NRLLN+&A<\!1_)#-*9&1L,+26D
M6*""K:TJT=J$@3:FAUCPM*YN9BGFWW%Q$:$8E6@ARACK%=&)Z6@X"\HGQK-*
M6;C"B<(68^^ [0@+FOIHRIJ2X$'9:-.6XA;$R^GX9>2M-AI-(DIKD_B4$H,H
M'*-)+9QVUF+H4H$RB*I<H7H"2K(= VT:"FP&=Z7")1E01;"H:N\6"(5Y!,F*
M 52U<CYTNFAN6"UY.BO*3GP,G>#PT\GX_3B>X(77=U[+>>W2<S+R?B2!G$P_
M+IW"\0G2(";X(GT8XWEH[ \R*68W_F;^@L2Y_-U(A20<.8HLEN+)%A2U!B09
MYE(I(5E:+3MV<&V+\Y%HW;$Q.G2SV'Y#6_H\[VO[H>GL2^]Q9J^]D<6PY"72
M.(UDT1?)4K)!.3 BA7L=@WV#?KIJO#^N!VR VVF3N)#H&TS3]Y/Q?V,>25-;
MHUG!I(;(M.>6 2>Y.NFT=(@"[?ZW[ULP'XDN[H&C-FUZ;Z%]C;,RG9W6DYM7
MD2;74DIOZ>N\C#'7A"7\-)Z>S2]REIQ1.MBJ!1Y,O7)[65+D&!DDP)$+DN/>
MO,Y^T)^ YC7D\K8VVH&ZNKS!*LSQY/U:]",,&:&VQN:0EY5HY%AK85ER.<8L
M+,FK28"P$[I'IE/#,W);;5S;7BT>G$"R0 7YU8RT.['(->W@T6)RT4AIFZ0J
M/HA>+;NHQF!2/W32U(:KKIQ+&DM1S%I=:G9F9B$:RX3(VF3K)'3JG?? ;@(<
MCM6[[_GK(]V]7?/6!=33NN>O%TV=[GO;1L9[4X!H<W80!<LE -.@D46,D3EG
MG4Z::]NIL=<Q$M_OGK_A>>\CVJ%C_#<N1G&U'V<B9PM4'9K5M-UQ56W<E*0/
M0=&VU^F\YACOCNDEY8UWQ_0148/054UI>U5>S&8P>;_<XI<J:3BD:$)F7H$@
ME43'O$FV]E,5$HWB/C=IO+\6S:/9GH>3>8-ZI&MP:F+*[],)?/W)LD,\G%>Y
M7';;[0"W92)R3[R'R4D>@.GI_FEJ$ +M"[MP@QS1,)!%,HT^,["R,-HG;0*#
M,O$F,?.CT*I[<I0/KU1]V!D\._EKN. 37@/^UWCQX?H5NCP#3\5*)I,@>0BR
MKVKG>6:2S(H7VG)7CTHWY25W>^'^#Z.:LC9M+/+]-&"_$5NZ"BUME4^XZ5$#
MY YV0KF2)PAD,AHOR5E K\E# (O>&'(@K':$VXPZX!U$EDMS:$B)7CRPG5S7
M(;[5@5[98)7ET43-0029C41=L@GHG)>;I'L;^R ROO'CRP30LQH\77S ]7]S
M-3=W2*%MB*8=NX/+:D4U<LG69 Q2 &AKK0_D] 7:=(L.WOJ-$V\(7+O&']<O
MXQ>;1]KPZ^L[R=?3;(/)QA@-BTJ1VZHCK?75=RTT;8R5Q@2)+0RT(0=QB(L1
MN),E:<W)6^1 <@/-8BJ%>0A"^V0=MLD;?A 7(QQ,0X>X1*$/LPT.<BX@_SY=
M;$(],O6^OAC)-"NEEHTYR2#GR,A\",HX2=(*#77O#FC/JC84;PU\]\O-:B20
M<^M,8JG4SB%<ZWI-B&9(/S0F2K+QFUQP<PG@64OZ<=#@E/!M^H#Y[ 1?E0%$
M<WZ2:CF6P)>)+[;FP=C(H)" <@G"%<UYZ-2(I;=6#3^4?:4:'(U6'E@;CB&9
MX:+8\M7L+<X^C=-Y>P ;33$I&&:EK#?1\<"B$))E3SYELL6+W,4X[A3:7 ?@
M4!&30^O#=$!>!HZ#7^"IX[] =%GSVP74T(D0&]'L/Q%B=Z)NLSZ0E/>F @8,
M^D)*[F*J#7J=8('V>29=<J+0__1J6<.#H?Z.5(@],=]'N VLYU\)RF1^V7VA
MR) !DF3&J%I5ELA\D\XP^KGA(=*>V^ERD][&S@T4^TV@&(B9Z5!B;>![7XSK
M DS&G'.*DED=@6EKEI6#FK:L L71H+,030S:ZR@> \?;B[7!/%X?=95&NEQB
M8:"-9=KI0-])8#G+F@:"PCR!1)DC,?N&8^H(TFNZP'U.K]F=Z1TS(;:AZ0C2
M:X2)R&VQC(=J944#+"9AZ[$B[92$W/LF9LA1:-56Z37[5*H^[!PJO49:SWD,
MA7&YO#PV9N83K=>2ER)!>NG<2A?IQYY>TXNU;=)K^HC\H.DU2] W?C=\$L+F
M=[1++>@XKI6$ 2\20@3R7774/&?(3CB%H  %3\%O2AC8_+8C2@-0BLRT#)XY
MH7RM1JR7*&32?)M+-J:F(C7I:GT,:0![[XA@4Q+2*L,X)]]6 P#S$"T+ 83$
MH+2SN=.:^ZB[7QQ,OP_6*:./7@S=#O8W^#P^/3M]<5K[U5X.NK8DG9Z>D@<Y
MAI.KX<SO' 0Z0@E9,YGK==1D;-7=S;.DN$!PP'7JUOIS*$1/57,/PFB[M(5[
MRNDM+U&:;!GR3$95)OL-2BKUF@OMBI-:JB9]6XZTP<'!5; =>P\C&T+9$CDM
MV,Q%!?6>%<_ ",]09UT<8@JA28[-<S;$SBI[8&TX=#;$W><GRBH;N"^,%GX:
M"4U.V@QL9 )#26BS1M5$KQ_[07DO#>ET4-Z'J2,XRNP"]_F@?'>F=SS3W(:F
M(] N<#&8Q!5#%3+36I-M04]E061O9,S<J28MSH]"J[8Z*-^G4O5AYU 'Y5Z
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M/-:S1=YYHO^\*F^F7^!D\>75Y'=<O 6R3[-( 7603,D2R3XUDAPJRYF)2MJ
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M^4:7W>KW5T?^#$Y^@\6RX6Z;H-(N2-I&C@:3T4IXJ#BNH^6.7%FE0S( 45L
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MHIO/W=]^N:-TI\.(9NCN/:]GTUA7\ LH4G@O?%&,=,S5>]MI"9>@F2133;H
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MVXK9 ZYJ6V[K.J/6Z!9"VE/^FN1%A5S.J*&RQ1K(9^LA+Q;32ZYZH6ZKY:H
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M5.T@ZM3,H.B2<W"Q!(HN?Z2-E0HEO,#R$9)MMD EC@?*@IID+46JZ5)E$-"
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M)G @BQ3-",;5M=,DX5C*$G*$,8C.%?.G/J!Q5A(K,X4+>H3;?D2F+;:^<^N
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MN5OB\Q&-E+(YY<!0@8/'/TW);6T972GOX7+:>JJR]<4C8M&=NLL#2K[06;[
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M?60S\K^9,_@_Z^P@%QG>'FY4.*NSO^.;Q^15R::JR4-:)_Q&*_'TGUJG$*E
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MD^^]9"F.H=AS/))T*0CQ>7O[AFGGL:L_,V)Y$K_7]*VA& =/,H%(>0*<CG2
M;N^N0+XVG?Z9-KC,!(3L:L:V:3VH=7:OM.7KA5#9RM]HRD]5=N:_7NS__4X!
MX@#>R7K<+F1]A8."NE':6_#1W+8H/[](K^OZS#?RO(X*L/,&(/8:8@8"XZ'*
M'6TD?7)-2%WW!9@.\4#R6-,D(F#:^.%=_<V2*-!2[J!8J*I6/[/^6_3P+.C]
ML8'EQMK,CA&/P)OPHH4X%_I ]ML+_2_7IAH^":W_8+_+*U314C(EE?<PXT12
ML.2UWTQ8!3;HQ]!+'1>GAYR/8T1]A_U(;5N"=<*6P%N(=9.X&/4?P3"G8XN9
M,9HF9Z7S]_QQ;07R_WC9ZLKD4TP@NHD"_KMU; 032.G K9^!M4,7C9B >"0Q
MCM$H V$"NHF8V?O?TDNRU'U!9/O^[[XXL17'8 ?IM\0$)8P)/!ZCGQLT[39>
MDZ/Q2C$,&DG'& 3L]M/\K^&S'+7Z?YA-Z8W'_XQM9J12I$!J$E$#(_/G@?1F
M[D[C7R7_!916CX'FDX^_1[D[C0T0_Z-:C1P!YW$O-YJN#UH5.3M-#6TFJ1MJ
MKMO<S>3X&CPWF[E@X._P),78ZJR> ME^MGM#J?:^ V%!Z_"E&_(A>HJE]B.*
MTPFI^(A&N)\Y=I%*LC,GAA>^A^=[MB+OAXK6V3B'&S,!VXX,CNOXU0-/%+>S
M0+1QI;_&$IX@3@FJ=LH@VCD]-/8HGSHZM9*Y0WIB).F[-G3@[$&=G5A)1PHZ
M7,7JB^8[?79,7EP%ZZA<ZM<!.E4!E3)ZQ*57]E33W$2^<?)R3X1]2H9N?J7H
M@M//5X,KU>B'?G?#10[0D9? R,QF-(ZEG=CNQ<41T/PW,EBT^W6EUORUR&:G
MA>$N_'@6&*0[<E!Y_^>,4TTG5@]X\^]Q>]7BLDZBP(,YG,/<])NSH'BT:CU"
M\67[ZM>!&XK>!3R8/CF/9L_Z@:W%=;MU14W$$&C);72,UM)%HI*JGN%,*PGE
M;RR]H=XX4W;],$\[;?_.8_0"ZZH3IEW&]/KHZ6+$=U9] 7_WE^"47&G=G5O)
MM)KQXX%\4=.*N>6N3H9OWOF@'Y1_SL1%_ZQT^.Q1_8^XRJT".K*QYIW =&JZ
MI47_'/E0_B:??+$V/NRJ67P" !@/TK @:F<BQ]#$@HV,B  &1^4((>RL4VG%
MI,SJ?-Q>5&\ZQ.M(O]OL\MFS/#I;5G+CF4J7GWN4;C?/[=UX@VUV'M.<L6$L
MU([N:B"9.![''EBN=C1\UG5XGF[5:0F+<O)4IG$?(P]5TC%(L<7<*$?X[EGG
MSCFEESSR"6%/3S"!A/#S+)M\++ZWB]K?&,#J2[+M@UI=C!K&I]K.E15MRS;+
M<,Y&K">?;")Z:NR,M8BKC8U1M,$JC9F,9FTX_:PS:%>_FQ2\+<_8]Y8*TJS:
MZXR.PJYY)0;<O_Q4GD&O<K9UL=-821%TH_--E&H2%&&:\L;6;4W:5NT@OY7;
M4=T->+,,+$H->:+]=(F2A85"@ZI1"I_XS(#<.571Z<Y-=QIG'ADTT !O.GJ\
MSTT7)5<OJ'![9=DO6W!P;%<U1YKJ[;*#B1_\-C5]-#5YZ&U14PIG6P^H[8$0
M?(LPSVA#9<A'3$"6$OWJC-FHG85B Q29^=XG:D#34]-,[F?2PBLPX/?DS9^=
M'/,E8QI&D3:E)4>,*]-K4>LS]L8"'9  ]!\RYZX?"+_6'_YRW=SQIXZI/M&4
MH0MYB5V4MP/99U?)3ZA ^6)7;]-$F<"]]U"ZX)OGC(BTI."I\W_*4 YF9?NE
MW!F#W;EL9V?'I>^B]H-31?BFV<=X(C?P\VNP;V-^P"BR[DL%XO[Y*B#)>+;R
MO:(WR0)[^#O_5E*1R)&LO/[FL$45U4L'+T?>D%RN<6[:TF6P.8'>O:.2GL>0
M+(B-5J_'UC(!CNO-GP<_I [!E@LF,^C3DQ+"$H''>1&TVM\68GK-Q.3TL,8?
M0N#=?^%)PG]^1S?50?GHC<0#(Y_7S$?,F_(N*\@::G^\81P3>/(%X'MNUX.D
MK8JO/P*3K#S>F^=WYU/-,'(KT[K>WAXWRZ.;)B637C2+O 8V%'9L=X+(\!KT
MP7>.L'R?59H2J:!@.GG<2:,M6T:Q/UFVZ)O6<\V^/9P7(X,X.&U8 JNC5ZYM
ME3'VI5+9S!CUZ-V=\.0 ^#%*$.>$1>D=Y2B7-P57&9.>YX17SEAW/X1HXQ2R
M? XD>SOP5#-Z*H\6DU(7FTG'M KVX\R+ A15)2YECUOIZA@\5EW5XAF]V2+P
MV),U;2-=@F8 3DC$XP>$#3E:JI[9&L0$]NV)\TZ]>AL%B9MYD5"WM>LI3F5>
M$XDS!;$=S3H_1M1?&?JQY3K[3HF(K!#,2@YH2:E/=%&02IBW/GF,G_^@ZE%Z
M"^4RR4B+,D9LO$QZYN="#A.OX[7W=!ZK2PR4J,W+L+W]S%:XP-ZHY- BTN;G
M^YQ,8-7LE\IPW@DFH!4\PP1L."C"/-@E.ZJ\AW7C=Q(GG...8\-":][Y(^7:
M+Y6-+$*5T?SG5HM<&=+/VEPA?];T5>":SC.!%A7&<28P#,;M&^ZN6^^"OV5Y
M.B"U&(-,(%<PC\J#@)<0 ])=%74?O)!36-([L6ID4(0((R@KU61GAY:%LVV<
M\$598?&QI=!:7OH;!74X(3O$_K-L%F=VOEJMXLQ0\I'8<RGPCX4YHCMJ%A\;
MWU)\ *[%%"0)<(HC9*!R?$*G8*W<&K^T'1M9@/)TC1?T25-'>7S=*S"JLKW3
M$0^C")LNQ:/L8!%88L""NY7^2YKG68MS,3D"_I2M>W'H4HB&A>O\2^(;A,&!
MM]1S,#2*^#@BC)!#8<=##^3)#2KJ(?5T^"C!%A;ECU"J*9B.:S1-<-WYC"X_
M<CK]V[("???0S4Z$1/*%[EV0<JH-H?VCT(Z/0U.JW*$!MSO""Q0V)2T@3U#5
M>]04E0*I7##+%@U+NWJ^N,=1Q2W22AT;*VN7F "FK[(/<X8>AF1%U2HSOH^R
M$>\$9[@GVZ>31U(EG3^+F1&](Y2TJM?KO=RN?QQI^459_]-'(G]H'#,S##96
MD$.5D$P9#8XK]*.]DZ"[>?W4>1P,_:?C&'HH;FQ;,:,)A(+Y\$:5/XJ JC_B
M!/!W.O1\>A#V/OREAA(]4N/8_""V%L4Z;_XEA4!5#<G("#M[2K0X,FGWQ_C0
M6/%T#.@$@2C$82:09(J'T;@U&3QQ^9JK\EO;OXK"[=U__IP;58NMW L:FQ11
MCL$F!/(*]:^0/+NUC5^1;)V="1QD4(29P!5,%98B$4*3^,L(WK<$V]#MN%^D
M(ZQ#CJ9*Q4?0.;$[0:68)$=,9@C0B5J,(-@+%-& CV*P=--;"06%_0)*J M8
MXLJ*+W3]&@V\C^\K;$T$Q7VS&K(MB@0G6GT%1M JN+@X0*/_*J7HX)!_GBV4
M,#:V"S4;0^$#@?HPRE^PE_4_>_9(8.Z=95]!VF5[.[CZ2&_MKN CUF=UI 1?
MW'JB_PV3B[)&4X1FZB#A[V*^9$RD.2-8"/)! LY&1U/&-X:.L\;G=;L6"Y]X
MB8S9'B)2\7%^2,[ZO)I1+N)8('=8*E5>+Z#GVZ;$)W1CEAN/;/(L&_II-$6<
M>+D6DM=8^Q["1M'2#=3I7">M-J#E6V=6=(03K*XV2GNJ"#QGR4P*_MLBIY]M
M"\=@4Z>RS3&!PL;J()FE6';8T8>2FT=YUD)W3MIF?8:N_;B^ TVXF_6#K8@0
M$4233_.0JW,?O)IEIX%.G\NK*.C-_UZH+7H)#!)I)W#K.3 TEFB&HH@_I*00
MOJ-#!-F_C8Q;"AX8W/AP:LTA-@V*2Q.P#=)2'SPS'WSLVI/"T""M]*US?PCR
M)M,7_UG\-ZR7NBA9*B^<O,?$*,#P_"$?^__E"W0T:"#74=67A>E?&0)R+Q$&
M7ECB-X2\,TLY9FW!)..Y+&MF2-5KK]=C=9?H8; V7 TZV'RF6O_5._W@<F4?
ML?=9#XMVC@_:;!SGN4>[UG(M-X'_ME\?UI,)W$<-;EX& _S>?DJR[NJ2FT2.
M4Z9]V:;&1U= NC+EV(JPN]& WXZ7$TX&^;9/<2#S:/WTVZ.#;#GR"PJ)L#*0
M09#%3,AQC?B\U^VZ/Y*CO>;\64WDC-_FYV=5+*E/G^\3>)#^U6+6RZE^::I.
MJ?"9B\):N_S+\",]G*VM'FR 2'353NPAT.#2H$4CN*7WI(?]LVMM'"#5.'"M
M<^[T$[1S]&M<U*F9IT\.04H_W.5%]%@_NYYBW81UB!BTJ(,4I#:$&358"<5M
MXL*F!LTS'LB<']!9Q>O;[IK$.]]O];2V<O^=F5Q\]:]C#QU4=;YRJ&I5%.%,
MKPSRM$=7(T/T/**$V!LZ5S_9XEE^%S7U3E"8L>8[O,MRE 7D!-_IOABH$S1T
MI^6U<UDT5D()I].#65MDEU?*9[OLS>IAK>'K"?LNH!ZOJW.VUYZ7^?(^=;#6
M]MX]-HLABYH7PKX*.XRY#_Y\@K:>^54W\;-U;^QL4G#=WYCT?W8: GL!B_>'
MY6V^8)Q'!\.(;SU,+Y&4R3"R?C\3R'?BG%@<M1MR7QP^J/SH^D1VY]RU&RT3
MUV9F5OXU]#!!]O+]MT.S__=@<19\'Z-A;!^"'5%DKE\+8[D]<FHXKS')8BL-
M-?#$/Q"O^<O]QJ&+W=1="$-ZAAL[BJ))D_<HO=X6V ?O&9SKE'ULT79O;8*:
M$PA:-YS^ ASW7247_57^,ZP9ZRN$DP]'G&=F&V\GVW&N Z5/IQHCFYOM&D7V
M2]+%OAY^K,+R:3TI[\V0Y!EMT!*C?/]   [RD3\Q@6A["D@Z[_](80*?<W%K
MZ3\7;4J]B6K.IUUA CEVAC^_3-%QJP>,PPY7W?Z85LVZ_G^]HJ/2%CSD>A3(
M+(51P\H@L7P6L]Z+^ X>7# 3>.-"N\H$BN&,#TN2R:4LQ.X_3"@[^L,_18T_
MUV"8GOFKJGL-Z=S@-KB3>N&/A=\#PIP94A*V]WSW+L#"(41#]  /UA8;GJ>7
M,AA/@XP_V2S5,5@U_\ @XZ#K;:\&H<7-S2=PBV&>L*40JD(_LA>]<P/&/N)Y
M>OX8LC?%4J5]0+9#("RA94"BG\'G3,'XD=A?3B1,.7]4I,Z[OX&@;V_KV"_8
M=="-:@0UXMCM(C/,F$!>;[YD=LNV?A^'%2U;QQEYK--<4))8F8A'<\X?U<AP
ME(E-21G6<72#GZB]+'3&Q&C]1)\/ZLB/LR\_V&3VS6QKWOALQZ.BFOK5\0'Z
MUN]56#\?O:0BF]#YL8E42=J3+H2QW72;W3$?M%'^U<8AI^,19S22=\2I\_.-
M8N%JPN-MT$8KWNZ-++%YU24YDZ+PY:YQ:)GTC<28"D_6Q$G3M058(H1X%3Y(
M7=SD0HCBLK'N)Z/6:KNTQ]Q*[+.T<-.1/G5^I<'TO&K&Z>T$.2J$2VZD%SGA
M(S[49>&5,H)N@VI'<*#R'[._^F9 W]AMGU*>OKGAAZ/)C-E$=%Z32,*F<1 Z
M_GZ=WM8*@^T U:F?T83:_^QV\X'V,,6ZA^OO#5GVLEXM>8UR4679'&)Y?1R#
M?C<=_ZALGYJS[)UOOF6HI.6A3MG,C=SC$<<^6,_9EB#.?>UYIKOFM*[C,';E
MO1J:P99#]6$"->D=V1K'/32H\* -[6?SN,=%;2D6H HRR1JTY]XXGO2!:*9-
MPV94GB3MW@Q1'&HS,BQ-H-[L$7,,>1^$=HW6;I1N]8YZ>BN#4A1"R>!"6X_*
M%D::7U(7AJQY%_5NB<1M&Q!6=MZE&)T*AP5L?ME(5W4\Y[YNH>EJY51HH,FS
MFCKRLYB+R\Q,+]WJ,AS.'7WGCDJX2J>[0NB-G2^&HR[4(W'(:FS>?F@N9G$S
M93:J'D)F)(9=-H_QE'N"MY6G]^,<]C]^%ELE[4@ ]1!N,8,)L%N,TRK5>Y<0
M;:S542P/!)X4F;_@OU&!2-&PNW^D'A<)^VI,%\=CV:B2G#]([*,?)S@DZ.F(
MP=Q5_61H*#+JCN=&Z'45ZWURSSZFFHS8X,H@5#>-!V4%?2<UN4U7Q%?3_N:M
MUE8L\39F2PM2!Z?^/^R]=UA3:_8O'D5%44 %!*1$!4%$X$A56D2DB1B1CD)4
M1)HTZ1H2%1&D"@@(")$FG4CO1+J B/0F)!2I 1)*"*3=S3EWYNN94V?NS/SF
MWM\\C_N/S?.8O??[KK4^G[7>59X#1N)S=VT\.@Z)*X"MA$$"L1NL#%!/8KJA
MUP7$T>\/)[I_=JSWB[S:?RC':OLZCPR%<!5CGV#V56M,LEI@)F#C(_N<TZ^Y
M=..O&\LQ0'8C+"J#)JLM1)L)SSQBQH13U43' V>(,7$W/K;LC$R)V8B2H:<1
MCY' JQW#F&L0' 8F.%*/W0.7(I ^.Y8)BE<[:E+%D>UYI?)"[%IQ?0'5>S"B
M -8/OW&O>#56^K. ^+$_\J^ ?Q04?=\ZP%\<^Q@@6PN1EF;8(9%J M9OZ6FG
MU>V]^S/MB>ML#]BC]K.%J'GR/WZ;\^K;[72W">0!;P,C8FD)6T+*7.7SO,RO
M_!H.UDX;')>10Y=VA^/$9\.?0PC:SN%(CCO/;^-*OTB(-(OTHT\4B:&6+^F\
M1F*Y*'($$Y(7 8)?&.]*)XLW*$(#\CS]7XZH4Q9"W*7;W(1#E_!ZGM%168,8
MFZ_4EP0LE6^1*+UR;#@CI)H](U*F=#0___(:;EI8L*(.$N9@0C\^2XRE<4(/
M +@&H,,D+,?0D*)I<@)R<CV<K- P<88%641UQ>6\&WDI>62:/:'G6RAY@R;N
M3_2B'FR?+'O>%9J(]H=?,#EWY&CY12RT6-C"EP@K-C0@A9P_1-Y!W$_?-TK$
MC+^,*'%^;GGZ;+.VSQE'9+'0%8^3>9^"F&M=+2&9=F5'5=9BRF)6S4<O>K9R
M?K2*8$\V^(B>0U2@ [%[J">)R*L4J:!JF;?D,*R=D=[E>O%$/UKB_.6D39YC
M/49*4?A.@,K]"#/H(10  NHH/Q2'50R2-;\ IZ)6:)0KR=J1;#6:_+J@I5"1
MA8PB 8#[5)1J298NXZX%/^^<V!/!9JH:_7HY6LNS%/D:1;ICQRYGGW*WO!CN
M^R,-,4ITN%1-&,MQO9UI;F&WT1]FE30V+1)D>M/#V!CT5&5OA_%F37;K[Q)%
MS'4D+@A#@#X9SSL],@D..8.<N(WD98">W?GL/CU\!#?V$AG:? D1J.M6<YGL
M3#W<0]_GZTO1\8YL;[&4+XSO'%]*D&YW=I3F0A[2SCC."=[T8E[&$!_D4*^@
M"HQ)Q*$Z_A^:(]0//[ND,9R9^A@D  +(<(ILR,/"RW\Y\%05W\9N>ETLN+BE
MX92RX[B#2 4QPP]WBT24M.Z[_\ L17],N]7FPOG[E2$Q^C ^@+X!_P.7'HGX
M.';<>0^Y9KJ<[)M[<WG5Q5)OC^<'Z>QUVX30V?,\7ZN73&AOT$^1N%0(04L7
M%E;Y+GD2$&*K;O@-=W-?=>WH9_(/J]:E-4>/QU7-3#UX<%G@T["F[KTKJ7E=
M/<@Z-> 9* 4(07_4I*[V#"$\% YQ2!N<*]3@_!3JQC6A/=ZO/2;S5#&\866C
M<S"#Y%5!>X6Y!SW@O6?5(,"TXHM&9YS7 9%3WV0L]%SK([5'IA>G5LN4;9B(
MZ'&;15%B WU?PZ1#'MN8'JS!J7"Y\HM'@L')Z#KFW8W.S7S@A1.G37>L'@K:
M&AF?H?++Y]R*(!>-9SFDZU=.ZO2=Y0\8%CL8S0!A0@=&(IJ-"T_J6,[,12/<
MZ;U8PL4%5#!,8'V9TUNAR5PJ0#;4$UF&M+EIKHVU3MR,O:T>ZK_RX9;C:+'+
M;H4F,,$%^WP1GZ8HU>#X8&42?*RF=Z+TRF36J4A!=J?)[EHS6BH&E\L \4+L
MW1WW?)Y3EDB=/W#KJ$U ]Z4D@L).A5@1D\\N1BPY-M&RFM+JKR+68A=' <9U
MII:\CW"T$[<1 +_M/,$ !1),6:4:DTZ_-^ W?J+98JB4H'"E6BD''EI.1:]D
M) +;"7AFMQ;009!#>0AQ[YAF;>K9\;B-V:S3M^R]/GI'N/6?@Y[GY]WY^&H+
M)P!:! WD8?BUOC-P7:)Y_T*#*D]HOV$7[*R]^6O^Q9<>92%KYQN?W07%L<-R
M!;D(^0DX).O@[)9*:'Y"NMW[O)J\O.H[Y_(F]?V-]#^ ],6$<Y]%.>$!AB N
M<^'O:9:YN0G(+$"X6Y?@1@!EC:<P0)HE/@#&6&* %0"<QZBO9  SK>0VZ*'V
M*X":5:86?/X^@/T[N>20MS"RZ#(UCKT>33ER!KEV>>"]23BP2A#DU$<$%W*P
MP KP,8QKGE:P3KX'P/+ W]WCV)JM7-FO]V&7!@BAA*R#87# 'A ^(Q2B)MB?
MW?<D<S>:@.<\"1FM*9;G19V81Y^K1R9&%[YA?4S5VO8!8HGLXZ1PXHT/6QG/
MJ6I6;!DI"_*+#EZ.IS:M-3?F]^*>_J &"CG(BCA('T,5.!50.*@.Y5^<JA<Z
MV>?Y\MU5=&*_59=UCMXYMVKUT42P_-;.PO[>;[X'O@EFO/@>RK->_UZ>01\>
M\QZ]&)Z':(+QY<%UK&8L9LL2'#UJY&X$4^Y/X01WO6@7<O6+2,S]0/[)_=)U
M@:2AGF,/K<&":YFZJ_7&1\@>$MSF93<2=%^''SZ^+J#.%'W:Q>@)\ZY#-Z+)
M0P!X!@,;'  >BFT)QB&/8+D(W"\D04$^J*DNR1&0;M3&;003R2!@DA4U)'=K
M(>*C"GN>6YN\?$C^3SR9B[B=JA=.9SF,*;1I</[1;T,1WE=#G>#/-7<7.UA%
M.Z1 :EW:>2"-O!5#3[NKWM^' XB].WW[H0R0,VP,SD>PWMAB3?4G:N#9Z;5&
MYRF'W].YSDE;Y8!0]3BZ,W6LM^CSAHR.<%BWCM"1[0)H'V&4.100-"L^<1Z%
MGR68!OXN9UAF@.Y!AAH:(24VS1;B=4E\ 1YC;T>6),UT J!EUY7;7T"&KFE5
M'<Z6-F5J]G[44#8F.8 OSI/\/'FMMT2L>[A_>)>4\$H%2V;V>>%(D. Z)198
MO"':L_O(.T@_!X&).H])YX.GH?F6(CR:FI='-+&KGY63D"^"%:[LX(B.T _M
M-*2]0=ITLB/:L7ME47O(][ZV9,Q%T%=LF#[7Q%5$^NR=Q_NH//[  ]HQJJ_A
MEO"+T0 (9T U&B$K(G )!@C= ?B.%\K0W2Q4+ /D%XB<ND*^P0#!XL/I3YR-
M!%IC6KX-?$<*+42._^[IW1R*RI?1,\E-JT-N'(?%H11*$'' TRI]5<\BOW(S
M0 ^XN%0/IU9L60,4]OS[OW.JX8YZ>B]XQ1%R"((WZ\6LQ9C3/8#=H /^JCW[
MICPJ$$4Z,P_;TI5 *@+/==3^_/9/JL>..4P!E)JD50^C\!<C:9+/,<E!].W
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MO86P?H\W<^=_.S+(],LB![?M# L %I%3!61=>H,\<DM%; <-K*_!U>;^/0B
M P$"8RX5Y$@4(A$&\/T72;4<125=;\]/?H,J0MMTTL"$HYNZP.]C20E$'_(3
MBI8WY::TCY\QD8LV_&;*\=$+W@L+'W;MP(L';M;D9"OQJ/S)2@0F/(HL%(M7
MLJ% X;<KB28O\HP7ZNC[O*?DNP^T9%F6=7!>@03)@JK"&* 3+XWB,39<%R69
M0>Z"T:LPZF'(N#MD/\!\.W?O"KV^T'BV/6^TG &*02L_2X9H&P.<^/% =W2'
MF$6"AAGPD=>O_2U^?&. BI%X9\(,*;\+T3X)8QV:YS[[KMU7\_@4=AA9(4T=
M9$[,. 4UDMMLH>@"L+4'[HA+R E>?OZP!!WB7KT4#JV).+-^*F##2_YX%'CL
MT]T9?W1_V^E7\2>;9#9'B!OX1*+2^/T5T4!5,+E!]Y"-='NZWM2;G3J'=Y]J
M *WLXS_Z[3Y=<&$KM*W!.7F!X]/F<,20]J=!WG,@FW<.6U=3<H8Y\)T?EI^A
M"'J04,")0 OI*8POU62,5$POFP90Y'?!EN\YI@=0GH07 .8#X+3DX^'^=&Z8
M^0**4VZ_\U'[+^\C9!/<K;N3;]-6!A^%M1PX](CK-@S>I=-[/YTS$+]XO"?O
M1%E9T#G'<35^U^;DZW),.R[P@YA!+)%!IUE^%K[!OH#L@TL1PR\HPH*HD%1R
M,'0J4([O4KFA*#G61>G&UUM!FYW-@ AIH!ZK2I5'.B!9Y^,/1-XM(SGE2>=#
M70KC.'U!3,.U^2F)PTR3&'9D'6LMTVS9'=T$")=]&QL\I^9FMF U8L[*>:#D
MT4P=;(AY/!R/5R?+U"FR!;ASVPQWL\L3T,E)%[LC\.8U)X+.O\Y]&G0J[8>_
MMT/__]5.Q[;-:&6 [G<.B:O1"FOWP;RAIB/.GI!NV;Q+(G.R(V_9AIBSDXQB
MR='AZD]5[@2!Z,[T'^!" [6[X)?[J*(3#B(]ZWE'W'8W:D6K] & =%CZ9=LH
MR\M' W( 45N$4+D"Z/N64"49#5"R#E7&'@.P;2DF/@^USP7WI3OLD2/,$KQT
MHO@'.'JBKZDZ)O:PNJSS@:ZS6EI\9CPN:@*!^:_;9IOUWV._6Y/,E[^;TKEN
M0]_;\+]3LP-2S*DGB-&DQ4>ZS] !SJ+(A&ME&L(C9U7NOE 37S@ZF6V-$:MU
MMB\;7SX(\]:U+.R3;<_">TC( \A?\:1-Q_GT#W<]A%[6/3ZV%12G.=^D:6RS
M5J(!!RCLK@%:]7VD(])O?J!0S6$RG#U%/6]8DO.R=OVH)F;U\Q7^)QM\XCUV
MJHM$CHDCX034AV'T"V4U7[:$5-O210\OU^.;5AKTNP00?^0%7F$3E5S\?8 )
M+J92;LPB"S+JE):Y[)N5$J8[:J,RG$=$4MW5AOW*]3?BJDZIZ(#H^ZDP<@D:
M[D&.SO4N:ASHS'0P'ZTK+W]%Z_M+HUG^W=>43-(08Y!2SP** ]6I8F!9>4&/
M&3KJD&R77GM#W!'K$P"5O[+'<T9T?V+V6^^,CL4;]?*]S=?_[@X,,'M %H\C
M<4FBI&CB!'FUJ5^IFGF\*OQKG;2U1U53W2'<NO\YR8=GZ]UBA]_D94I DP%V
M&((B7%TE8"^5DBLF=5EKC_4=%VWH-\CHR+BA.+EXAEWGY/6+&Z:M2U-2LWHL
MR=Q,CQ79+XO'7W<<34B_E1(D]@L1_]<=UF*N &\[JHKBP2P!@%#!0OT$R-=:
M)YVU9XX83,=A*"\SLPC1 IT]IT^E5'0\_9-Y//\]SOLG'N?]Z 5U !AA !XZ
MB.@%[TRKZ%Y\EB1)R'PT*F6[N13%U '0RR?^NY$C&KR@$M_C&CX5S48!G]Y[
M_' NW5O/;-/3H4/%)%XE2;"SP$?26DNV3LDP77C 9A0B)OZN\EWG3'17ZH/<
M=+.K>X5>VI60F*E<#20UP+*($6]Y3VJ4K%!E)L6&,@QOG@S=W)VH$G/A0/"2
M, ^(A4S'!+CA8P^]FIR_=1;"*4@[.CL098Z:6V9QE>> M&5.#RHL]9J4F;;;
M:6PVC?HL%=\&O)$PWX-__:3Y@.T!W@!^^%<0FFK!"[&6-H'50B *Q\>A1^V@
MB^B^E)/7&*!"JX4.A,F "4%W@EY X)A("I[H8(-)Z7<M[6I+&Q=5;VC$XBN/
M&. =%LA"0:?OFJ6==2 [C\8O<V,ZG&HDBFQF:D4(<I*G/\[?$H@VI?1^&W:P
MGI/RWU1:BJ!,:CQ [:)+V8$%:X_,UDI\^;8J2[/_>B5;6X)IS3L!W!C""RV7
MZQL@U;"L+1B$VE\E1NK)%4$-Z3:;J4'U?0W&28+5-VWV3 IOZ"G)4K?SRTO/
M_T6\]NB<:.!3*LS.;#][#O0PG@IHP=.WB+%0B@:YB2HP_@C8L&?@BV\VHS2Q
MDD4NU3[/-EZP760+B)WY-H*'$(R1(\L4P?[5<:B?,[)[Q@ <N)SLO+X7^:V#
M?>,U,E?HK=+YD_7T!R:K <'\OHO6VTWG*HNS3O8!IL W=GAI;7:9%H%C]Q>L
M_V$B9$R0&CW;E!?% ,6&>B&M"C?*[+>'_3T!]_^UG,V: H$?Z66 ;)$AYNQ^
M:Q&E"V85AZK+VT8NJ=I9.]^]T+$<XB%'221@QTFQA(P/YEK/UVYXE':OZ1H6
MEZD-V(?<W2KBCWP4"7VXR4[?.[J=BEU?1K9Q(_*9E@[E>E="1/785!T>@3XL
MD59O[F& / Z&5SLL!@&[&>Z/+'J 10_ :M VT\DDD\X)I&0+ =+-' XI=4/C
M<\^@U5F&>^P,*5#Z*-DD/LH<X"WBZT6;U%_8Q_\HE^#38M^GV++K>N*\)^."
MJP1S&Z>BKFS69 T<63&_J<,9U-7*Q^EQ^VF:B]H[ZEA?_^\'*O[G!HS!$*YV
M( 8:,>\'ZD>"97B?0]AOF)?%7%7^:-(:53$#=T3!UV954C!22%P K$PU8=Q6
MA*PT$3R([U^9RZ?*N2DMAJ:_#)?N%/4_@U5DG[CWTL;U O):3OSE3\.2LW^;
MB/&OO/Y569[T)T@<"K-R%\*"P9L6;.?36-990@ F0P,PZ#@9(*YWFL+I+\Q)
M+%,*8=M%$W\O#?[KA6Y?)DLH4#G*Y[A-D+S*W%8)-P)&)X)Y.&BZ2;OG,^E'
ME'5F&R''*F"]1]'9=IY;TPFNUC[.K'V)4WJ["%>>3,;+[S8S@^[^L8JQ3]/X
MCOW,JL9/R3V]2((A=)!M@21#+J$EIS;(CH&(LFB1:,B9,R>_Q7=TWLS\MH_2
M.F]$7)GI6+38][7AUN_5\W\7FANC=X"+30*1ULB0>&BHLH)\^Z@<J</I$SR!
MXMD2M\NO\AS8Z+CI[5>'UD2IG MT%B_1Q3C!B'',_A;?-&^1ME-HJ6.H_?+)
M#Z\=%FZA%CV+S%:4V>.&BG)NP?[([R6-'H4M]?^LSXC?'Y><Y@>/B]8G>DW&
M-H:"ZQ%'"Z*N]9>T/W%V9%EKG:H"CVM<,WM-R$Y+VGU,A8_$00OU0(^83/JB
M ^[#%_38VAW[*[)V;]YW+/HBF.2 RY9RB]HP"J2-DYT)"YID+9R*:(.JX':/
M'_<;'B7%9>%IMK4967<>Z IN3RC6 [@HWH0B9 LK0-6)@_?/B0LT)XM(ROEJ
MW1/N=0K<\69CK^J\%"%S29=C(;I3[.;P6<#UX#KYJQ-B_QL&_O]G&/C'$D-L
M.')W<?@PW[A(R;B '?)+2> !A]/YEOWZJUK2R.(0)K86'N7#XH29B8WZ&BM<
M>&.-57WE&MBF3_;&\[+7[%7'Y@O%EL+2S: N'P:6F^"Z +SXTUXBQ^_"56$O
MS 7R%YWK"?B^Z[*;Z#-NB3-,,<\BW6CU0Y2W)I-T"4(X*8R9HGL \TC#8>S:
M*-J4JMNVX!D^ZPR0X4#8X!":)"EMW#!A7D(*U8M:2XI P-&7XC8? 9*R$D>;
M^KYYC"\@4[O\:>\AX_K4*\X!PXMCG6SDRMLD[HC:[5(X_=8/9IH'&:!BH;D8
MN:UD6*>LC%QUCO#]KE;> [D9N[6G#CZZ@[D+^!%OP"7=]#[DSF1Z5[D)T>OY
M4S,'%F@'A+FMHB7MR=6'\'GJCB#Z2X)S,"U=(>).^K+F4H*O\1)$8B!Z2QC)
MYRM4K4*2,^'$62U][LJ-U7'D98!&L >J-RU7;+[TZFL@R,A3/RH<?#OF<(I6
M=9P6H[Q[>^";$'G9\AGMY0$%TEW18U_+YY+V:JB8<GR\SIZ.& 27. 53A.#"
M%<0]Z:4+U\NW'<X]PQL;/+A')P@656QQ)]6H9N14HI(YN75RT:!Q[$0-8(7D
M[$(&.!28OIP."PKZ(3OU,>>.;LQQHGJXL8$Z18E)BO0BSYQRR!?92.^T1CLP
M0&ID\+AN)]'AW*=Q>JO.+(I:'3\WLY>6OSPZ,%8JL8@?CIX:X.;0=75U610N
M_-B4I"EZ\J<AH%-1U[HTD&+R(U60FNLZ9G^ME:CQ(@G1XO(A]NAA)AW"="ND
M8-RY=(%#1"O*]ADWKP!OZ]Z,HG,J.] GT(/LY).H[22I PL4U89L>^,Q6)#R
M78YK-6.JCVS/4@)5WN=:/)F2#6$?Y=I($B 4?5ZU[<[$>$#'4"G#$-)J3_=R
M\J9-,-6]W.I8XD/)OGG**\J[_D(&J.Q(346%P=<M@RL]CFL6BF.?NWD6\QQ/
M;)?NLT2<>,QER/88!!)\FJNO@;1I%A,7HHZ\>I,X-J[!:7#P/UQW(6]0PWSU
M>3A8^-BY+EYX:1=5#7G7T'-E21AJ,#>//#H%_-"6%9UEG=!*/XH8HTNKPF(=
M)ICVE-QW#9VPC?T$V=BT%B2CX^@_DA.EGV'>;].W_9QYN[)G/X6%\)I=Y=6>
M55M'?UD>=*#O]\_T9FOK; !SIU0/R'XL;6 .S&N)\W6J81X68H!BVLYM#FR\
M9CYQT6'U)ZZ:?BJCO*> )@@_21X9!X?1>2VLZL9.=,,U,OCWQ+2Y'G\6\;)0
M:BRT@"K)Q'YYWF&SB,#>&'X0?IK(K]CRW"//0*WO."76F%O*^10O,]^KIX:X
MNX+L+@YXJ2=@@D5X$);MR'X8MYDM7;EGLKXX2G30.2CLAY.!]Y6];%]'8?-=
MW;'J&G*]M*"46ADRX!OO;B/+$ ]9!32RYI,%UQ^SDBCJ;@[E)+-;8ZY+LT]K
MWY(=B"-U,-X\Y>5]Y**&VA-Z58$]ZWOS!9@IEW/-H 6@WG,E%5Y:9AJ<U__E
M(T;_W0',2>R'9;(D=U M,U60,."W"&<=IRPXL]I]F>NZJ>LEW2K=G*S^ _].
MU^%*-#D0U@Q;NTJ5 9SX(L ;=EN1,1)&Y.G#7F&(!S$AF-E$L@T#Q&2SG1<^
M<1S)B^Q2(G32]W32.2MX-B.V2C00UQF@QHMT:08HQ6L<165%;2>$!_I3K1F@
M2\L-$#(?A*S_L2$.G&-H\DV*>DEJ4FI+% $8UP]#@*<6_K>/YP\Y_W_[CXHO
M+0\RD3)Z(?>=A\9&FN-CHFQ2+?1\76T=\]+LA';*@_C+SI]/;GI['6HU\D>.
M#YO"Y,8'-#N]&[FO)'P/.7Y@4=$2?:2^O3&FF^VZ;2>A4GZOZN#Y77YD48HQ
M_5/2,5H$778^B95XP#J]1-4C>CA_L(3/6+0]425AUZ&HDNA7*^\PR?.;&W06
M<0J;';:TL\[NC-6-1S >V]M+LGP;..%GK%_.;_<3=00Q0.[^3IZXKR>WFY$0
MW'Z:#T,_0WB7CH-QS!^5+[!V?3=?:=$P/#K\N>KN4\.39J8/G[)>VZS)>=OX
M)U(U_XX;TQ2[;X8:-EZWLK.E39,>LYO3DK=KB  BJF)"TB>[,4#[8$%G>N%J
M1+GRU>L:NXL=#)X?:>C6'$_;8,'4ZVPNT/=6 0QCF0%Z%J5?1&Z9U 638X=:
M,0U'##*H\"L98,=;2/^])Y37;V/(AJC>H.:T2B'MEDR <4>\_4U"^"O13]HQ
M= <#1#X70+_4Z8]9W\QD@&:/K.M_C;N/L/@9LMSYW>K>OZ78FW$ $_^">6]#
MY90RH_DAQT_3/Q*68M'(>B,25&'1K1JA-42E57FN=R8-=6YH7(GN"PJ;6=[-
MM0G0N4/[R>WT%]CG2((\DI!*/\%-C*5Q8+;S2@& &C=]('/U[I]2]0<_3&O-
M]_V)G]028OM_[A<),U0.#)T%,P$>@4Y.C;'W*8NFVI9VV<G,0VQ+*B*U)/@:
MDUV^WMI$I?NVZ.0X7?<"8/[E]SX:O]2O]OQ SZ)_/3YMW!LR_SUZF\?]-A41
M3/BUB#-Z!O5K/4),#;_V)]5I<!I;^_^:*_G]]2LQ9_&Y[%_V"#'2<F<>S_C>
MIQ0]]YNNV?]QC[_M*]/)T:JV-)(W-<SVWO5(S7E>"^VZ78)[A4*.Q@<=K0WA
ML!L%!R,)USJ'I)V'U"<[^A+?2#% >_-K*BD:KZ:R-:&=3M"-%*NPM,53T#$T
M,WH$/1),,B^AY=8RS1]E&[0:.+/Z*/5F.5-KQ367-)+.'OV:':Q/#4TF$"6I
M%F0WLZJ>Y<7IHMKW<8M+QZ(]6P\$-IGQ>!Y_LNMA$%V)*/,,6>"FH+A_@\OY
M% F:B[!0CE^%=$%WPR_>U(L\[9T%X[C8A?*1*H)0?,0ARZ*%MCF .S0]@W_R
MEY89EF@*#[W'"UL8T.(KU?AEL\C."=&:8P[8N_ <+2%O)DK;!0\&R XTJ^>C
MP37PI,6X;N)X4$-[C(M=QC0F[]$;WG=FSS^Y>/S \W'5((N;5W)N;H/T*",;
M\G:9E1S4TBP(+N@K;G^]+$N[O*NR-$EF18\OT_HV7FT/VF0&0SV40*JAZ.5B
M]WDLH,<N"E<3UB(5QF[&Q/?Z2G=+%;STU(<E<]$P]=4:6DKM=I.SLV.1L/:3
ME303]Q[()R=E'!5Z8$;N0:YFMB0A=E6-*DT#VXE4[G9#'D&<ML7L5A683SI%
MY)H8LE.\(F*'RCD_F^E'3GSMK_\UXD:E/U7Q*DJNK[=K9'A$L[M#-H3KA ;O
MO3O>()".: GB(K).&^D$6$7[Y4#DT%'^U0:<WL[K9U+/PQ;%*EC=%Y8_7O Q
M$B98/%X]-QEB>Y>'V6RH+[I7:'0#.6J!T,U:](:-CXD&NQD%F(2R>'K8#"%/
MSW5(Q#I:Q!LKCY#*:5ERZ.'.B<6!P'7-R+%FY;KT.<J&5L:(7WU84[BQ\X3J
M8Y!R99 XN5T@#!V"5C86N6J04.6<@QQHMZ(=:W_P51[V+.-)7=W%1-E4SE(=
MI'E9SL.:B]N#L\I_"@^_>U^08%C[O'^85U)24N!.T*G>HH]X%\X=K<(OS^J)
MC+Y\$VEBTX4B7&$?@M*/0DE^3U>OETE[P^IWRPEH/?@F*=RY)-%)P:<'+D64
M3Y[ W,EI@=P.'XH$#QF0X-W5D!.:'E5U)-H]ZYE/E2X*IU3Z0'M5+LYDR>$]
M:(GC RRY46*ABL$;)2IS6S6 7^Z4I^*TA9K>"%%V)R= $LVE:P6CQZ%%.@L0
MBN\"7="0M-VE9HV:]JMGV/]10>X$),'%Y$.<U!K[+JIV<8 7"1[^UEZ2^\RA
M5;D*U2">JS(+)\*H=-AV@2,'O1>V\S[&+ORQH!A!9558!VTF>^U*PXGA<6UO
MZQ;*X6QYI<=:#^D/X3;CK+KC&\$E*OM-2R);C+J6T@JKRE["O[3S<5E#+K(Z
M7C4W;7.X$8?]OK7XA3_1%.S7K*!$-'[8\:O;2(=$-:%T+5+^]*RO&K^?_O^.
M8"U!6)"X=# _@FWO9#?BA$/9D0*"Q+J6Q>5CF-&=+M^T*&DFW<C]$!P.Q6\;
MRFGY P$: %=C&3>W4/1QG^ND:'G%/Z/LUE];@*&0/PWX.&WM)D."C9M0N;5P
M96'QYSPZR3K*?"Y?96"FM'=?P39EDH,;=V$+,!VX."V#+D!UU@9PDH-8]KQD
M[B[O$5(9L:2> :HY=$*#:FBRFO<KY=WV*O&S$-O.N<@@Z@ZRVG9R +F+H))J
MP3S!'7BT7WEW<:_(4?_WL*7 &39.9)7?,LR(RL, ^3VEZJ6]SJ/ZXA+%S0-O
MFZ]J)N9.,X6_;A%9\USX<.K\H@%^"#Y+,TBIM2,+ #_J2!8@-J4\A7!)^:^+
MN=(#)GB:7C#W= A_@+Z/4NU;\_>G'DU_XW6D2-W563H@S/2-HG9&\BX7K>ZB
M(@V.OS,Z^:<BF%3J;S1:1,-^P]^ST!_\_7;8_Y_<P(HQ!'74Y@^C$'J#"7;K
MZ,#$P"__V.\A+YDT,\BIKW'+_H_Z0</W [L5!:R!%^ YX0A?&2 N9;Z,):)Q
ML!.D-.\8-,&X1(U>O&/CW0M-%?.S89EOZ9>W555Z8'*#>H2/OF^< 3I FSRO
M*N2MVM).@ 8Z07H6;T%'9\O"'NW8N/URI2;ZA>4.M1L&L9HVI]95^;X[A,@Q
M^.$?ZXN;,X<EBX#Q^STHMO ;%.,\UD;5'82O69)H%VF4(X+W?M=SMAG^ N;3
M;PAF;E/(PF7\P 1XN&52,A:'96L)#I[&NKG/7U'TK9S\E 0E&0HFF@5E3@71
MEFA)M3N]O4CWR#IIW@H-1S V/>ZO2^-XV!57#-H[Q4!.$2.1#[=KY?>X11=K
M:"HH+HI>+OWBGN/ Q^=]'X^?,)7 ^>_4VF6_,_MTV,['() +*(=3WY3O=ZG;
MO_!$X-]_PSR,)*AA-U7:,90CSI UQQI$J\FD,_6@%QWZ8)G>E-!)XW.&%1IU
M&KB9/P*^_MKWH?S_GC#\'Y\P_'A1AP%-;D=\A!'"%]Y33;XX>@[9WX^II+KF
M[U+@/V,"UMESJ)SI0=94!;K;O)G( #V1Q;P88^E35LHSSYN.SKVADO=)@JK=
MP/_PA_F]4P?WSL'.-O,KZ"JWBS[)2BOSHYM)H#*TIH9(=$%B.H+[\]P]]_QQ
M0F\XP"%U^VPG:5.5X,YO7+.P$F[\9C;B$X1/+GSO_*.T&V+*[4J1Y3=&;*;/
M:_6Z7)AM:RCQ640>ND,H<2G)"$ +FC45]\SVAS! >@^HO@><CB;)[#]YVN/P
M*_.A=_FO 4;QV?,O&G/4DIWHF8H#<\T-CT5YG(S)2OMZLB^7B(H7.^0G1FVY
M^LQD<08?3-&Q8X!*H!]&19N,$3<5(J6&UI4TSE,$AG=,BU(RCK_:,+'<Y");
M6<81.$B%1!1^Y*UW#I20GW(_A6C]LB01$S14-^$=3FCCK'R^B%$QTJ9Q-]2>
M@T."X]$^^O$;D=@X*0^T:G@K-@4B2/1KX&HJ9W%FZ765C?\6U76N]%7*<'_K
MHW9?H]C&SAS(=FU:&88JO#& 8J&"O;%#_84^B..U_N3*:*A\D!9!C,F'+L+W
M4&R4H'(NL45T6J*WQV':.S:PP&Q,U11OT#<;J]V29I(QL;2%<JR#@Y^,YV8G
MF3PQUS+3S9W:B%KUY;X4:7X,D(D/JKG_T["0 2(+9?Q8#ZT^T8@]6.+@NP7V
ML]Y_1P!Q(_%"2!9XO4D;><^VTPHF#(<01-*)2LU;)@'N#IZ5?7():<6E@4B.
MB@^=*6%I:R".88P;Q ;Z9-@&_XU@I4Y O,K^,B<_?N^-).O7Q55=F4=%D:Z#
MM]A Z'[XR7'HXIG.A;Z^N6M%*VX4\6]$R*6D&1P"0IPA2>K08OVC<R:BPA*:
M42.(FUB6]2CSQB7@;>E%D,>_F6KUGY=B93(-I7(+D7A?WD36SQ(ZWDVY"J!?
MX$(1<SS:SF?G0@LP[X3.?0NDR6?'3[^PF7 \LJS7*W&[YCW&?W')<?H"L9/O
M:6X(^ZZ#VL>V^C2-O3A,(/&P'\E%;?9V;S=DW;D2R""VY<'"0X&:IHV&T'MN
MI/VY<7Q7(BHH9UI*SP^V+)^:-Y6#YP!O>]%K\,\>Z?\S;OIF44Q(!^@+<)'C
M2@<.P^-P](S]2'S7R=7[4RH(6[#[%=^VF?A5S(\?$X-#Q-([8 38@'%93ZVX
MMX69MWKNK/HN=][(H<X),_Y'HO84"@ZY>!SG/*S>H)M-%FT<OH=Q*.8]O$_^
MZPV;XO>EPB$4Q2"Z>ZVS_0!!-'R]\[G@J9)^JE*._5&1O+LC;ZL*$Y/C(; X
M[7,J>V>UF.7>9.7[9Q5M74W!_("T@I E1_M>Q52R-]^ E*@WVDWH*8(*156<
M''MO!U#T01? KB^$$:^\^5KBI1JQ+&8+28)]9SP2P=?"/Y55%;_6Y<S!:[E^
M\?MX[.D.KC<I_=-!.O&]^AK:?Y@.^!_1N.S?<D/+ &15L+Z+7A?O(%V8&]^T
M*B:TS(J[^W!E+U6<: 50:BR4+(*M-ZME033"V-V5,H?Y9GJ0Q4[ZSP6$*R.6
M+I=1+I_<OUC&%:T7G%&Q)*NO<></62I7U&3GSCD(!YPWVQMI61!PO6L]V*ND
MJO25];W0YWO7F<N%=AW<6P?J+_%A7RR@6,XB"P+J^)8Y[9,L^M,E'8M]%1 #
MO4Z!)TUZ3]!FG-J4"JY=@' CG:%#TLZ#/:07O=5"I-EU 7GM?@9(%_7)0,9<
MV_18M-9HQ.7"))!CU>,=C]%'MZ/EY#RB[DWR )'#F&CR0BJMMR3/'O?UYB=Z
MQN-LB+_1!2/]^NS'BB800#NO_\R9?O>[#,I@T7%X9?J<@=.FZ8FE6SF1+M)7
M08)3C\5^ZN$)0BP"'!$P?K=K9$@29+$#TKXQ&\V"QRY5]J_O?=]V@_>&=T*U
M_A2. >(XXB0-VCJ-462 <,%8@CX[6<\] >9'EZW]7)#15-9@4@11>'^JM?@.
M\EN:_3YUJC8+X9H3C3/?SG(K0<L1$,ZL4[^;&?__4#MJU1Y A-FVG3X+P!DL
M @AAJN,"Z3+F#+!T8UA_F5&J&G$C3#@D+^\YZDC KF>NXAW'XB^H]*H=02ZD
M;,73KN0_3$A0OY7R-T4<_^TC_0_WD?ZUZ0EM&()1YY F=K+E@T,XAVG:67+4
M!X*N+W_(1=J[+ZP]]5<?[1ZK6$H[X"R"$7)8ZZ'O/T\Q0NTA'^D<#PMW+;M.
M/!Q<8Q%1:WNFKU8[/#EZ0/3-8LC3O0^I[>@I)(\XSMYF\38WAB==/^]-);SW
M?L*F4R(#]$4JM99;-K4^(D:%OF00E98T+X"X>O/SZ1$'S_@"#4Z3;S9+O]E$
M>?N59[FIA\1)KD5]SB68%\-^-V[>M"LLC4B_*&"6EW;7./Z>@%&08LK:^-3D
MKJ.TH^AF@*B)H!<?8@L[6TXE]TDJ8_9ZOTV/R>:AQH2^T?!@@.ZW'L<,VN!>
MEE $^)\:&1L?R)7>NPP;$&2?),@5\HP3<F+<1V8L;B9E6X;:5IF/LJ]NS+%&
M3WLC3L=(\6]F]061H"DAUZ\*%G@Y8Z1CWO0+ %\P'S!^_+>^ ":]/;L7\XT?
M>0BSQ,< 92A=WK+_%1*F/[J#;/>=%3/1^?R[YV1_$R<4?_TK4J+-/KNU'8M]
M^[=VIY78^:08^:+V8*\L*Q):TE?L:'X$0.IRO:Y/ 9E"!?P'M8X]5MO%M-T*
M51]*%D8'0JPI5=@CWB)\G8?@JG>ZVSAYI62/OUE\Q69Y4/&R(LAK\<,]VNOD
M5XJX%7;]!2->V>T)#O$_1236-TBCP->*>9M,WM](.D%V/HEZ2M43F;/N:3N4
MAL7 *E/E\;[7.">7=NJ:?.ML@0UA@"TL@@;S:1#+ CQ8V99%6WT,/&H&!<S%
M3,1.4++.S;IXYZ4*?_IJ?B[\.PW*_=VJG7_N3<X@8#(8H)&H%D@!,J06.YZP
M7&RG(,F6FC)ZUD%\?5V<>GA'MT:=P(:D(7GF+WT(WCH/+I-Z"5Z+&80-BDV#
M JMSIMFBGH%V^6U2GKSZFST"O'S,]X,;0 ]_L!;$P#YK?<"$)8G0WB!$[,;.
M$))211)R[?+J*%U?-1%KU]%:H8_K#/":>W<A9N@-J-+P  ;($>E'6-B"Q5KG
MF2[ZF7<'+T5!WX001U/AA\._WN67?L_S^8A\2/XC#4Y]LU=_1 W^S(6$0 C7
M()LJG4$8D@P,.=N//@:LS !@[=\B5QZAN)#X>[6 $.99J@'";.CY=X#WO_S&
MI'![4-O[LG#(_67N=-1S_-$!C:<7*I]7>(:4&HLW:RYOVHFP'T*+'DO,B6$A
M,:4"XGL/T:( *=E8/)XQ/&I>G'2(@(^85US+A7@2Q:TE5FES<9Z3^5_PJHN(
MI>QG-]E LRKB'0R0-6K(K1Y;*%7O -E'-A[,/0167%FZQMJ<ZG*!53:CBA\$
M&K\ <A'O%D^Z7O7]Q,O?OF1VW4P"S?N>8F*?@#6&<H\S/RYQYB ';0DH7.IR
M')Y?FKX:Z/=>P.Q%?79(S!W0KI?B!&?2-UK!.GK$8-)QX(54]8+*T0'Y8<GX
MSNCWI9V\+7NT/MC<[L7Y]EU3*:*S+  VA94!>AY/7/4&UWN-4'>/5T5-0_=;
MRU65M,4]4%T3^WBUHWTUNJ7IIU&C?7&73;Y\3V5['_\#"K7S<T#>F+>->7&O
M.R4K=QDOHAO\*/!FVDOM9]*5$1\!0[3.10&P=-=G6@W )1RA?FWQ(2]OD%<;
M,M\O&/OM)SWIDIR$+:FJWE*=G'(_=8, "%K^#,F%EJRL09&"6W;#K<<3PD6O
M]< .7VS<5'C_QN>E-K/A;?+3'3S'#AW^:0!L81 .>0\VK-2 *8'5U8@V(_@2
M/)+>5HF6>>YQ5!UWG58[)2"@(_@IW=3:E /[![F^_\+<B'_7C06AY;D'^U'O
ML!;M[OLSO7(JE]U+2TK]O724\R]F9ZX+!Q7A8#L<8!S51C;)9"_=VOX27[5&
M3U*,2YSU2\J.00]A K,HZ![&$HE[C2)<KD(.Z;82RT+I[5GP"^7/\FJJO2.Q
M%XQYK#6GE!M=/I^[=CE?[4R7F&EF\TPEHAY<N 8IY,9WOB5#SK9FGTY8M/3>
M-%NVKGOI-VJX.Q3J$>HPF/DKQ7#_+7;[)Q6[_56,E8@F$Y:Q!+?QYI*)4'MG
M4=TOBY;S#U170><TUN_=X=)Z\,%$ Y:P78 /'<ZA6)D7D(U2+>Z-7!7+='@G
M/SXM],,'5UJ?JA53LZ7J DRJF5\+*MPV;Y5.=-P]!K6>+4/HH%S'L<Q&$_=)
M82;[,Q4Z]-%%NXD0$P)Z618.(V(FZ#G$A8G:BHE%NPW8@I?>^0M-,:.*PI>A
MA)3=^OB4"L53Z E^C8?1V9=+3'QT2D?FQ_*HG6N3^_W3GZ<>D-N;6;]/4^Q^
MI+&.S_:XASO_<WSJBR0@Z?O4)Z0",86J!9./4CT<)G+*C1F@ALH+-WVS1]7N
MK>[@Q0*D+8>)IS[R*@,4 R.?Q. /,4#[5YL.D6>:/!T9H+WW@B%;)ZNS5A84
M3B.6]FXF7U1U^M3@#%&%&-7[ ^8?_96J0/B<9/4\QBI!8T5/3N_^NO',IF_2
MLD4>\MLR+_Q^7M3D[:@IZ:MYY\6,8N;,,O"U2*<1*<\-)VRG3*KF-[/+A6\
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M9<?/Y5#NA-H:9QPM3IP4CG>XEY2%-J!V-8[/CR]<]O<N_RSQ+BE4%M^S"KT
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MZA%R( 9(>U)$G_P6O6. >C[3V\ PLL6PH+K'^?:$[J/,H[P&\[D[P-%(7;F
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M+X]=HVOU<R!>^@#]#F,LB6;P2FAWDO*WW7\TMXF8F',KA/CX)MUKPAGW>4@
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M^7?7(@R8]N-6FC[:PFI%W*.'HDV*\%:1>:M2L!"V)0%E3#THE&%*C?WF"2K
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M#RK-DT*;JF^B^&&8O/$2"$G<*5IL(NDB]ANN/X!S^42JQ44$TZFV%99G7)M
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MP!;RP.3*VD!H;#DQB<\?7\#\&'AB9-9)6<LTS+!BORS<Q1JQ[>K^Y,$-
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MS!J@2<9.?(KU$S^S5)G:CP7<^BKUUN1U1Z1(7W<B5U^J NE/(%6,F*G-W@'
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M8<29V_IRPLNM=TF@,P?-;-V8;B@F7!IZCH(UMP\#WI#T?:9$DS+T,.CMDO!
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ML<CVK4M1"@SR1F(@:DTN@/:1LMAZG#-6!KNZB49@9*+:!O^RC$4J]0!K12Y
MHPJH= %K9<#M=$-BL5&<:&@FVD...41V&\P!<.W<>Y[3_G3;T@%0V-JQ#M%>
MSP#7>QTG_6%5>Z$EJ[NKO$@>U&99.\74E=>(B+"#0PPYPP0BBBBDE 30#2/J
M>33F++#R&37I='9+5"FS]K'?2 T:L2]*SRO+:G=60V!F% \-[-@KSQ"8VD?#
M6H T:$RL2;_31L9:(+$7'VOS;L_\)77QYFOYEN3Z;E;_1R?B?R9+G?GH5OO+
MZFHL93&61>0PSF*.(!:A8BF!7!A[PH,^5ZV'+&;4B:QREUAU/S>^:J37>4N^
M"OU!),NDLA_4;[0J%^7_@I9&%TWUZR)+F+XZU ]8)BZQ&S,S6AMO)$8FN/8@
ME&"7&2MW4 >_EO*/4U>H'W2#9B>QDV#:S"2]T-G+2M*OE9ZD>##-22O?S9N7
MS2-U.IQ+G:;Q^K%,[GC]5.2%^@P587]^*J_?(DJ#V'4%E#R*(.),0!P3'_IQ
MS -. M]G1A6*1Y-P;M1:RPG2C:#@!V7$Y&5ZHN-^%A.-IR&GON8HC4V[K8Q0
M;>W:::$ ?3F<.4KK> %J+=4/&STO0*7I@.P\UB ,2N"#"SDMQX^%\=XR,%I'
M/0- GTFRU$N/3@6J5J)W@A8W@CUE9;!%R^>HO([XMLH$629_%UQ?D;T1,LW$
M+?F^T''T3A3$$+FA^A^?>A![KH2>5"M%Y",N8]3D439;'P:1RXAMMI,IC[PJ
MZ)N&O$E,WJ@(E;@P)SJH\DYK Y[6ZH"E^K=MEO=AQM1LA9ANG":*DE/R@XT"
M%^#RP"BU'2=+O<!&L?+B_@+04C>=<7G  -DAL1XTGG80P:8-OQT2R[UHW4$;
M[T?L3=&@&Y$])^Q(XL//:<E'@I=+3%X6ZV[__6V:%Y_3XK]$H4\'[E9:R(7C
M>LR34JH- &<0,0]!(HD+F7"(PV)"A&MUA#*:I'/;$NB!;F3;+EA6%Q:RH_GQ
M1MB,^F<Q;A-N$@ZFC5WKU^P)M$+JMP5X$078Z*06C0=]!#K<:C Z_$.N$.,)
M.^FJ,3KFNRO)^!WV<&[Y1+XG#T\/U0=]M4SNDFJITS5>1,82LOR4+)5 Z4JH
MQ4TUNG5SF:\O+!<2!8Z4C$(LF0=1@!VU;8@XQ"+V1.#'@7"-#I4&E6INJT:M
M%R"E8D#4FI4%/=A:-_"P5JY..KX50:]V&XU^%FX8@PUT]X+R:L,W\N+1C%RE
M$VB4*EW\-VJ!C5Z@5&P[O#S?>&^\QLA9>-.\Q@A.Y%HSV4C:^=D,C7BGT\U@
MG4WG@3,T/EON.(,W;K<2YUFA1/AOU5^32/WR>Y(OB-J3J<V8!ZG.UX9PR"#U
MB \Q0@QYC,:(^R9+ZN'FY[8VKO.C_ZJE,W2I.8)<]QIU/AXC+S:F4!@S3+?&
M'9L#]6)K8Z#^M;LI.-+R)+S0K54SP4\\U;O@LA19)GA9H*(L1['@4:B3T!+(
MD4XE0CP$L9JCT"6""Q*YC@RMXD$.]#&W.;L6L:J <P'^M_.3X[C@D63@N2K6
MXCH7CN/45Z6 /!7W:58>FFC/B%7:_"$I:WQ8UUS>&P2SXXXSH1UY^F]0O:E0
MK>O>?.C&J$\AY6,H#%PX>:^;J0LE']/S0&'DHX^>%SRZD#$)4"P#R"-'J UR
M3'7]=0S#D"&"W)"$'NL3+CHW3FCDZA<5:AD'.J-9>U+OWH&>8TS*==NO$LQY
M;/KM_?U</]+=VYO-S<W'9"4^%.(A7U"L)J#V?PI=@M7$)!S&NC"YBUW*J2#8
M(U85+:UZG]OL-;@S!;]JZ4$IOJ7GN]W F%'!:'"/S!>#(7V&BZ@%8N-XB)H(
M\$H.HA;8'/</M6ED&*>?30_Z _M$BOI?NE)PLKI>B?\2)'M/DJRREYTP# *A
MALAS<:S(3WH0!S&#*/1U<C(B&#:J1#6,.'-CPTK>U5U9:4/-Q!<EK!H=L!0=
MX=QC#),9%4X'_NMRXTWIN:,%;[9&M6XOZLEE28#U!O-&#9[BT>;/X%T99Z35
M!DK]\=QY^B$_IA^/I42OZL#3#[U3GCL]6^U'R]]N;C-!\J?LY7+%?]&UD5;Z
M@+A.@.4%D<\I$C#RB#[9Q0ABY#+H"$*9),3%U"J^LK.WN9'JMY]N?@*-O.4L
MO5M+#//'=)6G^NQ#_4MDCUEB[3+9#;T9DPX&Z,A$^>UF&\F-J"/DG34"94@.
MZ^YP4HHRTGV7@<Q>ZD<P914A[1F2B7NQRI-G\6'%T@>A_0X_B^):WI+O7ZJ"
M89=%D27TJ2BCDM(OI,SP'D8N07J;2Z7'(7)%#(GCN1!% :*!BY!PHH62F*:F
M)'2F1#:SJBW7>).K*G_%VAKIVFM*)?"#]N6V#/PY=\3,F&O"41B9VRKXMU0!
M'VKXM38_7@"ED(ZT5"I=@%HIT-9*%Z>N]!J.!0<">$B>/%>D29ET(/QVN7:H
M9ON77_J/)Y(IDV7Y\E7H2HT+'A/FA#*$C@PCB$3 8:RK5[I.P(03J%]RH]Q/
M'7W,S;1;UR5:RPDJ0>T+-.VBV<U^ V$T]K;6&IY>)9R. #! -:?=EB<O['1$
MM4,UGHX]VC-M3OKPD*[*6T%%&-?93:'/&,J=XA>1E;Z\"QSZS&>80APR"E'
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M3 I"(X=8[;!.=3@WJZ>1%Q1:5+L-UTEPS;9@0T(V]F5=@U;M+5P*6YY'JY]
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MKJ:FAG9(<"B%A"+&.ILUB70IRDB?E45!') P%$:6K56O<R.7[02"I$\"06/
MNREF-!A'9II:Y(N==''Y;KZX'@6\C9&U".L9 ^&)PG &0]HN+L86L<XX%N/&
MIHL[L=5O*T[$^N4^J9J:MI2U^?8I+]('D;W-!$^*_+T0N2*NMZFR52_S/,D+
M_5P]*T0@D8Q#";GK!Q 1&D$<8;68QL*7DGD<,:. CW.$F!O?5W91HP"H-?A9
MJU =[J?PD;R C1HV28IZCI/!NC !^F,?E#8:Z'QU>P-P ;0:%\T0?-D:@CY+
M1]^QL$DC-?Z83)5<:LRQL<P]=1ZHW1FI>K8]89ZJ\[3?SEYU9EN#>HU>/PKM
MLMKVQUI@&7&/!!$,!'$A"C&'!#LA9+$KXH"C2(A@4:0%69J=:IAW;;4HK048
M;_YIY\7R8OZQY;R8-G*W7$4'\10]-!9FIQ_C(#SRPG/",W0M?,LS='1WT [$
M)G #/=3['-P_.U Q=/OL:J&G9]>]/AG^L+IDI6FOFK[*B^2!%.+-RZUJ4I=
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M,2'_!+J6@2=>, L=(])1\O]I%[6WJ]5RREY758+::F$Z&9B8D! +W/,@>0W
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M#^D;2EU*?9,)[^XL/.Z^F\)L<A(1K&BJ"$Q)W6Q&0!8I!;.8\4RO"F5,G$I
MGY0VMKFE5;9R#SN[?ZX!TJ< MN,I;[ %YJ4MQ+H;)HVJ/L.?+1#Q&_1\2N#
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M_WD'!4 [74+96[V2:ZYK3FD -5C<@$6-QHTI!V_P,&>W;0QD57RANA>\&%#
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MMHWK^3:3EP'<.]S/&]#7B?F[ /!+0O^L4'.(_SO]O&L% 5I9>2(2T.[^'C/
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MQTE.8:II&**"4D@$4C!*E,RBA*4YMDHC/"MI;+Y"K:P)E 3;ZH):7WNOX33
MY]T';[ %9I#>B#EY%%9H7.!:G'[^8#Z&E9E=9\/NAGY>QR>YHM.Y%&T3I6:3
MKZ!<X9QI'R,O!$28YGKY@".8I"A'+)8DQDZMC@Z+&1LQW'+^^OPZJ^+F/DB-
M\]2R;LP9-.W\B<LQ"K[C7"L(UEW/_ ?"G ;!I]]P1-*@_L)I:W?]A#-7]R.
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M%F@C=&P<N=9Y^SBH5;OW*9[5 %@NX#S#&GK]=CFB[HLW!XB\KMULY Z[='-
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MQ)4)&D'F$YY,MZF_-*773)!_I60T%*CKXNAXU12HAR* )Q^5)U\]J0>\V;&
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M)444FQOL?H]EGN9;"B^4+UER*#S4.PA;8U<O !VB4M:'(IO40'V9M&F3"(T
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M/:*FO0GN!W"'ZFE$U)WB<OCZ-FJS*I]J8$>[&'[DX]M="N_#ST@7PA<??_W
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M4^:V,(>MAB%_B;8NP_L#P7!_N.*HFNG"S7^(J:OD[\>9,THKU(D 46=1II2
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MD)M3LM:6,.9:6+V3)_F?T@7],6?W9.B8VMB><C2*28D+(S4P9C6H0*>>"]&
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ML>@^P77+$'#TT;YWNTN-QQ1+H',P%D-4.X_@"S,@9$R<%RQ.[C/@Z<_FT(,
M\:7FT"':Z0-=F_L-3"R+8"0%!JATK:)+!EQ=)FQRRDEP+IG:QX?^JII#!REV
MK^;0(5+N(/RZW;D8%=.%:PN<F0BJD#WW=<4/O4+<6^95RJS%$=M]<^@@K7ZV
M.72(B#O Q^W.12>$MDC$>XKA0'GZR@5+KXMAM;:]1-=F95+WS:''X.-P$7>
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MZ-.Z(QRD^7W[MX]10P=&;M0\JW"*WN- !X6O@T%%+6XKF8&4/E@A&<\LM;"
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ME$(9+B]0YHYR2 :=-ID#9ZI)5D\U#LXF2^T4Z*ZK[^Z!?J^^@(C2/C:B.+E
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M50>(JYI^*'DT4;((-N,7$80$BWX'^"AB8DE3;__.BC\H*WXO5+7,BM]'Q1W
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M3FX:$R,5ZUU.8INOQ9#BK="V?NSGO\JWZ8A4JIJO;VCY*\BCCXV"$:U5&=F
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MC+.;\[)W'15&XJ#S.&Z;M7,^F'F6"VO=OG3]J>6$"Y&R5F6RN4AH9:P$+VT
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MMW:33GR#^TEY)3!M:0E-[CIWB8OY=&*ZV2M=?VWN^+[_2<]'W(16G(^<FJP
M1MGQ"7VR8[ P.&;F-]BQTF#5)V*ZDMVK='<1K4_ =+"36#9PAYV-&_OW^LL@
MU8R_E.N+!QD2VO?-E25C*7P\=@[ B AV2M>/ZUO;EI6UGRA&3RLK][JA_>'+
M]VRE"^;+_2R4>!9 RN?+ER6Y*H9<PV_KSWWD98GZ-TC,3*R<U49ZY:/^++B'
M^@O=$LQ.(^SO<LH^XE^S0KWNSTBF2T1_N9'U7?<,O+U[>_<,WCT#!T%KE4_,
M^AJ__X\8+?>FW8<<;YZV-T_;R_2T]=X\;2_"T]8T?^F2_N;FA_\'4$L#!!0
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M_S*Y; "?47S6>H.%=A3]@9%*+_C>W8#(,<Z/AO,GZ&LH45'L.!/0SPG9 4C
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M9!=S[WP3(?]T+T78US,N_@)02P,$%     @ MH)E4?APOV7+!0  BAT  !H
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M2P$"% ,4    " "V@F51R/YH.+P1  "?O   $0              @ &'D0(
M97AE;"TR,#(P,3 P,BYX<V102P$"% ,4    " "V@F51S( S\M,=  !P/@$
M%0              @ %RHP( 97AE;"TR,#(P,3 P,E]C86PN>&UL4$L! A0#
M%     @ MH)E4?0Q/4P>4   IY8# !4              ( !>,$" &5X96PM
M,C R,#$P,#)?9&5F+GAM;%!+ 0(4 Q0    ( +:"95%AT2J161$! ,+& 0 4
M              "  <D1 P!E>&5L+3(P,C Q,# R7V<Q+FIP9U!+ 0(4 Q0
M   ( +:"95%4:U.[4+8  #V4!P 5              "  50C! !E>&5L+3(P
M,C Q,# R7VQA8BYX;6Q02P$"% ,4    " "V@F51S-GYA*US  !2; 4 %0
M            @ '7V00 97AE;"TR,#(P,3 P,E]P<F4N>&UL4$L! A0#%
M  @ MH)E47E%-$:6$@  SG,  !H              ( !MTT% &5X96PR,#(P
M,#DS,&5X:&EB:70Q,#$N:'1M4$L! A0#%     @ MH)E4;E>)FXG"   QR$
M !H              ( !A6 % &5X96PR,#(P,#DS,&5X:&EB:70S,3$N:'1M
M4$L! A0#%     @ MH)E40!Q<K8S"   ^2$  !H              ( !Y&@%
M &5X96PR,#(P,#DS,&5X:&EB:70S,3(N:'1M4$L! A0#%     @ MH)E4?AP
MOV7+!0  BAT  !H              ( !3W$% &5X96PR,#(P,#DS,&5X:&EB
?:70S,C$N:'1M4$L%!@     +  L [ (  %)W!0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
